Cover
Cover | 12 Months Ended |
Dec. 31, 2021shares | |
Document Information [Line Items] | |
Document Type | 20-F/A |
Document Registration Statement | false |
Document Annual Report | true |
Document Period End Date | Dec. 31, 2021 |
Current Fiscal Year End Date | --12-31 |
Document Transition Report | false |
Document Shell Company Report | false |
Entity Registrant Name | Barclays PLC |
Entity File Number | 1-09246 |
Entity Incorporation, State or Country Code | X0 |
Entity Address, Address Line One | 1 CHURCHILL PLACE |
Entity Address, City or Town | LONDON |
Entity Address, Postal Zip Code | E14 5HP |
Entity Address, Country | GB |
Entity Common Stock, Shares Outstanding | 16,752,457,128 |
Entity Well-known Seasoned Issuer | Yes |
Entity Voluntary Filers | No |
Entity Current Reporting Status | Yes |
Entity Interactive Data Current | Yes |
Entity Filer Category | Large Accelerated Filer |
Entity Emerging Growth Company | false |
ICFR Auditor Attestation Flag | true |
Document Accounting Standard | International Financial Reporting Standards |
Entity Shell Company | false |
Amendment Description | Barclays PLC (the Company) is filing this Amendment No. 1 on Form 20-F/A (Amendment No. 1) to amend its Annual Report on Form 20-F for the fiscal year ended 31 December 2021 (Original Filing) that was filed with the U.S. Securities and Exchange Commission (SEC) on 23 February 2022 (Original Filing Date). The purpose of this Amendment No. 1 is to:•reflect the restatement of the Company's financial statements and consolidated financial statements as at and for the year ended 31 December 2021, including the notes thereto (Restated Financial Statements), which are hereby refiled to reflect both a £220m litigation and conduct provision and associated income statement charge recognised in the year ended 31 December 2021 and a contingent liability disclosure in respect of the impact of the c.$15bn over-issuance of securities by Barclays Bank PLC (BBPLC) in excess of the maximum aggregate offering price registered under BBPLC’s Registration Statement on Form F-3, as declared effective by the SEC in August 2019 (2019 F-3) (the Over-issuance of Securities), and related potential claims and enforcement actions against BBPLC and its affiliates, as well as a small number of non-adjusting post-balance sheet events, as described in further detail under Note 1a to the Restated Financial Statements;•amend related disclosures in the Original Filing to reflect the Restated Financial Statements;•amend the disclosure under the headings ‘Governance—Directors’ report—Board Audit Committee report’, ‘Governance—Directors’ report—How we comply—Audit, Risk and Internal Control’, ‘Governance—Remuneration report—Annual report on Directors’ remuneration’, ‘Additional information—Disclosure controls and procedures’ and include disclosure under the heading ‘Governance—Directors’ report—How we comply—Audit, Risk and Internal Control —Material Weakness’, to reflect management’s conclusion that the Company’s internal control over financial reporting and disclosure controls and procedures were not effective under the applicable Committee of Sponsoring Organizations (COSO) Framework as at 31 December 2021 due to a material weakness in the Company’s internal control over financial reporting identified subsequent to the Original Filing Date as a result of the Over-issuance of Securities having occurred and not being immediately identified, as publicly disclosed by the Company in its announcement of 28 March 2022, and to disclose the remediation efforts undertaken by the Company’s management as at the date of this filing;•amend disclosure under the heading ‘Risk review—Material existing and emerging risks’ to include a risk factor on the material weakness in the Group’s internal control over financial reporting identified subsequent to the Original Filing Date and a risk factor on the Over-issuance of Securities;•include the revised Report of Independent Registered Public Accounting Firm of KPMG LLP (KPMG) on the Restated Financial Statements;•include the revised Report of Independent Registered Public Accounting Firm of KPMG on Internal Controls Over Financial Reporting;•include 'Contract of Employment - Anna Cross' as Exhibit 4.19, as a result of Anna Cross having assumed the position, effective 23 April 2022, of Group Finance Director and Executive Director of the Company;•include currently-dated certifications from the Group Chief Executive and Group Finance Director, as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, included in this Amendment No. 1 as Exhibits 12.1 and 13.1•include a currently-dated consent letter from the Company’s independent registered public accounting firm, KPMG, as Exhibit 15.1; and•amend Exhibit 99.1 to reflect the Restated Financial Statements.Other disclosure in this Amendment No. 1 is included for the convenience of the reader only and has not been updated from the Original Filing. Therefore, except for the changes expressly described above, this Amendment No. 1 continues to present information as at the Original Filing Date and does not amend, supplement or update any information contained in the Original Filing to give effect to any subsequent events. Accordingly, this Amendment No. 1 should be read in conjunction with the Company's reports filed with the SEC subsequent to the Original Filing Date. The filing of this Amendment No. 1, and the inclusion of newly executed certifications, should not be understood to mean that any other statements or disclosure contained in the Original Filing are true and complete as of any date subsequent to the Original Filing Date, except as expressly noted above.See Restatement of financial statements (Note 1a) on page 228 for further details on the Over-issuance of Securities. |
Entity Central Index Key | 0000312069 |
Document Fiscal Year Focus | 2021 |
Document Fiscal Period Focus | FY |
Amendment Flag | true |
American Depositary Shares, each representing four 25p ordinary shares | |
Document Information [Line Items] | |
Title of 12(b) Security | American Depositary Shares, each representing four 25p ordinary shares |
Trading Symbol | BCS |
Security Exchange Name | NYSE |
4.338% Fixed-to-Floating Rate Senior Notes due 2024 | |
Document Information [Line Items] | |
Title of 12(b) Security | 4.338% Fixed-to-Floating Rate Senior Notes due 2024 |
Trading Symbol | BCS24A |
Security Exchange Name | NYSE |
Floating Rate Senior Notes due 2024 | |
Document Information [Line Items] | |
Title of 12(b) Security | Floating Rate Senior Notes due 2024 |
Trading Symbol | BCS24B |
Security Exchange Name | NYSE |
4.972% Fixed-to-Floating Rate Senior Notes due 2029 | |
Document Information [Line Items] | |
Title of 12(b) Security | 4.972% Fixed-to-Floating Rate Senior Notes due 2029 |
Trading Symbol | BCS29 |
Security Exchange Name | NYSE |
4.610% Fixed-to-Floating Rate Senior Notes due 2023 | |
Document Information [Line Items] | |
Title of 12(b) Security | 4.610% Fixed-to-Floating Rate Senior Notes due 2023 |
Trading Symbol | BCS23B |
Security Exchange Name | NYSE |
Floating Rate Senior Notes due 2023 | |
Document Information [Line Items] | |
Title of 12(b) Security | Floating Rate Senior Notes due 2023 |
Trading Symbol | BCS23C |
Security Exchange Name | NYSE |
4.375% Fixed Rate Subordinated Notes due 2024 | |
Document Information [Line Items] | |
Title of 12(b) Security | 4.375% Fixed Rate Subordinated Notes due 2024 |
Trading Symbol | BCS24 |
Security Exchange Name | NYSE |
3.65% Fixed Rate Senior Notes due 2025 | |
Document Information [Line Items] | |
Title of 12(b) Security | 3.65% Fixed Rate Senior Notes due 2025 |
Trading Symbol | BCS25 |
Security Exchange Name | NYSE |
5.25% Fixed Rate Senior Notes due 2045 | |
Document Information [Line Items] | |
Title of 12(b) Security | 5.25% Fixed Rate Senior Notes due 2045 |
Trading Symbol | BCS45 |
Security Exchange Name | NYSE |
4.375% Fixed Rate Senior Notes due 2026 | |
Document Information [Line Items] | |
Title of 12(b) Security | 4.375% Fixed Rate Senior Notes due 2026 |
Trading Symbol | BCS26 |
Security Exchange Name | NYSE |
5.20% Fixed Rate Subordinated Notes due 2026 | |
Document Information [Line Items] | |
Title of 12(b) Security | 5.20% Fixed Rate Subordinated Notes due 2026 |
Trading Symbol | BCS26A |
Security Exchange Name | NYSE |
Floating Rate Senior Notes due 2023 | |
Document Information [Line Items] | |
Title of 12(b) Security | Floating Rate Senior Notes due 2023 |
Trading Symbol | BCS23 |
Security Exchange Name | NYSE |
3.684% Fixed Rate Senior Notes due 2023 | |
Document Information [Line Items] | |
Title of 12(b) Security | 3.684% Fixed Rate Senior Notes due 2023 |
Trading Symbol | BCS23A |
Security Exchange Name | NYSE |
4.337% Fixed Rate Senior Notes due 2028 | |
Document Information [Line Items] | |
Title of 12(b) Security | 4.337% Fixed Rate Senior Notes due 2028 |
Trading Symbol | BCS28 |
Security Exchange Name | NYSE |
4.950% Fixed Rate Senior Notes due 2047 | |
Document Information [Line Items] | |
Title of 12(b) Security | 4.950% Fixed Rate Senior Notes due 2047 |
Trading Symbol | BCS47 |
Security Exchange Name | NYSE |
4.836% Fixed Rate Subordinated Callable Notes due 2028 | |
Document Information [Line Items] | |
Title of 12(b) Security | 4.836% Fixed Rate Subordinated Callable Notes due 2028 |
Trading Symbol | BCS28A |
Security Exchange Name | NYSE |
3.250% Fixed Rate Senior Notes due 2033 | |
Document Information [Line Items] | |
Title of 12(b) Security | 3.250% Fixed Rate Senior Notes due 2033 |
Trading Symbol | BCS33 |
Security Exchange Name | NYSE |
3.932% Fixed-to-Floating Rate Senior Notes due 2025 | |
Document Information [Line Items] | |
Title of 12(b) Security | 3.932% Fixed-to-Floating Rate Senior Notes due 2025 |
Trading Symbol | BCS25A |
Security Exchange Name | NYSE |
5.088% Fixed-to-Floating Rate Subordinated Notes due 2030 | |
Document Information [Line Items] | |
Title of 12(b) Security | 5.088% Fixed-to-Floating Rate Subordinated Notes due 2030 |
Trading Symbol | BCS30 |
Security Exchange Name | NYSE |
2.852% Fixed-to-Floating Rate Senior Notes due 2026 | |
Document Information [Line Items] | |
Title of 12(b) Security | 2.852% Fixed-to-Floating Rate Senior Notes due 2026 |
Trading Symbol | BCS26B |
Security Exchange Name | NYSE |
2.645% Fixed Rate Resetting Senior Callable Notes due 2031 | |
Document Information [Line Items] | |
Title of 12(b) Security | 2.645% Fixed Rate Resetting Senior Callable Notes due 2031 |
Trading Symbol | BCS31 |
Security Exchange Name | NYSE |
3.564% Fixed Rate Resetting Subordinated Callable Notes due 2035 | |
Document Information [Line Items] | |
Title of 12(b) Security | 3.564% Fixed Rate Resetting Subordinated Callable Notes due 2035 |
Trading Symbol | BCS35 |
Security Exchange Name | NYSE |
1.007% Fixed Rate Resetting Senior Callable Notes due 2024 | |
Document Information [Line Items] | |
Title of 12(b) Security | 1.007% Fixed Rate Resetting Senior Callable Notes due 2024 |
Trading Symbol | BCS24C |
Security Exchange Name | NYSE |
2.667% Fixed Rate Resetting Senior Callable Notes due 2032 | |
Document Information [Line Items] | |
Title of 12(b) Security | 2.667% Fixed Rate Resetting Senior Callable Notes due 2032 |
Trading Symbol | BCS32 |
Security Exchange Name | NYSE |
3.811% Fixed Rate Resetting Subordinated Callable Notes due 2042 | |
Document Information [Line Items] | |
Title of 12(b) Security | 3.811% Fixed Rate Resetting Subordinated Callable Notes due 2042 |
Trading Symbol | BCS42 |
Security Exchange Name | NYSE |
2.279% Fixed Rate Resetting Senior Callable Notes due 2027 | |
Document Information [Line Items] | |
Title of 12(b) Security | 2.279% Fixed Rate Resetting Senior Callable Notes due 2027 |
Trading Symbol | BCS27 |
Security Exchange Name | NYSE |
2.894% Fixed Rate Resetting Senior Callable Notes due 2032 | |
Document Information [Line Items] | |
Title of 12(b) Security | 2.894% Fixed Rate Resetting Senior Callable Notes due 2032 |
Trading Symbol | BCS32A |
Security Exchange Name | NYSE |
3.330% Fixed Rate Resetting Senior Callable Notes due 2042 | |
Document Information [Line Items] | |
Title of 12(b) Security | 3.330% Fixed Rate Resetting Senior Callable Notes due 2042 |
Trading Symbol | BCS42A |
Security Exchange Name | NYSE |
Business Contact [Member] | |
Document Information [Line Items] | |
Entity Address, Address Line One | 1 CHURCHILL PLACE |
Entity Address, City or Town | LONDON |
Entity Address, Postal Zip Code | E14 5HP |
Entity Address, Country | GB |
Contact Personnel Name | GARTH WRIGHT |
City Area Code | +44 |
Local Phone Number | (0)20 7116 3170 |
Contact Personnel Email Address | GARTH.WRIGHT@BARCLAYS.COM |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2021 | |
Audit Information [Abstract] | |
Auditor Name | KPMG LLP |
Auditor Location | London, United Kingdom |
Auditor Firm ID | 1118 |
Consolidated income statement
Consolidated income statement - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Profit or loss [abstract] | ||||
Interest and similar income | £ 11,240 | [1] | £ 11,892 | £ 15,456 |
Interest and similar expense | (3,167) | [1] | (3,770) | (6,049) |
Net interest income | 8,073 | [1] | 8,122 | 9,407 |
Fee and commission income | 9,880 | [1] | 8,641 | 9,122 |
Fee and commission expense | (2,206) | [1] | (2,070) | (2,362) |
Net fee and commission income | 7,674 | [1] | 6,571 | 6,760 |
Net trading income | 5,794 | [1] | 7,029 | 4,235 |
Net investment income | 311 | [1] | 13 | 1,131 |
Other income | 88 | [1] | 31 | 99 |
Total income | 21,940 | [1] | 21,766 | 21,632 |
Credit impairment releases/(charges) | 653 | [1] | (4,838) | (1,912) |
Net operating income | 22,593 | [1] | 16,928 | 19,720 |
Staff costs | (8,511) | [1] | (8,097) | (8,315) |
Infrastructure costs | (3,614) | [1] | (3,323) | (2,970) |
Administration and general expenses | (2,137) | [1] | (2,313) | (2,300) |
Litigation and conduct | (397) | [1] | (153) | (1,849) |
Operating expenses | (14,659) | [1] | (13,886) | (15,434) |
Share of post-tax results of associates and joint ventures | 260 | [1] | 6 | 61 |
Profit on disposal of subsidiaries, associates and joint ventures | 0 | [1] | 17 | 10 |
Profit before tax | 8,194 | [2] | 3,065 | 4,357 |
Taxation | (1,138) | [1] | (604) | (1,003) |
Profit after tax | 7,056 | [1],[3] | 2,461 | 3,354 |
Attributable to: | ||||
Profit attributable to ordinary equity holders of the parent | 6,205 | [1] | 1,526 | 2,461 |
Other equity instrument holders | 804 | [1] | 857 | 813 |
Total equity holders of the parent | 7,009 | [1] | 2,383 | 3,274 |
Non-controlling interests | 47 | [1] | 78 | 80 |
Profit after tax | £ 7,056 | [1],[3] | £ 2,461 | £ 3,354 |
Earnings per share | ||||
Basic earnings per ordinary share (in GBP per share) | £ 0.365 | [1] | £ 0.088 | £ 0.143 |
Diluted earnings per ordinary share (in GBP per share) | £ 0.356 | [1] | £ 0.086 | £ 0.141 |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details |
Consolidated statement of compr
Consolidated statement of comprehensive income - GBP (£) £ in Millions | 12 Months Ended | |||||
Dec. 31, 2021 | [2] | Dec. 31, 2020 | Dec. 31, 2019 | |||
Statement of comprehensive income [abstract] | ||||||
Profit after tax | £ 7,056 | [1] | £ 2,461 | £ 3,354 | ||
Currency translation reserve | ||||||
Currency translation differences | [4] | (131) | [3] | (473) | [3] | (544) |
Fair value through other comprehensive income reserve movements relating to debt securities | ||||||
Net (losses)/gains from changes in fair value | (1,668) | 2,902 | 2,901 | |||
Net gains transferred to net profit on disposal | (305) | (295) | (502) | |||
Net (gains)/losses relating to (releases of) impairment | (8) | 2 | 1 | |||
Net gains/(losses) due to fair value hedging | 1,354 | (2,000) | (2,172) | |||
Other movements | 0 | 0 | (5) | |||
Tax | 198 | (155) | (57) | |||
Cash flow hedging reserve | ||||||
Net gains/(losses) from changes in fair value | (2,280) | 1,299 | 724 | |||
Net gains transferred to net profit | (1,173) | (510) | (277) | |||
Tax | 1,025 | (216) | (105) | |||
Other | 0 | 5 | [3] | 16 | ||
Other comprehensive (loss)/income that may be recycled to profit or loss | (2,988) | 559 | (20) | |||
Other comprehensive income/(loss) not recycled to profit or loss: | ||||||
Retirement benefit remeasurements | 1,298 | (80) | (280) | |||
Fair value through other comprehensive income reserve movements relating to equity instruments | 141 | (262) | (95) | |||
Own credit | (106) | (810) | (316) | |||
Tax | (563) | 198 | 150 | |||
Other comprehensive income/(loss) not recycled to profit or loss | 770 | (954) | (541) | |||
Other comprehensive loss for the year | (2,218) | (395) | (561) | |||
Total comprehensive income for the year | 4,838 | [3] | 2,066 | [3] | 2,793 | |
Attributable to: | ||||||
Equity holders of the parent | 4,791 | 1,988 | 2,713 | |||
Non-controlling interests | 47 | 78 | 80 | |||
Total comprehensive income for the year | £ 4,838 | [3] | £ 2,066 | [3] | £ 2,793 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details | |||||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||
[4] | Includes £26m loss (2020: £17m gain; 2019: £15m loss) on recycling of currency translation differences to net profit. |
Consolidated statement of com_2
Consolidated statement of comprehensive income (Parenthetical) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Statement of comprehensive income [abstract] | |||
(Loss) gain on recycling of currency translation differences | £ (26) | £ 17 | £ (15) |
Consolidated balance sheet
Consolidated balance sheet £ in Millions, $ in Billions | Dec. 31, 2021GBP (£) | Dec. 31, 2020GBP (£) | ||
Assets | ||||
Cash and balances at central banks | £ 238,574 | [1] | £ 191,127 | |
Cash collateral and settlement balances | 92,542 | [2] | 101,367 | |
Loans and advances at amortised cost | 361,451 | [2] | 342,632 | |
Reverse repurchase agreements and other similar secured lending | 3,227 | [2] | 9,031 | |
Trading portfolio assets | 147,035 | [2] | 127,950 | |
Financial assets at fair value through the income statement | 191,972 | [2] | 175,151 | |
Derivative financial instruments | 262,572 | [2] | 302,446 | |
Financial assets at fair value through other comprehensive income | 61,753 | [2] | 78,688 | |
Investments in associates and joint ventures | 999 | [2] | 781 | |
Goodwill and intangible assets | 8,061 | [2] | 7,948 | |
Property, plant and equipment | 3,555 | [2] | 4,036 | |
Current tax assets | 261 | [2] | 477 | |
Deferred tax assets | 4,619 | [2] | 3,444 | |
Retirement benefit assets | 3,879 | [2] | 1,814 | |
Other assets | 3,785 | [2] | 2,622 | |
Total assets | 1,384,285 | [2] | 1,349,514 | |
Liabilities | ||||
Deposits at amortised cost | 519,433 | [2] | 481,036 | |
Cash collateral and settlement balances | 79,371 | [2] | 85,423 | |
Repurchase agreements and other similar secured borrowing | 28,352 | [2] | 14,174 | |
Debt securities in issue | 98,867 | [2] | 75,796 | |
Subordinated liabilities | 12,759 | [2] | 16,341 | |
Trading portfolio liabilities | 54,169 | [2] | 47,405 | |
Financial liabilities designated at fair value | 250,960 | [2] | 249,765 | |
Derivative financial instruments | 256,883 | [2] | 300,775 | |
Current tax liabilities | 689 | [2] | 645 | |
Deferred tax liabilities | 37 | [2] | 15 | |
Retirement benefit liabilities | 311 | [2] | 291 | |
Other liabilities | 10,505 | [2] | 8,662 | |
Provisions | 1,908 | [2] | 2,304 | |
Total liabilities | 1,314,244 | [2] | 1,282,632 | |
Equity | ||||
Called up share capital and share premium | 4,536 | [2] | 4,637 | |
Other equity instruments | 12,259 | [2] | 11,172 | |
Other reserves | 1,770 | [2] | 4,461 | |
Retained earnings | 50,487 | [2] | 45,527 | |
Total equity excluding non-controlling interests | 69,052 | [2] | 65,797 | |
Non-controlling interests | 989 | [2] | 1,085 | |
Total equity | 70,041 | [2] | 66,882 | [3] |
Total liabilities and equity | £ 1,384,285 | [2] | £ 1,349,514 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Consolidated statement of chang
Consolidated statement of changes in equity - GBP (£) £ in Millions | Total | Total equity excluding non-controlling interests | Called up share capital and share premium | Other equity instruments | Other reserves | [2] | Retained earnings | Non-controlling interests | ||||||
Beginning balance, equity at Dec. 31, 2018 | £ 63,779 | £ 62,556 | £ 4,311 | [1] | £ 9,632 | [1] | £ 5,153 | £ 43,460 | £ 1,223 | |||||
Profit after tax | 3,354 | 3,274 | 813 | [1] | 0 | 2,461 | 80 | |||||||
Currency translation movements | (544) | [3] | (544) | (544) | ||||||||||
Fair value through other comprehensive income reserve | 71 | 71 | 71 | |||||||||||
Cash flow hedges | 342 | 342 | 342 | |||||||||||
Retirement benefit remeasurements | (194) | (194) | (194) | |||||||||||
Own credit reserve | (252) | (252) | (252) | |||||||||||
Other | 16 | 16 | 16 | |||||||||||
Total comprehensive income for the year | 2,793 | 2,713 | 813 | [1] | (383) | 2,283 | 80 | |||||||
Issue of new ordinary shares | 182 | 182 | 182 | [1] | ||||||||||
Employee share schemes and hedging thereof | 579 | 579 | 101 | [1] | 478 | |||||||||
Issue and redemption of other equity instruments | 832 | 832 | 1,238 | [1] | (406) | |||||||||
Other equity instruments coupons paid | (813) | (813) | (813) | [1] | ||||||||||
Increase in treasury shares | (224) | (224) | (224) | |||||||||||
Vesting of shares under employee share schemes | (190) | (190) | 214 | (404) | ||||||||||
Dividends paid | (1,281) | (1,201) | (1,201) | (80) | ||||||||||
Other reserve movements | 3 | (5) | 1 | [1] | (6) | 8 | ||||||||
Ending balance, equity at Dec. 31, 2019 | 65,660 | [4] | 64,429 | [4] | 4,594 | [1] | 10,871 | [1] | 4,760 | 44,204 | [4] | 1,231 | ||
Profit after tax | 2,461 | [4] | 2,383 | [4] | 857 | [1] | 1,526 | [4] | 78 | |||||
Currency translation movements | (473) | [3],[4] | (473) | [4] | (473) | |||||||||
Fair value through other comprehensive income reserve | 192 | [4] | 192 | [4] | 192 | |||||||||
Cash flow hedges | 573 | [4] | 573 | [4] | 573 | |||||||||
Retirement benefit remeasurements | [4] | (111) | (111) | (111) | ||||||||||
Own credit reserve | (581) | [4] | (581) | [4] | (581) | |||||||||
Other | [4] | 5 | 5 | 5 | ||||||||||
Total comprehensive income for the year | 2,066 | [4] | 1,988 | [4] | 857 | [1] | (289) | 1,420 | [4] | 78 | ||||
Employee share schemes and hedging thereof | 346 | [4] | 346 | [4] | 43 | [1] | 0 | 303 | [4] | |||||
Issue and redemption of other equity instruments | 98 | [4] | 256 | [4] | 311 | [1] | (55) | [4] | (158) | |||||
Other equity instruments coupons paid | (857) | [4] | (857) | [4] | (857) | [1] | ||||||||
Increase in treasury shares | (207) | [4] | (207) | [4] | (207) | |||||||||
Vesting of shares under employee share schemes | (150) | [4] | (150) | [4] | 197 | (347) | [4] | |||||||
Dividends paid | (79) | [4] | (79) | |||||||||||
Other reserve movements | 5 | [4] | (8) | [4] | 0 | (10) | [1] | 2 | [4] | 13 | ||||
Ending balance, equity at Dec. 31, 2020 | 66,882 | [4] | 65,797 | [4] | 4,637 | [1] | 11,172 | [1] | 4,461 | 45,527 | [4] | 1,085 | ||
Profit after tax | 7,056 | [4] | 7,009 | [4] | 804 | [1] | 6,205 | [4] | 47 | |||||
Currency translation movements | (131) | [3],[4],[5] | (131) | [4] | (131) | |||||||||
Fair value through other comprehensive income reserve | (288) | [4] | (288) | [4] | (288) | |||||||||
Cash flow hedges | (2,428) | [4] | (2,428) | [4] | (2,428) | |||||||||
Retirement benefit remeasurements | 643 | [4] | 643 | [4] | 0 | 643 | [4] | |||||||
Own credit reserve | (14) | [4] | (14) | [4] | (14) | |||||||||
Other | [5] | 0 | ||||||||||||
Total comprehensive income for the year | 4,838 | [4],[5] | 4,791 | [4] | 804 | [1] | (2,861) | 6,848 | [4] | 47 | ||||
Employee share schemes and hedging thereof | 295 | [4] | 295 | [4] | 60 | [1] | 0 | 235 | [4] | |||||
Issue and redemption of other equity instruments | 1,009 | [4] | 1,084 | [4] | 1,078 | [1] | 6 | [4] | (75) | |||||
Other equity instruments coupons paid | (804) | [4] | (804) | [4] | (804) | [1] | ||||||||
Increase in treasury shares | (240) | [4] | (240) | [4] | (240) | |||||||||
Vesting of shares under employee share schemes | (169) | [4] | (169) | [4] | 241 | (410) | [4] | |||||||
Dividends paid | (556) | [4] | (512) | [4] | (512) | [4] | (44) | |||||||
Repurchase of shares | (1,200) | [4] | (1,200) | [4] | (161) | [1] | 0 | 161 | (1,200) | [4] | ||||
Other reserve movements | (14) | [4] | 10 | [4] | 0 | 9 | [1] | 8 | (7) | [4] | (24) | |||
Ending balance, equity at Dec. 31, 2021 | £ 70,041 | [6] | £ 69,052 | [4] | £ 4,536 | [1] | £ 12,259 | [1] | £ 1,770 | £ 50,487 | [4] | £ 989 | ||
[1] | For further details refer to Note 28. | |||||||||||||
[2] | For further details refer to Note 29. | |||||||||||||
[3] | Includes £26m loss (2020: £17m gain; 2019: £15m loss) on recycling of currency translation differences to net profit. | |||||||||||||
[4] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||||||||||
[5] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details | |||||||||||||
[6] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Consolidated cash flow statemen
Consolidated cash flow statement £ in Millions, $ in Millions | 12 Months Ended | |||||
Dec. 31, 2021GBP (£) | [1] | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | |||
Reconciliation of profit before tax to net cash flows from operating activities: | ||||||
Profit before tax | £ 8,194 | £ 3,065 | £ 4,357 | |||
Adjustment for non-cash items: | ||||||
Credit impairment (releases)/charges | (653) | 4,838 | 1,912 | |||
Depreciation, amortisation and impairment of property, plant, equipment and intangibles | 2,076 | 1,734 | 1,520 | |||
Other provisions, including pensions | 468 | 1,365 | 2,336 | |||
Net loss on disposal of investments and property, plant and equipment | 39 | 47 | 7 | |||
Other non-cash movements including exchange rate movements | 3,093 | (2,977) | (280) | |||
Changes in operating assets and liabilities | ||||||
Net decrease/(increase) in cash collateral and settlement balances | 4,101 | 4,321 | (6,436) | |||
Net increase in loans and advances at amortised cost | (10,728) | (4,365) | (2,255) | |||
Net decrease/(increase) in reverse repurchase agreements and other similar secured lending | 5,804 | (5,652) | (1,071) | |||
Net increase in deposits at amortised cost | 38,397 | 65,249 | 20,949 | |||
Net increase/(decrease) in debt securities in issue | 18,131 | (6,309) | (9,911) | |||
Net increase/(decrease) in repurchase agreements and other similar secured borrowing | 14,178 | (343) | (4,061) | |||
Net (increase)/decrease in derivative financial instruments | (4,018) | (1,845) | 2,863 | |||
Net increase in trading portfolio assets | (19,085) | (13,755) | (10,008) | |||
Net increase/(decrease) in trading portfolio liabilities | 6,764 | 10,489 | (966) | |||
Net (increase)/decrease in financial assets and liabilities at fair value through the income statement | (15,626) | 3,374 | 4,054 | |||
Net (increase)/decrease in other assets | (2,133) | 452 | (412) | |||
Net increase/(decrease) in other liabilities | 1,252 | (1,500) | (2,872) | |||
Corporate income tax paid | (1,335) | (683) | (228) | |||
Net cash from operating activities | 48,919 | 57,505 | (502) | |||
Net cash from investing activities | ||||||
Purchase of debt securities at amortised cost | (12,500) | (14,671) | (14,729) | |||
Proceeds from sale or redemption of debt securities at amortised cost | 3,757 | 8,480 | 3,590 | |||
Purchase of financial assets at fair value through other comprehensive income | (75,673) | (91,744) | (92,365) | |||
Proceeds from sale or redemption of financial assets at fair value through other comprehensive income | 89,342 | 80,895 | 81,202 | |||
Purchase of property, plant and equipment and intangibles | (1,720) | (1,324) | (1,793) | |||
Proceeds from sale of property, plant and equipment and intangibles | 0 | 0 | 46 | |||
Disposal of subsidiaries and associates, net of cash disposed | 1,057 | 0 | 0 | |||
Other cash flows associated with investing activities | 7 | (12) | 84 | |||
Net cash from investing activities | 4,270 | (18,376) | (23,965) | |||
Net cash from financing activities | ||||||
Dividends paid and other coupon payments on equity instruments | (1,360) | (936) | (1,912) | |||
Issuance of subordinated liabilities | 1,890 | 1,438 | 1,352 | |||
Redemption of subordinated liabilities | (4,807) | (3,258) | (3,248) | |||
Issue of shares and other equity instruments | 1,118 | 1,165 | 3,582 | |||
Repurchase of shares and other equity instruments | (1,275) | (1,056) | (2,668) | |||
Issuance of debt securitiesb | 8,415 | [2] | 5,736 | [2] | 3,994 | [2] |
Redemptions | (3,475) | [2] | 0 | [2] | 0 | [2] |
Net purchase of treasury shares | (399) | (357) | (410) | |||
Net cash from financing activities | 107 | 2,732 | 690 | |||
Effect of exchange rates on cash and cash equivalents | (4,232) | 1,668 | (3,347) | |||
Net increase/(decrease) in cash and cash equivalents | 49,064 | 43,529 | (27,124) | |||
Cash and cash equivalents at beginning of year | 210,142 | 166,613 | 193,737 | |||
Cash and cash equivalents at end of year | 259,206 | 210,142 | [1] | 166,613 | ||
Cash and cash equivalents comprise: | ||||||
Cash and balances at central banks | 238,574 | 191,127 | 150,258 | |||
Loans and advances to banks with original maturity less than three months | 6,488 | 5,955 | 8,021 | |||
Cash collateral balances with central banks with original maturity less than three months | 13,532 | 12,204 | 7,854 | |||
Treasury and other eligible bills with original maturity less than three months | 612 | 856 | 480 | |||
Cash and cash equivalents | £ 259,206 | £ 210,142 | [1] | £ 166,613 | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||
[2] | Issuance of debt securities and Redemption of debt securities included in financing activities relate to instruments that qualify as eligible liabilities and satisfy regulatory requirements for MREL instruments which came into effect during 2019. Refer to Note 1, paragraph 4(vi), for further details. Interest received was £17,194m (2020: £18,748m; 2019: £34,061m) and interest paid was £8,063m (2020: £9,577m; 2019: £23,186m). These amounts include interest paid and received arising from trading activities. Dividends received were £20m (2020: £37m; 2019: £76m). The Group is required to maintain balances with central banks and other regulatory authorities. These amounted to £4,750m (2020: £3,392m; 2019: £4,893m) and are included within the Cash and cash equivalents. For the purposes of the cash flow statement, cash comprises cash on hand and demand deposits and cash equivalents comprise highly liquid investments that are convertible into cash with an insignificant risk of changes in value with original maturities of three months or less. Repurchase and reverse repurchase agreements are not considered to be part of cash equivalents. |
Consolidated cash flow statem_2
Consolidated cash flow statement (Parenthetical) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Statement of cash flows [abstract] | |||
Interest received | £ 17,194 | £ 18,748 | £ 34,061 |
Interest paid | 8,063 | 9,577 | 23,186 |
Dividends received | 20 | 37 | 76 |
Balances with banks and other regulatory authorities | £ 4,750 | £ 3,392 | £ 4,893 |
Financial statements of Barclay
Financial statements of Barclays PLC, Parent company accounts - Statement of comprehensive income - GBP (£) £ in Millions | 12 Months Ended | ||||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |||
Condensed Statement of Income Captions [Line Items] | |||||
Dividends received from subsidiary | £ 20 | £ 37 | £ 76 | ||
Net interest (expense)/income | 8,073 | [1] | 8,122 | 9,407 | |
Other income | 88 | [1] | 31 | 99 | |
Impairment reversal/(charge) of investment in subsidiary | 653 | [1] | (4,838) | (1,912) | |
Operating expenses | (14,659) | [1] | (13,886) | (15,434) | |
Profit before tax | 8,194 | [2] | 3,065 | 4,357 | |
Taxation | (1,138) | [1] | (604) | (1,003) | |
Profit after tax | 7,056 | [1],[3] | 2,461 | 3,354 | |
Other comprehensive income | (2,218) | [3] | (395) | (561) | |
Total comprehensive income for the year | 4,838 | [3],[4] | 2,066 | [4] | 2,793 |
Attributable to: | |||||
Equity holders of the parent | 6,205 | [1] | 1,526 | 2,461 | |
Other equity instrument holders | 804 | [1] | 857 | 813 | |
Profit after tax | 7,056 | [1],[3] | 2,461 | 3,354 | |
Total comprehensive income/(loss) attributable to: | |||||
Equity holders of the parent | 4,791 | [3] | 1,988 | 2,713 | |
Other equity instrument holders | 47 | [3] | 78 | 80 | |
Total comprehensive income for the year | 4,838 | [3],[4] | 2,066 | [4] | 2,793 |
Barclays PLC | |||||
Condensed Statement of Income Captions [Line Items] | |||||
Dividends received from subsidiary | 1,356 | 763 | 1,560 | ||
Net interest (expense)/income | (161) | (175) | 214 | ||
Other income | 659 | 1,192 | 1,760 | ||
Impairment reversal/(charge) of investment in subsidiary | 2,573 | (2,573) | 0 | ||
Operating expenses | (160) | (241) | (267) | ||
Profit before tax | 4,267 | (1,034) | 3,267 | ||
Taxation | 76 | 16 | (86) | ||
Profit after tax | 4,343 | (1,018) | 3,181 | ||
Other comprehensive income | 0 | 0 | 0 | ||
Total comprehensive income for the year | 4,343 | (1,018) | 3,181 | ||
Attributable to: | |||||
Equity holders of the parent | 3,539 | (1,875) | 2,368 | ||
Other equity instrument holders | 804 | 857 | 813 | ||
Profit after tax | 4,343 | (1,018) | 3,181 | ||
Total comprehensive income/(loss) attributable to: | |||||
Equity holders of the parent | 3,539 | (1,875) | 2,368 | ||
Other equity instrument holders | 804 | 857 | 813 | ||
Total comprehensive income for the year | £ 4,343 | £ (1,018) | £ 3,181 | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details | ||||
[4] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Financial statements of Barcl_2
Financial statements of Barclays PLC, Parent company accounts - Statement of comprehensive income (Parenthetical) | 12 Months Ended | ||||
Dec. 31, 2021GBP (£)Employees | Dec. 31, 2020GBP (£)Employees | Dec. 31, 2019GBP (£) | |||
Condensed Statement of Income Captions [Line Items] | |||||
Profit after tax | £ 7,056,000,000 | [1],[2] | £ 2,461,000,000 | £ 3,354,000,000 | |
Profit after tax and other comprehensive income | £ 4,838,000,000 | [2],[3] | £ 2,066,000,000 | [3] | £ 2,793,000,000 |
Number of employees (full time equivalent) | 81,600 | 83,000 | 80,800 | ||
Barclays PLC | |||||
Condensed Statement of Income Captions [Line Items] | |||||
Profit after tax | £ 4,343,000,000 | £ (1,018,000,000) | £ 3,181,000,000 | ||
Profit after tax and other comprehensive income | £ 4,343,000,000 | £ (1,018,000,000) | £ 3,181,000,000 | ||
Number of employees (full time equivalent) | Employees | 65 | 60 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details | ||||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Financial statements of Barcl_3
Financial statements of Barclays PLC, Parent company accounts - Balance sheet £ in Millions, $ in Billions | Dec. 31, 2021GBP (£) | Dec. 31, 2020GBP (£) | ||
Assets | ||||
Loans and advances to subsidiaries | £ 361,451 | [1] | £ 342,632 | |
Financial assets at fair value through the income statement | 191,972 | [1] | 175,151 | |
Derivative financial instruments | 262,572 | [1] | 302,446 | |
Other assets | 3,785 | [1] | 2,622 | |
Total assets | 1,384,285 | [1] | 1,349,514 | |
Liabilities | ||||
Deposits at amortised cost | 519,433 | [1] | 481,036 | |
Debt securities in issue | 98,867 | [1] | 75,796 | |
Subordinated liabilities | 12,759 | [1] | 16,341 | |
Financial liabilities designated at fair value | 250,960 | [1] | 249,765 | |
Derivative financial instruments | 256,883 | [1] | 300,775 | |
Other liabilities | 10,505 | [1] | 8,662 | |
Total liabilities | 1,314,244 | [1] | 1,282,632 | |
Equity | ||||
Other equity instruments | 12,259 | [1] | 11,172 | |
Other reserves | 1,770 | [1] | 4,461 | |
Retained earnings | 50,487 | [1] | 45,527 | |
Total equity | 70,041 | [1] | 66,882 | [2] |
Total liabilities and equity | 1,384,285 | [1] | 1,349,514 | |
Barclays PLC | ||||
Assets | ||||
Investment in subsidiaries | 62,528 | 58,886 | ||
Loans and advances to subsidiaries | 22,072 | 24,710 | ||
Financial assets at fair value through the income statement | 25,091 | 17,521 | ||
Derivative financial instruments | 4 | 7 | ||
Other assets | 68 | 65 | ||
Total assets | 109,763 | 101,189 | ||
Liabilities | ||||
Deposits at amortised cost | 488 | 482 | ||
Debt securities in issue | 25,658 | 28,428 | ||
Subordinated liabilities | 9,301 | 7,724 | ||
Financial liabilities designated at fair value | 16,319 | 9,507 | ||
Derivative financial instruments | 43 | 0 | ||
Other liabilities | 117 | 176 | ||
Total liabilities | 51,926 | 46,317 | ||
Equity | ||||
Called up share capital | 4,188 | 4,340 | ||
Share premium account | 348 | 297 | ||
Other equity instruments | 12,241 | 11,169 | ||
Other reserves | 555 | 394 | ||
Retained earnings | 40,505 | 38,672 | ||
Total equity | 57,837 | 54,872 | ||
Total liabilities and equity | £ 109,763 | £ 101,189 | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Financial statements of Barcl_4
Financial statements of Barclays PLC, Parent company accounts - Statement of changes in equity - GBP (£) £ in Millions | Total | Equity attributable to owners of parent | Called up share capital and share premium | Other equity instruments | Other reserves | [2] | Retained earnings | Barclays PLC | Barclays PLCCalled up share capital and share premium | Barclays PLCOther equity instruments | Barclays PLCOther reserves | Barclays PLCRetained earnings | |||||
Beginning balance, equity at Dec. 31, 2018 | £ 63,779 | £ 62,556 | £ 4,311 | [1] | £ 9,632 | [1] | £ 5,153 | £ 43,460 | £ 54,180 | £ 4,311 | £ 9,633 | £ 394 | £ 39,842 | ||||
Profit after tax and other comprehensive income | 2,793 | 2,713 | 813 | [1] | (383) | 2,283 | 3,181 | 813 | 2,368 | ||||||||
Issue of new ordinary shares | 182 | 182 | 182 | [1] | 182 | 182 | |||||||||||
Issue of shares under employee share schemes | 579 | 579 | 101 | [1] | 478 | 121 | 101 | 20 | |||||||||
Issue and exchange of other equity instruments | 832 | 832 | 1,238 | [1] | (406) | 836 | 1,232 | (396) | |||||||||
Vesting of shares under employee share schemes | (190) | (190) | 214 | (404) | (19) | (19) | |||||||||||
Dividends paid | (1,281) | (1,201) | (1,201) | (1,201) | (1,201) | ||||||||||||
Other equity instruments coupons paid | (813) | (813) | (813) | [1] | (813) | (813) | |||||||||||
Other reserve movements | 3 | (5) | 1 | [1] | (6) | ||||||||||||
Ending balance, equity at Dec. 31, 2019 | 65,660 | [3] | 64,429 | [3] | 4,594 | [1] | 10,871 | [1] | 4,760 | 44,204 | [3] | 56,467 | 4,594 | 10,865 | 394 | 40,614 | |
Profit after tax and other comprehensive income | 2,066 | [3] | 1,988 | [3] | 857 | [1] | (289) | 1,420 | [3] | (1,018) | 857 | (1,875) | |||||
Issue of new ordinary shares | 0 | ||||||||||||||||
Issue of shares under employee share schemes | 346 | [3] | 346 | [3] | 43 | [1] | 0 | 303 | [3] | 63 | 43 | 20 | |||||
Issue and exchange of other equity instruments | 98 | [3] | 256 | [3] | 311 | [1] | (55) | [3] | 231 | 304 | (73) | ||||||
Vesting of shares under employee share schemes | (150) | [3] | (150) | [3] | 197 | (347) | [3] | (14) | (14) | ||||||||
Dividends paid | (79) | [3] | 0 | ||||||||||||||
Other equity instruments coupons paid | (857) | [3] | (857) | [3] | (857) | [1] | (857) | (857) | |||||||||
Other reserve movements | 5 | [3] | (8) | [3] | 0 | (10) | [1] | 2 | [3] | ||||||||
Ending balance, equity at Dec. 31, 2020 | 66,882 | [3] | 65,797 | [3] | 4,637 | [1] | 11,172 | [1] | 4,461 | 45,527 | [3] | 54,872 | 4,637 | 11,169 | 394 | 38,672 | |
Profit after tax and other comprehensive income | 4,838 | [3],[4] | 4,791 | [3] | 804 | [1] | (2,861) | 6,848 | [3] | 4,343 | 804 | 3,539 | |||||
Issue of shares under employee share schemes | 295 | [3] | 295 | [3] | 60 | [1] | 0 | 235 | [3] | 89 | 60 | 29 | |||||
Issue and exchange of other equity instruments | 1,009 | [3] | 1,084 | [3] | 1,078 | [1] | 6 | [3] | 1,072 | 1,072 | |||||||
Vesting of shares under employee share schemes | (169) | [3] | (169) | [3] | 241 | (410) | [3] | (18) | (18) | ||||||||
Dividends paid | (556) | [3] | (512) | [3] | (512) | [3] | (512) | (512) | |||||||||
Other equity instruments coupons paid | (804) | [3] | (804) | [3] | (804) | [1] | (804) | (804) | |||||||||
Repurchase of shares | (1,200) | [3] | (1,200) | [3] | (161) | [1] | 0 | 161 | (1,200) | [3] | (1,200) | (161) | 161 | (1,200) | |||
Other reserve movements | (14) | [3] | 10 | [3] | 0 | 9 | [1] | 8 | (7) | [3] | (5) | (5) | |||||
Ending balance, equity at Dec. 31, 2021 | £ 70,041 | [5] | £ 69,052 | [3] | £ 4,536 | [1] | £ 12,259 | [1] | £ 1,770 | £ 50,487 | [3] | £ 57,837 | £ 4,536 | £ 12,241 | £ 555 | £ 40,505 | |
[1] | For further details refer to Note 28. | ||||||||||||||||
[2] | For further details refer to Note 29. | ||||||||||||||||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||||||||||||||
[4] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details | ||||||||||||||||
[5] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Financial statements of Barcl_5
Financial statements of Barclays PLC, Parent company accounts - Cash flow statement £ in Millions, $ in Millions | 12 Months Ended | |||||
Dec. 31, 2021GBP (£) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | ||||
Reconciliation of profit before tax to net cash flows from operating activities: | ||||||
Profit/(loss) before tax | £ 8,194 | [1] | £ 3,065 | £ 4,357 | ||
Adjustment for non-cash items: | ||||||
Impairment (reversal)/charge of investment in subsidiary | (653) | [1] | 4,838 | 1,912 | ||
Other non-cash items | 3,093 | [1] | (2,977) | (280) | ||
Net cash from operating activities | 48,919 | [1] | 57,505 | (502) | ||
Net cash from investing activities | ||||||
Net cash from investing activities | 4,270 | [1] | (18,376) | (23,965) | ||
Cash flows from financing activities | ||||||
Issue of shares and other equity instruments | 1,118 | [1] | 1,165 | 3,582 | ||
Proceeds of borrowings and issuance of subordinated debt | 1,890 | [1] | 1,438 | 1,352 | ||
Repurchase of shares | 1,275 | [1] | 1,056 | 2,668 | ||
Other inflows (outflows) of cash, classified as investing activities | 7 | [1] | (12) | 84 | ||
Net cash from financing activities | 107 | [1] | 2,732 | 690 | ||
Net increase/(decrease) in cash and cash equivalents | 49,064 | [1] | 43,529 | (27,124) | ||
Cash and cash equivalents at beginning of year | 210,142 | [1] | 166,613 | 193,737 | ||
Cash and cash equivalents at end of year | 259,206 | [1] | 210,142 | [1] | 166,613 | |
Net cash generated from operating activities includes: | ||||||
Dividends received | 20 | 37 | 76 | |||
Barclays PLC | ||||||
Reconciliation of profit before tax to net cash flows from operating activities: | ||||||
Profit/(loss) before tax | 4,267 | (1,034) | 3,267 | |||
Adjustment for non-cash items: | ||||||
Impairment (reversal)/charge of investment in subsidiary | (2,573) | 2,573 | ||||
Other non-cash items | 383 | 528 | (582) | |||
Changes in operating assets and liabilities | 17 | 0 | 87 | |||
Net cash from operating activities | 2,094 | 2,067 | 2,772 | |||
Net cash from investing activities | ||||||
Net increase in loans and advances to subsidiaries of the parent | [2],[3] | (6,118) | (4,732) | (4,464) | ||
Capital contribution to and investment in subsidiary | (1,083) | (393) | (1,187) | |||
Net cash from investing activities | (7,201) | (5,125) | (5,651) | |||
Cash flows from financing activities | ||||||
Issue of shares and other equity instruments | 1,114 | 1,175 | 3,597 | |||
Redemption of other equity instruments | 0 | (898) | (2,668) | |||
Net increase in debt securities in issue | [4] | 4,939 | 3,720 | 2,588 | ||
Proceeds of borrowings and issuance of subordinated debt | 1,579 | 158 | 1,194 | |||
Repurchase of shares | 1,200 | 0 | 0 | |||
Dividends paid | (512) | 0 | (1,019) | |||
Coupons paid on other equity instruments | (804) | (857) | (813) | |||
Net cash from financing activities | 5,116 | 3,298 | 2,879 | |||
Net increase/(decrease) in cash and cash equivalents | 9 | 240 | 0 | |||
Cash and cash equivalents at beginning of year | 240 | 0 | 0 | |||
Cash and cash equivalents at end of year | 249 | 240 | 0 | |||
Net cash generated from operating activities includes: | ||||||
Dividends received | 1,356 | 763 | 1,560 | |||
Net interest (paid)/received | £ (161) | (175) | 214 | |||
Barclays PLC | Increase due to changes in accounting policy | ||||||
Adjustment for non-cash items: | ||||||
Net cash from operating activities | (4,732) | (4,464) | ||||
Net cash from investing activities | ||||||
Net cash from investing activities | £ 4,732 | £ 4,464 | ||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||
[2] | Following a review of the Barclays parent company cash flow statement, in order to make the cash flow statement more relevant, cash movements resulting from loans and advances to subsidiaries are now presented within investing activities, whereas previously they were presented in financing activities. Comparatives have been restated. The effect of this change was to increase the net cash outflow due to investing activities increased by £4,732m in 2020 and £4,464m in 2019, with the net cash inflow relating to financing activities increasing by the same amount . | |||||
[3] | Includes financial assets at fair value through the income statement. | |||||
[4] | Includes financial liabilities designated at fair value. |
Other disclosures - Risk Manage
Other disclosures - Risk Management and Principal Risks (audited) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of credit risk exposure [abstract] | |
Other disclosures - Risk Management and Principal Risks | Credit risk management (audited) The risk of loss to the Group from the failure of clients, customers or counterparties, including sovereigns, to fully honour their obligations to the Group, including the whole and timely payment of principal, interest, collateral and other receivables. Overview The credit risk that the Group faces arises from wholesale and retail loans and advances together with the counterparty credit risk arising from derivative contracts with clients; trading activities, including: debt securities, settlement balances with market counterparties, FVOCI (Fair Value through Other Comprehensive Income) assets and reverse repurchase loans. Credit risk management objectives are to: • maintain a framework of controls to oversee credit risk • identify, assess and measure credit risk clearly and accurately across the Group and within each separate business, from the level of individual facilities up to the total portfolio • control and plan credit risk taking in line with external stakeholder expectations and avoiding undesirable concentrations • monitor credit risk and adherence to agreed controls. Organisation, roles and responsibilities The first line of defence has primary responsibility for managing credit risk within the risk appetite and limits set by the Risk function, supported by a defined set of policies, standards and controls. In the entities, business risk committees (attended by the first line) monitor and review the credit risk profile of each business unit where the most material issues are escalated to the Retail Credit Risk Management Committee, Wholesale Credit Risk Management Committee and Group Risk Committee. Wholesale and retail portfolios are managed separately to reflect the differing nature of the assets; wholesale balances tend to be larger and are managed on an individual basis, while retail balances are greater in number but lesser in value and are, therefore, managed in aggregated segments. The responsibilities of the credit risk management teams in the businesses, the sanctioning team and other shared services include: sanctioning new credit agreements (principally wholesale); setting strategies for approval of transactions (principally retail); setting risk appetite; monitoring risk against limits and other parameters; maintaining robust processes, data gathering, quality, storage and reporting methods for effective credit risk management; performing effective turnaround and workout scenarios for wholesale portfolios via dedicated restructuring and recoveries teams; maintaining robust collections and recovery processes/units for retail portfolios; and review and validation of credit risk measurement models. The credit risk management teams in each legal entity are accountable to the relevant Legal Entity CRO, who reports to the Group CRO. For wholesale portfolios, credit risk managers are organised in sanctioning teams by geography, industry and/or product. In wholesale portfolios, credit risk approval is undertaken by experienced credit risk professionals operating within a clearly defined delegated authority framework, with only the most senior credit officers assigned the higher levels of delegated authority. The largest credit exposures, which are outside the Risk Sanctioning Unit or Risk Distribution Committee authority, require the support of a legal entity Senior Credit Officer. For exposures in excess of the legal entity Senior Credit Officer’s authority, approval by Group Senior Credit Officer/Board Risk Committee is also required. The Group Credit Risk Committee, attended by legal entity Senior Credit Officers, provides a formal mechanism for the Group Senior Credit Officer to exercise the highest level of credit authority over the most material Group single name exposures. Credit risk mitigation The Group employs a range of techniques and strategies to actively mitigate credit risks. These can broadly be divided into three types: • netting and set-off • collateral • risk transfer. Netting and set-off Credit risk exposures can be reduced by applying netting and set-off. For derivative transactions, the Group’s normal practice is, on a legal entity basis, to enter into standard master agreements with counterparties (e.g. ISDAs). These master agreements typically allow for netting of credit risk exposure to a counterparty resulting from derivative transactions against the obligations to the counterparty in the event of default, and so produce a lower net credit exposure. These agreements may also reduce settlement exposure (e.g. for foreign exchange transactions) by allowing payments on the same day in the same currency to be set-off against one another. Collateral The Group has the ability to call on collateral in the event of default of the counterparty, comprising: • home loans: a fixed charge over residential property in the form of houses, flats and other dwellings • wholesale lending: a fixed charge over commercial property and other physical assets, in various forms • other retail lending: includes charges over motor vehicles and other physical assets; second lien charges over residential property; and finance lease receivables • derivatives: the Group also often seeks to enter into a margin agreement (e.g. Credit Support Annex) with counterparties with which the Group has master netting agreements in place. These annexes to master agreements provide a mechanism for further reducing credit risk, whereby collateral (margin) is posted on a regular basis (typically daily) to collateralise the mark to market exposure of a derivative portfolio measured on a net basis • reverse repurchase agreements: collateral typically comprises highly liquid securities which have been legally transferred to the Group subject to an agreement to return them for a fixed price • financial guarantees and similar off-balance sheet commitments: cash collateral may be held against these arrangements. Risk transfer A range of instruments including guarantees, credit insurance, credit derivatives and securitisation can be used to transfer credit risk from one counterparty to another. These mitigate credit risk in two main ways: • if the risk is transferred to a counterparty which is more creditworthy than the original counterparty, then overall credit risk is reduced • where recourse to the first counterparty remains, both counterparties must default before a loss materialises. This is less likely than the default of either counterparty individually so credit risk is reduced. Detailed policies are in place to appropriately recognise and record credit risk mitigation. For more information, refer to pages 177 to 179 of the Barclays PLC Pillar 3 Report 2021 (unaudited). Market risk management (audited) The risk of loss arising from potential adverse changes in the value of the Group’s assets and liabilities from fluctuation in market variables including, but not limited to, interest rates, foreign exchange, equity prices, commodity prices, credit spreads, implied volatilities and asset correlations. Overview Market risk arises primarily as a result of client facilitation in wholesale markets, involving market-making activities, risk management solutions and execution of syndications. Upon execution of a trade with a client, the Group will look to hedge against the risk of the trade moving in an adverse direction. Mismatches between client transactions and hedges result in market risk due to changes in asset prices, volatility or correlations. Organisation, roles and responsibilities Market risk in the businesses resides primarily in Barclays International and Treasury. These businesses have the mandate to assume market risk. The front office and Treasury trading desks are responsible for managing market risk on a day-to-day basis, where they are required to understand and adhere to all limits applicable to their businesses. The Market Risk team supports the trading desks with the day-to-day limit management of market risk exposures through governance processes which are outlined in supporting market risk policies and standards. Market risk oversight and challenge is provided by business committees and Group committees, including the Market Risk Committee (MRC). The objectives of market risk management are to: • identify, understand and control market risk by robust measurement, limit setting, reporting and oversight • facilitate business growth within a controlled and transparent risk management framework • control market risk in the businesses according to the allocated appetite. To meet the above objectives, a governance structure is in place to manage these risks consistent with the ERMF. The BRC recommends market risk appetite to the Board for their approval. The Market Risk Principal Risk Lead (PR Lead) is responsible for the Market Risk Control Framework and, under delegated authority from the Group CRO, agrees with the business CROs a limit framework within the context of the approved market risk appetite. The MRC reviews and makes recommendations concerning the group-wide market risk profile. This includes overseeing the operation of the Market Risk Framework and associated standards and policies; reviewing market or regulatory issues and limits and utilisation. The committee is chaired by the PR Lead and attendees include the business heads of market risk and business aligned market risk managers. In addition to MRC, the Corporate and Investment Bank Risk Committee (‘CIBRC’) is the main forum in which market risk exposures are discussed and reviewed with senior business heads. The Committee is chaired by the CRO of Barclays International and meets weekly, covering current market events, notable market risk exposures, and key risk topics. New business initiatives are generally socialised at CIBRC before any changes to risk appetite or associated limits are considered in other governance committees. The head of each business is accountable for all market risks associated with its activities, while the head of the market risk team covering each business is responsible for implementing the risk control framework for market risk. For more information on market risk management, refer to the Barclays PLC Pillar 3 Report 2021 (unaudited). Management value at risk (VaR) VaR is an estimate of the potential loss arising from unfavourable market movements if the current positions were to be held unchanged for one business day. For internal market risk management purposes, a historical simulation methodology with a one-year equally weighted historical period, at the 95% confidence level is used for all trading books and some banking books. Limits are applied at the total level as well as by risk factor type, which are then cascaded down to particular trading desks and businesses by the market risk management function. See the market risk performance section for a review of management VaR. Treasury and capital risk management This comprises: Liquidity risk: The risk that the Group is unable to meet its contractual or contingent obligations or that it does not have the appropriate amount, tenor and composition of funding and liquidity to support its assets. Capital risk: The risk that the Group has an insufficient level or composition of capital to support its normal business activities and to meet its regulatory capital requirements under normal operating environments and stressed conditions (both actual and as defined for internal planning or regulatory testing purposes). This also includes the risk from the Group’s pension plans. Interest rate risk in the banking book: The risk that the Group is exposed to capital or income volatility because of a mismatch between the interest rate exposures of its (non-traded) assets and liabilities. The Treasury function manages treasury and capital risk exposure on a day-to-day basis with the Group Treasury Committee acting as the principal management body. The Treasury and Capital Risk function is responsible for oversight and provide insight into key capital, liquidity, interest rate risk in the banking book (IRRBB) and pension risk management activities. Liquidity risk management (audited) Overview The efficient management of liquidity is essential to the Group in order to retain the confidence of the financial markets and maintain the sustainability of the business. Treasury and Capital Risk have created a framework to manage all liquidity risk exposures under both normal and stressed conditions. The framework is designed to maintain liquidity resources that are sufficient in amount, quality and funding tenor profile to remain within the liquidity risk appetite as expressed by the Barclays PLC Board. The liquidity risk appetite is monitored against both internal and regulatory liquidity metrics. Organisation, roles and responsibilities Treasury has the primary responsibility for managing liquidity risk within the set risk appetite. Both Risk and Treasury contribute to the production of the Internal Liquidity Adequacy Assessment Process (ILAAP). The Treasury and Capital Risk function is responsible for the management and governance of the liquidity risk mandate, as defined by the Board. The framework established by treasury and capital risk is designed to deliver the appropriate term and structure of funding, consistent with the liquidity risk appetite set by the Board. The framework incorporates a range of ongoing business management tools to monitor, limit and stress test the Group’s balance sheet, contingent liabilities and the recovery plan. Limit setting and transfer pricing are tools that are designed to control the level of liquidity risk taken and drive the appropriate mix of funds. Together, these tools reduce the likelihood that a liquidity stress event could lead to an inability to meet Group’s obligations as they fall due. The Board approves the Group funding plan, internal stress tests, regulatory stress test results, recovery plan and liquidity risk appetite. The Group Treasury Committee is responsible for monitoring and managing liquidity risk in line with the Group’s funding management objectives, funding plan and risk appetite. The Treasury and Capital Risk Committee monitors and reviews the liquidity risk profile and control environment, providing second line oversight of the management of liquidity risk. The Board Risk Committee reviews the risk profile, and reviews liquidity risk appetite at least annually and the impact of stress scenarios on the Group funding plan/forecast in order to agree the Group’s projected funding abilities. Capital risk management (audited) Overview Capital risk is managed through ongoing monitoring and management of the capital position, regular stress testing and a robust capital governance framework. The objectives of the framework are to maintain adequate capital for the Group and legal entities to withstand the impact of the risks that may arise under normal and stressed conditions, and maintain adequate capital to cover current and forecast business needs and associated risks to provide a viable and sustainable business offering. Organisation, roles and responsibilities Treasury has the primary responsibility for managing and monitoring capital adequacy. The Treasury and Capital Risk function provides oversight of capital risk. Production of the Barclays PLC Internal Capital Adequacy Assessment Process (ICAAP) is the responsibility of Treasury. Capital risk management is underpinned by a control framework and policy. The capital management strategy, outlined in the Group and legal entity capital plans, is developed in alignment with the control framework and policy for capital risk, and is implemented consistently in order to deliver on the Group’s objectives. The Board approves the Group capital plan, internal stress tests and results of regulatory stress tests, and the Group recovery plan. The Group Treasury Committee is responsible for monitoring and managing capital risk in line with the Group’s capital management objectives, capital plan and risk frameworks. The Treasury and Capital Risk Committee monitors and reviews the capital risk profile and control environment, providing second line oversight of the management of capital risk. The BRC reviews the risk profile, and reviews risk appetite at least annually and the impact of stress scenarios on the Group capital plan/forecast in order to agree the Group’s projected capital adequacy. Local management assures compliance with an entity’s minimum regulatory capital requirements by reporting to local Asset and Liability Committees (ALCOs) with oversight by the Group Treasury Committee, as required. In 2021, Barclays complied with all regulatory minimum capital requirements. Pension risk The Group maintains a number of defined benefit pension schemes for past and current employees. The ability of schemes to meet pension payments is achieved with investments and contributions. Maximum exposure and effects of netting, collateral and risk transfer (audited) Maximum exposure Netting and set-off Cash collateral Non-cash collateral Risk transfer Net exposure As at 31 December 2021 £m £m £m £m £m £m On-balance sheet: Cash and balances at central banks 238,574 — — — — 238,574 Cash collateral and settlement balances 92,542 — — — — 92,542 Loans and advances at amortised cost: Home loans 169,205 — (339) (168,627) (146) 93 Credit cards, unsecured loans and other retail lending 41,793 — (1,050) (4,560) (252) 35,931 Wholesale loans 150,453 (5,001) (128) (42,691) (23,104) 79,529 Total loans and advances at amortised cost 361,451 (5,001) (1,517) (215,878) (23,502) 115,553 Of which credit-impaired (Stage 3): Home loans 1,725 — (11) (1,714) — — Credit cards, unsecured loans and other retail lending 828 — (29) (229) (3) 567 Wholesale loans 2,161 — (1) (717) (765) 678 Total credit-impaired loans and advances at amortised cost 4,714 — (41) (2,660) (768) 1,245 Reverse repurchase agreements and other similar secured lending 3,227 — — (3,227) — — Trading portfolio assets: Debt securities 50,864 — — (461) — 50,403 Traded loans 12,525 — — (268) — 12,257 Total trading portfolio assets 63,389 — — (729) — 62,660 Financial assets at fair value through the income statement: Loans and advances 38,667 — — (31,263) — 7,404 Debt securities 2,305 — — (319) — 1,986 Reverse repurchase agreements 145,014 — (1,428) (143,057) — 529 Other financial assets 111 — — — — 111 Total financial assets at fair value through the income statement 186,097 — (1,428) (174,639) — 10,030 Derivative financial instruments 262,572 (202,519) (34,598) (5,887) (5,738) 13,830 Financial assets at fair value through other comprehensive income 60,851 — — (53) (1,164) 59,634 Other assets 1,212 — — — — 1,212 Total on-balance sheet 1,269,915 (207,520) (37,543) (400,413) (30,404) 594,035 Off-balance sheet: Contingent liabilities 21,346 — (906) (1,367) (256) 18,817 Loan commitments 345,711 — (141) (44,777) (1,668) 299,125 Total off-balance sheet 367,057 — (1,047) (46,144) (1,924) 317,942 Total 1,636,972 (207,520) (38,590) (446,557) (32,328) 911,977 Off-balance sheet exposures are shown gross of provisions of £542m (2020: £1,064m ) . See Note 25 for further details. In addition to the above, the Group holds forward starting reverse repos with notional contract amounts of £39.3bn (2020: £34.6bn). These balances are fully collateralised. Wholesale loans and advances at amortised cost include £11.4bn (2020: £12.2bn) of BBLs, CBILs and CLBILs supported by UK government guarantees of £11.0bn (2020: £11.7bn), which are included within the Risk transfer column in the table. For further information on credit risk mitigation techniques, refer to the Credit risk management section. Maximum exposure and effects of netting, collateral and risk transfer (audited) Maximum exposure Netting and set-off Cash collateral Non-cash collateral Risk transfer Net exposure As at 31 December 2020 £m £m £m £m £m £m On-balance sheet: Cash and balances at central banks 191,127 — — — — 191,127 Cash collateral and settlement balances 101,367 — — — — 101,367 Loans and advances at amortised cost: Home loans 159,647 — (284) (159,203) (85) 75 Credit cards, unsecured loans and other retail lending 40,813 — (967) (3,825) (195) 35,826 Wholesale loans 142,172 (6,988) (62) (37,103) (23,963) 74,056 Total loans and advances at amortised cost 342,632 (6,988) (1,313) (200,131) (24,243) 109,957 Of which credit-impaired (Stage 3): Home loans 1,813 — (14) (1,796) — 3 Credit cards, unsecured loans and other retail lending 921 — (14) (237) (2) 668 Wholesale loans 2,525 — (4) (872) (232) 1,417 Total credit-impaired loans and advances at amortised cost 5,259 — (32) (2,905) (234) 2,088 Reverse repurchase agreements and other similar secured lending 9,031 — — (9,031) — — Trading portfolio assets: Debt securities 56,482 — — (391) — 56,091 Traded loans 8,348 — — (374) — 7,974 Total trading portfolio assets 64,830 — — (765) — 64,065 Financial assets at fair value through the income statement: Loans and advances 30,879 — (9) (23,677) — 7,193 Debt securities 1,693 — — (292) — 1,401 Reverse repurchase agreements 137,616 — (672) (136,537) — 407 Other financial assets 343 — — — — 343 Total financial assets at fair value through the income statement 170,531 — (681) (160,506) — 9,344 Derivative financial instruments 302,446 (233,080) (43,291) (4,773) (6,409) 14,893 Financial assets at fair value through other comprehensive income 77,927 — — (106) (1,385) 76,436 Other assets 850 — — — — 850 Total on-balance sheet 1,260,741 (240,068) (45,285) (375,312) (32,037) 568,039 Off-balance sheet: Contingent liabilities 21,609 — (1,095) (2,135) (282) 18,097 Loan commitments 333,049 — (128) (40,714) (1,520) 290,687 Total off-balance sheet 354,658 — (1,223) (42,849) (1,802) 308,784 Total 1,615,399 (240,068) (46,508) (418,161) (33,839) 876,823 Loans and advances at amortised cost by stage (audited) Gross exposure Impairment allowance Net exposure Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total As at 31 December 2021 £m £m £m £m £m £m £m £m £m Barclays UK 160,695 22,779 2,915 186,389 261 949 728 1,938 184,451 Barclays International 25,981 2,691 1,566 30,238 603 795 858 2,256 27,982 Head Office 3,735 429 705 4,869 2 36 347 385 4,484 Total Barclays Group retail 190,411 25,899 5,186 221,496 866 1,780 1,933 4,579 216,917 Barclays UK 35,571 1,917 969 38,457 153 43 111 307 38,150 Barclays International 92,341 13,275 1,059 106,675 187 192 458 837 105,838 Head Office 542 2 21 565 — — 19 19 546 Total Barclays Group wholesale a 128,454 15,194 2,049 145,697 340 235 588 1,163 144,534 Total loans and advances at amortised cost 318,865 41,093 7,235 367,193 1,206 2,015 2,521 5,742 361,451 Off-balance sheet loan commitments and financial guarantee contracts b 312,142 34,815 1,298 348,255 217 302 23 542 347,713 Total c 631,007 75,908 8,533 715,448 1,423 2,317 2,544 6,284 709,164 Loan impairment charge and loan loss rate Coverage ratio Loan impairment charge/(release) Loan loss rate Stage 1 Stage 2 Stage 3 Total As at 31 December 2021 % % % % £m bps Barclays UK 0.2 4.2 25.0 1.0 (227) — Barclays International 2.3 29.5 54.8 7.5 181 60 Head Office 0.1 8.4 49.2 7.9 — — Total Barclays Group retail 0.5 6.9 37.3 2.1 (46) — Barclays UK 0.4 2.2 11.5 0.8 122 32 Barclays International 0.2 1.4 43.2 0.8 (197) — Head Office — — 90.5 3.4 — — Total Barclays Group wholesale a 0.3 1.5 28.7 0.8 (75) — Total loans and advances at amortised cost 0.4 4.9 34.8 1.6 (121) — Off-balance sheet loan commitments and financial guarantee contracts b — 0.9 1.8 0.2 (514) Other financial assets subject to impairment c (18) Total 0.2 3.1 29.8 0.9 (653) Notes a Includes Wealth and Private Banking exposures measured on an individual customer exposure basis, and excludes Business Banking exposures, including BBLs of £9.4bn that are managed on a collective basis and reported within BUK Retail. The net impact is a difference in total exposure of £5,994m of balances reported as wholesale loans in the Loans and advances at amortised cost by product disclosure. b Excludes loan commitments and financial guarantees of £18.8bn carried at fair value. c Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £155.2bn and impairment allowance of £114m. This comprises £6m ECL on £154.9bn Stage 1 assets, £1m on £157m Stage 2 fair value through other comprehensive income assets, other assets, cash collateral and settlement assets and £107m on £110m Stage 3 other assets. Loans and advances at amortised cost by stage (audited) Gross exposure Impairment allowance Net exposure Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total As at 31 December 2020 £m £m £m £m £m £m £m £m £m Barclays UK 153,250 23,896 2,732 179,878 332 1,509 1,147 2,988 176,890 Barclays International a 21,048 5,500 1,992 28,540 396 1,329 1,205 2,930 25,610 Head Office 4,267 720 844 5,831 4 51 380 435 5,396 Total Barclays Group retail 178,565 30,116 5,568 214,249 732 2,889 2,732 6,353 207,896 Barclays UK 31,918 4,325 1,126 37,369 13 129 116 258 37,111 Barclays International a 79,911 16,565 2,270 98,746 288 546 859 1,693 97,053 Head Office 570 — 33 603 — — 31 31 572 Total Barclays Group wholesale b 112,399 20,890 3,429 136,718 301 675 1,006 1,982 134,736 Total loans and advances at amortised cost 290,964 51,006 8,997 350,967 1,033 3,564 3,738 8,335 342,632 Off-balance sheet loan commitments and financial guarantee contracts c 289,939 52,891 2,330 345,160 256 758 50 1,064 344,096 Total d 580,903 103,897 11,327 696,127 1,289 4,322 3,788 9,399 686,728 Loan impairment charge and loan loss rate Coverage ratio Loan impairment charge Loan loss rate Stage 1 Stage 2 Stage 3 Total As at 31 December 2020 % % % % £m bps Barclays UK 0.2 6.3 42.0 1.7 1,070 59 Barclays International a 1.9 24.2 60.5 10.3 1,680 589 Head Office 0.1 7.1 45.0 7.5 91 156 Total Barclays Group retail 0.4 9.6 49.1 3.0 2,841 133 Barclays UK — 3.0 10.3 0.7 154 41 Barclays International a 0.4 3.3 37.8 1.7 914 93 Head Office — — 93.9 5.1 — — Total Barclays Group wholesale b 0.3 3.2 29.3 1.4 1,068 78 Total loans and advances at amortised cost 0.4 7.0 41.5 2.4 3,909 111 Off-balance sheet loan commitments and financial guarantee contracts c 0.1 1.4 2.1 0.3 776 Other financial assets subject to impairment d 153 Total e 0.2 4.2 33.4 1.4 4,838 Notes a Private Banking have refined the methodology to classify £5bn of their exposure between Wholesale and Retail during the year. b Included in the above analysis are Wealth and Private Banking exposures measured on an individual customer exposure basis, and excludes Business Banking exposures that are managed on a collective basis. The net impact is a difference in total exposure of £7,551m of balances reported as wholesale loans in the Loans and advances at amortised cost by product disclosure. c Excludes loan commitments and financial guarantees of £9.5bn carried at fair value. d Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £180.3bn and impairment allowance of £165m. This comprises £11m ECL on £175.7bn Stage 1 assets £9m on £4.4bn Stage 2 fair value through other comprehensive income assets, cash collateral and settlement balances and £145m on £154m Stage 3 other assets. e The loan loss rate is 138bps after applying the total impairment charge of £4,838m. Loans and advances at amortised cost by product (audited) The table below presents a breakdown of loans and advances at amortised cost and the impairment allowance with stage allocation by asset classification. Loans and advances at amortised cost by product (audited) Stage 2 As at 31 December 2021 Stage 1 Not past due <=30 days past due >30 days past due Total Stage 3 Total Gross exposure £m £m £m £m £m £m £m Home loans 148,058 17,133 1,660 707 19,500 2,122 169,680 Credit cards, unsecured loans and other retail lending 37,840 5,102 300 248 5,650 2,332 45,822 Wholesale loans 132,967 15,246 306 391 15,943 2,781 151,691 Total 318,865 37,481 2,266 1,346 41,093 7,235 367,193 Impairment allowance Home loans 19 46 6 7 59 397 475 Credit cards, unsecured loans and other retail lending 824 1,493 85 123 1,701 1,504 4,029 Wholesale loans 363 248 4 3 255 620 1,238 Total 1,206 1,787 95 133 2,015 2,521 5,742 Net exposure Home loans 148,039 17,087 1,654 700 19,441 1,725 169,205 Credit cards, unsecured loans and other retail lending 37,016 3,609 215 125 3,949 828 41,793 Wholesale loans 132,604 14,998 302 388 15,688 2,161 150,453 Total 317,659 35,694 2,171 1,213 39,078 4,714 361,451 Coverage ratio % % % % % % % Home loans — 0.3 0.4 1.0 0.3 18.7 0.3 Credit cards, unsecured loans and other retail lending 2.2 29.3 28.3 49.6 30.1 64.5 8.8 Wholesale loans 0.3 1.6 1.3 0.8 1.6 22.3 0.8 Total 0.4 4.8 4.2 9.9 4.9 34.8 1.6 As at 31 December 2020 Gross exposure £m £m £m £m £m £m £m Home loans 138,639 16,651 1,785 876 19,312 2,234 160,185 Credit cards, unsecured loans and other retail lending 33,021 9,470 544 306 10,320 3,172 46,513 Wholesale loans 119,304 19,501 1,097 776 21,374 3,591 144,269 Total 290,964 45,622 3,426 1,958 51,006 8,997 350,967 Impairment allowance Home loans 33 57 13 14 84 421 538 Credit cards, unsecured loans and other retail lending 680 2,382 180 207 2,769 2,251 5,700 Wholesale loans 320 650 50 11 711 1,066 2,097 Total 1,033 3,089 243 232 3,564 3,738 8,335 Net exposure Home loans 138,606 16,594 1,772 862 19,228 1,813 159,647 Credit cards, unsecured loans and other retail lending 32,341 7,088 364 99 7,551 921 40,813 Wholesale loans 118,984 18,851 1,047 765 20,663 2,525 142,172 Total 289,931 42,533 3,183 1,726 47,442 5,259 342,632 Coverage ratio % % % % % % % Home loans — 0.3 0.7 1.6 0.4 18.8 0.3 Credit cards, unsecured loans and other retail lending 2.1 25.2 33.1 67.6 26.8 71.0 12.3 Wholesale loans 0.3 3.3 4.6 1.4 3.3 29.7 1.5 Total 0.4 6.8 7.1 11.8 7.0 41.5 2.4 The increase in coverage on Credit cards, unsecured loans and other retail lending Stage 2 not past due is driven by a reduction in balances and the economic uncertainty adjustments held for specific customers and clients who may be more vulnerable to the full withdrawal of support and emerging economic uncertainty. Movement in gross exposures and impairment allowance including provisions for loan commitments and financial guarantees The following tables present a reconciliation of the opening to the closing balance of the exposure and impairment allowance. An explanation of the methodology used to determine credit impairment provisions is included in Note 7. Transfers between stages in the tables have been reflected as if they had taken place at the beginning of the year. The movements are measured over a 12-month period. Loans and advances at amortised cost (audited) Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2021 138,639 33 19,312 84 2,234 421 160,185 538 Transfers from Stage 1 to Stage 2 (7,672) (2) 7,672 2 — — — — Transfers from Stage 2 to Stage 1 5,336 32 (5,336) (32) — — — — Transfers to Stage 3 (282) — (469) (9) 751 9 — — Transfers from Stage 3 35 1 203 5 (238) (6) — — Business activity in the year a 32,744 7 1,243 5 4 — 33,991 12 Refinements to models used for calculation b — — — (4) — 38 — 34 Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes (8,131) (50) (1,090) 12 (216) (26) (9,437) (64) Final repayments (12,039) (2) (2,009) (4) (392) (18) (14,440) (24) Disposals c (572) — (26) — — — (598) — Write-offs d — — — — (21) (21) (21) (21) As at 31 December 2021 e 148,058 19 19,500 59 2,122 397 169,680 475 Credit cards, unsecured loans and other retail lending As at 1 January 2021 33,021 680 10,320 2,769 3,172 2,251 46,513 5,700 Transfers from Stage 1 to Stage 2 (1,894) (78) 1,894 78 — — — — Transfers from Stage 2 to Stage 1 4,717 1,174 (4,717) (1,174) — — — — Transfers to Stage 3 (529) (22) (790) (370) 1,319 392 — — Transfers from Stage 3 55 26 32 19 (87) (45) — — Business activity in the year a 7,842 119 257 62 42 19 8,141 200 Refinements to models used for calculation b — (5) — (33) — 14 — (24) Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes f (2,793) (1,030) (848) 389 (165) 620 (3,806) (21) Final repayments (2,579) (40) (498) (39) (212) (92) (3,289) (171) Disposals c — — — — (287) (205) (287) ( |
Significant accounting policies
Significant accounting policies | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of objectives, policies and processes for managing capital [abstract] | |
Significant accounting policies | Significant accounting policies 1. Reporting entity Barclays PLC is a public company limited by shares registered in England under company number 48839, having its registered office at 1 Churchill Place, London, E14 5HP. These financial statements are prepared for Barclays PLC and its subsidiaries (the Group) under Section 399 of the Companies Act 2006. The Group is a major global financial services provider engaged in retail banking, credit cards, wholesale banking, investment banking, wealth management and investment management services. In addition, separate financial statements have been presented for the holding company. 2. Compliance with International Financial Reporting Standards The consolidated financial statements of the Group, and the separate financial statements of Barclays PLC, have been prepared in accordance with UK-adopted international accounting standards. The consolidated financial statements of the Group, and the separate financial statements of Barclays PLC, have also been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB), including interpretations issued by the IFRS Interpretations Committee, as there are no applicable differences from IFRS as issued by the IASB for the periods presented. The principal accounting policies applied in the preparation of the consolidated and separate financial statements are set out below, and in the relevant notes to the financial statements. These policies have been consistently applied, with the exception of the Interest Rate Benchmark Reform Phase 2 amendments (amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16) which were applied from 1 January 2020. 3. Basis of preparation The consolidated and separate financial statements have been prepared under the historical cost convention modified to include the fair valuation of investment property, and particular financial instruments, to the extent required or permitted under IFRS as set out in the relevant accounting policies. These financial statements are stated in millions of pounds Sterling (£m), the functional currency of Barclays PLC. The financial statements have been prepared for Barclays PLC and its subsidiaries (the Group) under Section 399 of the Companies Act 2006 as applicable to companies using IFRS. The financial statements are prepared on a going concern basis, as the Board is satisfied that the Group and the parent company have the resources to continue in business for a period of at least 12 months from approval of the financial statements. In making this assessment, the Board has considered a wide range of information relating to present and future conditions and includes a review of a working capital report (WCR). The WCR is used by the Board to assess the future performance of the Group and that it has the resources in place that are required to meet its ongoing regulatory requirements. The assessment is based upon business plans which contain future projections of profitability taken from the Group’s medium-term plan as well as projections of regulatory capital requirements and business funding needs. The WCR also includes an assessment of the impact of internally generated stress testing scenarios on the liquidity and capital requirement forecasts. The stress tests used were based upon an assessment of reasonably possible downside economic scenarios that the Group could experience. The WCR showed that the Group had sufficient capital and liquidity in place to support its future business requirements and remained above its regulatory minimum requirements in the stress scenarios. Accordingly, the Directors concluded that there was a reasonable expectation that the Group and parent company has adequate resources to continue as a Going Concern for a period of at least 12 months from the date of approval of the financial statements. 4. Accounting policies The Group prepares financial statements in accordance with IFRS. The Group’s significant accounting policies relating to specific financial statement items, together with a description of the accounting estimates and judgements that were critical to preparing those items, are set out under the relevant notes. Accounting policies that affect the financial statements as a whole are set out below. (i) Consolidation The Group applies IFRS 10 Consolidated financial statements. The consolidated financial statements combine the financial statements of Barclays PLC and all its subsidiaries. Subsidiaries are entities over which Barclays PLC has control. The Group has control over another entity when the Group has all of the following: 1) power over the relevant activities of the investee, for example through voting or other rights 2) exposure to, or rights to, variable returns from its involvement with the investee, and 3) the ability to affect those returns through its power over the investee. The assessment of control is based on the consideration of all facts and circumstances. The Group reassesses whether it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Intra-group transactions and balances are eliminated on consolidation. Consistent accounting policies are used throughout the Group for the purposes of the consolidation. Changes in ownership interests in subsidiaries are accounted for as equity transactions if they occur after control has already been obtained and they do not result in loss of control. As the consolidated financial statements include partnerships where the Group member is a partner, advantage has been taken of the exemption under Regulation 7 of the Partnership (Accounts) Regulations 2008 with regard to preparing and filing of individual partnership financial statements. Details of the principal subsidiaries are given in Note 34. (ii) Foreign currency translation The Group applies IAS 21 The Effects of Changes in Foreign Exchange Rates. Transactions in foreign currencies are translated into Sterling at the rate ruling on the date of the transaction. Foreign currency monetary balances are translated into Sterling at the period end exchange rates. Exchange gains and losses on such balances are taken to the income statement. Non-monetary foreign currency balances in relation to items measured in terms of historical cost are carried at historical transaction date exchange rates. Non-monetary foreign currency balances in relation to items measured at fair value are translated using the exchange rate at the date when the fair value was measured. The Group’s foreign operations (including subsidiaries, joint ventures, associates and branches) based mainly outside the UK may have different functional currencies. The functional currency of an operation is the currency of the main economy to which it is exposed. Prior to consolidation (or equity accounting) the assets and liabilities of non-Sterling operations are translated at the period end exchange rate and items of income, expense and other comprehensive income are translated into Sterling at the rate on the date of the transactions. Exchange differences arising on the translation of foreign operations are included in currency translation reserves within equity. These are transferred to the income statement when the Group disposes of the entire interest in a foreign operation, when partial disposal results in the loss of control of an interest in a subsidiary, when an investment previously accounted for using the equity method is accounted for as a financial asset, or on the disposal of a foreign operation within a branch. (iii) Financial assets and liabilities The Group applies IFRS 9 Financial Instruments to the recognition, classification and measurement, and derecognition of financial assets and financial liabilities and the impairment of financial assets. The Group applies the requirements of IAS 39 Financial Instruments: Recognition and Measurement for hedge accounting purposes. Recognition The Group recognises financial assets and liabilities when it becomes a party to the terms of the contract. Trade date or settlement date accounting is applied depending on the classification of the financial asset. Classification and measurement Financial assets are classified on the basis of two criteria: i) the business model within which financial assets are managed, and ii) their contractual cash flow characteristics (whether the cash flows represent ‘solely payments of principal and interest’ (SPPI)). The Group assesses the business model criteria at a portfolio level. Information that is considered in determining the applicable business model includes (i) policies and objectives for the relevant portfolio, (ii) how the performance and risks of the portfolio are managed, evaluated and reported to management, and (iii) the frequency, volume and timing of sales in prior periods, sales expectation for future periods, and the reasons for such sales. The contractual cash flow characteristics of financial assets are assessed with reference to whether the cash flows represent SPPI. In assessing whether contractual cash flows are SPPI compliant, interest is defined as consideration primarily for the time value of money and the credit risk of the principal outstanding. The time value of money is defined as the element of interest that provides consideration only for the passage of time and not consideration for other risks or costs associated with holding the financial asset. Terms that could change the contractual cash flows so that it would not meet the condition for SPPI are considered, including: (i) contingent and leverage features, (ii) non-recourse arrangements and (iii) features that could modify the time value of money. Financial assets are measured at amortised cost if they are held within a business model whose objective is to hold financial assets in order to collect contractual cash flows, and their contractual cash flows represent SPPI. Financial assets are measured at fair value through other comprehensive income if they are held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets, and their contractual cash flows represent SPPI. Other financial assets are measured at fair value through profit and loss. There is an option to make an irrevocable election on initial recognition for non traded equity investments to be measured at fair value through other comprehensive income, in which case dividends are recognised in profit or loss, but gains or losses are not reclassified to profit or loss upon derecognition, and the impairment requirements of IFRS 9 do not apply. The accounting policy for each type of financial asset or liability is included within the relevant note for the item. The Group’s policies for determining the fair values of the assets and liabilities are set out in Note 17. Derecognition The Group derecognises a financial asset, or a portion of a financial asset, from its balance sheet where (i) the contractual rights to cash flows from the asset have expired, or (ii) the contractual rights to cash flows from the asset have been transferred (usually by sale) and with them either (a) substantially all the risks and rewards of the asset have been transferred, or (b) where neither substantially all the risks and reward have been transferred or retained, where control over the asset has been lost. Financial liabilities are de-recognised when the liability has been settled, has expired or has been extinguished. An exchange of an existing financial liability for a new liability with the same lender on substantially different terms – generally a difference of 10% or more in the present value of the cash flows or a substantive qualitative amendment – is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. Transactions in which the Group transfers assets and liabilities, portions of them, or financial risks associated with them can be complex and it may not be obvious whether substantially all of the risks and rewards have been transferred. It is often necessary to perform a quantitative analysis. Such an analysis compares the Group’s exposure to variability in asset cash flows before the transfer with its retained exposure after the transfer. A cash flow analysis of this nature may require judgement. In particular, it is necessary to estimate the asset’s expected future cash flows as well as potential variability around this expectation. The method of estimating expected future cash flows depends on the nature of the asset, with market and market-implied data used to the greatest extent possible. The potential variability around this expectation is typically determined by stressing underlying parameters to create reasonable alternative upside and downside scenarios. Probabilities are then assigned to each scenario. Stressed parameters may include default rates, loss severity, or prepayment rates. Accounting for reverse repurchase and repurchase agreements including other similar lending and borrowing Reverse repurchase agreements (and stock borrowing or similar transactions) are a form of secured lending whereby the Group provides a loan or cash collateral in exchange for the transfer of collateral, generally in the form of marketable securities subject to an agreement to transfer the securities back at a fixed price in the future. Repurchase agreements are where the Group obtains such loans or cash collateral, in exchange for the transfer of collateral. The Group purchases (a reverse repurchase agreement) or borrows securities subject to a commitment to resell or return them. The securities are not included in the balance sheet as the Group does not acquire the risks and rewards of ownership. Consideration paid (or cash collateral provided) is accounted for as a loan asset at amortised cost, unless it is designated or mandatorily at fair value through profit and loss. The Group may also sell (a repurchase agreement) or lend securities subject to a commitment to repurchase or redeem them. The securities are retained on the balance sheet as the Group retains substantially all the risks and rewards of ownership. Consideration received (or cash collateral provided) is accounted for as a financial liability at amortised cost, unless it is designated at fair value through profit and loss. (iv) Issued debt and equity instruments The Group applies IAS 32, Financial Instruments: Presentation, to determine whether funding is either a financial liability (debt) or equity. Issued financial instruments or their components are classified as liabilities if the contractual arrangement results in the Group having an obligation to either deliver cash or another financial asset, or a variable number of equity shares, to the holder of the instrument. If this is not the case, the instrument is generally an equity instrument and the proceeds included in equity, net of transaction costs. Dividends and other returns to equity holders are recognised when paid or declared by the members at the Annual General Meeting and treated as a deduction from equity. Where issued financial instruments contain both liability and equity components, these are accounted for separately. The fair value of the debt is estimated first and the balance of the proceeds is included within equity. (v) Changes in the basis for determining contractual cash flows resulting from interest rate benchmark reform A change in the basis of determining the contractual cash flows of a financial instrument that is required by interest rate benchmark reform is accounted for by updating the effective interest rate, without the recognition of an immediate gain or loss. This practical expedient is only applied where (1) the change to the contractual cash flows is necessary as a direct consequence of the reform and (2) the new basis for determining the contractual cash flows is economically equivalent to the previous basis. For changes made in addition to those required by the interest rate benchmark reform, the practical expedient is applied first, after which the normal IFRS 9 requirements for modifications of financial instruments is applied. Refer to Note 14 for further details regarding hedge accounting policies in respect of interest rate benchmark reform. Refer to Note 41 for further disclosure related to interest rate benchmark reform. (vi) Cash flow statement Cash comprises cash on hand and balances at central banks. Cash equivalents comprise loans and advances to banks, cash collateral balances with central banks related to payment schemes and treasury and other eligible bills, all with original maturities of three months or less. Repurchase and reverse repurchase agreements are not considered to be part of cash equivalents. Investments in debt securities at amortised cost, presented within loans and advances on the balance sheet, are deemed to be investing activities for the purposes of the cash flow statement, except those instruments considered to be cash equivalents. Debt securities issued and redeemed are considered to be operating activities, except qualifying eligible liabilities that satisfy regulatory requirements for MREL instruments (or have previously satisfied these requirements since 2019 when they came into effect), which are considered to be financing activities. 5. New and amended standards and interpretations The accounting policies adopted have been consistently applied, with the exception of the Interest Rate Benchmark Reform Phase 2 amendments (amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16) which were applied from 1 January 2020. Future accounting developments The following accounting standards have been issued by the IASB but are not yet effective: IFRS 17 – Insurance contracts In May 2017, the IASB issued IFRS 17 Insurance Contracts, a comprehensive new accounting standard for insurance contracts covering recognition and measurement, presentation and disclosure. Once effective, IFRS 17 will replace IFRS 4 Insurance Contracts that was issued in 2005. IFRS 17 applies to all types of insurance contracts (i.e. life, non-life, direct insurance and re-insurance), regardless of the type of entities that issue them, as well as to certain guarantees and financial instruments with discretionary participation features. A few scope exceptions will apply. In June 2020, the IASB published amendments to IFRS 17. The amendments that are relevant to the Group are the scope exclusion for credit card contracts and similar contracts that provide insurance coverage, the optional scope exclusion for loan contracts that transfer significant insurance risk, and the clarification that only financial guarantees issued are in scope of IFRS 9. The amendments also defer the effective date of IFRS 17, including the above amendments, to annual reporting periods beginning on or after 1 January 2023. IFRS 17, including the 2020 amendments to IFRS 17, has been endorsed by the EU. Following the UK’s withdrawal from the EU on 31 December 2020, the UK-adopted international accounting standards will be applicable. IFRS 17, including the amendments to IFRS 17, has not yet been endorsed by the UK. The Group does not expect the impact of IFRS 17 to be material. Disclosure of Accounting Policies - Amendments to IAS 1 and IFRS Practice Statement 2 In February 2021 the IASB issued amendments to IAS 1 that require entities to disclose their material accounting policies rather than their significant accounting policies. The amendments to IFRS Practice Statement 2 provide guidance on the concept of materiality and its application to accounting policy information. Under the amendments, accounting policy information is material if, when considered together with other information included in an entity’s financial statements, it can reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements. The amendments are effective for annual periods beginning on or after 1 January 2023, and will be applied from that date. Definition of Accounting Estimate - Amendments to IAS 8 In February 2021 the IASB issued amendments to IAS 8 that replace the definition of a change in accounting estimates with a definition of accounting estimates. Under the new definition, accounting estimates are clarified as monetary amounts in financial statements that are subject to measurement uncertainty. Where an entity's accounting policy requires an item to be measured at monetary amounts that cannot be observed directly, it should develop an accounting estimate to achieve this objective. The amendments are effective for annual periods beginning on or after 1 January 2023, and will be applied from that date. 6. Critical accounting estimates and judgements The preparation of financial statements in accordance with IFRS requires the use of estimates. It also requires management to exercise judgement in applying the accounting policies. The key areas involving a higher degree of judgement or complexity or areas where assumptions are significant to the consolidated and individual financial statements are highlighted under the relevant note. Critical accounting estimates and judgements are disclosed in: ▪ Credit impairment charges on page 236 ▪ Tax on page 240 ▪ Fair value of financial instruments on page 255 ▪ Goodwill and intangible assets on page 270 ▪ Pensions and post-retirement benefits – obligations on page 290 ▪ Provisions including conduct and legal, competition and regulatory matters on page 274. 7. Other disclosures To improve transparency and ease of reference, by concentrating related information in one place, certain disclosures required under IFRS have been included within the Risk review section as follows: ▪ Credit risk on pages 116 to 117 and 123 to 158 ▪ Market risk on page 117 to 118 and 159 to 160 ▪ Treasury and capital risk – liquidity on pages 118 and 163 to 172 ▪ Treasury and capital risk – capital on pages 118 to 119 and 173 to 179. These disclosures are covered by the Audit opinion (included on pages 214 to 215) where referenced as audited. 1a Restatement of financial statements Barclays PLC has restated these financial statements to reflect both a provision and a contingent liability disclosure in respect of the impact of an over-issuance of securities in excess of the maximum aggregate offering price registered under BBPLC’s registration statement on Form F-3, as declared effective by the SEC in August 2019 (2019 F-3). Due to a historic SEC settlement order, at the time the 2019 F-3 was filed, BBPLC had ceased to be a “well-known seasoned issuer” (or WKSI) and had become an “ineligible issuer,” as defined in Rule 405 under the Securities Act of 1933, as amended (Securities Act), thus being required to register upfront a certain amount of securities with the SEC. In March 2022, BBPLC became aware that it had issued securities in the US in excess of the amount it had registered with the SEC under the 2019 F-3. It has been estimated that the maximum offering price set forth in the 2019 F-3 was exceeded in February 2021, with issuances through to March 2022 exceeding the $20.8bn limit by approximately $15bn. The securities that were issued in this period comprise structured notes and exchange traded notes (ETNs). As such, certain offers and sales of these securities were not made in compliance with the Securities Act, giving rise to rights of rescission for certain purchasers of the securities. Under Section 12(a)(1) of the Securities Act, certain purchasers of unregistered securities have a right to recover, upon the tender of such security, the consideration paid for such security with interest, less the amount of any income received, or damages if the purchaser no longer owns the security (the Rescission Price). As a result, BBPLC has elected to make a rescission offer to eligible purchasers of the relevant affected securities at the Rescission Price. |
Segmental reporting
Segmental reporting | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of operating segments [abstract] | |
Segmental reporting | Segmental reporting Presentation of segmental reporting The Group’s segmental reporting is in accordance with IFRS 8 Operating Segments . Operating segments are reported in a manner consistent with the internal reporting provided to the Executive Committee, which is responsible for allocating resources and assessing performance of the operating segments, and has been identified as the chief operating decision maker. All transactions between business segments are conducted on an arm’s-length basis, with intra-segment revenue and costs being eliminated in Head Office. Income and expenses directly associated with each segment are included in determining business segment performance. The Group is a British universal bank diversified by business, geography and income type, serving consumer and wholesale customers and clients globally and for segmental reporting purposes it defines its two operating divisions as Barclays UK and Barclays International. ▪ Barclays UK consists of our UK Personal Banking, UK Business Banking and Barclaycard Consumer UK businesses. These businesses are carried on by our UK ring-fenced bank (Barclays Bank UK PLC) and certain other entities within the Group. ▪ Barclays International consists of our Corporate and Investment Bank and Consumer, Cards and Payments businesses. These businesses are carried on by our non ring-fenced bank (Barclays Bank PLC) and its subsidiaries, and certain other entities within the Group. The below table also includes Head Office which comprises head office and legacy businesses, as well as the FTE employed by Barclays Execution Services. Analysis of results by business Barclays UK Restated a Barclays International Head Office Restated a Group Results £m £m £m £m For the year ended 31 December 2021 Total income 6,536 15,665 (261) 21,940 Credit impairment releases 365 288 — 653 Net operating income/(expenses) 6,901 15,953 (261) 22,593 Operating costs (4,357) (9,076) (659) (14,092) UK bank levy (36) (134) — (170) Litigation and conduct (37) (345) (15) (397) Total operating expenses (4,430) (9,555) (674) (14,659) Other net income b — 40 220 260 Profit/(loss) before tax 2,471 6,438 (715) 8,194 Total assets (£bn) 321.2 1,044.1 19.0 1,384.3 Number of employees (full time equivalent) c 7,100 10,400 64,100 81,600 Average number of employees (full time equivalent) 82,900 Notes a 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. b Other net income represents the share of post-tax results of associates and joint ventures, profit on disposal of subsidiaries, associates and joint ventures, and gains on acquisitions. c Barclays UK has transformed its business this year and consolidated all Customer Care employees, who directly serve customers, into Barclays Execution Services, within the Head Office segment, to improve customer service and experience. Costs are recharged, while FTE's are reported within Head Office, as at 31 December 2021 10,700 FTE were impacted by the move from Barclays UK to Head Office, prior years have not been restated. Barclays UK b Barclays International b Head Office Group results £m £m £m £m For the year ended 31 December 2020 Total income 6,347 15,921 (502) 21,766 Credit impairment charges (1,467) (3,280) (91) (4,838) Net operating income/(expenses) 4,880 12,641 (593) 16,928 Operating costs (4,270) (8,765) (399) (13,434) UK bank levy (50) (240) (9) (299) Litigation and conduct (32) (48) (73) (153) Total operating expenses (4,352) (9,053) (481) (13,886) Other net income/(expenses) a 18 28 (23) 23 Profit/(loss) before tax 546 3,616 (1,097) 3,065 Total assets (£bn) 289.1 1,041.8 18.6 1,349.5 Number of employees (full time equivalent) 21,300 10,800 50,900 83,000 Average number of employees (full time equivalent) 81,800 Notes a Other net income/(expenses) represents the share of post-tax results of associates and joint ventures, profit (or loss) on disposal of subsidiaries, associates and joint ventures, and gains on acquisitions. b On 1 April 2020, assets of £2.2bn relating to the Barclays Partner Finance business were moved from Barclays International to Barclays UK, with net operating income of £19m and loss before tax of £5m subsequently recognised in Barclays UK for the rest of 2020. The 2019 comparative figures have not been restated. Barclays UK Barclays International Head Group results £m £m £m £m For the year ended 31 December 2019 Total income 7,353 14,675 (396) 21,632 Credit impairment charges (712) (1,173) (27) (1,912) Net operating income/(expenses) 6,641 13,502 (423) 19,720 Operating costs (3,996) (9,163) (200) (13,359) UK bank levy (41) (174) (11) (226) Litigation and conduct (1,582) (116) (151) (1,849) Total operating expenses (5,619) (9,453) (362) (15,434) Other net income a — 69 2 71 Profit/(loss) before tax 1,022 4,118 (783) 4,357 Total assets (£bn) 257.8 861.4 21.0 1,140.2 Number of employees (full time equivalent) 21,400 11,200 48,200 80,800 Average number of employees (full time equivalent) 82,700 Note a Other net income represents the share of post-tax results of associates and joint ventures, profit (or loss) on disposal of subsidiaries, associates and joint ventures, and gains on acquisitions. Income by geographic region a 2021 2020 2019 For the year ended 31 December £m £m £m United Kingdom 11,256 11,211 11,809 Europe 2,372 2,059 1,754 Americas 7,199 7,425 7,064 Africa and Middle East 45 36 59 Asia 1,068 1,035 946 Total 21,940 21,766 21,632 . Income from individual countries which represent more than 5% of total income a 2021 2020 2019 For the year ended 31 December £m £m £m United Kingdom 11,256 11,211 11,809 United States 7,048 7,318 6,939 Note |
Net interest income
Net interest income | 12 Months Ended |
Dec. 31, 2021 | |
Analysis of income and expense [abstract] | |
Net interest income | Net interest income Accounting for interest income and expenses Interest income on loans and advances at amortised cost and financial assets at fair value through other comprehensive income, and interest expense on financial liabilities held at amortised cost, are calculated using the effective interest method which allocates interest, and direct and incremental fees and costs, over the expected lives of the assets and liabilities. The effective interest method requires the Group to estimate future cash flows, in some cases based on its experience of customers’ behaviour, considering all contractual terms of the financial instrument, as well as the expected lives of the assets and liabilities. The Group incurs certain costs to originate credit card balances with the most significant being co-brand partner fees. To the extent these costs are attributed to customers that continuously carry an outstanding balance (revolvers) and incremental to the origination of credit card balances, they are capitalised and subsequently included within the calculation of the effective interest rate. They are amortised to interest income over the period of expected repayment of the originated balance. Costs attributed to customers that settle their outstanding balances each period (transactors) are deferred on the balance sheet as a cost of obtaining a contract and amortised to fee and commission expense over the life of the customer relationship (refer to Note 4). There are no other individual estimates involved in the calculation of effective interest rates that are material to the results or financial position. 2021 2020 2019 £m £m £m Cash and balances at central banks 184 275 1,091 Loans and advances at amortised cost 9,540 10,180 12,450 Fair value through other comprehensive income 550 776 1,032 Negative interest on liabilities 248 68 13 Other 718 593 870 Interest and similar income 11,240 11,892 15,456 Deposits at amortised cost (561) (1,030) (2,449) Debt securities in issue a (1,340) (1,360) (1,906) Subordinated liabilities (507) (670) (1,068) Negative interest on assets (374) (344) (278) Other (385) (366) (348) Interest and similar expense (3,167) (3,770) (6,049) Net interest income 8,073 8,122 9,407 Note a Barclays has amended the presentation of the premium paid for purchased financial guarantees which are embedded in notes it issues directly to the market. From 2020 onwards, the full note coupon is presented as interest expense within net interest income. The financial guarantee element of the coupon had previously been recognised in net investment income. The comparatives of £25m in 2019 have not been restated. Interest and similar income presented above represents interest revenue calculated using the effective interest method. Costs to originate credit card balances of £652m (2020: £698m; 2019: £697m) have been amortised to interest and similar income during the year. Interest and similar income includes £37m (2020: £40m; 2019: £48m) accrued on impaired loans. Other interest expense includes £64m (2020: £70m; 2019:£76m) relating to IFRS 16 lease interest expenses. |
Net fee and commission income
Net fee and commission income | 12 Months Ended |
Dec. 31, 2021 | |
Fee and commission income (expense) [abstract] | |
Net fee and commission income | Net fee and commission income Accounting for net fee and commission income The Group applies IFRS 15 Revenue from Contracts with Customers. IFRS 15 establishes a five-step model governing revenue recognition. The five-step model requires the Group to (i) identify the contract with the customer, (ii) identify each of the performance obligations included in the contract, (iii) determine the amount of consideration in the contract, (iv) allocate the consideration to each of the identified performance obligations and (v) recognise revenue as each performance obligation is satisfied. The Group recognises fee and commission income charged for services provided by the Group as the services are provided, for example, on completion of the underlying transaction. Where the contractual arrangements also result in the Group recognising financial instruments in scope of IFRS 9, such financial instruments are initially recognised at fair value in accordance with IFRS 9 before applying the provisions of IFRS 15. Fee and commission income is disaggregated below by fee types that reflect the nature of the services offered across the Group and operating segments, in accordance with IFRS 15. The below table includes a total for fees in scope of IFRS 15. Refer to Note 2 for more detailed information about operating segments. 2021 Barclays UK Barclays International Head Office Total £m £m £m £m Fee type Transactional 871 2,572 — 3,443 Advisory 172 1,096 1 1,269 Brokerage and execution 228 1,135 — 1,363 Underwriting and syndication — 3,425 — 3,425 Other 74 182 3 259 Total revenue from contracts with customers 1,345 8,410 4 9,759 Other non-contract fee income — 121 — 121 Fee and commission income 1,345 8,531 4 9,880 Fee and commission expense (218) (1,983) (5) (2,206) Net fee and commission income 1,127 6,548 (1) 7,674 2020 Barclays UK Barclays International Head Office Total £m £m £m £m Fee type Transactional 810 2,353 — 3,163 Advisory 159 693 2 854 Brokerage and execution 212 1,173 — 1,385 Underwriting and syndication — 2,867 — 2,867 Other 71 173 9 253 Total revenue from contracts with customers 1,252 7,259 11 8,522 Other non-contract fee income — 119 — 119 Fee and commission income 1,252 7,378 11 8,641 Fee and commission expense (308) (1,754) (8) (2,070) Net fee and commission income 944 5,624 3 6,571 2019 Barclays UK Barclays International Head Office Total £m £m £m £m Fee type Transactional 1,074 2,809 — 3,883 Advisory 177 903 — 1,080 Brokerage and execution 208 1,131 — 1,339 Underwriting and syndication — 2,358 — 2,358 Other 92 242 12 346 Total revenue from contracts with customers 1,551 7,443 12 9,006 Other non-contract fee income — 116 — 116 Fee and commission income 1,551 7,559 12 9,122 Fee and commission expense (365) (1,990) (7) (2,362) Net fee and commission income 1,186 5,569 5 6,760 Fee types Transactional Transactional fees are service charges on deposit accounts, cash management services and transactional processing fees. These include interchange and merchant fee income generated from credit and bank card usage. Transaction and processing fees are recognised at the point in time the transaction occurs or service is performed. Interchange and merchant fees are recognised upon settlement of the card transaction payment. The Group incurs certain card related costs including those related to cardholder reward programmes and payments to co-brand partners. Cardholder reward programmes costs related to customers that settle their outstanding balance each period (transactors) are expensed when incurred and presented in fee and commission expense while costs related to customers that continuously carry an outstanding balance (revolvers) are included in the effective interest rate of the receivable (refer to Note 3). Payments to partners for new cardholder account originations related to transactor accounts are deferred as costs to obtain a contract under IFRS 15, while costs related to revolver accounts are included in the effective interest rate of the receivable (refer to Note 3). Those costs deferred under IFRS 15 are capitalised and amortised over the estimated life of the customer relationship. Payments to co-brand partners based on revenue sharing are presented as a reduction of fee and commission income while payments based on profitability are presented in fee and commission expense. Advisory Advisory fees are generated from wealth management services and investment banking advisory services related to mergers, acquisitions and financial restructurings. Wealth management advisory fees are earned over the period the services are provided and are generally recognised quarterly when the market value of client assets is determined. Investment banking advisory fees are recognised at the point in time when the services related to the transaction have been completed under the terms of the engagement. Investment banking advisory costs are recognised as incurred in fee and commission expense if direct and incremental to the advisory services or are otherwise recognised in operating expenses. Brokerage and execution Brokerage and execution fees are earned for executing client transactions with various exchanges and over-the-counter markets and assisting clients in clearing transactions. Brokerage and execution fees are recognised at the point in time the associated service has been completed which is generally the trade date of the transaction. Underwriting and syndication Underwriting and syndication fees are earned for the distribution of client equity or debt securities and the arrangement and administration of a loan syndication. This includes commitment fees to provide loan financing. Underwriting fees are generally recognised on trade date if there is no remaining contingency, such as the transaction being conditional on the closing of an acquisition or another transaction. Underwriting costs are deferred and recognised in fee and commission expense when the associated underwriting fees are recorded. Syndication fees are earned for arranging and administering a loan syndication; however, the associated fee may be subject to variability until the loan has been syndicated to other syndicate members or until other contingencies have been resolved and therefore the fee revenue is deferred until the uncertainty is resolved. Included in the underwriting and syndication fees are loan commitment fees which are not presented as part of the carrying value of the loan in accordance with IFRS 9. Such commitment fees are recognised over time through to the contractual maturity of the commitment. Contract assets and contract liabilities The Group had no material contract assets or contract liabilities as at 31 December 2021 (2020: £nil; 2019: £nil). Impairment of fee receivables and contract assets During 2021, there have been no material impairments recognised in relation to fees receivable and contract assets (2020: £nil; 2019: £nil). Fees in relation to transactional business can be added to outstanding customer balances. These amounts may be subsequently impaired as part of the overall loans and advances balance. Remaining performance obligations The Group applies the practical expedient of IFRS 15 and does not disclose information about remaining performance obligations that have original expected durations of one year or less or because the Group has a right to consideration that corresponds directly with the value of the service provided to the client or customer. Costs incurred in obtaining or fulfilling a contract The Group expects that incremental costs of obtaining a contract such as success fee and commission fees paid are recoverable and therefore capitalised such contract costs. Capitalised contract costs net of amortisation as at 31 December 2021 is £154m (2020: £141m; 2019: £159m). Capitalised contract costs are amortised based on the transfer of services to which the asset relates which typically ranges over the expected life of the relationship. In 2021, the amount of amortisation was £36m (2020: £36m; 2019: £30m) and there was no impairment loss recognised in connection with the capitalised contract costs (2020: £nil; 2019: £nil). |
Net trading income
Net trading income | 12 Months Ended |
Dec. 31, 2021 | |
Trading income (expense) [abstract] | |
Net trading income | Net trading income Accounting for net trading income In accordance with IFRS 9, trading positions are held at fair value, and the resulting gains and losses are included in the income statement, together with interest and dividends arising from long and short positions and funding costs relating to trading activities. Income arises from both the sale and purchase of trading positions, margins which are achieved through market making and customer business and from changes in fair value caused by movements in interest and exchange rates, equity prices and other market variables. Gains or losses on non-trading financial instruments designated or mandatorily at fair value with changes in fair value recognised in the income statement are included in net trading income where the business model is to manage assets and liabilities on a fair value basis which includes use of derivatives or where an instrument is designated at fair value to eliminate an accounting mismatch and the related instrument's gain and losses are reported in trading income. 2021 2020 2019 £m £m £m Net gains on financial instruments held for trading 3,992 5,342 2,941 Net gains on financial instruments designated at fair value 692 700 256 Net gains on financial instruments mandatorily at fair value 1,110 987 1,038 Net trading income 5,794 7,029 4,235 |
Net investment income
Net investment income | 12 Months Ended |
Dec. 31, 2021 | |
Gains (losses) on financial instruments [abstract] | |
Net investment income | Net investment income Accounting for net investment income Dividends are recognised when the right to receive the dividend has been established. Other accounting policies relating to net investment income are set out in Note 13 and Note 15. 2021 2020 2019 £m £m £m Net gains/(losses) from financial instruments mandatorily at fair value 73 (50) 510 Net gains from disposal of debt instruments at fair value through other comprehensive income 305 295 502 Net gains/(losses) from disposal of financial assets and liabilities measured at amortised cost a 114 (61) 257 Dividend income 20 37 76 Net (losses)/gains on other investments b (201) (208) (214) Net investment income 311 13 1,131 Notes a Included within the 2021 balance are gains of £83m relating to the sale of loans and advances at amortised cost. Included within the 2020 balance are losses of £115m relating to partial redemption of contingent capital notes. b Barclays has amended the presentation of the premium paid for purchased financial guarantees which are embedded in notes it issues directly to the market. From 2020 onwards, the full note coupon is presented as interest expense within net interest income. The financial guarantee element of the coupon had previously been recognised in net investment income. The comparative of £25m in 2019 has not been restated. |
Credit impairment charges_(rele
Credit impairment charges/(release) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of impairment loss and reversal of impairment loss [abstract] | |
Credit impairment charges/(release) | Credit impairment charge/(release) Accounting for the impairment of financial assets Impairment In accordance with IFRS 9, the Group is required to recognise expected credit losses (ECLs) based on unbiased forward-looking information for all financial assets at amortised cost, lease receivables, debt financial assets at fair value through other comprehensive income, loan commitments and financial guarantee contracts. At the reporting date, an allowance (or provision for loan commitments and financial guarantees) is required for the 12 month (Stage 1) ECLs. If the credit risk has significantly increased since initial recognition (Stage 2), or if the financial instrument is credit impaired (Stage 3), an allowance (or provision) should be recognised for the lifetime ECLs. The measurement of ECL is calculated using three main components: (i) probability of default (PD) (ii) loss given default (LGD) and (iii) the exposure at default (EAD). The 12 month and lifetime ECLs are calculated by multiplying the respective PD, LGD and the EAD. The 12 month and lifetime PDs represent the PD occurring over the next 12 months and the remaining maturity of the instrument respectively. The EAD represents the expected balance at default, taking into account the repayment of principal and interest from the balance sheet date to the default event together with any expected drawdowns of committed facilities. The LGD represents expected losses on the EAD given the event of default, taking into account, among other attributes, the mitigating effect of collateral value at the time it is expected to be realised and the time value of money. Determining a significant increase in credit risk since initial recognition: The Group assesses when a significant increase in credit risk has occurred based on quantitative and qualitative assessments. The credit risk of an exposure is considered to have significantly increased when: i) Quantitative test The annualised lifetime PD has increased by more than an agreed threshold relative to the equivalent at origination. PD deterioration thresholds are defined as percentage increases, and are set at an origination score band and segment level to ensure the test appropriately captures significant increases in credit risk at all risk levels. Generally, thresholds are inversely correlated to the origination PD, i.e. as the origination PD increases, the threshold value reduces. The assessment of the point at which a PD increase is deemed ‘significant’, is based upon analysis of the portfolio’s risk profile against a common set of principles and performance metrics (consistent across both retail and wholesale businesses), incorporating expert credit judgement where appropriate. Application of quantitative PD floors does not represent the use of the low credit risk exemption as exposures can separately move into Stage 2 via the qualitative route described below. Wholesale assets apply a 100% increase in PD and 0.2% PD floor to determine a significant increase in credit risk. Retail assets apply bespoke relative increase and absolute PD thresholds based on product type and origination PD. Thresholds are subject to maximums defined by Group policy and typically apply minimum relative thresholds of 50-100% and a maximum relative threshold of 400%. For existing/historical exposures where origination point scores or data are no longer available or do not represent a comparable estimate of lifetime PD, a proxy origination score is defined, based upon: • back-population of the approved lifetime PD score either to origination date or, where this is not feasible, as far back as possible (subject to a data start point no later than 1 January 2015); or • use of available historical account performance data and other customer information, to derive a comparable ‘proxy’ estimation of origination PD. ii) Qualitative test This is relevant for accounts that meet the portfolio’s ‘high risk’ criteria and are subject to closer credit monitoring. High risk customers may not be in arrears but either through an event or an observed behaviour exhibit credit distress. The definition and assessment of high risk includes as wide a range of information as reasonably available, such as industry and Group-wide customer level data, including but not limited to bureau scores and high consumer indebtedness index, wherever possible or relevant. Whilst the high risk populations applied for IFRS 9 impairment purposes are aligned with risk management processes, they are also regularly reviewed and validated to ensure that they capture any incremental segments where there is evidence of credit deterioration. iii) Backstop criteria This is relevant for accounts that are more than 30 calendar days past due. The 30 days past due criteria is a backstop rather than a primary driver of moving exposures into Stage 2. The criteria for determining a significant increase in credit risk for assets with bullet repayments follows the same principle as all other assets, i.e. quantitative, qualitative and backstop tests are all applied. Exposures will move back to Stage 1 once they no longer meet the criteria for a significant increase in credit risk. This means that, at a minimum all payments must be up-to-date, the PD deterioration test is no longer met, the account is no longer classified as high risk, and the customer has evidenced an ability to maintain future payments. Exposures are only removed from Stage 3 and re-assigned to Stage 2 once the original default trigger event no longer applies. Exposures being removed from Stage 3 must no longer qualify as credit impaired, and: a) the obligor will also have demonstrated consistently good payment behaviour over a 12-month period, by making all consecutive contractual payments due and, for forborne exposures, the relevant EBA defined probationary period has also been successfully completed or; b) (for non-forborne exposures) the performance conditions are defined and approved within an appropriately sanctioned restructure plan, including 12 months’ payment history have been met. Management overlays and other exceptions to model outputs are applied only if consistent with the objective of identifying significant increases in credit risk. Forward-looking information The measurement of ECL involves complexity and judgement, including estimation of PD, LGD, a range of unbiased future economic scenarios, estimation of expected lives (where contractual life is not appropriate), and estimation of EAD and assessing significant increases in credit risk. Credit losses are the expected cash shortfalls from what is contractually due over the expected life of the financial instrument, discounted at the original effective interest rate (EIR). ECLs are the unbiased probability-weighted credit losses determined by evaluating a range of possible outcomes and considering future economic conditions. The Group uses a five-scenario model to calculate ECL. An external consensus forecast is assembled from key sources, including HM Treasury (short and medium term forecasts), Bloomberg (based on median of economic forecasts) and the Urban Land Institute (for US House Prices), which forms the baseline scenario. In addition, two adverse scenarios (Downside 1 and Downside 2) and two favourable scenarios (Upside 1 and Upside 2) are derived, with associated probability weightings. The adverse scenarios are calibrated to a similar severity to internal stress tests, whilst also considering IFRS 9 specific sensitivities and non-linearity. Downside 2 is benchmarked to the Bank of England’s annual cyclical scenarios and to the most severe scenario from Moody’s inventory, but is not designed to be the same. The favourable scenarios are calibrated to be symmetric to the adverse scenarios, subject to a ceiling calibrated to relevant recent favourable benchmark scenarios. The scenarios include eight economic variables (GDP, unemployment, House Price Index (HPI) and base rates in both the UK and US markets) and expanded variables using statistical models based on historical correlations. The upside and downside shocks are designed to evolve over a five-year stress horizon, with all five scenarios converging to a steady state after approximately eight years. The methodology for estimating probability weights for each of the scenarios involves a comparison of the distribution of key historical UK and US macroeconomic variables against the forecast paths of the five scenarios. The methodology works such that the baseline (reflecting current consensus outlook) has the highest weight and the weights of adverse and favourable scenarios depend on the deviation from the baseline; the further from the baseline, the smaller the weight. A single set of five scenarios is used across all portfolios and all five weights are normalised to equate to 100%. The same scenarios and weights that are used in the estimation of expected credit losses are also used for the Group internal planning purposes. The impacts across the portfolios are different because of the sensitivities of each of the portfolios to specific macroeconomic variables, for example, mortgages are highly sensitive to house prices, and credit cards and unsecured consumer loans are highly sensitive to unemployment. Definition of default, credit impaired assets, write-offs, and interest income recognition The definition of default for the purpose of determining ECLs, and for internal credit risk management purposes, has been aligned to the Regulatory Capital CRR Article 178 definition of default, to maintain a consistent approach with IFRS 9 and associated regulatory guidance. The Regulatory Capital CRR Article 178 definition of default considers indicators that the debtor is unlikely to pay, includes exposures in forbearance and is no later than when the exposure is more than 90 days past due or 180 days past due in the case of UK mortgages. When exposures are identified as credit impaired at the time when they are purchased or originated interest income is calculated on the carrying value net of the impairment allowance. An asset is considered credit impaired when one or more events occur that have a detrimental impact on the estimated future cash flows of the financial asset. This comprises assets defined as defaulted and other individually assessed exposures where imminent default or actual loss is identified. Uncollectable loans are written off against the related allowance for loan impairment on completion of the Group’s internal processes and when all reasonably expected recoverable amounts have been collected. Subsequent recoveries of amounts previously written off are credited to the income statement. The timing and extent of write-offs may involve some element of subjective judgement. Nevertheless, a write-off will often be prompted by a specific event, such as the inception of insolvency proceedings or other formal recovery action, which makes it possible to establish that some or the entire advance is beyond realistic prospect of recovery. Accounting for purchased financial guarantee contracts The Group may enter into a financial guarantee contract which requires the issuer of such contract to reimburse the Group for a loss it incurs because a specified debtor fails to make payment when due in accordance with the terms of a debt instrument. For these separate financial guarantee contracts, the Group recognises a reimbursement asset aligned with the recognition of the underlying ECLs, if it is considered virtually certain that a reimbursement would be received if the specified debtor fails to make payment when due in accordance with the terms of the debt instrument. Loan modifications and renegotiations that are not credit-impaired When modification of a loan agreement occurs as a result of commercial restructuring activity rather than due to the credit risk of the borrower, an assessment must be performed to determine whether the terms of the new agreement are substantially different from the terms of the existing agreement. This assessment considers both the change in cash flows arising from the modified terms as well as the change in overall instrument risk profile. In respect of payment holidays granted to borrowers which are not due to forbearance, if the revised cash flows on a present value basis (based on the original EIR) are not substantially different from the original cash flows, the loan is not considered to be substantially modified. Where terms are substantially different, the existing loan will be derecognised and a new loan will be recognised at fair value, with any difference in valuation recognised immediately within the income statement, subject to observability criteria. Where terms are not substantially different, the loan carrying value will be adjusted to reflect the present value of modified cash flows discounted at the original EIR, with any resulting gain or loss recognised immediately within the income statement as a modification gain or loss. Note 1 sets out details for changes in the basis of determining the contractual cash flows of a financial instrument that are required by interest rate benchmark reform. Expected life Lifetime ECLs must be measured over the expected life. This is restricted to the maximum contractual life and takes into account expected prepayment, extension, call and similar options. The exceptions are certain revolving financial instruments, such as credit cards and bank overdrafts, that include both a drawn and an undrawn component where the entity’s contractual ability to demand repayment and cancel the undrawn commitment does not limit the entity’s exposure to credit losses to the contractual notice period. For revolving facilities, expected life is analytically derived to reflect the behavioural life of the asset, i.e. the full period over which the business expects to be exposed to credit risk. Behavioural life is typically based upon historical analysis of the average time to default, closure or withdrawal of facility. Where data is insufficient or analysis inconclusive, an additional ‘maturity factor’ may be incorporated to reflect the full estimated life of the exposures, based upon experienced judgement and/or peer analysis. Potential future modifications of contracts are not taken into account when determining the expected life or EAD until they occur. Discounting ECLs are discounted at the EIR at initial recognition or an approximation thereof and consistent with income recognition. For loan commitments the EIR is the rate that is expected to apply when the loan is drawn down and a financial asset is recognised. Issued financial guarantee contracts are discounted at the risk free rate. Lease receivables are discounted at the rate implicit in the lease. For variable/floating rate financial assets, the spot rate at the reporting date is used and projections of changes in the variable rate over the expected life are not made to estimate future interest cash flows or for discounting. Modelling techniques The regulatory Basel Committee of Banking Supervisors (BCBS) ECL calculations are leveraged for IFRS 9 modelling but adjusted for key differences which include: ▪ BCBS requires 12 month through the economic cycle losses whereas IFRS 9 requires 12 months or lifetime point in time losses based on conditions at the reporting date and multiple forecasts of the future economic conditions over the expected lives; ▪ IFRS 9 models do not include certain conservative BCBS model floors and downturn assessments and require discounting to the reporting date at the original EIR rather than using the cost of capital to the date of default; ▪ Management adjustments are made to modelled output to account for situations where known or expected risk factors and information have not been considered in the modelling process, for example forecast economic scenarios for uncertain political events; and ▪ ECL is measured at the individual financial instrument level, however a collective approach where financial instruments with similar risk characteristics are grouped together, with apportionment to individual financial instruments, is used where effects can only be seen at a collective level, for example for forward-looking information. For the IFRS 9 impairment assessment, the Group’s risk models are used to determine the PD, LGD and EAD. For Stage 2 and 3, the Group applies lifetime PDs but uses 12 month PDs for Stage 1. The ECL drivers of PD, EAD and LGD are modelled at an account level which considers vintage, among other credit factors. Also, the assessment of significant increase in credit risk is based on the initial lifetime PD curve, which accounts for the different credit risk underwritten over time. Forbearance A financial asset is subject to forbearance when it is modified due to the credit distress of the borrower. A modification made to the terms of an asset due to forbearance will typically be assessed as a non-substantial modification that does not result in derecognition of the original loan, except in circumstances where debt is exchanged for equity. Both performing and non-performing forbearance assets are classified as Stage 3 except where it is established that the concession granted has not resulted in diminished financial obligation and that no other regulatory definition of default criteria have been triggered, in which case the asset is classified as Stage 2. The minimum probationary period for non-performing forbearance is 12 months and for performing forbearance, 24 months. Hence, a minimum of 36 months is required for non-performing forbearance to move out of a forborne state. No financial instrument in forbearance can transfer back to Stage 1 until all of the Stage 2thresholds are no longer met and can only move out of Stage 3 when no longer credit impaired. Critical accounting estimates and judgements IFRS 9 impairment involves several important areas of judgement, including estimating forward looking modelled parameters (PD, LGD and EAD), developing a range of unbiased future economic scenarios, estimating expected lives and assessing significant increases in credit risk, based on the Group’s experience of managing credit risk. The determination of expected life is most material for Barclays credit card portfolios which is obtained via behavioural life analysis to materially capture the risk of these facilities. Within the retail and small businesses portfolios, which comprise large numbers of small homogenous assets with similar risk characteristics where credit scoring techniques are generally used, the impairment allowance is calculated using forward looking modelled parameters which are typically run at account level. There are many models in use, each tailored to a product, line of business or customer category. Judgement and knowledge is needed in selecting the statistical methods to use when the models are developed or revised. Management adjustments to impairment models, which contain an element of subjectivity, are applied in order to factor in certain conditions or changes in policy that are not fully incorporated into the impairment models, or to reflect additional facts and circumstances at the period end. Management adjustments are reviewed and incorporated into future model development where appropriate. The impairment release reflected in the income statement for retail portfolios is £289m (2020: £3,116m charge; 2019: £1,696m charge) of the total impairment release on loans and advances and off balance sheet loan commitments and financial guarantee contracts. For individually significant assets in Stage 3, impairment allowances are calculated on an individual basis and all relevant considerations that have a bearing on the expected future cash flows across a range of economic scenarios are taken into account. These considerations can be particularly subjective and can include the business prospects for the customer, the realisable value of collateral, the Group’s position relative to other claimants, the reliability of customer information and the likely cost and duration of the work-out process. The level of the impairment allowance is the difference between the value of the discounted expected future cash flows (discounted at the loan’s original effective interest rate), and its carrying amount. Furthermore, judgements change with time as new information becomes available or as work-out strategies evolve, resulting in frequent revisions to the impairment allowance as individual decisions are taken. Changes in these estimates would result in a change in the allowances and have a direct impact on the impairment charge. The impairment release reflected in the financial statements in relation to wholesale portfolios is £346m (2020: £1,569m charge; 2019: £208m release) of the total impairment release on loans and advances and off balance sheet loan commitments and financial guarantee contracts. Further information on impairment allowances, impairment charges, management adjustments to models for impairment, measurement uncertainty, sensitivity analysis and related credit information is set out within the Credit risk performance section. Temporary adjustments to calculated IFRS9 impairment allowances may be applied in limited circumstances to account for situations where known or expected risk factors or information have not been considered in the ECL assessment or modelling process. For further information please see page 135 in the credit risk performance section. 2021 2020 2019 Impairment charges Recoveries and reimburse-ments a Total Impairment charges Recoveries and reimburse-ments a Total Impairment charges Recoveries and reimburse-ments a Total £m £m £m £m £m £m £m £m £m Loans and advances (361) 240 (121) 4,308 (399) 3,909 1,957 (124) 1,833 Provision for undrawn contractually committed facilities and guarantees provided (514) — (514) 776 — 776 71 — 71 Loans impairment (875) 240 (635) 5,084 (399) 4,685 2,028 (124) 1,904 Cash collateral and settlement balances (4) — (4) 2 — 2 1 — 1 Financial assets at fair value through other comprehensive income (8) — (8) 2 — 2 1 — 1 Other financial assets measured at cost (6) — (6) 149 — 149 6 — 6 Credit impairment (releases)/charges (893) 240 (653) 5,237 (399) 4,838 2,036 (124) 1,912 Note a Recoveries and reimbursements includes a net reduction in amounts recoverable from financial guarantee contracts held with third parties of £306m (2020 gain: £364m) and cash recoveries of previously written off amounts of £66m (2020: £35m) . Write-offs that can be subjected to enforcement activity The contractual amount outstanding on financial assets that were written off during the year and that can still be subjected to enforcement activity is £1,190m (2020: £1,246m). This is lower than the write-offs presented in the movement in gross exposures and impairment allowance table due to assets sold during the year post write-offs and post write-off recoveries. Modification of financial assets Financial assets with a loss allowance measured at an amount equal to lifetime ECL of £3,446m (2020: £4,275m) were subject to non-substantial modification during the year, with a resulting loss of £11m (2020: £34m). The gross carrying amount of financial assets subject to non-substantial modification for which the loss allowance has changed to a 12 month ECL during the year amounts to £419m (2020: £1,194m). |
Operating expenses
Operating expenses | 12 Months Ended |
Dec. 31, 2021 | |
Expenses by nature [abstract] | |
Operating expenses | Operating expenses Restated a 2021 2020 2019 £m £m £m Infrastructure costs Property and equipment 1,506 1,556 1,409 Depreciation and amortisation 1,673 1,539 1,487 Lease payments 32 34 41 Impairment of property, equipment and intangible assets 403 194 33 Total infrastructure costs 3,614 3,323 2,970 Administration and general expenses Consultancy, legal and professional fees 610 567 590 Marketing and advertising 399 330 425 UK bank levy 170 299 226 Other administration and general expenses 958 1,117 1,059 Total administration and general expenses 2,137 2,313 2,300 Staff costs 8,511 8,097 8,315 Provisions for litigation and conduct 397 153 1,849 Operating expenses b 14,659 13,886 15,434 Notes a 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. b Operating expenses includes £648m relating to structural cost actions of which £266m pertains to impairment of property taken as part of real estate review. For further details on staff costs including accounting policies, refer to Note 31. |
Tax
Tax | 12 Months Ended |
Dec. 31, 2021 | |
Major components of tax expense (income) [abstract] | |
Tax | Tax Accounting for income taxes The Group applies IAS 12 Income Taxes in accounting for taxes on income. Income tax payable on taxable profits (current tax) is recognised as an expense in the periods in which the profits arise. Withholding taxes are also treated as income taxes. Income tax recoverable on tax allowable losses is recognised as a current tax asset only to the extent that it is regarded as recoverable by offsetting against taxable profits arising in the current or prior periods. Current tax is measured using tax rates and tax laws that have been enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised. Deferred tax liabilities are recognised for all taxable temporary differences except from the initial recognition of goodwill. Deferred tax is not recognised where the temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss. Deferred tax is determined using tax rates and legislation enacted or substantively enacted by the balance sheet date which are expected to apply when the deferred tax asset is realised or the deferred tax liability is settled. Deferred tax assets and liabilities are only offset when there is both a legal right to set-off and an intention to settle on a net basis. The Group considers an uncertain tax position to exist when it considers that ultimately, in the future, the amount of profit subject to tax may be greater than the amount initially reflected in the Group’s tax returns. The Group accounts for provisions in respect of uncertain tax positions in two different ways. A current tax provision is recognised when it is considered probable that the outcome of a review by a tax authority of an uncertain tax position will alter the amount of cash tax due to, or from, a tax authority in the future. From recognition, the current tax provision is then measured at the amount the Group ultimately expects to pay the tax authority to resolve the position. The accrual of interest and penalty amounts in respect of uncertain income tax positions is recognised as an expense within profit before tax. Deferred tax provisions are adjustments made to the carrying value of deferred tax assets in respect of uncertain tax positions. A deferred tax provision is recognised when it is considered probable that the outcome of a review by a tax authority of an uncertain tax position will result in a reduction in the carrying value of the deferred tax asset. From recognition of a provision, measurement of the underlying deferred tax asset is adjusted to take into account the expected impact of resolving the uncertain tax position on the loss or temporary difference giving rise to the deferred tax asset. The approach taken to measurement takes account of whether the uncertain tax position is a discrete position that will be reviewed by the tax authority in isolation from any other position, or one of a number of issues which are expected to be reviewed together concurrently and resolved simultaneously with a tax authority. The Group’s measurement of provisions is based upon its best estimate of the additional profit that will become subject to tax. For a discrete position, consideration is given only to the merits of that position. Where a number of issues are expected to be reviewed and resolved together, the Group will take into account not only the merits of its position in respect of each particular issue but also the overall level of provision relative to the aggregate of the uncertain tax positions across all the issues that are expected to be resolved at the same time. In addition, in assessing provision levels, it is assumed that tax authorities will review uncertain tax positions and that all facts will be fully and transparently disclosed. Critical accounting estimates and judgements There are two key areas of judgement that impact the reported tax position. Firstly, the level of provisioning for uncertain tax positions; and secondly, the recognition and measurement of deferred tax assets. The Group does not consider there to be a significant risk of a material adjustment to the carrying amount of current and deferred tax balances, including provisions for uncertain tax positions in the next financial year. The provisions for uncertain tax positions cover a diverse range of issues and reflect advice from external counsel where relevant. It should be noted that only a proportion of the total uncertain tax positions will be under audit at any point in time, and could therefore be subject to challenge by a tax authority over the next year. Deferred tax assets have been recognised based on business profit forecasts. Details on the recognition of deferred tax assets are provided in this note. Restated a 2021 2020 2019 £m £m £m Current tax charge/(credit) Current year 1,417 1,255 1,037 Adjustments in respect of prior years 317 31 (45) 1,734 1,286 992 Deferred tax (credit)/charge Current year (352) (830) 86 Adjustments in respect of prior years (244) 148 (75) (596) (682) 11 Tax charge 1,138 604 1,003 Note a 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. The table below shows the reconciliation between the actual tax charge and the tax charge that would result from applying the standard UK corporation tax rate to the Group’s profit before tax. Restated a 2021 Restated a 2021 2020 2020 2019 2019 £m % £m % £m % Profit before tax 8,194 3,065 4,357 Tax charge based on the standard UK corporation tax rate of 19% (2020: 19%; 2019: 19% ) 1,557 19.0 % 582 19.0 % 828 19.0 % Impact of profits/losses earned in territories with different statutory rates to the UK (weighted average tax rate is 22.4% (2020: 25.1%; 2019: 24.2% )) 277 3.4 % 188 6.1 % 227 5.2 % Recurring items: Non-creditable taxes including withholding taxes 134 1.6 % 109 3.5 % 150 3.4 % Banking surcharge and other items 83 1.0 % 6 0.2 % 57 1.3 % Non-deductible expenses 80 1.0 % 48 1.6 % 45 1.0 % Adjustments in respect of prior years 73 0.9 % 179 5.8 % (120) (2.7 %) Impact of UK bank levy being non-deductible 32 0.4 % 57 1.9 % 43 1.0 % Impact of Barclays Bank PLC's overseas branches being taxed both locally and in the UK 25 0.3 % 25 0.8 % 15 0.3 % Tax adjustments in respect of share-based payments (5) (0.1 %) 26 0.8 % (6) (0.1 %) Changes in recognition of deferred tax and effect of unrecognised tax losses (140) (1.7 %) (123) (4.0 %) (82) (1.9 %) Tax relief on payments made under AT1 instruments (149) (1.8 %) (165) (5.4 %) (157) (3.6 %) Non-taxable gains and income (367) (4.5 %) (208) (6.8 %) (260) (6.0 %) Non-recurring items: Remeasurement of UK deferred tax assets due to tax rate changes (462) (5.6 %) (118) (3.8 %) — — Non-deductible provisions for UK customer redress — — (7) (0.2 %) 263 6.1 % Non-deductible provisions for investigations and litigation — — 5 0.2 % — — Total tax charge 1,138 13.9 % 604 19.7 % 1,003 23.0 % Note a 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. Factors driving the effective tax rate The effective tax rate of 13.9% is lower than the UK corporation tax rate of 19% primarily due to adjustments for the remeasurement of UK deferred tax assets as a result of the enactment in 2021 of an increase in the UK corporation tax rate to 25% from 1 April 2023, the impact of non-taxable gains and income, tax relief on payments made under AT1 instruments and the use of unrecognised tax losses in the period. These factors, which have each decreased the effective tax rate, are partially offset by profits earned outside the UK being taxed at local statutory tax rates that are higher than the UK tax rate and non-creditable taxes. The Group’s future tax charge will be sensitive to the geographic mix of profits earned, the tax rates in force and changes to the tax rules in the jurisdictions that the Group operates in. In its Budget held in October 2021, the UK Government announced that the banking surcharge rate will be reduced from 8% to 3% from 1 April 2023. This reduction in the banking surcharge rate was substantively enacted on 2 February 2022 and is a non-adjusting post balance sheet event. If the reduction in the banking surcharge rate had been substantively enacted at the balance sheet date then this would have resulted in the Group’s UK deferred tax assets being remeasured and decreasing with a tax charge in the income statement of £346m and tax credit within other comprehensive income of £87m. In October 2021, the OECD and G20 Inclusive Framework on Base Erosion and Profit Shifting announced plans to introduce a global minimum tax rate of 15% from 2023. The model rules, which set out the scope of and the mechanism for calculating the global minimum tax, were released by the OECD on 20 December 2021. The Group is reviewing the model rules and awaiting the OECD’s anticipated publication of further guidance, as well as new legislation expected to be released by governments implementing this new tax regime, and will assess the potential impact of new legislation during 2022. In the USA, a proposed Build Back Better Act has been passed by the House of Representatives but has not been passed by the Senate and at this time it is uncertain whether the Act will progress further. The proposed Act passed by the House of Representatives included proposals to implement material changes to international tax provisions, including amendments to the Base Erosion and Anti-Abuse Tax and the imposition of an alternative minimum tax based on accounting profits. It is unclear at this time whether any of these proposals could have a significant impact on the Group if enacted. The Group will continue to monitor developments and assess the potential impact of any future legislative changes ultimately enacted. Tax in the consolidated statement of comprehensive income The tax relating to each component of other comprehensive income can be found in the consolidated statement of comprehensive income which includes within Other a tax credit of £nil (2020: £5m). The total amount recognised in relation to the remeasurement of UK deferred tax through other comprehensive income was a £111m charge (2020: £52m). Tax included directly in equity Tax included directly in equity comprises a £58m credit (2020: £18m) relating to share-based payments and deductible costs on issuing other equity instruments. Deferred tax assets and liabilities The deferred tax amounts on the balance sheet were as follows: 2021 2020 £m £m UK Tax Group 2,183 886 US Intermediate Holding Company Tax Group ('IHC Tax Group') 1,004 1,001 US Branch Tax Group 1,002 1,048 Other (outside the UK and US tax groups) 430 509 Deferred tax asset 4,619 3,444 Deferred tax liability (37) (15) Net deferred tax 4,582 3,429 US deferred tax assets in the IHC and US Branch Tax Groups The deferred tax asset in the IHC Tax Group of £1,004m (2020: £1,001m) includes £1m (2020: £nil) relating to tax losses, with the balance relating to temporary differences. The deferred tax asset in Barclays Bank PLC’s US Branch Tax Group of £1,002m (2020: £1,048m) relates entirely to temporary differences. In relation to the IHC Tax Group, these temporary differences include £301m (2020: £330m) arising from New York State and City prior net operating loss conversion which can be carried forward and will expire in 2034. Business profit forecasts indicate these amounts will be fully recovered before expiry. UK Tax Group deferred tax asset The deferred tax asset in the UK Tax Group of £2,183m (2020: £886m) includes £1,098m (2020: £565m) relating to tax losses, with the balance relating to temporary differences. There is no time limit on utilisation of UK tax losses and business profit forecasts indicate that these losses will be fully recovered. Other deferred tax assets (outside the UK and US tax groups) The deferred tax asset of £430m (2020: £509m) in other entities within the Group includes £121m (2020: £170m) relating to tax losses. These deferred tax assets relate to a number of different territories and their recognition is based on profit forecasts or local country law which indicate that it is probable that those deferred tax assets will be fully recovered. Of the deferred tax asset of £430m (2020: £509m), an amount of £9m (2020: £8m) relates to entities which have suffered a loss in either the current or prior year and for which the utilisation of the deferred tax is dependent on future taxable profits. This has been taken into account in reaching the above conclusion that these deferred tax assets will be fully recovered in the future. The table below shows movements on deferred tax assets and liabilities during the year. The amounts are different from those disclosed on the balance sheet and in the preceding table as they are presented before offsetting asset and liability balances where there is a legal right to set-off and an intention to settle on a net basis. Fixed asset timing differences Fair value through other comprehensive income Cash flow hedges Retirement benefit obligations Loan impairment allowance Other provisions Share-based payments and deferred compensation Other temporary differences Tax losses carried forward Total £m £m £m £m £m £m £m £m £m £m Assets 1,465 — — 43 666 143 363 1,564 735 4,979 Liabilities (41) (38) (566) (826) — — — (79) — (1,550) As at 1 January 2021 1,424 (38) (566) (783) 666 143 363 1,485 735 3,429 Income statement 184 (6) — 5 39 7 12 (130) 485 596 Other comprehensive income and reserves — 198 1,088 (855) — — 36 97 — 564 Other movements (3) 1 (1) (1) (12) — 3 6 — (7) 1,605 155 521 (1,634) 693 150 414 1,458 1,220 4,582 Assets 1,647 155 521 40 693 150 414 1,524 1,220 6,364 Liabilities (42) — — (1,674) — — — (66) — (1,782) As at 31 December 2021 1,605 155 521 (1,634) 693 150 414 1,458 1,220 4,582 Assets 1,338 119 — 38 501 128 344 1,458 523 4,449 Liabilities (31) (18) (181) (640) — — — (312) — (1,182) As at 1 January 2020 1,307 101 (181) (602) 501 128 344 1,146 523 3,267 Income statement 129 — — 6 156 22 20 134 215 682 Other comprehensive income and reserves — (137) (377) (191) — — 5 238 — (462) Other movements (12) (2) (8) 4 9 (7) (6) (33) (3) (58) 1,424 (38) (566) (783) 666 143 363 1,485 735 3,429 Assets 1,465 — — 43 666 143 363 1,564 735 4,979 Liabilities (41) (38) (566) (826) — — — (79) — (1,550) As at 31 December 2020 1,424 (38) (566) (783) 666 143 363 1,485 735 3,429 Other movements include the impact of changes in foreign exchange rates as well as deferred tax amounts relating to acquisitions and disposals. The amount of deferred tax assets expected to be recovered after more than 12 months is £5,886m (2020: £4,544m). The amount of deferred tax liability expected to be settled after more than 12 months is £1,778m (2020: £1,510m). These amounts are before offsetting asset and liability balances where there is a legal right to set-off and an intention to settle on a net basis. Unrecognised deferred tax Tax losses and temporary differences Deferred tax assets have not been recognised in respect of gross deductible temporary differences of £110m (2020: £125m), unused tax credits of £283m (2020: £236m), and gross tax losses of £22,835m (2020: £20,913m). The tax losses include capital losses of £3,981m (2020: £3,947m). Of these tax losses, £63m (2020: £139m) expire within five years, £370m (2020: £236m) expire within six to ten years, £10,529m (2020: £7,271m) expire within 11 to 20 years and £11,873m (2020: £13,267m) can be carried forward indefinitely. Deferred tax assets have not been recognised in respect of these items because it is not probable that future taxable profits and gains will be available against which they can be utilised. Group investments in subsidiaries, branches and associates Deferred tax is not recognised in respect of the value of the Group's investments in subsidiaries, branches and associates where the Group is able to control the timing of the reversal of the temporary differences and it is probable that such differences will not reverse in the foreseeable future. The aggregate amount of these temporary differences for which deferred tax liabilities have not been recognised was £0.9bn (2020: £0.8bn). |
Earnings per share
Earnings per share | 12 Months Ended |
Dec. 31, 2021 | |
Earnings per share [abstract] | |
Earnings per share | Earnings per share Restated a 2021 2020 2019 £m £m £m Profit attributable to ordinary equity holders of the parent 6,205 1,526 2,461 2021 2020 2019 million million million Basic weighted average number of shares in issue 16,985 17,300 17,200 Number of potential ordinary shares 435 368 282 Diluted weighted average number of shares 17,420 17,668 17,482 Basic earnings per share Diluted earnings per share Restated a Restated a 2021 2020 2019 2021 2020 2019 p p p p p p Earnings per ordinary share 36.5 8.8 14.3 35.6 8.6 14.1 Note a 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. The calculation of basic earnings per share is based on the profit attributable to equity holders of the parent and the basic weighted average number of shares excluding treasury shares held in employee benefit trusts or held for trading. When calculating the diluted earnings per share, the weighted average number of shares in issue is adjusted for the effects of all expected dilutive potential ordinary shares held in respect of Barclays PLC, totaling 435m (2020: 368m) shares. The total number of share options outstanding, under schemes considered to be potentially dilutive, was 688m (2020: 719m). These options have strike prices ranging from £0.84 to £1.66. Of the total number of employee share options and share awards at 31 December 2021, 5m (2020: 69m) were anti-dilutive. The 315m decrease (2020: 100m increase) in the basic weighted average number of shares is primarily due to the impact of the share buyback programmes completed in the year. |
Dividends on ordinary shares
Dividends on ordinary shares | 12 Months Ended |
Dec. 31, 2021 | |
Dividends on ordinary shares | |
Dividends on ordinary shares | Dividends on ordinary shares The Directors have approved a total dividend in respect of 2021 of 6p per ordinary share of 25p each. The full year dividend for 2021 of 4p per ordinary share will be paid on 5 April 2022 to shareholders on the Share Register on 4 March 2022. On 31 December 2021, there were 16,752m ordinary shares in issue. The financial statements for the year ended 31 December 2021 do not reflect this dividend, which will be accounted for in shareholders’ equity as an appropriation of retained profits in the year ending 31 December 2022. The Directors confirmed their intention to initiate a share buyback of up to £1.0bn after the balance sheet date. The share buyback is expected to commence in the first half of 2022. The financial statements for the year ended 31 December 2021 do not reflect the impact of the proposed share buyback, which will be accounted for as and when shares are repurchased by the Company. The 2021 financial statements include the 2021 half year dividend of £339m (2020: nil); a full year dividend declared in relation to 2020 of £173m (2020: nil) and two share buybacks, £700m completed in H1 2021 (2020: nil) and £500m completed in H2 2021 (2020: nil) . Dividends and share buybacks are funded out of distributable reserves. |
Trading portfolio
Trading portfolio | 12 Months Ended |
Dec. 31, 2021 | |
Net assets (liabilities) [abstract] | |
Trading portfolio | Trading portfolio Accounting for trading portfolio assets and liabilities In accordance with IFRS 9, all assets and liabilities held for trading purposes are held at fair value with gains and losses in the changes in fair value taken to the income statement in net trading income (Note 5). Trading portfolio assets Trading portfolio liabilities 2021 2020 2021 2020 £m £m £m £m Debt securities and other eligible bills 50,864 56,482 (34,957) (30,102) Equity securities 83,113 62,192 (19,212) (17,303) Traded loans 12,525 8,348 — — Commodities 533 928 — — Trading portfolio assets/(liabilities) 147,035 127,950 (54,169) (47,405) |
Financial assets at fair value
Financial assets at fair value through the income statement | 12 Months Ended |
Dec. 31, 2021 | |
Financial assets at fair value through profit or loss [abstract] | |
Financial assets at fair value through the income statement | Financial assets at fair value through the income statement Accounting for financial assets mandatorily at fair value Financial assets that are held for trading are recognised at fair value through profit or loss. In addition, financial assets are held at fair value through profit or loss if they do not contain contractual terms that give rise on specified dates to cash flows that are SPPI, or if the financial asset is not held in a business model that is either (i) a business model to collect the contractual cash flows or (ii) a business model that is achieved by both collecting contractual cash flows and selling. Accounting for financial assets designated at fair value Financial assets, other than those held for trading, are classified in this category if they are so irrevocably designated at inception and the use of the designation removes or significantly reduces an accounting mismatch. Subsequent changes in fair value for these instruments are recognised in the income statement in net investment income, except if reporting it in trading income reduces an accounting mismatch. The details on how the fair value amounts are derived for financial assets at fair value are described in Note 17. Designated at fair value Mandatorily at fair value Total 2021 2020 2021 2020 2021 2020 £m £m £m £m £m £m Loans and advances 5,579 5,600 33,088 25,279 38,667 30,879 Debt securities 319 292 1,986 1,401 2,305 1,693 Equity securities — — 5,875 4,620 5,875 4,620 Reverse repurchase agreements and other — 19 145,014 137,597 145,014 137,616 Other financial assets — — 111 343 111 343 Financial assets at fair value through the income statement 5,898 5,911 186,074 169,240 191,972 175,151 Credit risk of financial assets designated at fair value and related credit derivatives The following table shows the maximum exposure to credit risk, the changes in fair value attributable to changes in credit risk, and the cumulative changes in fair value since initial recognition for loans and advances. The table does not include debt securities and reverse repurchase agreements and other similar secured lending designated at FV as they have minimal exposure to credit risk. Reverse repurchase agreements are collateralised and debt securities are primarily relating to high quality sovereigns. Maximum exposure as at 31 December Changes in fair value during the year ended Cumulative changes in fair value from inception 2021 2020 2021 2020 2021 2020 £m £m £m £m £m £m Loans and advances designated at fair value, attributable to credit risk 5,579 5,600 5 (47) (19) (73) Value mitigated by related credit derivatives 1,617 795 (3) 3 (3) 3 |
Derivative financial instrument
Derivative financial instruments | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of nature and extent of risks arising from financial instruments [abstract] | |
Derivative financial instruments | Derivative financial instruments Accounting for derivatives Derivative instruments are contracts whose value is derived from one or more underlying financial instruments or indices defined in the contract. They include swaps, forward-rate agreements, futures, options and combinations of these instruments and primarily affect the Group’s net interest income, net trading income and derivative assets and liabilities. Notional amounts of the contracts are not recorded on the balance sheet. Derivatives are used to hedge interest rate, credit risk, inflation risk, exchange rate, commodity equity exposures, and exposures to certain indices such as house price indices and retail price indices related to non-trading positions. All derivative instruments are held at fair value through profit or loss, except for derivatives that are in a designated cash flow or net investment hedge accounting relationship. Derivatives are classified as assets when their fair value is positive or as liabilities when their fair value is negative. This includes terms included in a contract or financial liability (the host), which, had it been a standalone contract, would have met the definition of a derivative. If these are separated from the host, i.e. when the economic characteristics of the embedded derivative are not closely related with those of the host contract and the combined instrument is not measured at fair value through profit or loss, then they are accounted for in the same way as derivatives. For financial assets, the requirements are whether the financial assets contain contractual terms that give rise on specified dates to cash flows that are SPPI, and consequently the requirements for accounting for embedded derivatives are not applicable to financial assets. Hedge accounting The Group applies the requirements of IAS 39 Financial Instruments: Recognition and Measurement for hedge accounting purposes. The Group applies hedge accounting to represent the economic effects of its interest rate, currency and contractually linked inflation risk management strategies. Where derivatives are held for risk management purposes, and when transactions meet the required criteria for documentation and hedge effectiveness, the Group applies fair value hedge accounting, cash flow hedge accounting, or hedging of a net investment in a foreign operation, as appropriate to the risks being hedged. The Group applies the ‘Amendments to IFRS 9, IAS 39 and IFRS 7 Interest Rate Benchmark Reform’ issued in September 2019 (the Phase 1 amendments). The amendments provide temporary relief from applying specific hedge accounting requirements to hedging relationships directly affected by IBOR (‘Interbank Offered Rates’) reform. The reliefs have the effect that IBOR reform should not generally cause hedge accounting to terminate. However, any hedge ineffectiveness continues to be recorded in the income statement. Furthermore, the amendments set out triggers for when the reliefs will end, which include the uncertainty arising from interest rate benchmark reform no longer being present. In summary, the reliefs provided by the Phase 1 amendments are: ▪ When considering the ‘highly probable’ requirement, the Group has assumed that the IBOR interest rates upon which our hedged items are based do not change as a result of IBOR Reform. ▪ In assessing whether the hedge is expected to be highly effective on a forward-looking basis the Group has assumed that the IBOR interest rates upon which the cash flows of the hedged items and the interest rate swaps that hedge them are based are not altered by IBOR reform. ▪ The Group will not discontinue hedge accounting during the period of IBOR-related uncertainty solely because the retrospective effectiveness falls outside the required 80–125% range. ▪ The Group has not recycled the cash flow hedge reserve relating to the period after the reforms are expected to take effect. ▪ The Group has assessed whether the hedged IBOR risk component is a separately identifiable risk only when it first designates a hedged item in a fair value hedge and not on an ongoing basis. The Group also applies the ‘Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 Interest Rate Benchmark Reform – Phase 2’ issued in August 2020. The Phase 2 amendments provide relief when changes are made to hedge relationships as a result of the interest rate benchmark reform. In summary, the reliefs provided by the Phase 2 amendments are: ▪ Under a temporary exception, the Group has considered that changes to the hedge designation and hedge documentation due to the interest rate benchmark reform would not constitute the discontinuation of the hedge relationship nor the designation of a new hedging relationship. ▪ In respect of the retrospective hedge effectiveness assessment, the Group may elect, on a hedge-by-hedge basis, to reset the cumulative fair value changes to zero when the exception to the retrospective assessment ends (Phase 1 relief). Any hedge ineffectiveness will continue to be measured and recognised in full in profit or loss. ▪ The Group has deemed the amounts accumulated in the cash flow hedge reserve to be based on the alternative benchmark rate (on which the hedge future cash flows are determined) when there is a change in basis for determining the contractual cash flows. ▪ For hedges of groups of items (such as those forming part of a macro cash flow hedging strategy), the amendments provide relief for items within a designated group of items that are amended for changes directly required by the reform. ▪ In respect of whether a risk component of a hedged item is separately identifiable, the amendments provide temporary relief to entities to meet this requirement when an alternative risk free rate (RFR) financial instrument is designated as a risk component. These amendments allow the Group upon designation of the hedge to assume that the separately identifiable requirement is met if the Group reasonably expects the RFR risk will become separately identifiable within the next 24 months. The Group applies this relief to each RFR on a rate-by-rate basis and starts when the Group first designates the RFR as a non-contractually specified risk component. Fair value hedge accounting Changes in fair value of derivatives that qualify and are designated as fair value hedges are recorded in the income statement, together with changes in the fair value of the hedged asset or liability that are attributable to the hedged risk. The fair value changes adjust the carrying value of the hedged asset or liability held at amortised cost. If hedge relationships no longer meet the criteria for hedge accounting, hedge accounting is discontinued. For fair value hedges of interest rate risk, the fair value adjustment to the hedged item is amortised to the income statement over the period to maturity of the previously designated hedge relationship using the effective interest method. If the hedged item is sold or repaid, the unamortised fair value adjustment is recognised immediately in the income statement. For items classified as fair value through other comprehensive income, the hedge accounting adjustment is included in other comprehensive income. Cash flow hedge accounting For qualifying cash flow hedges, the fair value gain or loss associated with the effective portion of the cash flow hedge is recognised initially in other comprehensive income, and then recycled to the income statement in the periods when the hedged item will affect profit or loss. Any ineffective portion of the gain or loss on the hedging instrument is recognised in the income statement immediately. When a hedging instrument expires or is sold, or when a hedge no longer meets the criteria for hedge accounting, any cumulative gain or loss existing in equity at that time remains in equity and is recognised when the hedged item is ultimately recognised in the income statement. When a forecast transaction is no longer expected to occur, the cumulative gain or loss that was recognised in equity is immediately transferred to the income statement. Hedges of net investments The Group’s net investments in foreign operations, including monetary items accounted for as part of the net investment, are hedged for foreign currency risks using both derivatives and foreign currency borrowings. Hedges of net investments are accounted for similarly to cash flow hedges; the effective portion of the gain or loss on the hedging instrument is being recognised directly in other comprehensive income and the ineffective portion being recognised immediately in the income statement. The cumulative gain or loss recognised in other comprehensive income is recognised in the income statement on the disposal or partial disposal of the foreign operation, or other reductions in the Group’s investment in the operation. Total derivatives 2021 2020 Notional contract amount Fair value Notional Fair value Assets Liabilities Assets Liabilities £m £m £m £m £m £m Total derivative assets/(liabilities) held for trading 47,812,774 261,678 (255,747) 43,169,971 301,880 (299,795) Total derivative assets/(liabilities) held for risk management 219,551 894 (1,136) 189,784 566 (980) Derivative assets/(liabilities) 48,032,325 262,572 (256,883) 43,359,755 302,446 (300,775) As part of the industry wide IBOR transition during the year, interest rate swap contracts held with Central Clearing Counterparties (CCPs) have been converted to alternative benchmarks. Operationally, this involved the CCPs splitting each contract into multiple component operational parts in order to preserve accrued IBOR cash flows. Legally, Barclays remains party to only one contract, and as such all notional amounts quoted in this disclosure reflect the legal contract notional. In total, 'operational-only' trade notional amounts of £1,828bn primarily with London Clearing House & Japan Securities Clearing Corporation have been explicitly excluded from these disclosures. Further information on netting arrangements of derivative financial instruments can be found within Note 18. The fair values and notional amounts of derivative instruments held for trading and held for risk management are set out in the following table: Derivatives held for trading and held for risk management 2021 2020 Notional Fair value Notional Fair value Assets Liabilities Assets Liabilities £m £m £m £m £m £m Derivatives held for trading Foreign exchange derivatives OTC derivatives 5,705,108 75,959 (74,226) 5,461,057 84,401 (84,043) Derivatives cleared by central counterparty 99,664 171 (208) 78,946 335 (335) Exchange traded derivatives 20,084 10 (3) 14,034 3 (3) Foreign exchange derivatives 5,824,856 76,140 (74,437) 5,554,037 84,739 (84,381) Interest rate derivatives OTC derivatives 14,216,846 123,819 (113,051) 13,547,990 170,808 (161,157) Derivatives cleared by central counterparty 19,398,748 1,122 (845) 18,737,415 965 (885) Exchange traded derivatives 5,200,838 905 (907) 2,971,966 371 (360) Interest rate derivatives 38,816,432 125,846 (114,803) 35,257,371 172,144 (162,402) Credit derivatives OTC derivatives 606,504 4,007 (4,752) 384,900 3,674 (3,909) Derivatives cleared by central counterparty 665,600 1,675 (1,809) 462,945 931 (1,095) Credit derivatives 1,272,104 5,682 (6,561) 847,845 4,605 (5,004) Equity and stock index derivatives OTC derivatives 278,683 18,822 (24,468) 466,151 18,807 (26,094) Exchange traded derivatives 1,469,078 32,901 (33,174) 927,114 20,165 (20,521) Equity and stock index derivatives 1,747,761 51,723 (57,642) 1,393,265 38,972 (46,615) Commodity derivatives OTC derivatives 4,670 56 (107) 4,244 89 (110) Exchange traded derivatives 146,951 2,231 (2,197) 113,209 1,331 (1,283) Commodity derivatives 151,621 2,287 (2,304) 117,453 1,420 (1,393) Derivative assets/(liabilities) held for trading 47,812,774 261,678 (255,747) 43,169,971 301,880 (299,795) Total OTC derivatives 20,811,811 222,663 (216,604) 19,864,342 277,779 (275,313) Total derivatives cleared by central counterparty 20,164,012 2,968 (2,862) 19,279,306 2,231 (2,315) Total exchange traded derivatives 6,836,951 36,047 (36,281) 4,026,323 21,870 (22,167) Derivative assets/(liabilities) held for trading 47,812,774 261,678 (255,747) 43,169,971 301,880 (299,795) Derivatives held for risk management Derivatives designated as cash flow hedges OTC foreign exchange derivatives 7,592 798 — 6,596 351 — OTC interest rate derivatives 788 — (3) 2,433 35 — Interest rate derivatives cleared by central counterparty 105,933 — — 65,408 — — Derivatives designated as cash flow hedges 114,313 798 (3) 74,437 386 — Derivatives designated as fair value hedges OTC interest rate derivatives 8,480 59 (1,118) 11,116 155 (980) Interest rate derivatives cleared by central counterparty 94,335 — (11) 103,440 — — Derivatives designated as fair value hedges 102,815 59 (1,129) 114,556 155 (980) Derivatives designated as hedges of net investments OTC foreign exchange derivatives 2,423 37 (4) 791 25 — Derivatives designated as hedges of net investments 2,423 37 (4) 791 25 — Derivative assets/(liabilities) held for risk management 219,551 894 (1,136) 189,784 566 (980) Total OTC derivatives 19,283 894 (1,125) 20,936 566 (980) Total derivatives cleared by central counterparty 200,268 — (11) 168,848 — — Derivative assets/(liabilities) held for risk management 219,551 894 (1,136) 189,784 566 (980) Hedge accounting Hedge accounting is applied predominantly for the following risks: ▪ Interest rate risk – arises due to a mismatch between fixed interest rates and floating interest rates. Interest rate risk also includes exposure to inflation risk for certain types of investments. ▪ Currency risk – arises due to assets or liabilities being denominated in different currencies than the functional currency of the relevant entity. At a consolidated level, currency risk also arises when the functional currency of subsidiaries are different from the parent. ▪ Contractually linked inflation risk – arises from financial instruments within contractually specified inflation risk. The Group does not hedge inflation risk that arises from other activities. In order to hedge these risks, the Group uses the following hedging instruments: ▪ Interest rate derivatives to swap interest rate exposures into either fixed or variable rates. ▪ Currency derivatives to swap foreign currency exposures into the entity’s functional currency, and net investment exposure to local currency. ▪ Inflation derivatives to swap inflation exposure into either fixed or variable interest rates. In some cases, certain items which are economically hedged may be ineligible hedged items for the purposes of IAS 39, such as core deposits and equity. In these instances, a proxy hedging solution can be utilised whereby portfolios of floating rate assets are designated as eligible hedged items in cash flow hedges. In some hedging relationships, the Group designates risk components of hedged items as follows: ▪ Benchmark interest rate risk as a component of interest rate risk, such as the LIBOR or Risk Free Rate (RFR) component. ▪ Inflation risk as a contractually specified component of a debt instrument. ▪ Spot exchange rate risk for foreign currency financial assets or financial liabilities. ▪ Components of cash flows of hedged items, for example certain interest payments for part of the life of an instrument. Using the benchmark interest rate risk results in other risks, such as credit risk and liquidity risk, being excluded from the hedge accounting relationship. Following market-wide interest rate benchmark reform, sensitivity to risk-free rates is considered to be the predominant interest rate risk and therefore the hedged items (which often reference risk-free or similar 'overnight' rates) change in fair value on a proportionate basis with reference to this risk. In respect of many of the Group’s hedge accounting relationships, the hedged item and hedging instrument change frequently due to the dynamic nature of the risk management and hedge accounting strategy. The Group applies hedge accounting to dynamic scenarios, predominantly in relation to interest rate risk, with a combination of hedged items in order for its financial statements to reflect as closely as possible the economic risk management undertaken. In some cases, if the hedge accounting objective changes, the relevant hedge accounting relationship is de-designated and is replaced with a different hedge accounting relationship. Changes in the GBP value of net investments due to foreign currency movements are captured in the currency translation reserve, resulting in a movement in CET1 capital. The Group mitigates this by matching the CET1 capital movements to the revaluation of the foreign currency RWA exposures. Net investment hedges are designated where necessary to reduce the exposure to movement in a particular exchange rate to within limits mandated by Risk. As far as possible, existing external currency liabilities are designated as the hedging instruments. The hedging instruments share the same risk exposures as the hedged items. Hedge effectiveness is determined with reference to quantitative tests, predominantly regression testing, but to the extent hedging instruments are exposed to different risks than the hedged items, this could result in hedge ineffectiveness or hedge accounting failures. Sources of ineffectiveness include the following: ▪ Mismatches between the contractual terms of the hedged item and hedging instrument, including basis differences. ▪ Changes in credit risk of the hedging instruments. ▪ If a hedging relationship becomes over-hedged, for example in hedges of net investments if the net asset value designated at the start of the period falls below the amount of the hedging instrument. ▪ Cash flow hedges using external swaps with non-zero fair values. ▪ The effects of the reforms to IBOR because these might take effect at a different time and have a different impact on hedged items and hedging instruments. The Group's risk exposure continues, in part, to be affected by interest rate benchmark reform. In most cases, hedged items and hedging instruments are expected to transition to relevant risk-free rates at the end of their current cash flow period. For GBP LIBOR contracts, where uncertainty around the timing and effects of LIBOR reform continues beyond the end of the current cash flow period, financial instruments are generally expected to utilise 'synthetic LIBOR' (as permitted by the FCA on a temporary basis until their contracts are fully remediated). USD LIBOR linked hedge accounting relationships are still exposed to uncertainty regarding the precise timing and effects of benchmark reform. USD LIBOR benchmarks will cease to be published from 30 June 2023, but certain hedged items and hedging instruments continue to contractually reference these benchmarks beyond the cessation date. The following table summarises the significant hedge accounting exposures impacted by the IBOR reform (see Note 41 for further updates) as at 31 December 2021: Current benchmark rate Expected convergence to RFR Nominal amount of hedged items directly impacted by IBOR reform Nominal amount of hedging instruments directly impacted by IBOR reform £m £m GBP London Interbank Offered rate (LIBOR) Reformed Sterling Overnight Index Average (SONIA) 10,032 200 USD LIBOR Secured Overnight Financing Rate (SOFR) 25,744 25,288 Singapore Swap Offered Rate (SOR) Singapore Overnight Rate Average (SORA) 110 110 Total 35,886 25,598 The disparity in outstanding GBP notionals between hedged items and hedging instruments results from a temporary timing mismatch where derivative contracts have been transitioned to SONIA prior to 31 December, whereas hedged items are expected to transition early 2022. Hedged items in fair value hedges Accumulated fair value adjustment included in carrying amount Hedged item statement of financial position classification and risk category Carrying amount Total Of which: Accumulated fair value adjustment on items no longer in a hedge relationship Change in fair value used as a basis to determine ineffectiveness Hedge ineffectiveness recognised in the income statements a £m £m £m £m £m 2021 Assets Loans and advances at amortised cost - Interest rate risk 8,512 671 (642) (1,643) 33 - Inflation risk 556 354 — 9 — Debt securities classified at amortised cost - Interest rate risk 1,378 (39) — (75) (18) - Inflation risk 4,087 400 — (16) (1) Financial assets at fair value through other comprehensive income - Interest rate risk 31,485 (258) 32 (1,436) 39 - Inflation risk 9,066 470 (32) 161 13 Total assets 55,084 1,598 (642) (3,000) 66 Liabilities Debt securities in issue - Interest rate risk (48,251) (1,084) 86 1,606 (48) Total liabilities (48,251) (1,084) 86 1,606 (48) Total hedged items 6,833 514 (556) (1,394) 18 2020 Assets Loans and advances at amortised cost - Interest rate risk 9,858 2,289 (638) 1,583 111 - Inflation risk 545 345 — 25 3 Debt securities classified at amortised cost - Interest rate risk 1,440 23 — 18 (7) - Inflation risk 4,071 (43) — 453 3 Financial assets at fair value through other comprehensive income - Interest rate risk 41,544 1,284 351 825 (13) - Inflation risk 10,821 367 (9) 307 1 Total assets 68,279 4,265 (296) 3,211 98 Liabilities Debt securities in issue - Interest rate risk (50,438) (2,859) (24) (1,466) (56) Total liabilities (50,438) (2,859) (24) (1,466) (56) Total hedged items 17,841 1,406 (320) 1,745 42 Note a Hedge ineffectiveness is recognised in net interest income. For items classified as fair value through other comprehensive income, the hedge accounting adjustment is not included in the carrying amount, but rather adjusts other comprehensive income. The following table shows the fair value hedging instruments which are carried on the Group’s balance sheet: Carrying value Nominal amount Change in fair value used as a basis to determine ineffectiveness Nominal amount directly impacted by IBOR reform Derivative assets Derivative liabilities Loan liabilities Hedge type Risk category £m £m £m £m £m £m As at 31 December 2021 Fair value Interest rate risk 54 (11) — 92,447 1,554 15,577 Inflation risk 5 (1,118) — 10,368 (142) 1,624 Total 59 (1,129) — 102,815 1,412 17,201 As at 31 December 2020 Fair value Interest rate risk 120 (166) — 103,623 (925) 30,072 Inflation risk 35 (815) — 10,933 (778) 1,487 Total 155 (980) — 114,556 (1,703) 31,559 The following table profiles the expected notional values of current hedging instruments in future years: 2021 2022 2023 2024 2025 2026 2027 and later As at 31 December £m £m £m £m £m £m £m Fair value hedges of: Interest rate risk (outstanding notional amount) 92,447 87,025 79,475 67,206 55,080 44,801 37,652 Inflation risk (outstanding notional amount) 10,368 9,874 8,999 6,503 5,445 3,472 1,159 There are 1,782 (2020: 1,906) interest rate risk fair value hedges with an average fixed rate of 1.88% (2020: 1.87%) across the relationships and 96 (2020: 104) inflation risk fair value hedges with an average rate of 0.51% (2020: 0.63%) across the relationships. Hedged items in cash flow hedges and hedges of net investments in foreign operations Description of hedge relationship and hedged risk Change in value of hedged item used as the basis for recognising ineffectiveness Balance in cash flow hedging reserve for continuing hedges Balance in currency translation reserve for continuing hedges Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied Balances remaining in currency translation reserve for which hedge accounting is no longer applied Hedging gains or losses recognised in other comprehensive income Hedge ineffectiveness recognised in the income statement a £m £m £m £m £m £m £m 2021 Cash flow hedge of: Interest rate risk Loans and advances at amortised cost 2,465 1,536 — (492) — 2,465 (347) Foreign exchange risk Loans and advances at amortised cost (88) (16) — — — (88) 1 Debt securities classified at amortised cost (356) 123 — — — (356) 1 Inflation risk Debt securities classified at amortised cost 252 204 — (12) — 252 (22) Total cash flow hedge 2,273 1,847 — (504) — 2,273 (367) Hedge of net investment in foreign operations USD foreign operations 138 — 943 — — 138 — EUR foreign operations (117) — 100 — — (117) — Other foreign operations (3) — 44 — 186 (3) — Total foreign operations 18 — 1,087 — 186 18 — 2020 Cash flow hedge of: Interest rate risk Loans and advances at amortised cost (1,124) (598) — (1,370) — (1,124) 27 Foreign exchange risk Loans and advances at amortised cost (70) (15) — — — (70) — Debt securities classified at amortised cost (278) (65) — — — (278) — Inflation risk Debt securities classified at amortised cost (41) (65) — — — (41) 1 Total cash flow hedge (1,513) (743) — (1,370) — (1,513) 28 Hedge of net investment in foreign operations USD foreign operations (240) — 857 — — (240) — EUR foreign operations (17) — (2) — — (17) — Other foreign operations (9) — 47 — 186 (9) — Total foreign operations (266) — 902 — 186 (266) — Note a Hedge ineffectiveness is recognised in net interest income. The following table shows the cash flow and net investment hedging instruments which are carried on the Group’s balance sheet: Carrying value Nominal amount Change in fair value used as a basis to determine ineffectiveness Nominal amount directly impacted by IBOR reform Derivative assets Derivative liabilities Loan liabilities Hedge type Risk category £m £m £m £m £m £m As at 31 December 2021 Cash flow Interest rate risk — — — 102,629 (2,812) 8,397 Foreign exchange risk 798 — — 7,592 446 — Inflation risk — (3) — 4,092 (274) — Total 798 (3) — 114,313 (2,640) 8,397 Net investment Foreign exchange risk 37 (4) (11,212) 13,635 (239) — As at 31 December 2020 Cash flow Interest rate risk 33 — — 65,042 1,151 18,195 Foreign exchange risk 351 — — 6,596 348 — Inflation risk 2 — — 2,799 42 — Total 386 — — 74,437 1,541 18,195 Net investment Foreign exchange risk 25 — (8,660) 9,451 265 — There are 36 (2020: 29) foreign exchange risk cash flow hedges with an average foreign exchange rate of 137.85 JPY: 1 GBP (2020: 135.29 JPY: 1 GBP) across the relationships. The effect on the income statement and other comprehensive income of recycling amounts in respect of cash flow hedges and net investment hedges of foreign operations is set out in the following table: 2021 2020 Amount recycled from other comprehensive income due to hedged item affecting income statement Amount recycled from other comprehensive income due to sale of investment, or cash flows no longer expected to occur Amount recycled from other comprehensive income due to hedged item affecting income statement Amount recycled from other comprehensive income due to sale of investment, or cash flows no longer expected to occur Description of hedge relationship and hedged risk £m £m £m £m Cash flow hedge of interest rate risk Recycled to net interest income 541 2 489 17 Cash flow hedge of foreign exchange risk Recycled to other income 630 — 268 — Hedge of net investment in foreign operations Recycled to other income — (26) — (4) A detailed reconciliation of the movements of the cash flow hedging reserve and the currency translation reserve is as follows: 2021 2020 Cash flow hedging reserve Currency translation reserve Cash flow hedging reserve Currency translation reserve £m £m £m £m Balance on 1 January 1,575 2,871 1,002 3,344 Currency translation movements (7) (139) 50 (743) Hedging gains/(losses) for the year (2,273) (18) 1,249 266 Amounts reclassified in relation to cash flows affecting profit or loss (1,173) 26 (510) 4 Tax 1,025 — (216) — Balance on 31 December (853) 2,740 1,575 2,871 In 2020, amounts recycled from other comprehensive income of £268m in respect of cash flow hedges of foreign exchange risk were presented within 'Hedging gains/(losses) for the year'. For 2021, the corresponding current year amounts of £630m were presented within 'Amounts reclassified in relation to cash flows affecting profit or loss'. |
Financial assets at fair valu_2
Financial assets at fair value through other comprehensive income | 12 Months Ended |
Dec. 31, 2021 | |
Financial assets at fair value through other comprehensive income [abstract] | |
Financial assets at fair value through other comprehensive income | Financial assets at fair value through other comprehensive income Accounting for financial assets at fair value through other comprehensive income (FVOCI) Financial assets that are debt instruments held in a business model that is achieved by both collecting contractual cash flows and selling and that contain contractual terms that give rise on specified dates to cash flows that are SPPI are measured at FVOCI. They are subsequently re-measured at fair value and changes therein (except for those relating to impairment, interest income and foreign currency exchange gains and losses) are recognised in other comprehensive income until the assets are sold. Interest (calculated using the effective interest method) is recognised in the income statement in net interest income (Note 3). Upon disposal, the cumulative gain or loss recognised in other comprehensive income is included in net investment income (Note 6). In determining whether the business model is achieved by both collecting contractual cash flows and selling financial assets, it is determined that both collecting contractual cash flows and selling financial assets are integral to achieving the objective of the business model. The Group will consider past sales and expectations about future sales to establish if the business model is achieved. For equity securities that are not held for trading, the Group may make an irrevocable election on initial recognition to present subsequent changes in the fair value of the instrument in other comprehensive income (except for dividend income which is recognised in profit or loss). Gains or losses on the de-recognition of these equity securities are not transferred to profit or loss. These assets are also not subject to the impairment requirements and therefore no amounts are recycled to the income statement. Where the Group has not made the irrevocable election to present subsequent changes in the fair value of the instrument in other comprehensive income, equity securities are measured at fair value through profit or loss. 2021 2020 £m £m Debt securities and other eligible bills 60,798 77,736 Equity securities 902 761 Loans and advances 53 191 Financial assets at fair value through other comprehensive income 61,753 78,688 On 21 April 2022, Barclays sold 63m ordinary shares in Absa Group Limited (7.4% of Absa’s issued share capital) at a price of ZAR164.0 per share, raising aggregate gross sale proceeds of ZAR10.3bn (£516m a ). The sale is expected to result in an increase of approximately 10 basis points to Barclays' CET1 ratio in the second quarter of 2022 primarily due to reduced capital deductions and RWAs, partially offset by a loss on sale of £42m through the income statement. Note a Exchange rate GBP/ZAR 20.04 as of 21 April 2022. |
Financial liabilities designate
Financial liabilities designated at fair value | 12 Months Ended |
Dec. 31, 2021 | |
Designated financial liabilities at fair value through profit or loss [abstract] | |
Financial liabilities designated at fair value | Financial liabilities designated at fair value Accounting for liabilities designated at fair value through profit and loss In accordance with IFRS 9, financial liabilities may be designated at fair value, with gains and losses taken to the income statement within net trading income (Note 5) and net investment income (Note 6). Movements in own credit are reported through other comprehensive income, unless the effects of changes in the liability's credit risk would create or enlarge an accounting mismatch in P&L. In these scenarios, all gains and losses on that liability (including the effects of changes in the credit risk of the liability) are presented in P&L. On derecognition of the financial liability no amount relating to own credit risk are recycled to the income statement. The Group has the ability to make the fair value designation when holding the instruments at fair value reduces an accounting mismatch (caused by an offsetting liability or asset being held at fair value), or is managed by the Group on the basis of its fair value, or includes terms that have substantive derivative characteristics (Note 14). The details on how the fair value amounts are arrived at for financial liabilities designated at fair value are described in Note 17. 2021 2020 Fair value Contractual Fair value Contractual £m £m £m £m Debt securities 53,647 61,946 50,437 57,650 Deposits 29,246 29,673 21,706 22,107 Repurchase agreements and other similar secured borrowing 168,060 168,129 177,371 177,389 Other financial liabilities 7 7 251 251 Financial liabilities designated at fair value 250,960 259,755 249,765 257,397 The cumulative own credit net loss recognised is £960m (2020: £954m loss). |
Fair value of financial instrum
Fair value of financial instruments | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of detailed information about financial instruments [abstract] | |
Fair value of financial instruments | Fair value of financial instruments Accounting for financial assets and liabilities – fair values Financial instruments that are held for trading are recognised at fair value through profit or loss. In addition, financial assets are held at fair value through profit or loss if they do not contain contractual terms that give rise on specified dates to cash flows that are SPPI, or if the financial asset is not held in a business model that is either (i) a business model to collect the contractual cash flows or (ii) a business model that is achieved by both collecting contractual cash flows and selling. Subsequent changes in fair value for these instruments are recognised in the income statement in net investment income, except if reporting it in trading income reduces an accounting mismatch. All financial instruments are initially recognised at fair value on the date of initial recognition (including transaction costs, other than financial instruments held at fair value through profit or loss) and depending on the subsequent classification of the financial asset or liability, may continue to be held at fair value either through profit or loss or other comprehensive income. The fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Wherever possible, fair value is determined by reference to a quoted market price for that instrument. For many of the Group’s financial assets and liabilities, especially derivatives, quoted prices are not available and valuation models are used to estimate fair value. The models calculate the expected cash flows under the terms of each specific contract and then discount these values back to a present value. These models use as their basis independently sourced market inputs including, for example, interest rate yield curves, equities and commodities prices, option volatilities and currency rates. For financial liabilities measured at fair value, the carrying amount reflects the effect on fair value of changes in own credit spreads derived from observable market data such as in primary issuance and redemption activity for structured notes. On initial recognition, it is presumed that the transaction price is the fair value unless there is observable information available in an active market to the contrary. The best evidence of an instrument’s fair value on initial recognition is typically the transaction price. However, if fair value can be evidenced by comparison with other observable current market transactions in the same instrument, or is based on a valuation technique whose inputs include only data from observable markets, then the instrument should be recognised at the fair value derived from such observable market data. For valuations that have made use of unobservable inputs, the difference between the model valuation and the initial transaction price (Day One profit) is recognised in profit or loss either: on a straight-line basis over the term of the transaction; or over the period until all model inputs will become observable where appropriate; or released in full when previously unobservable inputs become observable. Various factors influence the availability of observable inputs and these may vary from product to product and change over time. Factors include the depth of activity in the relevant market, the type of product, whether the product is new and not widely traded in the marketplace, the maturity of market modelling and the nature of the transaction (bespoke or generic). To the extent that valuation is based on models or inputs that are not observable in the market, the determination of fair value can be more subjective, dependent on the significance of the unobservable input to the overall valuation. Unobservable inputs are determined based on the best information available, for example by reference to similar assets, similar maturities or other analytical techniques. The sensitivity of valuations used in the financial statements to possible changes in significant unobservable inputs is shown on page 262. Critical accounting estimates and judgements The valuation of financial instruments often involves a significant degree of judgement and complexity, in particular where valuation models make use of unobservable inputs (‘Level 3’ assets and liabilities). This note provides information on these instruments, including the related unrealised gains and losses recognised in the period, a description of significant valuation techniques and unobservable inputs, and a sensitivity analysis. Valuation IFRS 13 Fair value measurement requires an entity to classify its assets and liabilities according to a hierarchy that reflects the observability of significant market inputs. The three levels of the fair value hierarchy are defined below with judgement applied in determining the boundary between Level 2 and 3 classification. Quoted market prices – Level 1 Assets and liabilities are classified as Level 1 if their value is observable in an active market. Such instruments are valued by reference to unadjusted quoted prices for identical assets or liabilities in active markets where the quoted price is readily available, and the price represents actual and regularly occurring market transactions. An active market is one in which transactions occur with sufficient volume and frequency to provide pricing information on an ongoing basis. Valuation technique using observable inputs – Level 2 Assets and liabilities classified as Level 2 have been valued using models whose inputs are observable either directly or indirectly. Valuations based on observable inputs include assets and liabilities such as swaps and forwards which are valued using market standard pricing techniques, and options that are commonly traded in markets where all the inputs to the market standard pricing models are observable. Valuation technique using significant unobservable inputs – Level 3 Assets and liabilities are classified as Level 3 if their valuation incorporates significant inputs that are not based on observable market data (unobservable inputs). A valuation input is considered observable if it can be directly observed from transactions in an active market, or if there is compelling external evidence demonstrating an executable exit price. Unobservable input levels are generally determined via reference to observable inputs, historical observations or using other analytical techniques. The following table shows the Group’s assets and liabilities that are held at fair value disaggregated by valuation technique (fair value hierarchy) and balance sheet classification: Assets and liabilities held at fair value 2021 2020 Valuation technique using Valuation technique using Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total As at 31 December £m £m £m £m £m £m £m £m Trading portfolio assets 80,926 63,828 2,281 147,035 60,671 65,416 1,863 127,950 Financial assets at fair value through the income statement 5,093 177,167 9,712 191,972 4,503 162,142 8,506 175,151 Derivative financial assets 6,150 252,412 4,010 262,572 9,155 288,822 4,469 302,446 Financial assets at fair value through other comprehensive income 22,009 39,706 38 61,753 19,792 58,743 153 78,688 Investment property — — 7 7 — — 10 10 Total assets 114,178 533,113 16,048 663,339 94,121 575,123 15,001 684,245 Trading portfolio liabilities (27,529) (26,613) (27) (54,169) (24,391) (22,986) (28) (47,405) Financial liabilities designated at fair value (174) (250,376) (410) (250,960) (159) (249,251) (355) (249,765) Derivative financial liabilities (6,571) (244,253) (6,059) (256,883) (8,762) (285,774) (6,239) (300,775) Total liabilities (34,274) (521,242) (6,496) (562,012) (33,312) (558,011) (6,622) (597,945) The following table shows the Group’s Level 3 assets and liabilities that are held at fair value disaggregated by product type: Level 3 assets and liabilities held at fair value by product type 2021 2020 Assets Liabilities Assets Liabilities £m £m £m £m Interest rate derivatives 1,091 (1,351) 1,613 (1,615) Foreign exchange derivatives 376 (374) 144 (143) Credit derivatives 323 (709) 196 (351) Equity derivatives 2,220 (3,625) 2,498 (4,112) Corporate debt 1,205 (21) 698 (3) Reverse repurchase and repurchase agreements 13 (172) — (174) Non-asset backed loans 6,405 — 6,394 — Asset backed securities 558 — 767 (24) Equity cash products 393 — 542 — Private equity investments 1,095 (6) 873 (14) Other a 2,369 (238) 1,276 (186) Total 16,048 (6,496) 15,001 (6,622) Note a Other includes commercial real estate loans, asset backed loans, funds and fund-linked products, issued debt, government sponsored debt, commodity derivatives and investment property. Valuation techniques and sensitivity analysis Sensitivity analysis is performed on products with significant unobservable inputs (Level 3) to generate a range of reasonably possible alternative valuations. The sensitivity methodologies applied take account of the nature of the valuation techniques used, as well as the availability and reliability of observable proxy and historical data and the impact of using alternative models. Sensitivities are dynamically calculated on a monthly basis. The calculation is based on range or spread data of a reliable reference source or a scenario based on relevant market analysis alongside the impact of using alternative models. Sensitivities are calculated without reflecting the impact of any diversification in the portfolio. The valuation techniques used, observability and sensitivity analysis for material products within Level 3, are described below. Interest rate derivatives Description: Derivatives linked to interest rates or inflation indices. The category includes futures, interest rate and inflation swaps, swaptions, caps, floors, inflation options, balance guaranteed swaps and other exotic interest rate derivatives. Valuation: Interest rate and inflation derivatives are generally valued using curves of forward rates constructed from market data to project and discount the expected future cash flows of trades. Instruments with optionality are valued using volatilities implied from market inputs, and use industry standard or bespoke models depending on the product type. Observability: In general, inputs are considered observable up to liquid maturities which are determined separately for each input and underlying. Unobservable inputs are generally set by referencing liquid market instruments and applying extrapolation techniques or inferred via another reasonable method. Foreign exchange derivatives Description: Derivatives linked to the foreign exchange (FX) market. The category includes FX forward contracts, FX swaps and FX options. The majority are traded as over the counter (OTC) derivatives. Valuation: FX derivatives are valued using industry standard and bespoke models depending on the product type. Valuation inputs include FX rates, interest rates, FX volatilities, interest rate volatilities, FX interest rate correlations and others as appropriate. Observability: FX correlations, forwards and volatilities are generally observable up to liquid maturities which are determined separately for each input and underlying. Unobservable inputs are set by referencing liquid market instruments and applying extrapolation techniques, or inferred via another reasonable method. Credit derivatives Description: Derivatives linked to the credit spread of a referenced entity, index or basket of referenced entities or a pool of referenced assets (e.g. a securitised product). The category includes single name and index credit default swaps (CDS) and total return swaps (TRS). Valuation: CDS are valued on industry standard models using curves of credit spreads as the principal input. Credit spreads are observed directly from broker data, third party vendors or priced to proxies. Observability : CDS contracts referencing entities that are actively traded are generally considered observable. Other valuation inputs are considered observable if products with significant sensitivity to the inputs are actively traded in a liquid market. Unobservable valuation inputs are generally determined with reference to recent transactions or inferred from observable trades of the same issuer or similar entities. Equity derivatives Description : Exchange traded or OTC derivatives linked to equity indices and single names. The category includes vanilla and exotic equity products. Valuation: Equity derivatives are valued using industry standard models. Valuation inputs include stock prices, dividends, volatilities, interest rates, equity repurchase curves and, for multi-asset products, correlations. Observability : In general, valuation inputs are observable up to liquid maturities which are determined separately for each input and underlying. Unobservable inputs are set by referencing liquid market instruments and applying extrapolation techniques, or inferred via another reasonable method. Corporate debt Description: Primarily corporate bonds. Valuation: Corporate bonds are valued using observable market prices sourced from broker quotes, inter-dealer prices or other reliable pricing sources. Observability: Prices for actively traded bonds are considered observable. Unobservable bonds prices are generally determined by reference to bond yields or CDS spreads for actively traded instruments issued by or referencing the same (or a similar) issuer. Reverse repurchase and repurchase agreements Description: Includes securities purchased under resale agreements, securities sold under repurchase agreements, and other similar secured lending agreements. The agreements are primarily short-term in nature. Valuation: Repurchase and reverse repurchase agreements are generally valued by discounting the expected future cash flows using industry standard models that incorporate market interest rates and repurchase rates, based on the specific details of the transaction. Observability: Inputs are deemed observable up to liquid maturities, and are determined based on the specific features of the transaction. Unobservable inputs are generally set by referencing liquid market instruments and applying extrapolation techniques, or inferred via another reasonable method. Non-asset backed loans Description: Largely made up of fixed rate loans. Valuation: Fixed rate loans are valued using models that discount expected future cash flows based on interest rates and loan spreads. Observability: Within this loan population, the loan spread is generally unobservable. Unobservable loan spreads are determined by incorporating funding costs, the level of comparable assets such as gilts, issuer credit quality and other factors. Asset backed securities Description: Securities that are linked to the cash flows of a pool of referenced assets via securitisation. The category includes residential mortgage backed securities, commercial mortgage backed securities, CDOs, collateralised loan obligations (CLOs) and other asset backed securities. Valuation: Where available, valuations are based on observable market prices sourced from broker quotes and inter-dealer prices. Otherwise, valuations are determined using industry standard discounted cash flow analysis that calculates the fair value based on valuation inputs such as constant default rate, conditional prepayment rate, loss given default and yield. These inputs are determined by reference to a number of sources including proxying to observed transactions, market indices or market research, and by assessing underlying collateral performance. Proxying to observed transactions, indices or research requires an assessment and comparison of the relevant securities’ underlying attributes including collateral, tranche, vintage, underlying asset composition (historical losses, borrower characteristics and loan attributes such as loan to value ratio and geographic concentration) and credit ratings (original and current). Observability: Where an asset backed product does not have an observable market price and the valuation is determined using a discounted cash flow analysis, the instrument is considered unobservable. Equity cash products Description: Includes listed equities, Exchange Traded Funds (ETF) and preference shares. Valuation: Valuation of equity cash products is primarily determined through market observable prices. Observability: Prices for actively traded equity cash products are considered observable. Unobservable equity prices are generally determined by reference to actively traded instruments that are similar in nature, or inferred via another reasonable method. Private equity investments Description: Includes investments in equity holdings in operating companies not quoted on a public exchange. Valuation: Private equity investments are valued in accordance with the ‘International Private Equity and Venture Capital Valuation Guidelines’ which require the use of a number of individual pricing benchmarks such as the prices of recent transactions in the same or similar entities, discounted cash flow analysis and comparison with the earnings multiples of listed companies. While the valuation of unquoted equity instruments is subjective by nature, the relevant methodologies are commonly applied by other market participants and have been consistently applied over time. Observability : Inputs are considered observable if there is active trading in a liquid market of products with significant sensitivity to the inputs. Unobservable inputs include earnings estimates, multiples of comparative companies, marketability discounts and discount rates. Other Description: Other includes commercial real estate loans,, asset backed loans, funds and fund-linked products, issued debt, government sponsored debt, commodity derivatives and investment property. Assets and liabilities reclassified between Level 1 and Level 2 During the period, there were no material transfers between Level 1 and Level 2 (2020: there were no material transfers between Level 1 and Level 2). Level 3 movement analysis The following table summarises the movements in the Level 3 balances during the period. The table shows gains and losses and includes amounts for all financial assets and liabilities that are held at fair value transferred to and from Level 3 during the period. Transfers have been reflected as if they had taken place at the beginning of the year. Asset and liability transfers between Level 2 and Level 3 are primarily due to i) an increase or decrease in observable market activity related to an input or ii) a change in the significance of the unobservable input, with assets and liabilities classified as Level 3 if an unobservable input is deemed significant. Analysis of movements in Level 3 assets and liabilities As at 1 January 2021 Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 31 December 2021 Purchases Sales Issues Settlements Trading income Other income In Out £m £m £m £m £m £m £m £m £m £m £m Corporate debt 151 310 (123) — (12) 38 — — 41 (16) 389 Non-asset backed loans 709 1,580 (1,409) — (85) (1) — — 45 (81) 758 Asset backed securities 686 209 (370) — — (69) — — 114 (116) 454 Equity cash products 214 45 (53) — 4 23 — — 80 (10) 303 Other 103 117 (2) — (61) (3) — — 248 (25) 377 Trading portfolio assets 1,863 2,261 (1,957) — (154) (12) — — 528 (248) 2,281 Non-asset backed loans 5,580 1,380 (306) — (748) (181) (174) — 113 (17) 5,647 Equity cash products 326 3 (247) — — — 7 — 1 — 90 Private equity investments 874 166 (24) — (9) — 163 — 35 (110) 1,095 Other 1,726 11,253 (9,983) — (185) 2 20 — 48 (1) 2,880 Financial assets at fair value through the income statement 8,506 12,802 (10,560) — (942) (179) 16 — 197 (128) 9,712 Non-asset backed loans 106 — — — — — — — — (106) 0 Asset backed securities 47 — — — (7) — — (2) — — 38 Financial assets at fair value through other comprehensive income 153 — — — (7) — — (2) — (106) 38 Investment property 10 — (2) — — — (1) — — — 7 Trading portfolio liabilities (28) (5) 23 — — (6) — — (12) 1 (27) Financial liabilities designated at fair value (355) (4) — (101) 66 21 (1) — (68) 32 (410) Interest rate derivatives (2) 20 — — 105 (255) — — 90 (218) (260) Foreign exchange derivatives 1 — — — 40 (2) — — 10 (47) 2 Credit derivatives (155) (239) 9 — (45) 34 — — 10 — (386) Equity derivatives (1,614) 90 (1) — (15) (4) — — (3) 142 (1,405) Net derivative financial instruments a (1,770) (129) 8 — 85 (227) — — 107 (123) (2,049) Total 8,379 14,925 (12,488) (101) (952) (403) 14 (2) 752 (572) 9,552 Note a The derivative financial instruments are represented on a net basis. On a gross basis, derivative financial assets are £4,010m (2020: £4,469m) and derivative financial liabilities are £6,059m (2020: £6,239m). Analysis of movements in Level 3 assets and liabilities As at 1 January 2020 Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 31 December 2020 Purchases Sales Issues Settlements Trading income Other income In Out £m £m £m £m £m £m £m £m £m £m £m Corporate debt 120 77 (6) — — (35) — — 12 (17) 151 Non-asset backed loans 974 1,955 (2,182) — (12) (10) — — 39 (55) 709 Asset backed securities 656 458 (428) — (40) (25) — — 90 (25) 686 Equity cash products 392 5 (149) — — (41) — — 11 (4) 214 Other 122 — — — — (21) — — 2 — 103 Trading portfolio assets 2,264 2,495 (2,765) — (52) (132) — — 154 (101) 1,863 Non-asset backed loans 5,494 1,102 (283) — (706) 426 — — — (453) 5,580 Equity cash products 835 15 (404) — — (93) (36) — 9 — 326 Private equity investments 900 84 (54) — (3) — (56) — 15 (12) 874 Other 1,271 3,718 (3,606) — (32) 32 (43) — 386 — 1,726 Financial assets at fair value through the income statement 8,500 4,919 (4,347) — (741) 365 (135) — 410 (465) 8,506 Non-asset backed loans 343 — — — (237) — — — — — 106 Asset backed securities 86 — (35) — — — — (4) — — 47 Financial assets at fair value through other comprehensive income 429 — (35) — (237) — — (4) — — 153 Investment property 13 — (2) — — — (1) — — — 10 Trading portfolio liabilities — (27) — — — (1) — — — — (28) Financial liabilities designated at fair value (362) — 3 (21) 1 20 4 — (38) 38 (355) Interest rate derivatives (206) 17 (12) — 85 109 — — (18) 23 (2) Foreign exchange derivatives (7) — — — 21 (16) — — (19) 22 1 Credit derivatives 198 (125) 24 — (371) 24 — — (21) 116 (155) Equity derivatives (819) (699) (43) — 105 (101) — — (13) (44) (1,614) Net derivative financial instruments (834) (807) (31) — (160) 16 — — (71) 117 (1,770) Total 10,010 6,580 (7,177) (21) (1,189) 268 (132) (4) 455 (411) 8,379 Unrealised gains and losses on Level 3 financial assets and liabilities The following table discloses the unrealised gains and losses recognised in the year arising on Level 3 financial assets and liabilities held at year end. Unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at year end 2021 2020 Income statement Other compre- Total Income statement Other Total Trading income Other income Trading income Other income As at 31 December £m £m £m £m £m £m £m £m Trading portfolio assets (67) — — (67) (114) — — (114) Financial assets at fair value through the income statement (176) 154 — (22) 399 (89) — 310 Fair value through other comprehensive income — — — — — — (1) (1) Investment property — — — — — (1) — (1) Trading portfolio liabilities (5) — — (5) — — — — Financial liabilities designated at fair value 16 (1) — 15 20 (1) — 19 Net derivative financial instruments (196) — — (196) (91) — — (91) Total (428) 153 — (275) 214 (91) (1) 122 Significant unobservable inputs The following table discloses the valuation techniques and significant unobservable inputs for assets and liabilities recognised at fair value and classified as Level 3 along with the range of values used for those significant unobservable inputs: Valuation technique(s) a Significant unobservable inputs 2021 Range 2020 Range Min Max Min Max Units b Derivative financial instruments c Interest rate derivatives Discounted cash flows Inflation forwards — 3 1 3 % Credit spread 9 1,848 17 1,831 bps Correlation Model Inflation forwards (20) (13) (20) (13) % Comparable pricing Price — 38 — 84 points Option model Inflation volatility 31 130 31 227 bps vol Interest rate volatility 5 600 6 489 bps vol FX - IR correlation (20) 78 (30) 78 % IR - IR correlation (100) 99 (20) 99 % Credit derivatives Discounted cash flows Credit spread 2 2,925 5 480 bps Comparable pricing Price — — — 100 points Equity derivatives Option model Equity volatility 2 108 1 110 % Equity - equity correlation 10 100 (45) 100 % Discounted cash flow Discounted margin (129) 93 (225) 3,000 bps Foreign exchange derivatives Option Model Option Volatility — 100 — 30 points Non-derivative financial instruments Non-asset backed loans Discounted cash flows Loan spread 31 1,552 31 1,518 bps Credit spread 200 300 200 300 bps Price — 112 — 104 points Yield 3 10 5 8 % Comparable pricing Price — 145 — 137 points Asset backed securities Comparable pricing Price — 120 — 112 points Private equity investments EBITDA multiple EBITDA multiple 16 20 14 16 Multiple Earnings multiple Earnings multiple 5 28 3 28 Multiple Discounted cash flow Credit Spread 725 1,916 1,387 1,916 bps Discount margin 8 10 1 10 % Corporate debt Comparable pricing Price — 284 — 127 points Discounted Cash Flows Loan Spread 229 854 — — bps Price — 100 — 104 points Commercial Real Estate loans Discounted cash flows Credit spread 68 543 146 483 bps Equity cash products Discounted cash flows Discount Margin 26 34 49 49 bps Notes a A range has not been provided for Net Asset Value as there would be a wide range reflecting the diverse nature of the positions. b The units used to disclose ranges for significant unobservable inputs are percentages, points and basis points. Points are a percentage of par; for example, 100 points equals 100% of par. A basis point equals 1/100th of 1%; for example, 150 basis points equals 1.5%. c Certain derivative instruments are classified as Level 3 due to a significant unobservable credit spread input into the calculation of the Credit Valuation Adjustment for the instruments. The range of significant unobservable credit spreads is between 32-1848bps (2020: 17-1,831bps). The following section describes the significant unobservable inputs identified in the table above, and the sensitivity of fair value measurement of the instruments categorised as Level 3 assets or liabilities to increases in significant unobservable inputs. Where sensitivities are described, the inverse relationship will also generally apply. Where reliable interrelationships can be identified between significant unobservable inputs used in fair value measurement, a description of those interrelationships is included below. Forwards A price or rate that is applicable to a financial transaction that will take place in the future. In general, a significant increase in a forward in isolation will result in a fair value increase for the contracted receiver of the underlying (currency, bond, commodity, etc.), but the sensitivity is dependent on the specific terms of the instrument. Credit spread Credit spreads typically represent the difference in yield between an instrument and a benchmark security or reference rate. Credit spreads reflect the additional yield that a market participant demands for taking on exposure to the credit risk of an instrument and form part of the yield used in a discounted cash flow calculation. In general, a significant increase in credit spread in isolation will result in a movement in a fair value decrease for a cash asset. For a derivative instrument, a significant increase in credit spread in isolation can result in a fair value increase or decrease depending on the specific terms of the instrument. Volatility Volatility is a measure of the variability or uncertainty in return for a given derivative underlying. It is an estimate of how much a particular underlying instrument input or index will change in value over time. In general, volatilities are implied from observed option prices. For unobservable options the implied volatility may reflect additional assumptions about the nature of the underlying risk, and the strike/maturity profile of a specific contract. In general a significant increase in volatility in isolation will result in a fair value increase for the holder of a simple option, but the sensitivity is dependent on the specific terms of the instrument. There may be interrelationships between unobservable volatilities and other unobservable inputs (e.g. when equity prices fall, implied equity volatilities generally rise) but these are generally specific to individual markets and may vary over time. Correlation Correlation is a measure of the relationship between the movements of two variables. Correlation can be a significant input into valuation of derivative contracts with more than one underlying instrument. Credit correlation generally refers to the correlation between default processes for the separate names that make up the reference pool of a CDO structure. A significant increase in correlation in isolation can result in a fair value increase or decrease depending on the specific terms of the instrument. Comparable price Comparable instrument prices are used in valuation by calculating an implied yield (or spread over a liquid benchmark) from the price of a comparable observable instrument, then adjusting that yield (or spread) to account for relevant differences such as maturity or credit quality. Alternatively, a price-to-price basis can be assumed between the comparable and unobservable instruments in order to establish a value. In general, a significant increase in comparable price in isolation will result in an increase in the price of the unobservable instrument. For derivatives, a change in the comparable price in isolation can result in a fair value increase or decrease depending on the specific terms of the instrument. Loan spread Loan spreads typically represent the difference in yield between an instrument and a benchmark security or reference rate. Loan spreads typically reflect credit quality, the level of comparable assets such as gilts and other factors, and form part of the yield used in a discounted cash flow calculation. The ESHLA portfolio primarily consists of long-dated fixed rate loans extended to counterparties in the UK Education, Social Housing and Local Authority sectors. The loans are categorised as Level 3 in the fair value hierarchy due to their illiquid nature and the significance of unobservable loan spreads to the valuation. Valuation uncertainty arises from the long-dated nature of the portfolio, the lack of secondary market in the loans and the lack of observable loan spreads. The majority of ESHLA loans are to borrowers in heavily regulated sectors that are considered extremely low credit risk, and have a history of near zero defaults since inception. While the overall loan spread range is from 31bps to 1,552bps (2020: 31bps to 1,518bps), the vast majority of spreads are concentrated towards the bottom end of this range, with 97% of the loan notional being valued with spreads less than 200bps consistently for both years. In general, a significant increase in loan spreads in isolation will result in a fair value decrease for a loan. EBITDA multiple EBITDA multiple is the ratio of the valuation of the investment to the earnings before interest, taxes, depreciation and amortisation. In general, a significant increase in the multiple will result in a fair value increase for an investment. Sensitivity analysis of valuations using unobservable inputs 2021 2020 Favourable changes Unfavourable changes Favourable changes Unfavourable changes Income statement Equity Income statement Equity Income statement Equity Income statement Equity £m £m £m £m £m £m £m £m Interest rate derivatives 51 — (79) — 82 — (123) — Foreign exchange derivatives 20 — (28) — 6 — (11) — Credit derivatives 111 — (103) — 55 — (44) — Equity derivatives 187 — (195) — 174 — (179) — Corporate debt 38 — (28) — 16 — (14) — Non-asset backed loans 165 — (256) — 190 3 (409) (3) Equity cash products 42 — (61) — 158 — (141) — Private equity investments 246 — (236) — 199 — (227) — Other a 20 — (19) — 23 — (23) — Total 880 — (1,005) — 903 3 (1,171) (3) Note a Other includes commercial real estate loans and asset backed loans, funds and fund-linked products, issued debt, government sponsored debt, commodity derivatives a |
Offsetting financial assets and
Offsetting financial assets and financial liabilities | 12 Months Ended |
Dec. 31, 2021 | |
Offsetting financial assets and financial liabilities [Abstract] | |
Offsetting financial assets and financial liabilities | Offsetting financial assets and financial liabilities In accordance with IAS 32 Financial Instruments: Presentation, t he Group reports financial assets and financial liabilities on a net basis on the balance sheet only if there is a legally enforceable right to set-off the recognised amounts and there is intention to settle on a net basis, or to realise the asset and settle the liability simultaneously. The following table shows the impact of netting arrangements on: ▪ all financial assets and liabilities that are reported net on the balance sheet ▪ all derivative financial instruments and reverse repurchase and repurchase agreements and other similar secured lending and borrowing agreements that are subject to enforceable master netting arrangements or similar agreements, but do not qualify for balance sheet netting. The ‘Net amounts’ presented are not intended to represent the Group’s actual exposure to credit risk, as a variety of credit mitigation strategies are employed in addition to netting and collateral arrangements. Amounts subject to enforceable netting arrangements Amounts not subject to enforceable netting arrangements c Balance sheet total d Effects of offsetting on-balance sheet Related amounts not offset Gross amounts Amounts offset a Net amounts reported on the balance sheet Financial instruments Financial collateral b Net amount £m £m £m £m £m £m £m £m As at 31 December 2021 Derivative financial assets 279,568 (24,137) 255,431 (202,519) (40,485) 12,427 7,141 262,572 Reverse repurchase agreements and other similar secured lending e 514,360 (370,003) 144,357 — (143,854) 503 3,884 148,241 Total assets 793,928 (394,140) 399,788 (202,519) (184,339) 12,930 11,025 410,813 Derivative financial liabilities (274,356) 23,606 (250,750) 202,519 34,321 (13,910) (6,133) (256,883) Repurchase agreements and other similar secured borrowing e (535,653) 370,003 (165,650) — 165,650 — (30,762) (196,412) Total liabilities (810,009) 393,609 (416,400) 202,519 199,971 (13,910) (36,895) (453,295) As at 31 December 2020 Derivative financial assets 342,649 (44,305) 298,344 (233,080) (48,064) 17,200 4,102 302,446 Reverse repurchase agreements and other similar secured lending e 448,134 (306,398) 141,736 — (141,352) 384 4,911 146,647 Total assets 790,783 (350,703) 440,080 (233,080) (189,416) 17,584 9,013 449,093 Derivative financial liabilities (333,943) 41,982 (291,961) 233,080 46,804 (12,077) (8,814) (300,775) Repurchase agreements and other similar secured borrowing e (476,912) 306,398 (170,514) — 170,514 — (21,031) (191,545) Total liabilities (810,855) 348,380 (462,475) 233,080 217,318 (12,077) (29,845) (492,320) Notes a Amounts offset for derivative financial assets additionally includes cash collateral netted of £3,815m (2020: £4,990m). Amounts offset for derivative financial liabilities additionally includes cash collateral netted of £4,346m (2020: £7,313m). Settlements assets and liabilities have been offset amounting to £22,837m (2020: £18,143m). b Financial collateral of £40,485m (2020: £48,064m) was received in respect of derivative assets, including £34,598m (2020: £43,291m) of cash collateral and £5,887m (2020: £4,773m) of non-cash collateral. Financial collateral of £34,321m (2020: £46,804m) was placed in respect of derivative liabilities, including £32,031m (2020: £42,730m) of cash collateral and £2,290m (2020: £4,074m) of non-cash collateral. The collateral amounts are limited to net balance sheet exposure so as to not include overcollateralisation. c This column includes contractual rights of set-off that are subject to uncertainty under the laws of the relevant jurisdiction. d The balance sheet total is the sum of ‘Net amounts reported on the balance sheet’ that are subject to enforceable netting arrangements and ‘Amounts not subject to enforceable netting arrangements’. e Reverse repurchase agreements and other similar secured lending of £148,241m (2020: £146,647m) is split by fair value £145,014m (2020: £137,616m) and amortised cost £3,227m (2020: £9,031m). Repurchase agreements and other similar secured borrowing of £196,412m (2020: £191,545m) is split by fair value £168,060m (2020: £177,371m) and amortised cost £28,352m (2020: £14,174m). Derivative assets and liabilities The ‘Financial instruments’ column identifies financial assets and liabilities that are subject to set-off under netting agreements, such as the ISDA Master Agreement or derivative exchange or clearing counterparty agreements, whereby all outstanding transactions with the same counterparty can be offset and close-out netting applied across all outstanding transactions covered by the agreements if an event of default or other predetermined events occur. Financial collateral refers to cash and non-cash collateral obtained, typically daily or weekly, to cover the net exposure between counterparties by enabling the collateral to be realised in an event of default or if other predetermined events occur. Repurchase and reverse repurchase agreements and other similar secured lending and borrowing The ‘Financial instruments’ column identifies financial assets and liabilities that are subject to set-off under netting agreements, such as Global Master Repurchase Agreements and Global Master Securities Lending Agreements, whereby all outstanding transactions with the same counterparty can be offset and close-out netting applied across all outstanding transactions covered by the agreements if an event of default or other predetermined events occur. Financial collateral typically comprises highly liquid securities which are legally transferred and can be liquidated in the event of counterparty default. These offsetting and collateral arrangements and other credit risk mitigation strategies used by the Group are further explained in the Credit risk management section. |
Loans and advances and deposits
Loans and advances and deposits at amortised cost | 12 Months Ended |
Dec. 31, 2021 | |
Loans and advances and deposits at amortised cost | |
Loans and advances and deposits at amortised cost | Loans and advances and deposits at amortised cost Accounting for loans and advances and deposits held at amortised cost Loans and advances to customers and banks, customer accounts, debt securities and most financial liabilities, are held at amortised cost. That is, the initial fair value (which is normally the amount advanced or borrowed) is adjusted for repayments and the amortisation of coupon, fees and expenses to represent the effective interest rate of the asset or liability. Balances deferred on-balance sheet as effective interest rate adjustments are amortised to interest income over the life of the financial instrument to which they relate. Financial assets that are held in a business model to collect the contractual cash flows and that contain contractual terms that give rise on specified dates to cash flows that are SPPI, are measured at amortised cost. The carrying value of these financial assets at initial recognition includes any directly attributable transaction costs. Refer to Note 1 for details on ‘solely payments of principal and interest’. In determining whether the business model is a ‘hold to collect’ model, the objective of the business model must be to hold the financial asset to collect contractual cash flows rather than holding the financial asset for trading or short-term profit taking purposes. While the objective of the business model must be to hold the financial asset to collect contractual cash flows this does not mean the Group is required to hold the financial assets until maturity. When determining if the business model objective is to collect contractual cash flows the Group will consider past sales and expectations about future sales. Loans and advances and deposits at amortised cost 2021 2020 As at 31 December £m £m Loans and advances at amortised cost to banks 9,698 8,900 Loans and advances at amortised cost to customers 319,922 309,927 Debt securities at amortised cost 31,831 23,805 Total loans and advances at amortised cost 361,451 342,632 Deposits at amortised cost from banks 17,819 17,343 Deposits at amortised cost from customers 501,614 463,693 Total deposits at amortised cost 519,433 481,036 |
Property, plant and equipment
Property, plant and equipment | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of detailed information about property, plant and equipment [abstract] | |
Property, plant and equipment | Property, plant and equipment Accounting for property, plant and equipment The Group applies IAS 16 Property Plant and Equipment and IAS 40 Investment Properties. Property, plant and equipment is stated at cost, which includes direct and incremental acquisition costs less accumulated depreciation and provisions for impairment, if required. Subsequent costs are capitalised if these result in enhancement of the asset. Depreciation is provided on the depreciable amount of items of property, plant and equipment on a straight-line basis over their estimated useful economic lives. Depreciation rates, methods and the residual values underlying the calculation of depreciation of items of property, plant and equipment are kept under review to take account of any change in circumstances. The Group uses the following annual rates in calculating depreciation: Annual rates in calculating depreciation Depreciation rate Freehold land Not depreciated Freehold buildings and long-leasehold property (more than 50 years to run) 2-3.3% Leasehold property over the remaining life of the lease (less than 50 years to run) Over the remaining life of the lease Costs of adaptation of freehold and leasehold property 6-10% Equipment installed in freehold and leasehold property 6-10% Computers and similar equipment 17-33% Fixtures and fittings and other equipment 9-20% Costs of adaptation and installed equipment are depreciated over the shorter of the life of the lease or the depreciation rates noted in the table above. Investment property The Group initially recognises investment property at cost, and subsequently at fair value at each balance sheet date, reflecting market conditions at the reporting date. Gains and losses on remeasurement are included in the income statement. Investment Property Equipment Right of use assets a Total £m £m £m £m £m Cost As at 1 January 2021 10 4,002 3,091 1,934 9,037 Additions — 274 189 32 495 Disposals (2) (160) (74) (114) (350) Exchange and other movements (1) 15 4 68 86 As at 31 December 2021 7 4,131 3,210 1,920 9,268 Accumulated depreciation and impairment As at 1 January 2021 — (2,013) (2,421) (567) (5,001) Depreciation charge — (249) (222) (204) (675) Impairment b — (106) — (170) (276) Disposals — 136 66 60 262 Exchange and other movements — (23) (9) 9 (23) As at 31 December 2021 — (2,255) (2,586) (872) (5,713) Net book value 7 1,876 624 1,048 3,555 Cost As at 1 January 2020 13 3,938 2,986 1,826 8,763 Additions — 193 246 85 524 Disposals (1) (96) (100) (14) (211) Exchange and other movements (2) (33) (41) 37 (39) As at 31 December 2020 10 4,002 3,091 1,934 9,037 Accumulated depreciation and impairment As at 1 January 2020 — (1,901) (2,315) (332) (4,548) Depreciation charge — (187) (223) (231) (641) Impairment — (25) (2) (15) (42) Disposals — 82 92 2 176 Exchange and other movements — 18 27 9 54 As at 31 December 2020 — (2,013) (2,421) (567) (5,001) Net book value 10 1,989 670 1,367 4,036 Notes a Right of use (ROU) asset balances relate to property leases under IFRS 16. Refer to Note 21 for further details. b Impairment charge includes £266m related to structural cost action in relation to the real estate review. Property rentals of £16m (2020: £11m) have been included in other income. |
Leases
Leases | 12 Months Ended |
Dec. 31, 2021 | |
Leases [Abstract] | |
Leases | Leases Accounting for leases IFRS 16 applies to all leases with the exception of licenses of intellectual property, rights held by licensing agreement within the scope of IAS 38 Intangible Assets, service concession arrangements, leases of biological assets within the scope of IAS 41 Agriculture and leases of minerals, oil, natural gas and similar non-regenerative resources. IFRS 16 includes an accounting policy choice for a lessee to elect not to apply IFRS 16 to remaining assets within the scope of IAS 38 Intangible Assets which the Group has decided to apply. When the Group is the lessee, it is required to recognise both: ▪ A lease liability, measured at the present value of remaining cash flows on the lease, and ▪ A right of use (ROU) asset, measured at the amount of the initial measurement of the lease liability, plus any lease payments made prior to commencement date, initial direct costs, and estimated costs of restoring the underlying asset to the condition required by the lease, less any lease incentives received. Subsequently the lease liability will increase for the accrual of interest, resulting in a constant rate of return throughout the life of the lease, and reduce when payments are made. The right of use asset will amortise to the income statement over the life of the lease. The lease liability is remeasured when there is a change in one of the following: ▪ Future lease payments arising from a change in an index or rate; ▪ The Group’s estimate of the amount expected to be payable under a residual value guarantee; or ▪ The Group’s assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount of the ROU asset, or is recorded in the income statement if the carrying amount of the ROU asset has been reduced to nil. On the balance sheet, the ROU assets are included within property, plant and equipment and the lease liabilities are included within other liabilities. The Group applies the recognition exemption in IFRS 16 for leases with a term not exceeding 12 months. For these leases the lease payments are recognised as an expense on a straight line basis over the lease term unless another systematic basis is more appropriate. When the Group is the lessor, the lease must be classified as either a finance lease or an operating lease. A finance lease is a lease which confers substantially all the risks and rewards of the leased assets on the lessee. An operating lease is a lease where substantially all of the risks and rewards of the leased asset remain with the lessor. When the lease is deemed a finance lease, the leased asset is not held on the balance sheet; instead a finance lease receivable is recognised representing the minimum lease payments receivable under the terms of the lease, discounted at the rate of interest implicit in the lease. When the lease is deemed an operating lease, the lease income is recognised on a straight-line basis over the period of the lease unless another systematic basis is more appropriate. The Group holds the leased assets on-balance sheet within property, plant and equipment. As a Lessor Finance lease receivables are included within loans and advances at amortised cost. The following table sets out a maturity analysis of lease receivables, showing the lease payments to be received after the reporting date. 2021 2020 Gross investment in finance lease receivables Future finance income Present value of minimum lease payments Unguaranteed residual values Gross investment in finance lease receivables Future finance income Present value of minimum lease payments Unguaranteed residual values £m £m £m £m £m £m £m £m Not more than one year 29 (3) 26 — 535 (26) 509 70 One to two year 19 (2) 17 — 312 (15) 297 45 Two to three year 6 — 6 — 215 (12) 203 52 Three to four year 2 — 2 — 107 (6) 101 27 Four to five year 1 — 1 — 52 (3) 49 18 Over five years 1 — 1 — 24 (1) 23 13 Total 58 (5) 53 — 1,245 (63) 1,182 225 Barclays Asset Finance provided leasing and other asset finance facilities across a broad range of asset types to business and individual customers. In 2021, the Group sold the leasing portfolio held by Barclays Asset Finance leading to a decrease in gross investment in finance lease receivables. There is no impairment allowance for finance lease receivables in current year (2020: £29m). The Group does not have any material operating leases as a lessor. Finance lease income Finance lease income is included within interest income. The following table shows amounts recognised in the income statement during the year. 2021 2020 £m £m Finance income from net investment in lease 21 55 Profit/(loss) on sales 1 (25) As a Lessee The Group leases various offices, branches and other premises under non-cancellable lease arrangements to meet its operational business requirements. In some instances, Barclays will sublease property to third parties when it is no longer needed to meet business requirements. Currently, Barclays does not have any material subleasing arrangements. ROU asset balances relate to property leases only. Refer to Note 20 for a breakdown of the carrying amount of ROU assets. The total expenses recognised during the year for short term leases were £3m (2020: £4m). The portfolio of short term leases to which Barclays is exposed at the end of the year is not dissimilar to the expenses recognised in the year. Lease liabilities 2021 2020 £m £m As at 1 January 1,444 1,563 Interest expense 64 70 New leases 43 85 Disposals (54) (15) Cash payments (258) (306) Exchange and other movements 78 47 As at 31 December (see Note 23) 1,317 1,444 The below table sets out a maturity analysis of undiscounted lease liabilities, showing the lease payments to be paid after the reporting date. Undiscounted lease liabilities maturity analysis 2021 2020 £m £m Not more than one year 230 255 One to two years 215 221 Two to three years 197 198 Three to four years 182 176 Four to five years 149 162 Five to ten years 503 557 Greater than ten years 163 248 Total undiscounted lease liabilities as at 31 December 1,639 1,817 In addition to the cash flows identified above, Barclays is exposed to: ▪ Variable lease payments: This variability will typically arise from either inflation index instruments or market based pricing adjustments. Currently, Barclays has 609 (2020: 809) leases out of the total 1,111 (2020: 1,329) leases which have variable lease payment terms based on market based pricing adjustments. Of the gross cash flows identified above, £1,196m (2020: £1,096m) is attributable to leases with some degree of variability predominately linked to market based pricing adjustments. ▪ Extension and termination options: The table above represents Barclays best estimate of future cash out flows for leases, including assumptions regarding the exercising of contractual extension and termination options. The above gross cash flows have been reduced by £434m (2020: £446m) for leases where Barclays is highly expected to exercise an early termination option. However, there is no significant impact where Barclays is expected to exercise an extension option. In 2021, the Group recorded a gain on sale relating to a sale and leaseback transaction of the Monaco branch premises of £33m. The Group does not have any restrictions or covenants imposed by the lessor on its property leases which restrict its businesses. |
Goodwill and intangible assets
Goodwill and intangible assets | 12 Months Ended |
Dec. 31, 2021 | |
Intangible assets and goodwill [abstract] | |
Goodwill and intangible assets | Goodwill and intangible assets Accounting for goodwill and intangible assets Goodwill The carrying value of goodwill is determined in accordance with IFRS 3 Business Combinations and IAS 36 Impairment of Assets . Goodwill arising on the acquisition of subsidiaries represents the excess of the fair value of the purchase consideration over the fair value of the Group’s share of the assets acquired and the liabilities and contingent liabilities assumed on the date of the acquisition. Goodwill is reviewed annually for impairment, or more frequently when there are indications that impairment may have occurred. The test involves comparing the carrying value of a cash generating unit (CGU) including goodwill with the present value of the pre-tax cash flows, discounted at a rate of interest that reflects the inherent risks, of the CGU to which the goodwill relates, or the CGU's fair value if this is higher. Intangible assets Intangible assets other than goodwill are accounted for in accordance with IAS 38 Intangible Assets. Intangible assets are initially recognised when they are separable or arise from contractual or other legal rights, the cost can be measured reliably and, in the case of intangible assets not acquired in a business combination, where it is probable that future economic benefits attributable to the assets will flow from their use. For internally generated intangible assets, only costs incurred during the development phase are capitalised. Expenditure in the research phase is expensed when it is incurred. Intangible assets are stated at cost (which is, in the case of assets acquired in a business combination, the acquisition date fair value) less accumulated amortisation and impairment, if any, and are amortised over their useful lives in a manner that reflects the pattern to which they contribute to future cash flows, generally using the amortisation periods set out below: Annual rates in calculating amortisation Amortisation period Goodwill Not amortised Internally generated software a 12 months to 6 years Other software 12 months to 6 years Customer lists 12 months to 25 years Licences and other 12 months to 25 years Note a Exceptions to the above rate relate to useful lives of certain core banking platforms that are assessed individually and, if appropriate, amortised over longer periods ranging from 10 to 15 years. Intangible assets are reviewed for impairment when there are indications that impairment may have occurred. Intangible assets not yet available for use are reviewed annually for impairment. Intangible assets Goodwill Internally Other Customer Licences Total £m £m £m £m £m £m 2021 Cost As at 1 January 2021 4,716 7,247 639 1,419 490 14,511 Additions and disposals — (52) (9) (5) 404 338 Exchange and other movements 2 (15) (4) 17 14 14 As at 31 December 2021 4,718 7,180 626 1,431 908 14,863 Accumulated amortisation and impairment As at 1 January 2021 (825) (3,779) (328) (1,252) (379) (6,563) Disposals — 894 15 5 3 917 Amortisation charge — (867) (51) (36) (44) (998) Impairment charge — (127) — — — (127) Exchange and other movements — (5) — (17) (9) (31) As at 31 December 2021 (825) (3,884) (364) (1,300) (429) (6,802) Net book value 3,893 3,296 262 131 479 8,061 2020 Cost As at 1 January 2020 4,760 6,643 505 1,465 489 13,862 Additions and disposals (37) 646 131 — 22 762 Exchange and other movements (7) (42) 3 (46) (21) (113) As at 31 December 2020 4,716 7,247 639 1,419 490 14,511 Accumulated amortisation and impairment As at 1 January 2020 (861) (2,989) (279) (1,250) (364) (5,743) Disposals 37 97 10 — 3 147 Amortisation charge — (771) (51) (43) (33) (898) Impairment charge — (147) (6) — — (153) Exchange and other movements (1) 31 (2) 41 15 84 As at 31 December 2020 (825) (3,779) (328) (1,252) (379) (6,563) Net book value 3,891 3,468 311 167 111 7,948 Goodwill Goodwill and Intangible assets are allocated to business operations according to business segments as follows: 2021 2020 Goodwill Intangibles Total Goodwill Intangibles Total £m £m £m £m £m £m Barclays UK 3,560 1,233 4,793 3,560 1,618 5,178 Barclays International 291 2,930 3,221 289 2,435 2,724 Head Office 42 5 47 42 4 46 Total 3,893 4,168 8,061 3,891 4,057 7,948 Critical accounting estimates and judgements Goodwill Testing goodwill for impairment involves a significant amount of judgement. Goodwill is allocated to CGUs for the purpose of impairment testing. The review of goodwill for impairment involves calculating a value in use (VIU) valuation which is compared to the carrying value of a CGU associated with the goodwill to determine whether any impairment has occurred. This includes the identification of independent CGUs across the organisation and the allocation of goodwill to those CGUs. The calculation of a value in use contains a high degree of uncertainty in estimating the future cash flows and the rates used to discount them. Key judgements include determining the carrying value of the CGU, the cash flows and discount rates used in the calculation. ▪ The cash flow forecasts used by management involve judgement and are based upon a view of the future prospects of the business and market conditions at the point in time the assessment is prepared. The estimation of pre-tax cash flows is sensitive to the periods for which detailed forecasts are available and to assumptions regarding long-term sustainable cash flows. ▪ The discount rates applied to the future cash flows also involve judgement as they can have a significant impact on the valuation. The discount rates used are compared to market participants to ensure that they are appropriate and based on an estimated cost of equity for each CGU. ▪ The choice of a terminal growth rate used to determine the present value of the future cash flows of the CGUs is also a judgement that can impact the outcome of the assessment. The terminal growth rate and discount rates used may vary due to external market rates and economic conditions that are beyond management’s control. Further details of some of the key judgements are set out below. 2021 impairment review The 2021 impairment review was performed during Q4 2021 . In comparison to the prior year, the macroeconomic outlook has improved, with expectations of increased interest rates. However, unsecured balances are lower, reflecting reduced borrowing and higher repayments by customers. These factors impact favourably and adversely on the operating environments of the CGUs. A detailed assessment has been performed, with the approach and results of this analysis set out below. Determining the carrying value of CGUs The carrying value for each CGU is the sum of the tangible equity, goodwill and intangible asset balances associated with that CGU. The Group manages the assets and liabilities of its CGUs with reference to the tangible equity of the respective businesses. That tangible equity is derived from the level of risk weighted assets (RWAs) and capital required to be deployed in the CGU and therefore reflects its relative risk, as well as the level of capital that management consider a market participant would be required to hold and retain to support business growth. The goodwill held across the Group has been allocated to the CGU where it originated, based upon historical records. The intangible asset balances are allocated to the CGUs based upon their expected usage of these assets. Cash flows The five-year cash flows used in the calculation are based on the formally agreed medium term plans approved by the Board. These are prepared using macroeconomic assumptions which management consider reasonable and supportable, and reflect business agreed initiatives for the forecast period. The macroeconomic assumptions underpinning the medium term plan were determined in August 2021 and management has considered whether there are subsequent significant changes in those assumptions which would adversely impact the results of the impairment review. As required by IAS 36, all estimates of future cash flows exclude cash inflows or outflows that are expected to arise from restructuring initiatives where a constructive obligation to carry out the plan does not yet exist. In line with prior year treatment, the Education, Social Housing and Local Authority (ESHLA) portfolio has been excluded from the Business Banking CGU cash flows. This is a legacy loan portfolio which was previously within the Non-Core bank and was not part of the business to which the goodwill relates. As such, the cash flows relating to this portfolio have been excluded from the Business Banking VIU calculation. The Personal Banking CGU cash flows reflect increases in the yield curve observed during the course of 2021 and have not been extended to a sixth year. The 2020 impairment review used a sixth year to reflect an observed 15bp inflexion point in the yield curve which was beyond the period of the medium term plan. Discount rates IAS 36 requires that the discount rate used in a value in use calculation reflects the pre-tax rate an investor would require if they were to choose an investment that would generate similar cash flows to those that the entity expects to generate from the asset. In determining the discount rate, management have identified the cost of equity associated with market participants that closely resemble the Group's CGUs and adjusted them for tax to arrive at the pre-tax equivalent rate. A range of discount rates have been used across the CGUs ranging from 12.5% to 15.1% (2020: 12.0% to 16.3%). Terminal growth rate The terminal growth rate is used to estimate the effect of projecting cash flows to the end of an asset’s useful economic life. It is management’s judgement that the cash flows associated with the CGUs will grow in line with the major economies in which the Group operates. Inflation rates are used as an approximation of future growth rates and form the basis of the terminal growth rates applied. The terminal growth rate used is 2.0% (2020:2.0%). Outcome of goodwill and intangibles review The Personal Banking and Business Banking retail banking CGUs carry the majority of the Group’s goodwill balance, predominantly as a consequence of the Woolwich acquisition. The goodwill within Personal Banking was £2,752m (2020: £2,752m), of which £2,501m (2020: £2,501m) was attributable to Woolwich, and within Business Banking was £629m (2020: £629m), fully attributable to Woolwich. The recoverable amount for both Personal Banking and Business Banking have increased in comparison to the 2020 impairment review, reflective of improvements in the interest rate and macroeconomic outlook. The largest portion of the Group’s intangible assets sit within the Cards and Payments CGU, with an allocation of £1,351m (2020: £1,096m). The extent to which the recoverable amount of the Cards and Payments CGU exceeds its carrying value has reduced in comparison to the 2020 impairment review as a result of investment in new intangible assets and a reduction in card balances, reflecting reduced borrowing and higher repayments by customers. Based on management’s plans and assumptions the value in use exceeds the carrying value of the CGUs and no impairment has been indicated. The outcome of the impairment review for Personal Banking, Business Banking and Cards and Payments are set out below: Cash generating unit Tangible equity Goodwill Intangibles Carrying value Value in use Value in use exceeding carrying value Value in use exceeding carrying value 2020 £m £m £m £m £m £m £m Personal Banking 5,194 2,752 997 8,943 10,432 1,489 123 Business Banking 1,459 629 169 2,257 5,880 3,623 740 Cards and Payments 2,946 195 1,351 4,492 5,517 1,025 1,360 Total 9,599 3,576 2,517 15,692 21,829 6,137 2,223 Sensitivity of key judgements The CGUs are sensitive to possible adverse changes in the key assumptions that support the recoverable amount: Cash flows: The medium term plans used to determine the cash flows used in the VIU calculation rely on macroeconomic forecasts, including interest rates, GDP and unemployment, and forecast levels of market and client activity. Interest rate assumptions impact planned cash flows from both customer income and structural hedge contributions and therefore cash flow expectations are highly sensitive to movements in the yield curve. The cash flows also contain assumptions with regards to the prudential and financial conduct regulatory environment which may be subject to change. Given the current level of economic uncertainty, a 10% reduction in cash flows has been provided to show the sensitivity of the outcome to a change in these key assumptions. Discount rate: The discount rate should reflect the market risk-free rate adjusted for the inherent risks of the business it is applied to. Management have identified discount rates for comparable businesses and consider these to be a reasonable estimate of a suitable market rate for the profile of the business unit being tested. The risk that these discount rates may not be appropriate is quantified below and shows the impact of a 100 bps change in the discount rate. Terminal growth rate: The terminal growth rate is used to estimate the cash flows into perpetuity based on the expected longevity of the CGUs' businesses. The terminal growth rate is sensitive to uncertainties in the macroeconomic environment. The risk that using inflation data may not be appropriate for its determination is quantified below and shows the impact of 100 bps change in the terminal growth rate. Allocated capital rate: Tangible equity is allocated based on the level of risk weighted assets (RWAs) and capital required to be deployed in the CGU which is dependent on the relative risk of businesses. The capital ratio used in determining the level of tangible equity allocated to the CGU and its capital cash flows could move over time. The impact of a 50bps increase in capital ratio is quantified below. The sensitivity of the value in use to key judgements in the calculations is set out below: Cash generating unit Carrying value Value in use Value in use exceeding carrying value Discount rate Terminal growth rate Reduction in headroom Change required to reduce headroom to zero 100 bps increase in the discount rate 100 bps decrease in terminal growth rate 50 bps increase to allocated capital rate 10% reduction in forecasted cash flows Discount rate Terminal growth rate Allocated capital rate Cashflows £m £m £m % % £m £m £m £m % % % % Personal Banking 8,943 10,432 1,489 14.2 2.0 (946) (655) (291) (1,219) 1.7 (2.6) 2.6 (12.2) Cards and Payments 4,492 5,517 1,025 14.7 2.0 (597) (433) (227) (774) 1.8 (2.7) 2.3 (13.3) Total 13,435 15,949 2,514 |
Other liabilities
Other liabilities | 12 Months Ended |
Dec. 31, 2021 | |
Accruals and deferred income including contract liabilities [abstract] | |
Other liabilities | Other liabilities 2021 2020 £m £m Accruals and deferred income 4,173 3,683 Other creditors 4,793 3,447 Items in the course of collection due to other banks 202 88 Lease liabilities (refer to Note 21) 1,317 1,444 Liabilities included in disposal groups classified as held for sale 20 — Other liabilities 10,505 8,662 |
Provisions
Provisions | 12 Months Ended |
Dec. 31, 2021 | |
Provisions [abstract] | |
Provisions | Provisions Accounting for provisions The Group applies IAS 37 Provisions, Contingent Liabilities and Contingent Assets in accounting for non-financial liabilities. Provisions are recognised for present obligations arising as consequences of past events where it is more likely than not that a transfer of economic benefit will be necessary to settle the obligation, which can be reliably estimated. Provision is made for the anticipated cost of restructuring, including redundancy costs, when an obligation exists; for example, when the Group has a detailed formal plan for restructuring a business and has raised valid expectations in those affected by the restructuring by announcing its main features or starting to implement the plan. Critical accounting estimates and judgements The financial reporting of provisions involves a significant degree of judgement and is complex. Identifying whether a present obligation exists and estimating the probability, timing, nature and quantum of the outflows that may arise from past events requires judgements to be made based on the specific facts and circumstances relating to individual events and often requires specialist professional advice. When matters are at an early stage, accounting judgements and estimates can be difficult because of the high degree of uncertainty involved. Management continues to monitor matters as they develop to re-evaluate on an ongoing basis whether provisions should be recognised, however there can remain a wide range of possible outcomes and uncertainties, particularly in relation to legal, competition and regulatory matters, and as a result it is often not practicable to make meaningful estimates even when matters are at a more advanced stage. The complexity of such matters often requires the input of specialist professional advice in making assessments to produce estimates. Customer redress and legal, competition and regulatory matters are areas where a higher degree of professional judgement is required. The amount that is recognised as a provision can also be very sensitive to the assumptions made in calculating it. This gives rise to a large range of potential outcomes which require judgement in determining an appropriate provision level. See Note 26 for more detail of legal, competition and regulatory matters. Restated Undrawn contractually committed facilities and guarantees a Legal, competition and regulatory matters Sundry Total b Onerous contracts Redundancy and restructuring Customer redress b £m £m £m £m £m £m £m As at 1 January 2021 28 158 1,064 497 268 289 2,304 Additions 6 316 124 408 72 198 1,124 Amounts utilised (11) (82) — (318) (62) (140) (613) Unused amounts reversed (18) (25) (638) (54) (44) (101) (880) Exchange and other movements — (41) (8) (3) (8) 33 (27) As at 31 December 2021 b 5 326 542 530 226 279 1,908 Note a Undrawn contractually committed facilities and guarantees provisions are accounted for under IFRS 9. b 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. Provisions expected to be recovered or settled within no more than 12 months after 31 December 2021 were £1,754m (2020: £1,751m). Onerous contracts Onerous contract provisions comprise an estimate of unavoidable costs involved with fulfilling the terms and conditions of contracts net of any expected benefits to be received. Redundancy and restructuring These provisions comprise the estimated cost of restructuring, including redundancy costs where an obligation exists. Additions made during the year relate to formal restructuring plans and have either been utilised, or reversed where total costs are now expected to be lower than the original provision amount. Undrawn contractually committed facilities and guarantees Impairment allowance under IFRS 9 considers both the drawn and the undrawn counterparty exposure. For retail portfolios, the total impairment allowance is allocated to the drawn exposure to the extent that the allowance does not exceed the exposure as ECL is not reported separately. Any excess is reported on the liability side of the balance sheet as a provision. For wholesale portfolios, the impairment allowance on the undrawn exposure is reported on the liability side of the balance sheet as a provision. For further information, refer to the Credit risk section for loan commitments and financial guarantees on page 131. Customer redress Customer redress provisions comprise the estimated cost of making redress payments to customers, clients and counterparties for losses or damages associated with inappropriate judgement in the execution of the Group’s business activities. Provisions for other customer redress include £220m (2020; nil) in respect of the c.$13bn over-issuance of structured notes which represents the best estimate as at 31 December 2021 of the rescission right investors had for these securities. See Restatement of financial statements (Note 1a) on page 228 for further details and Legal, competition and regulatory matters (Note 26) for further details on provision dependencies and sensitivity. Legal, competition and regulatory matters The Group is engaged in various legal proceedings, both in the UK and a number of other overseas jurisdictions, including the US. For further information in relation to legal proceedings and discussion of the associated uncertainties, refer to Note 26. Sundry provisions This category includes provisions that do not fit into any of the other categories, such as fraud losses and dilapidation provisions. |
Contingent liabilities and comm
Contingent liabilities and commitments | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of contingent liabilities [abstract] | |
Contingent liabilities and commitments | Contingent liabilities and commitments Accounting for contingent liabilities Contingent liabilities are possible obligations whose existence will be confirmed only by uncertain future events and present obligations where the transfer of economic resources is uncertain or cannot be reliably measured. Contingent liabilities are not recognised on the balance sheet but are disclosed unless the likelihood of an outflow of economic resources is remote. The following table summarises the nominal principal amount of contingent liabilities and commitments which are not recorded on-balance sheet: 2021 2020 £m £m Guarantees and letters of credit pledged as collateral security 15,549 15,665 Performance guarantees, acceptances and endorsements 5,797 5,944 Total contingent liabilities and financial guarantees 21,346 21,609 Of which: Financial guarantees carried at fair value 231 229 Documentary credits and other short-term trade related transactions 1,584 1,086 Standby facilities, credit lines and other commitments 344,127 331,963 Total commitments 345,711 333,049 Of which: Loan commitments carried at fair value 18,571 9,269 Expected credit losses held against contingent liabilities and commitments equal £542m (2020: £1,064m) and are reported in Note 24. Further details on contingent liabilities relating to legal and competition and regulatory matters can be found in Note 26. |
Legal, competition and regulato
Legal, competition and regulatory matters | 12 Months Ended |
Dec. 31, 2021 | |
Legal, competition and regulatory matters [Abstract] | |
Legal, competition and regulatory matters | Legal, competition and regulatory matters The Group faces legal, competition and regulatory challenges, many of which are beyond our control. The extent of the impact of these matters cannot always be predicted but may materially impact our operations, financial results, condition and prospects. Matters arising from a set of similar circumstances can give rise to either a contingent liability or a provision, or both, depending on the relevant facts and circumstances. The recognition of provisions in relation to such matters involves critical accounting estimates and judgments in accordance with the relevant accounting policies applicable to Note 24, Provisions. We have not disclosed an estimate of the potential financial impact or effect on the Group of contingent liabilities where it is not currently practicable to do so. Various matters detailed in this note seek damages of an unspecified amount. While certain matters specify the damages claimed, such claimed amounts do not necessarily reflect the Group’s potential financial exposure in respect of those matters. Matters are ordered under headings corresponding to the financial statements in which they are disclosed. 1. Barclays PLC and Barclays Bank PLC Investigations into certain advisory services agreements FCA proceedings In 2008, Barclays Bank PLC and Qatar Holdings LLC entered into two advisory service agreements (the Agreements). The Financial Conduct Authority (FCA) conducted an investigation into whether the Agreements may have related to Barclays PLC’s capital raisings in June and November 2008 (the Capital Raisings) and therefore should have been disclosed in the announcements or public documents relating to the Capital Raisings. In 2013, the FCA issued warning notices (the Notices) finding that Barclays PLC and Barclays Bank PLC acted recklessly and in breach of certain disclosure-related listing rules, and that Barclays PLC was also in breach of Listing Principle 3. The financial penalty provided in the Notices is £50m. Barclays PLC and Barclays Bank PLC continue to contest the findings. Following the conclusion of the Serious Fraud Office (SFO) proceedings against certain former Barclays executives resulting in their acquittals, the FCA proceedings, which were stayed, have resumed and a hearing before the Regulatory Decisions Committee is scheduled for the first quarter of 2022. Investigations into LIBOR and other benchmarks and related civil actions Regulators and law enforcement agencies, including certain competition authorities, from a number of governments have conducted investigations relating to Barclays Bank PLC’s involvement in allegedly manipulating certain financial benchmarks, such as LIBOR. Various individuals and corporates in a range of jurisdictions have threatened or brought civil actions against the Group and other banks in relation to the alleged manipulation of LIBOR and/or other benchmarks. USD LIBOR civil actions The majority of the USD LIBOR cases, which have been filed in various US jurisdictions, have been consolidated for pre-trial purposes in the US District Court in the Southern District of New York (SDNY). The complaints are substantially similar and allege, among other things, that Barclays PLC, Barclays Bank PLC, Barclays Capital Inc. (BCI) and other financial institutions individually and collectively violated provisions of the US Sherman Antitrust Act (Antitrust Act), the US Commodity Exchange Act (CEA), the US Racketeer Influenced and Corrupt Organizations Act (RICO), the Securities Exchange Act of 1934 and various state laws by manipulating USD LIBOR rates. Putative class actions and individual actions seek unspecified damages with the exception of three lawsuits, in which the plaintiffs are seeking a combined total of approximately $100m in actual damages and additional punitive damages against all defendants, including Barclays Bank PLC. Some of the lawsuits also seek trebling of damages under the Antitrust Act and RICO. Barclays Bank PLC has previously settled certain claims. Two class action settlements where Barclays Bank PLC has respectively paid $7.1m and $20m have received final court approval. Barclays Bank PLC also settled a further matter for $7.5m. Sterling LIBOR civil actions In 2016, two putative class actions filed in the SDNY against Barclays Bank PLC, BCI and other Sterling LIBOR panel banks alleging, among other things, that the defendants manipulated the Sterling LIBOR rate in violation of the Antitrust Act, CEA and RICO, were consolidated. The defendants’ motion to dismiss the claims was granted in 2018. The plaintiffs have appealed the dismissal. Japanese Yen LIBOR civil actions In 2012, a putative class action was filed in the SDNY against Barclays Bank PLC and other Japanese Yen LIBOR panel banks by a lead plaintiff involved in exchange-traded derivatives and members of the Japanese Bankers Association’s Euroyen Tokyo Interbank Offered Rate (Euroyen TIBOR) panel. The complaint alleges, among other things, manipulation of the Euroyen TIBOR and Yen LIBOR rates and breaches of the CEA and the Antitrust Act. In 2014, the court dismissed the plaintiff’s antitrust claims, and, in 2020, the court dismissed the plaintiff’s remaining CEA claims. The plaintiff has appealed the lower court’s dismissal of such claims. In 2015, a second putative class action, making similar allegations to the above class action, was filed in the SDNY against Barclays PLC, Barclays Bank PLC and BCI. The plaintiffs filed an amended complaint in 2020. In 2021, the case was dismissed as against most defendants, including the Barclays entities. The plaintiffs and remaining defendants are seeking reconsideration of the decision. SIBOR/SOR civil action In 2016, a putative class action was filed in the SDNY against Barclays PLC, Barclays Bank PLC, BCI and other defendants, alleging manipulation of the Singapore Interbank Offered Rate (SIBOR) and Singapore Swap Offer Rate (SOR). In 2018, the court dismissed all claims against Barclays PLC, Barclays Bank PLC and BCI. The plaintiffs’ appeal of the dismissal of their claims was granted in March 2021 and the matter has been remanded to the lower court for further proceedings. Defendants’ petition for U.S. Supreme Court review was denied. Additionally, plaintiffs have filed an amended complaint, which defendants have moved to dismiss. ICE LIBOR civil actions In 2019, several putative class actions were filed in the SDNY against a panel of banks, including Barclays PLC, Barclays Bank PLC, BCI, other financial institution defendants and Intercontinental Exchange Inc. and certain of its affiliates (ICE), asserting antitrust claims that defendants manipulated USD LIBOR through defendants’ submissions to ICE. These actions have been consolidated. The defendants’ motion to dismiss was granted in 2020 and the plaintiffs appealed. In February 2022, the dismissal was affirmed on appeal. In August 2020, an ICE LIBOR-related action was filed by a group of individual plaintiffs in the US District Court for the Northern District of California on behalf of individual borrowers and consumers of loans and credit cards with variable interest rates linked to USD ICE LIBOR. Plaintiffs’ motions seeking, among other things, preliminary and permanent injunctions to enjoin the defendants from continuing to set LIBOR or enforce any financial instrument that relies in whole or in part on USD LIBOR were denied. The defendants have moved to dismiss the case. Non-US benchmarks civil actions Legal proceedings (which include the claims referred to below in ‘Local authority civil actions concerning LIBOR’) have been brought or threatened against Barclays Bank PLC (and, in certain cases, Barclays Bank UK PLC) and other banks in the UK in connection with alleged manipulation of LIBOR, EURIBOR and other benchmarks. Proceedings have also been brought in a number of other jurisdictions in Europe and Israel. Additional proceedings in other jurisdictions may be brought in the future. Credit Default Swap civil action A putative antitrust class action is pending in New Mexico federal court against Barclays Bank PLC, BCI, and various other financial institutions. The plaintiffs, the New Mexico State Investment Council and certain New Mexico pension funds, allege that the defendants conspired to manipulate the benchmark price used to value Credit Default Swap (CDS) contracts at settlement (i.e. the CDS final auction price). The plaintiffs allege violations of US antitrust laws and the CEA, and unjust enrichment under state law. Foreign Exchange investigations and related civil actions In 2015, the Group reached settlements totalling approximately $2.38bn with various US federal and state authorities and the FCA in relation to investigations into certain sales and trading practices in the Foreign Exchange market. The European Commission announced two settlements in May 2019 and the Group paid penalties totalling approximately €210m. In June 2019, the Swiss Competition Commission announced two settlements and the Group paid penalties totalling approximately CHF27m. In December 2021, the European Commission announced a final settlement which required the Group to pay penalties totalling approximately €54m, which amount has been provided for in previous periods. The financial impact of any ongoing matters is not expected to be material to the Group’s operating results, cash flows or financial position. Various individuals and corporates in a range of jurisdictions have threatened or brought civil actions against the Group and other banks in relation to alleged manipulation of Foreign Exchange markets. FX opt out civil action In 2018, Barclays Bank PLC and BCI settled a consolidated action filed in the SDNY, alleging manipulation of Foreign Exchange markets (Consolidated FX Action), for a total amount of $384m. Also in 2018, a group of plaintiffs who opted out of the Consolidated FX Action filed a complaint in the SDNY against Barclays PLC, Barclays Bank PLC, BCI and other defendants. Some of the plaintiff’s claims were dismissed in 2020. Retail basis civil action In 2015, a putative class action was filed against several international banks, including Barclays PLC and BCI, on behalf of a proposed class of individuals who exchanged currencies on a retail basis at bank branches (Retail Basis Claims). The SDNY has ruled that the Retail Basis Claims are not covered by the settlement agreement in the Consolidated FX Action. The Court subsequently dismissed all Retail Basis Claims against the Group and all other defendants. The plaintiffs have filed an amended complaint. Non-US FX civil actions Legal proceedings have been brought or are threatened against Barclays PLC, Barclays Bank PLC, BCI and Barclays Execution Services Limited (BX) in connection with alleged manipulation of Foreign Exchange in the UK, a number of other jurisdictions in Europe, Israel, Brazil and Australia and additional proceedings may be brought in the future. These include two purported class actions filed against Barclays PLC, Barclays Bank PLC, BX, BCI and other financial institutions in the UK Competition Appeal Tribunal in 2019 following the settlements with the European Commission described above. Also in 2019, a separate claim was filed in the UK in the High Court of Justice (High Court), and subsequently transferred to the UK Competition Appeal Tribunal, by various banks and asset management firms against Barclays Bank PLC and other financial institutions alleging breaches of European and UK competition laws related to FX trading. Metals related civil actions A number of US civil complaints, each on behalf of a proposed class of plaintiffs, have been consolidated and transferred to the SDNY. The complaints allege that Barclays Bank PLC and other members of The London Gold Market Fixing Ltd. manipulated the prices of gold and gold derivative contracts in violation of the Antitrust Act and other federal laws. The parties have reached a joint settlement to resolve this matter for $50m, which is subject to court approval. The financial impact of Barclays’ share of the joint settlement is not expected to be material to the Group’s operating results, cash flows or financial position. A separate US civil complaint by a proposed class of plaintiffs against a number of banks, including Barclays Bank PLC, BCI and BX, alleging manipulation of the price of silver in violation of the CEA, the Antitrust Act and state antitrust and consumer protection laws, has been dismissed as against the Barclays entities. The plaintiffs have the option to seek the court’s permission to appeal. Civil actions have also been filed in Canadian courts against Barclays PLC, Barclays Bank PLC, Barclays Capital Canada Inc. and BCI on behalf of proposed classes of plaintiffs alleging manipulation of gold and silver prices. US residential mortgage related civil actions There are various pending civil actions relating to US Residential Mortgage-Backed Securities (RMBS), including four actions arising from unresolved repurchase requests submitted by Trustees for certain RMBS, alleging breaches of various loan-level representations and warranties (R&Ws) made by Barclays Bank PLC and/or a subsidiary acquired in 2007. The unresolved repurchase requests had an original principal balance of approximately $2.1bn. The Trustees have also alleged that the relevant R&Ws may have been breached with respect to a greater (but unspecified) amount of loans than previously stated in the unresolved repurchase requests. These repurchase actions are ongoing. In one repurchase action, the New York Court of Appeals held that claims related to certain R&Ws are time-barred. Barclays Bank PLC has reached settlements to resolve two of the repurchase actions, subject to final court approval. Final court approval has been granted in relation to one of those matters and payment will be completed in the first quarter of 2022. The other matter is scheduled for a hearing in 2022 to seek approval of the settlement. The financial impact of the settlement is not expected to be material to the Group’s operating results, cash flows or financial position. The remaining two repurchase actions are pending. In 2020, a civil litigation claim was filed in the New Mexico First Judicial District Court by the State of New Mexico against six banks, including BCI, on behalf of two New Mexico state pension funds and the New Mexico State Investment Council relating to legacy RMBS purchases. As to BCI, the complaint alleges that the funds purchased approximately $22m in RMBS underwritten by BCI. The parties have reached a joint settlement to resolve this matter for $32.5m. The financial impact of BCI’s share of the joint settlement is not material to the Group’s operating results, cash flows or financial position. Government and agency securities civil actions Treasury auction securities civil actions Consolidated putative class action complaints filed in US federal court against Barclays Bank PLC, BCI and other financial institutions under the Antitrust Act and state common law allege that the defendants (i) conspired to manipulate the US Treasury securities market and/or (ii) conspired to prevent the creation of certain platforms by boycotting or threatening to boycott such trading platforms. The court dismissed the consolidated action in March 2021. The plaintiffs have filed an amended complaint, which the defendants have moved to dismiss. In addition, certain plaintiffs have filed a related, direct action against BCI and certain other financial institutions, alleging that defendants conspired to fix and manipulate the US Treasury securities market in violation of the Antitrust Act, the CEA and state common law. Supranational, Sovereign and Agency bonds civil actions Civil antitrust actions have been filed in the SDNY and Federal Court of Canada in Toronto against Barclays Bank PLC, BCI, BX, Barclays Capital Securities Limited and, with respect to the civil action filed in Canada only, Barclays Capital Canada, Inc. and other financial institutions alleging that the defendants conspired to fix prices and restrain competition in the market for US dollar-denominated Supranational, Sovereign and Agency bonds. In one of the actions filed in the SDNY, the court granted the defendants’ motions to dismiss the plaintiffs’ complaint. The dismissal was affirmed on appeal and this matter is now concluded. The plaintiffs have voluntarily dismissed the other SDNY action. In the Federal Court of Canada action, the plaintiffs reached settlements with a small number of banks in 2020 (not including Barclays Capital Canada Inc.), but the plaintiffs have not commenced the class certification process and the action remains at an early stage. Variable Rate Demand Obligations civil actions Civil actions have been filed against Barclays Bank PLC and BCI and other financial institutions alleging the defendants conspired or colluded to artificially inflate interest rates set for Variable Rate Demand Obligations (VRDOs). VRDOs are municipal bonds with interest rates that reset on a periodic basis, most commonly weekly. Two actions in state court have been filed by private plaintiffs on behalf of the states of Illinois and California. Three putative class action complaints have been consolidated in the SDNY. In the consolidated SDNY class action, certain of the plaintiff’s claims were dismissed in November 2020 and defendants’ motion for partial dismissal of the amended consolidated complaint is pending. In the California action, the plaintiffs’ claims were dismissed in June 2021. The plaintiffs have appealed the dismissal. Government bond civil actions In a putative class action filed in the SDNY in 2019, plaintiffs alleged that BCI and certain other bond dealers conspired to fix the prices of US Government sponsored entity bonds in violation of US antitrust law. BCI agreed to a settlement of $87m, which received final court approval in 2020. Separately, various entities in Louisiana, including the Louisiana Attorney General and the City of Baton Rouge, commenced litigation against Barclays Bank PLC and other financial institutions making similar allegations as the SDNY class action plaintiffs. The parties have reached a settlement to resolve these matters. The financial impact of the settlement is not material to the Group’s operating results, cash flows or financial position. In 2018, a separate putative class action against various financial institutions including Barclays PLC, Barclays Bank PLC, BCI, Barclays Bank Mexico, S.A., and certain other subsidiaries of the Group was consolidated in the SDNY. The plaintiffs asserted antitrust and state law claims arising out of an alleged conspiracy to fix the prices of Mexican Government bonds. The Barclays entities have settled the claim for $5.7m, and the settlement has received final court approval. Odd-lot corporate bonds antitrust class action In 2020, BCI, together with other financial institutions, were named as defendants in a putative class action. The complaint alleges a conspiracy to boycott developing electronic trading platforms for odd-lots and price fixing. Plaintiffs demand unspecified money damages. The defendants’ motion to dismiss was granted in 2021. Plaintiffs have appealed the dismissal. Interest rate swap and credit default swap US civil actions Barclays PLC, Barclays Bank PLC and BCI, together with other financial institutions that act as market makers for interest rate swaps (IRS) are named as defendants in several antitrust class actions which were consolidated in the SDNY in 2016. The complaints allege the defendants conspired to prevent the development of exchanges for IRS and demand unspecified money damages. In 2018, trueEX LLC filed an antitrust class action in the SDNY against a number of financial institutions including Barclays PLC, Barclays Bank PLC and BCI based on similar allegations with respect to trueEX LLC’s development of an IRS platform. In 2017, Tera Group Inc. filed a separate civil antitrust action in the SDNY claiming that certain conduct alleged in the IRS cases also caused the plaintiff to suffer harm with respect to the Credit Default Swaps market. In 2018 and 2019, respectively, the court dismissed certain claims in both cases for unjust enrichment and tortious interference but denied motions to dismiss the federal and state antitrust claims, which remain pending. BDC Finance L.L.C. In 2008, BDC Finance L.L.C. (BDC) filed a complaint in the Supreme Court of the State of New York (NY Supreme Court), demanding damages of $298m, alleging that Barclays Bank PLC had breached a contract in connection with a portfolio of total return swaps governed by an ISDA Master Agreement (the Agreement). Following a trial, the court ruled in 2018 that Barclays Bank PLC was not a defaulting party, which was affirmed on appeal. In April 2021, the trial court entered judgement in favour of Barclays Bank PLC for $3.3m and as yet to be determined legal fees and costs. BDC appealed. In January 2022, the appellate court reversed the trial court’s summary judgment decision in favour of Barclays Bank PLC and remanded the case to the lower court for further proceedings. In 2011, BDC’s investment advisor, BDCM Fund Adviser, L.L.C. and its parent company, Black Diamond Capital Holdings, L.L.C. also sued Barclays Bank PLC and BCI in Connecticut State Court for unspecified damages allegedly resulting from Barclays Bank PLC’s conduct relating to the Agreement, asserting claims for violation of the Connecticut Unfair Trade Practices Act and tortious interference with business and prospective business relations. This case is currently stayed. Civil actions in respect of the US Anti-Terrorism Act There are a number of civil actions, on behalf of more than 4,000 plaintiffs, filed in US federal courts in the US District Court in the Eastern District of New York (EDNY) and SDNY against Barclays Bank PLC and a number of other banks. The complaints generally allege that Barclays Bank PLC and those banks engaged in a conspiracy to facilitate US dollar-denominated transactions for the Iranian Government and various Iranian banks, which in turn funded acts of terrorism that injured or killed plaintiffs or plaintiffs’ family members. The plaintiffs seek to recover damages for pain, suffering and mental anguish under the provisions of the US Anti-Terrorism Act, which allow for the trebling of any proven damages. The court granted the defendants’ motions to dismiss three out of the six actions in the EDNY. Plaintiffs have appealed in one action. The remaining actions are stayed pending a decision on the appeal. Out of the two actions in the SDNY, the court also granted the defendants’ motion to dismiss the first action, which is stayed pending a decision on the EDNY appeal. The second SDNY action is stayed, pending any appeal on the dismissal of the first. Shareholder derivative action In November 2020, a purported Barclays shareholder filed a putative derivative action in New York state court against BCI and a number of current and former members of the Board of Directors of Barclays PLC and senior executives or employees of the Group. The shareholder filed the claim on behalf of nominal defendant Barclays PLC, alleging that the individual defendants harmed the company through breaches of their duties, including under the Companies Act 2006. The plaintiff seeks damages on behalf of Barclays PLC for the losses that Barclays PLC allegedly suffered as a result of these alleged breaches. An amended complaint was filed in April 2021, which BCI and certain other defendants have moved to dismiss. Derivative transactions civil action In 2021, Vestia (a Dutch housing association) brought a claim against Barclays Bank PLC in the UK in the High Court in relation to a series of derivative transactions entered into with Barclays Bank PLC between 2008 and 2011, seeking damages of £329m. Barclays Bank PLC is defending the claim and has made a counterclaim. Timeshare loans, skilled person review, and associated matters In August 2020, the FCA granted an application by Clydesdale Financial Services Limited (CFS), which trades as Barclays Partner Finance and houses Barclays’ point-of-sale finance business, for a validation order with respect to certain loans to customers brokered between April 2014 and April 2016 by Azure Services Limited (ASL), a timeshare operator, which did not, at the point of sale, hold the necessary broker licence. As a condition to the validation order, the FCA required CFS to undertake a skilled person review of the assessment of affordability processes for the loans brokered by ASL (ASL Loans) as well as CFS’ policies and procedures for assessing affordability and oversight of brokers more generally, and dictated a remediation methodology in the event that ASL Loans did not pass the affordability test. CFS has voluntarily agreed to remediate the ASL Loans, which is expected to amount to £37.4m, in accordance with the FCA’s methodology and the remediation exercise is at an advanced stage. The remaining scope of the skilled person review is complete. The skilled person made a number of observations, some of which were adverse, about both current and historic affordability practices as well as current oversight practices. CFS is not required to conduct a full back book review but, following a review of certain cohorts of loans to determine historic affordability and/or broker oversight practices that may have caused customer harm, where harm is identified, CFS’ intention is to remediate. Separately, and notwithstanding this, CFS decided in March 2022 to extend the proactive remediation of ASL Loans beyond those brokered between April 2014 to April 2016 to include the full portfolio of ASL Loans brokered between 2006 and 2018. As at 31 March 2022, a customer remediation provision of £181m has been recognised in relation to the remediation of the ASL Loans originated outside the April 2014 to April 2016 period. CFS continues to review complaints about other legacy partner finance loans, however, it is not currently possible to predict the outcome of this review or the financial impact on the Group. Over-issuance of securities in the US Barclays Bank PLC maintains a US shelf registration statement with the Securities and Exchange Commission (SEC) in order to issue securities to US investors. The current shelf registration statement was declared effective by the SEC and was valid for three years from 1 August 2019. At the time this shelf registration statement was filed, Barclays Bank PLC was not eligible to be a “well-known seasoned issuer” (or WKSI) due to an historic SEC settlement order and was required to pre-register a set amount of securities to be issued under the US shelf with the SEC. On 10 March 2022, executive management became aware that Barclays Bank PLC had issued securities in excess of the set amount. It has been estimated that the Barclays Bank PLC US shelf limit was exceeded in February 2021, with issuances through to 10 March 2022 exceeding the $20.8bn limit by c.$15bn. The securities that have been over issued in this period comprise structured notes and exchange traded notes (ETNs). Securities issued in excess of the limit are considered to be “unregistered securities” for the purposes of US securities law with certain purchasers of those securities having the right to require Barclays Bank PLC to repurchase those securities at their original purchase price with compensatory interest and the potential for certain purchasers to bring civil claims and the SEC and other regulators to take enforcement actions against Barclays Bank PLC. The Group has recognised a provision of £220m as at 31 December 2021 in relation to the c.$13bn over-issuance of structured notes which represents the best estimate of the rescission right investors have for these securities. The potential amount of the provision ultimately required is determined by (among other things) the market value of the structured notes subject to any rescission offer, participation rates in the rescission offer, prevailing interest rates and movements in foreign exchange rates. The majority of the structured notes subject to rescission provides an equity linked return to investors. As such, the value of these notes is highly sensitive to movements in the price of individual securities and range of indices. As at 31 March 2022, the estimated provision had increased to £540m, with the incremental £320m to be recognised in the 2022 financial statements. The increase in provision post year-end predominantly reflected a reduction in the market value of structured notes. For example, using the S&P 500 index as a benchmark proxy for how the portfolio of securities subject to rescission respond to equity market price movements implies a sensitivity of a c.£300m increase in the provision for a 5% reduction in the index. The provision calculation is non-linear and the sensitivity to a 5% change in the S&P 500 index is an indicative impact using information available as at 31 March 2022. The US equity markets have been volatile during H1 2022 with significant reductions in the value of US equity indices such as the S&P 500 from the year end 2021 levels. The sensitivity to a 5% change in the S&P index does not include the impact of market hedges that have been entered into subsequent to the year-end and were initiated from the end of Q1 2022, to reduce the net volatility to the income statement. When determining these market hedges, consideration was given to changes in the rescission costs which would arise from volatility in the market along with the positioning of the Markets business. The hedging arrangements may be modified, may not hedge all of the risks associated in the structured note population (in existing or modified form), may expire prior to the end of the Rescission Offer and do not cover any other losses arising out of potential private civil claims or enforcement actions. Any of the foregoing could result in material additional losses for the Group. A contingent liability exists in relation to the c.$2bn over-issuance of ETNs due to evidentiary challenges and the high level of trading in the securities. A contingent liability also exists in relation to any potential civil claims or enforcement actions taken against Barclays Bank PLC, but Barclays Bank PLC is unable to assess the likelihood of liabilities that may arise out of such claims or actions, there is currently no indication of the timetable for resolution and it is not practicable to provide an estimate of the financial effects. Any liabilities, claims or actions in connection with the over-issuance of securities under the US shelf could have an adverse effect on Barclays Bank PLC’s and the Group’s business, financial condition, results of operations and reputation as a frequent issuer in the securities markets. 2. Barclays PLC, Barclays Bank PLC and Barclays Bank UK PLC Investigation into UK cards’ affordability The FCA has been investigating certain aspects of the affordability assessment processes used by Barclays Bank UK PLC and Barclays Bank PLC for credit card applications made to Barclays’ UK credit card business. In October 2021, the FCA confirmed that this investigation was closed with no further action. HM Revenue & Customs (HMRC) assessments concerning UK Value Added Tax In 2018, HMRC issued notices that have the effect of removing certain overseas subsidiaries that have operations in the UK from Barclays’ UK VAT group, in which group supplies between members are generally free from VAT. The notices have retrospective effect and correspond to assessments of £181m (inclusive of interest), of which Barclays would expect to attribute an amount of approximately £128m to Barclays Bank UK PLC and £53m to Barclays Bank PLC. HMRC’s decision has been appealed to the First Tier Tribunal (Tax Chamber). Local authority civil actions concerning LIBOR Following settlement by Barclays Bank PLC of various governmental investigations concerning certain benchmark interest rate submissions referred to above in ‘Investigations into LIBOR and other benchmarks and related civil actions’, in the UK, certain local authorities brought claims in 2018 against Barclays Bank PLC and Barclays Bank UK PLC asserting that they entered into loans between 2006 and 2008 in reliance on misrepresentations made by Barclays Bank PLC in respect of its conduct in relation to LIBOR. Barclays Bank PLC and Barclays Bank UK PLC were successful in their applications to strike out the claims. The claims have been settled on terms suc |
Subordinated liabilities
Subordinated liabilities | 12 Months Ended |
Dec. 31, 2021 | |
Subordinated liabilities [abstract] | |
Subordinated liabilities | Subordinated liabilities Accounting for subordinated liabilities Subordinated liabilities are measured at amortised cost using the effective interest method under IFRS 9. 2021 2020 £m £m As at 1 January 16,341 18,156 Issuances 1,890 1,438 Redemptions (4,807) (3,464) Other (665) 211 As at 31 December 12,759 16,341 Issuances of £1,890m comprise £855m EUR 1.125% Fixed Rate Resetting Subordinated Callable Notes and £724m USD 3.811% Fixed Rate Resetting Subordinated Callable Notes, both issued externally by Barclays PLC and £229m USD Floating Rate Notes and £82m ZAR Floating Rate Notes issued externally by Barclays subsidiaries. Redemptions of £4,807m comprise £1,961m GBP 10% Fixed Rate Subordinated Notes, £1,339m EUR 6% Fixed Rate Subordinated Notes, £1,075m USD 10.179% Fixed Rate Subordinated Notes, £200m GBP 9.5% Subordinated Bonds and £86m EUR Subordinated Floating Rate Notes, issued externally by Barclays Bank PLC and £146m USD Floating Rate Notes issued externally by a Barclays subsidiary. Other movements predominantly comprise foreign exchange movements, fair value hedge adjustments and reclassification from Debt Securities in Issue of £67m Undated Subordinated Loan Notes (secured) issued externally by a Barclays securitisation special purpose vehicle (SPV) in 2020. Subordinated liabilities include accrued interest and comprise undated and dated subordinated liabilities as follows: 2021 2020 £m £m Undated subordinated liabilities 355 308 Dated subordinated liabilities 12,404 16,033 Total subordinated liabilities 12,759 16,341 None of the Group’s subordinated liabilities are secured other than the £67m Undated Subordinated Loan Notes (secured). Undated subordinated liabilities a 2021 2020 Initial call date £m £m Barclays Bank PLC issued Tier One Notes (TONs) 6% Callable Perpetual Core Tier One Notes 2032 15 17 6.86% Callable Perpetual Core Tier One Notes (USD 179m) 2032 194 205 Reserve Capital Instruments (RCIs) 5.3304% Step-up Callable Perpetual Reserve Capital Instruments 2036 51 56 Undated Notes Junior Undated Floating Rate Notes (USD 38m) Any interest payment date 28 28 Barclays securitisation SPV issued Undated Subordinated Loan Notes (secured) Undated Subordinated Loan Notes (secured) (GBP 67m) At any time 67 — Total undated subordinated liabilities 355 308 Note a Instrument values are disclosed to the nearest million. Undated subordinated liabilities The undated subordinated liabilities that are issued by Barclays Bank PLC and its subsidiaries are for the development and expansion of the businesses and to strengthen the capital bases. The principal terms of such undated subordinated liabilities are described below: Subordination All undated subordinated liabilities rank behind the claims against Barclays Bank PLC of depositors and other unsecured unsubordinated creditors and holders of dated subordinated liabilities in the following order: Junior Undated Floating Rate Notes; followed by TONs and RCIs ranking pari passu with each other. Interest The Junior Undated Notes are floating rate notes where rates are fixed periodically in advance based on the related market rate. The TONs and RCIs bear a fixed rate of interest until the initial call date. After the initial call date, in the event that they are not redeemed, the TONs and RCIs will bear interest at rates fixed periodically in advance based on market rates. Payment of interest No payment of principal or any interest may be made in relation to the TONs and RCIs unless Barclays Bank PLC satisfies a specified solvency test. Barclays Bank PLC may elect to defer any payment of interest on the RCIs. Any such deferred payment of interest must be paid on the earlier of: (i) the date of redemption of the RCIs, and (ii) the coupon payment date falling on or nearest to the tenth anniversary of the date of deferral of such payment. Whilst such deferral is continuing, (i) neither Barclays Bank PLC nor Barclays PLC may declare or pay a dividend, subject to certain exceptions, on any of its ordinary shares or preference shares and (ii) certain restrictions on the redemption, purchase or reduction of their respective share capital and certain other securities also apply. Barclays Bank PLC may elect to defer any payment of interest on the TONs if it determines that it is, or such payment would result in it being, in non-compliance with capital adequacy requirements and policies of the PRA. Any such deferred payment of interest will only be payable on a redemption of the TONs. Until such time as Barclays Bank PLC next makes a payment of interest on the TONs, (i) neither Barclays Bank PLC nor Barclays PLC may declare or pay a dividend, subject to certain exceptions, on any of their respective ordinary shares or preference shares, or make payments of interest in respect of Barclays Bank PLC’s Reserve Capital Instruments and (ii) certain restrictions on the redemption, purchase or reduction of their respective share capital and certain other securities also apply. Repayment All undated subordinated liabilities are repayable at the option of Barclays Bank PLC, generally in whole, at the initial call date and on any subsequent coupon or interest payment date. In addition, each issue of undated subordinated liabilities is repayable, at the option of Barclays Bank PLC in whole for certain tax reasons, either at any time, or on an interest payment date. There are no events of default except non-payment of principal or mandatory interest. Any repayments require the prior consent of the PRA. Other All issues of undated subordinated liabilities are non-convertible. Undated Subordinated Loan Notes (secured) The Undated Subordinated Loan Notes (secured) are direct, secured, subordinated and limited recourse obligations of the SPV issuer issued in connection with a securitisation of assets originated by a subsidiary of Barclays PLC. Payments of principal and interest are subject to the relevant priority of payments for the securitisation. The security is held on trust for the holders of such loan notes and the other secured creditors to the securitisation and any proceeds from the enforcement of such security shall be applied in accordance with the post enforcement priority of payments. Such loan notes have interest calculated periodically based on overnight market interest rates for Sterling and will mature on the first interest payment date following the date which is 12 months after the contractual maturity date of the longest dated remaining eligible receivable at the end of the revolving period for asset additions. Such loan notes may be accelerated upon the SPV issuer’s non-payment, breach of other obligations, material misrepresentation, insolvency, repudiation or change of control or it becomes unlawful for the SPV issuer to perform its obligations. The loans notes are non-convertible. Dated subordinated liabilities a 2021 2020 Initial call date Maturity date £m £m Barclays PLC issued 2% Fixed Rate Subordinated Callable Notes (EUR 1,500m) 2023 2028 1,283 1,384 4.375% Fixed Rate Subordinated Notes (USD 1,250m) 2024 974 990 3.75% Fixed Rate Resetting Subordinated Callable Notes (GBP 500m) 2025 2030 483 504 3.75% Fixed Rate Resetting Subordinated Callable Notes (SGD 200m) 2025 2030 113 119 5.20% Fixed Rate Subordinated Notes (USD 2,050m) 2026 1,564 1,610 1.125% Fixed Rate Resetting Subordinated Callable Notes (EUR 1,000m) 2026 2031 833 — 4.836% Fixed Rate Subordinated Callable Notes (USD 2,000m) 2027 2028 1,564 1,627 5.088% Fixed-to-Floating Rate Subordinated Callable Notes (USD 1,500m) 2029 2030 1,162 1,213 3.564% Fixed Rate Resetting Subordinated Callable Notes (USD 1,000m) 2030 2035 696 703 3.811% Fixed Rate Resetting Subordinated Callable Notes (USD 1,000m) 2041 2042 782 — Barclays Bank PLC issued 6% Fixed Rate Subordinated Notes (EUR 1,500m) 2021 — 1,427 9.5% Subordinated Bonds (ex-Woolwich Plc) 2021 — 221 Subordinated Floating Rate Notes (EUR 100m) 2021 — 90 10% Fixed Rate Subordinated Notes 2021 — 2,108 10.179% Fixed Rate Subordinated Notes (USD 1,521m) 2021 — 1,101 Subordinated Floating Rate Notes (EUR 50m) 2022 42 45 6.625% Fixed Rate Subordinated Notes (EUR 1,000m) 2022 889 982 7.625% Contingent Capital Notes (USD 3,000m) 2022 1,133 1,132 Subordinated Floating Rate Notes (EUR 50m) 2023 42 45 5.75% Fixed Rate Subordinated Notes 2026 322 351 5.4% Reverse Dual Currency Subordinated Loan (JPY 15,000m) 2027 97 108 6.33% Subordinated Notes 2032 59 64 Subordinated Floating Rate Notes (EUR 68m) 2040 57 61 External issuances by other subsidiaries 2026 311 146 Total dated subordinated liabilities 12,404 16,033 Note a Instrument values are disclosed to the nearest million. Dated subordinated liabilities Dated subordinated liabilities are issued by Barclays PLC, Barclays Bank PLC and its subsidiaries for the development and expansion of their businesses and to strengthen their respective capital bases. The principal terms of the dated subordinated liabilities are described below: Subordination Dated subordinated liabilities issued by Barclays PLC ranks behind the claims against Barclays PLC of unsecured unsubordinated creditors but before the claims of the holders of its equity. All dated subordinated liabilities externally issued by Barclays Bank PLC rank behind the claims against Barclays Bank PLC of depositors and other unsecured unsubordinated creditors but before the claims of the undated subordinated liabilities and the holders of its equity. The dated subordinated liabilities externally issued by other subsidiaries are similarly subordinated as the external subordinated liabilities issued by Barclays Bank PLC. Interest Interest on the Floating Rate Notes is fixed periodically in advance, based on the related market rates. Interest on Fixed Rate Notes is set by reference to market rates at the time of issuance and fixed until maturity. Interest on the 4.836% Fixed Rate Subordinated Callable Notes, 2% Fixed Rate Subordinated Callable Notes, 3.75% SGD Fixed Rate Resetting Subordinated Callable Notes, 3.75% GBP Fixed Rate Resetting Subordinated Callable Notes, 3.811% Fixed Rate Resetting Subordinated Callable notes, 1.125% Fixed Rate Resetting Subordinated Callable Notes, and the 3.564% Fixed Rate Resetting Subordinated Callable Notes are fixed until the call date. After the respective call dates, in the event that they are not redeemed, the interest rates will be reset and fixed until maturity based on a market rate. Interest on the 5.088% Fixed-to-Floating Rate Subordinated Callable Notes is fixed until the call date. After the call date, in the event that they are not redeemed, the interest rate will reset periodically in advance based on market rates. Repayment Those subordinated liabilities with a call date are repayable at the option of the issuer on such call date in accordance with the conditions governing the respective debt obligations, some in whole or in part, and some only in whole. The remaining dated subordinated liabilities outstanding at 31 December 2021 are redeemable only on maturity, subject in particular cases to provisions allowing an early redemption in the event of certain changes in tax law, or to certain changes in legislation or regulations. Any repayments prior to maturity require, in the case of Barclays PLC and Barclays Bank PLC, the prior consent of the PRA, or in the case of the overseas issues, the approval of the local regulator for that jurisdiction and of the PRA in certain circumstances. There are no committed facilities in existence at the balance sheet date which permit the refinancing of debt beyond the date of maturity. Other |
Ordinary shares, share premium,
Ordinary shares, share premium, and other equity | 12 Months Ended |
Dec. 31, 2021 | |
Equity [abstract] | |
Ordinary shares, share premium, and other equity | Ordinary shares, share premium, and other equity Called up share capital, allotted and fully paid Number of shares Ordinary share capital Ordinary share premium Total share capital and share premium Other m £m £m £m £m As at 1 January 2021 17,359 4,340 297 4,637 11,172 Issued to staff under share incentive plans 37 9 51 60 — AT1 securities issuance — — — — 1,078 Repurchase of shares (644) (161) — (161) — Other movements — — — — 9 As at 31 December 2021 16,752 4,188 348 4,536 12,259 As at 1 January 2020 17,322 4,331 263 4,594 10,871 Issued to staff under share incentive plans 37 9 34 43 — AT1 securities issuance — — — — 1,142 AT1 securities redemption — — — — (831) Other movements — — — — (10) As at 31 December 2020 17,359 4,340 297 4,637 11,172 Called up share capital Called up share capital comprises 16,752m (2020: 17,359m) ordinary shares of 25p each. Share repurchase At the 2021 AGM on 5 May 2021, Barclays PLC was authorised to repurchase up to an aggregate of 1,737m of its ordinary shares of 25p. The authorisation is effective until the AGM in 2022 or the close of business on 30 June 2022, whichever is the earlier. During 2021, 644m shares were repurchased with a total nominal value of £161m (2020: none). Other equity instruments Other equity instruments of £12,259m (2020: £11,172m) include AT1 securities issued by Barclays PLC. The AT1 securities are perpetual securities with no fixed maturity and are structured to qualify as AT1 instruments under prevailing capital rules applicable as at the relevant issue date . In 2021, there was one issuance of AT1 instruments, in the form of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities, for £1,078m (2020: one issuance for £1,142m) which includes issuance costs of £4m (2020: £4m). There were no redemptions in 2021 (2020: one redemption of £831m). AT1 equity instruments 2021 2020 Initial call date £m £m AT1 equity instruments - Barclays PLC 7.875% Perpetual Subordinated Contingent Convertible Securities a 2022 995 986 7.875% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) 2022 1,131 1,131 7.25% Perpetual Subordinated Contingent Convertible Securities 2023 1,245 1,245 7.75% Perpetual Subordinated Contingent Convertible Securities (USD 2,500m) a 2023 1,924 1,925 5.875% Perpetual Subordinated Contingent Convertible Securities 2024 1,244 1,244 8% Perpetual Subordinated Contingent Convertible Securities (USD 2,000m) 2024 1,509 1,509 7.125% Perpetual Subordinated Contingent Convertible Securities a 2025 996 994 6.375% Perpetual Subordinated Contingent Convertible Securities 2025 996 996 6.125% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) a 2025 1,141 1,142 4.375% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) 2028 1,078 — Total AT1 equity instruments 12,259 11,172 Note a Reported net of securities held by the Group. The principal terms of the AT1 securities are described below: ▪ AT1 securities rank behind the claims against Barclays PLC of 1) unsubordinated creditors; 2) claims which are expressed to be subordinated to the claims of unsubordinated creditors of Barclays PLC but not further or otherwise; or 3) claims which are, or are expressed to be, junior to the claims of other creditors of Barclays PLC, whether subordinated or unsubordinated, other than claims which rank, or are expressed to rank, pari passu with, or junior to, the claims of holders of the AT1 securities. ▪ AT1 securities are undated and are redeemable, at the option of Barclays PLC, in whole on (i) the initial reset date, or on any fifth anniversary after the initial reset date or (ii) any day falling in a named period ending on the initial reset date, or on any fifth anniversary after the initial reset date. In addition, the AT1 securities are redeemable, at the option of Barclays PLC, in whole in the event of certain changes in the tax or regulatory treatment of the securities. Any redemptions require the prior consent of the PRA. ▪ AT1 securities bear a fixed rate of interest until the initial reset date. After the initial reset date, in the event that they are not redeemed, the AT1 securities will bear interest at rates fixed periodically in advance for five-year periods based on market rates. ▪ Interest on the AT1 securities will be due and payable only at the sole discretion of Barclays PLC, and Barclays PLC has sole and absolute discretion at all times and for any reason to cancel (in whole or in part) any interest payment that would otherwise be payable on any interest payment date. |
Reserves
Reserves | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of reserves within equity [abstract] | |
Reserves | Reserves Currency translation reserve The currency translation reserve represents the cumulative gains and losses on the retranslation of the Group’s net investment in foreign operations, net of the effects of hedging. Fair value through other comprehensive income reserve The fair value through other comprehensive income reserve represents the changes in the fair value of fair value through other comprehensive income investments since initial recognition. Cash flow hedging reserve The cash flow hedging reserve represents the cumulative gains and losses on effective cash flow hedging instruments that will be recycled to profit or loss when the hedged transactions affect profit or loss. Own credit reserve The own credit reserve reflects the cumulative own credit gains and losses on financial liabilities at fair value. Amounts in the own credit reserve are not recycled to profit or loss in future periods. Other reserves and treasury shares Other reserves relate to redeemed ordinary and preference shares issued by the Group. Treasury shares relate to Barclays PLC shares held in relation to the Group’s various share schemes. These schemes are described in Note 32. Treasury shares are deducted from shareholders’ equity within other reserves. A transfer is made to retained earnings in line with the vesting of treasury shares held for the purposes of share-based payments. 2021 2020 £m £m Currency translation reserve 2,740 2,871 Fair value through other comprehensive income reserve (283) 5 Cash flow hedging reserve (853) 1,575 Own credit reserve (960) (954) Other reserves and treasury shares 1,126 964 Total 1,770 4,461 |
Non-controlling interests
Non-controlling interests | 12 Months Ended |
Dec. 31, 2021 | |
Non-controlling interests [Abstract] | |
Non-controlling interests | Non-controlling interests Profit attributable to non-controlling interest Equity attributable to non-controlling interest Dividends paid to non-controlling interest 2021 2020 2021 2020 2021 2020 £m £m £m £m £m £m Barclays Bank PLC issued: – Preference shares 27 42 529 529 27 42 – Upper Tier 2 instruments 17 37 458 533 17 37 Other non-controlling interests 3 (1) 2 23 — — Total 47 78 989 1,085 44 79 In 2021, there were no issuances (2020: none) and one redemption of £75m (2020: £158m) relating to the 9.25% perpetual subordinated bonds. Barclays Bank PLC and protective rights of non-controlling interests Barclays PLC holds 100% of the voting rights of Barclays Bank PLC. As at 31 December 2021, Barclays Bank PLC has in issue preference shares and Upper Tier 2 instruments. These are non-controlling interests to the Group. A fixed coupon rate is attached to all Upper Tier 2 instruments until the initial call date, with the exception of the 9% Bonds, which are fixed for the life of the issue and the Series 1, Series 2 and Series 3 Undated Notes, which are floating rate at rates fixed periodically in advance based on market rates. After the initial call date, in the event they are not redeemed, coupon payments in relation to the 6.125% Undated Notes are fixed periodically in advance for five-year periods based on market rates. Coupon payments for all other Upper Tier 2 instruments are at rates fixed periodically in advance based on market rates. The payment of preference share dividends and Upper Tier 2 coupons are typically at the discretion of Barclays Bank PLC, except for coupon payments that become compulsory where Barclays PLC has declared or paid a dividend on ordinary shares, or in certain cases, any class of preference shares, in the preceding six-month period. Coupons not paid becomes payable in each case if such a dividend is subsequently paid or in certain other circumstances. No dividend or coupon payments may be made unless Barclays Bank PLC satisfies a specified solvency test. Under the terms of these instruments, Barclays PLC may not pay dividends on ordinary shares until a dividend or coupon is next paid on these instruments or the instruments are redeemed or purchased by Barclays Bank PLC. There are no restrictions on Barclays Bank PLC’s ability to remit capital to the Parent as a result of these issued instruments. Preference share redemptions are typically at the discretion of Barclays Bank PLC. Upper Tier 2 instruments are repayable, at the option of Barclays Bank PLC generally in whole at the initial call date and on any subsequent coupon payment date or, in the case of the 6.125% Undated Notes on any fifth anniversary after the initial call date. In addition, each issue of Upper Tier 2 instruments is repayable, at the option of Barclays Bank PLC, in whole for certain tax reasons, either at any time, or on an interest payment date. There are no events of default except non-payment of principal or mandatory interest. Any repayments or redemptions require the prior consent of the PRA, and in respect of the preference shares, any such redemption will be subject to the Companies Act 2006 and the Articles of Barclays Bank PLC. 2021 2020 Instrument £m £m Preference Shares: US Dollar Preference Shares 318 318 Euro Preference Shares 211 211 Total Barclays Bank PLC Preference Shares 529 529 Upper Tier 2 Instruments: Undated Floating Rate Primary Capital Notes Series 1 93 93 Undated Floating Rate Primary Capital Notes Series 2 179 179 5.03% Undated Reverse Dual Currency Subordinated Loan (JPY8bn) 39 39 5.0% Reverse Dual Currency Undated Subordinated Loan (JPY12bn) 53 53 Undated Floating Rate Primary Capital Notes Series 3 (£145m) 20 20 9% Permanent Interest Bearing Capital Bonds (£100m) 40 40 6.125% Undated Subordinated Notes (£550m) 34 34 9.25% Perpetual Subordinated Bonds (ex Woolwich) (£150m) — 75 Total Upper Tier 2 Instruments 458 533 |
Staff costs
Staff costs | 12 Months Ended |
Dec. 31, 2021 | |
Classes of employee benefits expense [abstract] | |
Staff costs | Staff costs Accounting for staff costs The Group applies IAS 19 Employee benefits in its accounting for most of the components of staff costs. Short-term employee benefits – salaries, accrued performance costs and social security are recognised over the period in which the employees provide the services to which the payments relate. Performance costs – recognised to the extent that the Group has a present obligation to its employees that can be measured reliably and are recognised over the period of service that employees are required to work to qualify for the payments. Deferred cash and share awards are made to employees to incentivise performance over the period employees provide services. To receive payment under an award, employees must provide service over the vesting period. The period over which the expense for deferred cash and share awards is recognised is based upon the period employees consider their services contribute to the awards. For past awards, the Group considers that it is appropriate to recognise the awards over the period from the date of grant to the date that the awards vest. In relation to awards granted from 2017, the Group, taking into account the changing employee understanding surrounding those awards, considered it appropriate for expense to be recognised over the vesting period including the financial year prior to the grant date. The accounting policies for share-based payments, and pensions and other post-retirement benefits are included in Note 32 and Note 33 respectively. 2021 2020 2019 £m £m £m Incentive awards granted: Current year bonus 1,278 1,090 1,058 Deferred bonus 667 490 432 Total incentive awards granted 1,945 1,580 1,490 Reconciliation of incentive awards granted to income statement charge: Less: deferred bonuses granted but not charged in current year (457) (335) (293) Add: current year charges for deferred bonuses from previous years 280 293 308 Other differences between incentive awards granted and income statement charge (23) (34) (48) Income statement charge for performance costs 1,745 1,504 1,457 Other income statement charges: Salaries 4,290 4,322 4,332 Social security costs 619 613 573 Post-retirement benefits a 539 519 501 Other compensation costs 431 479 480 Total compensation costs b 7,624 7,437 7,343 Other resourcing costs: Outsourcing 357 342 433 Redundancy and restructuring 296 102 132 Temporary staff costs 109 102 256 Other 125 114 151 Total other resourcing costs 887 660 972 Total staff costs 8,511 8,097 8,315 Notes a Post-retirement benefits charge includes £289m (2020: £279m; 2019: £270m) in respect of defined contribution schemes and £250m (2020: £240m; 2019: £231m) in respect of defined benefit schemes. b £484m (2020: £451m; 2019: £439m) of Group compensation was capitalised as internally generated software and excluded from the Staff cost disclosed above . |
Share-based payments
Share-based payments | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of terms and conditions of share-based payment arrangement [abstract] | |
Share-based payments | Share-based payments Accounting for share-based payments The Group applies IFRS 2 Share-based Payments in accounting for employee remuneration in the form of shares. Employee incentives include awards in the form of shares and share options, as well as offering employees the opportunity to purchase shares on favourable terms. The cost of the employee services received in respect of the shares or share options granted is recognised in the income statement over the period that employees provide services. The overall cost of the award is calculated using the number of shares and options expected to vest and the fair value of the shares or options at the date of grant. The number of shares and options expected to vest takes into account the likelihood that performance and service conditions included in the terms of the awards will be met. Failure to meet the non-vesting condition is treated as a cancellation, resulting in an acceleration of recognition of the cost of the employee services. The fair value of shares is the market price ruling on the grant date, in some cases adjusted to reflect restrictions on transferability. The fair value of options granted is determined using option pricing models to estimate the numbers of shares likely to vest. These take into account the exercise price of the option, the current share price, the risk-free interest rate, the expected volatility of the share price over the life of the option and other relevant factors. Market conditions that must be met in order for the award to vest are also reflected in the fair value of the award, as are any other non-vesting conditions – such as continuing to make payments into a share-based savings scheme. The charge for the year arising from share-based payment schemes was as follows: Charge for the year 2021 2020 2019 £m £m £m Deferred Share Value Plan and Share Value Plan 256 245 272 Others 216 184 206 Total equity settled 472 429 478 Cash settled 5 2 3 Total share-based payments 477 431 481 The terms of the main current plans are as follows: Share Value Plan (SVP) The SVP was introduced in March 2010. SVP awards have been granted to participants in the form of a conditional right to receive Barclays PLC shares or provisional allocations of Barclays PLC shares which vest or are considered for release over a period of three, five or seven years. Participants do not pay to receive an award or to receive a release of shares. For awards granted before December 2017, the grantor may also make a dividend equivalent payment to participants on release of a SVP award. SVP awards are also made to eligible employees for recruitment purposes. All awards are subject to potential forfeiture in certain leaver scenarios. Deferred Share Value Plan (DSVP) The DSVP was introduced in February 2017. The terms of the DSVP are materially the same as the terms of the SVP as described above, save that Executive Directors are not eligible to participate in the DSVP and the DSVP operates over market purchase shares only. Other schemes In addition to the SVP and DSVP, the Barclays Group operates a number of other schemes settled in Barclays PLC Shares including Sharesave (both UK and Ireland), Sharepurchase (both UK and overseas), and the Barclays Group Long Term Incentive Plan. A delivery of upfront shares to ‘Material Risk Takers’ can be made as a Share Incentive Award (Holding Period). Share option and award plans The weighted average fair value per award granted, weighted average share price at the date of exercise/release of shares during the year, weighted average contractual remaining life and number of options and awards outstanding (including those exercisable) at the balance sheet date were as follows: 2021 2020 Weighted average fair value per award granted in year Weighted average share price at exercise/release during year Weighted Number of Weighted average fair value per award granted in year Weighted average share price at exercise/release during year Weighted Number of £ £ in years (000s) £ £ in years (000s) DSVP and SVP a,b 1.62 1.76 1 413,859 1.06 1.24 1 416,941 Others a 0.64-1.80 1.75-1.92 0-3 335,976 0.23-1.24 1.04-1.68 0-3 356,033 Notes a Options/award granted over Barclays PLC shares. b Weighted average exercise price is not applicable for SVP and DSVP awards as these are not share option schemes. SVP and DSVP are nil cost awards on which the performance conditions are substantially completed at the date of grant. Consequently, the fair value of these awards is based on the market value at that date. Sharesave has a contractual life of 3 and five years, the expected volatility is 30.97% for 3 years and 29.76% for 5 years. The risk free interest rates used for valuations are 1.20% and 1.18% for 3 and 5 years respectively. Movements in options and awards The movement in the number of options and awards for the major schemes and the weighted average exercise price of options was: DSVP and SVP a,b Others a,c Number (000s) Number (000s) Weighted average ex. price (£) 2021 2020 2021 2020 2021 2020 Outstanding at beginning of year/acquisition date 416,941 331,491 356,033 232,259 0.96 1.29 Granted in the year 187,667 232,379 120,385 365,166 1.43 0.84 Exercised/released in the year (160,460) (132,376) (107,688) (123,042) 1.38 1.22 Less: forfeited in the year (30,289) (14,553) (24,489) (105,068) 0.95 1.24 Less: expired in the year — — (8,265) (13,282) 1.67 1.35 Outstanding at end of year 413,859 416,941 335,976 356,033 0.95 0.96 Of which exercisable: — — 28,609 30,833 1.23 1.66 Notes a Options/award granted over Barclays PLC shares. b Weighted average exercise price is not applicable for SVP and DSVP awards as these are not share option schemes. c The number of awards within Others at the end of the year principally relates to Sharesave (number of awards exercisable at end of year was 8,821,715). The weighted average exercise price relates to Sharesave. Awards and options granted under the Group’s share plans may be satisfied using new issue shares, treasury shares and market purchase shares. Awards granted under the DSVP may be satisfied using market purchase shares only. There were no significant modifications to the share-based payments arrangements in 2021 and 2020. As at 31 December 2021, the total liability arising from cash-settled share-based payments transactions was £5m (2020: £2m). Holdings of Barclays PLC shares and hedges Various employee benefit trusts established by the Group hold shares in Barclays PLC to meet obligations under the Barclays share-based payment schemes. The total number of Barclays shares held in these employee benefit trusts at 31 December 2021 was 12.9m (2020: 17.1m). Dividend rights have been waived on all these shares. The total market value of the shares held in trust based on the year end share price of £1.87 (2020: £1.27) was £24m (2020: £22m). For accounting of treasury shares, see Note 29. The Group has entered into physically settled forward contracts to hedge the settlement of certain share-based payment schemes. The fixed forward price to be paid under these contracts is £416m and has been recorded in retained earnings. |
Pension and post-retirement ben
Pension and post-retirement benefits | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of defined benefit plans [abstract] | |
Pension and post-retirement benefits | Pensions and post-retirement benefits Accounting for pensions and post-retirement benefits The Group operates a number of pension schemes and post-employment benefit schemes. Defined contribution schemes – the Group recognises contributions due in respect of the accounting period in the income statement. Any contributions unpaid at the balance sheet date are included as a liability. Defined benefit schemes – the Group recognises its obligations to members of each scheme at the period end, less the fair value of the scheme assets after applying the asset ceiling test. Each scheme’s obligations are calculated using the projected unit credit method. Scheme assets are stated at fair value as at the period end. Changes in pension scheme liabilities or assets (remeasurements) that do not arise from regular pension cost, net interest on net defined benefit liabilities or assets, past service costs, settlements or contributions to the scheme, are recognised in other comprehensive income. Remeasurements comprise experience adjustments (differences between previous actuarial assumptions and what has actually occurred), the effects of changes in actuarial assumptions, return on scheme assets (excluding amounts included in the interest on the assets) and any changes in the effect of the asset ceiling restriction (excluding amounts included in the interest on the restriction). Post-employment benefit schemes – the cost of providing healthcare benefits to retired employees is accrued as a liability in the financial statements over the period that the employees provide services to the Group, using a methodology similar to that for defined benefit pension schemes. Pension schemes UK Retirement Fund (UKRF) The UKRF is the Group’s main scheme, representing 97% of the Group’s total retirement benefit obligations. Barclays Bank PLC is the principal employer of the UKRF. The UKRF was closed to new entrants on 1 October 2012, and comprises 10 sections, the two most significant of which are: ▪ Afterwork, which comprises a contributory cash balance defined benefit element, and a voluntary defined contribution element. The cash balance element is accrued each year and revalued until Normal Retirement Age in line with the increase in Retail Price Index (RPI) (up to a maximum of 5% p.a.). An increase of up to 2% a year may also be added at Barclays’ discretion. The costs of ill-health retirements and death in service benefits for Afterwork members are borne by the UKRF. The main risks that Barclays runs in relation to Afterwork are limited although additional contributions are required if pre-retirement investment returns are not sufficient to provide for the benefits. ▪ The 1964 Pension Scheme. Most employees recruited before July 1997 built up benefits in this non-contributory defined benefit scheme in respect of service up to 31 March 2010. Pensions were calculated by reference to service and pensionable salary. From 1 April 2010, members became eligible to accrue future service benefits in either Afterwork or the Pension Investment Plan, a historic defined contribution section which is now closed to future contributions. The risks that Barclays runs in relation to the 1964 section are typical of final salary pension schemes, principally that investment returns fall short of expectations, that inflation exceeds expectations, and that retirees live longer than expected. Barclays Pension Savings Plan (BPSP) The BPSP is a defined contribution scheme providing benefits for all new UK hires from 1 October 2012, BPSP is not subject to the same investment return, inflation or life expectancy risks for Barclays that defined benefit schemes are. Members’ benefits reflect contributions paid and the level of investment returns achieved. Other Apart from the UKRF and the BPSP, Barclays operates a number of smaller pension and long-term employee benefits and post-retirement healthcare plans globally, the largest of which are the US defined benefit and defined contribution schemes. Many of the schemes are funded, with assets backing the obligations held in separate legal vehicles such as trusts. Others are operated on an unfunded basis. The benefits provided, the approach to funding, and the legal basis of the schemes, reflect local environments. Governance The UKRF operates under trust law and is managed and administered on behalf of the members in accordance with the terms of the Trust Deed and Rules and all relevant legislation. The Corporate Trustee is Barclays Pension Funds Trustees Limited, a private limited company and a wholly owned subsidiary of Barclays Bank PLC. The Trustee is the legal owner of the assets of the UKRF which are held separately from the assets of the Group. The Trustee Board comprises six Management Directors selected by Barclays, of whom three are independent Directors with no relationship with Barclays (and who are not members of the UKRF), plus three Member Nominated Directors selected from eligible active staff, deferred and pensioner members who apply for the role. The BPSP is a Group Personal Pension arrangement which operates as a collection of personal pension plans. Each personal pension plan is a direct contract between the employee and the BPSP provider (Legal & General Assurance Society Limited), and is regulated by the FCA. Similar principles of pension governance apply to the Group’s other pension schemes, depending on local legislation. Amounts recognised The following tables include amounts recognised in the income statement and an analysis of benefit obligations and scheme assets for all Group defined benefit schemes. The net position is reconciled to the assets and liabilities recognised on the balance sheet. The tables include funded and unfunded post-retirement benefits. Income statement charge 2021 2020 2019 £m £m £m Current service cost 247 243 231 Net finance cost (26) (40) (48) Past service cost — (4) — Other movements 3 1 — Total 224 200 183 Balance sheet reconciliation 2021 2020 Total Of which relates to UKRF Total Of which relates to UKRF £m £m £m £m Benefit obligation at beginning of the year (33,190) (32,108) (30,333) (29,304) Current service cost (247) (225) (243) (217) Interest costs on scheme liabilities (422) (405) (573) (549) Past service cost — — 4 — Remeasurement (loss)/gain – financial 848 820 (3,439) (3,358) Remeasurement (loss)/gain – demographic 53 50 (281) (286) Remeasurement (loss)/gain – experience (249) (259) 244 237 Employee contributions (4) — (5) (1) Benefits paid 1,309 1,268 1,406 1,370 Exchange and other movements 3 — 30 — Benefit obligation at end of the year (31,899) (30,859) (33,190) (32,108) Fair value of scheme assets at beginning of the year 34,713 33,915 32,093 31,362 Interest income on scheme assets 448 434 613 595 Employer contribution 971 955 265 248 Remeasurement – return on scheme assets greater than discount rate 653 642 3,411 3,328 Employee contributions 4 — 5 1 Benefits paid (1,309) (1,268) (1,406) (1,370) Exchange and other movements (13) — (268) (249) Fair value of scheme assets at end of the year 35,467 34,678 34,713 33,915 Net surplus 3,568 3,819 1,523 1,807 Retirement benefit assets 3,879 3,819 1,814 1,807 Retirement benefit liabilities (311) — (291) — Net retirement benefit assets 3,568 3,819 1,523 1,807 Included within the benefit obligation was £821m (2020: £867m) relating to overseas pensions and £219m (2020: £215m) relating to other post-employment benefits. As at 31 December 2021, the UKRF’s scheme assets were in surplus versus IAS 19 obligations by £3,819m (2020: £1,807m). The movement for the UKRF was driven by £700m of deficit reduction contributions, higher corporate bond yields and favorable asset returns, partially offset by higher expected long term price inflation. The weighted average duration of the benefit payments reflected in the defined benefit obligation for the UKRF is 16 years. The UKRF expected benefits are projected to be paid out for in excess of 50 years, although 25% of the total benefits are expected to be paid in the next 10 years; 30% in years 11 to 20 and 25% in years 20 to 30. The remainder of the benefits are expected to be paid beyond 30 years. Of the £1,268m (2020: £1,370m) UKRF benefits paid out, £419m (2020: £520m) related to transfers out of the fund. Where a scheme’s assets exceed its obligation, an asset is recognised to the extent that it does not exceed the present value of future contribution holidays or refunds of contributions (the asset ceiling). In the case of the UKRF the asset ceiling is not applied as, in certain specified circumstances such as wind-up, the Group expects to be able to recover any surplus. Similarly, a liability in respect of future minimum funding requirements is not recognised. The Trustee does not have a substantive right to augment benefits, nor do they have the right to wind up the plan except in the dissolution of the Group or termination of contributions by the Group. The application of the asset ceiling to other plans and recognition of additional liabilities in respect of future minimum funding requirements are considered on an individual plan basis. Critical accounting estimates and judgements Actuarial valuation of the schemes’ obligation is dependent upon a series of assumptions. Below is a summary of the main financial and demographic assumptions adopted for the UKRF. 2021 2020 Key UKRF financial assumptions % p.a. % p.a. Discount rate 1.84 1.29 Inflation rate (RPI) 3.56 2.99 The UKRF discount rate assumption for 2021 was based on a standard Willis Towers Watson RATE Link model. The RPI inflation assumption for 2021 was set by reference to the Bank of England’s implied inflation curve. The inflation assumption incorporates a deduction of 20 basis points as an allowance for an inflation risk premium. The methodology used to derive the discount rate and inflation assumptions is consistent with that used at the prior year end. The UKRF’s post-retirement mortality assumptions are based on a best estimate assumption derived from an analysis in 2019 of the UKRF’s own post-retirement mortality experience, and taking account of recent evidence from published mortality surveys. An allowance has been made for future mortality improvements based on the 2020 core projection model published by the Continuous Mortality Investigation Bureau subject to a long-term trend of 1.5% per annum in future improvements. The methodology used is consistent with the prior year end, except that the 2019 core projection model was used at 2020. The table below shows how the assumed life expectancy at 60, for members of the UKRF, has varied over the past three years: Assumed life expectancy 2021 2020 2019 Life expectancy at 60 for current pensioners (years) – Males 27.3 27.2 27.1 – Females 29.6 29.4 29.3 Life expectancy at 60 for future pensioners currently aged 40 (years) – Males 29.1 29.0 28.9 – Females 31.4 31.2 31.1 The UKRF entered into a £5bn longevity swap in 2020 covering around a quarter of the pensioner liabilities. The swap is part of the UKRF’s investment portfolio and provide income in the event that pensions are paid out for longer than expected. The swap is not included directly within the balance sheet of Barclays PLC as it is an asset of the UKRF. At 31 December 2021, the swap is valued at nil (2020:nil) as experience since the swap was effected has been neutral. Sensitivity analysis on actuarial assumptions The sensitivity analysis has been calculated by valuing the UKRF liabilities using the amended assumptions shown in the table below and keeping the remaining assumptions the same as disclosed in the table above, except in the case of the inflation sensitivity where other assumptions that depend on assumed inflation have also been amended correspondingly. The difference between the recalculated liability figure and that stated in the balance sheet reconciliation table above is the figure shown. The selection of these movements to illustrate the sensitivity of the defined benefit obligation to key assumptions should not be interpreted as Barclays expressing any specific view of the probability of such movements happening. Change in key assumptions 2021 2020 (Decrease)/ Increase in UKRF defined benefit obligation (Decrease)/ Increase in UKRF defined benefit obligation £bn £bn Discount rate 0.5% p.a. increase (2.3) (2.5) 0.25% p.a. increase (1.2) (1.3) 0.25% p.a. decrease 1.3 1.4 0.5% p.a. decrease 2.6 2.9 Assumed RPI 0.5% p.a. increase 1.6 1.8 0.25% p.a. increase 0.8 0.9 0.25% p.a. decrease (0.8) (0.9) 0.5% p.a. decrease (1.6) (1.8) Life expectancy at 60 One year increase 1.2 1.2 One year decrease (1.2) (1.2) Assets A long-term investment strategy has been set for the UKRF, with its asset allocation comprising a mixture of equities, bonds, property and other appropriate assets. This recognises that different asset classes are likely to produce different long-term returns and some asset classes may be more volatile than others. The long-term investment strategy ensures, among other aims, that investments are adequately diversified. The UKRF also employs derivative instruments, where appropriate, to achieve a desired exposure or return, or to match assets more closely to liabilities. The value of assets shown reflects the assets held by the scheme, with any derivative holdings reflected on a fair value basis. The value of the assets of the schemes and their percentage in relation to total scheme assets were as follows: Analysis of scheme assets Total Of which relates to UKRF Quoted a £m Unquoted a £m Value % of total fair value of Quoted a £m Unquoted a £m Value % of total fair value of As at 31 December 2021 Equities 214 1,377 1,591 4.5 86 1,377 1,463 4.2 Private equities — 2,991 2,991 8.4 — 2,991 2,991 8.6 Bonds - fixed government 2,387 95 2,482 7.0 2,083 95 2,178 6.3 Bonds - index-linked government 13,478 679 14,157 39.9 13,455 679 14,134 40.8 Bonds - corporate and other 6,223 2,854 9,077 25.6 5,986 2,854 8,840 25.5 Property 14 1,490 1,504 4.3 — 1,490 1,490 4.3 Infrastructure — 1,815 1,815 5.1 — 1,815 1,815 5.2 Cash and liquid assets 189 1,577 1,766 5.0 176 1,577 1,753 5.1 Mixed investment funds 9 — 9 — — — — — Other 19 56 75 0.2 — 14 14 — Fair value of scheme assets 22,533 12,934 35,467 100.0 21,786 12,892 34,678 100.0 As at 31 December 2020 Equities 567 1,498 2,065 5.9 378 1,498 1,876 5.5 Private equities — 2,233 2,233 6.4 — 2,233 2,233 6.6 Bonds - fixed government 4,205 110 4,315 12.4 3,932 110 4,042 11.9 Bonds - index-linked government 10,706 1,014 11,720 33.8 10,697 1,014 11,711 34.6 Bonds - corporate and other 7,439 1,678 9,117 26.3 7,214 1,678 8,892 26.2 Property 10 1,416 1,426 4.1 — 1,416 1,416 4.2 Infrastructure — 1,812 1,812 5.2 — 1,812 1,812 5.3 Cash and liquid assets 64 1,830 1,894 5.5 46 1,830 1,876 5.5 Mixed investment funds 9 — 9 — — — — — Other 14 108 122 0.4 — 57 57 0.2 Fair value of scheme assets 23,014 11,699 34,713 100.0 22,267 11,648 33,915 100.0 Note a Valuations of unquoted assets are provided by the underlying managers or qualified independent valuers. Valuations of complex instruments are based on UKRF custodian valuations. All valuations are determined in accordance with relevant industry guidance. Included within the fair value of scheme assets were nil (2020: nil) relating to shares in Barclays PLC and nil (2020: nil) relating to bonds issued by Barclays PLC. The UKRF also invests in pooled investment vehicles which may hold shares or debt issued by Barclays PLC. The UKRF assets above do not include the Senior Notes asset referred to in the section below on Triennial Valuation, as these are non-transferable instruments and not recognised under IAS 19. Approximately 45% of the UKRF assets are invested in liability-driven investment strategies; primarily UK gilts as well as interest rate and inflation swaps. These are used to better match the assets to its liabilities. The swaps are used to reduce the scheme’s inflation and duration risks against its liabilities. Triennial valuation The latest annual update as at 30 September 2021 showed the funding position had improved to a surplus of £0.6bn from a deficit of £0.9bn shown at 30 September 2020. The improvement was mainly due to £0.7bn of deficit reduction contributions and favourable asset returns, partially offset by higher expected long term price inflation. The main differences between the funding and accounting assumptions are a different approach to setting the discount rate and a more conservative longevity assumption for funding. The deficit reduction contributions agreed with the UKRF Trustee as part of the 30 September 2019 triennial valuation recovery plan are shown in the table below. Deficit reduction contributions under the 30 September 2019 valuation Year £m Cash paid: 2021 700 Future commitments: 2022 294 2023 286 2024 and beyond — During 2019 and 2020 the UKRF subscribed for non-transferrable listed senior fixed rate notes for £1,250m, backed by UK gilts (the Senior Notes) and entitling the UKRF to semi-annual coupon payments for five years, and full repayment in cash in three tranches: £250m in 2023, £750m in 2024, and £250m in 2025. As a result of these transactions, the CET1 impact of the UKRF was deferred until 2023, 2024 and 2025 upon maturity of the notes. Following the PRA’s statement on 13 April 2022, Barclays is planning to unwind these transactions and to agree the terms and timing of this unwind with the UKRF Trustee as part of the next triennial actuarial valuation as at 30 September 2022. Upon unwind, this would result in a c30bps reduction to the CET1 ratio potentially being accelerated to Q422 from 2023, 2024 and 2025. As at 31 March 2022, the UKRF was in an accounting surplus of £4.4bn on an IAS 19 basis and as at 30 September 2021 was in a funding surplus of £0.6bn. There may also be a pension related reduction in Pillar 2A requirements in 2022 which could partially mitigate the impact of the unwind on the Group surplus capital position. As the UKRF's investment in these Senior Notes does not qualify as a plan asset under IAS 19, the £1,250m does not appear in the IAS 19 plan assets. The Senior Notes were issued by Heron Issuer Limited (Heron) for £500m and Heron Issuer Number 2 Limited (Heron 2) for £750m, entities consolidated within the Group under IFRS 10. Heron and Heron 2 acquired a total of £1,250m of gilts from Barclays Bank PLC for cash to support payments on the Senior Notes. There were no further transactions of this type in 2021. The deficit reduction contributions are in addition to the regular contributions to meet the Group’s share of the cost of benefits accruing over each year. The next funding valuation of the UKRF is due to be completed in 2023 with an effective date of 30 September 2022. Other support measures agreed which remain in place Collateral – The UKRF Trustee and Barclays Bank PLC have entered into an arrangement whereby a collateral pool has been put in place to provide security for the UKRF funding deficit as it increases or decreases over time. The collateral pool is currently made up of government securities, and agreement was made with the Trustee to cover at least 100% of the funding deficit with an overall cap of £9bn. The arrangement provides the UKRF Trustee with dedicated access to the pool of assets in the event of Barclays Bank PLC not paying a deficit reduction contribution to the UKRF or in the event of Barclays Bank PLC’s insolvency. These assets are included within Note 38 Assets pledged, collateral received and assets transferred. Support from Barclays PLC – In the event of Barclays Bank PLC not paying a deficit reduction contribution payment required by a specified pre-payment date, Barclays PLC has entered into an arrangement whereby it will be required to use, in first priority, dividends received from Barclays Bank UK PLC (if any) to invest the proceeds in Barclays Bank PLC (up to the maximum amount of the deficit reduction contribution unpaid by Barclays Bank PLC). The proceeds of the investment will be used to discharge Barclays Bank PLC’s unpaid deficit reduction contribution. Participation – As permitted under the Financial Services and Markets Act 2000 (Banking Reform) (Pensions) Regulations 2016, Barclays Bank UK PLC is a participating employer in the UKRF and will remain so during a transitional phase until September 2025 as set out in a deed of participation. Barclays Bank UK PLC will make contributions for the future service of its employees who are currently Afterwork members and, in the event of Barclays Bank PLC’s insolvency during this period provision has been made to require Barclays Bank UK PLC to become the principal employer of the UKRF. Barclays Bank PLC’s Section 75 debt would be triggered by the insolvency (the debt would be calculated after allowing for the payment to the UKRF of the collateral above). Defined benefit contributions paid with respect to the UKRF were as follows: Contributions paid £m 2021 955 2020 748 2019 1,231 There were nil (2020: nil; 2019: nil) Section 75 contributions included within the Group’s contributions paid as no participating employers left the UKRF in 2021. The Group’s expected contribution to the UKRF in respect of defined benefits in 2022 is £546m (2021: £959m). In addition, the expected contributions to UK defined contribution schemes in 2022 is £33m (2021: £35m) to the UKRF and £221m (2021: £209m) to the BPSP. |
Principal subsidiaries
Principal subsidiaries | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of subsidiaries [abstract] | |
Principal subsidiaries | Principal subsidiaries The Group applies IFRS 10 Consolidated Financial Statements. The consolidated financial statements combine the financial statements of the Group and all its subsidiaries. Subsidiaries are entities over which the Group has control. Under IFRS 10, this is when the Group is exposed or has rights to variable returns from its involvement in the entity and has the ability to affect those returns through its power over the entity. The Group reassesses whether it controls an entity if facts and circumstances indicate that there have been changes to its power, its rights to variable returns or its ability to use its power to affect the amount of its returns. Intra-group transactions and balances are eliminated on consolidation and consistent accounting policies are used throughout the Group for the purposes of the consolidation. Changes in ownership interests in subsidiaries are accounted for as equity transactions if they occur after control has been obtained and they do not result in loss of control. The significant judgements used in applying this policy are set out below. Accounting for investment in subsidiaries In the individual financial statements of Barclays PLC, investments in subsidiaries are stated at cost less impairment. Principal subsidiaries for the Group are set out below. This includes those subsidiaries that are most significant in the context of the Group’s business, results or financial position. Principal place of business or incorporation Percentage of voting rights held Non-controlling interests - proportion of ownership interests Non-controlling interests - proportion of voting interests Company name Nature of business % % % Barclays Bank PLC United Kingdom Banking, holding company 100 2 — Barclays Bank UK PLC United Kingdom Banking, holding company 100 — — Barclays Bank Ireland PLC Ireland Banking 100 — — Barclays Execution Services Limited United Kingdom Service company 100 — — Barclays Capital Inc. United States Securities dealing 100 — — Barclays Capital Securities Limited United Kingdom Securities dealing 100 — — Barclays Securities Japan Limited Japan Securities dealing 100 — — Barclays US LLC United States Holding company 100 — — Barclays Bank Delaware United States Credit card issuer 100 — — The country of registration or incorporation is also the principal area of operation of each of the above subsidiaries. Ownership interests are in some cases different to voting interests due to the existence of non-voting equity interests, such as preference shares. Refer to Note 30 for more information. Determining whether the Group has control of an entity is generally straightforward based on ownership of the majority of the voting capital. However, in certain instances, this determination will involve judgement, particularly in the case of structured entities where voting rights are often not the determining factor in decisions over the relevant activities. This judgement will involve assessing the purpose and design of the entity. It will also often be necessary to consider whether the Group, or another involved party with power over the relevant activities, is acting as a principal in its own right or as an agent on behalf of others. There is also often considerable judgement involved in the ongoing assessment of control over structured entities. In this regard, where market conditions have deteriorated such that the other investors’ exposures to the structure’s variable returns have been substantively eliminated, the Group may conclude that the managers of the structured entity are acting as its agent and therefore will consolidate the structured entity. An interest in equity voting rights exceeding 50% would typically indicate that the Group has control of an entity. However, the entity set out below is excluded from consolidation because the Group does not have exposure to its variable returns. Percentage of voting rights held Equity shareholders' funds Retained profit for the year Company name Country of registration or incorporation % £m £m Palomino Limited Cayman Islands 100 — — This entity is managed by an external counterparty and consequently is not controlled by the Group. Interests relating to this entity are included in Note 35. Significant restrictions As is typical for a group of its size and international scope, there are restrictions on the ability of Barclays PLC to obtain distributions of capital, access the assets or repay the liabilities of members of its Group due to the statutory, regulatory and contractual requirements of its subsidiaries and due to the protective rights of non-controlling interests. These are considered below. Regulatory requirements Barclays’ principal subsidiary companies have assets and liabilities before intercompany eliminations of £1,833bn (2020: £1,795bn) and £1,737bn (2020: £1,703bn) respectively. Certain of these assets and liabilities are subject to prudential regulation and regulatory capital requirements in the countries in which they are regulated. These require entities to maintain minimum capital levels which cannot be returned to the parent company, Barclays PLC, on a going concern basis. In order to meet capital requirements, subsidiaries may issue certain equity-accounted and debt-accounted financial instruments and non-equity instruments such as Tier 1 and Tier 2 capital instruments and other forms of subordinated liabilities. Refer to Note 27 and Note 28 for particulars of these instruments. These instruments may be subject to cancellation clauses or preference share restrictions that would limit the ability of the entity to repatriate the capital on a timely basis. Liquidity requirements Regulated subsidiaries of the Group are required to meet applicable PRA or local regulatory requirements pertaining to liquidity. Some of the regulated subsidiaries include Barclays Bank PLC and Barclays Capital Securities Limited (which are regulated on a combined basis under a Domestic Liquidity Sub-Group (DoLSub) arrangement), Barclays Bank UK PLC, Barclays Bank Ireland PLC, Barclays Capital Inc. and Barclays Bank Delaware. Refer to the Liquidity risk section for further details of liquidity requirements, including those of the Group’s significant subsidiaries. Statutory requirements The Group’s subsidiaries are subject to statutory requirements not to make distributions of capital and unrealised profits and generally to maintain solvency. These requirements restrict the ability of subsidiaries to make remittances of dividends to Barclays PLC, the ultimate parent, except in the event of a legal capital reduction or liquidation. In most cases, the regulatory restrictions referred to above exceed the statutory restrictions. Asset encumbrance The Group uses its financial assets to raise finance in the form of securitisations and through the liquidity schemes of central banks, as well as to provide security to the UK Retirement Fund. Once encumbered, the assets are not available for transfer around the Group. The assets typically affected are disclosed in Note 38. Other restrictions The Group is required to maintain balances with central banks and other regulatory authorities, and these amounted to £4,750m (2020: £3,392m). |
Structured entities
Structured entities | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of information about consolidated structured entities [abstract] | |
Structured entities | Structured entities A structured entity is an entity in which voting or similar rights are not the dominant factor in deciding who controls the entity. Voting rights may relate to administrative tasks only, with the relevant activities of the entity being directed by means of contractual arrangements. Structured entities are generally created to achieve a narrow and well-defined objective with restrictions around their ongoing activities. Depending on the Group’s power over the activities of the entity and its exposure to and ability to influence its own returns, it may consolidate the entity. In other cases, it may sponsor or have exposure to such an entity but not consolidate it. Consolidated structured entities The Group has contractual arrangements which may require it to provide financial support to the following types of consolidated structured entities: • Securitisation vehicles: The Group uses securitisation as a source of financing and a means of risk transfer. Where entities are controlled by the Group, they are consolidated. Refer to Note 37 for further detail. ▪ Commercial Paper (CP) conduits: These entities issue CP and use the proceeds to lend to clients as part of the Group's multi-seller conduit programme. The Group has provided £17.2bn (2020: £16.9bn) in contractual liquidity facilities to the CP conduits that the Group consolidates. These amounts represent the maximum the conduits can lend externally. The amounts of CP conduit lending (drawn and undrawn) to unconsolidated structured entities can be seen in Other interests in unconsolidated structured entities under multi-seller conduit programme in the Nature of interest table. ▪ Employee benefit trusts: The Group provides capital contributions to employee benefit trusts to enable them to meet obligations to employees in relation to share-based remuneration arrangements. ▪ Tender Option Bond (TOB) trusts: During 2021, the Group provided undrawn liquidity facilities of £3.3bn (2020: £2.9bn) to consolidated TOB trusts. These trusts invest in fixed income instruments issued by state, local or other municipalities in the United States, funded by long-term senior floating-rate notes and junior residual securities. Unconsolidated structured entities The term ‘unconsolidated structured entities’ refers to structured entities not controlled by Barclays, and are established either by Barclays or a third party. An interest in a structured entity is any form of contractual or non-contractual involvement which creates variability in returns arising from the performance of the entity for the Group. Such interests include holdings of debt or equity securities, derivatives that transfer financial risks from the entity to the Group, lending, loan commitments, financial guarantees and investment management agreements. The Group enters into transactions with unconsolidated structured entities in the normal course of business to facilitate customer transactions, to provide risk management services and for specific investment opportunities. This is predominantly within the CIB business. Structured entities may take the form of funds, trusts, securitisation vehicles, and private investment companies. The largest transactions for Barclays include loans and derivatives with hedge fund structures and special purpose entities, multi-seller conduit lending, holding notes issued by securitisation vehicles, and facilitating customer requirements through funds. The nature and extent of the Group’s interests in structured entities is summarised below: Summary of interests in unconsolidated structured entities Secured financing Short-term traded interests Traded derivatives Other interests Total £m £m £m £m £m As at 31 December 2021 Assets Trading portfolio assets — 7,170 — — 7,170 Financial assets at fair value through the income statement 61,816 — — 3,490 65,306 Derivative financial instruments — — 5,160 — 5,160 Financial assets at fair value through other comprehensive income — — — 91 91 Loans and advances at amortised cost — — — 28,227 28,227 Reverse repurchase agreements and other similar secured lending 104 — — — 104 Other assets — — — 17 17 Total assets 61,920 7,170 5,160 31,825 106,075 Liabilities Derivative financial instruments — — 9,543 — 9,543 As at 31 December 2020 Assets Trading portfolio assets — 11,361 — — 11,361 Financial assets at fair value through the income statement 56,265 — — 2,864 59,129 Derivative financial instruments — — 2,968 — 2,968 Financial assets at fair value through other comprehensive income — — — 153 153 Loans and advances at amortised cost — — — 20,946 20,946 Reverse repurchase agreements and other similar secured lending 10 — — — 10 Other assets — — — 16 16 Total assets 56,275 11,361 2,968 23,979 94,583 Liabilities Derivative financial instruments — — 7,075 — 7,075 Secured financing arrangements, short-term traded interests and traded derivatives are typically managed under market risk management policies described in the Market risk management section which includes an indication of the change of risk measures compared to last year. For this reason, the total assets of these entities are not considered meaningful for the purposes of understanding the related risks and so have not been presented. Other interests include conduits and lending where the interest is driven by normal customer demand. As at 31 December 2021, there were 5,891 (2020: 3,394) structured entities that Barclays entered into transactions with. Secured financing The Group routinely enters into reverse repurchase contracts, margin lending, stock borrowing and similar arrangements on normal commercial terms where the counterparty to the arrangement is a structured entity. Due to the nature of these arrangements, especially the transfer of collateral and ongoing margining, the Group is able to manage its variable exposure to the performance of the structured entity counterparty. The counterparties included in secured financing mainly include hedge fund limited structures, investment companies and special purpose entities. Short-term traded interests As part of its market making activities, the Group buys and sells interests in structured vehicles, which are predominantly debt securities issued by asset securitisation vehicles. Such interests are typically held individually or as part of a larger portfolio for no more than 90 days. In such cases, the Group typically has no other involvement with the structured entity other than the securities it holds as part of trading activities and its maximum exposure to loss is restricted to the carrying value of the asset. Traded derivatives The Group enters into a variety of derivative contracts with structured entities which reference market risk variables such as interest rates, foreign exchange rates and credit indices among other things. The main derivative types which are considered interests in structured entities include index-based and entity specific credit default swaps, balance guaranteed swaps, total return swaps, commodities swaps, and equity swaps. Interest rate swaps, foreign exchange derivatives that are not complex and which expose the Group to insignificant credit risk by being senior in the payment waterfall of a securitisation and derivatives that are determined to introduce risk or variability to a structured entity are not considered to be an interest in an entity and have been excluded from the disclosures. A description of the types of derivatives and the risk management practices are detailed in Note 14. The risk of loss may be mitigated through ongoing margining requirements as well as a right to cash flows from the structured entity which are senior in the payment waterfall. Such margining requirements are consistent with market practice for many derivative arrangements and in line with the Group’s normal credit policies. Derivative transactions require the counterparty to provide cash or other collateral under margining agreements to mitigate counterparty credit risk. The Group is mainly exposed to settlement risk on these derivatives which is mitigated through daily margining. Total notional contract amounts were £217,055m (2020: £153,894m). Except for credit default swaps where the maximum exposure to loss is the swap notional amount, it is not possible to estimate the maximum exposure to loss in respect of derivative positions as the fair value of derivatives is subject to changes in market rates of interest, exchange rates and credit indices which by their nature are uncertain. In addition, the Group’s losses would be subject to mitigating action under its traded market risk and credit risk policies that require the counterparty to provide collateral in cash or other assets in most cases. Other interests in unconsolidated structured entities The Group’s interests in structured entities not held for the purposes of short-term trading activities are set out below, summarised by the nature of the interest and limited to significant categories, based on maximum exposure to loss. Nature of interest Multi-seller conduit programme Lending Other Total Of which: Barclays owned, not consolidated entities a £m £m £m £m £m As at 31 December 2021 Financial assets at fair value through the income statement — 70 3,420 3,490 3,335 Financial assets at fair value through other comprehensive income — 53 38 91 — Loans and advances at amortised cost 5,184 14,538 8,505 28,227 — Other assets 8 4 5 17 — Total on-balance sheet exposures 5,192 14,665 11,968 31,825 3,335 Total off-balance sheet notional amounts 11,015 9,426 — 20,441 — Maximum exposure to loss 16,207 24,091 11,968 52,266 3,335 Total assets of the entity 65,441 166,238 52,873 284,552 11,513 As at 31 December 2020 Financial assets at fair value through the income statement — 98 2,766 2,864 2,698 Financial assets at fair value through other comprehensive income — 106 47 153 — Loans and advances at amortised cost 5,146 12,721 3,079 20,946 — Other assets 8 3 5 16 — Total on-balance sheet exposures 5,154 12,928 5,897 23,979 2,698 Total off-balance sheet notional amounts 11,750 7,555 — 19,305 — Maximum exposure to loss 16,904 20,483 5,897 43,284 2,698 Total assets of the entity 87,004 159,804 44,362 291,170 11,008 Note a Comprises of Barclays owned, not consolidated structured entities per IFRS 10 Consolidated Financial Statements, and Barclays sponsored entities, Refer to Note 34 Principal subsidiaries for more details on consolidation. Maximum exposure to loss Unless specified otherwise below, the Group’s maximum exposure to loss is the total of its on-balance sheet positions and its off-balance sheet arrangements, being loan commitments and financial guarantees. Exposure to loss is mitigated through collateral, financial guarantees, the availability of netting and credit protection held. Multi-seller conduit programme Barclays' multi-seller conduit programme engages in providing financing to various clients and holds whole or partial interests in pools of receivables or similar obligations. These instruments are protected from loss through over-collateralisation, seller guarantees, or other credit enhancements provided to the conduit entities. The Group’s off-balance sheet exposure included in the table above represents liquidity facilities that are provided to the conduit for the benefit of the holders of the commercial paper issued by the conduit and will only be drawn where the conduit is unable to access the commercial paper market. If these liquidity facilities are drawn, the Group is protected from loss through over-collateralisation, seller guarantees, or other credit enhancements provided to the conduit. Lending The portfolio includes lending provided by the Group to unconsolidated structured entities in the normal course of its lending business to earn income in the form of interest and lending fees and includes loans to structured entities that are generally collateralised by property, equipment or other assets. All loans are subject to the Group’s credit sanctioning process. Collateral arrangements are specific to the circumstances of each loan with additional guarantees and collateral sought from the sponsor of the structured entity for certain arrangements. During the period the Group incurred an impairment of £28m (2020: £23m) against such facilities. Other This includes fair value loans with structured entities where the market risk is materially hedged with corresponding derivative contracts, interests in debt securities issued by securitisation vehicles and drawn and undrawn loan facilities to these entities. In addition, other includes investment funds with interests restricted to management fees based on performance of the fund and trusts held on behalf of beneficiaries with interests restricted to unpaid fees. Assets transferred to sponsored unconsolidated structured entities Barclays is considered to sponsor another entity if, it had a key role in establishing that entity, it transferred assets to the entity, the Barclays name appears in the name of the entity or it provides guarantees on the entity’s performance. As at 31 December 2021, assets transferred to sponsored unconsolidated structured entities were £1,662m (2020: £730m). |
Investments in associates and j
Investments in associates and joint ventures | 12 Months Ended |
Dec. 31, 2021 | |
Investments in subsidiaries, joint ventures and associates reported in separate financial statements [abstract] | |
Investments in associates and joint ventures | Investments in associates and joint ventures Accounting for associates and joint ventures The Group applies IAS 28 Investments in Associates and IFRS 11 Joint Arrangements. Associates are entities in which the Group has significant influence, but not control, over the operating and financial policies. Generally the Group holds more than 20%, but less than 50%, of their voting shares. Joint ventures are arrangements where the Group has joint control and rights to the net assets of the entity. The Group’s investments in associates and joint ventures are initially recorded at cost and increased (or decreased) each year by the Group’s share of the post acquisition profit/(loss). The Group ceases to recognise its share of the losses of equity accounted associates when its share of the net assets and amounts due from the entity have been written off in full, unless it has a contractual or constructive obligation to make good its share of the losses. In some cases, investments in these entities may be held at fair value through profit or loss, for example, those held by private equity businesses. The equity accounted Associates includes the Groups investment in the Business Growth Fund £699m (2020: £441m) which has increased due to a fair value gain in its investments by £220m (2020: £(23)m). 2021 2020 Associates Joint ventures Total Associates Joint ventures Total £m £m £m £m £m £m Equity accounted 722 277 999 464 317 781 Held at fair value through profit or loss — 444 444 — 437 437 Total 722 721 1,443 464 754 1,218 Summarised financial information for the Group’s equity accounted associates and joint ventures is set out below. The amounts shown are the Group’s share of the net income of the investees for the year ended 31 December 2021, with the exception of certain undertakings for which the amounts are based on accounts made up to dates not earlier than three months before the balance sheet date. Associates Joint ventures 2021 2020 2021 2020 £m £m £m £m Profit/(loss) from continuing operations 219 (24) 35 24 Other comprehensive income/(loss) 1 (3) 5 (6) Total comprehensive income/(loss) from continuing operations 220 (27) 40 18 Unrecognised shares of the losses of individually immaterial associates and joint ventures were £nil (2020: £nil). The Barclays commitments and contingencies to its associates and joint ventures comprised unutilised credit facilities provided to customers of £1,760m (2020: £1,897m). In addition, the Group has made commitments to finance or otherwise provide resources to its joint ventures and associates of £482m (2020: £443m). |
Securitisations
Securitisations | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of transferred financial assets that are not derecognised in their entirety [abstract] | |
Securitisations | Securitisations Accounting for securitisations The Group uses securitisations as a source of finance and a means of risk transfer. Such transactions generally result in the transfer of contractual cash flows from portfolios of financial assets to holders of issued debt securities. Securitisations may, depending on the individual arrangement, result in continued recognition of the securitised assets and the recognition of the debt securities issued in the transaction; lead to partial continued recognition of the assets to the extent of the Group’s continuing involvement in those assets or lead to derecognition of the assets and the separate recognition, as assets or liabilities, of any rights and obligations created or retained in the transfer. Full derecognition only occurs when the Group transfers both its contractual right to receive cash flows from the financial assets, or retains the contractual rights to receive the cash flows, but assumes a contractual obligation to pay the cash flows to another party without material delay or reinvestment, and also transfers substantially all the risks and rewards of ownership, including credit risk, prepayment risk and interest rate risk. In the course of its normal banking activities, the Group makes transfers of financial assets, either where legal rights to the cash flows from the asset are passed to the counterparty or beneficially, where the Group retains the rights to the cash flows but assumes a responsibility to transfer them to the counterparty. Depending on the nature of the transaction, this may result in derecognition of the assets in their entirety, partial derecognition or no derecognition of the assets subject to the transfer. A summary of the main transactions, and the assets and liabilities and the financial risks arising from these transactions, is set out below: Transfers of financial assets that do not result in derecognition Securitisations The Group was party to securitisation transactions involving its credit card balances and other personal lending. In these transactions, the assets, interests in the assets, or beneficial interests in the cash flows arising from the assets, are transferred to a special purpose entity, which then issues interest bearing debt securities to third party investors. Securitisations may, depending on the individual arrangement, result in continued recognition of the securitised assets and the recognition of the debt securities issued in the transaction. Partial continued recognition of the assets to the extent of the Group’s continuing involvement in those assets can also occur or derecognition of the assets and the separate recognition, as assets or liabilities, of any rights and obligations created or retained in the transfer. The following table shows the carrying amount of securitised assets that have not resulted in full derecognition, together with the associated liabilities, for each category of asset on the balance sheet: 2021 2020 Assets Liabilities Assets Liabilities Carrying amount Fair value Carrying amount Fair value Carrying amount Fair value Carrying amount Fair value £m £m £m £m £m £m £m £m Loans and advances at amortised cost Credit cards, unsecured and other retail lending 1,303 1,423 (1,225) (1,219) 1,033 1,121 (1,019) (1,033) Balances included within loans and advances at amortised cost represent securitisations where substantially all the risks and rewards of the asset have been retained by the Group. The relationship between the transferred assets and the associated liabilities is that holders of notes may only look to cash flows from the securitised assets for payments of principal and interest due to them under the terms of their notes, although the contractual terms of their notes may be different to the maturity and interest of the transferred assets. If Barclays transfers a financial asset but does not transfer or retain substantially all the risk and rewards of the asset and retains control over it, the transferred assets is recognised to the extent of Barclays’ continuing involvement. In 2021, financial assets of £249m (2020: £nil) was transferred in this manner and the carrying value of the asset representing continued involvement is included in the table above. For transfers of assets in relation to repurchase agreements, refer to Note 38. Continuing involvement in financial assets that have been derecognised In some cases, the Group may have transferred a financial asset in its entirety but may have continuing involvement in it. This arises in asset securitisations where loans and asset backed securities were derecognised as a result of the Group’s involvement with asset backed securities, residential mortgage backed securities and commercial mortgage backed securities. Continuing involvement largely arises from providing financing into these structures in the form of retained notes, which do not bear first losses. The table below shows the potential financial implications of such continuing involvement: Continuing involvement a Gain/(loss) from continuing involvement Carrying amount Fair value Maximum exposure to loss For the year ended Cumulative to Cumulative to 31 December Type of transfer £m £m £m £m £m 2021 Asset backed securities 25 25 25 1 2 Residential mortgage backed securities 574 574 574 3 4 Commercial mortgage backed securities 311 307 311 5 11 Total 910 906 910 9 17 2020 Asset backed securities 56 56 56 1 1 Residential mortgage backed securities 49 49 49 1 1 Commercial mortgage backed securities 243 237 243 2 6 Total 348 342 348 4 8 Note a Assets which represent the Group’s continuing involvement in derecognised assets are recorded in Loans and advances at amortised cost and Debt securities at FVTP&L. |
Assets pledged, collateral rece
Assets pledged, collateral received and assets transferred | 12 Months Ended |
Dec. 31, 2021 | |
Assets pledged, collateral received and assets transferred [Abstract] | |
Assets pledged, collateral received and assets transferred | Assets pledged, collateral received and assets transferred Assets are pledged or transferred as collateral to secure liabilities under repurchase agreements, securitisations and stock lending agreements or as security deposits relating to derivatives. Assets transferred are non-cash assets transferred to a third party that do not qualify for derecognition from the Group balance sheet, for example because Barclays retains substantially all the exposure to those assets under an agreement to repurchase them in the future for a fixed price. Assets pledged or transferred as collateral include all assets categorised as encumbered in the disclosure on pages 221 to 223 of the Barclays PLC Pillar 3 Report 2021 (unaudited), other than those held in commercial paper conduits. In these transactions, the Group will be required to step in to provide financing itself under a liquidity facility if the vehicle cannot access the commercial paper market. Where non-cash assets are pledged or transferred as collateral for cash received, the asset continues to be recognised in full, and a related liability is also recognised on the balance sheet. Where non-cash assets are pledged or transferred as collateral in an exchange for non-cash assets, the transferred asset continues to be recognised in full, and there is no associated liability as the non-cash collateral received is not recognised on the balance sheet. The Group is unable to use, sell or pledge the transferred assets for the duration of the transaction and remains exposed to interest rate risk and credit risk on these pledged assets. Unless stated, the counterparty's recourse is not limited to the transferred assets. The following table summarises the nature and carrying amount of the assets pledged as security against these liabilities: 2021 2020 £m £m Cash collateral and settlements 66,138 72,042 Loans and advances at amortised cost 65,216 37,257 Trading portfolio assets 71,518 77,198 Financial assets at fair value through the income statement 5,595 5,584 Financial assets at fair value through other comprehensive income 13,748 22,185 Assets pledged 222,215 214,266 The following table summarises the transferred financial assets and the associated liabilities: Transferred assets Associated liabilities £m £m At 31 December 2021 Derivatives 66,744 (66,744) Repurchase agreements 71,820 (49,543) Securities lending arrangements 69,316 — Other 14,335 (12,121) 222,215 (128,408) At 31 December 2020 Derivatives 77,574 (77,574) Repurchase agreements 65,673 (44,076) Securities lending arrangements 61,183 — Other 9,836 (7,408) 214,266 (129,058) Included within Other are agreements where a counterparty's recourse is limited to the transferred assets. The relationship between the transferred assets and the associated liabilities is that holders of notes may only look to cash flows from the securitised assets for payments of principal and interest due to them under the terms of their notes. Carrying value Fair value Transferred assets Associated liabilities Transferred assets Associated liabilities Net position £m £m £m £m £m 2021 Recourse to transferred assets only 1,303 (1,225) 1,423 (1,219) 204 2020 Recourse to transferred assets only 1,033 (1,019) 1,121 (1,033) 88 The Group has an additional £5.8bn (2020: £6.3bn) of loans and advances within its asset backed funding programmes that can readily be used to raise additional secured funding and are available to support future issuances. Total assets pledged includes a collateral pool put in place to provide security for the UKRF funding deficit. Refer to Note 33 for further details. Collateral held as security for assets Under certain transactions, including reverse repurchase agreements and stock borrowing transactions, the Group is allowed to resell or re-pledge the collateral held. The fair value at the balance sheet date of collateral accepted and re-pledged or transferred to others was as follows: 2021 2020 £m £m Fair value of securities accepted as collateral 928,999 793,573 Of which fair value of securities re-pledged/transferred to others 814,448 685,300 Additional disclosure has been included in collateral and other credit enhancements in the Risk review section. Assets pledged as collateral include all assets categorised as encumbered in the disclosure on pages 221 to 223 of the Barclays PLC Pillar 3 Report 2021 (unaudited). The notes included in this section focus on related party transactions, Auditors’ remuneration and Directors’ remuneration. Related parties include any subsidiaries, associates, joint ventures and Key Management Personnel. |
Related party transactions and
Related party transactions and Directors' remuneration | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of transactions between related parties [abstract] | |
Related party transactions and Directors remuneration | Related party transactions and Directors’ remuneration Related party transactions Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions, or one other party controls both. Subsidiaries Transactions between Barclays PLC and its subsidiaries meet the definition of related party transactions. Where these are eliminated on consolidation, they are not disclosed in the Group’s financial statements. Transactions between Barclays PLC and its subsidiaries are fully disclosed in Barclays PLC’s financial statements. A list of the Group’s principal subsidiaries is shown in Note 34. Associates, joint ventures and other entities The Group provides banking services to its associates, joint ventures and the Group pension funds (principally the UK Retirement Fund), providing loans, overdrafts, interest and non-interest bearing deposits and current accounts to these entities as well as other services. Group companies also provide investment management and custodian services to the Group pension schemes. All of these transactions are conducted on the same terms as third party transactions. Summarised financial information for the Group’s investments in associates and joint ventures is set out in Note 36. Amounts included in the Group’s financial statements, in aggregate, by category of related party entity are as follows: Associates Joint ventures Pension funds £m £m £m For the year ended and as at 31 December 2021 Total income — 50 5 Credit impairment charges — — — Operating expenses (20) — (1) Total assets — 1,278 3 Total liabilities 177 — 81 For the year ended and as at 31 December 2020 Total income — 10 5 Credit impairment charges — — — Operating expenses (26) — (1) Total assets — 1,388 4 Total liabilities 66 — 69 Total liabilities includes derivatives transacted on behalf of the pension funds of £18m (2020: £13m). Key Management Personnel Key Management Personnel are defined as those persons having authority and responsibility for planning, directing and controlling the activities of Barclays PLC (directly or indirectly) and comprise the Directors and Officers of Barclays PLC, certain direct reports of the Group Chief Executive and the heads of major business units and functions. The Group provides banking services to Key Management Personnel and persons connected to them. Transactions during the year and the balances outstanding were as follows: Loans outstanding 2021 2020 £m £m As at 1 January 9.2 7.2 Loans issued during the year a 0.4 2.3 Loan repayments during the year b (1.8) (0.3) As at 31 December 7.8 9.2 Notes a Includes loans issued to existing Key Management Personnel and new or existing loans issued to newly appointed Key Management Personnel. b Includes loan repayments by existing Key Management Personnel and loans to former Key Management Personnel. No allowances for impairment were recognised in respect of loans to Key Management Personnel (or any connected person). Deposits outstanding 2021 2020 £m £m As at 1 January 10.4 12.1 Deposits received during the year a 37.6 41.6 Deposits repaid during the year b (38.9) (43.3) As at 31 December 9.1 10.4 Notes a Includes deposits received from existing Key Management Personnel and new or existing deposits received from newly appointed Key Management Personnel. b Includes deposits repaid by existing Key Management Personnel and deposits of former Key Management Personnel. Total commitments outstanding Total commitments outstanding refers to the total of any undrawn amounts on credit cards and/or overdraft facilities provided to Key Management Personnel. Total commitments outstanding as at 31 December 2021 were £0.6m (2020: £0.9m). All loans to Key Management Personnel (and persons connected to them) were made in the ordinary course of business; were made on substantially the same terms, including interest rates and collateral, as those prevailing at the same time for comparable transactions with other persons; and did not involve more than a normal risk of collectability or present other unfavourable features. Remuneration of Key Management Personnel Total remuneration awarded to Key Management Personnel below represents the awards made to individuals that have been approved by the Board Remuneration Committee as part of the latest remuneration decisions, and is consistent with the approach adopted for disclosures set out in the Directors’ Remuneration Report. Costs recognised in the income statement reflect the accounting charge for the year included within operating expenses. The difference between the values awarded and the recognised income statement charge principally relates to the recognition of deferred costs for prior year awards. Figures are provided for the period that individuals met the definition of Key Management Personnel. 2021 2020 £m £m Salaries and other short-term benefits 37.8 41.6 Pension costs — — Other long-term benefits 8.5 8.2 Share-based payments 12.2 13.2 Employer social security charges on emoluments 7.2 7.2 Costs recognised for accounting purposes 65.7 70.2 Employer social security charges on emoluments (7.2) (7.2) Other long-term benefits – difference between awards granted and costs recognised 3.1 — Share-based payments – difference between awards granted and costs recognised 6.9 1.1 Total remuneration awarded 68.5 64.1 Disclosure required by the Companies Act 2006 The following information regarding the Barclays PLC Board of Directors is presented in accordance with the Companies Act 2006: 2021 2020 £m £m Aggregate emoluments a 8.2 8.4 Amounts paid under LTIPs b 1.2 — 9.4 8.4 Notes a The aggregate emoluments include amounts paid for the 2021 year. In addition, deferred share awards for 2021 with a total value at grant of £1.4m (2020: £0.6m) will be made to CS Venkatakrishnan and Tushar Morzaria which will only vest subject to meeting certain conditions. b The figure above for "Amounts paid under LTIPs" in 2021 relates to LTIP awards that were released to Jes Staley and Tushar Morzaria in 2021. This includes the first tranche of the 2017 LTIP, the release of which was delayed from June 2020 to March 2021. Dividend shares released on the awards are excluded. The LTIP figure in the single total figure table for Executive Directors' 2021 remuneration in the Directors' Remuneration report relates to the award that is scheduled to be released in 2022 in respect of the 2019-2021 LTIP cycle. There were no pension contributions paid to defined contribution schemes on behalf of Directors (2020: £nil). There were no notional pension contributions to defined contribution schemes. As at 31 December 2021, there were no Directors accruing benefits under a defined benefit scheme (2020: nil). Directors’ and Officers’ shareholdings and options The beneficial ownership of ordinary share capital of Barclays PLC by all Directors and Officers of Barclays PLC (involving 22 persons) at 31 December 2021 amounted to 17,876,352 (2020: 27,470,067) ordinary shares of 25p each (0.11% of the ordinary share capital outstanding). As at 31 December 2021, Executive Directors and Officers of Barclays PLC (involving 12 persons) held options to purchase a total of 62,268 (2020: 78,495) Barclays PLC ordinary shares of 25p each at a weighted average price of 93p under Sharesave. Advances and credit to Directors and guarantees on behalf of Directors In accordance with Section 413 of the Companies Act 2006, the total amount of advances and credits made available in 2021 to persons who served as Directors during the year was £0.2m (2020: £0.1m). The total value of guarantees entered into on behalf of Directors during 2021 was £nil (2020: £nil). |
Auditor's remuneration
Auditor's remuneration | 12 Months Ended |
Dec. 31, 2021 | |
Auditor's remuneration [abstract] | |
Auditor's remuneration | Auditor’s remuneration Auditor’s remuneration is included within consultancy, legal and professional fees in administration and general expenses and comprises: 2021 2020 2019 £m £m £m Audit of the Barclays Group's annual accounts 9 9 10 Other services: Audit of the Company's subsidiaries a 41 38 35 Other audit related fees b 10 10 9 Other services 2 2 2 Total Auditor's remuneration 62 59 56 Notes a Comprises the fees for the statutory audit of subsidiaries both inside and outside the UK and fees for work performed by associates of KPMG in respect of the consolidated financial statements of the Company. b Comprises services in relation to statutory and regulatory filings. These include audit services for the review of the interim financial information under the Listing Rules of the UK listing authority. Audit scope changes are finalised following the completion of the audit and recognised when agreed. The 2021 audit fee includes £3m (2020: £2m) relating to the previous year’s audit. |
Interest rate benchmark reform
Interest rate benchmark reform | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of financial instruments by type of interest rate [abstract] | |
Interest rate benchmark reform | Interest rate benchmark reform Following the financial crisis, the reform and replacement of benchmark interest rates such as LIBOR has been a priority for global regulators. As a result, the UK’s Financial Conduct Authority (FCA) and other global regulators instructed market participants to prepare for the cessation of most LIBOR rates after the end of 2021, and to adopt “near Risk-Free Rates” (RFRs). Pursuant to FCA announcements during 2021, panel bank submissions for all GBP, JPY and CHF LIBOR and Euro Overnight Index Average (EONIA) LIBOR tenors ceased, and representative LIBOR rates also ceased after 31 December 2021. For USD, certain actively used tenors will continue to be provided until June 2023, however in line with the US banking regulators’ joint statement, Barclays ceased issuing or entering into new contracts that use USD LIBOR as a reference rate from 31 December 2021, other than in relation to those allowable use cases set out under the FCA's prohibition notice (ref 21A). These include market making in support of client activity; or transactions that reduce or hedge the Barclays' or any client of the Barclays' US dollar LIBOR exposure on contracts entered into before 1 January 2022. The Group’s exposure to rates subject to benchmark interest rate reform has been predominantly to GBP, USD, JPY and CHF LIBOR and EONIA with the vast majority concentrated in derivatives within the Corporate and Investment Bank. Some additional exposure resides on floating rate loans and advances, repurchase agreements and debt securities held and issued within the Corporate and Investment Bank. Retail lending and mortgage exposure in Barclays UK to LIBOR is minimal. Following transition activity in late 2021 and early 2022, GBP, USD (one week and two month tenors), JPY and CHF LIBOR and EONIA positions (“2021 scope”) have transitioned onto RFRs, and while there are a number of IBORs yet to cease, the Group’s risk exposure is now mainly to USD LIBOR. There are key differences between IBORs and RFRs. IBORs are ‘term rates’, which means that they are published for a borrowing period (for example three months), and they are ‘forward-looking’, because they are published at the beginning of a borrowing period, based upon an estimated inter-bank borrowing cost for the period. RFRs are based upon overnight rates from actual transactions, and are therefore published after the end of the overnight borrowing period. Furthermore, IBORs include a credit spread over the RFRs. Therefore, to transition existing contracts and agreements to RFRs, adjustments for term and credit differences may need to be applied to RFR-linked rates. The methodologies for these adjustments have been determined through in-depth consultations by industry working groups, on behalf of the respective global regulators and related market participants. How the Group is managing the transition to alternative benchmark rates Barclays has established a Group-wide LIBOR Transition Programme, with oversight from the Group Finance Director. The Transition Programme spans all business lines and has cross-functional governance which includes Legal, Compliance, Conduct Risk, Client Engagement and Communications, Risk, and Finance. The Transition Programme aims to drive strategic execution, and identify, manage and resolve key risks and issues as they arise. Barclays’ transition plans primarily focus on G5 currencies while providing quarterly updates on progress and exposures to the PRA/FCA and other regulators as required. The Transition Programme follows a risk based approach, using recognised ‘change delivery’ control standards. Accountable Executives are in place within key working groups and workstreams, with overall Board oversight delegated to the Board Risk Committee and the Group Finance Director. Barclays performs a prominent stewardship role to drive orderly transition via our representation on official sector and industry working groups across all major jurisdictions and product classes. Additionally, the Group Finance Director is Chair of the UK’s ‘Working Group on Sterling Risk-Free Reference Rates’ (UK £RFRWG), whose mandate is to catalyse a broad-based transition to using SONIA (‘Sterling Overnight Index Average’) as the primary sterling interest rate benchmark in bond, loan and derivatives markets. Approaches to transition exposure expiring post the expected end dates for LIBOR vary by product and nature of counterparty. The Group has actively engaged with the counterparties to transition or include appropriate fallback provisions and transition mechanisms in its floating rate assets and liabilities with maturities after 2021, when relevant IBORs excluding USD LIBOR cease to be published. The fallback will provide the relevant replacement rate, in the case of the ISDA Protocol this is the RFR plus a credit adjusted spread, that should be used post cessation or pre-cessation of the relevant IBOR. For the derivative population, adherence to the ISDA IBOR Fallbacks Protocol has provided Barclays with an efficient mechanism to amend outstanding trades to incorporate fallbacks. Beyond the ISDA IBOR Fallbacks Protocol, other options have included terminating or bilaterally agreeing new terms with counterparties. Derivative contracts facing central clearing counterparties have followed a market-wide, standardised approach to reform through a series of CCP-led conversions. The FCA has authorised broad usage of synthetic LIBOR as a temporary solution for the ‘tough legacy’ population of unremediated contracts for GBP and JPY. Given cleared derivatives for the 2021 scope transitioned via CCP driven conversions, synthetic LIBOR does not apply in this context. Barclays’ strategy remains to actively transition LIBOR exposure where viable, and/or to implement and utilise robust contractual fallbacks where possible. Where contracts remain unremediated, they may be able to utilise synthetic LIBOR on a temporary basis. Barclays will continue to monitor, assess and limit the reliance on synthetic LIBOR. As announced by the FCA on 5 March 2021, USD LIBOR tenors (except 1 week and 2 month tenors) will cease to be representative from 30 June 2023. As detailed above, the key area of focus for transition prior to 2022 was on the other non-USD IBOR currency-tenors that ceased to be published at the end of 2021. Cessation of new USD LIBOR trading and transition of USD LIBOR exposures is the priority for the Barclays LIBOR Transition Programme in 2022/23. Clients and colleagues have been notified that we have prohibited entering into new USD LIBOR transactions (with narrow permitted exceptions) from 1 January 2022 in line with regulatory expectations. Whilst synthetic LIBOR will be published on a temporary basis for 1, 3 and 6 month tenors of GBP and JPY LIBOR to assist the transition of certain exposures, no synthetic rate has been announced for USD LIBOR. New York State legislation has been enacted (with US Federal legislation to follow) which provides a solution for contracts governed under New York law for USD LIBOR to the Secured Overnight Financing Rate (SOFR) transition with the additional benefit of statutory contract continuity and safe harbour protection. This contrasts with the legislation implemented in the UK which provides for statutory contract continuity with safe harbour protection only for the administrator, and could expose market participants to additional litigation risk. Clients have been engaged on the transition of their legacy USD LIBOR exposures through active transition or the implementation of fallbacks, and have been issued with communications on key regulatory developments in the transition away from USD LIBOR. Progress made during 2021 During 2021, the Group delivered RFR product capabilities and alternatives to LIBOR across loans, bonds, securities financing transactions and derivatives required for LIBOR cessation to support transition of legacy contracts. Barclays has transitioned over 99% (by gross notional exposure) of legacy positions in those rates within the 2021 scope, onto new RFRs in line with official sector expectations and milestones. This has been achieved through bilateral negotiation of contracts with clients, including the use of appropriate fallback provisions (which became effective post 31 December 2021, however, note that the switch onto the RFR may not take place until next reset post 31 December 2021 and so exposures may still be reported as LIBOR) and taking part in large scale transition events at a number of Central Counterparty Clearing Houses (London Clearing House (LCH), Chicago Mercantile Exchange (CME), EUREX and Japan Securities Clearing Corporation (JSCC) for OTC derivatives and Intercontinental Exchange (ICE) EU and LCH CurveGlobal for exchange traded derivatives). In relation to those contracts yet to be transitioned, we remain in active dialogue with clients. Barclays transitioned the EONIA / LIBOR language in all active Credit Support Annexes (CSAs) via a number of mechanisms, primarily through bilateral CSA amendments but also by means of adherence to the ISDA 2021 EONIA Collateral Agreement Fallbacks Protocol. Barclays delivered technology and business process changes required to ensure operational readiness in preparation for LIBOR cessation and transitions to RFRs for those benchmark rates ceasing at the end of 2021. Any incremental Technology or Business Process changes required to support USD LIBOR cessation will be delivered ahead of 30 June 2023. Whilst the majority of IBOR exposures have moved to RFRs, where appropriate other rates such as fixed rates or Bank of England base rates have also been used. Risks to which the Group is exposed as a result of the transition Global regulators and central banks in the UK, US and EU have been driving international efforts to reform key benchmark interest rates and indices, such as LIBOR, which are used to determine the amounts payable under a wide range of transactions and make them more reliable and robust. These benchmark reforms have resulted in significant changes to the methodology and operation of certain benchmarks and indices, the adoption of RFRs, the discontinuation of certain reference rates (including LIBOR), and the introduction of implementing legislation and regulations. Specifically, regulators in the UK, US and EU have directed that certain non-US dollar LIBOR tenors cease at the end of 2021. Certain US dollar LIBOR tenors are to cease by the end of June 2023, and restrictions have been imposed on new use of USD LIBOR. Notwithstanding these developments, given the unpredictable consequences of benchmark reform, any of these developments could have an adverse impact on market participants, including the Group, in respect of any financial instruments linked to, or referencing, any of these benchmark interest rates. Uncertainty associated with such potential changes, including the availability and/or suitability of alternative RFRs, the participation of customers and third-party market participants in the transition process; challenges with respect to required documentation changes; and impact of legislation to deal with ‘certain legacy’ contracts that cannot convert into or add fall-back RFRs before cessation of the benchmark they reference, may adversely affect a broad range of transactions (including any securities, loans and derivatives which use LIBOR or any other affected benchmark to determine the amount of interest payable that are included in the Group’s financial assets and liabilities) that use these reference rates and indices, and present a number of risks for the Group, including, but not limited to: ▪ Conduct risk: in undertaking actions to transition away from using certain reference rates (such as LIBOR) to new alternative RFRs, the Group faces conduct risks. These may lead to customer complaints, regulatory sanctions or reputational impact if the Group is considered to be (among other things) (i) undertaking market activities that are manipulative or create a false or misleading impression, (ii) misusing sensitive information or not identifying or appropriately managing or mitigating conflicts of interest, (iii) providing customers with inadequate advice, misleading information, unsuitable products or unacceptable service, (iv)not taking a consistent approach to remediation for customers in similar circumstances, (v) unduly delaying the communication and migration activities in relation to client exposure, leaving them insufficient time to prepare, or (vi) colluding or inappropriately sharing information with competitors. ▪ Litigation risk: members of the Group may face legal proceedings, regulatory investigations and/or other actions or proceedings regarding (among other things) (i) the conduct risks identified above, (ii) the interpretation and enforceability of provisions in LIBOR-based contracts, and (iii) the Group’s preparation and readiness for the replacement of LIBOR with alternative RFRs. ▪ Financial risk: the valuation of certain of the Group’s financial assets and liabilities may change. Moreover, transitioning to alternative RFRs may impact the ability of members of the Group to calculate and model amounts receivable by them on certain financial assets and determine the amounts payable on certain financial liabilities (such as debt securities issued by them) because certain alternative RFRs (such as SONIA and the SOFR) are look-back rates whereas term rates (such as LIBOR) allow borrowers to calculate at the start of any interest period exactly how much is payable at the end of such interest period. This may have a material adverse effect on the Group’s cash flows. ▪ Pricing risk: changes to existing reference rates and indices, discontinuation of any reference rate or indices and transition to alternative RFRs may impact the pricing mechanisms used by the Group on certain transactions. ▪ Operational risk: changes to existing reference rates and indices, discontinuation of any reference rate or index and transition to alternative RFRs may require changes to the Group’s IT systems, trade reporting infrastructure, operational processes, and controls. In addition, if any reference rate or index (such as LIBOR) is no longer available to calculate amounts payable, the Group may incur additional expenses in amending documentation for new and existing transactions and/or effecting the transition from the original reference rate or index to a new reference rate or index. ▪ Accounting risk: an inability to apply hedge accounting in accordance with IAS 39 could lead to increased volatility in the Group’s financial results and performance. Any of these factors may have a material adverse effect on the Group’s business, results of operations, financial condition, prospects and reputation. While a number of the above risks in relation to transition of legacy 2021 scope onto RFRs have been substantially mitigated, they remain relevant in relation to USD and related LIBOR rate transitions. The Group does not expect material changes to its risk management approach and strategy as a result of interest rate benchmark reform. The following table summarises the significant exposures impacted by interest rate benchmark reform: GBP LIBOR USD LIBOR JPY LIBOR CHF LIBOR Others b Total As at 31 December 2021 £m £m £m £m £m £m Non-derivative financial assets Loans and advances at amortised cost 14,166 15,812 25 229 431 30,663 Reverse repurchase agreements and other similar secured lending — 186 — — — 186 Financial assets at fair value through the income statement 185 8,538 5 327 194 9,249 Financial assets at fair value through other comprehensive income — — — — — — Non-derivative financial assets 14,351 24,536 30 556 625 40,098 Non-derivative financial liabilities Debt securities in issue — (6,137) (1,083) — — (7,220) Subordinated liabilities — (1,088) — — (113) (1,201) Financial liabilities designated at fair value (708) (212) (920) Non-derivative financial liabilities (708) (7,437) (1,083) — (113) (9,341) Equity Other equity instruments — (3,374) (92) — — (3,466) Standby facilities, credit lines and other commitments a 60,490 42,767 1,284 371 12,724 117,636 GBP LIBOR USD LIBOR JPY LIBOR CHF LIBOR Others b Total As at 31 December 2020 £m £m £m £m £m £m Non-derivative financial assets Loans and advances at amortised cost 30,179 18,109 173 18 1,725 50,204 Reverse repurchase agreements and other similar secured lending — 334 — — — 334 Financial assets at fair value through the income statement 3,496 6,373 — 283 209 10,361 Financial assets at fair value through other comprehensive income 186 114 — — 8 308 Non-derivative financial assets 33,861 24,930 173 301 1,942 61,207 Non-derivative financial liabilities Debt securities in issue (1,023) (10,718) (1,201) — — (12,942) Subordinated liabilities (71) (1,592) — — — (1,663) Financial liabilities designated at fair value (149) (1,273) (759) — (139) (2,320) Non-derivative financial liabilities (1,243) (13,583) (1,960) — (139) (16,925) Equity Other equity instruments (3,500) (3,131) — — — (6,631) Standby facilities, credit lines and other commitments a 18,944 74,011 — 74 15,951 108,980 Notes a There has been a change on how exposures for multi currency loan facilities are reported in 2021, from base currency to the currency which needs to be remediated first. This has resulted in an increase in GBP LIBOR and a corresponding reduction in USD LIBOR exposure of £34bn. 2020 comparatives have not been restated to reflect this change. b Includes EUR LIBOR and SOR The table above represents the exposures to interest rate benchmark reform by balance sheet account, which have yet to transition. The exposure disclosed is for positions with contractual maturities after 31 December 2021 (apart from USD, which is for maturities after 30 June 2023). Trades with exposures to other IBORs whose respective cessation dates is in the future and mature before that date have been excluded (2020: exposures are disclosed for maturities after 31 December 2021 for all rates). Balances reported at amortised cost are disclosed at their gross carrying value and do not include any expected credit losses that may be held against them. The following table represents the derivative exposures to interest rate benchmark reform, which have yet to transition: GBP LIBOR USD LIBOR EONIA JPY LIBOR CHF LIBOR Others a Total As at 31 December 2021 £m £m £m £m £m £m £m Derivative notional contract amount OTC interest rate derivatives 240,183 2,283,236 7,811 140,357 4,396 61,937 2,737,920 OTC interest rate derivatives - cleared by central counterparty — 2,228,399 — — — 168,649 2,397,048 Exchange traded interest rate derivatives — 466,339 — — — — 466,339 OTC foreign exchange derivatives 183,477 461,680 — 122,823 32,900 1,419 802,299 OTC equity and stock index derivatives — 9,949 — — — — 9,949 Derivative notional contract amount 423,660 5,449,603 7,811 263,180 37,296 232,005 6,413,555 GBP LIBOR USD LIBOR EONIA JPY LIBOR CHF LIBOR Others a Total As at 31 December 2020 £m £m £m £m £m £m £m Derivative notional contract amount OTC interest rate derivatives 592,827 2,832,802 457,844 754,206 25,681 41,782 4,705,142 OTC interest rate derivatives - cleared by central counterparty 1,684,553 2,891,029 638,202 1,091,479 119,382 198,113 6,622,758 Exchange traded interest rate derivatives 300,182 333,705 — — 2,494 — 636,381 OTC foreign exchange derivatives 155,285 589,334 — 93,108 31,257 1,921 870,905 OTC equity and stock index derivatives 1,845 7,946 544 1,929 491 2,141 14,896 Derivative notional contract amount 2,734,692 6,654,816 1,096,590 1,940,722 179,305 243,957 12,850,082 Note a Includes EUR LIBOR, SOR and STIBOR The exposure disclosed is for positions with contractual maturities after 31 December 2021 (apart from USD, which is for maturities after 30 June 2023). Trades with exposures to other IBORs whose respective cessation dates is in the future and mature before that date have been excluded (2020: exposures are disclosed for maturities after 31 December 2021 for all rates). Derivatives are reported by using the notional contract amount and where derivatives have both pay and receive legs with exposure to benchmark reform such as cross currency swaps, the notional contract amount is disclosed for both legs. As at 31 December 2021, there were £256bn (2020: £264bn) of cross currency swaps where both the pay and receive legs are impacted by interest rate benchmark reform. The Group also had £9bn (2020: £28bn) of Barclays issued debt retained by the group, impacted by the interest rate benchmark reform, in USD LIBOR (2020: predominately in GBP and USD LIBOR.) Fallback clauses The 31 December 2021 exposure has been broken up into those with robust fallbacks and those without. Fallbacks here are defined as any mechanism involving a ‘switch’ or ‘hardwire’ or a contractual agreement to transition to an automatically selected rate. One of the most commonly used is the ISDA 2020 IBOR Protocol published in October 2020 which enabled market participants to incorporate fallback provisions into legacy non-cleared derivatives and certain non-derivatives transactions. Market participants who have adhered to the ISDA 2020 IBOR Protocol agree, between adhering parties, that their legacy contracts will be amended to include the relevant fallback provisions. In addition to this, ISDA developed bilateral Swap Rate Fallbacks templates for GBP and JPY Swap Rate bilateral derivative trades with the GBP ICE Swap Rate fallback provisions being published in August 2021 and the JPY ISDA Swap Rate fallback provisions being published in November 2021. Whilst the fallback provisions have been applied to the majority of trades, with some limited exceptions being worked through, the switch to the replacement rate as a result of fallback provision inclusion may not take place until the next rate reset post the cessation or pre-cessation event. The following tables present a breakdown of the exposures to IBOR reform (excluding USD LIBOR and other IBORs whose respective cessation dates is in the future) with fallbacks in place and those without: With appropriate fallback clause Without appropriate fallback clause GBP LIBOR JPY LIBOR CHF LIBOR EUR LIBOR Total GBP LIBOR JPY LIBOR CHF LIBOR EUR LIBOR Total As at 31 December 2021 £m £m £m £m £m £m £m £m £m £m Non-derivative financial assets Loans and advances at amortised cost 9,434 5 215 412 10,066 4,732 20 14 19 4,785 Financial assets at fair value through the income statement 125 5 327 8 465 60 — — 186 246 Non-derivative financial assets 9,559 10 542 420 10,531 4,792 20 14 205 5,031 Non-derivative financial liabilities Debt securities in issue — (1,083) — — (1,083) — — — — — Subordinated liabilities — — — — — — — — — — Financial liabilities designated at fair value (708) — — — (708) — — — — — Non-derivative financial liabilities (708) (1,083) — — (1,791) — — — — — Equity Other equity instruments — (92) — — (92) — — — — — Standby facilities, credit lines and other commitments 36,573 653 371 9,362 46,959 23,917 631 — 3,362 27,910 The majority of the remaining exposures without fallbacks in place are either undrawn facilities or syndicated facilities where the transition is led by a third party agent. Work is ongoing with clients and agents to transition facilities or insert fallbacks prior to the next rate reset. There may be some scenarios where synthetic LIBOR is temporarily used whilst Barclays continues to work with the client to remediate their exposures, with little expectation of longer term usage. With appropriate fallback clause Without appropriate fallback clause GBP LIBOR EONIA JPY LIBOR CHF LIBOR EUR LIBOR Total GBP LIBOR EONIA JPY LIBOR CHF LIBOR EUR LIBOR Total As at 31 December 2021 £m £m £m £m £m £m £m £m £m £m £m £m Derivative notional contract amount OTC interest rate derivatives 230,967 7,568 135,719 4,361 3,626 382,241 9,216 243 4,638 35 403 14,535 OTC foreign exchange derivatives 183,203 — 122,822 32,900 — 338,925 274 — 1 — — 275 Derivative notional contract amount 414,170 7,568 258,541 37,261 3,626 721,166 9,490 243 4,639 35 403 14,810 Exposures that have not actively transitioned and do not have robust fallbacks in place will not necessarily need to apply the FCA’s approach to ‘tough legacy’ and utilise synthetic LIBOR rates. In many cases, work is ongoing to transition trades or insert fallbacks prior to the next rate reset. There may be some scenarios where synthetic LIBOR is temporarily used whilst Barclays continues to work with the client to remediate their exposures, with little expectation of longer term usage. It is also key to note that not all remaining exposures can leverage synthetic LIBOR. CHF LIBOR, EUR LIBOR and EONIA do not have any synthetic LIBOR available and only the more commonly used, 1M, 3M and 6M GBP LIBOR and JPY LIBOR tenors have a synthetic rate being published. The volume of these residual exposures is very low and work is focused on transitioning these prior to next reset. |
Barclays PLC (the Parent compan
Barclays PLC (the Parent company) | 12 Months Ended |
Dec. 31, 2021 | |
Condensed Financial Information Disclosure [Abstract] | |
Barclays PLC (the Parent company) | Barclays PLC (the Parent company) Total income Dividends received from subsidiaries Dividends received from subsidiaries of £1,356m (2020: £763m, 2019: £1,560m) largely relates to dividends received from Barclays Bank PLC £794m, Barclays Bank UK PLC £510m and Barclays Execution Services Limited £82m. The dividends received in 2020 from its banking subsidiaries were paid up to Barclays PLC prior to the announcement made by the PRA on 31March 2020 that capital be preserved for use in serving Barclays customers and clients through the extraordinary challenges presented by the COVID-19 pandemic. As part of a response to this announcement, Barclays PLC took steps to provide additional capital to its banking subsidiaries. Other income Other income of £659m (2020: £1,192m, 2019: £1,760m) includes £804m (2020: £857m, 2019: £813m) of income received from gross coupon payments on Barclays Bank PLC and Barclays Bank UK PLC issued AT1 securities and £250m (2020: £248m) of fair value and foreign exchange losses on other positions with subsidiaries. Total assets and liabilities Investment in subsidiaries The investment in subsidiaries of £62,528m (2020: £58,886m) predominantly relates to investments in the ordinary shares of Barclays Bank PLC of £35,590m (2020: £35,590m) and their AT1 securities of £9,493m (2020: £8,425m), as well as investments in the ordinary shares of Barclays Bank UK PLC of £14,245m (2020: 11,675m) and their AT1 securities of £2,570m (2020: £2,570m). The increase of £3,642m during the year was predominantly driven by a £2,573m reversal of impairment in the cost of investment of Barclays Bank UK PLC and increased AT1 holdings of $1,500m in Barclays Bank PLC. On 29th April 2022 Barclays PLC made a capital contribution of £750m to Barclays Bank PLC. Impairment in subsidiaries At the end of each reporting period an impairment review is undertaken in respect of investment in the ordinary shares of subsidiaries. Where impairment may be indicated a test of the carrying value against the recoverable value is performed. Impairment being indicated where the investment exceeds the recoverable amount. The recoverable amount is calculated as a value in use (VIU) which is derived from the present value of future cash flows expected to be received from the investment. The VIU calculations use forecast attributable profit based on financial budgets approved by management, covering a five year period as an approximation of future cash flows discounted using a pre-tax discount rate appropriate to the subsidiary being tested. A terminal growth rate has then been applied to the cash flows thereafter which is based upon expectations of future inflation rates. The review identified the value in use calculated was higher than the carrying value for all subsidiaries. Due to the improved market conditions and interest rate environment for the Group’s UK banking business compared to December 2020 the review further identified that the accumulated impairment for the investment in Barclays Bank UK PLC of £2,573m no longer existed. The VIU of Barclays Bank UK PLC was found to be significantly higher than both the carrying amount of the investment and the gross cost of the investment and hence all accumulated impairment has been reversed in December 2021. For Barclays Bank UK PLC, a discount rate of 14.5% (2020: 13.8%) has been applied to the cash flow forecast. In determining the discount rate, management have identified a cost of equity associated with market participants that closely resemble the subsidiary and adjusted for tax to arrive at the pre-tax equivalent rate. A terminal growth rate of 2.0% (2020: 2.0%) has been used to calculate a terminal value for the investment based on inflation rates to approximate future long term growth. Loans and advances in subsidiaries During the year, loans and advances to subsidiaries decreased by £2,638m to £22,072m (2020: £24,710m). The decrease was driven by the maturity of £2,400m dated subordinated loans in relation to Barclays Bank PLC and the maturity of £1,100m dated subordinated notes in relation to Barclays Bank UK PLC. This was partially offset by c£1,600m new issuances of dated subordinated notes by Barclays Bank PLC to Barclays PLC. Financial assets and liabilities designated at fair value Financial liabilities designated at fair value of £16,319m (2020: £9,507m) primarily included new issuances during the year of $5,000m and €1,500m Fixed Rate Resetting Senior Callable Notes, €750m Floating Rate Senior Callable Notes and $500m Zero Coupon Callable Notes. The proceeds raised through these transactions were used to invest in subsidiaries of Barclays PLC and are included within the financial assets designated at fair value through the income statement balance of £25,091m (2020: £17,521m). The effect of changes in the liabilities’ fair value, including those due to credit risk, is expected to offset the changes in the fair value of the related financial asset in the income statement The difference between the financial liabilities’ carrying amount and the contractual amount on maturity is £271m (2020: £324m). Subordinated liabilities and debt securities in issue During the year, Barclays PLC issued €1,000m and $1,000m of Fixed Rate Resetting Subordinated Callable Notes, which are included within the subordinated liabilities balance of £9,301m (2020: £7,724m). Debt securities in issue of £25,658m (2020: £28,428m) have reduced in the year due to the maturity of positions with subsidiaries. Management of internal investments, loans and advances Barclays PLC retains the discretion to manage the nature of its internal investments in subsidiaries according to their regulatory and business needs. Barclays PLC may invest capital and funding into Barclays Bank PLC, Barclays Bank UK PLC and other Group subsidiaries such as Barclays Execution Services Limited and the US Intermediate Holding Company (IHC). Total equity Called up share capital and share premium Called up share capital and share premium of Barclays PLC is £4,536m (2020: £4,637m). The decrease in the year is primarily due to 644m shares repurchased with a total nominal value of £161m. This decrease was offset by shares issued under employee share schemes. Other equity instruments Other equity instruments of £12,241m (2020: £11,169m) comprises AT1 securities issued by Barclays PLC. AT1 securities are perpetual subordinated contingent convertible securities structured to qualify as AT1 instruments under prevailing capital rules applicable as at the relevant issue date. During the year there has been a new AT1 issuance with principal amount totaling $1,500m (£1,078m). For further details, please refer to Note 28. |
Significant accounting polici_2
Significant accounting policies (Policy) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of objectives, policies and processes for managing capital [abstract] | |
Compliance with International Financial Reporting Standards | The principal accounting policies applied in the preparation of the consolidated and separate financial statements are set out below, and in the relevant notes to the financial statements. These policies have been consistently applied, with the exception of the Interest Rate Benchmark Reform Phase 2 amendments (amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16) which were applied from 1 January 2020. |
Basis of preparation | The consolidated and separate financial statements have been prepared under the historical cost convention modified to include the fair valuation of investment property, and particular financial instruments, to the extent required or permitted under IFRS as set out in the relevant accounting policies. These financial statements are stated in millions of pounds Sterling (£m), the functional currency of Barclays PLC. The financial statements have been prepared for Barclays PLC and its subsidiaries (the Group) under Section 399 of the Companies Act 2006 as applicable to companies using IFRS. The financial statements are prepared on a going concern basis, as the Board is satisfied that the Group and the parent company have the resources to continue in business for a period of at least 12 months from approval of the financial statements. In making this assessment, the Board has considered a wide range of information relating to present and future conditions and includes a review of a working capital report (WCR). The WCR is used by the Board to assess the future performance of the Group and that it has the resources in place that are required to meet its ongoing regulatory requirements. The assessment is based upon business plans which contain future projections of profitability taken from the Group’s medium-term plan as well as projections of regulatory capital requirements and business funding needs. The WCR also includes an assessment of the impact of internally generated stress testing scenarios on the liquidity and capital requirement forecasts. The stress tests used were based upon an assessment of reasonably possible downside economic scenarios that the Group could experience. The WCR showed that the Group had sufficient capital and liquidity in place to support its future business requirements and remained above its regulatory minimum requirements in the stress scenarios. Accordingly, the Directors concluded that there was a reasonable expectation that the Group and parent company has adequate resources to continue as a Going Concern for a period of at least 12 months from the date of approval of the financial statements. |
Consolidation | Consolidation The Group applies IFRS 10 Consolidated financial statements. The consolidated financial statements combine the financial statements of Barclays PLC and all its subsidiaries. Subsidiaries are entities over which Barclays PLC has control. The Group has control over another entity when the Group has all of the following: 1) power over the relevant activities of the investee, for example through voting or other rights 2) exposure to, or rights to, variable returns from its involvement with the investee, and 3) the ability to affect those returns through its power over the investee. The assessment of control is based on the consideration of all facts and circumstances. The Group reassesses whether it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Intra-group transactions and balances are eliminated on consolidation. Consistent accounting policies are used throughout the Group for the purposes of the consolidation. Changes in ownership interests in subsidiaries are accounted for as equity transactions if they occur after control has already been obtained and they do not result in loss of control. As the consolidated financial statements include partnerships where the Group member is a partner, advantage has been taken of the exemption under Regulation 7 of the Partnership (Accounts) Regulations 2008 with regard to preparing and filing of individual partnership financial statements. Details of the principal subsidiaries are given in Note 34. |
Foreign currency translation | Foreign currency translation The Group applies IAS 21 The Effects of Changes in Foreign Exchange Rates. Transactions in foreign currencies are translated into Sterling at the rate ruling on the date of the transaction. Foreign currency monetary balances are translated into Sterling at the period end exchange rates. Exchange gains and losses on such balances are taken to the income statement. Non-monetary foreign currency balances in relation to items measured in terms of historical cost are carried at historical transaction date exchange rates. Non-monetary foreign currency balances in relation to items measured at fair value are translated using the exchange rate at the date when the fair value was measured. The Group’s foreign operations (including subsidiaries, joint ventures, associates and branches) based mainly outside the UK may have different functional currencies. The functional currency of an operation is the currency of the main economy to which it is exposed. Prior to consolidation (or equity accounting) the assets and liabilities of non-Sterling operations are translated at the period end exchange rate and items of income, expense and other comprehensive income are translated into Sterling at the rate on the date of the transactions. Exchange differences arising on the translation of foreign operations are included in currency translation reserves within equity. These are transferred to the income statement when the Group disposes of the entire interest in a foreign operation, when partial disposal results in the loss of control of an interest in a subsidiary, when an investment previously accounted for using the equity method is accounted for as a financial asset, or on the disposal of a foreign operation within a branch. |
Financial assets and liabilities | Financial assets and liabilities The Group applies IFRS 9 Financial Instruments to the recognition, classification and measurement, and derecognition of financial assets and financial liabilities and the impairment of financial assets. The Group applies the requirements of IAS 39 Financial Instruments: Recognition and Measurement for hedge accounting purposes. Recognition The Group recognises financial assets and liabilities when it becomes a party to the terms of the contract. Trade date or settlement date accounting is applied depending on the classification of the financial asset. Classification and measurement Financial assets are classified on the basis of two criteria: i) the business model within which financial assets are managed, and ii) their contractual cash flow characteristics (whether the cash flows represent ‘solely payments of principal and interest’ (SPPI)). The Group assesses the business model criteria at a portfolio level. Information that is considered in determining the applicable business model includes (i) policies and objectives for the relevant portfolio, (ii) how the performance and risks of the portfolio are managed, evaluated and reported to management, and (iii) the frequency, volume and timing of sales in prior periods, sales expectation for future periods, and the reasons for such sales. The contractual cash flow characteristics of financial assets are assessed with reference to whether the cash flows represent SPPI. In assessing whether contractual cash flows are SPPI compliant, interest is defined as consideration primarily for the time value of money and the credit risk of the principal outstanding. The time value of money is defined as the element of interest that provides consideration only for the passage of time and not consideration for other risks or costs associated with holding the financial asset. Terms that could change the contractual cash flows so that it would not meet the condition for SPPI are considered, including: (i) contingent and leverage features, (ii) non-recourse arrangements and (iii) features that could modify the time value of money. Financial assets are measured at amortised cost if they are held within a business model whose objective is to hold financial assets in order to collect contractual cash flows, and their contractual cash flows represent SPPI. Financial assets are measured at fair value through other comprehensive income if they are held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets, and their contractual cash flows represent SPPI. Other financial assets are measured at fair value through profit and loss. There is an option to make an irrevocable election on initial recognition for non traded equity investments to be measured at fair value through other comprehensive income, in which case dividends are recognised in profit or loss, but gains or losses are not reclassified to profit or loss upon derecognition, and the impairment requirements of IFRS 9 do not apply. The accounting policy for each type of financial asset or liability is included within the relevant note for the item. The Group’s policies for determining the fair values of the assets and liabilities are set out in Note 17. Derecognition The Group derecognises a financial asset, or a portion of a financial asset, from its balance sheet where (i) the contractual rights to cash flows from the asset have expired, or (ii) the contractual rights to cash flows from the asset have been transferred (usually by sale) and with them either (a) substantially all the risks and rewards of the asset have been transferred, or (b) where neither substantially all the risks and reward have been transferred or retained, where control over the asset has been lost. Financial liabilities are de-recognised when the liability has been settled, has expired or has been extinguished. An exchange of an existing financial liability for a new liability with the same lender on substantially different terms – generally a difference of 10% or more in the present value of the cash flows or a substantive qualitative amendment – is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. Transactions in which the Group transfers assets and liabilities, portions of them, or financial risks associated with them can be complex and it may not be obvious whether substantially all of the risks and rewards have been transferred. It is often necessary to perform a quantitative analysis. Such an analysis compares the Group’s exposure to variability in asset cash flows before the transfer with its retained exposure after the transfer. A cash flow analysis of this nature may require judgement. In particular, it is necessary to estimate the asset’s expected future cash flows as well as potential variability around this expectation. The method of estimating expected future cash flows depends on the nature of the asset, with market and market-implied data used to the greatest extent possible. The potential variability around this expectation is typically determined by stressing underlying parameters to create reasonable alternative upside and downside scenarios. Probabilities are then assigned to each scenario. Stressed parameters may include default rates, loss severity, or prepayment rates. |
Accounting for reverse repurchase and repurchase agreements including other similar lending and borrowing | Accounting for reverse repurchase and repurchase agreements including other similar lending and borrowing Reverse repurchase agreements (and stock borrowing or similar transactions) are a form of secured lending whereby the Group provides a loan or cash collateral in exchange for the transfer of collateral, generally in the form of marketable securities subject to an agreement to transfer the securities back at a fixed price in the future. Repurchase agreements are where the Group obtains such loans or cash collateral, in exchange for the transfer of collateral. The Group purchases (a reverse repurchase agreement) or borrows securities subject to a commitment to resell or return them. The securities are not included in the balance sheet as the Group does not acquire the risks and rewards of ownership. Consideration paid (or cash collateral provided) is accounted for as a loan asset at amortised cost, unless it is designated or mandatorily at fair value through profit and loss. The Group may also sell (a repurchase agreement) or lend securities subject to a commitment to repurchase or redeem them. The securities are retained on the balance sheet as the Group retains substantially all the risks and rewards of ownership. Consideration received (or cash collateral provided) is accounted for as a financial liability at amortised cost, unless it is designated at fair value through profit and loss. |
Issued debt and equity instruments | Issued debt and equity instruments The Group applies IAS 32, Financial Instruments: Presentation, to determine whether funding is either a financial liability (debt) or equity. Issued financial instruments or their components are classified as liabilities if the contractual arrangement results in the Group having an obligation to either deliver cash or another financial asset, or a variable number of equity shares, to the holder of the instrument. If this is not the case, the instrument is generally an equity instrument and the proceeds included in equity, net of transaction costs. Dividends and other returns to equity holders are recognised when paid or declared by the members at the Annual General Meeting and treated as a deduction from equity. Where issued financial instruments contain both liability and equity components, these are accounted for separately. The fair value of the debt is estimated first and the balance of the proceeds is included within equity. |
Changes in the basis for determining contractual cash flows resulting from interest rate benchmark reform | Changes in the basis for determining contractual cash flows resulting from interest rate benchmark reform A change in the basis of determining the contractual cash flows of a financial instrument that is required by interest rate benchmark reform is accounted for by updating the effective interest rate, without the recognition of an immediate gain or loss. This practical expedient is only applied where (1) the change to the contractual cash flows is necessary as a direct consequence of the reform and (2) the new basis for determining the contractual cash flows is economically equivalent to the previous basis. For changes made in addition to those required by the interest rate benchmark reform, the practical expedient is applied first, after which the normal IFRS 9 requirements for modifications of financial instruments is applied. Refer to Note 14 for further details regarding hedge accounting policies in respect of interest rate benchmark reform. Refer to Note 41 for further disclosure related to interest rate benchmark reform. |
Cash flow statement | Cash flow statement Cash comprises cash on hand and balances at central banks. Cash equivalents comprise loans and advances to banks, cash collateral balances with central banks related to payment schemes and treasury and other eligible bills, all with original maturities of three months or less. Repurchase and reverse repurchase agreements are not considered to be part of cash equivalents. Investments in debt securities at amortised cost, presented within loans and advances on the balance sheet, are deemed to be investing activities for the purposes of the cash flow statement, except those instruments considered to be cash equivalents. Debt securities issued and redeemed are considered to be operating activities, except qualifying eligible liabilities that satisfy regulatory requirements for MREL instruments (or have previously satisfied these requirements since 2019 when they came into effect), which are considered to be financing activities. |
New and amended standards and interpretations | New and amended standards and interpretations The accounting policies adopted have been consistently applied, with the exception of the Interest Rate Benchmark Reform Phase 2 amendments (amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16) which were applied from 1 January 2020. Future accounting developments The following accounting standards have been issued by the IASB but are not yet effective: IFRS 17 – Insurance contracts In May 2017, the IASB issued IFRS 17 Insurance Contracts, a comprehensive new accounting standard for insurance contracts covering recognition and measurement, presentation and disclosure. Once effective, IFRS 17 will replace IFRS 4 Insurance Contracts that was issued in 2005. IFRS 17 applies to all types of insurance contracts (i.e. life, non-life, direct insurance and re-insurance), regardless of the type of entities that issue them, as well as to certain guarantees and financial instruments with discretionary participation features. A few scope exceptions will apply. In June 2020, the IASB published amendments to IFRS 17. The amendments that are relevant to the Group are the scope exclusion for credit card contracts and similar contracts that provide insurance coverage, the optional scope exclusion for loan contracts that transfer significant insurance risk, and the clarification that only financial guarantees issued are in scope of IFRS 9. The amendments also defer the effective date of IFRS 17, including the above amendments, to annual reporting periods beginning on or after 1 January 2023. IFRS 17, including the 2020 amendments to IFRS 17, has been endorsed by the EU. Following the UK’s withdrawal from the EU on 31 December 2020, the UK-adopted international accounting standards will be applicable. IFRS 17, including the amendments to IFRS 17, has not yet been endorsed by the UK. The Group does not expect the impact of IFRS 17 to be material. Disclosure of Accounting Policies - Amendments to IAS 1 and IFRS Practice Statement 2 In February 2021 the IASB issued amendments to IAS 1 that require entities to disclose their material accounting policies rather than their significant accounting policies. The amendments to IFRS Practice Statement 2 provide guidance on the concept of materiality and its application to accounting policy information. Under the amendments, accounting policy information is material if, when considered together with other information included in an entity’s financial statements, it can reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements. The amendments are effective for annual periods beginning on or after 1 January 2023, and will be applied from that date. Definition of Accounting Estimate - Amendments to IAS 8 In February 2021 the IASB issued amendments to IAS 8 that replace the definition of a change in accounting estimates with a definition of accounting estimates. Under the new definition, accounting estimates are clarified as monetary amounts in financial statements that are subject to measurement uncertainty. Where an entity's accounting policy requires an item to be measured at monetary amounts that cannot be observed directly, it should develop an accounting estimate to achieve this objective. |
Critical accounting estimates and judgements | The preparation of financial statements in accordance with IFRS requires the use of estimates. It also requires management to exercise judgement in applying the accounting policies. The key areas involving a higher degree of judgement or complexity or areas where assumptions are significant to the consolidated and individual financial statements are highlighted under the relevant note. Critical accounting estimates and judgements are disclosed in: ▪ Credit impairment charges on page 236 ▪ Tax on page 240 ▪ Fair value of financial instruments on page 255 ▪ Goodwill and intangible assets on page 270 ▪ Pensions and post-retirement benefits – obligations on page 290 ▪ Provisions including conduct and legal, competition and regulatory matters on page 274. |
Presentation of segmental reporting | Presentation of segmental reporting The Group’s segmental reporting is in accordance with IFRS 8 Operating Segments . Operating segments are reported in a manner consistent with the internal reporting provided to the Executive Committee, which is responsible for allocating resources and assessing performance of the operating segments, and has been identified as the chief operating decision maker. All transactions between business segments are conducted on an arm’s-length basis, with intra-segment revenue and costs being eliminated in Head Office. Income and expenses directly associated with each segment are included in determining business segment performance. |
Accounting for interest income and expense | Accounting for interest income and expenses Interest income on loans and advances at amortised cost and financial assets at fair value through other comprehensive income, and interest expense on financial liabilities held at amortised cost, are calculated using the effective interest method which allocates interest, and direct and incremental fees and costs, over the expected lives of the assets and liabilities. The effective interest method requires the Group to estimate future cash flows, in some cases based on its experience of customers’ behaviour, considering all contractual terms of the financial instrument, as well as the expected lives of the assets and liabilities. The Group incurs certain costs to originate credit card balances with the most significant being co-brand partner fees. To the extent these costs are attributed to customers that continuously carry an outstanding balance (revolvers) and incremental to the origination of credit card balances, they are capitalised and subsequently included within the calculation of the effective interest rate. They are amortised to interest income over the period of expected repayment of the originated balance. Costs attributed to customers that settle their outstanding balances each period (transactors) are deferred on the balance sheet as a cost of obtaining a contract and amortised to fee and commission expense over the life of the customer relationship (refer to Note 4). There are no other individual estimates involved in the calculation of effective interest rates that are material to the results or financial position. |
Accounting for net fee and commission income | Accounting for net fee and commission income The Group applies IFRS 15 Revenue from Contracts with Customers. IFRS 15 establishes a five-step model governing revenue recognition. The five-step model requires the Group to (i) identify the contract with the customer, (ii) identify each of the performance obligations included in the contract, (iii) determine the amount of consideration in the contract, (iv) allocate the consideration to each of the identified performance obligations and (v) recognise revenue as each performance obligation is satisfied. |
Accounting for net trading income | Accounting for net trading income In accordance with IFRS 9, trading positions are held at fair value, and the resulting gains and losses are included in the income statement, together with interest and dividends arising from long and short positions and funding costs relating to trading activities. Income arises from both the sale and purchase of trading positions, margins which are achieved through market making and customer business and from changes in fair value caused by movements in interest and exchange rates, equity prices and other market variables. Gains or losses on non-trading financial instruments designated or mandatorily at fair value with changes in fair value recognised in the income statement are included in net trading income where the business model is to manage assets and liabilities on a fair value basis which includes use of derivatives or where an instrument is designated at fair value to eliminate an accounting mismatch and the related instrument's gain and losses are reported in trading income. |
Accounting for net investment income | Accounting for net investment income Dividends are recognised when the right to receive the dividend has been established. Other accounting policies relating to net investment income are set out in Note 13 and Note 15. |
Accounting for the impairment of financial assets | Accounting for the impairment of financial assets Impairment In accordance with IFRS 9, the Group is required to recognise expected credit losses (ECLs) based on unbiased forward-looking information for all financial assets at amortised cost, lease receivables, debt financial assets at fair value through other comprehensive income, loan commitments and financial guarantee contracts. At the reporting date, an allowance (or provision for loan commitments and financial guarantees) is required for the 12 month (Stage 1) ECLs. If the credit risk has significantly increased since initial recognition (Stage 2), or if the financial instrument is credit impaired (Stage 3), an allowance (or provision) should be recognised for the lifetime ECLs. The measurement of ECL is calculated using three main components: (i) probability of default (PD) (ii) loss given default (LGD) and (iii) the exposure at default (EAD). The 12 month and lifetime ECLs are calculated by multiplying the respective PD, LGD and the EAD. The 12 month and lifetime PDs represent the PD occurring over the next 12 months and the remaining maturity of the instrument respectively. The EAD represents the expected balance at default, taking into account the repayment of principal and interest from the balance sheet date to the default event together with any expected drawdowns of committed facilities. The LGD represents expected losses on the EAD given the event of default, taking into account, among other attributes, the mitigating effect of collateral value at the time it is expected to be realised and the time value of money. Determining a significant increase in credit risk since initial recognition: The Group assesses when a significant increase in credit risk has occurred based on quantitative and qualitative assessments. The credit risk of an exposure is considered to have significantly increased when: i) Quantitative test The annualised lifetime PD has increased by more than an agreed threshold relative to the equivalent at origination. PD deterioration thresholds are defined as percentage increases, and are set at an origination score band and segment level to ensure the test appropriately captures significant increases in credit risk at all risk levels. Generally, thresholds are inversely correlated to the origination PD, i.e. as the origination PD increases, the threshold value reduces. The assessment of the point at which a PD increase is deemed ‘significant’, is based upon analysis of the portfolio’s risk profile against a common set of principles and performance metrics (consistent across both retail and wholesale businesses), incorporating expert credit judgement where appropriate. Application of quantitative PD floors does not represent the use of the low credit risk exemption as exposures can separately move into Stage 2 via the qualitative route described below. Wholesale assets apply a 100% increase in PD and 0.2% PD floor to determine a significant increase in credit risk. Retail assets apply bespoke relative increase and absolute PD thresholds based on product type and origination PD. Thresholds are subject to maximums defined by Group policy and typically apply minimum relative thresholds of 50-100% and a maximum relative threshold of 400%. For existing/historical exposures where origination point scores or data are no longer available or do not represent a comparable estimate of lifetime PD, a proxy origination score is defined, based upon: • back-population of the approved lifetime PD score either to origination date or, where this is not feasible, as far back as possible (subject to a data start point no later than 1 January 2015); or • use of available historical account performance data and other customer information, to derive a comparable ‘proxy’ estimation of origination PD. ii) Qualitative test This is relevant for accounts that meet the portfolio’s ‘high risk’ criteria and are subject to closer credit monitoring. High risk customers may not be in arrears but either through an event or an observed behaviour exhibit credit distress. The definition and assessment of high risk includes as wide a range of information as reasonably available, such as industry and Group-wide customer level data, including but not limited to bureau scores and high consumer indebtedness index, wherever possible or relevant. Whilst the high risk populations applied for IFRS 9 impairment purposes are aligned with risk management processes, they are also regularly reviewed and validated to ensure that they capture any incremental segments where there is evidence of credit deterioration. iii) Backstop criteria This is relevant for accounts that are more than 30 calendar days past due. The 30 days past due criteria is a backstop rather than a primary driver of moving exposures into Stage 2. The criteria for determining a significant increase in credit risk for assets with bullet repayments follows the same principle as all other assets, i.e. quantitative, qualitative and backstop tests are all applied. Exposures will move back to Stage 1 once they no longer meet the criteria for a significant increase in credit risk. This means that, at a minimum all payments must be up-to-date, the PD deterioration test is no longer met, the account is no longer classified as high risk, and the customer has evidenced an ability to maintain future payments. Exposures are only removed from Stage 3 and re-assigned to Stage 2 once the original default trigger event no longer applies. Exposures being removed from Stage 3 must no longer qualify as credit impaired, and: a) the obligor will also have demonstrated consistently good payment behaviour over a 12-month period, by making all consecutive contractual payments due and, for forborne exposures, the relevant EBA defined probationary period has also been successfully completed or; b) (for non-forborne exposures) the performance conditions are defined and approved within an appropriately sanctioned restructure plan, including 12 months’ payment history have been met. Management overlays and other exceptions to model outputs are applied only if consistent with the objective of identifying significant increases in credit risk. Forward-looking information The measurement of ECL involves complexity and judgement, including estimation of PD, LGD, a range of unbiased future economic scenarios, estimation of expected lives (where contractual life is not appropriate), and estimation of EAD and assessing significant increases in credit risk. Credit losses are the expected cash shortfalls from what is contractually due over the expected life of the financial instrument, discounted at the original effective interest rate (EIR). ECLs are the unbiased probability-weighted credit losses determined by evaluating a range of possible outcomes and considering future economic conditions. The Group uses a five-scenario model to calculate ECL. An external consensus forecast is assembled from key sources, including HM Treasury (short and medium term forecasts), Bloomberg (based on median of economic forecasts) and the Urban Land Institute (for US House Prices), which forms the baseline scenario. In addition, two adverse scenarios (Downside 1 and Downside 2) and two favourable scenarios (Upside 1 and Upside 2) are derived, with associated probability weightings. The adverse scenarios are calibrated to a similar severity to internal stress tests, whilst also considering IFRS 9 specific sensitivities and non-linearity. Downside 2 is benchmarked to the Bank of England’s annual cyclical scenarios and to the most severe scenario from Moody’s inventory, but is not designed to be the same. The favourable scenarios are calibrated to be symmetric to the adverse scenarios, subject to a ceiling calibrated to relevant recent favourable benchmark scenarios. The scenarios include eight economic variables (GDP, unemployment, House Price Index (HPI) and base rates in both the UK and US markets) and expanded variables using statistical models based on historical correlations. The upside and downside shocks are designed to evolve over a five-year stress horizon, with all five scenarios converging to a steady state after approximately eight years. The methodology for estimating probability weights for each of the scenarios involves a comparison of the distribution of key historical UK and US macroeconomic variables against the forecast paths of the five scenarios. The methodology works such that the baseline (reflecting current consensus outlook) has the highest weight and the weights of adverse and favourable scenarios depend on the deviation from the baseline; the further from the baseline, the smaller the weight. A single set of five scenarios is used across all portfolios and all five weights are normalised to equate to 100%. The same scenarios and weights that are used in the estimation of expected credit losses are also used for the Group internal planning purposes. The impacts across the portfolios are different because of the sensitivities of each of the portfolios to specific macroeconomic variables, for example, mortgages are highly sensitive to house prices, and credit cards and unsecured consumer loans are highly sensitive to unemployment. Definition of default, credit impaired assets, write-offs, and interest income recognition The definition of default for the purpose of determining ECLs, and for internal credit risk management purposes, has been aligned to the Regulatory Capital CRR Article 178 definition of default, to maintain a consistent approach with IFRS 9 and associated regulatory guidance. The Regulatory Capital CRR Article 178 definition of default considers indicators that the debtor is unlikely to pay, includes exposures in forbearance and is no later than when the exposure is more than 90 days past due or 180 days past due in the case of UK mortgages. When exposures are identified as credit impaired at the time when they are purchased or originated interest income is calculated on the carrying value net of the impairment allowance. An asset is considered credit impaired when one or more events occur that have a detrimental impact on the estimated future cash flows of the financial asset. This comprises assets defined as defaulted and other individually assessed exposures where imminent default or actual loss is identified. Uncollectable loans are written off against the related allowance for loan impairment on completion of the Group’s internal processes and when all reasonably expected recoverable amounts have been collected. Subsequent recoveries of amounts previously written off are credited to the income statement. The timing and extent of write-offs may involve some element of subjective judgement. Nevertheless, a write-off will often be prompted by a specific event, such as the inception of insolvency proceedings or other formal recovery action, which makes it possible to establish that some or the entire advance is beyond realistic prospect of recovery. Accounting for purchased financial guarantee contracts The Group may enter into a financial guarantee contract which requires the issuer of such contract to reimburse the Group for a loss it incurs because a specified debtor fails to make payment when due in accordance with the terms of a debt instrument. For these separate financial guarantee contracts, the Group recognises a reimbursement asset aligned with the recognition of the underlying ECLs, if it is considered virtually certain that a reimbursement would be received if the specified debtor fails to make payment when due in accordance with the terms of the debt instrument. Loan modifications and renegotiations that are not credit-impaired When modification of a loan agreement occurs as a result of commercial restructuring activity rather than due to the credit risk of the borrower, an assessment must be performed to determine whether the terms of the new agreement are substantially different from the terms of the existing agreement. This assessment considers both the change in cash flows arising from the modified terms as well as the change in overall instrument risk profile. In respect of payment holidays granted to borrowers which are not due to forbearance, if the revised cash flows on a present value basis (based on the original EIR) are not substantially different from the original cash flows, the loan is not considered to be substantially modified. Where terms are substantially different, the existing loan will be derecognised and a new loan will be recognised at fair value, with any difference in valuation recognised immediately within the income statement, subject to observability criteria. Where terms are not substantially different, the loan carrying value will be adjusted to reflect the present value of modified cash flows discounted at the original EIR, with any resulting gain or loss recognised immediately within the income statement as a modification gain or loss. Note 1 sets out details for changes in the basis of determining the contractual cash flows of a financial instrument that are required by interest rate benchmark reform. Expected life Lifetime ECLs must be measured over the expected life. This is restricted to the maximum contractual life and takes into account expected prepayment, extension, call and similar options. The exceptions are certain revolving financial instruments, such as credit cards and bank overdrafts, that include both a drawn and an undrawn component where the entity’s contractual ability to demand repayment and cancel the undrawn commitment does not limit the entity’s exposure to credit losses to the contractual notice period. For revolving facilities, expected life is analytically derived to reflect the behavioural life of the asset, i.e. the full period over which the business expects to be exposed to credit risk. Behavioural life is typically based upon historical analysis of the average time to default, closure or withdrawal of facility. Where data is insufficient or analysis inconclusive, an additional ‘maturity factor’ may be incorporated to reflect the full estimated life of the exposures, based upon experienced judgement and/or peer analysis. Potential future modifications of contracts are not taken into account when determining the expected life or EAD until they occur. Discounting ECLs are discounted at the EIR at initial recognition or an approximation thereof and consistent with income recognition. For loan commitments the EIR is the rate that is expected to apply when the loan is drawn down and a financial asset is recognised. Issued financial guarantee contracts are discounted at the risk free rate. Lease receivables are discounted at the rate implicit in the lease. For variable/floating rate financial assets, the spot rate at the reporting date is used and projections of changes in the variable rate over the expected life are not made to estimate future interest cash flows or for discounting. Modelling techniques The regulatory Basel Committee of Banking Supervisors (BCBS) ECL calculations are leveraged for IFRS 9 modelling but adjusted for key differences which include: ▪ BCBS requires 12 month through the economic cycle losses whereas IFRS 9 requires 12 months or lifetime point in time losses based on conditions at the reporting date and multiple forecasts of the future economic conditions over the expected lives; ▪ IFRS 9 models do not include certain conservative BCBS model floors and downturn assessments and require discounting to the reporting date at the original EIR rather than using the cost of capital to the date of default; ▪ Management adjustments are made to modelled output to account for situations where known or expected risk factors and information have not been considered in the modelling process, for example forecast economic scenarios for uncertain political events; and ▪ ECL is measured at the individual financial instrument level, however a collective approach where financial instruments with similar risk characteristics are grouped together, with apportionment to individual financial instruments, is used where effects can only be seen at a collective level, for example for forward-looking information. For the IFRS 9 impairment assessment, the Group’s risk models are used to determine the PD, LGD and EAD. For Stage 2 and 3, the Group applies lifetime PDs but uses 12 month PDs for Stage 1. The ECL drivers of PD, EAD and LGD are modelled at an account level which considers vintage, among other credit factors. Also, the assessment of significant increase in credit risk is based on the initial lifetime PD curve, which accounts for the different credit risk underwritten over time. Forbearance A financial asset is subject to forbearance when it is modified due to the credit distress of the borrower. A modification made to the terms of an asset due to forbearance will typically be assessed as a non-substantial modification that does not result in derecognition of the original loan, except in circumstances where debt is exchanged for equity. Both performing and non-performing forbearance assets are classified as Stage 3 except where it is established that the concession granted has not resulted in diminished financial obligation and that no other regulatory definition of default criteria have been triggered, in which case the asset is classified as Stage 2. The minimum probationary period for non-performing forbearance is 12 months and for performing forbearance, 24 months. Hence, a minimum of 36 months is required for non-performing forbearance to move out of a forborne state. No financial instrument in forbearance can transfer back to Stage 1 until all of the Stage 2thresholds are no longer met and can only move out of Stage 3 when no longer credit impaired. Critical accounting estimates and judgements IFRS 9 impairment involves several important areas of judgement, including estimating forward looking modelled parameters (PD, LGD and EAD), developing a range of unbiased future economic scenarios, estimating expected lives and assessing significant increases in credit risk, based on the Group’s experience of managing credit risk. The determination of expected life is most material for Barclays credit card portfolios which is obtained via behavioural life analysis to materially capture the risk of these facilities. Within the retail and small businesses portfolios, which comprise large numbers of small homogenous assets with similar risk characteristics where credit scoring techniques are generally used, the impairment allowance is calculated using forward looking modelled parameters which are typically run at account level. There are many models in use, each tailored to a product, line of business or customer category. Judgement and knowledge is needed in selecting the statistical methods to use when the models are developed or revised. Management adjustments to impairment models, which contain an element of subjectivity, are applied in order to factor in certain conditions or changes in policy that are not fully incorporated into the impairment models, or to reflect additional facts and circumstances at the period end. Management adjustments are reviewed and incorporated into future model development where appropriate. The impairment release reflected in the income statement for retail portfolios is £289m (2020: £3,116m charge; 2019: £1,696m charge) of the total impairment release on loans and advances and off balance sheet loan commitments and financial guarantee contracts. For individually significant assets in Stage 3, impairment allowances are calculated on an individual basis and all relevant considerations that have a bearing on the expected future cash flows across a range of economic scenarios are taken into account. These considerations can be particularly subjective and can include the business prospects for the customer, the realisable value of collateral, the Group’s position relative to other claimants, the reliability of customer information and the likely cost and duration of the work-out process. The level of the impairment allowance is the difference between the value of the discounted expected future cash flows (discounted at the loan’s original effective interest rate), and its carrying amount. Furthermore, judgements change with time as new information becomes available or as work-out strategies evolve, resulting in frequent revisions to the impairment allowance as individual decisions are taken. Changes in these estimates would result in a change in the allowances and have a direct impact on the impairment charge. The impairment release reflected in the financial statements in relation to wholesale portfolios is £346m (2020: £1,569m charge; 2019: £208m release) of the total impairment release on loans and advances and off balance sheet loan commitments and financial guarantee contracts. |
Accounting for purchased financial guarantee contracts | The Group may enter into a financial guarantee contract which requires the issuer of such contract to reimburse the Group for a loss it incurs because a specified debtor fails to make payment when due in accordance with the terms of a debt instrument. For these separate financial guarantee contracts, the Group recognises a reimbursement asset aligned with the recognition of the underlying ECLs, if it is considered virtually certain that a reimbursement would be received if the specified debtor fails to make payment when due in accordance with the terms of the debt instrument. |
Accounting for income taxes | Accounting for income taxes The Group applies IAS 12 Income Taxes in accounting for taxes on income. Income tax payable on taxable profits (current tax) is recognised as an expense in the periods in which the profits arise. Withholding taxes are also treated as income taxes. Income tax recoverable on tax allowable losses is recognised as a current tax asset only to the extent that it is regarded as recoverable by offsetting against taxable profits arising in the current or prior periods. Current tax is measured using tax rates and tax laws that have been enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised. Deferred tax liabilities are recognised for all taxable temporary differences except from the initial recognition of goodwill. Deferred tax is not recognised where the temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss. Deferred tax is determined using tax rates and legislation enacted or substantively enacted by the balance sheet date which are expected to apply when the deferred tax asset is realised or the deferred tax liability is settled. Deferred tax assets and liabilities are only offset when there is both a legal right to set-off and an intention to settle on a net basis. The Group considers an uncertain tax position to exist when it considers that ultimately, in the future, the amount of profit subject to tax may be greater than the amount initially reflected in the Group’s tax returns. The Group accounts for provisions in respect of uncertain tax positions in two different ways. A current tax provision is recognised when it is considered probable that the outcome of a review by a tax authority of an uncertain tax position will alter the amount of cash tax due to, or from, a tax authority in the future. From recognition, the current tax provision is then measured at the amount the Group ultimately expects to pay the tax authority to resolve the position. The accrual of interest and penalty amounts in respect of uncertain income tax positions is recognised as an expense within profit before tax. Deferred tax provisions are adjustments made to the carrying value of deferred tax assets in respect of uncertain tax positions. A deferred tax provision is recognised when it is considered probable that the outcome of a review by a tax authority of an uncertain tax position will result in a reduction in the carrying value of the deferred tax asset. From recognition of a provision, measurement of the underlying deferred tax asset is adjusted to take into account the expected impact of resolving the uncertain tax position on the loss or temporary difference giving rise to the deferred tax asset. The approach taken to measurement takes account of whether the uncertain tax position is a discrete position that will be reviewed by the tax authority in isolation from any other position, or one of a number of issues which are expected to be reviewed together concurrently and resolved simultaneously with a tax authority. The Group’s measurement of provisions is based upon its best estimate of the additional profit that will become subject to tax. For a discrete position, consideration is given only to the merits of that position. Where a number of issues are expected to be reviewed and resolved together, the Group will take into account not only the merits of its position in respect of each particular issue but also the overall level of provision relative to the aggregate of the uncertain tax positions across all the issues that are expected to be resolved at the same time. In addition, in assessing provision levels, it is assumed that tax authorities will review uncertain tax positions and that all facts will be fully and transparently disclosed. Critical accounting estimates and judgements There are two key areas of judgement that impact the reported tax position. Firstly, the level of provisioning for uncertain tax positions; and secondly, the recognition and measurement of deferred tax assets. The Group does not consider there to be a significant risk of a material adjustment to the carrying amount of current and deferred tax balances, including provisions for uncertain tax positions in the next financial year. The provisions for uncertain tax positions cover a diverse range of issues and reflect advice from external counsel where relevant. It should be noted that only a proportion of the total uncertain tax positions will be under audit at any point in time, and could therefore be subject to challenge by a tax authority over the next year. Deferred tax assets have been recognised based on business profit forecasts. Details on the recognition of deferred tax assets are provided in this note. |
Accounting for trading portfolio assets and liabilities | Accounting for trading portfolio assets and liabilities In accordance with IFRS 9, all assets and liabilities held for trading purposes are held at fair value with gains and losses in the changes in fair value taken to the income statement in net trading income (Note 5). |
Accounting for financial insruments at fair value through profit and loss | Accounting for financial assets mandatorily at fair value Financial assets that are held for trading are recognised at fair value through profit or loss. In addition, financial assets are held at fair value through profit or loss if they do not contain contractual terms that give rise on specified dates to cash flows that are SPPI, or if the financial asset is not held in a business model that is either (i) a business model to collect the contractual cash flows or (ii) a business model that is achieved by both collecting contractual cash flows and selling. Accounting for financial assets designated at fair value Financial assets, other than those held for trading, are classified in this category if they are so irrevocably designated at inception and the use of the designation removes or significantly reduces an accounting mismatch. Subsequent changes in fair value for these instruments are recognised in the income statement in net investment income, except if reporting it in trading income reduces an accounting mismatch. The details on how the fair value amounts are derived for financial assets at fair value are described in Note 17. |
Accounting for derivatives | Accounting for derivatives Derivative instruments are contracts whose value is derived from one or more underlying financial instruments or indices defined in the contract. They include swaps, forward-rate agreements, futures, options and combinations of these instruments and primarily affect the Group’s net interest income, net trading income and derivative assets and liabilities. Notional amounts of the contracts are not recorded on the balance sheet. Derivatives are used to hedge interest rate, credit risk, inflation risk, exchange rate, commodity equity exposures, and exposures to certain indices such as house price indices and retail price indices related to non-trading positions. All derivative instruments are held at fair value through profit or loss, except for derivatives that are in a designated cash flow or net investment hedge accounting relationship. Derivatives are classified as assets when their fair value is positive or as liabilities when their fair value is negative. This includes terms included in a contract or financial liability (the host), which, had it been a standalone contract, would have met the definition of a derivative. If these are separated from the host, i.e. when the economic characteristics of the embedded derivative are not closely related with those of the host contract and the combined instrument is not measured at fair value through profit or loss, then they are accounted for in the same way as derivatives. For financial assets, the requirements are whether the financial assets contain contractual terms that give rise on specified dates to cash flows that are SPPI, and consequently the requirements for accounting for embedded derivatives are not applicable to financial assets. |
Hedge accounting | Hedge accounting The Group applies the requirements of IAS 39 Financial Instruments: Recognition and Measurement for hedge accounting purposes. The Group applies hedge accounting to represent the economic effects of its interest rate, currency and contractually linked inflation risk management strategies. Where derivatives are held for risk management purposes, and when transactions meet the required criteria for documentation and hedge effectiveness, the Group applies fair value hedge accounting, cash flow hedge accounting, or hedging of a net investment in a foreign operation, as appropriate to the risks being hedged. The Group applies the ‘Amendments to IFRS 9, IAS 39 and IFRS 7 Interest Rate Benchmark Reform’ issued in September 2019 (the Phase 1 amendments). The amendments provide temporary relief from applying specific hedge accounting requirements to hedging relationships directly affected by IBOR (‘Interbank Offered Rates’) reform. The reliefs have the effect that IBOR reform should not generally cause hedge accounting to terminate. However, any hedge ineffectiveness continues to be recorded in the income statement. Furthermore, the amendments set out triggers for when the reliefs will end, which include the uncertainty arising from interest rate benchmark reform no longer being present. In summary, the reliefs provided by the Phase 1 amendments are: ▪ When considering the ‘highly probable’ requirement, the Group has assumed that the IBOR interest rates upon which our hedged items are based do not change as a result of IBOR Reform. ▪ In assessing whether the hedge is expected to be highly effective on a forward-looking basis the Group has assumed that the IBOR interest rates upon which the cash flows of the hedged items and the interest rate swaps that hedge them are based are not altered by IBOR reform. ▪ The Group will not discontinue hedge accounting during the period of IBOR-related uncertainty solely because the retrospective effectiveness falls outside the required 80–125% range. ▪ The Group has not recycled the cash flow hedge reserve relating to the period after the reforms are expected to take effect. ▪ The Group has assessed whether the hedged IBOR risk component is a separately identifiable risk only when it first designates a hedged item in a fair value hedge and not on an ongoing basis. The Group also applies the ‘Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 Interest Rate Benchmark Reform – Phase 2’ issued in August 2020. The Phase 2 amendments provide relief when changes are made to hedge relationships as a result of the interest rate benchmark reform. In summary, the reliefs provided by the Phase 2 amendments are: ▪ Under a temporary exception, the Group has considered that changes to the hedge designation and hedge documentation due to the interest rate benchmark reform would not constitute the discontinuation of the hedge relationship nor the designation of a new hedging relationship. ▪ In respect of the retrospective hedge effectiveness assessment, the Group may elect, on a hedge-by-hedge basis, to reset the cumulative fair value changes to zero when the exception to the retrospective assessment ends (Phase 1 relief). Any hedge ineffectiveness will continue to be measured and recognised in full in profit or loss. ▪ The Group has deemed the amounts accumulated in the cash flow hedge reserve to be based on the alternative benchmark rate (on which the hedge future cash flows are determined) when there is a change in basis for determining the contractual cash flows. ▪ For hedges of groups of items (such as those forming part of a macro cash flow hedging strategy), the amendments provide relief for items within a designated group of items that are amended for changes directly required by the reform. ▪ In respect of whether a risk component of a hedged item is separately identifiable, the amendments provide temporary relief to entities to meet this requirement when an alternative risk free rate (RFR) financial instrument is designated as a risk component. These amendments allow the Group upon designation of the hedge to assume that the separately identifiable requirement is met if the Group reasonably expects the RFR risk will become separately identifiable within the next 24 months. The Group applies this relief to each RFR on a rate-by-rate basis and starts when the Group first designates the RFR as a non-contractually specified risk component. Fair value hedge accounting Changes in fair value of derivatives that qualify and are designated as fair value hedges are recorded in the income statement, together with changes in the fair value of the hedged asset or liability that are attributable to the hedged risk. The fair value changes adjust the carrying value of the hedged asset or liability held at amortised cost. If hedge relationships no longer meet the criteria for hedge accounting, hedge accounting is discontinued. For fair value hedges of interest rate risk, the fair value adjustment to the hedged item is amortised to the income statement over the period to maturity of the previously designated hedge relationship using the effective interest method. If the hedged item is sold or repaid, the unamortised fair value adjustment is recognised immediately in the income statement. For items classified as fair value through other comprehensive income, the hedge accounting adjustment is included in other comprehensive income. Cash flow hedge accounting For qualifying cash flow hedges, the fair value gain or loss associated with the effective portion of the cash flow hedge is recognised initially in other comprehensive income, and then recycled to the income statement in the periods when the hedged item will affect profit or loss. Any ineffective portion of the gain or loss on the hedging instrument is recognised in the income statement immediately. When a hedging instrument expires or is sold, or when a hedge no longer meets the criteria for hedge accounting, any cumulative gain or loss existing in equity at that time remains in equity and is recognised when the hedged item is ultimately recognised in the income statement. When a forecast transaction is no longer expected to occur, the cumulative gain or loss that was recognised in equity is immediately transferred to the income statement. Hedges of net investments The Group’s net investments in foreign operations, including monetary items accounted for as part of the net investment, are hedged for foreign currency risks using both derivatives and foreign currency borrowings. Hedges of net investments are accounted for similarly to cash flow hedges; the effective portion of the gain or loss on the hedging instrument is being recognised directly in other comprehensive income and the ineffective portion being recognised immediately in the income statement. The cumulative gain or loss recognised in other comprehensive income is recognised in the income statement on the disposal or partial disposal of the foreign operation, or other reductions in the Group’s investment in the operation. |
Accounting for financial assets | Accounting for financial assets at fair value through other comprehensive income (FVOCI) Financial assets that are debt instruments held in a business model that is achieved by both collecting contractual cash flows and selling and that contain contractual terms that give rise on specified dates to cash flows that are SPPI are measured at FVOCI. They are subsequently re-measured at fair value and changes therein (except for those relating to impairment, interest income and foreign currency exchange gains and losses) are recognised in other comprehensive income until the assets are sold. Interest (calculated using the effective interest method) is recognised in the income statement in net interest income (Note 3). Upon disposal, the cumulative gain or loss recognised in other comprehensive income is included in net investment income (Note 6). In determining whether the business model is achieved by both collecting contractual cash flows and selling financial assets, it is determined that both collecting contractual cash flows and selling financial assets are integral to achieving the objective of the business model. The Group will consider past sales and expectations about future sales to establish if the business model is achieved. For equity securities that are not held for trading, the Group may make an irrevocable election on initial recognition to present subsequent changes in the fair value of the instrument in other comprehensive income (except for dividend income which is recognised in profit or loss). Gains or losses on the de-recognition of these equity securities are not transferred to profit or loss. These assets are also not subject to the impairment requirements and therefore no amounts are recycled to the income statement. Where the Group has not made the irrevocable election to present subsequent changes in the fair value of the instrument in other comprehensive income, equity securities are measured at fair value through profit or loss. |
Accounting for financial liabilities | Accounting for liabilities designated at fair value through profit and loss In accordance with IFRS 9, financial liabilities may be designated at fair value, with gains and losses taken to the income statement within net trading income (Note 5) and net investment income (Note 6). Movements in own credit are reported through other comprehensive income, unless the effects of changes in the liability's credit risk would create or enlarge an accounting mismatch in P&L. In these scenarios, all gains and losses on that liability (including the effects of changes in the credit risk of the liability) are presented in P&L. On derecognition of the financial liability no amount relating to own credit risk are recycled to the income statement. The Group has the ability to make the fair value designation when holding the instruments at fair value reduces an accounting mismatch (caused by an offsetting liability or asset being held at fair value), or is managed by the Group on the basis of its fair value, or includes terms that have substantive derivative characteristics (Note 14). The details on how the fair value amounts are arrived at for financial liabilities designated at fair value are described in Note 17. Accounting for loans and advances and deposits held at amortised cost Loans and advances to customers and banks, customer accounts, debt securities and most financial liabilities, are held at amortised cost. That is, the initial fair value (which is normally the amount advanced or borrowed) is adjusted for repayments and the amortisation of coupon, fees and expenses to represent the effective interest rate of the asset or liability. Balances deferred on-balance sheet as effective interest rate adjustments are amortised to interest income over the life of the financial instrument to which they relate. Financial assets that are held in a business model to collect the contractual cash flows and that contain contractual terms that give rise on specified dates to cash flows that are SPPI, are measured at amortised cost. The carrying value of these financial assets at initial recognition includes any directly attributable transaction costs. Refer to Note 1 for details on ‘solely payments of principal and interest’. In determining whether the business model is a ‘hold to collect’ model, the objective of the business model must be to hold the financial asset to collect contractual cash flows rather than holding the financial asset for trading or short-term profit taking purposes. While the objective of the business model must be to hold the financial asset to collect contractual cash flows this does not mean the Group is required to hold the financial assets until maturity. When determining if the business model objective is to collect contractual cash flows the Group will consider past sales and expectations about future sales. |
Accounting for financial assets and liabilities - fair values | Accounting for financial assets and liabilities – fair values Financial instruments that are held for trading are recognised at fair value through profit or loss. In addition, financial assets are held at fair value through profit or loss if they do not contain contractual terms that give rise on specified dates to cash flows that are SPPI, or if the financial asset is not held in a business model that is either (i) a business model to collect the contractual cash flows or (ii) a business model that is achieved by both collecting contractual cash flows and selling. Subsequent changes in fair value for these instruments are recognised in the income statement in net investment income, except if reporting it in trading income reduces an accounting mismatch. All financial instruments are initially recognised at fair value on the date of initial recognition (including transaction costs, other than financial instruments held at fair value through profit or loss) and depending on the subsequent classification of the financial asset or liability, may continue to be held at fair value either through profit or loss or other comprehensive income. The fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Wherever possible, fair value is determined by reference to a quoted market price for that instrument. For many of the Group’s financial assets and liabilities, especially derivatives, quoted prices are not available and valuation models are used to estimate fair value. The models calculate the expected cash flows under the terms of each specific contract and then discount these values back to a present value. These models use as their basis independently sourced market inputs including, for example, interest rate yield curves, equities and commodities prices, option volatilities and currency rates. For financial liabilities measured at fair value, the carrying amount reflects the effect on fair value of changes in own credit spreads derived from observable market data such as in primary issuance and redemption activity for structured notes. On initial recognition, it is presumed that the transaction price is the fair value unless there is observable information available in an active market to the contrary. The best evidence of an instrument’s fair value on initial recognition is typically the transaction price. However, if fair value can be evidenced by comparison with other observable current market transactions in the same instrument, or is based on a valuation technique whose inputs include only data from observable markets, then the instrument should be recognised at the fair value derived from such observable market data. For valuations that have made use of unobservable inputs, the difference between the model valuation and the initial transaction price (Day One profit) is recognised in profit or loss either: on a straight-line basis over the term of the transaction; or over the period until all model inputs will become observable where appropriate; or released in full when previously unobservable inputs become observable. Various factors influence the availability of observable inputs and these may vary from product to product and change over time. Factors include the depth of activity in the relevant market, the type of product, whether the product is new and not widely traded in the marketplace, the maturity of market modelling and the nature of the transaction (bespoke or generic). To the extent that valuation is based on models or inputs that are not observable in the market, the determination of fair value can be more subjective, dependent on the significance of the unobservable input to the overall valuation. Unobservable inputs are determined based on the best information available, for example by reference to similar assets, similar maturities or other analytical techniques. The sensitivity of valuations used in the financial statements to possible changes in significant unobservable inputs is shown on page 262. Critical accounting estimates and judgements The valuation of financial instruments often involves a significant degree of judgement and complexity, in particular where valuation models make use of unobservable inputs (‘Level 3’ assets and liabilities). This note provides information on these instruments, including the related unrealised gains and losses recognised in the period, a description of significant valuation techniques and unobservable inputs, and a sensitivity analysis. |
IAS 32 Financial Instruments | In accordance with IAS 32 Financial Instruments: Presentation, t he Group reports financial assets and financial liabilities on a net basis on the balance sheet only if there is a legally enforceable right to set-off the recognised amounts and there is intention to settle on a net basis, or to realise the asset and settle the liability simultaneously. The following table shows the impact of netting arrangements on: ▪ all financial assets and liabilities that are reported net on the balance sheet ▪ all derivative financial instruments and reverse repurchase and repurchase agreements and other similar secured lending and borrowing agreements that are subject to enforceable master netting arrangements or similar agreements, but do not qualify for balance sheet netting. The ‘Net amounts’ presented are not intended to represent the Group’s actual exposure to credit risk, as a variety of credit mitigation strategies are employed in addition to netting and collateral arrangements. |
Accounting for loans and advances and deposits held at amortised cost | Accounting for loans and advances and deposits held at amortised cost Loans and advances to customers and banks, customer accounts, debt securities and most financial liabilities, are held at amortised cost. That is, the initial fair value (which is normally the amount advanced or borrowed) is adjusted for repayments and the amortisation of coupon, fees and expenses to represent the effective interest rate of the asset or liability. Balances deferred on-balance sheet as effective interest rate adjustments are amortised to interest income over the life of the financial instrument to which they relate. Financial assets that are held in a business model to collect the contractual cash flows and that contain contractual terms that give rise on specified dates to cash flows that are SPPI, are measured at amortised cost. The carrying value of these financial assets at initial recognition includes any directly attributable transaction costs. Refer to Note 1 for details on ‘solely payments of principal and interest’. In determining whether the business model is a ‘hold to collect’ model, the objective of the business model must be to hold the financial asset to collect contractual cash flows rather than holding the financial asset for trading or short-term profit taking purposes. While the objective of the business model must be to hold the financial asset to collect contractual cash flows this does not mean the Group is required to hold the financial assets until maturity. When determining if the business model objective is to collect contractual cash flows the Group will consider past sales and expectations about future sales. |
Accounting for property, plant and equipment | Accounting for property, plant and equipment The Group applies IAS 16 Property Plant and Equipment and IAS 40 Investment Properties. Property, plant and equipment is stated at cost, which includes direct and incremental acquisition costs less accumulated depreciation and provisions for impairment, if required. Subsequent costs are capitalised if these result in enhancement of the asset. Depreciation is provided on the depreciable amount of items of property, plant and equipment on a straight-line basis over their estimated useful economic lives. Depreciation rates, methods and the residual values underlying the calculation of depreciation of items of property, plant and equipment are kept under review to take account of any change in circumstances. The Group uses the following annual rates in calculating depreciation: Annual rates in calculating depreciation Depreciation rate Freehold land Not depreciated Freehold buildings and long-leasehold property (more than 50 years to run) 2-3.3% Leasehold property over the remaining life of the lease (less than 50 years to run) Over the remaining life of the lease Costs of adaptation of freehold and leasehold property 6-10% Equipment installed in freehold and leasehold property 6-10% Computers and similar equipment 17-33% Fixtures and fittings and other equipment 9-20% Costs of adaptation and installed equipment are depreciated over the shorter of the life of the lease or the depreciation rates noted in the table above. Investment property The Group initially recognises investment property at cost, and subsequently at fair value at each balance sheet date, reflecting market conditions at the reporting date. Gains and losses on remeasurement are included in the income statement. |
Accounting for leases under IFRS 16 effective from 1 January 2019 | Accounting for leases IFRS 16 applies to all leases with the exception of licenses of intellectual property, rights held by licensing agreement within the scope of IAS 38 Intangible Assets, service concession arrangements, leases of biological assets within the scope of IAS 41 Agriculture and leases of minerals, oil, natural gas and similar non-regenerative resources. IFRS 16 includes an accounting policy choice for a lessee to elect not to apply IFRS 16 to remaining assets within the scope of IAS 38 Intangible Assets which the Group has decided to apply. When the Group is the lessee, it is required to recognise both: ▪ A lease liability, measured at the present value of remaining cash flows on the lease, and ▪ A right of use (ROU) asset, measured at the amount of the initial measurement of the lease liability, plus any lease payments made prior to commencement date, initial direct costs, and estimated costs of restoring the underlying asset to the condition required by the lease, less any lease incentives received. Subsequently the lease liability will increase for the accrual of interest, resulting in a constant rate of return throughout the life of the lease, and reduce when payments are made. The right of use asset will amortise to the income statement over the life of the lease. The lease liability is remeasured when there is a change in one of the following: ▪ Future lease payments arising from a change in an index or rate; ▪ The Group’s estimate of the amount expected to be payable under a residual value guarantee; or ▪ The Group’s assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount of the ROU asset, or is recorded in the income statement if the carrying amount of the ROU asset has been reduced to nil. On the balance sheet, the ROU assets are included within property, plant and equipment and the lease liabilities are included within other liabilities. The Group applies the recognition exemption in IFRS 16 for leases with a term not exceeding 12 months. For these leases the lease payments are recognised as an expense on a straight line basis over the lease term unless another systematic basis is more appropriate. When the Group is the lessor, the lease must be classified as either a finance lease or an operating lease. A finance lease is a lease which confers substantially all the risks and rewards of the leased assets on the lessee. An operating lease is a lease where substantially all of the risks and rewards of the leased asset remain with the lessor. When the lease is deemed a finance lease, the leased asset is not held on the balance sheet; instead a finance lease receivable is recognised representing the minimum lease payments receivable under the terms of the lease, discounted at the rate of interest implicit in the lease. |
Accounting for goodwill and intangible assets | Accounting for goodwill and intangible assets Goodwill The carrying value of goodwill is determined in accordance with IFRS 3 Business Combinations and IAS 36 Impairment of Assets . Goodwill arising on the acquisition of subsidiaries represents the excess of the fair value of the purchase consideration over the fair value of the Group’s share of the assets acquired and the liabilities and contingent liabilities assumed on the date of the acquisition. Goodwill is reviewed annually for impairment, or more frequently when there are indications that impairment may have occurred. The test involves comparing the carrying value of a cash generating unit (CGU) including goodwill with the present value of the pre-tax cash flows, discounted at a rate of interest that reflects the inherent risks, of the CGU to which the goodwill relates, or the CGU's fair value if this is higher. Intangible assets Intangible assets other than goodwill are accounted for in accordance with IAS 38 Intangible Assets. Intangible assets are initially recognised when they are separable or arise from contractual or other legal rights, the cost can be measured reliably and, in the case of intangible assets not acquired in a business combination, where it is probable that future economic benefits attributable to the assets will flow from their use. For internally generated intangible assets, only costs incurred during the development phase are capitalised. Expenditure in the research phase is expensed when it is incurred. Intangible assets are stated at cost (which is, in the case of assets acquired in a business combination, the acquisition date fair value) less accumulated amortisation and impairment, if any, and are amortised over their useful lives in a manner that reflects the pattern to which they contribute to future cash flows, generally using the amortisation periods set out below: Annual rates in calculating amortisation Amortisation period Goodwill Not amortised Internally generated software a 12 months to 6 years Other software 12 months to 6 years Customer lists 12 months to 25 years Licences and other 12 months to 25 years Note a Exceptions to the above rate relate to useful lives of certain core banking platforms that are assessed individually and, if appropriate, amortised over longer periods ranging from 10 to 15 years. Intangible assets are reviewed for impairment when there are indications that impairment may have occurred. Intangible assets not yet available for use are reviewed annually for impairment. |
Accounting for provisions | Accounting for provisions The Group applies IAS 37 Provisions, Contingent Liabilities and Contingent Assets in accounting for non-financial liabilities. Provisions are recognised for present obligations arising as consequences of past events where it is more likely than not that a transfer of economic benefit will be necessary to settle the obligation, which can be reliably estimated. Provision is made for the anticipated cost of restructuring, including redundancy costs, when an obligation exists; for example, when the Group has a detailed formal plan for restructuring a business and has raised valid expectations in those affected by the restructuring by announcing its main features or starting to implement the plan. Critical accounting estimates and judgements The financial reporting of provisions involves a significant degree of judgement and is complex. Identifying whether a present obligation exists and estimating the probability, timing, nature and quantum of the outflows that may arise from past events requires judgements to be made based on the specific facts and circumstances relating to individual events and often requires specialist professional advice. When matters are at an early stage, accounting judgements and estimates can be difficult because of the high degree of uncertainty involved. Management continues to monitor matters as they develop to re-evaluate on an ongoing basis whether provisions should be recognised, however there can remain a wide range of possible outcomes and uncertainties, particularly in relation to legal, competition and regulatory matters, and as a result it is often not practicable to make meaningful estimates even when matters are at a more advanced stage. The complexity of such matters often requires the input of specialist professional advice in making assessments to produce estimates. Customer redress and legal, competition and regulatory matters are areas where a higher degree of professional judgement is required. The amount that is recognised as a provision can also be very sensitive to the assumptions made in calculating it. This gives rise to a large range of potential outcomes which require judgement in determining an appropriate provision level. See Note 26 for more detail of legal, competition and regulatory matters. |
Accounting for contingent liabilities | Accounting for contingent liabilities Contingent liabilities are possible obligations whose existence will be confirmed only by uncertain future events and present obligations where the transfer of economic resources is uncertain or cannot be reliably measured. Contingent liabilities are not recognised on the balance sheet but are disclosed unless the likelihood of an outflow of economic resources is remote. |
Accounting for subordinated liabilities | Accounting for subordinated liabilities Subordinated liabilities are measured at amortised cost using the effective interest method under IFRS 9. |
Accounting for staff costs, pensions and post-retirement benefits | Accounting for staff costs The Group applies IAS 19 Employee benefits in its accounting for most of the components of staff costs. Short-term employee benefits – salaries, accrued performance costs and social security are recognised over the period in which the employees provide the services to which the payments relate. Performance costs – recognised to the extent that the Group has a present obligation to its employees that can be measured reliably and are recognised over the period of service that employees are required to work to qualify for the payments. Deferred cash and share awards are made to employees to incentivise performance over the period employees provide services. To receive payment under an award, employees must provide service over the vesting period. The period over which the expense for deferred cash and share awards is recognised is based upon the period employees consider their services contribute to the awards. For past awards, the Group considers that it is appropriate to recognise the awards over the period from the date of grant to the date that the awards vest. In relation to awards granted from 2017, the Group, taking into account the changing employee understanding surrounding those awards, considered it appropriate for expense to be recognised over the vesting period including the financial year prior to the grant date. The accounting policies for share-based payments, and pensions and other post-retirement benefits are included in Note 32 and Note 33 respectively. Accounting for pensions and post-retirement benefits The Group operates a number of pension schemes and post-employment benefit schemes. Defined contribution schemes – the Group recognises contributions due in respect of the accounting period in the income statement. Any contributions unpaid at the balance sheet date are included as a liability. Defined benefit schemes – the Group recognises its obligations to members of each scheme at the period end, less the fair value of the scheme assets after applying the asset ceiling test. Each scheme’s obligations are calculated using the projected unit credit method. Scheme assets are stated at fair value as at the period end. Changes in pension scheme liabilities or assets (remeasurements) that do not arise from regular pension cost, net interest on net defined benefit liabilities or assets, past service costs, settlements or contributions to the scheme, are recognised in other comprehensive income. Remeasurements comprise experience adjustments (differences between previous actuarial assumptions and what has actually occurred), the effects of changes in actuarial assumptions, return on scheme assets (excluding amounts included in the interest on the assets) and any changes in the effect of the asset ceiling restriction (excluding amounts included in the interest on the restriction). Post-employment benefit schemes – the cost of providing healthcare benefits to retired employees is accrued as a liability in the financial statements over the period that the employees provide services to the Group, using a methodology similar to that for defined benefit pension schemes. |
Accounting for share-based payments | Accounting for share-based payments The Group applies IFRS 2 Share-based Payments in accounting for employee remuneration in the form of shares. Employee incentives include awards in the form of shares and share options, as well as offering employees the opportunity to purchase shares on favourable terms. The cost of the employee services received in respect of the shares or share options granted is recognised in the income statement over the period that employees provide services. The overall cost of the award is calculated using the number of shares and options expected to vest and the fair value of the shares or options at the date of grant. The number of shares and options expected to vest takes into account the likelihood that performance and service conditions included in the terms of the awards will be met. Failure to meet the non-vesting condition is treated as a cancellation, resulting in an acceleration of recognition of the cost of the employee services. |
Accounting for investment in subsidiaries | The Group applies IFRS 10 Consolidated Financial Statements. The consolidated financial statements combine the financial statements of the Group and all its subsidiaries. Subsidiaries are entities over which the Group has control. Under IFRS 10, this is when the Group is exposed or has rights to variable returns from its involvement in the entity and has the ability to affect those returns through its power over the entity. The Group reassesses whether it controls an entity if facts and circumstances indicate that there have been changes to its power, its rights to variable returns or its ability to use its power to affect the amount of its returns. Intra-group transactions and balances are eliminated on consolidation and consistent accounting policies are used throughout the Group for the purposes of the consolidation. Changes in ownership interests in subsidiaries are accounted for as equity transactions if they occur after control has been obtained and they do not result in loss of control. The significant judgements used in applying this policy are set out below. Accounting for investment in subsidiaries In the individual financial statements of Barclays PLC, investments in subsidiaries are stated at cost less impairment. |
Accounting for associates and joint ventures | Accounting for associates and joint ventures The Group applies IAS 28 Investments in Associates and IFRS 11 Joint Arrangements. Associates are entities in which the Group has significant influence, but not control, over the operating and financial policies. Generally the Group holds more than 20%, but less than 50%, of their voting shares. Joint ventures are arrangements where the Group has joint control and rights to the net assets of the entity. |
Accounting for securitisations | Accounting for securitisations The Group uses securitisations as a source of finance and a means of risk transfer. Such transactions generally result in the transfer of contractual cash flows from portfolios of financial assets to holders of issued debt securities. Securitisations may, depending on the individual arrangement, result in continued recognition of the securitised assets and the recognition of the debt securities issued in the transaction; lead to partial continued recognition of the assets to the extent of the Group’s continuing involvement in those assets or lead to derecognition of the assets and the separate recognition, as assets or liabilities, of any rights and obligations created or retained in the transfer. Full derecognition only occurs when the Group transfers both its contractual right to receive cash flows from the financial assets, or retains the contractual rights to receive the cash flows, but assumes a contractual obligation to pay the cash flows to another party without material delay or reinvestment, and also transfers substantially all the risks and rewards of ownership, including credit risk, prepayment risk and interest rate risk. |
Accounting for assets pledged, collateral received and assets transferred | Assets are pledged or transferred as collateral to secure liabilities under repurchase agreements, securitisations and stock lending agreements or as security deposits relating to derivatives. Assets transferred are non-cash assets transferred to a third party that do not qualify for derecognition from the Group balance sheet, for example because Barclays retains substantially all the exposure to those assets under an agreement to repurchase them in the future for a fixed price. Assets pledged or transferred as collateral include all assets categorised as encumbered in the disclosure on pages 221 to 223 of the Barclays PLC Pillar 3 Report 2021 (unaudited), other than those held in commercial paper conduits. In these transactions, the Group will be required to step in to provide financing itself under a liquidity facility if the vehicle cannot access the commercial paper market. Where non-cash assets are pledged or transferred as collateral for cash received, the asset continues to be recognised in full, and a related liability is also recognised on the balance sheet. Where non-cash assets are pledged or transferred as collateral in an exchange for non-cash assets, the transferred asset continues to be recognised in full, and there is no associated liability as the non-cash collateral received is not recognised on the balance sheet. The Group is unable to use, sell or pledge the transferred assets for the duration of the transaction and remains exposed to interest rate risk and credit risk on these pledged assets. Unless stated, the counterparty's recourse is not limited to the transferred assets. |
Other disclosures - Risk Mana_2
Other disclosures - Risk Management and Principal Risks (audited) (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of credit risk exposure [abstract] | |
Maximum exposure and effects of collateral and other credit enhancements (audited) | Maximum exposure and effects of netting, collateral and risk transfer (audited) Maximum exposure Netting and set-off Cash collateral Non-cash collateral Risk transfer Net exposure As at 31 December 2021 £m £m £m £m £m £m On-balance sheet: Cash and balances at central banks 238,574 — — — — 238,574 Cash collateral and settlement balances 92,542 — — — — 92,542 Loans and advances at amortised cost: Home loans 169,205 — (339) (168,627) (146) 93 Credit cards, unsecured loans and other retail lending 41,793 — (1,050) (4,560) (252) 35,931 Wholesale loans 150,453 (5,001) (128) (42,691) (23,104) 79,529 Total loans and advances at amortised cost 361,451 (5,001) (1,517) (215,878) (23,502) 115,553 Of which credit-impaired (Stage 3): Home loans 1,725 — (11) (1,714) — — Credit cards, unsecured loans and other retail lending 828 — (29) (229) (3) 567 Wholesale loans 2,161 — (1) (717) (765) 678 Total credit-impaired loans and advances at amortised cost 4,714 — (41) (2,660) (768) 1,245 Reverse repurchase agreements and other similar secured lending 3,227 — — (3,227) — — Trading portfolio assets: Debt securities 50,864 — — (461) — 50,403 Traded loans 12,525 — — (268) — 12,257 Total trading portfolio assets 63,389 — — (729) — 62,660 Financial assets at fair value through the income statement: Loans and advances 38,667 — — (31,263) — 7,404 Debt securities 2,305 — — (319) — 1,986 Reverse repurchase agreements 145,014 — (1,428) (143,057) — 529 Other financial assets 111 — — — — 111 Total financial assets at fair value through the income statement 186,097 — (1,428) (174,639) — 10,030 Derivative financial instruments 262,572 (202,519) (34,598) (5,887) (5,738) 13,830 Financial assets at fair value through other comprehensive income 60,851 — — (53) (1,164) 59,634 Other assets 1,212 — — — — 1,212 Total on-balance sheet 1,269,915 (207,520) (37,543) (400,413) (30,404) 594,035 Off-balance sheet: Contingent liabilities 21,346 — (906) (1,367) (256) 18,817 Loan commitments 345,711 — (141) (44,777) (1,668) 299,125 Total off-balance sheet 367,057 — (1,047) (46,144) (1,924) 317,942 Total 1,636,972 (207,520) (38,590) (446,557) (32,328) 911,977 Maximum exposure and effects of netting, collateral and risk transfer (audited) Maximum exposure Netting and set-off Cash collateral Non-cash collateral Risk transfer Net exposure As at 31 December 2020 £m £m £m £m £m £m On-balance sheet: Cash and balances at central banks 191,127 — — — — 191,127 Cash collateral and settlement balances 101,367 — — — — 101,367 Loans and advances at amortised cost: Home loans 159,647 — (284) (159,203) (85) 75 Credit cards, unsecured loans and other retail lending 40,813 — (967) (3,825) (195) 35,826 Wholesale loans 142,172 (6,988) (62) (37,103) (23,963) 74,056 Total loans and advances at amortised cost 342,632 (6,988) (1,313) (200,131) (24,243) 109,957 Of which credit-impaired (Stage 3): Home loans 1,813 — (14) (1,796) — 3 Credit cards, unsecured loans and other retail lending 921 — (14) (237) (2) 668 Wholesale loans 2,525 — (4) (872) (232) 1,417 Total credit-impaired loans and advances at amortised cost 5,259 — (32) (2,905) (234) 2,088 Reverse repurchase agreements and other similar secured lending 9,031 — — (9,031) — — Trading portfolio assets: Debt securities 56,482 — — (391) — 56,091 Traded loans 8,348 — — (374) — 7,974 Total trading portfolio assets 64,830 — — (765) — 64,065 Financial assets at fair value through the income statement: Loans and advances 30,879 — (9) (23,677) — 7,193 Debt securities 1,693 — — (292) — 1,401 Reverse repurchase agreements 137,616 — (672) (136,537) — 407 Other financial assets 343 — — — — 343 Total financial assets at fair value through the income statement 170,531 — (681) (160,506) — 9,344 Derivative financial instruments 302,446 (233,080) (43,291) (4,773) (6,409) 14,893 Financial assets at fair value through other comprehensive income 77,927 — — (106) (1,385) 76,436 Other assets 850 — — — — 850 Total on-balance sheet 1,260,741 (240,068) (45,285) (375,312) (32,037) 568,039 Off-balance sheet: Contingent liabilities 21,609 — (1,095) (2,135) (282) 18,097 Loan commitments 333,049 — (128) (40,714) (1,520) 290,687 Total off-balance sheet 354,658 — (1,223) (42,849) (1,802) 308,784 Total 1,615,399 (240,068) (46,508) (418,161) (33,839) 876,823 |
Loans and advances at amortised cost by stage and product (audited) | Loans and advances at amortised cost by stage (audited) Gross exposure Impairment allowance Net exposure Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total As at 31 December 2021 £m £m £m £m £m £m £m £m £m Barclays UK 160,695 22,779 2,915 186,389 261 949 728 1,938 184,451 Barclays International 25,981 2,691 1,566 30,238 603 795 858 2,256 27,982 Head Office 3,735 429 705 4,869 2 36 347 385 4,484 Total Barclays Group retail 190,411 25,899 5,186 221,496 866 1,780 1,933 4,579 216,917 Barclays UK 35,571 1,917 969 38,457 153 43 111 307 38,150 Barclays International 92,341 13,275 1,059 106,675 187 192 458 837 105,838 Head Office 542 2 21 565 — — 19 19 546 Total Barclays Group wholesale a 128,454 15,194 2,049 145,697 340 235 588 1,163 144,534 Total loans and advances at amortised cost 318,865 41,093 7,235 367,193 1,206 2,015 2,521 5,742 361,451 Off-balance sheet loan commitments and financial guarantee contracts b 312,142 34,815 1,298 348,255 217 302 23 542 347,713 Total c 631,007 75,908 8,533 715,448 1,423 2,317 2,544 6,284 709,164 Loan impairment charge and loan loss rate Coverage ratio Loan impairment charge/(release) Loan loss rate Stage 1 Stage 2 Stage 3 Total As at 31 December 2021 % % % % £m bps Barclays UK 0.2 4.2 25.0 1.0 (227) — Barclays International 2.3 29.5 54.8 7.5 181 60 Head Office 0.1 8.4 49.2 7.9 — — Total Barclays Group retail 0.5 6.9 37.3 2.1 (46) — Barclays UK 0.4 2.2 11.5 0.8 122 32 Barclays International 0.2 1.4 43.2 0.8 (197) — Head Office — — 90.5 3.4 — — Total Barclays Group wholesale a 0.3 1.5 28.7 0.8 (75) — Total loans and advances at amortised cost 0.4 4.9 34.8 1.6 (121) — Off-balance sheet loan commitments and financial guarantee contracts b — 0.9 1.8 0.2 (514) Other financial assets subject to impairment c (18) Total 0.2 3.1 29.8 0.9 (653) Notes a Includes Wealth and Private Banking exposures measured on an individual customer exposure basis, and excludes Business Banking exposures, including BBLs of £9.4bn that are managed on a collective basis and reported within BUK Retail. The net impact is a difference in total exposure of £5,994m of balances reported as wholesale loans in the Loans and advances at amortised cost by product disclosure. b Excludes loan commitments and financial guarantees of £18.8bn carried at fair value. c Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £155.2bn and impairment allowance of £114m. This comprises £6m ECL on £154.9bn Stage 1 assets, £1m on £157m Stage 2 fair value through other comprehensive income assets, other assets, cash collateral and settlement assets and £107m on £110m Stage 3 other assets. Loans and advances at amortised cost by stage (audited) Gross exposure Impairment allowance Net exposure Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total As at 31 December 2020 £m £m £m £m £m £m £m £m £m Barclays UK 153,250 23,896 2,732 179,878 332 1,509 1,147 2,988 176,890 Barclays International a 21,048 5,500 1,992 28,540 396 1,329 1,205 2,930 25,610 Head Office 4,267 720 844 5,831 4 51 380 435 5,396 Total Barclays Group retail 178,565 30,116 5,568 214,249 732 2,889 2,732 6,353 207,896 Barclays UK 31,918 4,325 1,126 37,369 13 129 116 258 37,111 Barclays International a 79,911 16,565 2,270 98,746 288 546 859 1,693 97,053 Head Office 570 — 33 603 — — 31 31 572 Total Barclays Group wholesale b 112,399 20,890 3,429 136,718 301 675 1,006 1,982 134,736 Total loans and advances at amortised cost 290,964 51,006 8,997 350,967 1,033 3,564 3,738 8,335 342,632 Off-balance sheet loan commitments and financial guarantee contracts c 289,939 52,891 2,330 345,160 256 758 50 1,064 344,096 Total d 580,903 103,897 11,327 696,127 1,289 4,322 3,788 9,399 686,728 Loan impairment charge and loan loss rate Coverage ratio Loan impairment charge Loan loss rate Stage 1 Stage 2 Stage 3 Total As at 31 December 2020 % % % % £m bps Barclays UK 0.2 6.3 42.0 1.7 1,070 59 Barclays International a 1.9 24.2 60.5 10.3 1,680 589 Head Office 0.1 7.1 45.0 7.5 91 156 Total Barclays Group retail 0.4 9.6 49.1 3.0 2,841 133 Barclays UK — 3.0 10.3 0.7 154 41 Barclays International a 0.4 3.3 37.8 1.7 914 93 Head Office — — 93.9 5.1 — — Total Barclays Group wholesale b 0.3 3.2 29.3 1.4 1,068 78 Total loans and advances at amortised cost 0.4 7.0 41.5 2.4 3,909 111 Off-balance sheet loan commitments and financial guarantee contracts c 0.1 1.4 2.1 0.3 776 Other financial assets subject to impairment d 153 Total e 0.2 4.2 33.4 1.4 4,838 Notes a Private Banking have refined the methodology to classify £5bn of their exposure between Wholesale and Retail during the year. b Included in the above analysis are Wealth and Private Banking exposures measured on an individual customer exposure basis, and excludes Business Banking exposures that are managed on a collective basis. The net impact is a difference in total exposure of £7,551m of balances reported as wholesale loans in the Loans and advances at amortised cost by product disclosure. c Excludes loan commitments and financial guarantees of £9.5bn carried at fair value. d Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £180.3bn and impairment allowance of £165m. This comprises £11m ECL on £175.7bn Stage 1 assets £9m on £4.4bn Stage 2 fair value through other comprehensive income assets, cash collateral and settlement balances and £145m on £154m Stage 3 other assets. e The loan loss rate is 138bps after applying the total impairment charge of £4,838m. Loans and advances at amortised cost by product (audited) Stage 2 As at 31 December 2021 Stage 1 Not past due <=30 days past due >30 days past due Total Stage 3 Total Gross exposure £m £m £m £m £m £m £m Home loans 148,058 17,133 1,660 707 19,500 2,122 169,680 Credit cards, unsecured loans and other retail lending 37,840 5,102 300 248 5,650 2,332 45,822 Wholesale loans 132,967 15,246 306 391 15,943 2,781 151,691 Total 318,865 37,481 2,266 1,346 41,093 7,235 367,193 Impairment allowance Home loans 19 46 6 7 59 397 475 Credit cards, unsecured loans and other retail lending 824 1,493 85 123 1,701 1,504 4,029 Wholesale loans 363 248 4 3 255 620 1,238 Total 1,206 1,787 95 133 2,015 2,521 5,742 Net exposure Home loans 148,039 17,087 1,654 700 19,441 1,725 169,205 Credit cards, unsecured loans and other retail lending 37,016 3,609 215 125 3,949 828 41,793 Wholesale loans 132,604 14,998 302 388 15,688 2,161 150,453 Total 317,659 35,694 2,171 1,213 39,078 4,714 361,451 Coverage ratio % % % % % % % Home loans — 0.3 0.4 1.0 0.3 18.7 0.3 Credit cards, unsecured loans and other retail lending 2.2 29.3 28.3 49.6 30.1 64.5 8.8 Wholesale loans 0.3 1.6 1.3 0.8 1.6 22.3 0.8 Total 0.4 4.8 4.2 9.9 4.9 34.8 1.6 As at 31 December 2020 Gross exposure £m £m £m £m £m £m £m Home loans 138,639 16,651 1,785 876 19,312 2,234 160,185 Credit cards, unsecured loans and other retail lending 33,021 9,470 544 306 10,320 3,172 46,513 Wholesale loans 119,304 19,501 1,097 776 21,374 3,591 144,269 Total 290,964 45,622 3,426 1,958 51,006 8,997 350,967 Impairment allowance Home loans 33 57 13 14 84 421 538 Credit cards, unsecured loans and other retail lending 680 2,382 180 207 2,769 2,251 5,700 Wholesale loans 320 650 50 11 711 1,066 2,097 Total 1,033 3,089 243 232 3,564 3,738 8,335 Net exposure Home loans 138,606 16,594 1,772 862 19,228 1,813 159,647 Credit cards, unsecured loans and other retail lending 32,341 7,088 364 99 7,551 921 40,813 Wholesale loans 118,984 18,851 1,047 765 20,663 2,525 142,172 Total 289,931 42,533 3,183 1,726 47,442 5,259 342,632 Coverage ratio % % % % % % % Home loans — 0.3 0.7 1.6 0.4 18.8 0.3 Credit cards, unsecured loans and other retail lending 2.1 25.2 33.1 67.6 26.8 71.0 12.3 Wholesale loans 0.3 3.3 4.6 1.4 3.3 29.7 1.5 Total 0.4 6.8 7.1 11.8 7.0 41.5 2.4 |
Movement in gross exposure and impairment allowance including provisions for loan commitments and financial guarantees (audited) | The following tables present a reconciliation of the opening to the closing balance of the exposure and impairment allowance. An explanation of the methodology used to determine credit impairment provisions is included in Note 7. Transfers between stages in the tables have been reflected as if they had taken place at the beginning of the year. The movements are measured over a 12-month period. Loans and advances at amortised cost (audited) Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2021 138,639 33 19,312 84 2,234 421 160,185 538 Transfers from Stage 1 to Stage 2 (7,672) (2) 7,672 2 — — — — Transfers from Stage 2 to Stage 1 5,336 32 (5,336) (32) — — — — Transfers to Stage 3 (282) — (469) (9) 751 9 — — Transfers from Stage 3 35 1 203 5 (238) (6) — — Business activity in the year a 32,744 7 1,243 5 4 — 33,991 12 Refinements to models used for calculation b — — — (4) — 38 — 34 Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes (8,131) (50) (1,090) 12 (216) (26) (9,437) (64) Final repayments (12,039) (2) (2,009) (4) (392) (18) (14,440) (24) Disposals c (572) — (26) — — — (598) — Write-offs d — — — — (21) (21) (21) (21) As at 31 December 2021 e 148,058 19 19,500 59 2,122 397 169,680 475 Credit cards, unsecured loans and other retail lending As at 1 January 2021 33,021 680 10,320 2,769 3,172 2,251 46,513 5,700 Transfers from Stage 1 to Stage 2 (1,894) (78) 1,894 78 — — — — Transfers from Stage 2 to Stage 1 4,717 1,174 (4,717) (1,174) — — — — Transfers to Stage 3 (529) (22) (790) (370) 1,319 392 — — Transfers from Stage 3 55 26 32 19 (87) (45) — — Business activity in the year a 7,842 119 257 62 42 19 8,141 200 Refinements to models used for calculation b — (5) — (33) — 14 — (24) Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes f (2,793) (1,030) (848) 389 (165) 620 (3,806) (21) Final repayments (2,579) (40) (498) (39) (212) (92) (3,289) (171) Disposals c — — — — (287) (205) (287) (205) Write-offs d — — — — (1,450) (1,450) (1,450) (1,450) As at 31 December 2021 e 37,840 824 5,650 1,701 2,332 1,504 45,822 4,029 Wholesale loans As at 1 January 2021 119,304 320 21,374 711 3,591 1,066 144,269 2,097 Transfers from Stage 1 to Stage 2 (6,115) (19) 6,115 19 — — — — Transfers from Stage 2 to Stage 1 9,137 257 (9,137) (257) — — — — Transfers to Stage 3 (804) (4) (377) (21) 1,181 25 — — Transfers from Stage 3 580 23 410 22 (990) (45) — — Business activity in the year a 34,804 95 1,774 18 283 50 36,861 163 Refinements to models used for calculation b — 8 — 11 — — — 19 Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes (417) (268) 721 (68) (211) 67 93 (269) Final repayments (22,219) (34) (4,734) (174) (545) (131) (27,498) (339) Disposals c (1,303) (15) (203) (6) (163) (47) (1,669) (68) Write-offs d — — — — (365) (365) (365) (365) As at 31 December 2021 e 132,967 363 15,943 255 2,781 620 151,691 1,238 Notes a Business activity in the year does not include additional drawdowns on the existing facility which are reported under 'Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes'. b Refinements to models used for calculation include a £34m movement in Home loans, £24m in Credit cards, unsecured loans and other retail lending and £19m in Wholesale loans. These reflect methodology changes made during the year. Barclays continually review the output of models to determine accuracy of the ECL calculation including review of model monitoring, external benchmarking and experience of model operation over an extended period of time. This ensures that the models used continue to reflect the risks inherent across the businesses. c The £598m disposals reported within Home loans relate to transfer of facilities to a non-consolidated special purpose vehicle for the purpose of securitisation. The £287m disposals reported within Credit cards, unsecured loans and other retail lending portfolio relate to debt sales undertaken during the year. The £1.7bn disposal reported within Wholesale loans includes a £1.0bn sale of Barclays Asset Finance and a £0.7bn of debt sales. d In 2021, gross write-offs amounted to £1,836m (2020: £1,964m) and post write-off recoveries amounted to £66m (2020: £35m). Net write-offs represent gross write-offs less post write-off recoveries and amounted to £1,770m (2020: £1,929m). e Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £155.2bn (December 2020: £180.3bn) and impairment allowance of £114m (December 2020: £165m). This comprises £6m ECL (December 2020: £11m) on £154.9bn Stage 1 assets (December 2020: £175.7bn), £1m (December 2020: £9m) on £157m Stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets (December 2020: £4.4bn) and £107m (December 2020: £145m) on £110m Stage 3 other assets (December 2020: £154m). f Transfers and risk parameters change include a £0.3bn (2020: £0.6bn) net release in ECL arising from reclassification of £1.9bn (2020: £2.0bn) gross loans and advances from Stage 2 to Stage 1 in Credit cards, unsecured loans and other retail lending. The reclassification followed a review of back-testing of results which indicated that accuracy of origination probability of default characteristics require management adjustments to correct and was first established in Q220. Reconciliation of ECL movement to credit impairment (release)/charge for the period £m Home loans (42) Credit cards, unsecured loans and other retail lending (16) Wholesale loans (426) ECL movement excluding assets derecognised due to disposals and write-offs (484) Recoveries and reimbursements a 240 Exchange and other adjustments b 123 Credit impairment release on loan commitments and financial guarantees (514) Credit impairment release on other financial assets c (18) Credit impairment release for the year (653) Notes a Recoveries and reimbursements includes a net reduction in amounts recoverable from financial guarantee contracts held with third parties of £306m and cash recoveries of previously written off amounts of £66m. b Includes foreign exchange and interest and fees in suspense. c Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £155.2bn (December 2020: £180.3bn) and impairment allowance of £114m (December 2020: £165m). This comprises £6m ECL (December 2020: £11m) on £154.9bn Stage 1 assets (December 2020: £175.7bn), £1m (December 2020: £9m) on £157m Stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets (December 2020: £4.4bn) and £107m (December 2020: £145m) on £110m Stage 3 other assets (December 2020: £154m). Loan commitments and financial guarantees (audited) Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2021 11,861 — 516 — 5 — 12,382 — Net transfers between stages (131) — 124 — 7 — — — Business activity in the year 7,034 — — — — — 7,034 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (7,556) — (64) — (4) — (7,624) — Limit management and final repayments (375) — (44) — (5) — (424) — As at 31 December 2021 10,833 — 532 — 3 — 11,368 — Credit cards, unsecured loans and other retail lending As at 1 January 2021 114,371 55 12,117 305 229 23 126,717 383 Net transfers between stages 5,769 206 (6,379) (213) 610 7 — — Business activity in the year 11,206 — 430 — 2 — 11,638 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (742) (207) 217 (24) (526) (10) (1,051) (241) Limit management and final repayments (7,785) (4) (667) (7) (97) — (8,549) (11) As at 31 December 2021 122,819 50 5,718 61 218 20 128,755 131 Wholesale loans As at 1 January 2021 163,707 201 40,258 453 2,096 27 206,061 681 Net transfers between stages 8,227 221 (7,174) (215) (1,053) (6) — — Business activity in the year 44,085 14 4,658 102 10 — 48,753 116 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 8,819 (229) (151) 7 515 (11) 9,183 (233) Limit management and final repayments (46,348) (40) (9,026) (106) (491) (7) (55,865) (153) As at 31 December 2021 178,490 167 28,565 241 1,077 3 208,132 411 Loans and advances at amortised cost (audited) Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2020 135,713 22 17,043 64 2,155 346 154,911 432 Transfers from Stage 1 to Stage 2 (8,724) (1) 8,724 1 — — — — Transfers from Stage 2 to Stage 1 4,618 14 (4,618) (14) — — — — Transfers to Stage 3 (308) — (420) (10) 728 10 — — Transfers from Stage 3 47 1 219 2 (266) (3) — — Business activity in the year a 22,548 7 714 2 4 — 23,266 9 Refinements to models used for calculation b — — — — — — — — Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes (6,195) (9) (841) 42 (57) 105 (7,093) 138 Final repayments (9,060) (1) (1,509) (3) (308) (15) (10,877) (19) Disposals c — — — — — — — — Write-offs d — — — — (22) (22) (22) (22) As at 31 December 2020 e 138,639 33 19,312 84 2,234 421 160,185 538 Credit cards, unsecured loans and other retail lending As at 1 January 2020 46,012 542 10,759 2,007 3,409 2,335 60,180 4,884 Transfers from Stage 1 to Stage 2 (6,571) (134) 6,571 134 — — — — Transfers from Stage 2 to Stage 1 3,080 482 (3,080) (482) — — — — Transfers to Stage 3 (712) (25) (1,162) (398) 1,874 423 — — Transfers from Stage 3 76 39 67 12 (143) (51) — — Business activity in the year a 5,598 67 324 83 59 28 5,981 178 Refinements to models used for calculation b — 13 — 296 — — — 309 Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes f (9,678) (229) (2,706) 1,174 (10) 1,353 (12,394) 2,298 Final repayments (3,291) (67) (270) (37) (204) (84) (3,765) (188) Disposals c (1,493) (8) (183) (20) (204) (144) (1,880) (172) Write-offs d — — — — (1,609) (1,609) (1,609) (1,609) As at 31 December 2020 e 33,021 680 10,320 2,769 3,172 2,251 46,513 5,700 Wholesale loans As at 1 January 2020 117,541 143 10,432 302 2,359 547 130,332 992 Transfers from Stage 1 to Stage 2 (12,531) (35) 12,531 35 — — — — Transfers from Stage 2 to Stage 1 4,121 40 (4,121) (40) — — — — Transfers to Stage 3 (1,137) (4) (875) (58) 2,012 62 — — Transfers from Stage 3 471 22 247 13 (718) (35) — — Business activity in the year a 27,863 46 2,336 149 634 85 30,833 280 Refinements to models used for calculation b — — — — — — — — Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes 13,828 130 3,811 339 (64) 799 17,575 1,268 Final repayments (28,458) (22) (2,977) (29) (299) (59) (31,734) (110) Disposals c (2,394) — (10) — — — (2,404) — Write-offs d — — — — (333) (333) (333) (333) As at 31 December 2020 e 119,304 320 21,374 711 3,591 1,066 144,269 2,097 Notes a Business activity in the year does not include additional drawdowns on the existing facility which are reported under 'Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes'. b Refinements to models used for calculation include a £309m adjustment which largely represents model remediation for over recovery of debt in UK unsecured lending. Barclays continually review the output of models to determine accuracy of the ECL calculation including review of model monitoring, external benchmarking and experience of model operation over an extended period of time. This ensures that the models used continue to reflect the risks inherent across the businesses. c The £1.9bn disposals reported within Credit cards, unsecured loans and other retail lending portfolio includes £1.7bn sale of motor financing business within the Barclays Partner Finance business and £0.2bn relate to debt sales undertaken during the year. The £2.4bn disposal reported within Wholesale loans include sale of debt securities as part of the Group Treasury operations. d In 2020, gross write-offs amounted to £1,964m (2019: £1,883m) and post write-off recoveries amounted to £35m (2019: £124m). Net write-offs represent gross write-offs less post write-off recoveries and amounted to £1,929m (2019: £1,759m). e Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £180.3bn (December 2019: £149.3bn) and impairment allowance of £165m (December 2019: £24m). This comprises £11m ECL (December 2019: £12m) on £175.7bn Stage 1 assets (December 2019: £148.5bn), £9m (December 2019: £2m) on £4.4bn Stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets (December 2019: £0.8bn) and £145m (December 2019: £10m) on £154m Stage 3 other assets (December 2019: £10m). f Transfers and risk parameter changes has seen an ECL increase which is materially driven by stage migration in response to the macroeconomic scenario updates, partially offset by a net release in ECL of £0.6bn due to a reclassification of £2.0bn gross loans and advances from Stage 2 to Stage 1 in credit cards and unsecured loans. The reclassification followed a review of back-testing of results which indicated that origination probability of default characteristics were unnecessarily moving Stage 1 accounts into Stage 2. Reconciliation of ECL movement to credit impairment charge/(release) for the period £m Home loans 128 Credit cards, unsecured loans and other retail lending 2,597 Wholesale loans 1,438 ECL movement excluding assets derecognised due to disposals and write-offs 4,163 Recoveries and reimbursements a (399) Exchange and other adjustments b 145 Credit impairment charge on loan commitments and financial guarantees 776 Credit impairment charge on other financial assets c 153 Credit impairment charge for the year 4,838 Notes a Recoveries and reimbursements includes £364m for reimbursements expected to be received under the arrangement where Group has entered into financial guarantee contracts which provide credit protection over certain loan assets with third parties. Cash recoveries of previously written off amounts to £35m. b Includes foreign exchange and interest and fees in suspense. c Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £180.3bn (December 2019: £149.3bn) and impairment allowance of £165m (December 2019: £24m). This comprises £11m ECL (December 2019: £12m) on £175.7bn Stage 1 assets (December 2019: £148.5bn), £9m (December 2019: £2m) on £4.4bn Stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets (December 2019: £0.8bn) and £145m (December 2019: £10m) on £154m Stage 3 other assets (December 2019: £10m). Loan commitments and financial guarantees (audited) Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2020 9,542 — 500 — 4 — 10,046 — Net transfers between stages (82) — 78 — 4 — — — Business activity in the year 7,975 — — — — — 7,975 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (5,332) — (27) — (2) — (5,361) — Limit management and final repayments (242) — (35) — (1) — (278) — As at 31 December 2020 11,861 — 516 — 5 — 12,382 — Credit cards, unsecured loans and other retail lending As at 1 January 2020 125,759 35 6,238 71 250 14 132,247 120 Net transfers between stages (5,477) 43 4,725 (40) 752 (3) — — Business activity in the year 5,214 2 158 3 2 1 5,374 6 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 1,298 (22) 1,636 272 (671) 15 2,263 265 Limit management and final repayments (12,423) (3) (640) (1) (104) (4) (13,167) (8) As at 31 December 2020 114,371 55 12,117 305 229 23 126,717 383 Wholesale loans As at 1 January 2020 185,839 62 12,447 99 681 41 198,967 202 Net transfers between stages (28,325) 67 27,319 (72) 1,006 5 — — Business activity in the year 42,917 32 4,708 102 774 2 48,399 136 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 13,637 47 (44) 338 (69) (20) 13,524 365 Limit management and final repayments (50,361) (7) (4,172) (14) (296) (1) (54,829) (22) As at 31 December 2020 163,707 201 40,258 453 2,096 27 206,061 681 |
Management adjustments to models for impairment and Economic uncertainty management adjustments to models for impairment (audited) | Total management adjustments to impairment allowance are presented by product below: Overview of management adjustments to models for impairment allowance (audited) a 2021 2020 Management adjustments to impairment allowances Proportion of total impairment allowances Management adjustments to impairment allowances Proportion of total impairment allowances As at 31 December £m % £m % Home loans 103 21.7 131 24.3 Credit cards, unsecured loans and other retail lending 1,362 32.7 1,234 20.3 Wholesale loans 21 1.3 23 0.8 Total 1,486 23.6 1,388 14.8 Note a Positive values reflect an increase in impairment allowance and negative values reflect a reduction in the impairment allowance. Management adjustments to models are presented by product below: (audited) a Impairment allowance pre management adjustments b Economic uncertainty adjustments (a) Other adjustments (b) Total adjustments (a+b) Total impairment allowance c As at 31 December 2021 £m £m £m £m £m Home loans 372 72 31 103 475 Credit cards, unsecured loans and other retail lending 2,798 1,217 145 1,362 4,160 Wholesale loans d 1,628 403 (382) 21 1,649 Total 4,798 1,692 (206) 1,486 6,284 As at 31 December 2020 £m £m £m £m £m Home loans 407 21 110 131 538 Credit cards, unsecured loans and other retail lending 4,849 1,625 (391) 1,234 6,083 Wholesale loans d 2,755 421 (398) 23 2,778 Total 8,011 2,067 (679) 1,388 9,399 Notes a Positive values reflect an increase in impairment allowance and negative values reflect a reduction in the impairment allowance. b Includes £4.1bn (2020: £6.8bn) of modelled ECL, £0.5bn (2020: £0.9bn) of individually assessed impairments and £0.2bn (2020: £0.3bn) ECL from non-modelled exposures. c Total impairment allowance consist of ECL stock on drawn and undrawn exposure. |
Core macroeconomic variables for each scenario and the respective scenario weights | Baseline average macroeconomic variables used in the calculation of ECL 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP a 6.2 4.9 2.3 1.9 1.7 UK unemployment b 4.8 4.7 4.5 4.3 4.2 UK HPI c 4.7 1.0 1.9 1.9 2.3 UK bank rate 0.1 0.8 1.0 1.0 0.8 US GDP a 5.5 3.9 2.6 2.4 2.4 US unemployment d 5.5 4.2 3.6 3.6 3.6 US HPI e 11.8 4.5 5.2 4.9 5.0 US federal funds rate 0.2 0.3 0.9 1.2 1.3 2020 2021 2022 2023 2024 As at 31 December 2020 % % % % % UK GDP a (10.1) 6.3 3.3 2.6 2.0 UK unemployment b 4.5 6.7 6.4 5.8 5.1 UK HPI c 6.1 2.4 2.3 5.0 2.4 UK bank rate 0.2 0.0 (0.1) 0.0 0.1 US GDP a (4.4) 3.9 3.1 2.9 2.9 US unemployment d 8.4 6.9 5.7 5.6 5.6 US HPI e 2.3 2.8 4.7 4.7 4.7 US federal funds rate 0.5 0.3 0.3 0.3 0.4 Downside 2 average macroeconomic variables used in the calculation of ECL 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP a 6.2 0.2 (4.0) 2.8 4.3 UK unemployment b 4.8 7.2 9.0 7.6 6.3 UK HPI c 4.7 (14.3) (21.8) 11.9 15.2 UK bank rate 0.1 2.2 3.9 3.1 2.2 US GDP a 5.5 (0.8) (3.5) 2.5 3.2 US unemployment d 5.5 6.4 9.1 8.1 6.4 US HPI e 11.8 (6.6) (9.0) 5.9 6.7 US federal funds rate 0.2 2.1 3.4 2.6 2.0 2020 2021 2022 2023 2024 As at 31 December 2020 % % % % % UK GDP a (10.1) (3.9) 6.5 2.6 1.4 UK unemployment b 4.5 8.0 9.3 7.8 6.3 UK HPI c 6.1 (13.6) (10.8) 0.5 1.5 UK bank rate 0.2 (0.2) (0.2) (0.1) (0.1) US GDP a (4.4) (2.4) 3.6 2.1 2.0 US unemployment d 8.4 13.4 11.9 10.1 8.2 US HPI e 2.3 (17.2) (0.7) 0.6 1.3 US federal funds rate 0.5 0.3 0.3 0.3 0.3 Notes a Average Real GDP seasonally adjusted change in year. b Average UK unemployment rate 16-year+. c Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. d Average US civilian unemployment rate 16-year+. e Change in year end US HPI = FHFA house price index, relative to prior year end. Downside 1 average macroeconomic variables used in the calculation of ECL 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP a 6.2 2.8 (0.7) 2.3 2.9 UK unemployment b 4.8 6.2 6.8 6.0 5.3 UK HPI c 4.7 (6.8) (10.5) 6.9 8.6 UK bank rate 0.1 1.6 2.7 2.3 1.6 US GDP a 5.5 1.6 (0.4) 2.4 2.7 US unemployment d 5.5 5.4 6.6 6.1 5.2 US HPI e 11.8 (1.2) (2.1) 4.8 5.2 US federal funds rate 0.2 1.3 2.3 2.1 1.8 2020 2021 2022 2023 2024 As at 31 December 2020 % % % % % UK GDP a (10.1) 0.1 6.6 3.2 1.8 UK unemployment b 4.5 7.3 8.0 6.9 5.8 UK HPI c 6.1 (6.7) (3.5) 1.7 2.0 UK bank rate 0.2 (0.1) (0.1) 0.0 0.0 US GDP a (4.4) 0.4 3.6 2.3 2.2 US unemployment d 8.4 11.0 8.9 6.9 6.1 US HPI e 2.3 (5.9) 1.8 2.6 3.6 US federal funds rate 0.5 0.3 0.3 0.3 0.3 Upside 2 average macroeconomic variables used in the calculation of ECL 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP a 6.2 7.2 4.0 2.7 2.1 UK unemployment b 4.8 4.5 4.1 4.0 4.0 UK HPI c 4.7 8.5 9.0 5.2 4.2 UK bank rate 0.1 0.2 0.5 0.5 0.3 US GDP a 5.5 5.3 4.1 3.5 3.4 US unemployment d 5.5 3.9 3.4 3.3 3.3 US HPI e 11.8 10.6 8.5 7.2 6.6 US federal funds rate 0.2 0.3 0.4 0.7 1.0 2020 2021 2022 2023 2024 As at 31 December 2020 % % % % % UK GDP a (10.1) 12.2 5.3 3.9 2.9 UK unemployment b 4.5 6.2 5.5 4.8 4.4 UK HPI c 6.1 6.6 10.4 10.8 7.3 UK bank rate 0.2 0.1 0.3 0.3 0.5 US GDP a (4.4) 7.1 4.6 4.0 3.5 US unemployment d 8.4 5.5 4.3 4.1 4.1 US HPI e 2.3 8.8 9.1 8.9 7.5 US federal funds rate 0.5 0.3 0.4 0.6 0.9 Notes a Average Real GDP seasonally adjusted change in year. b Average UK unemployment rate 16-year+. c Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. d Average US civilian unemployment rate 16-year+. e Change in year end US HPI = FHFA house price index, relative to prior year end. Upside 1 average macroeconomic variables used in the calculation of ECL 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP a 6.2 6.0 3.1 2.3 1.9 UK unemployment b 4.8 4.6 4.3 4.2 4.1 UK HPI c 4.7 5.0 5.0 3.9 3.3 UK bank rate 0.1 0.6 0.8 0.8 0.5 US GDP a 5.5 4.6 3.4 2.9 2.9 US unemployment d 5.5 4.0 3.5 3.5 3.5 US HPI e 11.8 8.3 7.0 6.0 5.7 US federal funds rate 0.2 0.3 0.6 1.0 1.1 2020 2021 2022 2023 2024 As at 31 December 2020 % % % % % UK GDP a (10.1) 9.3 3.9 3.4 2.5 UK unemployment b 4.5 6.4 6.0 5.2 4.7 UK HPI c 6.1 4.6 6.1 6.1 4.7 UK bank rate 0.2 0.1 0.1 0.3 0.3 US GDP a (4.4) 5.5 4.0 3.7 3.3 US unemployment d 8.4 6.0 4.8 4.6 4.6 US HPI e 2.3 6.8 6.7 6.3 5.6 US federal funds rate 0.5 0.3 0.3 0.5 0.8 Notes a Average Real GDP seasonally adjusted change in year. b Average UK unemployment rate 16-year+. c Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. d Average US civilian unemployment rate 16-year+. e Change in year end US HPI = FHFA house price index, relative to prior year end. Scenario probability weighting (audited) Upside 2 Upside 1 Baseline Downside 1 Downside 2 % % % % % As at 31 December 2021 Scenario probability weighting 20.9 27.2 30.1 14.8 7.0 As at 31 December 2020 Scenario probability weighting 20.2 24.2 24.7 15.5 15.4 Macroeconomic variables (specific bases) a Upside 2 Upside 1 Baseline Downside 1 Downside 2 As at 31 December 2021 % % % % % UK GDP b 21.4 18.3 3.4 (1.6) (1.6) UK unemployment c 4.0 4.1 4.5 7.0 9.2 UK HPI d 35.7 23.8 2.4 (12.7) (29.9) UK bank rate 0.1 0.1 0.7 2.8 4.0 US GDP b 22.8 19.6 3.4 1.5 (1.3) US unemployment c 3.3 3.5 4.1 6.8 9.5 US HPI d 53.3 45.2 6.2 2.2 (5.0) US federal funds rate 0.1 0.1 0.8 2.3 3.5 As at 31 December 2020 UK GDP b 14.2 8.8 0.7 (22.1) (22.1) UK unemployment c 4.0 4.0 5.7 8.4 10.1 UK HPI d 48.2 30.8 3.6 (4.5) (18.3) UK bank rate 0.1 0.1 0.0 0.6 0.6 US GDP b 15.7 12.8 1.6 (10.6) (10.6) US unemployment c 3.8 3.8 6.4 13.0 13.7 US HPI d 42.2 30.9 3.8 (3.7) (15.9) US federal funds rate 0.1 0.1 0.3 1.3 1.3 Macroeconomic variables (5 year averages) a Upside 2 Upside 1 Baseline Downside 1 Downside 2 As at 31 December 2021 % % % % % UK GDP e 4.4 3.9 3.4 2.7 1.8 UK unemployment f 4.3 4.4 4.5 5.8 7.0 UK HPI g 6.3 4.4 2.4 0.3 (2.0) UK bank rate 0.3 0.5 0.7 1.7 2.3 US GDP e 4.4 3.9 3.4 2.4 1.3 US unemployment f 3.9 4.0 4.1 5.7 7.1 US HPI g 8.9 7.7 6.2 3.6 1.4 US federal funds rate 0.5 0.6 0.8 1.5 2.1 As at 31 December 2020 UK GDP e 2.5 1.6 0.7 0.1 (0.9) UK unemployment f 5.0 5.3 5.7 6.5 7.2 UK HPI g 8.2 5.5 3.6 (0.2) (3.6) UK bank rate 0.3 0.2 0.0 0.0 (0.1) US GDP e 2.9 2.4 1.6 0.8 0.1 US unemployment f 5.3 5.7 6.4 8.3 10.4 US HPI g 7.3 5.5 3.8 0.8 (3.0) US federal funds rate 0.5 0.5 0.3 0.3 0.3 Notes a UK GDP = Real GDP growth seasonally adjusted; UK unemployment = UK unemployment rate 16-year+; UK HPI = Halifax All Houses, All Buyers Index; US GDP = Real GDP growth seasonally adjusted; US unemployment = US civilian unemployment rate 16-year+; US HPI = FHFA house price index. 20 quarter period starts from Q121 (2020: Q120). b Maximum growth relative to Q420 (2020: Q419), based on 20 quarter period in Upside scenarios; 5-year yearly average CAGR in Baseline; minimum growth relative to Q420 (2020: Q419), based on 20 quarter period in Downside scenarios. c Lowest quarter in Upside scenarios; 5-year average in Baseline; highest quarter in Downside scenarios. Period based on 20 quarters from Q121 (2020: Q120). d Maximum growth relative to Q420 (2020: Q419), based on 20 quarter period in Upside scenarios; 5-year quarter end CAGR in Baseline; minimum growth relative to Q420 (2020: Q419), based on 20 quarter period in Downside scenarios. e 5-year yearly average CAGR, starting 2020 (2020: 2019). f 5-year average, Period based on 20 quarters from Q121 (2020: Q120). g 5-year quarter end CAGR, starting Q420 (2020: Q419). |
ECL under 100% weighted scenarios for key principal portfolios | ECL under 100% weighted scenarios for modelled portfolios (audited) The table below shows the ECL assuming scenarios have been 100% weighted. Model exposures are allocated to a stage based on the individual scenario rather than through a probability-weighted approach as required for Barclays reported impairment allowances. As a result, it is not possible to back solve to the final reported weighted ECL from the individual scenarios as a balance may be assigned to a different stage dependent on the scenario. Model exposure uses exposure at default (EAD) values and is not directly comparable to gross exposure used in prior disclosures. For Credit cards, unsecured loans and other retail lending, an average EAD measure is used (12-month or lifetime, depending on stage allocation in each scenario). Therefore, the model exposure movement into Stage 2 is higher than the corresponding Stage 1 reduction. All ECL using a model is included, with the exception of Treasury assets (£3.9m of ECL). Non-modelled exposures and management adjustments are excluded. For information on management adjustments, please see pages 135 to 136. Model exposures allocated to Stage 3 do not change in any of the scenarios as the transition criteria relies only on observable evidence of default as at 31 December 2021 and not on macroeconomic scenarios. The Downside 2 scenario represents a severe global recession with substantial falls in both UK and US GDP. Unemployment in UK markets rises towards 9.2% and US markets rises towards 9.5% and there are substantial falls in asset prices including housing. Under the Downside 2 scenario, model exposure moves between stages as the economic environment weakens. This can be seen in the movement of £23.6bn of model exposure into Stage 2 between the Weighted and Downside 2 scenario. ECL increases in Stage 2 predominantly due to unsecured portfolios as economic conditions deteriorate. Scenarios As at 31 December 2021 Weighted Upside 2 Upside 1 Baseline Downside 1 Downside 2 Stage 1 Model exposure (£m) Home loans 137,279 139,117 138,424 137,563 135,544 133,042 Credit cards, unsecured loans and other retail lending 45,503 46,170 45,963 45,751 43,131 38,820 Wholesale loans 174,249 177,453 176,774 175,451 169,814 161,998 Stage 1 Model ECL (£m) Home loans 4 2 2 3 6 14 Credit cards, unsecured loans and other retail lending 324 266 272 279 350 418 Wholesale loans 290 240 262 286 327 350 Stage 1 Coverage (%) Home loans — — — — — — Credit cards, unsecured loans and other retail lending 0.7 0.6 0.6 0.6 0.8 1.1 Wholesale loans 0.2 0.1 0.1 0.2 0.2 0.2 Stage 2 Model exposure (£m) Home loans 22,915 21,076 21,769 22,631 24,649 27,151 Credit cards, unsecured loans and other retail lending 7,200 6,260 6,521 6,795 9,708 14,290 Wholesale loans 32,256 29,052 29,732 31,054 36,692 44,507 Stage 2 Model ECL (£m) Home loans 15 10 11 12 22 47 Credit cards, unsecured loans and other retail lending 1,114 925 988 1,058 1,497 3,295 Wholesale loans 572 431 467 528 851 1,510 Stage 2 Coverage (%) Home loans 0.1 — 0.1 0.1 0.1 0.2 Credit cards, unsecured loans and other retail lending 15.5 14.8 15.2 15.6 15.4 23.1 Wholesale loans 1.8 1.5 1.6 1.7 2.3 3.4 Stage 3 Model exposure (£m) Home loans 1,724 1,724 1,724 1,724 1,724 1,724 Credit cards, unsecured loans and other retail lending 1,922 1,922 1,922 1,922 1,922 1,922 Wholesale loans a 1,811 1,811 1,811 1,811 1,811 1,811 Stage 3 Model ECL (£m) Home loans 303 292 295 299 320 346 Credit cards, unsecured loans and other retail lending 1,255 1,236 1,245 1,255 1,277 1,297 Wholesale loans a 323 321 322 323 326 332 Stage 3 Coverage (%) Home loans 17.6 16.9 17.1 17.3 18.6 20.1 Credit cards, unsecured loans and other retail lending 65.3 64.3 64.8 65.3 66.4 67.5 Wholesale loans a 17.8 17.7 17.8 17.8 18 18.3 Total Model ECL (£m) Home loans 322 304 308 314 348 407 Credit cards, unsecured loans and other retail lending 2,693 2,427 2,505 2,592 3,124 5,010 Wholesale loans a 1,185 992 1,051 1,137 1,504 2,192 Total ECL 4,200 3,723 3,864 4,043 4,976 7,609 Note a Material wholesale loan defaults are individually assessed across different recovery strategies. As a result, ECL of £524m is reported as individually assessed impairments in the table below. Reconciliation to total ECL £m Total model ECL 4,200 ECL from individually assessed impairments 524 ECL from non-modelled and other management adjustments a 1,560 Total ECL 6,284 Note a Includes £1.5bn of post model adjustments, of which £0.2bn is included as part of total model ECL and £0.2bn ECL from non-modelled exposures. Scenarios As at 31 December 2020 Weighted Upside 2 Upside 1 Baseline Downside 1 Downside 2 Stage 1 Model exposure (£m) Home loans 131,422 134,100 133,246 132,414 130,547 128,369 Credit cards, unsecured loans and other retail lending 51,952 53,271 52,932 51,995 50,168 48,717 Wholesale loans 149,099 155,812 154,578 152,141 144,646 131,415 Stage 1 Model ECL (£m) Home loans 6 4 5 6 14 42 Credit cards, unsecured loans and other retail lending 392 316 340 372 415 415 Wholesale loans 262 242 258 249 278 290 Stage 1 Coverage (%) Home loans — — — — — — Credit cards, unsecured loans and other retail lending 0.8 0.6 0.6 0.7 0.8 0.9 Wholesale loans 0.2 0.2 0.2 0.2 0.2 0.2 Stage 2 Model exposure (£m) Home loans 19,180 16,502 17,356 18,188 20,055 22,233 Credit cards, unsecured loans and other retail lending 13,399 10,572 11,579 13,176 16,477 19,322 Wholesale loans 32,677 25,963 27,198 29,635 37,130 50,361 Stage 2 Model ECL (£m) Home loans 37 31 32 33 42 63 Credit cards, unsecured loans and other retail lending 2,207 1,618 1,837 2,138 2,865 3,564 Wholesale loans 1,410 952 1,047 1,223 1,771 2,911 Stage 2 Coverage (%) Home loans 0.2 0.2 0.2 0.2 0.2 0.3 Credit cards, unsecured loans and other retail lending 16.5 15.3 15.9 16.2 17.4 18.4 Wholesale loans 4.3 3.7 3.8 4.1 4.8 5.8 Stage 3 Model exposure (£m) Home loans 1,778 1,778 1,778 1,778 1,778 1,778 Credit cards, unsecured loans and other retail lending 2,585 2,585 2,585 2,585 2,585 2,585 Wholesale loans a 2,211 2,211 2,211 2,211 2,211 2,211 Stage 3 Model ECL (£m) Home loans 307 282 286 290 318 386 Credit cards, unsecured loans and other retail lending 2,003 1,947 1,972 2,001 2,055 2,078 Wholesale loans a 146 128 134 141 157 184 Stage 3 Coverage (%) Home loans 17.3 15.9 16.1 16.3 17.9 21.7 Credit cards, unsecured loans and other retail lending 77.5 75.3 76.3 77.4 79.5 80.4 Wholesale loans a 6.6 5.8 6.1 6.4 7.1 8.3 Total Model ECL (£m) Home loans 350 317 323 329 374 491 Credit cards, unsecured loans and other retail lending 4,602 3,881 4,149 4,511 5,335 6,057 Wholesale loans a 1,818 1,322 1,439 1,613 2,206 3,385 Total ECL 6,770 5,520 5,911 6,453 7,915 9,933 Note a Material wholesale loan defaults are individually assessed across different recovery strategies. As a result, ECL of £902m is reported as individually assessed impairments in the table below. Reconciliation to total ECL a £m Total model ECL 6,770 ECL from individually assessed impairments 902 ECL from non-modelled and other management adjustments 1,727 Total ECL 9,399 Note a Includes £1.4bn of post-model adjustment and £0.3bn ECL from non-model exposures. |
Concentrations of Credit Risk by geography and industry (audited) | Credit risk concentrations by geography (audited) United Americas Europe Asia Africa and Middle East Total £m £m £m £m £m £m As at 31 December 2021 On-balance sheet: Cash and balances at central banks 114,959 38,735 76,846 7,789 245 238,574 Cash collateral and settlement balances 34,249 28,469 21,822 7,260 742 92,542 Loans and advances at amortised cost 270,261 51,599 24,352 11,039 4,200 361,451 Reverse repurchase agreements and other similar secured lending 9 123 401 2,508 186 3,227 Trading portfolio assets 12,926 29,539 15,092 4,943 889 63,389 Financial assets at fair value through the income statement 28,737 95,478 30,083 21,800 9,999 186,097 Derivative financial instruments 78,710 92,010 75,247 14,709 1,896 262,572 Financial assets at fair value through other comprehensive income 7,661 27,391 19,235 6,164 400 60,851 Other assets 949 223 39 1 — 1,212 Total on-balance sheet 548,461 363,567 263,117 76,213 18,557 1,269,915 Off-balance sheet: Contingent liabilities 5,527 10,328 3,957 1,131 403 21,346 Loan commitments 105,844 192,303 40,523 5,104 1,937 345,711 Total off-balance sheet 111,371 202,631 44,480 6,235 2,340 367,057 Total 659,832 566,198 307,597 82,448 20,897 1,636,972 As at 31 December 2020 On-balance sheet: Cash and balances at central banks 66,459 36,063 69,963 17,987 655 191,127 Cash collateral and settlement balances 33,893 27,287 30,121 9,558 508 101,367 Loans and advances at amortised cost 262,231 41,094 24,949 10,728 3,630 342,632 Reverse repurchase agreements and other similar secured lending 10 152 373 8,285 211 9,031 Trading portfolio assets 9,829 31,000 17,107 5,948 946 64,830 Financial assets at fair value through the income statement 34,229 88,327 25,709 14,742 7,524 170,531 Derivative financial instruments 93,430 90,801 101,102 14,532 2,581 302,446 Financial assets at fair value through other comprehensive income 10,672 27,504 28,607 11,006 138 77,927 Other assets 608 185 57 — — 850 Total on-balance sheet 511,361 342,413 297,988 92,786 16,193 1,260,741 Off-balance sheet: Contingent liabilities 5,876 10,122 3,809 1,222 580 21,609 Loan commitments 112,561 175,926 38,836 4,169 1,557 333,049 Total off-balance sheet 118,437 186,048 42,645 5,391 2,137 354,658 Total 629,798 528,461 340,633 98,177 18,330 1,615,399 Credit risk concentrations by industry (audited) Banks Other financial Manu- Const- Govern- Energy Whole- Business Home Cards, Other Total £m £m £m £m £m £m £m £m £m £m £m £m As at 31 December 2021 On-balance sheet: Cash and balances at central banks 52 74 — — 238,448 — — — — — — 238,574 Cash collateral and settlement balances 14,811 61,581 320 79 14,526 390 60 366 — 68 341 92,542 Loans and advances at amortised cost 8,519 32,332 6,701 25,722 30,827 4,345 11,455 19,113 169,205 42,198 11,034 361,451 Reverse repurchase agreements and other similar secured lending 645 2,049 — — 533 — — — — — — 3,227 Trading portfolio assets 2,586 8,817 4,881 1,097 32,574 4,043 1,734 4,716 — — 2,941 63,389 Financial assets at fair value through the income statement 26,074 131,264 771 7,999 13,945 87 181 3,753 1,595 — 428 186,097 Derivative financial instruments 120,666 117,400 4,169 1,898 7,233 3,544 1,172 2,696 — — 3,794 262,572 Financial assets at fair value through other comprehensive income 14,441 4,274 — 662 40,872 — — 455 — — 147 60,851 Other assets 618 450 1 3 8 — 2 104 — 21 5 1,212 Total on-balance sheet 188,412 358,241 16,843 37,460 378,966 12,409 14,604 31,203 170,800 42,287 18,690 1,269,915 Off-balance sheet: Contingent liabilities 1,006 5,356 3,080 1,341 1,682 3,284 1,209 2,518 — 73 1,797 21,346 Loan commitments 1,395 55,071 42,587 16,673 1,362 26,461 16,299 25,682 11,656 121,680 26,845 345,711 Total off-balance sheet 2,401 60,427 45,667 18,014 3,044 29,745 17,508 28,200 11,656 121,753 28,642 367,057 Total 190,813 418,668 62,510 55,474 382,010 42,154 32,112 59,403 182,456 164,040 47,332 1,636,972 As at 31 December 2020 On-balance sheet: Cash and balances at central banks 56 84 — — 190,981 — — 6 — — — 191,127 Cash collateral and settlement balances 17,986 67,305 375 35 13,946 871 30 575 — — 244 101,367 Loans and advances at amortised cost 8,133 22,062 8,142 26,125 28,445 4,722 12,569 19,538 159,647 41,312 11,937 342,632 Reverse repurchase agreements and other similar secured lending 706 7,964 — — 361 — — — — — — 9,031 Trading portfolio assets 2,743 11,464 4,104 516 35,902 3,052 1,883 2,625 — — 2,541 64,830 Financial assets at fair value through the income statement 21,824 131,943 608 5,668 5,530 13 64 3,712 971 — 198 170,531 Derivative financial instruments 155,767 116,526 4,126 2,725 11,649 3,288 1,235 2,361 — 0 4,769 302,446 Financial assets at fair value through other comprehensive income 18,829 5,843 1 425 51,955 — — 733 — — 141 77,927 Other assets 439 224 6 12 1 10 18 98 — 34 8 850 Total on-balance sheet 226,483 363,415 17,362 35,506 338,770 11,956 15,799 29,648 160,618 41,346 19,838 1,260,741 Off-balance sheet: Contingent liabilities 1,150 5,501 3,187 1,260 1,678 3,223 1,005 2,283 — 155 2,167 21,609 Loan commitments 1,813 53,936 39,638 14,002 1,398 25,780 17,165 24,554 12,385 119,807 22,571 333,049 Total off-balance sheet 2,963 59,437 42,825 15,262 3,076 29,003 18,170 26,837 12,385 119,962 24,738 354,658 Total 229,446 422,852 60,187 50,768 341,846 40,959 33,969 56,485 173,003 161,308 44,576 1,615,399 |
Balance Sheet credit quality (audited) | Balance sheet credit quality (audited) PD range Total PD range Total 0.0 to <0.60% 0.60 to <11.35% 11.35 to 100% 0.0 to <0.60% 0.60 to <11.35% 11.35 to 100% £m £m £m £m % % % % As at 31 December 2021 Cash and balances at central banks 238,574 — — 238,574 100 — — 100 Cash collateral and settlement balances 83,257 9,275 10 92,542 90 10 — 100 Loans and advances at amortised cost: Home loans 161,314 5,547 2,344 169,205 96 3 1 100 Credit cards, unsecured loans and other retail lending 25,664 14,293 1,836 41,793 62 34 4 100 Wholesale loans 104,823 40,437 5,193 150,453 70 27 3 100 Total loans and advances at amortised cost 291,801 60,277 9,373 361,451 80 17 3 100 Reverse repurchase agreements and other similar secured lending 3,141 86 — 3,227 97 3 — 100 Trading portfolio assets: Debt securities 44,652 5,735 477 50,864 88 11 1 100 Traded loans 2,172 10,144 209 12,525 17 81 2 100 Total trading portfolio assets 46,824 15,879 686 63,389 74 25 1 100 Financial assets at fair value through the income statement: Loans and advances 19,642 18,979 46 38,667 51 49 — 100 Debt securities 1,389 864 52 2,305 61 37 2 100 Reverse repurchase agreements 108,437 36,047 530 145,014 75 25 — 100 Other financial assets 93 18 — 111 84 16 — 100 Total financial assets at fair value through the income statement 129,561 55,908 628 186,097 70 30 — 100 Derivative financial instruments 246,628 15,678 266 262,572 94 6 — 100 Financial assets at fair value through other comprehensive income 60,845 6 — 60,851 100 — — 100 Other assets 1,155 55 2 1,212 95 5 — 100 Total on-balance sheet 1,101,786 157,164 10,965 1,269,915 87 12 1 100 As at 31 December 2020 Cash and balances at central banks 191,127 — — 191,127 100 — — 100 Cash collateral and settlement balances 90,633 10,725 9 101,367 89 11 — 100 Loans and advances at amortised cost: — — — — Home loans 150,748 6,310 2,589 159,647 94 4 2 100 Credit cards, unsecured loans and other retail lending 15,870 22,427 2,516 40,813 39 55 6 100 Wholesale loans 105,968 31,538 4,666 142,172 75 22 3 100 Total loans and advances at amortised cost 272,586 60,275 9,771 342,632 79 18 3 100 Reverse repurchase agreements and other similar secured lending 9,019 12 — 9,031 100 — — 100 Trading portfolio assets: Debt securities 51,395 4,871 216 56,482 91 9 — 100 Traded loans 704 5,107 2,537 8,348 9 61 30 100 Total trading portfolio assets 52,099 9,978 2,753 64,830 81 15 4 100 Financial assets at fair value through the income statement: Loans and advances 16,467 14,369 43 30,879 53 47 — 100 Debt securities 1,126 521 46 1,693 66 31 3 100 Reverse repurchase agreements 95,376 41,566 674 137,616 70 30 — 100 Other financial assets 330 13 — 343 96 4 — 100 Total financial assets at fair value through the income statement 113,299 56,469 763 170,531 67 33 — 100 Derivative financial instruments 282,617 19,352 477 302,446 94 6 — 100 Financial assets at fair value through other comprehensive income 77,919 8 — 77,927 100 — — 100 Other assets 778 68 4 850 92 8 — 100 Total on-balance sheet 1,090,077 156,887 13,777 1,260,741 87 12 1 100 |
Credit risk profile by internal PD band for loans and advances at amortised cost, contingent liabilities and loan commitments (audited) | Credit risk profile by internal PD grade for loans and advances at amortised cost (audited) Gross carrying amount Allowance for ECL Net exposure Coverage ratio Grading PD range Credit quality description Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total % £m £m £m £m £m £m £m £m £m % As at 31 December 2021 1 - 3 0.0 to <0.05% Strong 95,795 1,554 — 97,349 283 8 — 291 97,058 0.3 4 - 5 0.05 to <0.15% Strong 83,818 3,584 — 87,402 19 3 — 22 87,380 — 6 - 8 0.15 to <0.30% Strong 58,409 9,722 — 68,131 41 12 — 53 68,078 0.1 9 - 11 0.30 to <0.60% Strong 35,794 3,649 — 39,443 129 29 — 158 39,285 0.4 12 - 14 0.60 to <2.15% Satisfactory 30,654 7,090 — 37,744 326 264 — 590 37,154 1.6 15 - 19 2.15 to <10% Satisfactory 7,977 6,645 — 14,622 230 780 — 1,010 13,612 6.9 19 10 to <11.35% Satisfactory 5,572 4,364 — 9,936 99 326 — 425 9,511 4.3 20 - 21 11.35 to <100% Higher Risk 846 4,485 — 5,331 79 593 — 672 4,659 12.6 22 100% Credit Impaired — — 7,235 7,235 — — 2,521 2,521 4,714 34.8 Total 318,865 41,093 7,235 367,193 1,206 2,015 2,521 5,742 361,451 1.6 As at 31 December 2020 1 - 3 0.0 to <0.05% Strong 82,312 3,095 — 85,407 6 35 — 41 85,366 — 4 - 5 0.05 to <0.15% Strong 101,309 9,715 — 111,024 34 25 — 59 110,965 0.1 6 - 8 0.15 to <0.30% Strong 30,697 6,263 — 36,960 47 64 — 111 36,849 0.3 9 - 11 0.30 to <0.60% Strong 34,601 5,093 — 39,694 120 168 — 288 39,406 0.7 12 - 14 0.60 to <2.15% Satisfactory 29,498 8,399 — 37,897 379 593 — 972 36,925 2.6 15 - 19 2.15 to <10% Satisfactory 8,125 9,136 — 17,261 302 1,283 — 1,585 15,676 9.2 19 10 to <11.35% Satisfactory 3,505 4,437 — 7,942 73 195 — 268 7,674 3.4 20 - 21 11.35 to <100% Higher Risk 917 4,868 — 5,785 72 1,201 — 1,273 4,512 22.0 22 100% Credit Impaired — — 8,997 8,997 — — 3,738 3,738 5,259 41.5 Total 290,964 51,006 8,997 350,967 1,033 3,564 3,738 8,335 342,632 2.4 Credit risk profile by internal PD grade for contingent liabilities (audited) a Gross carrying amount Allowance for ECL Net exposure Coverage ratio Grading PD range Credit quality description Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total % £m £m £m £m £m £m £m £m £m % As at 31 December 2021 1 - 3 0.0 to <0.05% Strong 6,389 172 — 6,561 8 1 — 9 6,552 0.1 4 - 5 0.05 to <0.15% Strong 2,929 503 — 3,432 2 2 — 4 3,428 0.1 6 - 8 0.15 to <0.30% Strong 1,996 199 — 2,195 2 2 — 4 2,191 0.2 9 - 11 0.30 to <0.60% Strong 2,794 216 — 3,010 4 1 — 5 3,005 0.2 12 - 14 0.60 to <2.15% Satisfactory 1,990 287 — 2,277 19 8 — 27 2,250 1.2 15 - 19 2.15 to <10% Satisfactory 817 479 — 1,296 5 10 — 15 1,281 1.2 19 10 to <11.35% Satisfactory 607 254 — 861 21 42 — 63 798 7.3 20 - 21 11.35 to <100% Higher Risk 141 1,162 — 1,303 3 77 — 80 1,223 6.1 22 100% Credit Impaired — — 180 180 — — 2 2 178 1.1 Total 17,663 3,272 180 21,115 64 143 2 209 20,906 1.0 As at 31 December 2020 1 - 3 0.0 to <0.05% Strong 6,178 189 — 6,367 1 — — 1 6,366 — 4 - 5 0.05 to <0.15% Strong 2,765 428 — 3,193 3 2 — 5 3,188 0.2 6 - 8 0.15 to <0.30% Strong 1,468 165 — 1,633 3 3 — 6 1,627 0.4 9 - 11 0.30 to <0.60% Strong 3,524 552 — 4,076 5 33 — 38 4,038 0.9 12 - 14 0.60 to <2.15% Satisfactory 2,712 546 — 3,258 8 25 — 33 3,225 1.0 15 - 19 2.15 to <10% Satisfactory 305 398 — 703 7 21 — 28 675 4.0 19 10 to <11.35% Satisfactory 264 423 — 687 17 83 — 100 587 14.6 20 - 21 11.35 to <100% Higher Risk 40 769 — 809 — 61 — 61 748 7.5 22 100% Credit Impaired — — 654 654 — — 10 10 644 1.5 Total 17,256 3,470 654 21,380 44 228 10 282 21,098 1.3 Credit risk profile by internal PD grade for loan commitments (audited) a Gross carrying amount Allowance for ECL Net exposure Coverage ratio Grading PD range Credit quality description Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total % £m £m £m £m £m £m £m £m £m % As at 31 December 2021 1 - 3 0.0 to <0.05% Strong 104,204 3,034 — 107,238 6 4 — 10 107,228 — 4 - 5 0.05 to <0.15% Strong 68,986 5,524 — 74,510 10 5 — 15 74,495 — 6 - 8 0.15 to <0.30% Strong 30,968 2,387 — 33,355 8 6 — 14 33,341 — 9 - 11 0.30 to <0.60% Strong 40,539 2,524 — 43,063 8 6 — 14 43,049 — 12 - 14 0.60 to <2.15% Satisfactory 30,065 4,713 — 34,778 81 30 — 111 34,667 0.3 15 - 19 2.15 to <10% Satisfactory 7,091 3,516 — 10,607 21 37 — 58 10,549 0.5 19 10 to <11.35% Satisfactory 10,407 3,091 — 13,498 8 13 — 21 13,477 0.2 20 - 21 11.35 to <100% Higher Risk 2,219 6,754 — 8,973 11 58 — 69 8,904 0.8 22 100% Credit Impaired — — 1,118 1,118 — — 21 21 1,097 1.9 Total 294,479 31,543 1,118 327,140 153 159 21 333 326,807 0.1 As at 31 December 2020 1 - 3 0.0 to <0.05% Strong 60,525 5,525 — 66,050 4 2 — 6 66,044 — 4 - 5 0.05 to <0.15% Strong 74,860 6,322 — 81,182 12 16 — 28 81,154 — 6 - 8 0.15 to <0.30% Strong 51,255 6,719 — 57,974 17 47 — 64 57,910 0.1 9 - 11 0.30 to <0.60% Strong 43,650 6,950 — 50,600 17 72 — 89 50,511 0.2 12 - 14 0.60 to <2.15% Satisfactory 30,994 9,908 — 40,902 119 131 — 250 40,652 0.6 15 - 19 2.15 to <10% Satisfactory 5,702 4,971 — 10,673 27 113 — 140 10,533 1.3 19 10 to <11.35% Satisfactory 4,886 5,129 — 10,015 11 25 — 36 9,979 0.4 20 - 21 11.35 to <100% Higher Risk 811 3,897 — 4,708 5 124 — 129 4,579 2.7 22 100% Credit Impaired — — 1,676 1,676 — — 40 40 1,636 2.4 Total 272,683 49,421 1,676 323,780 212 530 40 782 322,998 0.2 Note a Excludes loan commitments and financial guarantees of £18.8bn (2020: £9.5bn) carried at fair value. |
Derivative assets (audited) | Derivative assets (audited) 2021 2020 Balance sheet Counterparty Net Balance sheet Counterparty Net As at 31 December £m £m £m £m £m £m Foreign exchange 76,975 60,525 16,450 85,115 68,108 17,007 Interest rate 125,905 92,669 33,236 172,334 128,072 44,262 Credit derivatives 5,682 4,525 1,157 4,605 3,584 1,021 Equity and stock index 51,723 43,084 8,639 38,972 32,183 6,789 Commodity derivatives 2,287 1,717 570 1,420 1,133 287 Total derivative assets 262,572 202,520 60,052 302,446 233,080 69,366 Cash collateral held 34,598 43,291 Net exposure less collateral 25,454 26,075 |
Management Value at Risk (audited) | Management VaR (95%, one day) (audited) 2021 2020 Average High a Low a Average High a Low a For the year ended 31 December £m £m £m £m £m £m Credit risk 14 30 7 20 38 10 Interest rate risk 7 15 4 10 17 6 Equity risk 9 29 4 13 35 6 Basis risk 6 10 3 10 16 7 Spread risk 4 6 3 5 9 3 Foreign exchange risk 4 16 1 5 7 2 Commodity risk — 1 — 1 1 — Inflation risk 3 5 2 2 3 1 Diversification effect a (28) n/a n/a (34) n/a n/a Total management VaR 19 36 6 32 57 18 Note a Diversification effects recognise that forecast losses from different assets or businesses are unlikely to occur concurrently, hence the expected aggregate loss is lower than the sum of the expected losses from each area. Historical correlations between losses are taken into account in making these assessments. The high and low VaR figures reported for each category did not necessarily occur on the same day as the high and low VaR reported as a whole. Consequently, a diversification effect balance for the high and low VaR figures would not be meaningful and is therefore omitted from the above table. |
Deposit funding (audited) | Deposit funding (audited) 2021 2020 Funding of loans and advances Loans and advances at amortised cost Deposits at amortised cost Loan: deposit ratio a Loan: deposit As at 31 December 2021 £bn £bn % % Barclays UK 222 260 85 % 89 % Barclays International 134 259 52 % 51 % Head Office 5 — Barclays Group 361 519 70 % 71 % Note a The loan: deposit ratio is calculated as loans and advances at amortised cost divided by deposits at amortised cost. |
Contractual maturity of financial assets and liabilities (audited) | Contractual maturity of financial assets and liabilities (audited) Restated a As at 31 December 2021 On Not more Over three Over six Over nine Over one Over two Over three Over five Over ten Total £m £m £m £m £m £m £m £m £m £m £m Assets Cash and balances at central banks 238,369 205 — — — — — — — — 238,574 Cash collateral and settlement balances 2,807 89,735 — — — — — — — — 92,542 Loans and advances at amortised cost 19,749 8,670 8,879 5,291 10,192 23,716 26,037 47,614 39,822 171,481 361,451 Reverse repurchase agreements and other similar secured lending 58 2,984 — — — 184 — — — 1 3,227 Trading portfolio assets 147,035 — — — — — — — — — 147,035 Financial assets at fair value through the income statement 24,257 127,085 9,281 7,042 3,451 5,889 5,394 2,590 2,564 4,419 191,972 Derivative financial instruments 261,678 58 48 — — 82 145 537 15 9 262,572 Financial assets at fair value through other comprehensive income — 4,280 1,488 1,245 1,419 3,834 8,205 13,188 18,226 9,868 61,753 Other financial assets 707 474 26 2 — 1 — — 1 2 1,213 Total financial assets 694,660 233,491 19,722 13,580 15,062 33,706 39,781 63,929 60,628 185,780 1,360,339 Other assets 23,946 Total assets 1,384,285 Liabilities Deposits at amortised cost 454,961 40,755 13,524 2,994 3,724 2,025 433 241 545 231 519,433 Cash collateral and settlement balances 2,983 76,388 — — — — — — — — 79,371 Repurchase agreements and other similar secured borrowing 20 6,621 — — — 2,195 8,925 10,504 — 87 28,352 Debt securities in issue — 24,399 12,606 5,845 3,254 9,792 8,957 12,948 12,218 8,848 98,867 Subordinated liabilities — 1,007 — 74 1,218 27 1,063 1,885 5,603 1,882 12,759 Trading portfolio liabilities 54,169 — — — — — — — — — 54,169 Financial liabilities designated at fair value 21,339 157,900 16,857 10,268 3,588 6,540 6,114 7,734 7,366 13,254 250,960 Derivative financial instruments 255,747 4 22 18 5 124 177 302 122 362 256,883 Other financial liabilities 184 4,331 43 42 40 691 145 266 420 139 6,301 Total financial liabilities 789,403 311,405 43,052 19,241 11,829 21,394 25,814 33,880 26,274 24,803 1,307,095 Other liabilities 7,149 Total liabilities 1,314,244 Cumulative liquidity gap (94,743) (172,657) (195,987) (201,648) (198,415) (186,103) (172,136) (142,087) (107,733) 53,244 70,041 Note a 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. The contractual maturity profile of financial liabilities designated at fair value has been restated to reflect the impact of the Over-issuance of Securities. Securities issued by BBPLC in excess of the maximum aggregate offering price registered under BBPLC's 2019 F-3 with a value of £6,997m have been classified as "on demand". Contractual maturity of financial assets and liabilities (audited) As at 31 December 2020 On Not more Over three Over six Over nine Over one Over two Over three Over five Over ten Total £m £m £m £m £m £m £m £m £m £m £m Assets Cash and balances at central banks 190,347 182 598 — — — — — — — 191,127 Cash collateral and settlement balances 1,177 100,190 — — — — — — — — 101,367 Loans and advances at amortised cost 14,098 11,970 8,388 4,956 5,234 25,392 22,133 36,286 47,944 166,231 342,632 Reverse repurchase agreements and other similar secured lending 150 8,698 — — — — 183 — — — 9,031 Trading portfolio assets 127,950 — — — — — — — — — 127,950 Financial assets at fair value through the income statement 17,377 123,044 7,548 6,960 4,151 4,911 1,346 2,431 2,345 5,038 175,151 Derivative financial instruments 301,880 23 — — — 70 55 310 87 21 302,446 Financial assets at fair value through other comprehensive income — 9,655 3,517 1,393 948 6,469 5,566 17,552 24,450 9,138 78,688 Other financial assets 357 451 19 22 — 1 — — — — 850 Total financial assets 653,336 254,213 20,070 13,331 10,333 36,843 29,283 56,579 74,826 180,428 1,329,242 Other assets 20,272 Total assets 1,349,514 Liabilities Deposits at amortised cost 410,894 41,468 15,886 5,073 3,082 2,264 625 601 764 379 481,036 Cash collateral and settlement balances 1,900 83,523 — — — — — — — — 85,423 Repurchase agreements and other similar secured borrowing 4 3,276 — — — 1,400 2,329 7,073 — 92 14,174 Debt securities in issue — 16,344 4,048 5,100 1,937 5,780 10,402 13,608 12,721 5,856 75,796 Subordinated liabilities — 1,589 3,209 294 — 2,192 14 989 6,915 1,139 16,341 Trading portfolio liabilities 47,405 — — — — — — — — — 47,405 Financial liabilities designated at fair value 15,555 172,153 8,677 5,067 2,938 8,594 6,939 8,580 8,344 12,918 249,765 Derivative financial instruments 299,795 1 49 — — 79 67 185 196 403 300,775 Other financial liabilities 101 2,915 49 46 45 738 156 273 436 210 4,969 Total financial liabilities 775,654 321,269 31,918 15,580 8,002 21,047 20,532 31,309 29,376 20,997 1,275,684 Other liabilities 6,948 Total liabilities 1,282,632 Cumulative liquidity gap (122,318) (189,374) (201,222) (203,471) (201,140) (185,344) (176,593) (151,323) (105,873) 53,558 66,882 |
Contractual maturity of financial liabilities - undiscounted (audited) | Contractual maturity of financial liabilities - undiscounted (audited) Restated a On Not more Over three Over six Over one Over three Over five Over ten Total £m £m £m £m £m £m £m £m £m As at 31 December 2021 Deposits at amortised cost 454,961 40,755 13,524 6,718 2,461 239 559 261 519,478 Cash collateral and settlement balances 2,983 76,388 — — — — — — 79,371 Repurchase agreements and other similar secured borrowing 20 6,621 — — 11,356 10,885 — 146 29,028 Debt securities in issue — 24,450 12,625 9,075 19,225 14,060 14,147 13,690 107,272 Subordinated liabilities — 1,063 — 1,379 1,213 2,316 6,627 2,867 15,465 Trading portfolio liabilities 54,169 — — — — — — — 54,169 Financial liabilities designated at fair value 21,339 158,070 16,887 13,946 12,944 8,086 7,544 21,638 260,454 Derivative financial instruments 255,747 5 22 24 305 316 134 449 257,002 Other financial liabilities 184 4,344 57 111 932 327 502 162 6,619 Total financial liabilities 789,403 311,696 43,115 31,253 48,436 36,229 29,513 39,213 1,328,858 As at 31 December 2020 Deposits at amortised cost 410,894 41,468 15,886 8,156 2,893 599 768 385 481,049 Cash collateral and settlement balances 1,900 83,523 — — — — — — 85,423 Repurchase agreements and other similar secured borrowing 4 3,276 — — 3,729 7,089 — 154 14,252 Debt securities in issue — 16,368 4,058 7,061 16,684 14,715 14,882 9,852 83,620 Subordinated liabilities — 1,597 3,328 311 2,498 1,152 8,578 1,587 19,051 Trading portfolio liabilities 47,405 — — — — — — — 47,405 Financial liabilities designated at fair value 15,555 172,186 8,683 8,007 15,604 8,586 8,369 20,835 257,825 Derivative financial instruments 299,795 1 49 — 147 187 204 443 300,826 Other financial liabilities 101 2,929 62 116 981 338 557 248 5,332 Total financial liabilities 775,654 321,348 32,066 23,651 42,536 32,666 33,358 33,504 1,294,783 Note a 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. The contractual maturity profile of financial liabilities designated at fair value has been restated to reflect the impact of the Over-issuance of Securities. Securities issued by BBPLC in excess of the maximum aggregate offering price registered under BBPLC's 2019 F-3 with a value of £6,997m have been classified as "on demand". |
Maturity analysis of off-balance sheet commitments received (audited) | Maturity analysis of off-balance sheet commitments received (audited) On Not more than three months Over three months but not more than six months Over six months but not more than nine months Over nine months but not more than one year Over one year but not more than two years Over two years but not more than three years Over three years but not more than five years Over five years but not more than ten years Over ten years Total £m £m £m £m £m £m £m £m £m £m £m As at 31 December 2021 Guarantees, letters of credit and credit insurance 25,613 31 21 10 12 4 12 83 65 19 25,870 Other commitments received 455 — — — — — — — — — 455 Total off-balance sheet commitments received 26,068 31 21 10 12 4 12 83 65 19 26,325 As at 31 December 2020 Guarantees, letters of credit and credit insurance 26,368 86 37 68 8 18 14 47 40 25 26,711 Other commitments received 92 — — — — — — — — — 92 Total off-balance sheet commitments received 26,460 86 37 68 8 18 14 47 40 25 26,803 |
Maturity analysis of off-balance sheet commitments given (audited) | Maturity analysis of off-balance sheet commitments given (audited) On Not more than three months Over three months but not more than six months Over six months but not more than nine months Over nine months but not more than one year Over one year but not more than two years Over two years but not more than three years Over three years but not more than five years Over five years but not more than ten years Over ten years Total £m £m £m £m £m £m £m £m £m £m £m As at 31 December 2021 Contingent liabilities 21,207 135 4 — — — — — — — 21,346 Documentary credits and other short-term trade related transactions 1,582 2 — — — — — — — — 1,584 Standby facilities, credit lines and other commitments 344,055 — — — — 72 — — — — 344,127 Total off-balance sheet commitments given 366,844 137 4 — — 72 — — — — 367,057 As at 31 December 2020 Contingent liabilities 21,307 213 57 6 1 25 — — — — 21,609 Documentary credits and other short-term trade related transactions 1,084 1 1 — — — — — — — 1,086 Standby facilities, credit lines and other commitments 330,499 564 93 123 95 160 199 202 21 7 331,963 Total off-balance sheet commitments given 352,890 778 151 129 96 185 199 202 21 7 354,658 |
Captial resources (audited) | Capital ratios a,b,c Restated d As at 31 December 2021 2020 CET1 15.1 % 15.1 % Tier 1 (T1) 19.1 % 19.0 % Total regulatory capital 22.2 % 22.1 % Capital resources (audited) Restated d 2021 2020 As at 31 December £m £m Total equity excluding non-controlling interests per the balance sheet 69,052 65,797 Less: other equity instruments (recognised as AT1 capital) (12,259) (11,172) Adjustment to retained earnings for foreseeable ordinary share dividends (666) (174) Adjustment to retained earnings for foreseeable repurchase of shares — — Adjustment to retained earnings for foreseeable other equity coupons (32) (30) Other regulatory adjustments and deductions Additional value adjustments (PVA) (1,585) (1,146) Goodwill and intangible assets (6,804) (6,914) Deferred tax assets that rely on future profitability excluding temporary differences (1,028) (595) Fair value reserves related to gains or losses on cash flow hedges 852 (1,575) Gains or losses on liabilities at fair value resulting from own credit 892 870 Defined benefit pension fund assets (2,619) (1,326) Direct and indirect holdings by an institution of own CET1 instruments (50) (50) Adjustment under IFRS 9 transitional arrangements 1,229 2,556 Other regulatory adjustments 345 55 CET1 capital 47,327 46,296 AT1 capital Capital instruments and related share premium accounts 12,259 11,172 Qualifying AT1 capital (including minority interests) issued by subsidiaries 637 646 Other regulatory adjustments and deductions (80) (80) AT1 capital 12,816 11,738 T1 capital 60,143 58,034 T2 capital Capital instruments and related share premium accounts 8,713 7,836 Qualifying T2 capital (including minority interests) issued by subsidiaries 1,113 1,893 Credit risk adjustments (excess of impairment over expected losses) 73 57 Other regulatory adjustments and deductions (160) (160) Total regulatory capital 69,882 67,660 Total RWAs 314,136 306,203 Notes a CET1, T1 and T2 capital, and RWAs are calculated applying the transitional arrangements of the CRR as amended by CRR II. This includes IFRS 9 transitional arrangements and the grandfathering of CRR and CRR II non-compliant capital instruments. b The fully loaded CET1 ratio, as is relevant for assessing against the conversion trigger in Barclays PLC AT1 securities, was 14.7%, with £46.1bn of CET1 capital and £313.9bn of RWAs calculated without applying the transitional arrangements of the CRR as amended by CRR II. c The Group’s CET1 ratio, as is relevant for assessing against the conversion trigger in Barclays Bank PLC 7.625% Contingent Capital Notes, was 15.1%. For this calculation CET1 capital and RWAs are calculated applying the transitional arrangements under the CRR as amended by CRR II, including the IFRS 9 transitional arrangements. The benefit of the Financial Services Authority (FSA) October 2012 interpretation of the transitional provisions, relating to the implementation of CRD IV, expired in December 2017. d 2021 capital metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Impact of over-issuance of securities in the US on page 173 for further details. |
Functional currency of the operation (audited) | Functional currency of operations (audited) Foreign currency net investments Borrowings which hedge the net investments Derivatives which hedge the net investments Structural currency exposures pre-economic hedges Economic hedges Remaining structural currency exposures £m £m £m £m £m £m As at 31 December 2021 USD 25,958 (7,707) (2,356) 15,895 (7,389) 8,506 EUR 8,453 (3,408) (3) 5,042 (268) 4,774 JPY 614 (97) — 517 — 517 Other currencies 2,448 — (64) 2,384 — 2,384 Total 37,473 (11,212) (2,423) 23,838 (7,657) 16,181 As at 31 December 2020 USD 24,204 (7,666) (764) 15,774 (6,193) 9,581 EUR 5,275 (952) (3) 4,320 (286) 4,034 JPY 582 — — 582 — 582 Other currencies 2,020 (42) (24) 1,954 — 1,954 Total 32,081 (8,660) (791) 22,630 (6,479) 16,151 |
Sensitivity analysis to changes in risk exposures that arise from contracts within scope of IFRS 17 | Net interest income sensitivity (AEaR) by business unit (audited) Barclays UK Barclays International Head Office Total As at 31 December £m £m £m £m 2021 +25bps (2) 68 5 71 -25bps (54) (99) (5) (158) 2020 +25bps 10 86 4 100 -25bps (141) (263) (4) (408) Note • +25bps AEaR in Barclays International reflects refined modelling of pricing assumptions for 2021. Based on these assumptions, the 2020 scenario would have shown an AEaR of £121m. • The Group’s customer banking book hedging activity is risk reducing from an NII sensitivity perspective. The hedges in place remove interest rate risk and smooth income over the medium term. The NII sensitivity for the Group at 31 December 2021 without hedging in place for +/-25bp rate shocks would be £218m/£305m respectively. Net interest income sensitivity (AEaR) by currency (audited) As at 31 December 2021 2020 +25 basis points -25 basis points +25 basis points -25 basis points £m £m £m £m GBP 14 (85) 48 (313) USD 58 (62) 48 (63) EUR 5 (15) 10 (34) Other currencies (6) 4 (6) 2 Total 71 (158) 100 (408) Note +25bps AEaR in Barclays International reflects refined modelling of pricing assumptions for 2021. Based on these assumptions, the 2020 scenario would have shown a GBP AEaR of £83m. Equity sensitivity measures the overall impact of a +/-25bps movement in interest rates on retained earnings, FVOCI, cash flow hedge reserves and pensions. For non-NII items a DV01 metric is used, which is an indicator of the shift in value for a 1bp movement in the yield curve. Analysis of equity sensitivity (audited) As at 31 December 2021 2020 Restated a +25 basis -25 basis +25 basis -25 basis £m £m £m £m Net interest income 71 (158) 100 (408) Taxation effects on the above (15) 33 (27) 110 Effect on profit for the year 56 (125) 73 (298) As percentage of net profit after tax 0.8 % (1.8 %) 3.0 % (12.1 %) Effect on profit for the year (per above) 56 (125) 73 (298) Fair value through other comprehensive income reserve (479) 408 (437) 453 Cash flow hedge reserve (859) 859 (570) 570 Taxation effects on the above 361 (342) 272 (276) Effect on equity (921) 800 (662) 449 As percentage of equity (1.3 %) 1.2 % (1.0 %) 0.7 % Note +25bps AEaR in Barclays International reflects refined modelling of pricing assumptions for 2021. Based on these assumptions, the 2020 scenario would have shown an effect on equity of £(636)m. a 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Segmental reporting (Tables)
Segmental reporting (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of operating segments [abstract] | |
Analysis of results by business | The below table also includes Head Office which comprises head office and legacy businesses, as well as the FTE employed by Barclays Execution Services. Analysis of results by business Barclays UK Restated a Barclays International Head Office Restated a Group Results £m £m £m £m For the year ended 31 December 2021 Total income 6,536 15,665 (261) 21,940 Credit impairment releases 365 288 — 653 Net operating income/(expenses) 6,901 15,953 (261) 22,593 Operating costs (4,357) (9,076) (659) (14,092) UK bank levy (36) (134) — (170) Litigation and conduct (37) (345) (15) (397) Total operating expenses (4,430) (9,555) (674) (14,659) Other net income b — 40 220 260 Profit/(loss) before tax 2,471 6,438 (715) 8,194 Total assets (£bn) 321.2 1,044.1 19.0 1,384.3 Number of employees (full time equivalent) c 7,100 10,400 64,100 81,600 Average number of employees (full time equivalent) 82,900 Notes a 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. b Other net income represents the share of post-tax results of associates and joint ventures, profit on disposal of subsidiaries, associates and joint ventures, and gains on acquisitions. c Barclays UK has transformed its business this year and consolidated all Customer Care employees, who directly serve customers, into Barclays Execution Services, within the Head Office segment, to improve customer service and experience. Costs are recharged, while FTE's are reported within Head Office, as at 31 December 2021 10,700 FTE were impacted by the move from Barclays UK to Head Office, prior years have not been restated. Barclays UK b Barclays International b Head Office Group results £m £m £m £m For the year ended 31 December 2020 Total income 6,347 15,921 (502) 21,766 Credit impairment charges (1,467) (3,280) (91) (4,838) Net operating income/(expenses) 4,880 12,641 (593) 16,928 Operating costs (4,270) (8,765) (399) (13,434) UK bank levy (50) (240) (9) (299) Litigation and conduct (32) (48) (73) (153) Total operating expenses (4,352) (9,053) (481) (13,886) Other net income/(expenses) a 18 28 (23) 23 Profit/(loss) before tax 546 3,616 (1,097) 3,065 Total assets (£bn) 289.1 1,041.8 18.6 1,349.5 Number of employees (full time equivalent) 21,300 10,800 50,900 83,000 Average number of employees (full time equivalent) 81,800 Notes a Other net income/(expenses) represents the share of post-tax results of associates and joint ventures, profit (or loss) on disposal of subsidiaries, associates and joint ventures, and gains on acquisitions. b On 1 April 2020, assets of £2.2bn relating to the Barclays Partner Finance business were moved from Barclays International to Barclays UK, with net operating income of £19m and loss before tax of £5m subsequently recognised in Barclays UK for the rest of 2020. The 2019 comparative figures have not been restated. Barclays UK Barclays International Head Group results £m £m £m £m For the year ended 31 December 2019 Total income 7,353 14,675 (396) 21,632 Credit impairment charges (712) (1,173) (27) (1,912) Net operating income/(expenses) 6,641 13,502 (423) 19,720 Operating costs (3,996) (9,163) (200) (13,359) UK bank levy (41) (174) (11) (226) Litigation and conduct (1,582) (116) (151) (1,849) Total operating expenses (5,619) (9,453) (362) (15,434) Other net income a — 69 2 71 Profit/(loss) before tax 1,022 4,118 (783) 4,357 Total assets (£bn) 257.8 861.4 21.0 1,140.2 Number of employees (full time equivalent) 21,400 11,200 48,200 80,800 Average number of employees (full time equivalent) 82,700 Note a Other net income represents the share of post-tax results of associates and joint ventures, profit (or loss) on disposal of subsidiaries, associates and joint ventures, and gains on acquisitions. |
Income by geographic region | Income by geographic region a 2021 2020 2019 For the year ended 31 December £m £m £m United Kingdom 11,256 11,211 11,809 Europe 2,372 2,059 1,754 Americas 7,199 7,425 7,064 Africa and Middle East 45 36 59 Asia 1,068 1,035 946 Total 21,940 21,766 21,632 . Income from individual countries which represent more than 5% of total income a 2021 2020 2019 For the year ended 31 December £m £m £m United Kingdom 11,256 11,211 11,809 United States 7,048 7,318 6,939 Note |
Net interest income (Table)
Net interest income (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Analysis of income and expense [abstract] | |
Net interest income | 2021 2020 2019 £m £m £m Cash and balances at central banks 184 275 1,091 Loans and advances at amortised cost 9,540 10,180 12,450 Fair value through other comprehensive income 550 776 1,032 Negative interest on liabilities 248 68 13 Other 718 593 870 Interest and similar income 11,240 11,892 15,456 Deposits at amortised cost (561) (1,030) (2,449) Debt securities in issue a (1,340) (1,360) (1,906) Subordinated liabilities (507) (670) (1,068) Negative interest on assets (374) (344) (278) Other (385) (366) (348) Interest and similar expense (3,167) (3,770) (6,049) Net interest income 8,073 8,122 9,407 Note a Barclays has amended the presentation of the premium paid for purchased financial guarantees which are embedded in notes it issues directly to the market. From 2020 onwards, the full note coupon is presented as interest expense within net interest income. The financial guarantee element of the coupon had previously been recognised in net investment income. The comparatives of £25m in 2019 have not been restated. |
Net fee and commission income (
Net fee and commission income (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Fee and commission income (expense) [abstract] | |
Total fees in scope of IFRS 15 Revenues from Contracts with Customers | Fee and commission income is disaggregated below by fee types that reflect the nature of the services offered across the Group and operating segments, in accordance with IFRS 15. The below table includes a total for fees in scope of IFRS 15. Refer to Note 2 for more detailed information about operating segments. 2021 Barclays UK Barclays International Head Office Total £m £m £m £m Fee type Transactional 871 2,572 — 3,443 Advisory 172 1,096 1 1,269 Brokerage and execution 228 1,135 — 1,363 Underwriting and syndication — 3,425 — 3,425 Other 74 182 3 259 Total revenue from contracts with customers 1,345 8,410 4 9,759 Other non-contract fee income — 121 — 121 Fee and commission income 1,345 8,531 4 9,880 Fee and commission expense (218) (1,983) (5) (2,206) Net fee and commission income 1,127 6,548 (1) 7,674 2020 Barclays UK Barclays International Head Office Total £m £m £m £m Fee type Transactional 810 2,353 — 3,163 Advisory 159 693 2 854 Brokerage and execution 212 1,173 — 1,385 Underwriting and syndication — 2,867 — 2,867 Other 71 173 9 253 Total revenue from contracts with customers 1,252 7,259 11 8,522 Other non-contract fee income — 119 — 119 Fee and commission income 1,252 7,378 11 8,641 Fee and commission expense (308) (1,754) (8) (2,070) Net fee and commission income 944 5,624 3 6,571 2019 Barclays UK Barclays International Head Office Total £m £m £m £m Fee type Transactional 1,074 2,809 — 3,883 Advisory 177 903 — 1,080 Brokerage and execution 208 1,131 — 1,339 Underwriting and syndication — 2,358 — 2,358 Other 92 242 12 346 Total revenue from contracts with customers 1,551 7,443 12 9,006 Other non-contract fee income — 116 — 116 Fee and commission income 1,551 7,559 12 9,122 Fee and commission expense (365) (1,990) (7) (2,362) Net fee and commission income 1,186 5,569 5 6,760 |
Net trading income (Table)
Net trading income (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Trading income (expense) [abstract] | |
Net trading income | 2021 2020 2019 £m £m £m Net gains on financial instruments held for trading 3,992 5,342 2,941 Net gains on financial instruments designated at fair value 692 700 256 Net gains on financial instruments mandatorily at fair value 1,110 987 1,038 Net trading income 5,794 7,029 4,235 |
Net investment income (Table)
Net investment income (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Gains (losses) on financial instruments [abstract] | |
Net investment income | 2021 2020 2019 £m £m £m Net gains/(losses) from financial instruments mandatorily at fair value 73 (50) 510 Net gains from disposal of debt instruments at fair value through other comprehensive income 305 295 502 Net gains/(losses) from disposal of financial assets and liabilities measured at amortised cost a 114 (61) 257 Dividend income 20 37 76 Net (losses)/gains on other investments b (201) (208) (214) Net investment income 311 13 1,131 Notes a Included within the 2021 balance are gains of £83m relating to the sale of loans and advances at amortised cost. Included within the 2020 balance are losses of £115m relating to partial redemption of contingent capital notes. b Barclays has amended the presentation of the premium paid for purchased financial guarantees which are embedded in notes it issues directly to the market. From 2020 onwards, the full note coupon is presented as interest expense within net interest income. The financial guarantee element of the coupon had previously been recognised in net investment income. The comparative of £25m in 2019 has not been restated. |
Credit impairment charges_(re_2
Credit impairment charges/(release) (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of impairment loss and reversal of impairment loss [abstract] | |
Credit impairment charges and other provisions | 2021 2020 2019 Impairment charges Recoveries and reimburse-ments a Total Impairment charges Recoveries and reimburse-ments a Total Impairment charges Recoveries and reimburse-ments a Total £m £m £m £m £m £m £m £m £m Loans and advances (361) 240 (121) 4,308 (399) 3,909 1,957 (124) 1,833 Provision for undrawn contractually committed facilities and guarantees provided (514) — (514) 776 — 776 71 — 71 Loans impairment (875) 240 (635) 5,084 (399) 4,685 2,028 (124) 1,904 Cash collateral and settlement balances (4) — (4) 2 — 2 1 — 1 Financial assets at fair value through other comprehensive income (8) — (8) 2 — 2 1 — 1 Other financial assets measured at cost (6) — (6) 149 — 149 6 — 6 Credit impairment (releases)/charges (893) 240 (653) 5,237 (399) 4,838 2,036 (124) 1,912 Note a Recoveries and reimbursements includes a net reduction in amounts recoverable from financial guarantee contracts held with third parties of £306m (2020 gain: £364m) and cash recoveries of previously written off amounts of £66m (2020: £35m) . |
Operating expenses (Table)
Operating expenses (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Expenses by nature [abstract] | |
Operating expenses | Restated a 2021 2020 2019 £m £m £m Infrastructure costs Property and equipment 1,506 1,556 1,409 Depreciation and amortisation 1,673 1,539 1,487 Lease payments 32 34 41 Impairment of property, equipment and intangible assets 403 194 33 Total infrastructure costs 3,614 3,323 2,970 Administration and general expenses Consultancy, legal and professional fees 610 567 590 Marketing and advertising 399 330 425 UK bank levy 170 299 226 Other administration and general expenses 958 1,117 1,059 Total administration and general expenses 2,137 2,313 2,300 Staff costs 8,511 8,097 8,315 Provisions for litigation and conduct 397 153 1,849 Operating expenses b 14,659 13,886 15,434 Notes a 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. b Operating expenses includes £648m relating to structural cost actions of which £266m pertains to impairment of property taken as part of real estate review. |
Tax (Tables)
Tax (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Major components of tax expense (income) [abstract] | |
Tax charge | Restated a 2021 2020 2019 £m £m £m Current tax charge/(credit) Current year 1,417 1,255 1,037 Adjustments in respect of prior years 317 31 (45) 1,734 1,286 992 Deferred tax (credit)/charge Current year (352) (830) 86 Adjustments in respect of prior years (244) 148 (75) (596) (682) 11 Tax charge 1,138 604 1,003 Note a 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Reconciliation between the actual tax charge and the corporate tax rate | The table below shows the reconciliation between the actual tax charge and the tax charge that would result from applying the standard UK corporation tax rate to the Group’s profit before tax. Restated a 2021 Restated a 2021 2020 2020 2019 2019 £m % £m % £m % Profit before tax 8,194 3,065 4,357 Tax charge based on the standard UK corporation tax rate of 19% (2020: 19%; 2019: 19% ) 1,557 19.0 % 582 19.0 % 828 19.0 % Impact of profits/losses earned in territories with different statutory rates to the UK (weighted average tax rate is 22.4% (2020: 25.1%; 2019: 24.2% )) 277 3.4 % 188 6.1 % 227 5.2 % Recurring items: Non-creditable taxes including withholding taxes 134 1.6 % 109 3.5 % 150 3.4 % Banking surcharge and other items 83 1.0 % 6 0.2 % 57 1.3 % Non-deductible expenses 80 1.0 % 48 1.6 % 45 1.0 % Adjustments in respect of prior years 73 0.9 % 179 5.8 % (120) (2.7 %) Impact of UK bank levy being non-deductible 32 0.4 % 57 1.9 % 43 1.0 % Impact of Barclays Bank PLC's overseas branches being taxed both locally and in the UK 25 0.3 % 25 0.8 % 15 0.3 % Tax adjustments in respect of share-based payments (5) (0.1 %) 26 0.8 % (6) (0.1 %) Changes in recognition of deferred tax and effect of unrecognised tax losses (140) (1.7 %) (123) (4.0 %) (82) (1.9 %) Tax relief on payments made under AT1 instruments (149) (1.8 %) (165) (5.4 %) (157) (3.6 %) Non-taxable gains and income (367) (4.5 %) (208) (6.8 %) (260) (6.0 %) Non-recurring items: Remeasurement of UK deferred tax assets due to tax rate changes (462) (5.6 %) (118) (3.8 %) — — Non-deductible provisions for UK customer redress — — (7) (0.2 %) 263 6.1 % Non-deductible provisions for investigations and litigation — — 5 0.2 % — — Total tax charge 1,138 13.9 % 604 19.7 % 1,003 23.0 % Note a 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Deferred tax assets and liabilities | The deferred tax amounts on the balance sheet were as follows: 2021 2020 £m £m UK Tax Group 2,183 886 US Intermediate Holding Company Tax Group ('IHC Tax Group') 1,004 1,001 US Branch Tax Group 1,002 1,048 Other (outside the UK and US tax groups) 430 509 Deferred tax asset 4,619 3,444 Deferred tax liability (37) (15) Net deferred tax 4,582 3,429 |
Movements on deferred tax assets and liabilities during the year before offsetting | The deferred tax amounts on the balance sheet were as follows: 2021 2020 £m £m UK Tax Group 2,183 886 US Intermediate Holding Company Tax Group ('IHC Tax Group') 1,004 1,001 US Branch Tax Group 1,002 1,048 Other (outside the UK and US tax groups) 430 509 Deferred tax asset 4,619 3,444 Deferred tax liability (37) (15) Net deferred tax 4,582 3,429 US deferred tax assets in the IHC and US Branch Tax Groups The deferred tax asset in the IHC Tax Group of £1,004m (2020: £1,001m) includes £1m (2020: £nil) relating to tax losses, with the balance relating to temporary differences. The deferred tax asset in Barclays Bank PLC’s US Branch Tax Group of £1,002m (2020: £1,048m) relates entirely to temporary differences. In relation to the IHC Tax Group, these temporary differences include £301m (2020: £330m) arising from New York State and City prior net operating loss conversion which can be carried forward and will expire in 2034. Business profit forecasts indicate these amounts will be fully recovered before expiry. UK Tax Group deferred tax asset The deferred tax asset in the UK Tax Group of £2,183m (2020: £886m) includes £1,098m (2020: £565m) relating to tax losses, with the balance relating to temporary differences. There is no time limit on utilisation of UK tax losses and business profit forecasts indicate that these losses will be fully recovered. Other deferred tax assets (outside the UK and US tax groups) The deferred tax asset of £430m (2020: £509m) in other entities within the Group includes £121m (2020: £170m) relating to tax losses. These deferred tax assets relate to a number of different territories and their recognition is based on profit forecasts or local country law which indicate that it is probable that those deferred tax assets will be fully recovered. Of the deferred tax asset of £430m (2020: £509m), an amount of £9m (2020: £8m) relates to entities which have suffered a loss in either the current or prior year and for which the utilisation of the deferred tax is dependent on future taxable profits. This has been taken into account in reaching the above conclusion that these deferred tax assets will be fully recovered in the future. The table below shows movements on deferred tax assets and liabilities during the year. The amounts are different from those disclosed on the balance sheet and in the preceding table as they are presented before offsetting asset and liability balances where there is a legal right to set-off and an intention to settle on a net basis. Fixed asset timing differences Fair value through other comprehensive income Cash flow hedges Retirement benefit obligations Loan impairment allowance Other provisions Share-based payments and deferred compensation Other temporary differences Tax losses carried forward Total £m £m £m £m £m £m £m £m £m £m Assets 1,465 — — 43 666 143 363 1,564 735 4,979 Liabilities (41) (38) (566) (826) — — — (79) — (1,550) As at 1 January 2021 1,424 (38) (566) (783) 666 143 363 1,485 735 3,429 Income statement 184 (6) — 5 39 7 12 (130) 485 596 Other comprehensive income and reserves — 198 1,088 (855) — — 36 97 — 564 Other movements (3) 1 (1) (1) (12) — 3 6 — (7) 1,605 155 521 (1,634) 693 150 414 1,458 1,220 4,582 Assets 1,647 155 521 40 693 150 414 1,524 1,220 6,364 Liabilities (42) — — (1,674) — — — (66) — (1,782) As at 31 December 2021 1,605 155 521 (1,634) 693 150 414 1,458 1,220 4,582 Assets 1,338 119 — 38 501 128 344 1,458 523 4,449 Liabilities (31) (18) (181) (640) — — — (312) — (1,182) As at 1 January 2020 1,307 101 (181) (602) 501 128 344 1,146 523 3,267 Income statement 129 — — 6 156 22 20 134 215 682 Other comprehensive income and reserves — (137) (377) (191) — — 5 238 — (462) Other movements (12) (2) (8) 4 9 (7) (6) (33) (3) (58) 1,424 (38) (566) (783) 666 143 363 1,485 735 3,429 Assets 1,465 — — 43 666 143 363 1,564 735 4,979 Liabilities (41) (38) (566) (826) — — — (79) — (1,550) As at 31 December 2020 1,424 (38) (566) (783) 666 143 363 1,485 735 3,429 |
Earnings per share (Tables)
Earnings per share (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Earnings per share [abstract] | |
Earnings per share | Restated a 2021 2020 2019 £m £m £m Profit attributable to ordinary equity holders of the parent 6,205 1,526 2,461 2021 2020 2019 million million million Basic weighted average number of shares in issue 16,985 17,300 17,200 Number of potential ordinary shares 435 368 282 Diluted weighted average number of shares 17,420 17,668 17,482 Basic earnings per share Diluted earnings per share Restated a Restated a 2021 2020 2019 2021 2020 2019 p p p p p p Earnings per ordinary share 36.5 8.8 14.3 35.6 8.6 14.1 Note a 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Trading portfolio (Table)
Trading portfolio (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Net assets (liabilities) [abstract] | |
Trading portfolio assets | Trading portfolio assets Trading portfolio liabilities 2021 2020 2021 2020 £m £m £m £m Debt securities and other eligible bills 50,864 56,482 (34,957) (30,102) Equity securities 83,113 62,192 (19,212) (17,303) Traded loans 12,525 8,348 — — Commodities 533 928 — — Trading portfolio assets/(liabilities) 147,035 127,950 (54,169) (47,405) |
Trading portfolio liabilities | Trading portfolio assets Trading portfolio liabilities 2021 2020 2021 2020 £m £m £m £m Debt securities and other eligible bills 50,864 56,482 (34,957) (30,102) Equity securities 83,113 62,192 (19,212) (17,303) Traded loans 12,525 8,348 — — Commodities 533 928 — — Trading portfolio assets/(liabilities) 147,035 127,950 (54,169) (47,405) |
Financial assets at fair valu_3
Financial assets at fair value through the income statement (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Financial assets at fair value through profit or loss [abstract] | |
Financial assets designated at fair value | Designated at fair value Mandatorily at fair value Total 2021 2020 2021 2020 2021 2020 £m £m £m £m £m £m Loans and advances 5,579 5,600 33,088 25,279 38,667 30,879 Debt securities 319 292 1,986 1,401 2,305 1,693 Equity securities — — 5,875 4,620 5,875 4,620 Reverse repurchase agreements and other — 19 145,014 137,597 145,014 137,616 Other financial assets — — 111 343 111 343 Financial assets at fair value through the income statement 5,898 5,911 186,074 169,240 191,972 175,151 2021 2020 Fair value Contractual Fair value Contractual £m £m £m £m Debt securities 53,647 61,946 50,437 57,650 Deposits 29,246 29,673 21,706 22,107 Repurchase agreements and other similar secured borrowing 168,060 168,129 177,371 177,389 Other financial liabilities 7 7 251 251 Financial liabilities designated at fair value 250,960 259,755 249,765 257,397 The cumulative own credit net loss recognised is £960m (2020: £954m loss). |
Credit risk of loans and advances designated at fair value and related credit derivatives | The following table shows the maximum exposure to credit risk, the changes in fair value attributable to changes in credit risk, and the cumulative changes in fair value since initial recognition for loans and advances. The table does not include debt securities and reverse repurchase agreements and other similar secured lending designated at FV as they have minimal exposure to credit risk. Reverse repurchase agreements are collateralised and debt securities are primarily relating to high quality sovereigns. Maximum exposure as at 31 December Changes in fair value during the year ended Cumulative changes in fair value from inception 2021 2020 2021 2020 2021 2020 £m £m £m £m £m £m Loans and advances designated at fair value, attributable to credit risk 5,579 5,600 5 (47) (19) (73) Value mitigated by related credit derivatives 1,617 795 (3) 3 (3) 3 |
Derivative financial instrume_2
Derivative financial instruments (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of nature and extent of risks arising from financial instruments [abstract] | |
Total derivatives | Total derivatives 2021 2020 Notional contract amount Fair value Notional Fair value Assets Liabilities Assets Liabilities £m £m £m £m £m £m Total derivative assets/(liabilities) held for trading 47,812,774 261,678 (255,747) 43,169,971 301,880 (299,795) Total derivative assets/(liabilities) held for risk management 219,551 894 (1,136) 189,784 566 (980) Derivative assets/(liabilities) 48,032,325 262,572 (256,883) 43,359,755 302,446 (300,775) As part of the industry wide IBOR transition during the year, interest rate swap contracts held with Central Clearing Counterparties (CCPs) have been converted to alternative benchmarks. Operationally, this involved the CCPs splitting each contract into multiple component operational parts in order to preserve accrued IBOR cash flows. Legally, Barclays remains party to only one contract, and as such all notional amounts quoted in this disclosure reflect the legal contract notional. In total, 'operational-only' trade notional amounts of £1,828bn primarily with London Clearing House & Japan Securities Clearing Corporation have been explicitly excluded from these disclosures. |
Derivatives held for trading and risk management | The fair values and notional amounts of derivative instruments held for trading and held for risk management are set out in the following table: Derivatives held for trading and held for risk management 2021 2020 Notional Fair value Notional Fair value Assets Liabilities Assets Liabilities £m £m £m £m £m £m Derivatives held for trading Foreign exchange derivatives OTC derivatives 5,705,108 75,959 (74,226) 5,461,057 84,401 (84,043) Derivatives cleared by central counterparty 99,664 171 (208) 78,946 335 (335) Exchange traded derivatives 20,084 10 (3) 14,034 3 (3) Foreign exchange derivatives 5,824,856 76,140 (74,437) 5,554,037 84,739 (84,381) Interest rate derivatives OTC derivatives 14,216,846 123,819 (113,051) 13,547,990 170,808 (161,157) Derivatives cleared by central counterparty 19,398,748 1,122 (845) 18,737,415 965 (885) Exchange traded derivatives 5,200,838 905 (907) 2,971,966 371 (360) Interest rate derivatives 38,816,432 125,846 (114,803) 35,257,371 172,144 (162,402) Credit derivatives OTC derivatives 606,504 4,007 (4,752) 384,900 3,674 (3,909) Derivatives cleared by central counterparty 665,600 1,675 (1,809) 462,945 931 (1,095) Credit derivatives 1,272,104 5,682 (6,561) 847,845 4,605 (5,004) Equity and stock index derivatives OTC derivatives 278,683 18,822 (24,468) 466,151 18,807 (26,094) Exchange traded derivatives 1,469,078 32,901 (33,174) 927,114 20,165 (20,521) Equity and stock index derivatives 1,747,761 51,723 (57,642) 1,393,265 38,972 (46,615) Commodity derivatives OTC derivatives 4,670 56 (107) 4,244 89 (110) Exchange traded derivatives 146,951 2,231 (2,197) 113,209 1,331 (1,283) Commodity derivatives 151,621 2,287 (2,304) 117,453 1,420 (1,393) Derivative assets/(liabilities) held for trading 47,812,774 261,678 (255,747) 43,169,971 301,880 (299,795) Total OTC derivatives 20,811,811 222,663 (216,604) 19,864,342 277,779 (275,313) Total derivatives cleared by central counterparty 20,164,012 2,968 (2,862) 19,279,306 2,231 (2,315) Total exchange traded derivatives 6,836,951 36,047 (36,281) 4,026,323 21,870 (22,167) Derivative assets/(liabilities) held for trading 47,812,774 261,678 (255,747) 43,169,971 301,880 (299,795) Derivatives held for risk management Derivatives designated as cash flow hedges OTC foreign exchange derivatives 7,592 798 — 6,596 351 — OTC interest rate derivatives 788 — (3) 2,433 35 — Interest rate derivatives cleared by central counterparty 105,933 — — 65,408 — — Derivatives designated as cash flow hedges 114,313 798 (3) 74,437 386 — Derivatives designated as fair value hedges OTC interest rate derivatives 8,480 59 (1,118) 11,116 155 (980) Interest rate derivatives cleared by central counterparty 94,335 — (11) 103,440 — — Derivatives designated as fair value hedges 102,815 59 (1,129) 114,556 155 (980) Derivatives designated as hedges of net investments OTC foreign exchange derivatives 2,423 37 (4) 791 25 — Derivatives designated as hedges of net investments 2,423 37 (4) 791 25 — Derivative assets/(liabilities) held for risk management 219,551 894 (1,136) 189,784 566 (980) Total OTC derivatives 19,283 894 (1,125) 20,936 566 (980) Total derivatives cleared by central counterparty 200,268 — (11) 168,848 — — Derivative assets/(liabilities) held for risk management 219,551 894 (1,136) 189,784 566 (980) |
Significant hedge accounting exposures impacted by the IBOR reform | The following table summarises the significant hedge accounting exposures impacted by the IBOR reform (see Note 41 for further updates) as at 31 December 2021: Current benchmark rate Expected convergence to RFR Nominal amount of hedged items directly impacted by IBOR reform Nominal amount of hedging instruments directly impacted by IBOR reform £m £m GBP London Interbank Offered rate (LIBOR) Reformed Sterling Overnight Index Average (SONIA) 10,032 200 USD LIBOR Secured Overnight Financing Rate (SOFR) 25,744 25,288 Singapore Swap Offered Rate (SOR) Singapore Overnight Rate Average (SORA) 110 110 Total 35,886 25,598 |
Hedged items in fair value hedge accounting relationships and Hedged items in cash flow hedge accounting and hedges of net investments in foreign operations | Hedged items in fair value hedges Accumulated fair value adjustment included in carrying amount Hedged item statement of financial position classification and risk category Carrying amount Total Of which: Accumulated fair value adjustment on items no longer in a hedge relationship Change in fair value used as a basis to determine ineffectiveness Hedge ineffectiveness recognised in the income statements a £m £m £m £m £m 2021 Assets Loans and advances at amortised cost - Interest rate risk 8,512 671 (642) (1,643) 33 - Inflation risk 556 354 — 9 — Debt securities classified at amortised cost - Interest rate risk 1,378 (39) — (75) (18) - Inflation risk 4,087 400 — (16) (1) Financial assets at fair value through other comprehensive income - Interest rate risk 31,485 (258) 32 (1,436) 39 - Inflation risk 9,066 470 (32) 161 13 Total assets 55,084 1,598 (642) (3,000) 66 Liabilities Debt securities in issue - Interest rate risk (48,251) (1,084) 86 1,606 (48) Total liabilities (48,251) (1,084) 86 1,606 (48) Total hedged items 6,833 514 (556) (1,394) 18 2020 Assets Loans and advances at amortised cost - Interest rate risk 9,858 2,289 (638) 1,583 111 - Inflation risk 545 345 — 25 3 Debt securities classified at amortised cost - Interest rate risk 1,440 23 — 18 (7) - Inflation risk 4,071 (43) — 453 3 Financial assets at fair value through other comprehensive income - Interest rate risk 41,544 1,284 351 825 (13) - Inflation risk 10,821 367 (9) 307 1 Total assets 68,279 4,265 (296) 3,211 98 Liabilities Debt securities in issue - Interest rate risk (50,438) (2,859) (24) (1,466) (56) Total liabilities (50,438) (2,859) (24) (1,466) (56) Total hedged items 17,841 1,406 (320) 1,745 42 Note Hedged items in cash flow hedges and hedges of net investments in foreign operations Description of hedge relationship and hedged risk Change in value of hedged item used as the basis for recognising ineffectiveness Balance in cash flow hedging reserve for continuing hedges Balance in currency translation reserve for continuing hedges Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied Balances remaining in currency translation reserve for which hedge accounting is no longer applied Hedging gains or losses recognised in other comprehensive income Hedge ineffectiveness recognised in the income statement a £m £m £m £m £m £m £m 2021 Cash flow hedge of: Interest rate risk Loans and advances at amortised cost 2,465 1,536 — (492) — 2,465 (347) Foreign exchange risk Loans and advances at amortised cost (88) (16) — — — (88) 1 Debt securities classified at amortised cost (356) 123 — — — (356) 1 Inflation risk Debt securities classified at amortised cost 252 204 — (12) — 252 (22) Total cash flow hedge 2,273 1,847 — (504) — 2,273 (367) Hedge of net investment in foreign operations USD foreign operations 138 — 943 — — 138 — EUR foreign operations (117) — 100 — — (117) — Other foreign operations (3) — 44 — 186 (3) — Total foreign operations 18 — 1,087 — 186 18 — 2020 Cash flow hedge of: Interest rate risk Loans and advances at amortised cost (1,124) (598) — (1,370) — (1,124) 27 Foreign exchange risk Loans and advances at amortised cost (70) (15) — — — (70) — Debt securities classified at amortised cost (278) (65) — — — (278) — Inflation risk Debt securities classified at amortised cost (41) (65) — — — (41) 1 Total cash flow hedge (1,513) (743) — (1,370) — (1,513) 28 Hedge of net investment in foreign operations USD foreign operations (240) — 857 — — (240) — EUR foreign operations (17) — (2) — — (17) — Other foreign operations (9) — 47 — 186 (9) — Total foreign operations (266) — 902 — 186 (266) — Note |
Hedging instruments which are carried on the Group's balance sheet | The following table shows the fair value hedging instruments which are carried on the Group’s balance sheet: Carrying value Nominal amount Change in fair value used as a basis to determine ineffectiveness Nominal amount directly impacted by IBOR reform Derivative assets Derivative liabilities Loan liabilities Hedge type Risk category £m £m £m £m £m £m As at 31 December 2021 Fair value Interest rate risk 54 (11) — 92,447 1,554 15,577 Inflation risk 5 (1,118) — 10,368 (142) 1,624 Total 59 (1,129) — 102,815 1,412 17,201 As at 31 December 2020 Fair value Interest rate risk 120 (166) — 103,623 (925) 30,072 Inflation risk 35 (815) — 10,933 (778) 1,487 Total 155 (980) — 114,556 (1,703) 31,559 The following table shows the cash flow and net investment hedging instruments which are carried on the Group’s balance sheet: Carrying value Nominal amount Change in fair value used as a basis to determine ineffectiveness Nominal amount directly impacted by IBOR reform Derivative assets Derivative liabilities Loan liabilities Hedge type Risk category £m £m £m £m £m £m As at 31 December 2021 Cash flow Interest rate risk — — — 102,629 (2,812) 8,397 Foreign exchange risk 798 — — 7,592 446 — Inflation risk — (3) — 4,092 (274) — Total 798 (3) — 114,313 (2,640) 8,397 Net investment Foreign exchange risk 37 (4) (11,212) 13,635 (239) — As at 31 December 2020 Cash flow Interest rate risk 33 — — 65,042 1,151 18,195 Foreign exchange risk 351 — — 6,596 348 — Inflation risk 2 — — 2,799 42 — Total 386 — — 74,437 1,541 18,195 Net investment Foreign exchange risk 25 — (8,660) 9,451 265 — |
The expected notional values of current hedging instruments in future years | The following table profiles the expected notional values of current hedging instruments in future years: 2021 2022 2023 2024 2025 2026 2027 and later As at 31 December £m £m £m £m £m £m £m Fair value hedges of: Interest rate risk (outstanding notional amount) 92,447 87,025 79,475 67,206 55,080 44,801 37,652 Inflation risk (outstanding notional amount) 10,368 9,874 8,999 6,503 5,445 3,472 1,159 |
Effect on the income statement, OCI, and reserves as a result of hedge accounting | The effect on the income statement and other comprehensive income of recycling amounts in respect of cash flow hedges and net investment hedges of foreign operations is set out in the following table: 2021 2020 Amount recycled from other comprehensive income due to hedged item affecting income statement Amount recycled from other comprehensive income due to sale of investment, or cash flows no longer expected to occur Amount recycled from other comprehensive income due to hedged item affecting income statement Amount recycled from other comprehensive income due to sale of investment, or cash flows no longer expected to occur Description of hedge relationship and hedged risk £m £m £m £m Cash flow hedge of interest rate risk Recycled to net interest income 541 2 489 17 Cash flow hedge of foreign exchange risk Recycled to other income 630 — 268 — Hedge of net investment in foreign operations Recycled to other income — (26) — (4) A detailed reconciliation of the movements of the cash flow hedging reserve and the currency translation reserve is as follows: 2021 2020 Cash flow hedging reserve Currency translation reserve Cash flow hedging reserve Currency translation reserve £m £m £m £m Balance on 1 January 1,575 2,871 1,002 3,344 Currency translation movements (7) (139) 50 (743) Hedging gains/(losses) for the year (2,273) (18) 1,249 266 Amounts reclassified in relation to cash flows affecting profit or loss (1,173) 26 (510) 4 Tax 1,025 — (216) — Balance on 31 December (853) 2,740 1,575 2,871 |
Financial assets at fair valu_4
Financial assets at fair value through other comprehensive income (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Financial assets at fair value through other comprehensive income [abstract] | |
Detailed information about financial assets at fair value through other comprehensive income | 2021 2020 £m £m Debt securities and other eligible bills 60,798 77,736 Equity securities 902 761 Loans and advances 53 191 Financial assets at fair value through other comprehensive income 61,753 78,688 |
Financial liabilities designa_2
Financial liabilities designated at fair value (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Designated financial liabilities at fair value through profit or loss [abstract] | |
Financial liabilities designated at fair value | Designated at fair value Mandatorily at fair value Total 2021 2020 2021 2020 2021 2020 £m £m £m £m £m £m Loans and advances 5,579 5,600 33,088 25,279 38,667 30,879 Debt securities 319 292 1,986 1,401 2,305 1,693 Equity securities — — 5,875 4,620 5,875 4,620 Reverse repurchase agreements and other — 19 145,014 137,597 145,014 137,616 Other financial assets — — 111 343 111 343 Financial assets at fair value through the income statement 5,898 5,911 186,074 169,240 191,972 175,151 2021 2020 Fair value Contractual Fair value Contractual £m £m £m £m Debt securities 53,647 61,946 50,437 57,650 Deposits 29,246 29,673 21,706 22,107 Repurchase agreements and other similar secured borrowing 168,060 168,129 177,371 177,389 Other financial liabilities 7 7 251 251 Financial liabilities designated at fair value 250,960 259,755 249,765 257,397 The cumulative own credit net loss recognised is £960m (2020: £954m loss). |
Fair value of financial instr_2
Fair value of financial instruments (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of detailed information about financial instruments [abstract] | |
Assets and liabilities held at fair value, disaggregated by valuation technique and by product type | The following table shows the Group’s assets and liabilities that are held at fair value disaggregated by valuation technique (fair value hierarchy) and balance sheet classification: Assets and liabilities held at fair value 2021 2020 Valuation technique using Valuation technique using Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total As at 31 December £m £m £m £m £m £m £m £m Trading portfolio assets 80,926 63,828 2,281 147,035 60,671 65,416 1,863 127,950 Financial assets at fair value through the income statement 5,093 177,167 9,712 191,972 4,503 162,142 8,506 175,151 Derivative financial assets 6,150 252,412 4,010 262,572 9,155 288,822 4,469 302,446 Financial assets at fair value through other comprehensive income 22,009 39,706 38 61,753 19,792 58,743 153 78,688 Investment property — — 7 7 — — 10 10 Total assets 114,178 533,113 16,048 663,339 94,121 575,123 15,001 684,245 Trading portfolio liabilities (27,529) (26,613) (27) (54,169) (24,391) (22,986) (28) (47,405) Financial liabilities designated at fair value (174) (250,376) (410) (250,960) (159) (249,251) (355) (249,765) Derivative financial liabilities (6,571) (244,253) (6,059) (256,883) (8,762) (285,774) (6,239) (300,775) Total liabilities (34,274) (521,242) (6,496) (562,012) (33,312) (558,011) (6,622) (597,945) |
Analysis of movements in Level 3 assets | The following table shows the Group’s Level 3 assets and liabilities that are held at fair value disaggregated by product type: Level 3 assets and liabilities held at fair value by product type 2021 2020 Assets Liabilities Assets Liabilities £m £m £m £m Interest rate derivatives 1,091 (1,351) 1,613 (1,615) Foreign exchange derivatives 376 (374) 144 (143) Credit derivatives 323 (709) 196 (351) Equity derivatives 2,220 (3,625) 2,498 (4,112) Corporate debt 1,205 (21) 698 (3) Reverse repurchase and repurchase agreements 13 (172) — (174) Non-asset backed loans 6,405 — 6,394 — Asset backed securities 558 — 767 (24) Equity cash products 393 — 542 — Private equity investments 1,095 (6) 873 (14) Other a 2,369 (238) 1,276 (186) Total 16,048 (6,496) 15,001 (6,622) Note a Other includes commercial real estate loans, asset backed loans, funds and fund-linked products, issued debt, government sponsored debt, commodity derivatives and investment property. Analysis of movements in Level 3 assets and liabilities As at 1 January 2021 Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 31 December 2021 Purchases Sales Issues Settlements Trading income Other income In Out £m £m £m £m £m £m £m £m £m £m £m Corporate debt 151 310 (123) — (12) 38 — — 41 (16) 389 Non-asset backed loans 709 1,580 (1,409) — (85) (1) — — 45 (81) 758 Asset backed securities 686 209 (370) — — (69) — — 114 (116) 454 Equity cash products 214 45 (53) — 4 23 — — 80 (10) 303 Other 103 117 (2) — (61) (3) — — 248 (25) 377 Trading portfolio assets 1,863 2,261 (1,957) — (154) (12) — — 528 (248) 2,281 Non-asset backed loans 5,580 1,380 (306) — (748) (181) (174) — 113 (17) 5,647 Equity cash products 326 3 (247) — — — 7 — 1 — 90 Private equity investments 874 166 (24) — (9) — 163 — 35 (110) 1,095 Other 1,726 11,253 (9,983) — (185) 2 20 — 48 (1) 2,880 Financial assets at fair value through the income statement 8,506 12,802 (10,560) — (942) (179) 16 — 197 (128) 9,712 Non-asset backed loans 106 — — — — — — — — (106) 0 Asset backed securities 47 — — — (7) — — (2) — — 38 Financial assets at fair value through other comprehensive income 153 — — — (7) — — (2) — (106) 38 Investment property 10 — (2) — — — (1) — — — 7 Trading portfolio liabilities (28) (5) 23 — — (6) — — (12) 1 (27) Financial liabilities designated at fair value (355) (4) — (101) 66 21 (1) — (68) 32 (410) Interest rate derivatives (2) 20 — — 105 (255) — — 90 (218) (260) Foreign exchange derivatives 1 — — — 40 (2) — — 10 (47) 2 Credit derivatives (155) (239) 9 — (45) 34 — — 10 — (386) Equity derivatives (1,614) 90 (1) — (15) (4) — — (3) 142 (1,405) Net derivative financial instruments a (1,770) (129) 8 — 85 (227) — — 107 (123) (2,049) Total 8,379 14,925 (12,488) (101) (952) (403) 14 (2) 752 (572) 9,552 Note a The derivative financial instruments are represented on a net basis. On a gross basis, derivative financial assets are £4,010m (2020: £4,469m) and derivative financial liabilities are £6,059m (2020: £6,239m). Analysis of movements in Level 3 assets and liabilities As at 1 January 2020 Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 31 December 2020 Purchases Sales Issues Settlements Trading income Other income In Out £m £m £m £m £m £m £m £m £m £m £m Corporate debt 120 77 (6) — — (35) — — 12 (17) 151 Non-asset backed loans 974 1,955 (2,182) — (12) (10) — — 39 (55) 709 Asset backed securities 656 458 (428) — (40) (25) — — 90 (25) 686 Equity cash products 392 5 (149) — — (41) — — 11 (4) 214 Other 122 — — — — (21) — — 2 — 103 Trading portfolio assets 2,264 2,495 (2,765) — (52) (132) — — 154 (101) 1,863 Non-asset backed loans 5,494 1,102 (283) — (706) 426 — — — (453) 5,580 Equity cash products 835 15 (404) — — (93) (36) — 9 — 326 Private equity investments 900 84 (54) — (3) — (56) — 15 (12) 874 Other 1,271 3,718 (3,606) — (32) 32 (43) — 386 — 1,726 Financial assets at fair value through the income statement 8,500 4,919 (4,347) — (741) 365 (135) — 410 (465) 8,506 Non-asset backed loans 343 — — — (237) — — — — — 106 Asset backed securities 86 — (35) — — — — (4) — — 47 Financial assets at fair value through other comprehensive income 429 — (35) — (237) — — (4) — — 153 Investment property 13 — (2) — — — (1) — — — 10 Trading portfolio liabilities — (27) — — — (1) — — — — (28) Financial liabilities designated at fair value (362) — 3 (21) 1 20 4 — (38) 38 (355) Interest rate derivatives (206) 17 (12) — 85 109 — — (18) 23 (2) Foreign exchange derivatives (7) — — — 21 (16) — — (19) 22 1 Credit derivatives 198 (125) 24 — (371) 24 — — (21) 116 (155) Equity derivatives (819) (699) (43) — 105 (101) — — (13) (44) (1,614) Net derivative financial instruments (834) (807) (31) — (160) 16 — — (71) 117 (1,770) Total 10,010 6,580 (7,177) (21) (1,189) 268 (132) (4) 455 (411) 8,379 |
Analysis of movements in Level 3 liabilities | The following table shows the Group’s Level 3 assets and liabilities that are held at fair value disaggregated by product type: Level 3 assets and liabilities held at fair value by product type 2021 2020 Assets Liabilities Assets Liabilities £m £m £m £m Interest rate derivatives 1,091 (1,351) 1,613 (1,615) Foreign exchange derivatives 376 (374) 144 (143) Credit derivatives 323 (709) 196 (351) Equity derivatives 2,220 (3,625) 2,498 (4,112) Corporate debt 1,205 (21) 698 (3) Reverse repurchase and repurchase agreements 13 (172) — (174) Non-asset backed loans 6,405 — 6,394 — Asset backed securities 558 — 767 (24) Equity cash products 393 — 542 — Private equity investments 1,095 (6) 873 (14) Other a 2,369 (238) 1,276 (186) Total 16,048 (6,496) 15,001 (6,622) Note a Other includes commercial real estate loans, asset backed loans, funds and fund-linked products, issued debt, government sponsored debt, commodity derivatives and investment property. Analysis of movements in Level 3 assets and liabilities As at 1 January 2021 Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 31 December 2021 Purchases Sales Issues Settlements Trading income Other income In Out £m £m £m £m £m £m £m £m £m £m £m Corporate debt 151 310 (123) — (12) 38 — — 41 (16) 389 Non-asset backed loans 709 1,580 (1,409) — (85) (1) — — 45 (81) 758 Asset backed securities 686 209 (370) — — (69) — — 114 (116) 454 Equity cash products 214 45 (53) — 4 23 — — 80 (10) 303 Other 103 117 (2) — (61) (3) — — 248 (25) 377 Trading portfolio assets 1,863 2,261 (1,957) — (154) (12) — — 528 (248) 2,281 Non-asset backed loans 5,580 1,380 (306) — (748) (181) (174) — 113 (17) 5,647 Equity cash products 326 3 (247) — — — 7 — 1 — 90 Private equity investments 874 166 (24) — (9) — 163 — 35 (110) 1,095 Other 1,726 11,253 (9,983) — (185) 2 20 — 48 (1) 2,880 Financial assets at fair value through the income statement 8,506 12,802 (10,560) — (942) (179) 16 — 197 (128) 9,712 Non-asset backed loans 106 — — — — — — — — (106) 0 Asset backed securities 47 — — — (7) — — (2) — — 38 Financial assets at fair value through other comprehensive income 153 — — — (7) — — (2) — (106) 38 Investment property 10 — (2) — — — (1) — — — 7 Trading portfolio liabilities (28) (5) 23 — — (6) — — (12) 1 (27) Financial liabilities designated at fair value (355) (4) — (101) 66 21 (1) — (68) 32 (410) Interest rate derivatives (2) 20 — — 105 (255) — — 90 (218) (260) Foreign exchange derivatives 1 — — — 40 (2) — — 10 (47) 2 Credit derivatives (155) (239) 9 — (45) 34 — — 10 — (386) Equity derivatives (1,614) 90 (1) — (15) (4) — — (3) 142 (1,405) Net derivative financial instruments a (1,770) (129) 8 — 85 (227) — — 107 (123) (2,049) Total 8,379 14,925 (12,488) (101) (952) (403) 14 (2) 752 (572) 9,552 Note a The derivative financial instruments are represented on a net basis. On a gross basis, derivative financial assets are £4,010m (2020: £4,469m) and derivative financial liabilities are £6,059m (2020: £6,239m). Analysis of movements in Level 3 assets and liabilities As at 1 January 2020 Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 31 December 2020 Purchases Sales Issues Settlements Trading income Other income In Out £m £m £m £m £m £m £m £m £m £m £m Corporate debt 120 77 (6) — — (35) — — 12 (17) 151 Non-asset backed loans 974 1,955 (2,182) — (12) (10) — — 39 (55) 709 Asset backed securities 656 458 (428) — (40) (25) — — 90 (25) 686 Equity cash products 392 5 (149) — — (41) — — 11 (4) 214 Other 122 — — — — (21) — — 2 — 103 Trading portfolio assets 2,264 2,495 (2,765) — (52) (132) — — 154 (101) 1,863 Non-asset backed loans 5,494 1,102 (283) — (706) 426 — — — (453) 5,580 Equity cash products 835 15 (404) — — (93) (36) — 9 — 326 Private equity investments 900 84 (54) — (3) — (56) — 15 (12) 874 Other 1,271 3,718 (3,606) — (32) 32 (43) — 386 — 1,726 Financial assets at fair value through the income statement 8,500 4,919 (4,347) — (741) 365 (135) — 410 (465) 8,506 Non-asset backed loans 343 — — — (237) — — — — — 106 Asset backed securities 86 — (35) — — — — (4) — — 47 Financial assets at fair value through other comprehensive income 429 — (35) — (237) — — (4) — — 153 Investment property 13 — (2) — — — (1) — — — 10 Trading portfolio liabilities — (27) — — — (1) — — — — (28) Financial liabilities designated at fair value (362) — 3 (21) 1 20 4 — (38) 38 (355) Interest rate derivatives (206) 17 (12) — 85 109 — — (18) 23 (2) Foreign exchange derivatives (7) — — — 21 (16) — — (19) 22 1 Credit derivatives 198 (125) 24 — (371) 24 — — (21) 116 (155) Equity derivatives (819) (699) (43) — 105 (101) — — (13) (44) (1,614) Net derivative financial instruments (834) (807) (31) — (160) 16 — — (71) 117 (1,770) Total 10,010 6,580 (7,177) (21) (1,189) 268 (132) (4) 455 (411) 8,379 |
Unrealised gains and losses on Level 3 financial assets and liabilities | The following table discloses the unrealised gains and losses recognised in the year arising on Level 3 financial assets and liabilities held at year end. Unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at year end 2021 2020 Income statement Other compre- Total Income statement Other Total Trading income Other income Trading income Other income As at 31 December £m £m £m £m £m £m £m £m Trading portfolio assets (67) — — (67) (114) — — (114) Financial assets at fair value through the income statement (176) 154 — (22) 399 (89) — 310 Fair value through other comprehensive income — — — — — — (1) (1) Investment property — — — — — (1) — (1) Trading portfolio liabilities (5) — — (5) — — — — Financial liabilities designated at fair value 16 (1) — 15 20 (1) — 19 Net derivative financial instruments (196) — — (196) (91) — — (91) Total (428) 153 — (275) 214 (91) (1) 122 |
Significant unobservable inputs, assets | The following table discloses the valuation techniques and significant unobservable inputs for assets and liabilities recognised at fair value and classified as Level 3 along with the range of values used for those significant unobservable inputs: Valuation technique(s) a Significant unobservable inputs 2021 Range 2020 Range Min Max Min Max Units b Derivative financial instruments c Interest rate derivatives Discounted cash flows Inflation forwards — 3 1 3 % Credit spread 9 1,848 17 1,831 bps Correlation Model Inflation forwards (20) (13) (20) (13) % Comparable pricing Price — 38 — 84 points Option model Inflation volatility 31 130 31 227 bps vol Interest rate volatility 5 600 6 489 bps vol FX - IR correlation (20) 78 (30) 78 % IR - IR correlation (100) 99 (20) 99 % Credit derivatives Discounted cash flows Credit spread 2 2,925 5 480 bps Comparable pricing Price — — — 100 points Equity derivatives Option model Equity volatility 2 108 1 110 % Equity - equity correlation 10 100 (45) 100 % Discounted cash flow Discounted margin (129) 93 (225) 3,000 bps Foreign exchange derivatives Option Model Option Volatility — 100 — 30 points Non-derivative financial instruments Non-asset backed loans Discounted cash flows Loan spread 31 1,552 31 1,518 bps Credit spread 200 300 200 300 bps Price — 112 — 104 points Yield 3 10 5 8 % Comparable pricing Price — 145 — 137 points Asset backed securities Comparable pricing Price — 120 — 112 points Private equity investments EBITDA multiple EBITDA multiple 16 20 14 16 Multiple Earnings multiple Earnings multiple 5 28 3 28 Multiple Discounted cash flow Credit Spread 725 1,916 1,387 1,916 bps Discount margin 8 10 1 10 % Corporate debt Comparable pricing Price — 284 — 127 points Discounted Cash Flows Loan Spread 229 854 — — bps Price — 100 — 104 points Commercial Real Estate loans Discounted cash flows Credit spread 68 543 146 483 bps Equity cash products Discounted cash flows Discount Margin 26 34 49 49 bps Notes a A range has not been provided for Net Asset Value as there would be a wide range reflecting the diverse nature of the positions. b The units used to disclose ranges for significant unobservable inputs are percentages, points and basis points. Points are a percentage of par; for example, 100 points equals 100% of par. A basis point equals 1/100th of 1%; for example, 150 basis points equals 1.5%. c Certain derivative instruments are classified as Level 3 due to a significant unobservable credit spread input into the calculation of the Credit Valuation Adjustment for the instruments. The range of significant unobservable credit spreads is between 32-1848bps (2020: 17-1,831bps). |
Significant unobservable inputs, liabilities | The following table discloses the valuation techniques and significant unobservable inputs for assets and liabilities recognised at fair value and classified as Level 3 along with the range of values used for those significant unobservable inputs: Valuation technique(s) a Significant unobservable inputs 2021 Range 2020 Range Min Max Min Max Units b Derivative financial instruments c Interest rate derivatives Discounted cash flows Inflation forwards — 3 1 3 % Credit spread 9 1,848 17 1,831 bps Correlation Model Inflation forwards (20) (13) (20) (13) % Comparable pricing Price — 38 — 84 points Option model Inflation volatility 31 130 31 227 bps vol Interest rate volatility 5 600 6 489 bps vol FX - IR correlation (20) 78 (30) 78 % IR - IR correlation (100) 99 (20) 99 % Credit derivatives Discounted cash flows Credit spread 2 2,925 5 480 bps Comparable pricing Price — — — 100 points Equity derivatives Option model Equity volatility 2 108 1 110 % Equity - equity correlation 10 100 (45) 100 % Discounted cash flow Discounted margin (129) 93 (225) 3,000 bps Foreign exchange derivatives Option Model Option Volatility — 100 — 30 points Non-derivative financial instruments Non-asset backed loans Discounted cash flows Loan spread 31 1,552 31 1,518 bps Credit spread 200 300 200 300 bps Price — 112 — 104 points Yield 3 10 5 8 % Comparable pricing Price — 145 — 137 points Asset backed securities Comparable pricing Price — 120 — 112 points Private equity investments EBITDA multiple EBITDA multiple 16 20 14 16 Multiple Earnings multiple Earnings multiple 5 28 3 28 Multiple Discounted cash flow Credit Spread 725 1,916 1,387 1,916 bps Discount margin 8 10 1 10 % Corporate debt Comparable pricing Price — 284 — 127 points Discounted Cash Flows Loan Spread 229 854 — — bps Price — 100 — 104 points Commercial Real Estate loans Discounted cash flows Credit spread 68 543 146 483 bps Equity cash products Discounted cash flows Discount Margin 26 34 49 49 bps Notes a A range has not been provided for Net Asset Value as there would be a wide range reflecting the diverse nature of the positions. b The units used to disclose ranges for significant unobservable inputs are percentages, points and basis points. Points are a percentage of par; for example, 100 points equals 100% of par. A basis point equals 1/100th of 1%; for example, 150 basis points equals 1.5%. c Certain derivative instruments are classified as Level 3 due to a significant unobservable credit spread input into the calculation of the Credit Valuation Adjustment for the instruments. The range of significant unobservable credit spreads is between 32-1848bps (2020: 17-1,831bps). |
Sensitivity analysis of valuations using unobservable inputs, assets | Sensitivity analysis of valuations using unobservable inputs 2021 2020 Favourable changes Unfavourable changes Favourable changes Unfavourable changes Income statement Equity Income statement Equity Income statement Equity Income statement Equity £m £m £m £m £m £m £m £m Interest rate derivatives 51 — (79) — 82 — (123) — Foreign exchange derivatives 20 — (28) — 6 — (11) — Credit derivatives 111 — (103) — 55 — (44) — Equity derivatives 187 — (195) — 174 — (179) — Corporate debt 38 — (28) — 16 — (14) — Non-asset backed loans 165 — (256) — 190 3 (409) (3) Equity cash products 42 — (61) — 158 — (141) — Private equity investments 246 — (236) — 199 — (227) — Other a 20 — (19) — 23 — (23) — Total 880 — (1,005) — 903 3 (1,171) (3) Note |
Sensitivity analysis of valuations using unobservable inputs, liabilities | Sensitivity analysis of valuations using unobservable inputs 2021 2020 Favourable changes Unfavourable changes Favourable changes Unfavourable changes Income statement Equity Income statement Equity Income statement Equity Income statement Equity £m £m £m £m £m £m £m £m Interest rate derivatives 51 — (79) — 82 — (123) — Foreign exchange derivatives 20 — (28) — 6 — (11) — Credit derivatives 111 — (103) — 55 — (44) — Equity derivatives 187 — (195) — 174 — (179) — Corporate debt 38 — (28) — 16 — (14) — Non-asset backed loans 165 — (256) — 190 3 (409) (3) Equity cash products 42 — (61) — 158 — (141) — Private equity investments 246 — (236) — 199 — (227) — Other a 20 — (19) — 23 — (23) — Total 880 — (1,005) — 903 3 (1,171) (3) Note |
Fair value adjustments | Key balance sheet valuation adjustments are quantified below: 2021 2020 £m £m Exit price adjustments derived from market bid-offer spreads (506) (493) Uncollateralised derivative funding (127) (115) Derivative credit valuation adjustments (212) (268) Derivative debit valuation adjustments 91 113 |
Comparison of carrying amounts and fair values for assets and liabilities not held at fair value | The following table summarises the fair value of financial assets and liabilities measured at amortised cost on the Group’s balance sheet: 2021 2020 Carrying amount Fair value Level 1 Level 2 Level 3 Carrying amount Fair value Level 1 Level 2 Level 3 As at 31 December £m £m £m £m £m £m £m £m £m £m Financial assets Loans and advances at amortised cost 361,451 362,424 17,381 83,191 261,852 342,632 340,516 8,824 81,322 250,370 Reverse repurchase agreements and other similar secured lending 3,227 3,227 — 3,227 — 9,031 9,031 — 9,031 — Financial liabilities Deposits at amortised cost (519,433) (519,436) (434,431) (83,501) (1,504) (481,036) (481,106) (396,124) (82,874) (2,108) Repurchase agreements and other similar secured borrowing (28,352) (28,358) — (28,358) — (14,174) (14,174) — (14,174) — Debt securities in issue (98,867) (100,657) — (98,364) (2,293) (75,796) (77,813) — (75,957) (1,856) Subordinated liabilities (12,759) (13,334) — (13,267) (67) (16,341) (16,918) — (16,918) — |
Offsetting financial assets a_2
Offsetting financial assets and financial liabilities (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Offsetting financial assets and financial liabilities [Abstract] | |
Offsetting of financial assets | Amounts subject to enforceable netting arrangements Amounts not subject to enforceable netting arrangements c Balance sheet total d Effects of offsetting on-balance sheet Related amounts not offset Gross amounts Amounts offset a Net amounts reported on the balance sheet Financial instruments Financial collateral b Net amount £m £m £m £m £m £m £m £m As at 31 December 2021 Derivative financial assets 279,568 (24,137) 255,431 (202,519) (40,485) 12,427 7,141 262,572 Reverse repurchase agreements and other similar secured lending e 514,360 (370,003) 144,357 — (143,854) 503 3,884 148,241 Total assets 793,928 (394,140) 399,788 (202,519) (184,339) 12,930 11,025 410,813 Derivative financial liabilities (274,356) 23,606 (250,750) 202,519 34,321 (13,910) (6,133) (256,883) Repurchase agreements and other similar secured borrowing e (535,653) 370,003 (165,650) — 165,650 — (30,762) (196,412) Total liabilities (810,009) 393,609 (416,400) 202,519 199,971 (13,910) (36,895) (453,295) As at 31 December 2020 Derivative financial assets 342,649 (44,305) 298,344 (233,080) (48,064) 17,200 4,102 302,446 Reverse repurchase agreements and other similar secured lending e 448,134 (306,398) 141,736 — (141,352) 384 4,911 146,647 Total assets 790,783 (350,703) 440,080 (233,080) (189,416) 17,584 9,013 449,093 Derivative financial liabilities (333,943) 41,982 (291,961) 233,080 46,804 (12,077) (8,814) (300,775) Repurchase agreements and other similar secured borrowing e (476,912) 306,398 (170,514) — 170,514 — (21,031) (191,545) Total liabilities (810,855) 348,380 (462,475) 233,080 217,318 (12,077) (29,845) (492,320) Notes a Amounts offset for derivative financial assets additionally includes cash collateral netted of £3,815m (2020: £4,990m). Amounts offset for derivative financial liabilities additionally includes cash collateral netted of £4,346m (2020: £7,313m). Settlements assets and liabilities have been offset amounting to £22,837m (2020: £18,143m). b Financial collateral of £40,485m (2020: £48,064m) was received in respect of derivative assets, including £34,598m (2020: £43,291m) of cash collateral and £5,887m (2020: £4,773m) of non-cash collateral. Financial collateral of £34,321m (2020: £46,804m) was placed in respect of derivative liabilities, including £32,031m (2020: £42,730m) of cash collateral and £2,290m (2020: £4,074m) of non-cash collateral. The collateral amounts are limited to net balance sheet exposure so as to not include overcollateralisation. c This column includes contractual rights of set-off that are subject to uncertainty under the laws of the relevant jurisdiction. d The balance sheet total is the sum of ‘Net amounts reported on the balance sheet’ that are subject to enforceable netting arrangements and ‘Amounts not subject to enforceable netting arrangements’. |
Offsetting of financial liabilities | Amounts subject to enforceable netting arrangements Amounts not subject to enforceable netting arrangements c Balance sheet total d Effects of offsetting on-balance sheet Related amounts not offset Gross amounts Amounts offset a Net amounts reported on the balance sheet Financial instruments Financial collateral b Net amount £m £m £m £m £m £m £m £m As at 31 December 2021 Derivative financial assets 279,568 (24,137) 255,431 (202,519) (40,485) 12,427 7,141 262,572 Reverse repurchase agreements and other similar secured lending e 514,360 (370,003) 144,357 — (143,854) 503 3,884 148,241 Total assets 793,928 (394,140) 399,788 (202,519) (184,339) 12,930 11,025 410,813 Derivative financial liabilities (274,356) 23,606 (250,750) 202,519 34,321 (13,910) (6,133) (256,883) Repurchase agreements and other similar secured borrowing e (535,653) 370,003 (165,650) — 165,650 — (30,762) (196,412) Total liabilities (810,009) 393,609 (416,400) 202,519 199,971 (13,910) (36,895) (453,295) As at 31 December 2020 Derivative financial assets 342,649 (44,305) 298,344 (233,080) (48,064) 17,200 4,102 302,446 Reverse repurchase agreements and other similar secured lending e 448,134 (306,398) 141,736 — (141,352) 384 4,911 146,647 Total assets 790,783 (350,703) 440,080 (233,080) (189,416) 17,584 9,013 449,093 Derivative financial liabilities (333,943) 41,982 (291,961) 233,080 46,804 (12,077) (8,814) (300,775) Repurchase agreements and other similar secured borrowing e (476,912) 306,398 (170,514) — 170,514 — (21,031) (191,545) Total liabilities (810,855) 348,380 (462,475) 233,080 217,318 (12,077) (29,845) (492,320) Notes a Amounts offset for derivative financial assets additionally includes cash collateral netted of £3,815m (2020: £4,990m). Amounts offset for derivative financial liabilities additionally includes cash collateral netted of £4,346m (2020: £7,313m). Settlements assets and liabilities have been offset amounting to £22,837m (2020: £18,143m). b Financial collateral of £40,485m (2020: £48,064m) was received in respect of derivative assets, including £34,598m (2020: £43,291m) of cash collateral and £5,887m (2020: £4,773m) of non-cash collateral. Financial collateral of £34,321m (2020: £46,804m) was placed in respect of derivative liabilities, including £32,031m (2020: £42,730m) of cash collateral and £2,290m (2020: £4,074m) of non-cash collateral. The collateral amounts are limited to net balance sheet exposure so as to not include overcollateralisation. c This column includes contractual rights of set-off that are subject to uncertainty under the laws of the relevant jurisdiction. d The balance sheet total is the sum of ‘Net amounts reported on the balance sheet’ that are subject to enforceable netting arrangements and ‘Amounts not subject to enforceable netting arrangements’. e Reverse repurchase agreements and other similar secured lending of £148,241m (2020: £146,647m) is split by fair value £145,014m (2020: £137,616m) and amortised cost £3,227m (2020: £9,031m). Repurchase agreements and other similar secured borrowing of £196,412m (2020: £191,545m) is split by fair value £168,060m (2020: £177,371m) and amortised cost £28,352m (2020: £14,174m). |
Loans and advances and deposi_2
Loans and advances and deposits at amortised cost (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Loans and advances and deposits at amortised cost | |
Disclosure of loans and advances and deposits at amortised cost | Loans and advances and deposits at amortised cost 2021 2020 As at 31 December £m £m Loans and advances at amortised cost to banks 9,698 8,900 Loans and advances at amortised cost to customers 319,922 309,927 Debt securities at amortised cost 31,831 23,805 Total loans and advances at amortised cost 361,451 342,632 Deposits at amortised cost from banks 17,819 17,343 Deposits at amortised cost from customers 501,614 463,693 Total deposits at amortised cost 519,433 481,036 |
Property, plant and equipment (
Property, plant and equipment (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of detailed information about property, plant and equipment [abstract] | |
Property, plant and equipment | . The Group uses the following annual rates in calculating depreciation: Annual rates in calculating depreciation Depreciation rate Freehold land Not depreciated Freehold buildings and long-leasehold property (more than 50 years to run) 2-3.3% Leasehold property over the remaining life of the lease (less than 50 years to run) Over the remaining life of the lease Costs of adaptation of freehold and leasehold property 6-10% Equipment installed in freehold and leasehold property 6-10% Computers and similar equipment 17-33% Fixtures and fittings and other equipment 9-20% Investment Property Equipment Right of use assets a Total £m £m £m £m £m Cost As at 1 January 2021 10 4,002 3,091 1,934 9,037 Additions — 274 189 32 495 Disposals (2) (160) (74) (114) (350) Exchange and other movements (1) 15 4 68 86 As at 31 December 2021 7 4,131 3,210 1,920 9,268 Accumulated depreciation and impairment As at 1 January 2021 — (2,013) (2,421) (567) (5,001) Depreciation charge — (249) (222) (204) (675) Impairment b — (106) — (170) (276) Disposals — 136 66 60 262 Exchange and other movements — (23) (9) 9 (23) As at 31 December 2021 — (2,255) (2,586) (872) (5,713) Net book value 7 1,876 624 1,048 3,555 Cost As at 1 January 2020 13 3,938 2,986 1,826 8,763 Additions — 193 246 85 524 Disposals (1) (96) (100) (14) (211) Exchange and other movements (2) (33) (41) 37 (39) As at 31 December 2020 10 4,002 3,091 1,934 9,037 Accumulated depreciation and impairment As at 1 January 2020 — (1,901) (2,315) (332) (4,548) Depreciation charge — (187) (223) (231) (641) Impairment — (25) (2) (15) (42) Disposals — 82 92 2 176 Exchange and other movements — 18 27 9 54 As at 31 December 2020 — (2,013) (2,421) (567) (5,001) Net book value 10 1,989 670 1,367 4,036 Notes a Right of use (ROU) asset balances relate to property leases under IFRS 16. Refer to Note 21 for further details. |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Leases [Abstract] | |
Finance lease receivables | The following table sets out a maturity analysis of lease receivables, showing the lease payments to be received after the reporting date. 2021 2020 Gross investment in finance lease receivables Future finance income Present value of minimum lease payments Unguaranteed residual values Gross investment in finance lease receivables Future finance income Present value of minimum lease payments Unguaranteed residual values £m £m £m £m £m £m £m £m Not more than one year 29 (3) 26 — 535 (26) 509 70 One to two year 19 (2) 17 — 312 (15) 297 45 Two to three year 6 — 6 — 215 (12) 203 52 Three to four year 2 — 2 — 107 (6) 101 27 Four to five year 1 — 1 — 52 (3) 49 18 Over five years 1 — 1 — 24 (1) 23 13 Total 58 (5) 53 — 1,245 (63) 1,182 225 |
Finance lease income | Finance lease income is included within interest income. The following table shows amounts recognised in the income statement during the year. 2021 2020 £m £m Finance income from net investment in lease 21 55 Profit/(loss) on sales 1 (25) |
Lease liabilities and Lease liabilities maturity analysis | Lease liabilities 2021 2020 £m £m As at 1 January 1,444 1,563 Interest expense 64 70 New leases 43 85 Disposals (54) (15) Cash payments (258) (306) Exchange and other movements 78 47 As at 31 December (see Note 23) 1,317 1,444 The below table sets out a maturity analysis of undiscounted lease liabilities, showing the lease payments to be paid after the reporting date. Undiscounted lease liabilities maturity analysis 2021 2020 £m £m Not more than one year 230 255 One to two years 215 221 Two to three years 197 198 Three to four years 182 176 Four to five years 149 162 Five to ten years 503 557 Greater than ten years 163 248 Total undiscounted lease liabilities as at 31 December 1,639 1,817 |
Goodwill and intangible assets
Goodwill and intangible assets (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Intangible assets and goodwill [abstract] | |
Goodwill and intangible assets, amortisation periods | amortisation periods set out below: Annual rates in calculating amortisation Amortisation period Goodwill Not amortised Internally generated software a 12 months to 6 years Other software 12 months to 6 years Customer lists 12 months to 25 years Licences and other 12 months to 25 years Note a Exceptions to the above rate relate to useful lives of certain core banking platforms that are assessed individually and, if appropriate, amortised over longer periods ranging from 10 to 15 years. |
Intangible assets | Intangible assets Goodwill Internally Other Customer Licences Total £m £m £m £m £m £m 2021 Cost As at 1 January 2021 4,716 7,247 639 1,419 490 14,511 Additions and disposals — (52) (9) (5) 404 338 Exchange and other movements 2 (15) (4) 17 14 14 As at 31 December 2021 4,718 7,180 626 1,431 908 14,863 Accumulated amortisation and impairment As at 1 January 2021 (825) (3,779) (328) (1,252) (379) (6,563) Disposals — 894 15 5 3 917 Amortisation charge — (867) (51) (36) (44) (998) Impairment charge — (127) — — — (127) Exchange and other movements — (5) — (17) (9) (31) As at 31 December 2021 (825) (3,884) (364) (1,300) (429) (6,802) Net book value 3,893 3,296 262 131 479 8,061 2020 Cost As at 1 January 2020 4,760 6,643 505 1,465 489 13,862 Additions and disposals (37) 646 131 — 22 762 Exchange and other movements (7) (42) 3 (46) (21) (113) As at 31 December 2020 4,716 7,247 639 1,419 490 14,511 Accumulated amortisation and impairment As at 1 January 2020 (861) (2,989) (279) (1,250) (364) (5,743) Disposals 37 97 10 — 3 147 Amortisation charge — (771) (51) (43) (33) (898) Impairment charge — (147) (6) — — (153) Exchange and other movements (1) 31 (2) 41 15 84 As at 31 December 2020 (825) (3,779) (328) (1,252) (379) (6,563) Net book value 3,891 3,468 311 167 111 7,948 |
Goodwill | Goodwill and Intangible assets are allocated to business operations according to business segments as follows: 2021 2020 Goodwill Intangibles Total Goodwill Intangibles Total £m £m £m £m £m £m Barclays UK 3,560 1,233 4,793 3,560 1,618 5,178 Barclays International 291 2,930 3,221 289 2,435 2,724 Head Office 42 5 47 42 4 46 Total 3,893 4,168 8,061 3,891 4,057 7,948 |
The assumptions used in the impairment test and the sensitivity of value in use to changes in the key assumptions | The outcome of the impairment review for Personal Banking, Business Banking and Cards and Payments are set out below: Cash generating unit Tangible equity Goodwill Intangibles Carrying value Value in use Value in use exceeding carrying value Value in use exceeding carrying value 2020 £m £m £m £m £m £m £m Personal Banking 5,194 2,752 997 8,943 10,432 1,489 123 Business Banking 1,459 629 169 2,257 5,880 3,623 740 Cards and Payments 2,946 195 1,351 4,492 5,517 1,025 1,360 Total 9,599 3,576 2,517 15,692 21,829 6,137 2,223 The sensitivity of the value in use to key judgements in the calculations is set out below: Cash generating unit Carrying value Value in use Value in use exceeding carrying value Discount rate Terminal growth rate Reduction in headroom Change required to reduce headroom to zero 100 bps increase in the discount rate 100 bps decrease in terminal growth rate 50 bps increase to allocated capital rate 10% reduction in forecasted cash flows Discount rate Terminal growth rate Allocated capital rate Cashflows £m £m £m % % £m £m £m £m % % % % Personal Banking 8,943 10,432 1,489 14.2 2.0 (946) (655) (291) (1,219) 1.7 (2.6) 2.6 (12.2) Cards and Payments 4,492 5,517 1,025 14.7 2.0 (597) (433) (227) (774) 1.8 (2.7) 2.3 (13.3) Total 13,435 15,949 2,514 |
Other liabilities (Table)
Other liabilities (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Accruals and deferred income including contract liabilities [abstract] | |
Other liabilities | 2021 2020 £m £m Accruals and deferred income 4,173 3,683 Other creditors 4,793 3,447 Items in the course of collection due to other banks 202 88 Lease liabilities (refer to Note 21) 1,317 1,444 Liabilities included in disposal groups classified as held for sale 20 — Other liabilities 10,505 8,662 |
Provisions (Tables)
Provisions (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Provisions [abstract] | |
Provisions | Restated Undrawn contractually committed facilities and guarantees a Legal, competition and regulatory matters Sundry Total b Onerous contracts Redundancy and restructuring Customer redress b £m £m £m £m £m £m £m As at 1 January 2021 28 158 1,064 497 268 289 2,304 Additions 6 316 124 408 72 198 1,124 Amounts utilised (11) (82) — (318) (62) (140) (613) Unused amounts reversed (18) (25) (638) (54) (44) (101) (880) Exchange and other movements — (41) (8) (3) (8) 33 (27) As at 31 December 2021 b 5 326 542 530 226 279 1,908 Note a Undrawn contractually committed facilities and guarantees provisions are accounted for under IFRS 9. b 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Contingent liabilities and co_2
Contingent liabilities and commitments (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of contingent liabilities [abstract] | |
Contingent liabilities and commitments | The following table summarises the nominal principal amount of contingent liabilities and commitments which are not recorded on-balance sheet: 2021 2020 £m £m Guarantees and letters of credit pledged as collateral security 15,549 15,665 Performance guarantees, acceptances and endorsements 5,797 5,944 Total contingent liabilities and financial guarantees 21,346 21,609 Of which: Financial guarantees carried at fair value 231 229 Documentary credits and other short-term trade related transactions 1,584 1,086 Standby facilities, credit lines and other commitments 344,127 331,963 Total commitments 345,711 333,049 Of which: Loan commitments carried at fair value 18,571 9,269 |
Subordinated Liabilities (Table
Subordinated Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Subordinated liabilities [abstract] | |
Detailed disclosure of subordinated liabilities | 2021 2020 £m £m As at 1 January 16,341 18,156 Issuances 1,890 1,438 Redemptions (4,807) (3,464) Other (665) 211 As at 31 December 12,759 16,341 Subordinated liabilities include accrued interest and comprise undated and dated subordinated liabilities as follows: 2021 2020 £m £m Undated subordinated liabilities 355 308 Dated subordinated liabilities 12,404 16,033 Total subordinated liabilities 12,759 16,341 Undated subordinated liabilities a 2021 2020 Initial call date £m £m Barclays Bank PLC issued Tier One Notes (TONs) 6% Callable Perpetual Core Tier One Notes 2032 15 17 6.86% Callable Perpetual Core Tier One Notes (USD 179m) 2032 194 205 Reserve Capital Instruments (RCIs) 5.3304% Step-up Callable Perpetual Reserve Capital Instruments 2036 51 56 Undated Notes Junior Undated Floating Rate Notes (USD 38m) Any interest payment date 28 28 Barclays securitisation SPV issued Undated Subordinated Loan Notes (secured) Undated Subordinated Loan Notes (secured) (GBP 67m) At any time 67 — Total undated subordinated liabilities 355 308 Note a Instrument values are disclosed to the nearest million. Dated subordinated liabilities a 2021 2020 Initial call date Maturity date £m £m Barclays PLC issued 2% Fixed Rate Subordinated Callable Notes (EUR 1,500m) 2023 2028 1,283 1,384 4.375% Fixed Rate Subordinated Notes (USD 1,250m) 2024 974 990 3.75% Fixed Rate Resetting Subordinated Callable Notes (GBP 500m) 2025 2030 483 504 3.75% Fixed Rate Resetting Subordinated Callable Notes (SGD 200m) 2025 2030 113 119 5.20% Fixed Rate Subordinated Notes (USD 2,050m) 2026 1,564 1,610 1.125% Fixed Rate Resetting Subordinated Callable Notes (EUR 1,000m) 2026 2031 833 — 4.836% Fixed Rate Subordinated Callable Notes (USD 2,000m) 2027 2028 1,564 1,627 5.088% Fixed-to-Floating Rate Subordinated Callable Notes (USD 1,500m) 2029 2030 1,162 1,213 3.564% Fixed Rate Resetting Subordinated Callable Notes (USD 1,000m) 2030 2035 696 703 3.811% Fixed Rate Resetting Subordinated Callable Notes (USD 1,000m) 2041 2042 782 — Barclays Bank PLC issued 6% Fixed Rate Subordinated Notes (EUR 1,500m) 2021 — 1,427 9.5% Subordinated Bonds (ex-Woolwich Plc) 2021 — 221 Subordinated Floating Rate Notes (EUR 100m) 2021 — 90 10% Fixed Rate Subordinated Notes 2021 — 2,108 10.179% Fixed Rate Subordinated Notes (USD 1,521m) 2021 — 1,101 Subordinated Floating Rate Notes (EUR 50m) 2022 42 45 6.625% Fixed Rate Subordinated Notes (EUR 1,000m) 2022 889 982 7.625% Contingent Capital Notes (USD 3,000m) 2022 1,133 1,132 Subordinated Floating Rate Notes (EUR 50m) 2023 42 45 5.75% Fixed Rate Subordinated Notes 2026 322 351 5.4% Reverse Dual Currency Subordinated Loan (JPY 15,000m) 2027 97 108 6.33% Subordinated Notes 2032 59 64 Subordinated Floating Rate Notes (EUR 68m) 2040 57 61 External issuances by other subsidiaries 2026 311 146 Total dated subordinated liabilities 12,404 16,033 Note a Instrument values are disclosed to the nearest million. |
Ordinary shares, share premiu_2
Ordinary shares, share premium, and other equity (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Equity [abstract] | |
Called up share capital, allotted and fully paid | Called up share capital, allotted and fully paid Number of shares Ordinary share capital Ordinary share premium Total share capital and share premium Other m £m £m £m £m As at 1 January 2021 17,359 4,340 297 4,637 11,172 Issued to staff under share incentive plans 37 9 51 60 — AT1 securities issuance — — — — 1,078 Repurchase of shares (644) (161) — (161) — Other movements — — — — 9 As at 31 December 2021 16,752 4,188 348 4,536 12,259 As at 1 January 2020 17,322 4,331 263 4,594 10,871 Issued to staff under share incentive plans 37 9 34 43 — AT1 securities issuance — — — — 1,142 AT1 securities redemption — — — — (831) Other movements — — — — (10) As at 31 December 2020 17,359 4,340 297 4,637 11,172 |
AT1 equity instruments | AT1 equity instruments 2021 2020 Initial call date £m £m AT1 equity instruments - Barclays PLC 7.875% Perpetual Subordinated Contingent Convertible Securities a 2022 995 986 7.875% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) 2022 1,131 1,131 7.25% Perpetual Subordinated Contingent Convertible Securities 2023 1,245 1,245 7.75% Perpetual Subordinated Contingent Convertible Securities (USD 2,500m) a 2023 1,924 1,925 5.875% Perpetual Subordinated Contingent Convertible Securities 2024 1,244 1,244 8% Perpetual Subordinated Contingent Convertible Securities (USD 2,000m) 2024 1,509 1,509 7.125% Perpetual Subordinated Contingent Convertible Securities a 2025 996 994 6.375% Perpetual Subordinated Contingent Convertible Securities 2025 996 996 6.125% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) a 2025 1,141 1,142 4.375% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) 2028 1,078 — Total AT1 equity instruments 12,259 11,172 Note a Reported net of securities held by the Group. |
Reserves (Table)
Reserves (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of reserves within equity [abstract] | |
Other reserves | 2021 2020 £m £m Currency translation reserve 2,740 2,871 Fair value through other comprehensive income reserve (283) 5 Cash flow hedging reserve (853) 1,575 Own credit reserve (960) (954) Other reserves and treasury shares 1,126 964 Total 1,770 4,461 |
Non-controlling interests (Tabl
Non-controlling interests (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Non-controlling interests [Abstract] | |
Non-controlling interests by group | Profit attributable to non-controlling interest Equity attributable to non-controlling interest Dividends paid to non-controlling interest 2021 2020 2021 2020 2021 2020 £m £m £m £m £m £m Barclays Bank PLC issued: – Preference shares 27 42 529 529 27 42 – Upper Tier 2 instruments 17 37 458 533 17 37 Other non-controlling interests 3 (1) 2 23 — — Total 47 78 989 1,085 44 79 |
Non-controlling interests by instruments | 2021 2020 Instrument £m £m Preference Shares: US Dollar Preference Shares 318 318 Euro Preference Shares 211 211 Total Barclays Bank PLC Preference Shares 529 529 Upper Tier 2 Instruments: Undated Floating Rate Primary Capital Notes Series 1 93 93 Undated Floating Rate Primary Capital Notes Series 2 179 179 5.03% Undated Reverse Dual Currency Subordinated Loan (JPY8bn) 39 39 5.0% Reverse Dual Currency Undated Subordinated Loan (JPY12bn) 53 53 Undated Floating Rate Primary Capital Notes Series 3 (£145m) 20 20 9% Permanent Interest Bearing Capital Bonds (£100m) 40 40 6.125% Undated Subordinated Notes (£550m) 34 34 9.25% Perpetual Subordinated Bonds (ex Woolwich) (£150m) — 75 Total Upper Tier 2 Instruments 458 533 |
Staff costs (Table)
Staff costs (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Classes of employee benefits expense [abstract] | |
Staff costs | 2021 2020 2019 £m £m £m Incentive awards granted: Current year bonus 1,278 1,090 1,058 Deferred bonus 667 490 432 Total incentive awards granted 1,945 1,580 1,490 Reconciliation of incentive awards granted to income statement charge: Less: deferred bonuses granted but not charged in current year (457) (335) (293) Add: current year charges for deferred bonuses from previous years 280 293 308 Other differences between incentive awards granted and income statement charge (23) (34) (48) Income statement charge for performance costs 1,745 1,504 1,457 Other income statement charges: Salaries 4,290 4,322 4,332 Social security costs 619 613 573 Post-retirement benefits a 539 519 501 Other compensation costs 431 479 480 Total compensation costs b 7,624 7,437 7,343 Other resourcing costs: Outsourcing 357 342 433 Redundancy and restructuring 296 102 132 Temporary staff costs 109 102 256 Other 125 114 151 Total other resourcing costs 887 660 972 Total staff costs 8,511 8,097 8,315 Notes a Post-retirement benefits charge includes £289m (2020: £279m; 2019: £270m) in respect of defined contribution schemes and £250m (2020: £240m; 2019: £231m) in respect of defined benefit schemes. b £484m (2020: £451m; 2019: £439m) of Group compensation was capitalised as internally generated software and excluded from the Staff cost disclosed above . |
Share-based payments (Tables)
Share-based payments (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of terms and conditions of share-based payment arrangement [abstract] | |
Share-based payment schemes | The charge for the year arising from share-based payment schemes was as follows: Charge for the year 2021 2020 2019 £m £m £m Deferred Share Value Plan and Share Value Plan 256 245 272 Others 216 184 206 Total equity settled 472 429 478 Cash settled 5 2 3 Total share-based payments 477 431 481 |
Share option and award plans | The weighted average fair value per award granted, weighted average share price at the date of exercise/release of shares during the year, weighted average contractual remaining life and number of options and awards outstanding (including those exercisable) at the balance sheet date were as follows: 2021 2020 Weighted average fair value per award granted in year Weighted average share price at exercise/release during year Weighted Number of Weighted average fair value per award granted in year Weighted average share price at exercise/release during year Weighted Number of £ £ in years (000s) £ £ in years (000s) DSVP and SVP a,b 1.62 1.76 1 413,859 1.06 1.24 1 416,941 Others a 0.64-1.80 1.75-1.92 0-3 335,976 0.23-1.24 1.04-1.68 0-3 356,033 Notes a Options/award granted over Barclays PLC shares. b Weighted average exercise price is not applicable for SVP and DSVP awards as these are not share option schemes. |
Movements in options and awards | The movement in the number of options and awards for the major schemes and the weighted average exercise price of options was: DSVP and SVP a,b Others a,c Number (000s) Number (000s) Weighted average ex. price (£) 2021 2020 2021 2020 2021 2020 Outstanding at beginning of year/acquisition date 416,941 331,491 356,033 232,259 0.96 1.29 Granted in the year 187,667 232,379 120,385 365,166 1.43 0.84 Exercised/released in the year (160,460) (132,376) (107,688) (123,042) 1.38 1.22 Less: forfeited in the year (30,289) (14,553) (24,489) (105,068) 0.95 1.24 Less: expired in the year — — (8,265) (13,282) 1.67 1.35 Outstanding at end of year 413,859 416,941 335,976 356,033 0.95 0.96 Of which exercisable: — — 28,609 30,833 1.23 1.66 Notes a Options/award granted over Barclays PLC shares. b Weighted average exercise price is not applicable for SVP and DSVP awards as these are not share option schemes. c The number of awards within Others at the end of the year principally relates to Sharesave (number of awards exercisable at end of year was 8,821,715). The weighted average exercise price relates to Sharesave. |
Pension and post-retirement b_2
Pension and post-retirement benefits (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of defined benefit plans [abstract] | |
Income statement charge | The following tables include amounts recognised in the income statement and an analysis of benefit obligations and scheme assets for all Group defined benefit schemes. The net position is reconciled to the assets and liabilities recognised on the balance sheet. The tables include funded and unfunded post-retirement benefits. Income statement charge 2021 2020 2019 £m £m £m Current service cost 247 243 231 Net finance cost (26) (40) (48) Past service cost — (4) — Other movements 3 1 — Total 224 200 183 |
Balance sheet reconciliation | Balance sheet reconciliation 2021 2020 Total Of which relates to UKRF Total Of which relates to UKRF £m £m £m £m Benefit obligation at beginning of the year (33,190) (32,108) (30,333) (29,304) Current service cost (247) (225) (243) (217) Interest costs on scheme liabilities (422) (405) (573) (549) Past service cost — — 4 — Remeasurement (loss)/gain – financial 848 820 (3,439) (3,358) Remeasurement (loss)/gain – demographic 53 50 (281) (286) Remeasurement (loss)/gain – experience (249) (259) 244 237 Employee contributions (4) — (5) (1) Benefits paid 1,309 1,268 1,406 1,370 Exchange and other movements 3 — 30 — Benefit obligation at end of the year (31,899) (30,859) (33,190) (32,108) Fair value of scheme assets at beginning of the year 34,713 33,915 32,093 31,362 Interest income on scheme assets 448 434 613 595 Employer contribution 971 955 265 248 Remeasurement – return on scheme assets greater than discount rate 653 642 3,411 3,328 Employee contributions 4 — 5 1 Benefits paid (1,309) (1,268) (1,406) (1,370) Exchange and other movements (13) — (268) (249) Fair value of scheme assets at end of the year 35,467 34,678 34,713 33,915 Net surplus 3,568 3,819 1,523 1,807 Retirement benefit assets 3,879 3,819 1,814 1,807 Retirement benefit liabilities (311) — (291) — Net retirement benefit assets 3,568 3,819 1,523 1,807 |
Actuarial valuation of the schemes' obligation based on assumptions | Actuarial valuation of the schemes’ obligation is dependent upon a series of assumptions. Below is a summary of the main financial and demographic assumptions adopted for the UKRF. 2021 2020 Key UKRF financial assumptions % p.a. % p.a. Discount rate 1.84 1.29 Inflation rate (RPI) 3.56 2.99 Assumed life expectancy 2021 2020 2019 Life expectancy at 60 for current pensioners (years) – Males 27.3 27.2 27.1 – Females 29.6 29.4 29.3 Life expectancy at 60 for future pensioners currently aged 40 (years) – Males 29.1 29.0 28.9 – Females 31.4 31.2 31.1 The sensitivity analysis has been calculated by valuing the UKRF liabilities using the amended assumptions shown in the table below and keeping the remaining assumptions the same as disclosed in the table above, except in the case of the inflation sensitivity where other assumptions that depend on assumed inflation have also been amended correspondingly. The difference between the recalculated liability figure and that stated in the balance sheet reconciliation table above is the figure shown. The selection of these movements to illustrate the sensitivity of the defined benefit obligation to key assumptions should not be interpreted as Barclays expressing any specific view of the probability of such movements happening. Change in key assumptions 2021 2020 (Decrease)/ Increase in UKRF defined benefit obligation (Decrease)/ Increase in UKRF defined benefit obligation £bn £bn Discount rate 0.5% p.a. increase (2.3) (2.5) 0.25% p.a. increase (1.2) (1.3) 0.25% p.a. decrease 1.3 1.4 0.5% p.a. decrease 2.6 2.9 Assumed RPI 0.5% p.a. increase 1.6 1.8 0.25% p.a. increase 0.8 0.9 0.25% p.a. decrease (0.8) (0.9) 0.5% p.a. decrease (1.6) (1.8) Life expectancy at 60 One year increase 1.2 1.2 One year decrease (1.2) (1.2) |
Analysis of scheme assets | The value of the assets of the schemes and their percentage in relation to total scheme assets were as follows: Analysis of scheme assets Total Of which relates to UKRF Quoted a £m Unquoted a £m Value % of total fair value of Quoted a £m Unquoted a £m Value % of total fair value of As at 31 December 2021 Equities 214 1,377 1,591 4.5 86 1,377 1,463 4.2 Private equities — 2,991 2,991 8.4 — 2,991 2,991 8.6 Bonds - fixed government 2,387 95 2,482 7.0 2,083 95 2,178 6.3 Bonds - index-linked government 13,478 679 14,157 39.9 13,455 679 14,134 40.8 Bonds - corporate and other 6,223 2,854 9,077 25.6 5,986 2,854 8,840 25.5 Property 14 1,490 1,504 4.3 — 1,490 1,490 4.3 Infrastructure — 1,815 1,815 5.1 — 1,815 1,815 5.2 Cash and liquid assets 189 1,577 1,766 5.0 176 1,577 1,753 5.1 Mixed investment funds 9 — 9 — — — — — Other 19 56 75 0.2 — 14 14 — Fair value of scheme assets 22,533 12,934 35,467 100.0 21,786 12,892 34,678 100.0 As at 31 December 2020 Equities 567 1,498 2,065 5.9 378 1,498 1,876 5.5 Private equities — 2,233 2,233 6.4 — 2,233 2,233 6.6 Bonds - fixed government 4,205 110 4,315 12.4 3,932 110 4,042 11.9 Bonds - index-linked government 10,706 1,014 11,720 33.8 10,697 1,014 11,711 34.6 Bonds - corporate and other 7,439 1,678 9,117 26.3 7,214 1,678 8,892 26.2 Property 10 1,416 1,426 4.1 — 1,416 1,416 4.2 Infrastructure — 1,812 1,812 5.2 — 1,812 1,812 5.3 Cash and liquid assets 64 1,830 1,894 5.5 46 1,830 1,876 5.5 Mixed investment funds 9 — 9 — — — — — Other 14 108 122 0.4 — 57 57 0.2 Fair value of scheme assets 23,014 11,699 34,713 100.0 22,267 11,648 33,915 100.0 Note a Valuations of unquoted assets are provided by the underlying managers or qualified independent valuers. Valuations of complex instruments are based on UKRF custodian valuations. All valuations are determined in accordance with relevant industry guidance. |
Deficit reduction contributions | The deficit reduction contributions agreed with the UKRF Trustee as part of the 30 September 2019 triennial valuation recovery plan are shown in the table below. Deficit reduction contributions under the 30 September 2019 valuation Year £m Cash paid: 2021 700 Future commitments: 2022 294 2023 286 2024 and beyond — |
Defined benefit contributions paid | Defined benefit contributions paid with respect to the UKRF were as follows: Contributions paid £m 2021 955 2020 748 2019 1,231 |
Principal subsidiaries (Tables)
Principal subsidiaries (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of subsidiaries [abstract] | |
Principal subsidiaries details | Principal subsidiaries for the Group are set out below. This includes those subsidiaries that are most significant in the context of the Group’s business, results or financial position. Principal place of business or incorporation Percentage of voting rights held Non-controlling interests - proportion of ownership interests Non-controlling interests - proportion of voting interests Company name Nature of business % % % Barclays Bank PLC United Kingdom Banking, holding company 100 2 — Barclays Bank UK PLC United Kingdom Banking, holding company 100 — — Barclays Bank Ireland PLC Ireland Banking 100 — — Barclays Execution Services Limited United Kingdom Service company 100 — — Barclays Capital Inc. United States Securities dealing 100 — — Barclays Capital Securities Limited United Kingdom Securities dealing 100 — — Barclays Securities Japan Limited Japan Securities dealing 100 — — Barclays US LLC United States Holding company 100 — — Barclays Bank Delaware United States Credit card issuer 100 — — |
Entities excluded from consolidation | However, the entity set out below is excluded from consolidation because the Group does not have exposure to its variable returns. Percentage of voting rights held Equity shareholders' funds Retained profit for the year Company name Country of registration or incorporation % £m £m Palomino Limited Cayman Islands 100 — — |
Structured entities (Tables)
Structured entities (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of information about consolidated structured entities [abstract] | |
Summary of interests in unconsolidated structured entities | The nature and extent of the Group’s interests in structured entities is summarised below: Summary of interests in unconsolidated structured entities Secured financing Short-term traded interests Traded derivatives Other interests Total £m £m £m £m £m As at 31 December 2021 Assets Trading portfolio assets — 7,170 — — 7,170 Financial assets at fair value through the income statement 61,816 — — 3,490 65,306 Derivative financial instruments — — 5,160 — 5,160 Financial assets at fair value through other comprehensive income — — — 91 91 Loans and advances at amortised cost — — — 28,227 28,227 Reverse repurchase agreements and other similar secured lending 104 — — — 104 Other assets — — — 17 17 Total assets 61,920 7,170 5,160 31,825 106,075 Liabilities Derivative financial instruments — — 9,543 — 9,543 As at 31 December 2020 Assets Trading portfolio assets — 11,361 — — 11,361 Financial assets at fair value through the income statement 56,265 — — 2,864 59,129 Derivative financial instruments — — 2,968 — 2,968 Financial assets at fair value through other comprehensive income — — — 153 153 Loans and advances at amortised cost — — — 20,946 20,946 Reverse repurchase agreements and other similar secured lending 10 — — — 10 Other assets — — — 16 16 Total assets 56,275 11,361 2,968 23,979 94,583 Liabilities Derivative financial instruments — — 7,075 — 7,075 Nature of interest Multi-seller conduit programme Lending Other Total Of which: Barclays owned, not consolidated entities a £m £m £m £m £m As at 31 December 2021 Financial assets at fair value through the income statement — 70 3,420 3,490 3,335 Financial assets at fair value through other comprehensive income — 53 38 91 — Loans and advances at amortised cost 5,184 14,538 8,505 28,227 — Other assets 8 4 5 17 — Total on-balance sheet exposures 5,192 14,665 11,968 31,825 3,335 Total off-balance sheet notional amounts 11,015 9,426 — 20,441 — Maximum exposure to loss 16,207 24,091 11,968 52,266 3,335 Total assets of the entity 65,441 166,238 52,873 284,552 11,513 As at 31 December 2020 Financial assets at fair value through the income statement — 98 2,766 2,864 2,698 Financial assets at fair value through other comprehensive income — 106 47 153 — Loans and advances at amortised cost 5,146 12,721 3,079 20,946 — Other assets 8 3 5 16 — Total on-balance sheet exposures 5,154 12,928 5,897 23,979 2,698 Total off-balance sheet notional amounts 11,750 7,555 — 19,305 — Maximum exposure to loss 16,904 20,483 5,897 43,284 2,698 Total assets of the entity 87,004 159,804 44,362 291,170 11,008 Note a Comprises of Barclays owned, not consolidated structured entities per IFRS 10 Consolidated Financial Statements, and Barclays sponsored entities, Refer to Note 34 Principal subsidiaries for more details on consolidation. |
Investments in associates and_2
Investments in associates and joint ventures (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Investments in subsidiaries, joint ventures and associates reported in separate financial statements [abstract] | |
Investments in associates and joint ventures | 2021 2020 Associates Joint ventures Total Associates Joint ventures Total £m £m £m £m £m £m Equity accounted 722 277 999 464 317 781 Held at fair value through profit or loss — 444 444 — 437 437 Total 722 721 1,443 464 754 1,218 |
Summarised financial information, equity accounted associates and joint ventures | Summarised financial information for the Group’s equity accounted associates and joint ventures is set out below. The amounts shown are the Group’s share of the net income of the investees for the year ended 31 December 2021, with the exception of certain undertakings for which the amounts are based on accounts made up to dates not earlier than three months before the balance sheet date. Associates Joint ventures 2021 2020 2021 2020 £m £m £m £m Profit/(loss) from continuing operations 219 (24) 35 24 Other comprehensive income/(loss) 1 (3) 5 (6) Total comprehensive income/(loss) from continuing operations 220 (27) 40 18 |
Securitisations (Tables)
Securitisations (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of transferred financial assets that are not derecognised in their entirety [abstract] | |
Transfers of financial assets that do not result in derecognition | The following table shows the carrying amount of securitised assets that have not resulted in full derecognition, together with the associated liabilities, for each category of asset on the balance sheet: 2021 2020 Assets Liabilities Assets Liabilities Carrying amount Fair value Carrying amount Fair value Carrying amount Fair value Carrying amount Fair value £m £m £m £m £m £m £m £m Loans and advances at amortised cost Credit cards, unsecured and other retail lending 1,303 1,423 (1,225) (1,219) 1,033 1,121 (1,019) (1,033) |
Continuing involvement in financial assets that have been derecognised | The table below shows the potential financial implications of such continuing involvement: Continuing involvement a Gain/(loss) from continuing involvement Carrying amount Fair value Maximum exposure to loss For the year ended Cumulative to Cumulative to 31 December Type of transfer £m £m £m £m £m 2021 Asset backed securities 25 25 25 1 2 Residential mortgage backed securities 574 574 574 3 4 Commercial mortgage backed securities 311 307 311 5 11 Total 910 906 910 9 17 2020 Asset backed securities 56 56 56 1 1 Residential mortgage backed securities 49 49 49 1 1 Commercial mortgage backed securities 243 237 243 2 6 Total 348 342 348 4 8 Note a Assets which represent the Group’s continuing involvement in derecognised assets are recorded in Loans and advances at amortised cost and Debt securities at FVTP&L. |
Assets pledged, collateral re_2
Assets pledged, collateral received and assets transferred (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Assets pledged, collateral received and assets transferred [Abstract] | |
Assets pledged and assets transferred as security against liabilities | The following table summarises the nature and carrying amount of the assets pledged as security against these liabilities: 2021 2020 £m £m Cash collateral and settlements 66,138 72,042 Loans and advances at amortised cost 65,216 37,257 Trading portfolio assets 71,518 77,198 Financial assets at fair value through the income statement 5,595 5,584 Financial assets at fair value through other comprehensive income 13,748 22,185 Assets pledged 222,215 214,266 The following table summarises the transferred financial assets and the associated liabilities: Transferred assets Associated liabilities £m £m At 31 December 2021 Derivatives 66,744 (66,744) Repurchase agreements 71,820 (49,543) Securities lending arrangements 69,316 — Other 14,335 (12,121) 222,215 (128,408) At 31 December 2020 Derivatives 77,574 (77,574) Repurchase agreements 65,673 (44,076) Securities lending arrangements 61,183 — Other 9,836 (7,408) 214,266 (129,058) Included within Other are agreements where a counterparty's recourse is limited to the transferred assets. The relationship between the transferred assets and the associated liabilities is that holders of notes may only look to cash flows from the securitised assets for payments of principal and interest due to them under the terms of their notes. Carrying value Fair value Transferred assets Associated liabilities Transferred assets Associated liabilities Net position £m £m £m £m £m 2021 Recourse to transferred assets only 1,303 (1,225) 1,423 (1,219) 204 2020 Recourse to transferred assets only 1,033 (1,019) 1,121 (1,033) 88 |
Collateral held as security for assets | Under certain transactions, including reverse repurchase agreements and stock borrowing transactions, the Group is allowed to resell or re-pledge the collateral held. The fair value at the balance sheet date of collateral accepted and re-pledged or transferred to others was as follows: 2021 2020 £m £m Fair value of securities accepted as collateral 928,999 793,573 Of which fair value of securities re-pledged/transferred to others 814,448 685,300 |
Related party transactions an_2
Related party transactions and Directors' remuneration (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of transactions between related parties [abstract] | |
Amounts included in the Group's financial statements by category | Amounts included in the Group’s financial statements, in aggregate, by category of related party entity are as follows: Associates Joint ventures Pension funds £m £m £m For the year ended and as at 31 December 2021 Total income — 50 5 Credit impairment charges — — — Operating expenses (20) — (1) Total assets — 1,278 3 Total liabilities 177 — 81 For the year ended and as at 31 December 2020 Total income — 10 5 Credit impairment charges — — — Operating expenses (26) — (1) Total assets — 1,388 4 Total liabilities 66 — 69 |
Related party transactions Loans and deposits outstanding | The Group provides banking services to Key Management Personnel and persons connected to them. Transactions during the year and the balances outstanding were as follows: Loans outstanding 2021 2020 £m £m As at 1 January 9.2 7.2 Loans issued during the year a 0.4 2.3 Loan repayments during the year b (1.8) (0.3) As at 31 December 7.8 9.2 Notes a Includes loans issued to existing Key Management Personnel and new or existing loans issued to newly appointed Key Management Personnel. b Includes loan repayments by existing Key Management Personnel and loans to former Key Management Personnel. No allowances for impairment were recognised in respect of loans to Key Management Personnel (or any connected person). Deposits outstanding 2021 2020 £m £m As at 1 January 10.4 12.1 Deposits received during the year a 37.6 41.6 Deposits repaid during the year b (38.9) (43.3) As at 31 December 9.1 10.4 Notes a Includes deposits received from existing Key Management Personnel and new or existing deposits received from newly appointed Key Management Personnel. b Includes deposits repaid by existing Key Management Personnel and deposits of former Key Management Personnel. |
Remuneration of Directors and other Key Management Personnel | Total remuneration awarded to Key Management Personnel below represents the awards made to individuals that have been approved by the Board Remuneration Committee as part of the latest remuneration decisions, and is consistent with the approach adopted for disclosures set out in the Directors’ Remuneration Report. Costs recognised in the income statement reflect the accounting charge for the year included within operating expenses. The difference between the values awarded and the recognised income statement charge principally relates to the recognition of deferred costs for prior year awards. Figures are provided for the period that individuals met the definition of Key Management Personnel. 2021 2020 £m £m Salaries and other short-term benefits 37.8 41.6 Pension costs — — Other long-term benefits 8.5 8.2 Share-based payments 12.2 13.2 Employer social security charges on emoluments 7.2 7.2 Costs recognised for accounting purposes 65.7 70.2 Employer social security charges on emoluments (7.2) (7.2) Other long-term benefits – difference between awards granted and costs recognised 3.1 — Share-based payments – difference between awards granted and costs recognised 6.9 1.1 Total remuneration awarded 68.5 64.1 |
Disclosure required by the Companies Act 2006 | The following information regarding the Barclays PLC Board of Directors is presented in accordance with the Companies Act 2006: 2021 2020 £m £m Aggregate emoluments a 8.2 8.4 Amounts paid under LTIPs b 1.2 — 9.4 8.4 Notes a The aggregate emoluments include amounts paid for the 2021 year. In addition, deferred share awards for 2021 with a total value at grant of £1.4m (2020: £0.6m) will be made to CS Venkatakrishnan and Tushar Morzaria which will only vest subject to meeting certain conditions. b The figure above for "Amounts paid under LTIPs" in 2021 relates to LTIP awards that were released to Jes Staley and Tushar Morzaria in 2021. This includes the first tranche of the 2017 LTIP, the release of which was delayed from June 2020 to March 2021. Dividend shares released on the awards are excluded. The LTIP figure in the single total figure table for Executive Directors' 2021 remuneration in the Directors' Remuneration report relates to the award that is scheduled to be released in 2022 in respect of the 2019-2021 LTIP cycle. |
Auditor's remuneration (Tables)
Auditor's remuneration (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Auditor's remuneration [abstract] | |
Auditor's remuneration | Auditor’s remuneration is included within consultancy, legal and professional fees in administration and general expenses and comprises: 2021 2020 2019 £m £m £m Audit of the Barclays Group's annual accounts 9 9 10 Other services: Audit of the Company's subsidiaries a 41 38 35 Other audit related fees b 10 10 9 Other services 2 2 2 Total Auditor's remuneration 62 59 56 Notes a Comprises the fees for the statutory audit of subsidiaries both inside and outside the UK and fees for work performed by associates of KPMG in respect of the consolidated financial statements of the Company. b Comprises services in relation to statutory and regulatory filings. These include audit services for the review of the interim financial information under the Listing Rules of the UK listing authority. |
Interest rate benchmark reform
Interest rate benchmark reform (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of financial instruments by type of interest rate [abstract] | |
Significant hedge accounting exposures impacted by the interest rate benchmark reform | The following table summarises the significant exposures impacted by interest rate benchmark reform: GBP LIBOR USD LIBOR JPY LIBOR CHF LIBOR Others b Total As at 31 December 2021 £m £m £m £m £m £m Non-derivative financial assets Loans and advances at amortised cost 14,166 15,812 25 229 431 30,663 Reverse repurchase agreements and other similar secured lending — 186 — — — 186 Financial assets at fair value through the income statement 185 8,538 5 327 194 9,249 Financial assets at fair value through other comprehensive income — — — — — — Non-derivative financial assets 14,351 24,536 30 556 625 40,098 Non-derivative financial liabilities Debt securities in issue — (6,137) (1,083) — — (7,220) Subordinated liabilities — (1,088) — — (113) (1,201) Financial liabilities designated at fair value (708) (212) (920) Non-derivative financial liabilities (708) (7,437) (1,083) — (113) (9,341) Equity Other equity instruments — (3,374) (92) — — (3,466) Standby facilities, credit lines and other commitments a 60,490 42,767 1,284 371 12,724 117,636 GBP LIBOR USD LIBOR JPY LIBOR CHF LIBOR Others b Total As at 31 December 2020 £m £m £m £m £m £m Non-derivative financial assets Loans and advances at amortised cost 30,179 18,109 173 18 1,725 50,204 Reverse repurchase agreements and other similar secured lending — 334 — — — 334 Financial assets at fair value through the income statement 3,496 6,373 — 283 209 10,361 Financial assets at fair value through other comprehensive income 186 114 — — 8 308 Non-derivative financial assets 33,861 24,930 173 301 1,942 61,207 Non-derivative financial liabilities Debt securities in issue (1,023) (10,718) (1,201) — — (12,942) Subordinated liabilities (71) (1,592) — — — (1,663) Financial liabilities designated at fair value (149) (1,273) (759) — (139) (2,320) Non-derivative financial liabilities (1,243) (13,583) (1,960) — (139) (16,925) Equity Other equity instruments (3,500) (3,131) — — — (6,631) Standby facilities, credit lines and other commitments a 18,944 74,011 — 74 15,951 108,980 Notes a There has been a change on how exposures for multi currency loan facilities are reported in 2021, from base currency to the currency which needs to be remediated first. This has resulted in an increase in GBP LIBOR and a corresponding reduction in USD LIBOR exposure of £34bn. 2020 comparatives have not been restated to reflect this change. b Includes EUR LIBOR and SOR The following table represents the derivative exposures to interest rate benchmark reform, which have yet to transition: GBP LIBOR USD LIBOR EONIA JPY LIBOR CHF LIBOR Others a Total As at 31 December 2021 £m £m £m £m £m £m £m Derivative notional contract amount OTC interest rate derivatives 240,183 2,283,236 7,811 140,357 4,396 61,937 2,737,920 OTC interest rate derivatives - cleared by central counterparty — 2,228,399 — — — 168,649 2,397,048 Exchange traded interest rate derivatives — 466,339 — — — — 466,339 OTC foreign exchange derivatives 183,477 461,680 — 122,823 32,900 1,419 802,299 OTC equity and stock index derivatives — 9,949 — — — — 9,949 Derivative notional contract amount 423,660 5,449,603 7,811 263,180 37,296 232,005 6,413,555 GBP LIBOR USD LIBOR EONIA JPY LIBOR CHF LIBOR Others a Total As at 31 December 2020 £m £m £m £m £m £m £m Derivative notional contract amount OTC interest rate derivatives 592,827 2,832,802 457,844 754,206 25,681 41,782 4,705,142 OTC interest rate derivatives - cleared by central counterparty 1,684,553 2,891,029 638,202 1,091,479 119,382 198,113 6,622,758 Exchange traded interest rate derivatives 300,182 333,705 — — 2,494 — 636,381 OTC foreign exchange derivatives 155,285 589,334 — 93,108 31,257 1,921 870,905 OTC equity and stock index derivatives 1,845 7,946 544 1,929 491 2,141 14,896 Derivative notional contract amount 2,734,692 6,654,816 1,096,590 1,940,722 179,305 243,957 12,850,082 Note a Includes EUR LIBOR, SOR and STIBOR The following tables present a breakdown of the exposures to IBOR reform (excluding USD LIBOR and other IBORs whose respective cessation dates is in the future) with fallbacks in place and those without: With appropriate fallback clause Without appropriate fallback clause GBP LIBOR JPY LIBOR CHF LIBOR EUR LIBOR Total GBP LIBOR JPY LIBOR CHF LIBOR EUR LIBOR Total As at 31 December 2021 £m £m £m £m £m £m £m £m £m £m Non-derivative financial assets Loans and advances at amortised cost 9,434 5 215 412 10,066 4,732 20 14 19 4,785 Financial assets at fair value through the income statement 125 5 327 8 465 60 — — 186 246 Non-derivative financial assets 9,559 10 542 420 10,531 4,792 20 14 205 5,031 Non-derivative financial liabilities Debt securities in issue — (1,083) — — (1,083) — — — — — Subordinated liabilities — — — — — — — — — — Financial liabilities designated at fair value (708) — — — (708) — — — — — Non-derivative financial liabilities (708) (1,083) — — (1,791) — — — — — Equity Other equity instruments — (92) — — (92) — — — — — Standby facilities, credit lines and other commitments 36,573 653 371 9,362 46,959 23,917 631 — 3,362 27,910 The majority of the remaining exposures without fallbacks in place are either undrawn facilities or syndicated facilities where the transition is led by a third party agent. Work is ongoing with clients and agents to transition facilities or insert fallbacks prior to the next rate reset. There may be some scenarios where synthetic LIBOR is temporarily used whilst Barclays continues to work with the client to remediate their exposures, with little expectation of longer term usage. With appropriate fallback clause Without appropriate fallback clause GBP LIBOR EONIA JPY LIBOR CHF LIBOR EUR LIBOR Total GBP LIBOR EONIA JPY LIBOR CHF LIBOR EUR LIBOR Total As at 31 December 2021 £m £m £m £m £m £m £m £m £m £m £m £m Derivative notional contract amount OTC interest rate derivatives 230,967 7,568 135,719 4,361 3,626 382,241 9,216 243 4,638 35 403 14,535 OTC foreign exchange derivatives 183,203 — 122,822 32,900 — 338,925 274 — 1 — — 275 Derivative notional contract amount 414,170 7,568 258,541 37,261 3,626 721,166 9,490 243 4,639 35 403 14,810 |
Other disclosures - Risk Mana_3
Other disclosures - Risk Management and Principal Risks - Maximum exposure and effects of netting, collateral and risk transfer (audited) (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of detailed information about financial instruments [line items] | ||
Financial assets | £ 1,360,339 | £ 1,329,242 |
Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 1,636,972 | 1,615,399 |
Netting and set-off | (207,520) | (240,068) |
Cash collateral | (38,590) | (46,508) |
Non-cash collateral | (446,557) | (418,161) |
Risk transfer | (32,328) | (33,839) |
Net exposure | 911,977 | 876,823 |
Total on-balance sheet | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 1,269,915 | 1,260,741 |
Netting and set-off | (207,520) | (240,068) |
Cash collateral | (37,543) | (45,285) |
Non-cash collateral | (400,413) | (375,312) |
Risk transfer | (30,404) | (32,037) |
Net exposure | 594,035 | 568,039 |
Cash and balances at central banks | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 238,574 | 191,127 |
Netting and set-off | 0 | 0 |
Cash collateral | 0 | 0 |
Non-cash collateral | 0 | 0 |
Risk transfer | 0 | 0 |
Net exposure | 238,574 | 191,127 |
Cash collateral and settlement balances | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 92,542 | 101,367 |
Netting and set-off | 0 | 0 |
Cash collateral | 0 | 0 |
Non-cash collateral | 0 | 0 |
Risk transfer | 0 | 0 |
Net exposure | 92,542 | 101,367 |
Reverse repurchase agreements and other similar secured lending | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 3,227 | 9,031 |
Netting and set-off | 0 | 0 |
Cash collateral | 0 | 0 |
Non-cash collateral | (3,227) | (9,031) |
Risk transfer | 0 | 0 |
Net exposure | 0 | 0 |
Other assets | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 1,212 | 850 |
Netting and set-off | 0 | 0 |
Cash collateral | 0 | 0 |
Non-cash collateral | 0 | 0 |
Risk transfer | 0 | 0 |
Net exposure | 1,212 | 850 |
Provision for undrawn contractually committed facilities and guarantees provided | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 367,057 | 354,658 |
Netting and set-off | 0 | 0 |
Cash collateral | (1,047) | (1,223) |
Non-cash collateral | (46,144) | (42,849) |
Risk transfer | (1,924) | (1,802) |
Net exposure | 317,942 | 308,784 |
Notional contract amount | 39,300 | 34,600 |
Provision for undrawn contractually committed facilities and guarantees provided | Contingent liabilities | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 21,346 | 21,609 |
Netting and set-off | 0 | 0 |
Cash collateral | (906) | (1,095) |
Non-cash collateral | (1,367) | (2,135) |
Risk transfer | (256) | (282) |
Net exposure | 18,817 | 18,097 |
Financial assets at fair value through the income statement | Total on-balance sheet | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 186,097 | 170,531 |
Netting and set-off | 0 | 0 |
Cash collateral | (1,428) | (681) |
Non-cash collateral | (174,639) | (160,506) |
Risk transfer | 0 | 0 |
Net exposure | 10,030 | 9,344 |
Trading portfolio assets | Total on-balance sheet | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 63,389 | 64,830 |
Netting and set-off | 0 | 0 |
Cash collateral | 0 | 0 |
Non-cash collateral | (729) | (765) |
Risk transfer | 0 | 0 |
Net exposure | 62,660 | 64,065 |
Fair value through other comprehensive income | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 77,927 | |
Netting and set-off | 0 | |
Cash collateral | 0 | |
Non-cash collateral | (106) | |
Risk transfer | (1,385) | |
Net exposure | 76,436 | |
Fair value through other comprehensive income | Total on-balance sheet | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 60,851 | |
Netting and set-off | 0 | |
Cash collateral | 0 | |
Non-cash collateral | (53) | |
Risk transfer | (1,164) | |
Net exposure | 59,634 | |
Loans and advances at amortised cost | Financial assets at amortised cost | Total on-balance sheet | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 361,451 | 342,632 |
Netting and set-off | (5,001) | (6,988) |
Cash collateral | (1,517) | (1,313) |
Non-cash collateral | (215,878) | (200,131) |
Risk transfer | (23,502) | (24,243) |
Net exposure | 115,553 | 109,957 |
Loans and advances at amortised cost | Financial assets at amortised cost | Total on-balance sheet | Credit risk | Stage 3 | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 4,714 | 5,259 |
Netting and set-off | 0 | 0 |
Cash collateral | (41) | (32) |
Non-cash collateral | (2,660) | (2,905) |
Risk transfer | (768) | (234) |
Net exposure | 1,245 | 2,088 |
Loans and advances at amortised cost | Financial assets at fair value through the income statement | Total on-balance sheet | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 38,667 | 30,879 |
Netting and set-off | 0 | 0 |
Cash collateral | 0 | (9) |
Non-cash collateral | (31,263) | (23,677) |
Risk transfer | 0 | 0 |
Net exposure | 7,404 | 7,193 |
Home loans | Financial assets at amortised cost | Total on-balance sheet | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 169,205 | 159,647 |
Netting and set-off | 0 | 0 |
Cash collateral | (339) | (284) |
Non-cash collateral | (168,627) | (159,203) |
Risk transfer | (146) | (85) |
Net exposure | 93 | 75 |
Home loans | Financial assets at amortised cost | Total on-balance sheet | Credit risk | Stage 3 | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 1,725 | 1,813 |
Netting and set-off | 0 | 0 |
Cash collateral | (11) | (14) |
Non-cash collateral | (1,714) | (1,796) |
Risk transfer | 0 | 0 |
Net exposure | 0 | 3 |
Credit cards, unsecured and other retail lending | Financial assets at amortised cost | Total on-balance sheet | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 41,793 | 40,813 |
Netting and set-off | 0 | 0 |
Cash collateral | (1,050) | (967) |
Non-cash collateral | (4,560) | (3,825) |
Risk transfer | (252) | (195) |
Net exposure | 35,931 | 35,826 |
Credit cards, unsecured and other retail lending | Financial assets at amortised cost | Total on-balance sheet | Credit risk | Stage 3 | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 828 | 921 |
Netting and set-off | 0 | 0 |
Cash collateral | (29) | (14) |
Non-cash collateral | (229) | (237) |
Risk transfer | (3) | (2) |
Net exposure | 567 | 668 |
Wholesale loans | Financial assets at amortised cost | Total on-balance sheet | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 150,453 | 142,172 |
Netting and set-off | (5,001) | (6,988) |
Cash collateral | (128) | (62) |
Non-cash collateral | (42,691) | (37,103) |
Risk transfer | (23,104) | (23,963) |
Net exposure | 79,529 | 74,056 |
Wholesale loans | Financial assets at amortised cost | Total on-balance sheet | Credit risk | Stage 3 | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 2,161 | 2,525 |
Netting and set-off | 0 | 0 |
Cash collateral | (1) | (4) |
Non-cash collateral | (717) | (872) |
Risk transfer | (765) | (232) |
Net exposure | 678 | 1,417 |
BBLs and CBILs | Financial assets at amortised cost | Total on-balance sheet | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Risk transfer | (11,000) | (11,700) |
Financial assets | 11,400 | 12,200 |
Traded loans | Trading portfolio assets | Total on-balance sheet | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 12,525 | 8,348 |
Netting and set-off | 0 | 0 |
Cash collateral | 0 | 0 |
Non-cash collateral | (268) | (374) |
Risk transfer | 0 | 0 |
Net exposure | 12,257 | 7,974 |
Reverse repurchase agreements | Financial assets at fair value through the income statement | Total on-balance sheet | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 145,014 | 137,616 |
Netting and set-off | 0 | 0 |
Cash collateral | (1,428) | (672) |
Non-cash collateral | (143,057) | (136,537) |
Risk transfer | 0 | 0 |
Net exposure | 529 | 407 |
Other | Financial assets at fair value through the income statement | Total on-balance sheet | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 111 | 343 |
Netting and set-off | 0 | 0 |
Cash collateral | 0 | 0 |
Non-cash collateral | 0 | 0 |
Risk transfer | 0 | 0 |
Net exposure | 111 | 343 |
Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 262,572 | 302,446 |
Netting and set-off | (202,520) | (233,080) |
Cash collateral | (34,598) | (43,291) |
Notional contract amount | 48,032,325 | 43,359,755 |
Derivatives | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 5,682 | 4,605 |
Netting and set-off | (4,525) | (3,584) |
Derivatives | Total on-balance sheet | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 262,572 | 302,446 |
Netting and set-off | (202,519) | (233,080) |
Cash collateral | (34,598) | (43,291) |
Non-cash collateral | (5,887) | (4,773) |
Risk transfer | (5,738) | (6,409) |
Net exposure | 13,830 | 14,893 |
Debt securities classified at amortised cost | Financial assets at fair value through the income statement | Total on-balance sheet | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 2,305 | 1,693 |
Netting and set-off | 0 | 0 |
Cash collateral | 0 | 0 |
Non-cash collateral | (319) | (292) |
Risk transfer | 0 | 0 |
Net exposure | 1,986 | 1,401 |
Debt securities classified at amortised cost | Trading portfolio assets | Total on-balance sheet | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 50,864 | 56,482 |
Netting and set-off | 0 | 0 |
Cash collateral | 0 | 0 |
Non-cash collateral | (461) | (391) |
Risk transfer | 0 | 0 |
Net exposure | 50,403 | 56,091 |
Total commitments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 345,711 | 333,049 |
Total commitments | Provision for undrawn contractually committed facilities and guarantees provided | Credit risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Maximum exposure | 345,711 | 333,049 |
Netting and set-off | 0 | 0 |
Cash collateral | (141) | (128) |
Non-cash collateral | (44,777) | (40,714) |
Risk transfer | (1,668) | (1,520) |
Net exposure | £ 299,125 | £ 290,687 |
Other disclosures - Risk Mana_4
Other disclosures - Risk Management and Principal Risks - Loans and advances at amortised cost by stage (audited) (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 1,360,339 | £ 1,329,242 | ||
Coverage ratio | 0.90% | 1.40% | ||
Impairment reversal/(charge) of investment in subsidiary | £ (653) | [1] | £ 4,838 | £ 1,912 |
Loan loss rate | 1.38% | |||
Loans and advances at amortised cost | 361,451 | [2] | £ 342,632 | |
Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Loans and advances at amortised cost | 361,451 | 342,632 | ||
ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (6,284) | (9,399) | ||
Net gains on financial instruments designated at fair value | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | £ 18,800 | £ 9,500 | ||
Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 0.20% | 0.20% | ||
Lifetime expected credit losses | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 3.10% | 4.20% | ||
Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 29.80% | 33.40% | ||
Total Barclays Group Wholesale | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 5,994 | £ 7,551 | ||
Total Barclays Group Wholesale | Financial assets at amortised cost | Government | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Loans and advances at amortised cost | 9,400 | |||
Head Office | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Impairment reversal/(charge) of investment in subsidiary | 0 | 91 | 27 | |
Barclays UK | Operating segments | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Impairment reversal/(charge) of investment in subsidiary | (365) | 1,467 | 712 | |
Barclays International | Operating segments | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Impairment reversal/(charge) of investment in subsidiary | (288) | 3,280 | 1,173 | |
Loans and advances at amortised cost, including off balance sheet loan commitments and financial guarantee contracts | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 709,164 | 686,728 | ||
Loans and advances at amortised cost, including off balance sheet loan commitments and financial guarantee contracts | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 715,448 | 696,127 | ||
Loans and advances at amortised cost, including off balance sheet loan commitments and financial guarantee contracts | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (6,284) | (9,399) | ||
Loans and advances at amortised cost, including off balance sheet loan commitments and financial guarantee contracts | Stage 1 | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 631,007 | 580,903 | ||
Loans and advances at amortised cost, including off balance sheet loan commitments and financial guarantee contracts | Stage 1 | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (1,423) | (1,289) | ||
Loans and advances at amortised cost, including off balance sheet loan commitments and financial guarantee contracts | Lifetime expected credit losses | Stage 2 | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 75,908 | 103,897 | ||
Loans and advances at amortised cost, including off balance sheet loan commitments and financial guarantee contracts | Lifetime expected credit losses | Stage 2 | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (2,317) | (4,322) | ||
Loans and advances at amortised cost, including off balance sheet loan commitments and financial guarantee contracts | Lifetime expected credit losses | Stage 3 | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 8,533 | 11,327 | ||
Loans and advances at amortised cost, including off balance sheet loan commitments and financial guarantee contracts | Lifetime expected credit losses | Stage 3 | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (2,544) | (3,788) | ||
Loans and advances at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Impairment reversal/(charge) of investment in subsidiary | (635) | 4,685 | 1,904 | |
Loans and advances at amortised cost | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 361,451 | £ 342,632 | ||
Coverage ratio | 1.60% | 2.40% | ||
Impairment reversal/(charge) of investment in subsidiary | £ (121) | £ 3,909 | ||
Loan loss rate | 0.00% | 1.11% | ||
Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 367,193 | £ 350,967 | ||
Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (5,742) | (8,335) | ||
Loans and advances at amortised cost | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 317,659 | £ 289,931 | ||
Coverage ratio | 0.40% | 0.40% | ||
Loans and advances at amortised cost | Stage 1 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 318,865 | £ 290,964 | ||
Loans and advances at amortised cost | Stage 1 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (1,206) | (1,033) | ||
Loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 39,078 | £ 47,442 | ||
Coverage ratio | 4.90% | 7.00% | ||
Loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 41,093 | £ 51,006 | ||
Loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (2,015) | (3,564) | ||
Loans and advances at amortised cost | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 4,714 | £ 5,259 | ||
Coverage ratio | 34.80% | 41.50% | ||
Loans and advances at amortised cost | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 7,235 | £ 8,997 | ||
Loans and advances at amortised cost | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (2,521) | (3,738) | ||
Loans and advances at amortised cost | Total Barclays Group retail | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 216,917 | £ 207,896 | ||
Coverage ratio | 2.10% | 3.00% | ||
Impairment reversal/(charge) of investment in subsidiary | £ (46) | £ 2,841 | ||
Loan loss rate | 0.00% | 1.33% | ||
Loans and advances at amortised cost | Total Barclays Group retail | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 221,496 | £ 214,249 | ||
Loans and advances at amortised cost | Total Barclays Group retail | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (4,579) | £ (6,353) | ||
Loans and advances at amortised cost | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 0.50% | 0.40% | ||
Loans and advances at amortised cost | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 190,411 | £ 178,565 | ||
Loans and advances at amortised cost | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (866) | £ (732) | ||
Loans and advances at amortised cost | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 6.90% | 9.60% | ||
Loans and advances at amortised cost | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 25,899 | £ 30,116 | ||
Loans and advances at amortised cost | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (1,780) | £ (2,889) | ||
Loans and advances at amortised cost | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 37.30% | 49.10% | ||
Loans and advances at amortised cost | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 5,186 | £ 5,568 | ||
Loans and advances at amortised cost | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (1,933) | (2,732) | ||
Loans and advances at amortised cost | Total Barclays Group Wholesale | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 144,534 | £ 134,736 | ||
Coverage ratio | 0.80% | 1.40% | ||
Impairment reversal/(charge) of investment in subsidiary | £ (75) | £ 1,068 | ||
Loan loss rate | 0.00% | 0.78% | ||
Loans and advances at amortised cost | Total Barclays Group Wholesale | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 145,697 | £ 136,718 | ||
Loans and advances at amortised cost | Total Barclays Group Wholesale | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (1,163) | £ (1,982) | ||
Loans and advances at amortised cost | Total Barclays Group Wholesale | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 0.30% | 0.30% | ||
Loans and advances at amortised cost | Total Barclays Group Wholesale | Stage 1 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 128,454 | £ 112,399 | ||
Loans and advances at amortised cost | Total Barclays Group Wholesale | Stage 1 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (340) | £ (301) | ||
Loans and advances at amortised cost | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 1.50% | 3.20% | ||
Loans and advances at amortised cost | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 15,194 | £ 20,890 | ||
Loans and advances at amortised cost | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (235) | £ (675) | ||
Loans and advances at amortised cost | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 28.70% | 29.30% | ||
Loans and advances at amortised cost | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 2,049 | £ 3,429 | ||
Loans and advances at amortised cost | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (588) | (1,006) | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group retail | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 4,484 | £ 5,396 | ||
Coverage ratio | 7.90% | 7.50% | ||
Impairment reversal/(charge) of investment in subsidiary | £ 0 | £ 91 | ||
Loan loss rate | 0.00% | 1.56% | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group retail | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 4,869 | £ 5,831 | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group retail | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (385) | £ (435) | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 0.10% | 0.10% | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 3,735 | £ 4,267 | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (2) | £ (4) | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 8.40% | 7.10% | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 429 | £ 720 | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (36) | £ (51) | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 49.20% | 45.00% | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 705 | £ 844 | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (347) | (380) | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group Wholesale | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 546 | £ 572 | ||
Coverage ratio | 3.40% | 5.10% | ||
Impairment reversal/(charge) of investment in subsidiary | £ 0 | £ 0 | ||
Loan loss rate | 0.00% | 0.00% | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group Wholesale | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 565 | £ 603 | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group Wholesale | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (19) | £ (31) | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group Wholesale | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 0.00% | 0.00% | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group Wholesale | Stage 1 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 542 | £ 570 | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group Wholesale | Stage 1 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 0 | £ 0 | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 0.00% | 0.00% | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 2 | £ 0 | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 0 | £ 0 | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 90.50% | 93.90% | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 21 | £ 33 | ||
Loans and advances at amortised cost | Head Office | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (19) | (31) | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 184,451 | £ 176,890 | ||
Coverage ratio | 1.00% | 1.70% | ||
Impairment reversal/(charge) of investment in subsidiary | £ (227) | £ 1,070 | ||
Loan loss rate | 0.00% | 0.59% | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 186,389 | £ 179,878 | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (1,938) | £ (2,988) | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 0.20% | 0.20% | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 160,695 | £ 153,250 | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (261) | £ (332) | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 4.20% | 6.30% | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 22,779 | £ 23,896 | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (949) | £ (1,509) | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 25.00% | 42.00% | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 2,915 | £ 2,732 | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (728) | (1,147) | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group Wholesale | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 38,150 | £ 37,111 | ||
Coverage ratio | 0.80% | 0.70% | ||
Impairment reversal/(charge) of investment in subsidiary | £ 122 | £ 154 | ||
Loan loss rate | 0.32% | 0.41% | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group Wholesale | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 38,457 | £ 37,369 | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group Wholesale | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (307) | £ (258) | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group Wholesale | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 0.40% | 0.00% | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group Wholesale | Stage 1 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 35,571 | £ 31,918 | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group Wholesale | Stage 1 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (153) | £ (13) | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 2.20% | 3.00% | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 1,917 | £ 4,325 | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (43) | £ (129) | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 11.50% | 10.30% | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 969 | £ 1,126 | ||
Loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (111) | (116) | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 27,982 | £ 25,610 | ||
Coverage ratio | 7.50% | 10.30% | ||
Impairment reversal/(charge) of investment in subsidiary | £ 181 | £ 1,680 | ||
Loan loss rate | 0.60% | 5.89% | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 30,238 | £ 28,540 | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (2,256) | £ (2,930) | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 2.30% | 1.90% | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 25,981 | £ 21,048 | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (603) | £ (396) | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 29.50% | 24.20% | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 2,691 | £ 5,500 | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (795) | £ (1,329) | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 54.80% | 60.50% | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 1,566 | £ 1,992 | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (858) | (1,205) | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group Wholesale | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 105,838 | £ 97,053 | ||
Coverage ratio | 0.80% | 1.70% | ||
Impairment reversal/(charge) of investment in subsidiary | £ (197) | £ 914 | ||
Loan loss rate | 0.00% | 0.93% | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group Wholesale | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 106,675 | £ 98,746 | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group Wholesale | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (837) | £ (1,693) | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group Wholesale | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 0.20% | 0.40% | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group Wholesale | Stage 1 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 92,341 | £ 79,911 | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group Wholesale | Stage 1 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (187) | £ (288) | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 1.40% | 3.30% | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 13,275 | £ 16,565 | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (192) | £ (546) | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 43.20% | 37.80% | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 1,059 | £ 2,270 | ||
Loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group Wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (458) | (859) | ||
Off balance sheet loan commitments and financial guarantee contracts | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 347,713 | £ 344,096 | ||
Coverage ratio | 0.20% | 0.30% | ||
Impairment reversal/(charge) of investment in subsidiary | £ (514) | £ 776 | ||
Off balance sheet loan commitments and financial guarantee contracts | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 348,255 | 345,160 | ||
Off balance sheet loan commitments and financial guarantee contracts | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (542) | (1,064) | ||
Off balance sheet loan commitments and financial guarantee contracts | Financial assets at amortised cost | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (542) | £ (1,064) | ||
Off balance sheet loan commitments and financial guarantee contracts | Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 0.00% | 0.10% | ||
Off balance sheet loan commitments and financial guarantee contracts | Stage 1 | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 312,142 | £ 289,939 | ||
Off balance sheet loan commitments and financial guarantee contracts | Stage 1 | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (217) | £ (256) | ||
Off balance sheet loan commitments and financial guarantee contracts | Lifetime expected credit losses | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 0.90% | 1.40% | ||
Off balance sheet loan commitments and financial guarantee contracts | Lifetime expected credit losses | Stage 2 | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 34,815 | £ 52,891 | ||
Off balance sheet loan commitments and financial guarantee contracts | Lifetime expected credit losses | Stage 2 | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (302) | £ (758) | ||
Off balance sheet loan commitments and financial guarantee contracts | Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Coverage ratio | 1.80% | 2.10% | ||
Off balance sheet loan commitments and financial guarantee contracts | Lifetime expected credit losses | Stage 3 | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 1,298 | £ 2,330 | ||
Off balance sheet loan commitments and financial guarantee contracts | Lifetime expected credit losses | Stage 3 | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (23) | (50) | ||
Other financial assets subject to impairment | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Impairment reversal/(charge) of investment in subsidiary | (18) | 153 | ||
Other financial assets subject to impairment | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 155,200 | 180,300 | 149,300 | |
Other financial assets subject to impairment | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (114) | (165) | (24) | |
Other financial assets subject to impairment | Stage 1 | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 154,900 | 175,700 | 148,500 | |
Other financial assets subject to impairment | Stage 1 | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (6) | (11) | (12) | |
Other financial assets subject to impairment | Lifetime expected credit losses | Stage 2 | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 800 | |||
Other financial assets subject to impairment | Lifetime expected credit losses | Stage 2 | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (2) | |||
Fair value through other comprehensive income | Lifetime expected credit losses | Stage 2 | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 157 | 4,400 | ||
Fair value through other comprehensive income | Lifetime expected credit losses | Stage 2 | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (1) | (9) | ||
Other assets | Lifetime expected credit losses | Stage 3 | Carrying amount | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 110 | 154 | 10 | |
Other assets | Lifetime expected credit losses | Stage 3 | ECL | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (107) | £ (145) | £ (10) | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Other disclosures - Risk Mana_5
Other disclosures - Risk Management and Principal Risks - Loans and advances at amortised cost by product (audited) (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of financial assets [line items] | ||
Financial assets | £ 1,360,339 | £ 1,329,242 |
Coverage ratio | 0.90% | 1.40% |
ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ (6,284) | £ (9,399) |
Stage 1 | ||
Disclosure of financial assets [line items] | ||
Coverage ratio | 0.20% | 0.20% |
Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Coverage ratio | 3.10% | 4.20% |
Lifetime expected credit losses | Stage 3 | ||
Disclosure of financial assets [line items] | ||
Coverage ratio | 29.80% | 33.40% |
Financial assets at amortised cost | Loans and advances | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 361,451 | £ 342,632 |
Coverage ratio | 1.60% | 2.40% |
Financial assets at amortised cost | Loans and advances | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 367,193 | £ 350,967 |
Financial assets at amortised cost | Loans and advances | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (5,742) | (8,335) |
Financial assets at amortised cost | Loans and advances | Stage 1 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 317,659 | £ 289,931 |
Coverage ratio | 0.40% | 0.40% |
Financial assets at amortised cost | Loans and advances | Stage 1 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 318,865 | £ 290,964 |
Financial assets at amortised cost | Loans and advances | Stage 1 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (1,206) | (1,033) |
Financial assets at amortised cost | Loans and advances | Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 39,078 | £ 47,442 |
Coverage ratio | 4.90% | 7.00% |
Financial assets at amortised cost | Loans and advances | Lifetime expected credit losses | Stage 2 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 41,093 | £ 51,006 |
Financial assets at amortised cost | Loans and advances | Lifetime expected credit losses | Stage 2 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (2,015) | (3,564) |
Financial assets at amortised cost | Loans and advances | Lifetime expected credit losses | Stage 3 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 4,714 | £ 5,259 |
Coverage ratio | 34.80% | 41.50% |
Financial assets at amortised cost | Loans and advances | Lifetime expected credit losses | Stage 3 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 7,235 | £ 8,997 |
Financial assets at amortised cost | Loans and advances | Lifetime expected credit losses | Stage 3 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (2,521) | (3,738) |
Financial assets at amortised cost | Home loans | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 169,205 | £ 159,647 |
Coverage ratio | 0.30% | 0.30% |
Financial assets at amortised cost | Home loans | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 169,680 | £ 160,185 |
Financial assets at amortised cost | Home loans | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (475) | (538) |
Financial assets at amortised cost | Home loans | Stage 1 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 148,039 | £ 138,606 |
Coverage ratio | 0.00% | 0.00% |
Financial assets at amortised cost | Home loans | Stage 1 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 148,058 | £ 138,639 |
Financial assets at amortised cost | Home loans | Stage 1 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (19) | (33) |
Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 19,441 | £ 19,228 |
Coverage ratio | 0.30% | 0.40% |
Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 19,500 | £ 19,312 |
Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (59) | (84) |
Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 3 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 1,725 | £ 1,813 |
Coverage ratio | 18.70% | 18.80% |
Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 3 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 2,122 | £ 2,234 |
Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 3 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (397) | (421) |
Financial assets at amortised cost | Credit cards, unsecured and other retail lending | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 41,793 | £ 40,813 |
Coverage ratio | 8.80% | 12.30% |
Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 45,822 | £ 46,513 |
Financial assets at amortised cost | Credit cards, unsecured and other retail lending | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (4,029) | (5,700) |
Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Stage 1 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 37,016 | £ 32,341 |
Coverage ratio | 2.20% | 2.10% |
Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Stage 1 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 37,840 | £ 33,021 |
Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Stage 1 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (824) | (680) |
Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 3,949 | £ 7,551 |
Coverage ratio | 30.10% | 26.80% |
Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 5,650 | £ 10,320 |
Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (1,701) | (2,769) |
Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 3 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 828 | £ 921 |
Coverage ratio | 64.50% | 71.00% |
Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 3 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 2,332 | £ 3,172 |
Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 3 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (1,504) | (2,251) |
Financial assets at amortised cost | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 150,453 | £ 142,172 |
Coverage ratio | 0.80% | 1.50% |
Financial assets at amortised cost | Wholesale loans | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 151,691 | £ 144,269 |
Financial assets at amortised cost | Wholesale loans | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (1,238) | (2,097) |
Financial assets at amortised cost | Wholesale loans | Stage 1 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 132,604 | £ 118,984 |
Coverage ratio | 0.30% | 0.30% |
Financial assets at amortised cost | Wholesale loans | Stage 1 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 132,967 | £ 119,304 |
Financial assets at amortised cost | Wholesale loans | Stage 1 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (363) | (320) |
Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 15,688 | £ 20,663 |
Coverage ratio | 1.60% | 3.30% |
Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 15,943 | £ 21,374 |
Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (255) | (711) |
Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 3 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 2,161 | £ 2,525 |
Coverage ratio | 22.30% | 29.70% |
Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 3 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 2,781 | £ 3,591 |
Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 3 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (620) | (1,066) |
Not past due | Financial assets at amortised cost | Loans and advances | Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 35,694 | £ 42,533 |
Coverage ratio | 4.80% | 6.80% |
Not past due | Financial assets at amortised cost | Loans and advances | Lifetime expected credit losses | Stage 2 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 37,481 | £ 45,622 |
Not past due | Financial assets at amortised cost | Loans and advances | Lifetime expected credit losses | Stage 2 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (1,787) | (3,089) |
Not past due | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 17,087 | £ 16,594 |
Coverage ratio | 0.30% | 0.30% |
Not past due | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 17,133 | £ 16,651 |
Not past due | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (46) | (57) |
Not past due | Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 3,609 | £ 7,088 |
Coverage ratio | 29.30% | 25.20% |
Not past due | Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 5,102 | £ 9,470 |
Not past due | Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (1,493) | (2,382) |
Not past due | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 14,998 | £ 18,851 |
Coverage ratio | 1.60% | 3.30% |
Not past due | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 15,246 | £ 19,501 |
Not past due | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (248) | (650) |
Not later than one month | Financial assets at amortised cost | Loans and advances | Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 2,171 | £ 3,183 |
Coverage ratio | 4.20% | 7.10% |
Not later than one month | Financial assets at amortised cost | Loans and advances | Lifetime expected credit losses | Stage 2 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 2,266 | £ 3,426 |
Not later than one month | Financial assets at amortised cost | Loans and advances | Lifetime expected credit losses | Stage 2 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (95) | (243) |
Not later than one month | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 1,654 | £ 1,772 |
Coverage ratio | 0.40% | 0.70% |
Not later than one month | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 1,660 | £ 1,785 |
Not later than one month | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (6) | (13) |
Not later than one month | Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 215 | £ 364 |
Coverage ratio | 28.30% | 33.10% |
Not later than one month | Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 300 | £ 544 |
Not later than one month | Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (85) | (180) |
Not later than one month | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 302 | £ 1,047 |
Coverage ratio | 1.30% | 4.60% |
Not later than one month | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 306 | £ 1,097 |
Not later than one month | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (4) | (50) |
Greater than 30 days past due | Financial assets at amortised cost | Loans and advances | Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 1,213 | £ 1,726 |
Coverage ratio | 9.90% | 11.80% |
Greater than 30 days past due | Financial assets at amortised cost | Loans and advances | Lifetime expected credit losses | Stage 2 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 1,346 | £ 1,958 |
Greater than 30 days past due | Financial assets at amortised cost | Loans and advances | Lifetime expected credit losses | Stage 2 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (133) | (232) |
Greater than 30 days past due | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 700 | £ 862 |
Coverage ratio | 1.00% | 1.60% |
Greater than 30 days past due | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 707 | £ 876 |
Greater than 30 days past due | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (7) | (14) |
Greater than 30 days past due | Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 125 | £ 99 |
Coverage ratio | 49.60% | 67.60% |
Greater than 30 days past due | Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 248 | £ 306 |
Greater than 30 days past due | Financial assets at amortised cost | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | (123) | (207) |
Greater than 30 days past due | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 388 | £ 765 |
Coverage ratio | 0.80% | 1.40% |
Greater than 30 days past due | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | Carrying amount | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ 391 | £ 776 |
Greater than 30 days past due | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | ECL | ||
Disclosure of financial assets [line items] | ||
Financial assets | £ (3) | £ (11) |
Other disclosures - Risk Mana_6
Other disclosures - Risk Management and Principal Risks - Movement in gross exposures and impairment allowance including reconciliation of ECL (Details) £ in Millions, $ in Millions | 12 Months Ended | ||||
Dec. 31, 2021GBP (£) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | Dec. 31, 2020USD ($) | ||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Recoveries and reimbursements | £ 240 | £ (399) | £ (124) | ||
Exchange and other adjustments | 123 | 145 | |||
Credit impairment (releases)/charges | (653) | [1] | 4,838 | 1,912 | |
Post write-off recoveries | 66 | 35 | |||
Financial assets | 1,360,339 | 1,329,242 | |||
Total contingent liabilities and financial guarantees | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Recoveries and reimbursements | (306) | (364) | |||
Post write-off recoveries | 35 | ||||
Loans and advances | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 9,399 | ||||
Closing/Ending balance | 6,284 | 9,399 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
ECL movement excluding assets derecognised due to disposals and write-offs | (484) | 4,163 | |||
Credit impairment (releases)/charges | (635) | 4,685 | 1,904 | ||
Loans and advances | ECL from post-model adjustments | |||||
Loans and advances at amortised cost | |||||
Closing/Ending balance | (1,500) | ||||
Loans and advances | Total model ECL | |||||
Loans and advances at amortised cost | |||||
Closing/Ending balance | 200 | ||||
Loans and advances | ECL from non-modelled and other management adjustments | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | (300) | ||||
Closing/Ending balance | (200) | (300) | |||
Home loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 538 | ||||
Closing/Ending balance | 475 | 538 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
ECL movement excluding assets derecognised due to disposals and write-offs | (42) | 128 | |||
Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 6,083 | ||||
Closing/Ending balance | 4,160 | 6,083 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
ECL movement excluding assets derecognised due to disposals and write-offs | (16) | 2,597 | |||
Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 2,778 | ||||
Closing/Ending balance | 1,649 | 2,778 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
ECL movement excluding assets derecognised due to disposals and write-offs | (426) | 1,438 | |||
Credit impairment release on other financial assets | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Credit impairment (releases)/charges | (18) | 153 | |||
Provision for undrawn contractually committed facilities and guarantees provided | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Credit impairment (releases)/charges | (514) | 776 | |||
Financial assets | 347,713 | 344,096 | |||
Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 160,185 | 154,911 | |||
Business activity in the year | 33,991 | 23,266 | |||
Refinements to models used for calculation | 0 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (9,437) | (7,093) | |||
Final repayments | (14,440) | (10,877) | |||
Disposals | (598) | 0 | |||
Write-offs | (21) | (22) | |||
Closing/Ending balance | 169,680 | 160,185 | 154,911 | ||
Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 46,513 | 60,180 | |||
Business activity in the year | 8,141 | 5,981 | |||
Refinements to models used for calculation | 0 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (3,806) | (12,394) | |||
Final repayments | (3,289) | (3,765) | |||
Disposals | (287) | (1,880) | |||
Write-offs | (1,450) | (1,609) | |||
Closing/Ending balance | 45,822 | 46,513 | 60,180 | ||
Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 144,269 | 130,332 | |||
Business activity in the year | 36,861 | 30,833 | |||
Refinements to models used for calculation | 0 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | 93 | 17,575 | |||
Final repayments | (27,498) | (31,734) | |||
Disposals | (1,669) | (2,404) | |||
Write-offs | (365) | (333) | |||
Closing/Ending balance | 151,691 | 144,269 | 130,332 | ||
Carrying amount | Credit impairment release on other financial assets | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 155,200 | 180,300 | 149,300 | ||
Carrying amount | Provision for undrawn contractually committed facilities and guarantees provided | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 348,255 | 345,160 | |||
ECL | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (6,284) | (9,399) | |||
ECL | Total model ECL | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (4,200) | (6,770) | |||
ECL | ECL from individually assessed impairments | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (524) | (902) | $ (1,400) | ||
ECL | ECL from non-modelled and other management adjustments | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (1,560) | ||||
ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 538 | 432 | |||
Business activity in the year | 12 | 9 | |||
Refinements to models used for calculation | 34 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (64) | 138 | |||
Final repayments | 24 | 19 | |||
Disposals | 0 | 0 | |||
Write-offs | 21 | 22 | |||
Closing/Ending balance | 475 | 538 | 432 | ||
ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 5,700 | 4,884 | |||
Business activity in the year | 200 | 178 | |||
Refinements to models used for calculation | (24) | 309 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (21) | 2,298 | |||
Final repayments | 171 | 188 | |||
Disposals | 205 | 172 | |||
Write-offs | 1,450 | 1,609 | |||
Closing/Ending balance | 4,029 | 5,700 | 4,884 | ||
ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 2,097 | 992 | |||
Business activity in the year | 163 | 280 | |||
Refinements to models used for calculation | 19 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (269) | 1,268 | |||
Final repayments | 339 | 110 | |||
Disposals | 68 | 0 | |||
Write-offs | 365 | 333 | |||
Closing/Ending balance | 1,238 | 2,097 | 992 | ||
ECL | Credit impairment release on other financial assets | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (114) | (165) | (24) | ||
ECL | Provision for undrawn contractually committed facilities and guarantees provided | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (542) | (1,064) | |||
Stage 1 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 138,639 | 135,713 | |||
Business activity in the year | 32,744 | 22,548 | |||
Refinements to models used for calculation | 0 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (8,131) | (6,195) | |||
Final repayments | (12,039) | (9,060) | |||
Disposals | (572) | 0 | |||
Write-offs | 0 | 0 | |||
Closing/Ending balance | 148,058 | 138,639 | 135,713 | ||
Stage 1 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 33,021 | 46,012 | |||
Business activity in the year | 7,842 | 5,598 | |||
Refinements to models used for calculation | 0 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (2,793) | (9,678) | |||
Final repayments | (2,579) | (3,291) | |||
Disposals | 0 | (1,493) | |||
Write-offs | 0 | 0 | |||
Closing/Ending balance | 37,840 | 33,021 | 46,012 | ||
Stage 1 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 119,304 | 117,541 | |||
Business activity in the year | 34,804 | 27,863 | |||
Refinements to models used for calculation | 0 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (417) | 13,828 | |||
Final repayments | (22,219) | (28,458) | |||
Disposals | (1,303) | (2,394) | |||
Write-offs | 0 | 0 | |||
Closing/Ending balance | 132,967 | 119,304 | 117,541 | ||
Stage 1 | Carrying amount | Credit impairment release on other financial assets | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 154,900 | 175,700 | 148,500 | ||
Stage 1 | Carrying amount | Provision for undrawn contractually committed facilities and guarantees provided | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 312,142 | 289,939 | |||
Stage 1 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 33 | 22 | |||
Business activity in the year | 7 | 7 | |||
Refinements to models used for calculation | 0 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (50) | (9) | |||
Final repayments | 2 | 1 | |||
Disposals | 0 | 0 | |||
Write-offs | 0 | 0 | |||
Closing/Ending balance | 19 | 33 | 22 | ||
Stage 1 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 680 | 542 | |||
Business activity in the year | 119 | 67 | |||
Refinements to models used for calculation | (5) | 13 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (1,030) | (229) | |||
Final repayments | 40 | 67 | |||
Disposals | 0 | 8 | |||
Write-offs | 0 | 0 | |||
Closing/Ending balance | 824 | 680 | 542 | ||
Stage 1 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 320 | 143 | |||
Business activity in the year | 95 | 46 | |||
Refinements to models used for calculation | 8 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (268) | 130 | |||
Final repayments | 34 | 22 | |||
Disposals | 15 | 0 | |||
Write-offs | 0 | 0 | |||
Closing/Ending balance | 363 | 320 | 143 | ||
Stage 1 | ECL | Credit impairment release on other financial assets | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (6) | (11) | (12) | ||
Stage 1 | ECL | Provision for undrawn contractually committed facilities and guarantees provided | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (217) | (256) | |||
Lifetime expected credit losses | Stage 2 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 19,312 | 17,043 | |||
Business activity in the year | 1,243 | 714 | |||
Refinements to models used for calculation | 0 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (1,090) | (841) | |||
Final repayments | (2,009) | (1,509) | |||
Disposals | (26) | 0 | |||
Write-offs | 0 | 0 | |||
Closing/Ending balance | 19,500 | 19,312 | 17,043 | ||
Lifetime expected credit losses | Stage 2 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 10,320 | 10,759 | |||
Business activity in the year | 257 | 324 | |||
Refinements to models used for calculation | 0 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (848) | (2,706) | |||
Final repayments | (498) | (270) | |||
Disposals | 0 | (183) | |||
Write-offs | 0 | 0 | |||
Closing/Ending balance | 5,650 | 10,320 | 10,759 | ||
Lifetime expected credit losses | Stage 2 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 21,374 | 10,432 | |||
Business activity in the year | 1,774 | 2,336 | |||
Refinements to models used for calculation | 0 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | 721 | 3,811 | |||
Final repayments | (4,734) | (2,977) | |||
Disposals | (203) | (10) | |||
Write-offs | 0 | 0 | |||
Closing/Ending balance | 15,943 | 21,374 | 10,432 | ||
Lifetime expected credit losses | Stage 2 | Carrying amount | Credit impairment release on other financial assets | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 800 | ||||
Lifetime expected credit losses | Stage 2 | Carrying amount | Fair value through other comprehensive income | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 157 | 4,400 | |||
Lifetime expected credit losses | Stage 2 | Carrying amount | Provision for undrawn contractually committed facilities and guarantees provided | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 34,815 | 52,891 | |||
Lifetime expected credit losses | Stage 2 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 84 | 64 | |||
Business activity in the year | 5 | 2 | |||
Refinements to models used for calculation | (4) | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | 12 | 42 | |||
Final repayments | 4 | 3 | |||
Disposals | 0 | 0 | |||
Write-offs | 0 | 0 | |||
Closing/Ending balance | 59 | 84 | 64 | ||
Lifetime expected credit losses | Stage 2 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 2,769 | 2,007 | |||
Business activity in the year | 62 | 83 | |||
Refinements to models used for calculation | (33) | 296 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | 389 | 1,174 | |||
Final repayments | 39 | 37 | |||
Disposals | 0 | 20 | |||
Write-offs | 0 | 0 | |||
Closing/Ending balance | 1,701 | 2,769 | 2,007 | ||
Lifetime expected credit losses | Stage 2 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 711 | 302 | |||
Business activity in the year | 18 | 149 | |||
Refinements to models used for calculation | 11 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (68) | 339 | |||
Final repayments | 174 | 29 | |||
Disposals | 6 | 0 | |||
Write-offs | 0 | 0 | |||
Closing/Ending balance | 255 | 711 | 302 | ||
Lifetime expected credit losses | Stage 2 | ECL | Credit impairment release on other financial assets | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (2) | ||||
Lifetime expected credit losses | Stage 2 | ECL | Fair value through other comprehensive income | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (1) | (9) | |||
Lifetime expected credit losses | Stage 2 | ECL | Provision for undrawn contractually committed facilities and guarantees provided | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (302) | (758) | |||
Lifetime expected credit losses | Stage 3 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 2,234 | 2,155 | |||
Business activity in the year | 4 | 4 | |||
Refinements to models used for calculation | 0 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (216) | (57) | |||
Final repayments | (392) | (308) | |||
Disposals | 0 | 0 | |||
Write-offs | (21) | (22) | |||
Closing/Ending balance | 2,122 | 2,234 | 2,155 | ||
Lifetime expected credit losses | Stage 3 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 3,172 | 3,409 | |||
Business activity in the year | 42 | 59 | |||
Refinements to models used for calculation | 0 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (165) | (10) | |||
Final repayments | (212) | (204) | |||
Disposals | (287) | (204) | |||
Write-offs | (1,450) | (1,609) | |||
Closing/Ending balance | 2,332 | 3,172 | 3,409 | ||
Lifetime expected credit losses | Stage 3 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 3,591 | 2,359 | |||
Business activity in the year | 283 | 634 | |||
Refinements to models used for calculation | 0 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (211) | (64) | |||
Final repayments | (545) | (299) | |||
Disposals | (163) | 0 | |||
Write-offs | (365) | (333) | |||
Closing/Ending balance | 2,781 | 3,591 | 2,359 | ||
Lifetime expected credit losses | Stage 3 | Carrying amount | Other assets | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 110 | 154 | 10 | ||
Lifetime expected credit losses | Stage 3 | Carrying amount | Provision for undrawn contractually committed facilities and guarantees provided | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 1,298 | 2,330 | |||
Lifetime expected credit losses | Stage 3 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 421 | 346 | |||
Business activity in the year | 0 | 0 | |||
Refinements to models used for calculation | 38 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (26) | 105 | |||
Final repayments | 18 | 15 | |||
Disposals | 0 | 0 | |||
Write-offs | 21 | 22 | |||
Closing/Ending balance | 397 | 421 | 346 | ||
Lifetime expected credit losses | Stage 3 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 2,251 | 2,335 | |||
Business activity in the year | 19 | 28 | |||
Refinements to models used for calculation | 14 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | 620 | 1,353 | |||
Final repayments | 92 | 84 | |||
Disposals | 205 | 144 | |||
Write-offs | 1,450 | 1,609 | |||
Closing/Ending balance | 1,504 | 2,251 | 2,335 | ||
Lifetime expected credit losses | Stage 3 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening/Beginning balance | 1,066 | 547 | |||
Business activity in the year | 50 | 85 | |||
Refinements to models used for calculation | 0 | 0 | |||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | 67 | 799 | |||
Final repayments | 131 | 59 | |||
Disposals | 47 | 0 | |||
Write-offs | 365 | 333 | |||
Closing/Ending balance | 620 | 1,066 | 547 | ||
Lifetime expected credit losses | Stage 3 | ECL | Other assets | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (107) | (145) | (10) | ||
Lifetime expected credit losses | Stage 3 | ECL | Provision for undrawn contractually committed facilities and guarantees provided | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (23) | (50) | |||
Financial assets at amortised cost | Loans and advances | |||||
Loans and advances at amortised cost | |||||
Write-offs | (1,836) | (1,964) | (1,883) | ||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Credit impairment (releases)/charges | (121) | 3,909 | |||
Post write-off recoveries | 66 | 35 | 124 | ||
Impairment charges on loans and advances | 1,770 | 1,929 | £ 1,759 | ||
Financial assets | 361,451 | 342,632 | |||
Financial assets at amortised cost | Home loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 169,205 | 159,647 | |||
Financial assets at amortised cost | Credit cards, unsecured and other retail lending | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 41,793 | 40,813 | |||
Financial assets at amortised cost | Wholesale loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 150,453 | 142,172 | |||
Financial assets at amortised cost | Carrying amount | Loans and advances | |||||
Loans and advances at amortised cost | |||||
Final repayments | (200) | ||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 367,193 | 350,967 | |||
Financial assets at amortised cost | Carrying amount | Home loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 169,680 | 160,185 | |||
Financial assets at amortised cost | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Final repayments | (598) | (1,900) | |||
Disposals | (287) | ||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Transfers out of Level 2 into Level 1 of fair value hierarchy, assets held at end of reporting period | 1,900 | 2,000 | |||
Financial assets | 45,822 | 46,513 | |||
Financial assets at amortised cost | Carrying amount | Credit cards, unsecured and other retail lending | Barclays Partner Finance | |||||
Loans and advances at amortised cost | |||||
Final repayments | (1,700) | ||||
Financial assets at amortised cost | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Final repayments | (1,700) | (2,400) | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 151,691 | 144,269 | |||
Financial assets at amortised cost | Carrying amount | Wholesale loans | Barclays Asset Finance | |||||
Loans and advances at amortised cost | |||||
Final repayments | (700) | ||||
Financial assets at amortised cost | ECL | Loans and advances | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (5,742) | (8,335) | |||
Financial assets at amortised cost | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Refinements to models used for calculation | 34 | ||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (475) | (538) | |||
Financial assets at amortised cost | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Refinements to models used for calculation | (24) | ||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Recoveries and reimbursements | (300) | (600) | |||
Financial assets | (4,029) | (5,700) | |||
Financial assets at amortised cost | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Refinements to models used for calculation | (19) | ||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (1,238) | (2,097) | |||
Financial assets at amortised cost | ECL | Provision for undrawn contractually committed facilities and guarantees provided | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (542) | (1,064) | |||
Financial assets at amortised cost | Stage 1 | Loans and advances | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 317,659 | 289,931 | |||
Financial assets at amortised cost | Stage 1 | Home loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 148,039 | 138,606 | |||
Financial assets at amortised cost | Stage 1 | Credit cards, unsecured and other retail lending | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 37,016 | 32,341 | |||
Financial assets at amortised cost | Stage 1 | Wholesale loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 132,604 | 118,984 | |||
Financial assets at amortised cost | Stage 1 | Carrying amount | Loans and advances | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 318,865 | 290,964 | |||
Financial assets at amortised cost | Stage 1 | Carrying amount | Home loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 148,058 | 138,639 | |||
Financial assets at amortised cost | Stage 1 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 37,840 | 33,021 | |||
Financial assets at amortised cost | Stage 1 | Carrying amount | Wholesale loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 132,967 | 119,304 | |||
Financial assets at amortised cost | Stage 1 | ECL | Loans and advances | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (1,206) | (1,033) | |||
Financial assets at amortised cost | Stage 1 | ECL | Home loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (19) | (33) | |||
Financial assets at amortised cost | Stage 1 | ECL | Credit cards, unsecured and other retail lending | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (824) | (680) | |||
Financial assets at amortised cost | Stage 1 | ECL | Wholesale loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (363) | (320) | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Loans and advances | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 39,078 | 47,442 | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Home loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 19,441 | 19,228 | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Credit cards, unsecured and other retail lending | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 3,949 | 7,551 | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Wholesale loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 15,688 | 20,663 | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Carrying amount | Loans and advances | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 41,093 | 51,006 | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Carrying amount | Home loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 19,500 | 19,312 | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 5,650 | 10,320 | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Carrying amount | Wholesale loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 15,943 | 21,374 | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ECL | Loans and advances | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (2,015) | (3,564) | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ECL | Home loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (59) | (84) | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ECL | Credit cards, unsecured and other retail lending | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (1,701) | (2,769) | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ECL | Wholesale loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (255) | (711) | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Loans and advances | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 4,714 | 5,259 | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Home loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 1,725 | 1,813 | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Credit cards, unsecured and other retail lending | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 828 | 921 | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Wholesale loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 2,161 | 2,525 | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Carrying amount | Loans and advances | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 7,235 | 8,997 | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Carrying amount | Home loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 2,122 | 2,234 | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 2,332 | 3,172 | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Carrying amount | Wholesale loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | 2,781 | 3,591 | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ECL | Loans and advances | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (2,521) | (3,738) | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ECL | Home loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (397) | (421) | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ECL | Credit cards, unsecured and other retail lending | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (1,504) | (2,251) | |||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ECL | Wholesale loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Financial assets | (620) | (1,066) | |||
Transfers from Stage 1 to Stage 2 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 1 to Stage 2 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 1 to Stage 2 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 1 to Stage 2 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 1 to Stage 2 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 1 to Stage 2 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 1 to Stage 2 | Stage 1 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (7,672) | (8,724) | |||
Transfers from Stage 1 to Stage 2 | Stage 1 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | (1,894) | (6,571) | |||
Transfers from Stage 1 to Stage 2 | Stage 1 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (6,115) | (12,531) | |||
Transfers from Stage 1 to Stage 2 | Stage 1 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (2) | (1) | |||
Transfers from Stage 1 to Stage 2 | Stage 1 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | (78) | (134) | |||
Transfers from Stage 1 to Stage 2 | Stage 1 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (19) | (35) | |||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 2 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 7,672 | 8,724 | |||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 2 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 1,894 | 6,571 | |||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 2 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 6,115 | 12,531 | |||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 2 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 2 | 1 | |||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 2 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 78 | 134 | |||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 2 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 19 | 35 | |||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 3 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 3 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 3 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 3 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 3 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 3 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 2 to Stage 1 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 2 to Stage 1 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 2 to Stage 1 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 2 to Stage 1 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 2 to Stage 1 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 2 to Stage 1 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 2 to Stage 1 | Stage 1 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 5,336 | 4,618 | |||
Transfers from Stage 2 to Stage 1 | Stage 1 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 4,717 | 3,080 | |||
Transfers from Stage 2 to Stage 1 | Stage 1 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 9,137 | 4,121 | |||
Transfers from Stage 2 to Stage 1 | Stage 1 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 32 | 14 | |||
Transfers from Stage 2 to Stage 1 | Stage 1 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 1,174 | 482 | |||
Transfers from Stage 2 to Stage 1 | Stage 1 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 257 | 40 | |||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 2 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (5,336) | (4,618) | |||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 2 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | (4,717) | (3,080) | |||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 2 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (9,137) | (4,121) | |||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 2 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (32) | (14) | |||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 2 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | (1,174) | (482) | |||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 2 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (257) | (40) | |||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 3 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 3 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 3 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 3 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 3 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 3 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers to Stage 3 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers to Stage 3 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers to Stage 3 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers to Stage 3 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers to Stage 3 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers to Stage 3 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers to Stage 3 | Stage 1 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (282) | (308) | |||
Transfers to Stage 3 | Stage 1 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | (529) | (712) | |||
Transfers to Stage 3 | Stage 1 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (804) | (1,137) | |||
Transfers to Stage 3 | Stage 1 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers to Stage 3 | Stage 1 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | (22) | (25) | |||
Transfers to Stage 3 | Stage 1 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (4) | (4) | |||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 2 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (469) | (420) | |||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 2 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | (790) | (1,162) | |||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 2 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (377) | (875) | |||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 2 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (9) | (10) | |||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 2 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | (370) | (398) | |||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 2 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (21) | (58) | |||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 3 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 751 | 728 | |||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 3 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 1,319 | 1,874 | |||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 3 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 1,181 | 2,012 | |||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 3 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 9 | 10 | |||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 3 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 392 | 423 | |||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 3 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 25 | 62 | |||
Transfers from Stage 3 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 3 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 3 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 3 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 3 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 3 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 0 | 0 | |||
Transfers from Stage 3 | Stage 1 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 35 | 47 | |||
Transfers from Stage 3 | Stage 1 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 55 | 76 | |||
Transfers from Stage 3 | Stage 1 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 580 | 471 | |||
Transfers from Stage 3 | Stage 1 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 1 | 1 | |||
Transfers from Stage 3 | Stage 1 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 26 | 39 | |||
Transfers from Stage 3 | Stage 1 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 23 | 22 | |||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 2 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 203 | 219 | |||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 2 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 32 | 67 | |||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 2 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 410 | 247 | |||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 2 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 5 | 2 | |||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 2 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | 19 | 12 | |||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 2 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | 22 | 13 | |||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 3 | Carrying amount | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (238) | (266) | |||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 3 | Carrying amount | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | (87) | (143) | |||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 3 | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (990) | (718) | |||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 3 | ECL | Home loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (6) | (3) | |||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 3 | ECL | Credit cards, unsecured and other retail lending | |||||
Loans and advances at amortised cost | |||||
Transfers | (45) | (51) | |||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 3 | ECL | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Transfers | (45) | £ (35) | |||
Debt securities classified at amortised cost | Carrying amount | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Final repayments | £ (1,000) | ||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Other disclosures - Risk Mana_7
Other disclosures - Risk Management and Principal Risks - Gross exposure for loan commitment and financial guarantees (audited) (Details) - Provision for undrawn contractually committed facilities and guarantees provided - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Loan commitments and financial guarantee contracts | |||
Limit management and final repayments | £ 0 | £ 0 | £ 0 |
Carrying amount | |||
Loan commitments and financial guarantee contracts | |||
Net transfers between stages | 0 | 0 | |
Carrying amount | Home loans | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 12,382 | 10,046 | |
Net transfers between stages | 0 | 0 | |
Business activity in the year | 7,034 | 7,975 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (7,624) | (5,361) | |
Limit management and final repayments | (424) | (278) | |
Closing/Ending balance | 11,368 | 12,382 | 10,046 |
Carrying amount | Credit cards, unsecured and other retail lending | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 126,717 | 132,247 | |
Net transfers between stages | 0 | 0 | |
Business activity in the year | 11,638 | 5,374 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1,051) | 2,263 | |
Limit management and final repayments | (8,549) | (13,167) | |
Closing/Ending balance | 128,755 | 126,717 | 132,247 |
Carrying amount | Wholesale loans | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 206,061 | 198,967 | |
Business activity in the year | 48,753 | 48,399 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 9,183 | 13,524 | |
Limit management and final repayments | (55,865) | (54,829) | |
Closing/Ending balance | 208,132 | 206,061 | 198,967 |
ECL | |||
Loan commitments and financial guarantee contracts | |||
Net transfers between stages | 0 | 0 | |
ECL | Home loans | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 0 | 0 | |
Net transfers between stages | 0 | 0 | |
Business activity in the year | 0 | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | 0 | |
Limit management and final repayments | 0 | 0 | |
Closing/Ending balance | 0 | 0 | 0 |
ECL | Credit cards, unsecured and other retail lending | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 383 | 120 | |
Net transfers between stages | 0 | 0 | |
Business activity in the year | 0 | 6 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (241) | 265 | |
Limit management and final repayments | 11 | 8 | |
Closing/Ending balance | 131 | 383 | 120 |
ECL | Wholesale loans | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 681 | 202 | |
Business activity in the year | 116 | 136 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (233) | 365 | |
Limit management and final repayments | 153 | 22 | |
Closing/Ending balance | 411 | 681 | 202 |
Stage 1 | Carrying amount | Home loans | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 11,861 | 9,542 | |
Net transfers between stages | (131) | (82) | |
Business activity in the year | 7,034 | 7,975 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (7,556) | (5,332) | |
Limit management and final repayments | (375) | (242) | |
Closing/Ending balance | 10,833 | 11,861 | 9,542 |
Stage 1 | Carrying amount | Credit cards, unsecured and other retail lending | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 114,371 | 125,759 | |
Net transfers between stages | 5,769 | (5,477) | |
Business activity in the year | 11,206 | 5,214 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (742) | 1,298 | |
Limit management and final repayments | (7,785) | (12,423) | |
Closing/Ending balance | 122,819 | 114,371 | 125,759 |
Stage 1 | Carrying amount | Wholesale loans | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 163,707 | 185,839 | |
Net transfers between stages | 8,227 | (28,325) | |
Business activity in the year | 44,085 | 42,917 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 8,819 | 13,637 | |
Limit management and final repayments | (46,348) | (50,361) | |
Closing/Ending balance | 178,490 | 163,707 | 185,839 |
Stage 1 | ECL | Home loans | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 0 | 0 | |
Net transfers between stages | 0 | 0 | |
Business activity in the year | 0 | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | 0 | |
Limit management and final repayments | 0 | 0 | |
Closing/Ending balance | 0 | 0 | 0 |
Stage 1 | ECL | Credit cards, unsecured and other retail lending | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 55 | 35 | |
Net transfers between stages | 206 | 43 | |
Business activity in the year | 0 | 2 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (207) | (22) | |
Limit management and final repayments | 4 | 3 | |
Closing/Ending balance | 50 | 55 | 35 |
Stage 1 | ECL | Wholesale loans | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 201 | 62 | |
Net transfers between stages | 221 | 67 | |
Business activity in the year | 14 | 32 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (229) | 47 | |
Limit management and final repayments | 40 | 7 | |
Closing/Ending balance | 167 | 201 | 62 |
Lifetime expected credit losses | Stage 2 | Carrying amount | Home loans | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 516 | 500 | |
Net transfers between stages | 124 | 78 | |
Business activity in the year | 0 | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (64) | (27) | |
Limit management and final repayments | (44) | (35) | |
Closing/Ending balance | 532 | 516 | 500 |
Lifetime expected credit losses | Stage 2 | Carrying amount | Credit cards, unsecured and other retail lending | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 12,117 | 6,238 | |
Net transfers between stages | (6,379) | 4,725 | |
Business activity in the year | 430 | 158 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 217 | 1,636 | |
Limit management and final repayments | (667) | (640) | |
Closing/Ending balance | 5,718 | 12,117 | 6,238 |
Lifetime expected credit losses | Stage 2 | Carrying amount | Wholesale loans | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 40,258 | 12,447 | |
Net transfers between stages | (7,174) | 27,319 | |
Business activity in the year | 4,658 | 4,708 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (151) | (44) | |
Limit management and final repayments | (9,026) | (4,172) | |
Closing/Ending balance | 28,565 | 40,258 | 12,447 |
Lifetime expected credit losses | Stage 2 | ECL | Home loans | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 0 | 0 | |
Net transfers between stages | 0 | 0 | |
Business activity in the year | 0 | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | 0 | |
Limit management and final repayments | 0 | 0 | |
Closing/Ending balance | 0 | 0 | 0 |
Lifetime expected credit losses | Stage 2 | ECL | Credit cards, unsecured and other retail lending | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 305 | 71 | |
Net transfers between stages | (213) | (40) | |
Business activity in the year | 0 | 3 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (24) | 272 | |
Limit management and final repayments | 7 | 1 | |
Closing/Ending balance | 61 | 305 | 71 |
Lifetime expected credit losses | Stage 2 | ECL | Wholesale loans | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 453 | 99 | |
Net transfers between stages | (215) | (72) | |
Business activity in the year | 102 | 102 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 7 | 338 | |
Limit management and final repayments | 106 | 14 | |
Closing/Ending balance | 241 | 453 | 99 |
Lifetime expected credit losses | Stage 3 | Carrying amount | Home loans | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 5 | 4 | |
Net transfers between stages | 7 | 4 | |
Business activity in the year | 0 | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (4) | (2) | |
Limit management and final repayments | (5) | (1) | |
Closing/Ending balance | 3 | 5 | 4 |
Lifetime expected credit losses | Stage 3 | Carrying amount | Credit cards, unsecured and other retail lending | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 229 | 250 | |
Net transfers between stages | 610 | 752 | |
Business activity in the year | 2 | 2 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (526) | (671) | |
Limit management and final repayments | (97) | (104) | |
Closing/Ending balance | 218 | 229 | 250 |
Lifetime expected credit losses | Stage 3 | Carrying amount | Wholesale loans | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 2,096 | 681 | |
Net transfers between stages | (1,053) | 1,006 | |
Business activity in the year | 10 | 774 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 515 | (69) | |
Limit management and final repayments | (491) | (296) | |
Closing/Ending balance | 1,077 | 2,096 | 681 |
Lifetime expected credit losses | Stage 3 | ECL | Home loans | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 0 | 0 | |
Net transfers between stages | 0 | 0 | |
Business activity in the year | 0 | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | 0 | |
Limit management and final repayments | 0 | 0 | |
Closing/Ending balance | 0 | 0 | 0 |
Lifetime expected credit losses | Stage 3 | ECL | Credit cards, unsecured and other retail lending | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 23 | 14 | |
Net transfers between stages | 7 | (3) | |
Business activity in the year | 0 | 1 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (10) | 15 | |
Limit management and final repayments | 0 | 4 | |
Closing/Ending balance | 20 | 23 | 14 |
Lifetime expected credit losses | Stage 3 | ECL | Wholesale loans | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 27 | 41 | |
Net transfers between stages | (6) | 5 | |
Business activity in the year | 0 | 2 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (11) | (20) | |
Limit management and final repayments | 7 | 1 | |
Closing/Ending balance | £ 3 | £ 27 | £ 41 |
Other disclosures - Risk Mana_8
Other disclosures - Risk Management and Principal Risks - Management adjustments to models for impairment charges (audited) (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Loans and advances | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | £ 1,486 | £ 1,388 |
Proportion of total impairment allowances | 23.60% | 14.80% |
Impairment allowance, pre-management adjustments | £ 4,798 | £ 8,011 |
Impairment allowance | 6,284 | 9,399 |
Loans and advances | Economic uncertainty adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | 1,692 | 2,067 |
Loans and advances | Other adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | (206) | (679) |
Loans and advances | Total model ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | (4,100) | (6,800) |
Impairment allowance | 200 | |
Loans and advances | ECL from individually assessed impairments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | (500) | (900) |
Loans and advances | ECL from non-modelled exposures | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | (200) | (300) |
Home loans | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | £ 103 | £ 131 |
Proportion of total impairment allowances | 21.70% | 24.30% |
Impairment allowance, pre-management adjustments | £ 372 | £ 407 |
Impairment allowance | 475 | 538 |
Home loans | Economic uncertainty adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | 72 | 21 |
Home loans | Other adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | 31 | 110 |
Credit cards, unsecured and other retail lending | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | £ 1,362 | £ 1,234 |
Proportion of total impairment allowances | 32.70% | 20.30% |
Impairment allowance, pre-management adjustments | £ 2,798 | £ 4,849 |
Impairment allowance | 4,160 | 6,083 |
Credit cards, unsecured and other retail lending | Economic uncertainty adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | 1,217 | 1,625 |
Credit cards, unsecured and other retail lending | Other adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | 145 | (391) |
Wholesale loans | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | £ 21 | £ 23 |
Proportion of total impairment allowances | 1.30% | 0.80% |
Impairment allowance, pre-management adjustments | £ 1,628 | £ 2,755 |
Impairment allowance | 1,649 | 2,778 |
Wholesale loans | Economic uncertainty adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | 403 | 421 |
Wholesale loans | Other adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | (382) | (398) |
BBLs and CBILs | Economic uncertainty adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | 400 | 100 |
BBLs and CBILs | Other adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Management adjustments to impairment allowances | £ (400) | £ (100) |
Other disclosures - Risk Mana_9
Other disclosures - Risk Management and Principal Risks - Economic uncertainty adjustments (Details) £ in Millions | 12 Months Ended | |
Dec. 31, 2021GBP (£)method | Dec. 31, 2020GBP (£) | |
Loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 6,284 | £ 9,399 |
ECL movement excluding assets derecognised due to disposals and write-offs | (484) | 4,163 |
Credit cards, unsecured and other retail lending | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 4,160 | 6,083 |
ECL movement excluding assets derecognised due to disposals and write-offs | (16) | 2,597 |
Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 1,649 | 2,778 |
ECL movement excluding assets derecognised due to disposals and write-offs | £ (426) | 1,438 |
Covid-19 related adjustments | ||
Disclosure of financial assets [line items] | ||
Number of uncertainty adjustment methods | method | 2 | |
Allowance account for credit losses of financial assets | £ 1,700 | 2,100 |
Covid-19 related adjustments | Loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 1,100 | 1,000 |
Covid-19 related adjustments | Loans and advances at amortised cost | Guarantees | ||
Disclosure of financial assets [line items] | ||
ECL movement excluding assets derecognised due to disposals and write-offs | 300 | |
Covid-19 related adjustments | Credit cards, unsecured and other retail lending | UK | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 100 | 0 |
Covid-19 related adjustments | Credit cards, unsecured and other retail lending | US | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 800 | 800 |
Covid-19 related adjustments | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 300 | 200 |
Covid-19 related adjustments | Model uncertainty risk | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 200 | 400 |
ECL movement excluding assets derecognised due to disposals and write-offs | 200 | |
Covid-19 related adjustments | Customers | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 1,500 | 1,700 |
Covid-19 related adjustments | Customers | Loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 400 | £ 700 |
Other disclosures - Risk Man_10
Other disclosures - Risk Management and Principal Risks - Measurement uncertainty, narrative (Details) £ in Billions | 12 Months Ended | |
Dec. 31, 2021GBP (£)economic_scenarioeconomicVariable | Dec. 31, 2020GBP (£) | |
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Number of economic scenarios, percentage | 100.00% | |
Covid-19 related adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Allowance account for credit losses of financial assets | £ | £ 1.7 | £ 2.1 |
Covid-19 related adjustments | Customers | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Allowance account for credit losses of financial assets | £ | £ 1.5 | 1.7 |
Credit derivatives | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Number of economic scenarios | economic_scenario | 5 | |
Number of economic variables | economicVariable | 8 | |
Stress horizon period, ECL | 5 years | |
Term at which scenario converges to steady state | 8 years | |
Credit derivatives | Downside scenario | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Number of economic scenarios | economic_scenario | 2 | |
Credit derivatives | Upside scenario | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Number of economic scenarios | economic_scenario | 2 | |
Baseline | UK | Later than one month and not later than three months | Unemployment | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Unemployment rate | 5.00% | |
Downside 2 | UK | Not more than one year | Unemployment | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Bank rate | 4.00% | |
Downside 2 | UK | Over six months but not more than nine months | Unemployment | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Unemployment rate | 9.20% | |
Downside 2 | US | Not more than one year | Unemployment | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Federal Funds Purchased, Average Rate Paid | 3.50% | |
Downside 2 | US | Over six months but not more than nine months | Unemployment | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Unemployment rate | 9.50% | |
Model uncertainty risk | Covid-19 related adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Allowance account for credit losses of financial assets | £ | £ 0.2 | £ 0.4 |
Other disclosures - Risk Man_11
Other disclosures - Risk Management and Principal Risks - Measurement uncertainty and sensitivity analysis - Scenario probability weighting and Macroeconomic variables used in calculation of ECL (audited) (Details) | Dec. 31, 2021 | Dec. 31, 2020 |
Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 30.10% | 24.70% |
Baseline | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 0.70% |
Baseline | GDP | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 0.70% |
Baseline | GDP | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | (10.10%) |
Baseline | GDP | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.90% | 6.30% |
Baseline | GDP | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 3.30% |
Baseline | GDP | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 2.60% |
Baseline | GDP | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.70% | 2.00% |
Baseline | GDP | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 1.60% |
Baseline | GDP | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 1.60% |
Baseline | GDP | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | (4.40%) |
Baseline | GDP | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 3.90% |
Baseline | GDP | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 3.10% |
Baseline | GDP | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 2.90% |
Baseline | GDP | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 2.90% |
Baseline | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 5.70% |
Baseline | Unemployment | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 5.70% |
Baseline | Unemployment | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 4.50% |
Baseline | Unemployment | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 6.70% |
Baseline | Unemployment | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 6.40% |
Baseline | Unemployment | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 5.80% |
Baseline | Unemployment | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 5.10% |
Baseline | Unemployment | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 6.40% |
Baseline | Unemployment | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 6.40% |
Baseline | Unemployment | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 8.40% |
Baseline | Unemployment | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 6.90% |
Baseline | Unemployment | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 5.70% |
Baseline | Unemployment | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 5.60% |
Baseline | Unemployment | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 5.60% |
Baseline | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 3.60% |
Baseline | HPI | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 3.60% |
Baseline | HPI | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 6.10% |
Baseline | HPI | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.00% | 2.40% |
Baseline | HPI | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 2.30% |
Baseline | HPI | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 5.00% |
Baseline | HPI | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 2.40% |
Baseline | HPI | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | 3.80% |
Baseline | HPI | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | 3.80% |
Baseline | HPI | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 11.80% | 2.30% |
Baseline | HPI | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 2.80% |
Baseline | HPI | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 4.70% |
Baseline | HPI | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.90% | 4.70% |
Baseline | HPI | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.00% | 4.70% |
Baseline | UK bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.70% | 0.00% |
Baseline | UK bank rate | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.70% | 0.00% |
Baseline | UK bank rate | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.20% |
Baseline | UK bank rate | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.00% |
Baseline | UK bank rate | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.00% | (0.10%) |
Baseline | UK bank rate | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.00% | 0.00% |
Baseline | UK bank rate | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.10% |
Baseline | US federal funds rate | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.30% |
Baseline | US federal funds rate | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.30% |
Baseline | US federal funds rate | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.20% | 0.50% |
Baseline | US federal funds rate | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | 0.30% |
Baseline | US federal funds rate | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.90% | 0.30% |
Baseline | US federal funds rate | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.20% | 0.30% |
Baseline | US federal funds rate | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 0.40% |
Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.00% | 15.40% |
Downside 2 | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.60%) | (22.10%) |
Downside 2 | GDP | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.80% | (0.90%) |
Downside 2 | GDP | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | (10.10%) |
Downside 2 | GDP | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.20% | (3.90%) |
Downside 2 | GDP | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (4.00%) | 6.50% |
Downside 2 | GDP | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 2.60% |
Downside 2 | GDP | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 1.40% |
Downside 2 | GDP | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.30%) | (10.60%) |
Downside 2 | GDP | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 0.10% |
Downside 2 | GDP | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | (4.40%) |
Downside 2 | GDP | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.80%) | (2.40%) |
Downside 2 | GDP | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (3.50%) | 3.60% |
Downside 2 | GDP | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 2.10% |
Downside 2 | GDP | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 2.00% |
Downside 2 | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9.20% | 10.10% |
Downside 2 | Unemployment | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.00% | 7.20% |
Downside 2 | Unemployment | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 4.50% |
Downside 2 | Unemployment | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.20% | 8.00% |
Downside 2 | Unemployment | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9.00% | 9.30% |
Downside 2 | Unemployment | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.60% | 7.80% |
Downside 2 | Unemployment | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.30% | 6.30% |
Downside 2 | Unemployment | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9.50% | 13.70% |
Downside 2 | Unemployment | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.10% | 10.40% |
Downside 2 | Unemployment | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 8.40% |
Downside 2 | Unemployment | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.40% | 13.40% |
Downside 2 | Unemployment | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9.10% | 11.90% |
Downside 2 | Unemployment | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.10% | 10.10% |
Downside 2 | Unemployment | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.40% | 8.20% |
Downside 2 | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (29.90%) | (18.30%) |
Downside 2 | HPI | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (2.00%) | (3.60%) |
Downside 2 | HPI | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 6.10% |
Downside 2 | HPI | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (14.30%) | (13.60%) |
Downside 2 | HPI | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (21.80%) | (10.80%) |
Downside 2 | HPI | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 11.90% | 0.50% |
Downside 2 | HPI | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 15.20% | 1.50% |
Downside 2 | HPI | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (5.00%) | (15.90%) |
Downside 2 | HPI | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.40% | (3.00%) |
Downside 2 | HPI | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 11.80% | 2.30% |
Downside 2 | HPI | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (6.60%) | (17.20%) |
Downside 2 | HPI | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (9.00%) | (0.70%) |
Downside 2 | HPI | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.90% | 0.60% |
Downside 2 | HPI | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.70% | 1.30% |
Downside 2 | UK bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.00% | 0.60% |
Downside 2 | UK bank rate | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | (0.10%) |
Downside 2 | UK bank rate | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.20% |
Downside 2 | UK bank rate | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | (0.20%) |
Downside 2 | UK bank rate | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | (0.20%) |
Downside 2 | UK bank rate | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | (0.10%) |
Downside 2 | UK bank rate | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | (0.10%) |
Downside 2 | US federal funds rate | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 1.30% |
Downside 2 | US federal funds rate | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 0.30% |
Downside 2 | US federal funds rate | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.20% | 0.50% |
Downside 2 | US federal funds rate | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 0.30% |
Downside 2 | US federal funds rate | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 0.30% |
Downside 2 | US federal funds rate | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 0.30% |
Downside 2 | US federal funds rate | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.00% | 0.30% |
Downside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 14.80% | 15.50% |
Downside 1 | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.60%) | (22.10%) |
Downside 1 | GDP | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 0.10% |
Downside 1 | GDP | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | (10.10%) |
Downside 1 | GDP | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 0.10% |
Downside 1 | GDP | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.70%) | 6.60% |
Downside 1 | GDP | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 3.20% |
Downside 1 | GDP | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.90% | 1.80% |
Downside 1 | GDP | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.50% | (10.60%) |
Downside 1 | GDP | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 0.80% |
Downside 1 | GDP | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | (4.40%) |
Downside 1 | GDP | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 0.40% |
Downside 1 | GDP | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.40%) | 3.60% |
Downside 1 | GDP | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 2.30% |
Downside 1 | GDP | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 2.20% |
Downside 1 | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.00% | 8.40% |
Downside 1 | Unemployment | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.80% | 6.50% |
Downside 1 | Unemployment | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 4.50% |
Downside 1 | Unemployment | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | 7.30% |
Downside 1 | Unemployment | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.80% | 8.00% |
Downside 1 | Unemployment | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.00% | 6.90% |
Downside 1 | Unemployment | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.30% | 5.80% |
Downside 1 | Unemployment | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.80% | 13.00% |
Downside 1 | Unemployment | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.70% | 8.30% |
Downside 1 | Unemployment | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 8.40% |
Downside 1 | Unemployment | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.40% | 11.00% |
Downside 1 | Unemployment | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.60% | 8.90% |
Downside 1 | Unemployment | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.10% | 6.90% |
Downside 1 | Unemployment | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 6.10% |
Downside 1 | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (12.70%) | (4.50%) |
Downside 1 | HPI | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | (0.20%) |
Downside 1 | HPI | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 6.10% |
Downside 1 | HPI | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (6.80%) | (6.70%) |
Downside 1 | HPI | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (10.50%) | (3.50%) |
Downside 1 | HPI | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.90% | 1.70% |
Downside 1 | HPI | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.60% | 2.00% |
Downside 1 | HPI | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | (3.70%) |
Downside 1 | HPI | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 0.80% |
Downside 1 | HPI | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 11.80% | 2.30% |
Downside 1 | HPI | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.20%) | (5.90%) |
Downside 1 | HPI | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (2.10%) | 1.80% |
Downside 1 | HPI | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 2.60% |
Downside 1 | HPI | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 3.60% |
Downside 1 | UK bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 0.60% |
Downside 1 | UK bank rate | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.70% | 0.00% |
Downside 1 | UK bank rate | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.20% |
Downside 1 | UK bank rate | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | (0.10%) |
Downside 1 | UK bank rate | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | (0.10%) |
Downside 1 | UK bank rate | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 0.00% |
Downside 1 | UK bank rate | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 0.00% |
Downside 1 | US federal funds rate | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 1.30% |
Downside 1 | US federal funds rate | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.50% | 0.30% |
Downside 1 | US federal funds rate | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.20% | 0.50% |
Downside 1 | US federal funds rate | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 0.30% |
Downside 1 | US federal funds rate | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 0.30% |
Downside 1 | US federal funds rate | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 0.30% |
Downside 1 | US federal funds rate | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.80% | 0.30% |
Upside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 20.90% | 20.20% |
Upside 2 | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 21.40% | 14.20% |
Upside 2 | GDP | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 2.50% |
Upside 2 | GDP | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | (10.10%) |
Upside 2 | GDP | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.20% | 12.20% |
Upside 2 | GDP | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.00% | 5.30% |
Upside 2 | GDP | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 3.90% |
Upside 2 | GDP | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 2.90% |
Upside 2 | GDP | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 22.80% | 15.70% |
Upside 2 | GDP | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 2.90% |
Upside 2 | GDP | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | (4.40%) |
Upside 2 | GDP | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.30% | 7.10% |
Upside 2 | GDP | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 4.60% |
Upside 2 | GDP | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 4.00% |
Upside 2 | GDP | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 3.50% |
Upside 2 | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.00% | 4.00% |
Upside 2 | Unemployment | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 5.00% |
Upside 2 | Unemployment | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 4.50% |
Upside 2 | Unemployment | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 6.20% |
Upside 2 | Unemployment | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 5.50% |
Upside 2 | Unemployment | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.00% | 4.80% |
Upside 2 | Unemployment | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.00% | 4.40% |
Upside 2 | Unemployment | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 3.80% |
Upside 2 | Unemployment | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 5.30% |
Upside 2 | Unemployment | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 8.40% |
Upside 2 | Unemployment | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 5.50% |
Upside 2 | Unemployment | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 4.30% |
Upside 2 | Unemployment | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 4.10% |
Upside 2 | Unemployment | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 4.10% |
Upside 2 | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 35.70% | 48.20% |
Upside 2 | HPI | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.30% | 8.20% |
Upside 2 | HPI | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 6.10% |
Upside 2 | HPI | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.50% | 6.60% |
Upside 2 | HPI | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9.00% | 10.40% |
Upside 2 | HPI | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 10.80% |
Upside 2 | HPI | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 7.30% |
Upside 2 | HPI | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 53.30% | 42.20% |
Upside 2 | HPI | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.90% | 7.30% |
Upside 2 | HPI | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 11.80% | 2.30% |
Upside 2 | HPI | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 10.60% | 8.80% |
Upside 2 | HPI | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.50% | 9.10% |
Upside 2 | HPI | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.20% | 8.90% |
Upside 2 | HPI | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.60% | 7.50% |
Upside 2 | UK bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.10% |
Upside 2 | UK bank rate | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | 0.30% |
Upside 2 | UK bank rate | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.20% |
Upside 2 | UK bank rate | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.20% | 0.10% |
Upside 2 | UK bank rate | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.50% | 0.30% |
Upside 2 | UK bank rate | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.50% | 0.30% |
Upside 2 | UK bank rate | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | 0.50% |
Upside 2 | US federal funds rate | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.10% |
Upside 2 | US federal funds rate | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.50% | 0.50% |
Upside 2 | US federal funds rate | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.20% | 0.50% |
Upside 2 | US federal funds rate | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | 0.30% |
Upside 2 | US federal funds rate | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.40% | 0.40% |
Upside 2 | US federal funds rate | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.70% | 0.60% |
Upside 2 | US federal funds rate | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.00% | 0.90% |
Upside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 27.20% | 24.20% |
Upside 1 | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 18.30% | 8.80% |
Upside 1 | GDP | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 1.60% |
Upside 1 | GDP | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | (10.10%) |
Upside 1 | GDP | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.00% | 9.30% |
Upside 1 | GDP | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 3.90% |
Upside 1 | GDP | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 3.40% |
Upside 1 | GDP | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 2.50% |
Upside 1 | GDP | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 19.60% | 12.80% |
Upside 1 | GDP | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 2.40% |
Upside 1 | GDP | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | (4.40%) |
Upside 1 | GDP | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 5.50% |
Upside 1 | GDP | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 4.00% |
Upside 1 | GDP | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.90% | 3.70% |
Upside 1 | GDP | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.90% | 3.30% |
Upside 1 | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 4.00% |
Upside 1 | Unemployment | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 5.30% |
Upside 1 | Unemployment | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 4.50% |
Upside 1 | Unemployment | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 6.40% |
Upside 1 | Unemployment | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 6.00% |
Upside 1 | Unemployment | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 5.20% |
Upside 1 | Unemployment | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 4.70% |
Upside 1 | Unemployment | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.80% |
Upside 1 | Unemployment | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.00% | 5.70% |
Upside 1 | Unemployment | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 8.40% |
Upside 1 | Unemployment | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.00% | 6.00% |
Upside 1 | Unemployment | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 4.80% |
Upside 1 | Unemployment | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 4.60% |
Upside 1 | Unemployment | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 4.60% |
Upside 1 | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 23.80% | 30.80% |
Upside 1 | HPI | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 5.50% |
Upside 1 | HPI | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 6.10% |
Upside 1 | HPI | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.00% | 4.60% |
Upside 1 | HPI | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.00% | 6.10% |
Upside 1 | HPI | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 6.10% |
Upside 1 | HPI | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 4.70% |
Upside 1 | HPI | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 45.20% | 30.90% |
Upside 1 | HPI | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.70% | 5.50% |
Upside 1 | HPI | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 11.80% | 2.30% |
Upside 1 | HPI | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.30% | 6.80% |
Upside 1 | HPI | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.00% | 6.70% |
Upside 1 | HPI | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.00% | 6.30% |
Upside 1 | HPI | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.70% | 5.60% |
Upside 1 | UK bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.10% |
Upside 1 | UK bank rate | UK | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.50% | 0.20% |
Upside 1 | UK bank rate | UK | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.20% |
Upside 1 | UK bank rate | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.60% | 0.10% |
Upside 1 | UK bank rate | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.10% |
Upside 1 | UK bank rate | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.30% |
Upside 1 | UK bank rate | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.50% | 0.30% |
Upside 1 | US federal funds rate | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.10% |
Upside 1 | US federal funds rate | US | Five year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.60% | 0.50% |
Upside 1 | US federal funds rate | US | 2021 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.20% | 0.50% |
Upside 1 | US federal funds rate | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | 0.30% |
Upside 1 | US federal funds rate | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.60% | 0.30% |
Upside 1 | US federal funds rate | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.00% | 0.50% |
Upside 1 | US federal funds rate | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.10% | 0.80% |
Other disclosures - Risk Man_12
Other disclosures - Risk Management and Principal Risks - Measurement uncertainty - ECL under 100% weighted scenarios for modelled portfolios, narrative (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Weighted expected credit loss, uplift percentage | 100.00% | |
Average EAD period | 12 months | |
Financial assets | £ 1,360,339 | £ 1,329,242 |
Coverage ratio | 0.90% | 1.40% |
Loans and advances at amortised cost | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
ECL movement excluding assets derecognised due to disposals and write-offs | £ (484) | £ 4,163 |
Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | £ 361,451 | £ 342,632 |
Coverage ratio | 1.60% | 2.40% |
Home loans | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
ECL movement excluding assets derecognised due to disposals and write-offs | £ (42) | £ 128 |
Home loans | Financial assets at amortised cost | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | £ 169,205 | £ 159,647 |
Coverage ratio | 0.30% | 0.30% |
Credit cards, unsecured and other retail lending | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
ECL movement excluding assets derecognised due to disposals and write-offs | £ (16) | £ 2,597 |
Credit cards, unsecured and other retail lending | Downside 2 | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 23.10% | |
Credit cards, unsecured and other retail lending | Credit derivatives | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 15.50% | |
Credit cards, unsecured and other retail lending | Financial assets at amortised cost | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | £ 41,793 | £ 40,813 |
Coverage ratio | 8.80% | 12.30% |
Wholesale loans | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
ECL movement excluding assets derecognised due to disposals and write-offs | £ (426) | £ 1,438 |
Wholesale loans | Financial assets at amortised cost | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | £ 150,453 | £ 142,172 |
Coverage ratio | 0.80% | 1.50% |
UK | Home loans | Downside 2 | HPI | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Expected credit loss rate | 29.90% | |
ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Treasury assets ECL | £ 3.9 | |
Financial assets | £ (6,284) | £ (9,399) |
ECL | Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Weighted expected credit loss, uplift percentage | 3.90% | |
ECL | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | £ (5,742) | (8,335) |
ECL | Home loans | Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | (407) | |
ECL | Home loans | Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | £ (314) | |
Increase (decrease) in coverage rates | 2.50% | |
ECL | Home loans | Credit derivatives | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | £ (322) | |
ECL | Home loans | Financial assets at amortised cost | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | (475) | (538) |
ECL | Credit cards, unsecured and other retail lending | Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | (5,010) | |
ECL | Credit cards, unsecured and other retail lending | Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | £ (2,592) | |
Increase (decrease) in coverage rates | 3.90% | |
ECL | Credit cards, unsecured and other retail lending | Credit derivatives | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | £ (2,693) | |
ECL | Credit cards, unsecured and other retail lending | Financial assets at amortised cost | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | (4,029) | (5,700) |
ECL | Wholesale loans | Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | £ (1,137) | |
Increase (decrease) in coverage rates | 4.20% | |
ECL | Wholesale loans | Credit derivatives | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | £ (1,185) | |
ECL | Wholesale loans | Financial assets at amortised cost | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | (1,238) | (2,097) |
Carrying amount | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | 367,193 | 350,967 |
Carrying amount | Loans and advances at amortised cost | Financial assets at amortised cost | Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Transfers into Stage 2 | 23,600 | |
Carrying amount | Home loans | Financial assets at amortised cost | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | 169,680 | 160,185 |
Carrying amount | Credit cards, unsecured and other retail lending | Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
ECL movement excluding assets derecognised due to disposals and write-offs | 7,100 | |
Carrying amount | Credit cards, unsecured and other retail lending | Financial assets at amortised cost | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | 45,822 | 46,513 |
Carrying amount | Wholesale loans | Financial assets at amortised cost | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Financial assets | £ 151,691 | £ 144,269 |
Carrying amount | US | Loans and advances at amortised cost | Financial assets at amortised cost | Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Expected credit loss rate | 9.50% | |
Carrying amount | UK | Loans and advances at amortised cost | Financial assets at amortised cost | Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Expected credit loss rate | 9.20% |
Other disclosures - Risk Man_13
Other disclosures - Risk Management and Principal Risks - Measurement uncertainty and sensitivity analysis - ECL under 100% weighted scenarios for modelled portfolios (audited) (Details) £ in Millions, $ in Millions | Dec. 31, 2021GBP (£) | Dec. 31, 2020GBP (£) | Dec. 31, 2020USD ($) |
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 1,360,339 | £ 1,329,242 | |
Coverage ratio | 0.90% | 1.40% | 1.40% |
ECL | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (6,284) | £ (9,399) | |
Stage 1 | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 0.20% | 0.20% | 0.20% |
Lifetime expected credit losses | Stage 2 | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 3.10% | 4.20% | 4.20% |
Lifetime expected credit losses | Stage 3 | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 29.80% | 33.40% | 33.40% |
Loans and advances | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 361,451 | £ 342,632 | |
Coverage ratio | 1.60% | 2.40% | 2.40% |
Loans and advances | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 367,193 | £ 350,967 | |
Loans and advances | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (5,742) | (8,335) | |
Loans and advances | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 317,659 | £ 289,931 | |
Coverage ratio | 0.40% | 0.40% | 0.40% |
Loans and advances | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 318,865 | £ 290,964 | |
Loans and advances | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (1,206) | (1,033) | |
Loans and advances | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 39,078 | £ 47,442 | |
Coverage ratio | 4.90% | 7.00% | 7.00% |
Loans and advances | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 4,714 | £ 5,259 | |
Coverage ratio | 34.80% | 41.50% | 41.50% |
Loans and advances | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 41,093 | £ 51,006 | |
Loans and advances | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 7,235 | 8,997 | |
Loans and advances | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (2,015) | (3,564) | |
Loans and advances | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (2,521) | (3,738) | |
Home loans | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 169,205 | £ 159,647 | |
Coverage ratio | 0.30% | 0.30% | 0.30% |
Home loans | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 169,680 | £ 160,185 | |
Home loans | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (475) | (538) | |
Home loans | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 148,039 | £ 138,606 | |
Coverage ratio | 0.00% | 0.00% | 0.00% |
Home loans | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 148,058 | £ 138,639 | |
Home loans | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (19) | (33) | |
Home loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 19,441 | £ 19,228 | |
Coverage ratio | 0.30% | 0.40% | 0.40% |
Home loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 1,725 | £ 1,813 | |
Coverage ratio | 18.70% | 18.80% | 18.80% |
Home loans | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 19,500 | £ 19,312 | |
Home loans | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 2,122 | 2,234 | |
Home loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (59) | (84) | |
Home loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (397) | (421) | |
Credit cards, unsecured and other retail lending | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 41,793 | £ 40,813 | |
Coverage ratio | 8.80% | 12.30% | 12.30% |
Credit cards, unsecured and other retail lending | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 45,822 | £ 46,513 | |
Credit cards, unsecured and other retail lending | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (4,029) | (5,700) | |
Credit cards, unsecured and other retail lending | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 37,016 | £ 32,341 | |
Coverage ratio | 2.20% | 2.10% | 2.10% |
Credit cards, unsecured and other retail lending | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 37,840 | £ 33,021 | |
Credit cards, unsecured and other retail lending | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (824) | (680) | |
Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 3,949 | £ 7,551 | |
Coverage ratio | 30.10% | 26.80% | 26.80% |
Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 828 | £ 921 | |
Coverage ratio | 64.50% | 71.00% | 71.00% |
Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 5,650 | £ 10,320 | |
Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 2,332 | 3,172 | |
Credit cards, unsecured and other retail lending | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (1,701) | (2,769) | |
Credit cards, unsecured and other retail lending | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (1,504) | (2,251) | |
Wholesale loans | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 150,453 | £ 142,172 | |
Coverage ratio | 0.80% | 1.50% | 1.50% |
Wholesale loans | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 151,691 | £ 144,269 | |
Wholesale loans | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (1,238) | (2,097) | |
Wholesale loans | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 132,604 | £ 118,984 | |
Coverage ratio | 0.30% | 0.30% | 0.30% |
Wholesale loans | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 132,967 | £ 119,304 | |
Wholesale loans | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (363) | (320) | |
Wholesale loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 15,688 | £ 20,663 | |
Coverage ratio | 1.60% | 3.30% | 3.30% |
Wholesale loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 2,161 | £ 2,525 | |
Coverage ratio | 22.30% | 29.70% | 29.70% |
Wholesale loans | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 15,943 | £ 21,374 | |
Wholesale loans | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 2,781 | 3,591 | |
Wholesale loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (255) | (711) | |
Wholesale loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (620) | (1,066) | |
Credit derivatives | Home loans | ECL | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (322) | ||
Credit derivatives | Credit cards, unsecured and other retail lending | Stage 2 | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 15.50% | ||
Credit derivatives | Credit cards, unsecured and other retail lending | ECL | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (2,693) | ||
Credit derivatives | Wholesale loans | ECL | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (1,185) | ||
Baseline | Home loans | ECL | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (314) | ||
Baseline | Credit cards, unsecured and other retail lending | ECL | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (2,592) | ||
Baseline | Wholesale loans | ECL | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (1,137) | ||
Downside 2 | Home loans | ECL | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (407) | ||
Downside 2 | Credit cards, unsecured and other retail lending | Stage 2 | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 23.10% | ||
Downside 2 | Credit cards, unsecured and other retail lending | ECL | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (5,010) | ||
Total model ECL | ECL | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (4,200) | (6,770) | |
Total model ECL | Credit derivatives | Loans and advances | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (4,200) | (6,770) | |
Total model ECL | Credit derivatives | Home loans | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (322) | £ (350) | |
Total model ECL | Credit derivatives | Home loans | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 0.00% | 0.00% | 0.00% |
Total model ECL | Credit derivatives | Home loans | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 137,279 | £ 131,422 | |
Total model ECL | Credit derivatives | Home loans | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (4) | £ (6) | |
Total model ECL | Credit derivatives | Home loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 10.00% | 0.20% | 0.20% |
Total model ECL | Credit derivatives | Home loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 1760.00% | 17.30% | 17.30% |
Total model ECL | Credit derivatives | Home loans | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 22,915 | £ 19,180 | |
Total model ECL | Credit derivatives | Home loans | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,724 | 1,778 | |
Total model ECL | Credit derivatives | Home loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (15) | (37) | |
Total model ECL | Credit derivatives | Home loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (303) | (307) | |
Total model ECL | Credit derivatives | Credit cards, unsecured and other retail lending | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (2,693) | £ (4,602) | |
Total model ECL | Credit derivatives | Credit cards, unsecured and other retail lending | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 70.00% | 0.80% | 0.80% |
Total model ECL | Credit derivatives | Credit cards, unsecured and other retail lending | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 45,503 | £ 51,952 | |
Total model ECL | Credit derivatives | Credit cards, unsecured and other retail lending | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (324) | £ (392) | |
Total model ECL | Credit derivatives | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 1550.00% | 16.50% | 16.50% |
Total model ECL | Credit derivatives | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 6530.00% | 77.50% | 77.50% |
Total model ECL | Credit derivatives | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 7,200 | £ 13,399 | |
Total model ECL | Credit derivatives | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,922 | 2,585 | |
Total model ECL | Credit derivatives | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (1,114) | (2,207) | |
Total model ECL | Credit derivatives | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (1,255) | (2,003) | |
Total model ECL | Credit derivatives | Wholesale loans | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (1,185) | £ (1,818) | |
Total model ECL | Credit derivatives | Wholesale loans | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 20.00% | 0.20% | 0.20% |
Total model ECL | Credit derivatives | Wholesale loans | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 174,249 | £ 149,099 | |
Total model ECL | Credit derivatives | Wholesale loans | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (290) | £ (262) | |
Total model ECL | Credit derivatives | Wholesale loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 180.00% | 4.30% | 4.30% |
Total model ECL | Credit derivatives | Wholesale loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 1780.00% | 6.60% | 6.60% |
Total model ECL | Credit derivatives | Wholesale loans | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 32,256 | £ 32,677 | |
Total model ECL | Credit derivatives | Wholesale loans | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,811 | 2,211 | |
Total model ECL | Credit derivatives | Wholesale loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (572) | (1,410) | |
Total model ECL | Credit derivatives | Wholesale loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (323) | (146) | |
Total model ECL | Upside 2 | Loans and advances | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (3,723) | (5,520) | |
Total model ECL | Upside 2 | Home loans | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (304) | £ (317) | |
Total model ECL | Upside 2 | Home loans | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 0.00% | 0.00% | 0.00% |
Total model ECL | Upside 2 | Home loans | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 139,117 | £ 134,100 | |
Total model ECL | Upside 2 | Home loans | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (2) | £ (4) | |
Total model ECL | Upside 2 | Home loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 0.00% | 0.20% | 0.20% |
Total model ECL | Upside 2 | Home loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 1690.00% | 15.90% | 15.90% |
Total model ECL | Upside 2 | Home loans | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 21,076 | £ 16,502 | |
Total model ECL | Upside 2 | Home loans | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,724 | 1,778 | |
Total model ECL | Upside 2 | Home loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (10) | (31) | |
Total model ECL | Upside 2 | Home loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (292) | (282) | |
Total model ECL | Upside 2 | Credit cards, unsecured and other retail lending | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (2,427) | £ (3,881) | |
Total model ECL | Upside 2 | Credit cards, unsecured and other retail lending | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 60.00% | 0.60% | 0.60% |
Total model ECL | Upside 2 | Credit cards, unsecured and other retail lending | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 46,170 | £ 53,271 | |
Total model ECL | Upside 2 | Credit cards, unsecured and other retail lending | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (266) | £ (316) | |
Total model ECL | Upside 2 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 1480.00% | 15.30% | 15.30% |
Total model ECL | Upside 2 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 6430.00% | 75.30% | 75.30% |
Total model ECL | Upside 2 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 6,260 | £ 10,572 | |
Total model ECL | Upside 2 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,922 | 2,585 | |
Total model ECL | Upside 2 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (925) | (1,618) | |
Total model ECL | Upside 2 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (1,236) | (1,947) | |
Total model ECL | Upside 2 | Wholesale loans | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (992) | £ (1,322) | |
Total model ECL | Upside 2 | Wholesale loans | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 10.00% | 0.20% | 0.20% |
Total model ECL | Upside 2 | Wholesale loans | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 177,453 | £ 155,812 | |
Total model ECL | Upside 2 | Wholesale loans | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (240) | £ (242) | |
Total model ECL | Upside 2 | Wholesale loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 150.00% | 3.70% | 3.70% |
Total model ECL | Upside 2 | Wholesale loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 1770.00% | 5.80% | 5.80% |
Total model ECL | Upside 2 | Wholesale loans | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 29,052 | £ 25,963 | |
Total model ECL | Upside 2 | Wholesale loans | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,811 | 2,211 | |
Total model ECL | Upside 2 | Wholesale loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (431) | (952) | |
Total model ECL | Upside 2 | Wholesale loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (321) | (128) | |
Total model ECL | Upside 1 | Loans and advances | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (3,864) | (5,911) | |
Total model ECL | Upside 1 | Home loans | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (308) | £ (323) | |
Total model ECL | Upside 1 | Home loans | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 0.00% | 0.00% | 0.00% |
Total model ECL | Upside 1 | Home loans | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 138,424 | £ 133,246 | |
Total model ECL | Upside 1 | Home loans | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (2) | £ (5) | |
Total model ECL | Upside 1 | Home loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 10.00% | 0.20% | 0.20% |
Total model ECL | Upside 1 | Home loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 1710.00% | 16.10% | 16.10% |
Total model ECL | Upside 1 | Home loans | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 21,769 | £ 17,356 | |
Total model ECL | Upside 1 | Home loans | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,724 | 1,778 | |
Total model ECL | Upside 1 | Home loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (11) | (32) | |
Total model ECL | Upside 1 | Home loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (295) | (286) | |
Total model ECL | Upside 1 | Credit cards, unsecured and other retail lending | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (2,505) | £ (4,149) | |
Total model ECL | Upside 1 | Credit cards, unsecured and other retail lending | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 60.00% | 0.60% | 0.60% |
Total model ECL | Upside 1 | Credit cards, unsecured and other retail lending | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 45,963 | £ 52,932 | |
Total model ECL | Upside 1 | Credit cards, unsecured and other retail lending | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (272) | £ (340) | |
Total model ECL | Upside 1 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 1520.00% | 15.90% | 15.90% |
Total model ECL | Upside 1 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 6480.00% | 76.30% | 76.30% |
Total model ECL | Upside 1 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 6,521 | £ 11,579 | |
Total model ECL | Upside 1 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,922 | 2,585 | |
Total model ECL | Upside 1 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (988) | (1,837) | |
Total model ECL | Upside 1 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (1,245) | (1,972) | |
Total model ECL | Upside 1 | Wholesale loans | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (1,051) | £ (1,439) | |
Total model ECL | Upside 1 | Wholesale loans | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 10.00% | 0.20% | 0.20% |
Total model ECL | Upside 1 | Wholesale loans | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 176,774 | £ 154,578 | |
Total model ECL | Upside 1 | Wholesale loans | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (262) | £ (258) | |
Total model ECL | Upside 1 | Wholesale loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 160.00% | 3.80% | 3.80% |
Total model ECL | Upside 1 | Wholesale loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 1780.00% | 6.10% | 6.10% |
Total model ECL | Upside 1 | Wholesale loans | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 29,732 | £ 27,198 | |
Total model ECL | Upside 1 | Wholesale loans | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,811 | 2,211 | |
Total model ECL | Upside 1 | Wholesale loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (467) | (1,047) | |
Total model ECL | Upside 1 | Wholesale loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (322) | (134) | |
Total model ECL | Baseline | Loans and advances | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (4,043) | (6,453) | |
Total model ECL | Baseline | Home loans | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (314) | £ (329) | |
Total model ECL | Baseline | Home loans | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 0.00% | 0.00% | 0.00% |
Total model ECL | Baseline | Home loans | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 137,563 | £ 132,414 | |
Total model ECL | Baseline | Home loans | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (3) | £ (6) | |
Total model ECL | Baseline | Home loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 10.00% | 0.20% | 0.20% |
Total model ECL | Baseline | Home loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 1730.00% | 16.30% | 16.30% |
Total model ECL | Baseline | Home loans | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 22,631 | £ 18,188 | |
Total model ECL | Baseline | Home loans | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,724 | 1,778 | |
Total model ECL | Baseline | Home loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (12) | (33) | |
Total model ECL | Baseline | Home loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (299) | (290) | |
Total model ECL | Baseline | Credit cards, unsecured and other retail lending | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (2,592) | £ (4,511) | |
Total model ECL | Baseline | Credit cards, unsecured and other retail lending | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 60.00% | 0.70% | 0.70% |
Total model ECL | Baseline | Credit cards, unsecured and other retail lending | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 45,751 | £ 51,995 | |
Total model ECL | Baseline | Credit cards, unsecured and other retail lending | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (279) | £ (372) | |
Total model ECL | Baseline | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 1560.00% | 16.20% | 16.20% |
Total model ECL | Baseline | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 6530.00% | 77.40% | 77.40% |
Total model ECL | Baseline | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 6,795 | £ 13,176 | |
Total model ECL | Baseline | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,922 | 2,585 | |
Total model ECL | Baseline | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (1,058) | (2,138) | |
Total model ECL | Baseline | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (1,255) | (2,001) | |
Total model ECL | Baseline | Wholesale loans | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (1,137) | £ (1,613) | |
Total model ECL | Baseline | Wholesale loans | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 20.00% | 0.20% | 0.20% |
Total model ECL | Baseline | Wholesale loans | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 175,451 | £ 152,141 | |
Total model ECL | Baseline | Wholesale loans | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (286) | £ (249) | |
Total model ECL | Baseline | Wholesale loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 170.00% | 4.10% | 4.10% |
Total model ECL | Baseline | Wholesale loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 1780.00% | 6.40% | 6.40% |
Total model ECL | Baseline | Wholesale loans | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 31,054 | £ 29,635 | |
Total model ECL | Baseline | Wholesale loans | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,811 | 2,211 | |
Total model ECL | Baseline | Wholesale loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (528) | (1,223) | |
Total model ECL | Baseline | Wholesale loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (323) | (141) | |
Total model ECL | Downside 1 | Loans and advances | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (4,976) | (7,915) | |
Total model ECL | Downside 1 | Home loans | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (348) | £ (374) | |
Total model ECL | Downside 1 | Home loans | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 0.00% | 0.00% | 0.00% |
Total model ECL | Downside 1 | Home loans | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 135,544 | £ 130,547 | |
Total model ECL | Downside 1 | Home loans | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (6) | £ (14) | |
Total model ECL | Downside 1 | Home loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 10.00% | 0.20% | 0.20% |
Total model ECL | Downside 1 | Home loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 1860.00% | 17.90% | 17.90% |
Total model ECL | Downside 1 | Home loans | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 24,649 | £ 20,055 | |
Total model ECL | Downside 1 | Home loans | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,724 | 1,778 | |
Total model ECL | Downside 1 | Home loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (22) | (42) | |
Total model ECL | Downside 1 | Home loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (320) | (318) | |
Total model ECL | Downside 1 | Credit cards, unsecured and other retail lending | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (3,124) | £ (5,335) | |
Total model ECL | Downside 1 | Credit cards, unsecured and other retail lending | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 80.00% | 0.80% | 0.80% |
Total model ECL | Downside 1 | Credit cards, unsecured and other retail lending | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 43,131 | £ 50,168 | |
Total model ECL | Downside 1 | Credit cards, unsecured and other retail lending | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (350) | £ (415) | |
Total model ECL | Downside 1 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 1540.00% | 17.40% | 17.40% |
Total model ECL | Downside 1 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 6640.00% | 79.50% | 79.50% |
Total model ECL | Downside 1 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 9,708 | £ 16,477 | |
Total model ECL | Downside 1 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,922 | 2,585 | |
Total model ECL | Downside 1 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (1,497) | (2,865) | |
Total model ECL | Downside 1 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (1,277) | (2,055) | |
Total model ECL | Downside 1 | Wholesale loans | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (1,504) | £ (2,206) | |
Total model ECL | Downside 1 | Wholesale loans | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 20.00% | 0.20% | 0.20% |
Total model ECL | Downside 1 | Wholesale loans | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 169,814 | £ 144,646 | |
Total model ECL | Downside 1 | Wholesale loans | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (327) | £ (278) | |
Total model ECL | Downside 1 | Wholesale loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 230.00% | 4.80% | 4.80% |
Total model ECL | Downside 1 | Wholesale loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 1800.00% | 7.10% | 7.10% |
Total model ECL | Downside 1 | Wholesale loans | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 36,692 | £ 37,130 | |
Total model ECL | Downside 1 | Wholesale loans | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,811 | 2,211 | |
Total model ECL | Downside 1 | Wholesale loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (851) | (1,771) | |
Total model ECL | Downside 1 | Wholesale loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (326) | (157) | |
Total model ECL | Downside 2 | Loans and advances | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (7,609) | (9,933) | |
Total model ECL | Downside 2 | Home loans | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (407) | £ (491) | |
Total model ECL | Downside 2 | Home loans | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 0.00% | 0.00% | 0.00% |
Total model ECL | Downside 2 | Home loans | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 133,042 | £ 128,369 | |
Total model ECL | Downside 2 | Home loans | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (14) | £ (42) | |
Total model ECL | Downside 2 | Home loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 20.00% | 0.30% | 0.30% |
Total model ECL | Downside 2 | Home loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 2010.00% | 21.70% | 21.70% |
Total model ECL | Downside 2 | Home loans | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 27,151 | £ 22,233 | |
Total model ECL | Downside 2 | Home loans | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,724 | 1,778 | |
Total model ECL | Downside 2 | Home loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (47) | (63) | |
Total model ECL | Downside 2 | Home loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (346) | (386) | |
Total model ECL | Downside 2 | Credit cards, unsecured and other retail lending | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (5,010) | £ (6,057) | |
Total model ECL | Downside 2 | Credit cards, unsecured and other retail lending | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 110.00% | 0.90% | 0.90% |
Total model ECL | Downside 2 | Credit cards, unsecured and other retail lending | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 38,820 | £ 48,717 | |
Total model ECL | Downside 2 | Credit cards, unsecured and other retail lending | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (418) | £ (415) | |
Total model ECL | Downside 2 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 2310.00% | 18.40% | 18.40% |
Total model ECL | Downside 2 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 6750.00% | 80.40% | 80.40% |
Total model ECL | Downside 2 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 14,290 | £ 19,322 | |
Total model ECL | Downside 2 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,922 | 2,585 | |
Total model ECL | Downside 2 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (3,295) | (3,564) | |
Total model ECL | Downside 2 | Credit cards, unsecured and other retail lending | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (1,297) | (2,078) | |
Total model ECL | Downside 2 | Wholesale loans | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (2,192) | £ (3,385) | |
Total model ECL | Downside 2 | Wholesale loans | Stage 1 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 20.00% | 0.20% | 0.20% |
Total model ECL | Downside 2 | Wholesale loans | Stage 1 | Carrying amount | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 161,998 | £ 131,415 | |
Total model ECL | Downside 2 | Wholesale loans | Stage 1 | ECL | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (350) | £ (290) | |
Total model ECL | Downside 2 | Wholesale loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 340.00% | 5.80% | 5.80% |
Total model ECL | Downside 2 | Wholesale loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 1830.00% | 8.30% | 8.30% |
Total model ECL | Downside 2 | Wholesale loans | Lifetime expected credit losses | Carrying amount | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ 44,507 | £ 50,361 | |
Total model ECL | Downside 2 | Wholesale loans | Lifetime expected credit losses | Carrying amount | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | 1,811 | 2,211 | |
Total model ECL | Downside 2 | Wholesale loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (1,510) | (2,911) | |
Total model ECL | Downside 2 | Wholesale loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | (332) | (184) | |
ECL from individually assessed impairments | ECL | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (524) | (902) | $ (1,400) |
ECL from non-modelled and other management adjustments | ECL | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Financial assets | £ (1,727) |
Other disclosures - Risk Man_14
Other disclosures - Risk Management and Principal Risks - Credit risk concentrations by geography and industry (audited) (Details) £ in Millions, $ in Billions | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | |
On-balance sheet: | |||||
Cash and balances at central banks | £ 238,574 | [1] | £ 191,127 | £ 150,258 | |
Cash collateral and settlement balances | 92,542 | [2] | 101,367 | ||
Loans and advances at amortised cost | 361,451 | [2] | 342,632 | ||
Reverse repurchase agreements and other similar secured lending | 3,227 | [2] | 9,031 | ||
Trading portfolio assets | 147,035 | [2] | 127,950 | ||
Financial assets at fair value through the income statement | 191,972 | [2] | 175,151 | ||
Derivative financial instruments | 262,572 | [2] | 302,446 | ||
Financial assets at fair value through other comprehensive income | 61,753 | [2] | 78,688 | ||
Other assets | 1,213 | 850 | |||
Total assets | 1,384,285 | [2] | $ 1,384.3 | 1,349,514 | £ 1,140,200 |
Off-balance sheet: | |||||
Contingent liabilities | 21,346 | 21,609 | |||
Total off-balance sheet | 367,057 | 354,658 | |||
Credit risk | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 238,574 | 191,127 | |||
Cash collateral and settlement balances | 92,542 | 101,367 | |||
Loans and advances at amortised cost | 361,451 | 342,632 | |||
Reverse repurchase agreements and other similar secured lending | 3,227 | 9,031 | |||
Trading portfolio assets | 63,389 | 64,830 | |||
Financial assets at fair value through the income statement | 186,097 | 170,531 | |||
Derivative financial instruments | 262,572 | 302,446 | |||
Financial assets at fair value through other comprehensive income | 60,851 | 77,927 | |||
Other assets | 1,212 | 850 | |||
Total assets | 1,269,915 | 1,260,741 | |||
Off-balance sheet: | |||||
Contingent liabilities | 21,346 | 21,609 | |||
Loan commitments | 345,711 | 333,049 | |||
Total off-balance sheet | 367,057 | 354,658 | |||
Total | 1,636,972 | 1,615,399 | |||
Credit risk | Banks | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 52 | 56 | |||
Cash collateral and settlement balances | 14,811 | 17,986 | |||
Loans and advances at amortised cost | 8,519 | 8,133 | |||
Reverse repurchase agreements and other similar secured lending | 645 | 706 | |||
Trading portfolio assets | 2,586 | 2,743 | |||
Financial assets at fair value through the income statement | 26,074 | 21,824 | |||
Derivative financial instruments | 120,666 | 155,767 | |||
Financial assets at fair value through other comprehensive income | 14,441 | 18,829 | |||
Other assets | 618 | 439 | |||
Total assets | 188,412 | 226,483 | |||
Off-balance sheet: | |||||
Contingent liabilities | 1,006 | 1,150 | |||
Loan commitments | 1,395 | 1,813 | |||
Total off-balance sheet | 2,401 | 2,963 | |||
Total | 190,813 | 229,446 | |||
Credit risk | Other financial insti- tutions | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 74 | 84 | |||
Cash collateral and settlement balances | 61,581 | 67,305 | |||
Loans and advances at amortised cost | 32,332 | 22,062 | |||
Reverse repurchase agreements and other similar secured lending | 2,049 | 7,964 | |||
Trading portfolio assets | 8,817 | 11,464 | |||
Financial assets at fair value through the income statement | 131,264 | 131,943 | |||
Derivative financial instruments | 117,400 | 116,526 | |||
Financial assets at fair value through other comprehensive income | 4,274 | 5,843 | |||
Other assets | 450 | 224 | |||
Total assets | 358,241 | 363,415 | |||
Off-balance sheet: | |||||
Contingent liabilities | 5,356 | 5,501 | |||
Loan commitments | 55,071 | 53,936 | |||
Total off-balance sheet | 60,427 | 59,437 | |||
Total | 418,668 | 422,852 | |||
Credit risk | Manu- facturing | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 0 | 0 | |||
Cash collateral and settlement balances | 320 | 375 | |||
Loans and advances at amortised cost | 6,701 | 8,142 | |||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | |||
Trading portfolio assets | 4,881 | 4,104 | |||
Financial assets at fair value through the income statement | 771 | 608 | |||
Derivative financial instruments | 4,169 | 4,126 | |||
Financial assets at fair value through other comprehensive income | 0 | 1 | |||
Other assets | 1 | 6 | |||
Total assets | 16,843 | 17,362 | |||
Off-balance sheet: | |||||
Contingent liabilities | 3,080 | 3,187 | |||
Loan commitments | 42,587 | 39,638 | |||
Total off-balance sheet | 45,667 | 42,825 | |||
Total | 62,510 | 60,187 | |||
Credit risk | Const- ruction and property | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 0 | 0 | |||
Cash collateral and settlement balances | 79 | 35 | |||
Loans and advances at amortised cost | 25,722 | 26,125 | |||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | |||
Trading portfolio assets | 1,097 | 516 | |||
Financial assets at fair value through the income statement | 7,999 | 5,668 | |||
Derivative financial instruments | 1,898 | 2,725 | |||
Financial assets at fair value through other comprehensive income | 662 | 425 | |||
Other assets | 3 | 12 | |||
Total assets | 37,460 | 35,506 | |||
Off-balance sheet: | |||||
Contingent liabilities | 1,341 | 1,260 | |||
Loan commitments | 16,673 | 14,002 | |||
Total off-balance sheet | 18,014 | 15,262 | |||
Total | 55,474 | 50,768 | |||
Credit risk | Govern- ment and central bank | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 238,448 | 190,981 | |||
Cash collateral and settlement balances | 14,526 | 13,946 | |||
Loans and advances at amortised cost | 30,827 | 28,445 | |||
Reverse repurchase agreements and other similar secured lending | 533 | 361 | |||
Trading portfolio assets | 32,574 | 35,902 | |||
Financial assets at fair value through the income statement | 13,945 | 5,530 | |||
Derivative financial instruments | 7,233 | 11,649 | |||
Financial assets at fair value through other comprehensive income | 40,872 | 51,955 | |||
Other assets | 8 | 1 | |||
Total assets | 378,966 | 338,770 | |||
Off-balance sheet: | |||||
Contingent liabilities | 1,682 | 1,678 | |||
Loan commitments | 1,362 | 1,398 | |||
Total off-balance sheet | 3,044 | 3,076 | |||
Total | 382,010 | 341,846 | |||
Credit risk | Energy and water | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 0 | 0 | |||
Cash collateral and settlement balances | 390 | 871 | |||
Loans and advances at amortised cost | 4,345 | 4,722 | |||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | |||
Trading portfolio assets | 4,043 | 3,052 | |||
Financial assets at fair value through the income statement | 87 | 13 | |||
Derivative financial instruments | 3,544 | 3,288 | |||
Financial assets at fair value through other comprehensive income | 0 | 0 | |||
Other assets | 0 | 10 | |||
Total assets | 12,409 | 11,956 | |||
Off-balance sheet: | |||||
Contingent liabilities | 3,284 | 3,223 | |||
Loan commitments | 26,461 | 25,780 | |||
Total off-balance sheet | 29,745 | 29,003 | |||
Total | 42,154 | 40,959 | |||
Credit risk | Whole- sale and retail distri- bution and leisure | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 0 | 0 | |||
Cash collateral and settlement balances | 60 | 30 | |||
Loans and advances at amortised cost | 11,455 | 12,569 | |||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | |||
Trading portfolio assets | 1,734 | 1,883 | |||
Financial assets at fair value through the income statement | 181 | 64 | |||
Derivative financial instruments | 1,172 | 1,235 | |||
Financial assets at fair value through other comprehensive income | 0 | 0 | |||
Other assets | 2 | 18 | |||
Total assets | 14,604 | 15,799 | |||
Off-balance sheet: | |||||
Contingent liabilities | 1,209 | 1,005 | |||
Loan commitments | 16,299 | 17,165 | |||
Total off-balance sheet | 17,508 | 18,170 | |||
Total | 32,112 | 33,969 | |||
Credit risk | Business and other services | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 0 | 6 | |||
Cash collateral and settlement balances | 366 | 575 | |||
Loans and advances at amortised cost | 19,113 | 19,538 | |||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | |||
Trading portfolio assets | 4,716 | 2,625 | |||
Financial assets at fair value through the income statement | 3,753 | 3,712 | |||
Derivative financial instruments | 2,696 | 2,361 | |||
Financial assets at fair value through other comprehensive income | 455 | 733 | |||
Other assets | 104 | 98 | |||
Total assets | 31,203 | 29,648 | |||
Off-balance sheet: | |||||
Contingent liabilities | 2,518 | 2,283 | |||
Loan commitments | 25,682 | 24,554 | |||
Total off-balance sheet | 28,200 | 26,837 | |||
Total | 59,403 | 56,485 | |||
Credit risk | Home loans | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 0 | 0 | |||
Cash collateral and settlement balances | 0 | 0 | |||
Loans and advances at amortised cost | 169,205 | 159,647 | |||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | |||
Trading portfolio assets | 0 | 0 | |||
Financial assets at fair value through the income statement | 1,595 | 971 | |||
Derivative financial instruments | 0 | 0 | |||
Financial assets at fair value through other comprehensive income | 0 | 0 | |||
Other assets | 0 | 0 | |||
Total assets | 170,800 | 160,618 | |||
Off-balance sheet: | |||||
Contingent liabilities | 0 | 0 | |||
Loan commitments | 11,656 | 12,385 | |||
Total off-balance sheet | 11,656 | 12,385 | |||
Total | 182,456 | 173,003 | |||
Credit risk | Cards, unsecured loans and other personal lending | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 0 | 0 | |||
Cash collateral and settlement balances | 68 | 0 | |||
Loans and advances at amortised cost | 42,198 | 41,312 | |||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | |||
Trading portfolio assets | 0 | 0 | |||
Financial assets at fair value through the income statement | 0 | 0 | |||
Derivative financial instruments | 0 | 0 | |||
Financial assets at fair value through other comprehensive income | 0 | 0 | |||
Other assets | 21 | 34 | |||
Total assets | 42,287 | 41,346 | |||
Off-balance sheet: | |||||
Contingent liabilities | 73 | 155 | |||
Loan commitments | 121,680 | 119,807 | |||
Total off-balance sheet | 121,753 | 119,962 | |||
Total | 164,040 | 161,308 | |||
Credit risk | Other | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 0 | 0 | |||
Cash collateral and settlement balances | 341 | 244 | |||
Loans and advances at amortised cost | 11,034 | 11,937 | |||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | |||
Trading portfolio assets | 2,941 | 2,541 | |||
Financial assets at fair value through the income statement | 428 | 198 | |||
Derivative financial instruments | 3,794 | 4,769 | |||
Financial assets at fair value through other comprehensive income | 147 | 141 | |||
Other assets | 5 | 8 | |||
Total assets | 18,690 | 19,838 | |||
Off-balance sheet: | |||||
Contingent liabilities | 1,797 | 2,167 | |||
Loan commitments | 26,845 | 22,571 | |||
Total off-balance sheet | 28,642 | 24,738 | |||
Total | 47,332 | 44,576 | |||
Credit risk | United Kingdom | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 114,959 | 66,459 | |||
Cash collateral and settlement balances | 34,249 | 33,893 | |||
Loans and advances at amortised cost | 270,261 | 262,231 | |||
Reverse repurchase agreements and other similar secured lending | 9 | 10 | |||
Trading portfolio assets | 12,926 | 9,829 | |||
Financial assets at fair value through the income statement | 28,737 | 34,229 | |||
Derivative financial instruments | 78,710 | 93,430 | |||
Financial assets at fair value through other comprehensive income | 7,661 | 10,672 | |||
Other assets | 949 | 608 | |||
Total assets | 548,461 | 511,361 | |||
Off-balance sheet: | |||||
Contingent liabilities | 5,527 | 5,876 | |||
Loan commitments | 105,844 | 112,561 | |||
Total off-balance sheet | 111,371 | 118,437 | |||
Total | 659,832 | 629,798 | |||
Credit risk | Americas | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 38,735 | 36,063 | |||
Cash collateral and settlement balances | 28,469 | 27,287 | |||
Loans and advances at amortised cost | 51,599 | 41,094 | |||
Reverse repurchase agreements and other similar secured lending | 123 | 152 | |||
Trading portfolio assets | 29,539 | 31,000 | |||
Financial assets at fair value through the income statement | 95,478 | 88,327 | |||
Derivative financial instruments | 92,010 | 90,801 | |||
Financial assets at fair value through other comprehensive income | 27,391 | 27,504 | |||
Other assets | 223 | 185 | |||
Total assets | 363,567 | 342,413 | |||
Off-balance sheet: | |||||
Contingent liabilities | 10,328 | 10,122 | |||
Loan commitments | 192,303 | 175,926 | |||
Total off-balance sheet | 202,631 | 186,048 | |||
Total | 566,198 | 528,461 | |||
Credit risk | Europe | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 76,846 | 69,963 | |||
Cash collateral and settlement balances | 21,822 | 30,121 | |||
Loans and advances at amortised cost | 24,352 | 24,949 | |||
Reverse repurchase agreements and other similar secured lending | 401 | 373 | |||
Trading portfolio assets | 15,092 | 17,107 | |||
Financial assets at fair value through the income statement | 30,083 | 25,709 | |||
Derivative financial instruments | 75,247 | 101,102 | |||
Financial assets at fair value through other comprehensive income | 19,235 | 28,607 | |||
Other assets | 39 | 57 | |||
Total assets | 263,117 | 297,988 | |||
Off-balance sheet: | |||||
Contingent liabilities | 3,957 | 3,809 | |||
Loan commitments | 40,523 | 38,836 | |||
Total off-balance sheet | 44,480 | 42,645 | |||
Total | 307,597 | 340,633 | |||
Credit risk | Asia | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 7,789 | 17,987 | |||
Cash collateral and settlement balances | 7,260 | 9,558 | |||
Loans and advances at amortised cost | 11,039 | 10,728 | |||
Reverse repurchase agreements and other similar secured lending | 2,508 | 8,285 | |||
Trading portfolio assets | 4,943 | 5,948 | |||
Financial assets at fair value through the income statement | 21,800 | 14,742 | |||
Derivative financial instruments | 14,709 | 14,532 | |||
Financial assets at fair value through other comprehensive income | 6,164 | 11,006 | |||
Other assets | 1 | 0 | |||
Total assets | 76,213 | 92,786 | |||
Off-balance sheet: | |||||
Contingent liabilities | 1,131 | 1,222 | |||
Loan commitments | 5,104 | 4,169 | |||
Total off-balance sheet | 6,235 | 5,391 | |||
Total | 82,448 | 98,177 | |||
Credit risk | Africa and Middle East | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 245 | 655 | |||
Cash collateral and settlement balances | 742 | 508 | |||
Loans and advances at amortised cost | 4,200 | 3,630 | |||
Reverse repurchase agreements and other similar secured lending | 186 | 211 | |||
Trading portfolio assets | 889 | 946 | |||
Financial assets at fair value through the income statement | 9,999 | 7,524 | |||
Derivative financial instruments | 1,896 | 2,581 | |||
Financial assets at fair value through other comprehensive income | 400 | 138 | |||
Other assets | 0 | 0 | |||
Total assets | 18,557 | 16,193 | |||
Off-balance sheet: | |||||
Contingent liabilities | 403 | 580 | |||
Loan commitments | 1,937 | 1,557 | |||
Total off-balance sheet | 2,340 | 2,137 | |||
Total | £ 20,897 | £ 18,330 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Other disclosures - Risk Man_15
Other disclosures - Risk Management and Principal Risks - Balance sheet credit quality (audited) (Details) £ in Millions, $ in Billions | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | |
On-balance sheet: | |||||
Cash and balances at central banks | £ 238,574 | [1] | £ 191,127 | £ 150,258 | |
Cash collateral and settlement balances | 92,542 | [2] | 101,367 | ||
Loans and advances at amortised cost | 361,451 | [2] | 342,632 | ||
Reverse repurchase agreements and other similar secured lending | 3,227 | [2] | 9,031 | ||
Trading portfolio assets | 147,035 | [2] | 127,950 | ||
Financial assets at fair value through the income statement | 191,972 | [2] | 175,151 | ||
Derivative financial instruments | 262,572 | [2] | 302,446 | ||
Other assets | 1,213 | 850 | |||
Total assets | 1,384,285 | [2] | $ 1,384.3 | 1,349,514 | £ 1,140,200 |
Debt securities classified at amortised cost | |||||
On-balance sheet: | |||||
Trading portfolio assets | 50,864 | 56,482 | |||
Traded loans | |||||
On-balance sheet: | |||||
Trading portfolio assets | 12,525 | 8,348 | |||
Internal credit grades | |||||
On-balance sheet: | |||||
Cash and balances at central banks | 238,574 | 101,367 | |||
Cash collateral and settlement balances | 92,542 | 191,127 | |||
Reverse repurchase agreements and other similar secured lending | 3,227 | 9,031 | |||
Trading portfolio assets | 63,389 | 64,830 | |||
Financial assets at fair value through the income statement | 186,097 | 170,531 | |||
Derivative financial instruments | 262,572 | 302,446 | |||
Financial assets measured at fair value through other comprehensive income | 60,851 | 77,927 | |||
Other assets | 1,212 | 850 | |||
Total assets | £ 1,269,915 | £ 1,260,741 | |||
On-balance sheet, percentage | |||||
Cash and balances at central banks, percentage | 100.00% | 100.00% | 100.00% | ||
Cash collateral and settlement balance, percentage | 100.00% | 100.00% | 100.00% | ||
Reverse repurchase agreements, percentage | 100.00% | 100.00% | 100.00% | ||
Trading portfolio assets, percentage | 100.00% | 100.00% | 100.00% | ||
Financial assets at fair value through the income statement, percentage | 100.00% | 100.00% | 100.00% | ||
Derivative financial instruments, percentage | 100.00% | 100.00% | 100.00% | ||
Financial assets at fair value through other comprehensive income, percentage | 100.00% | 100.00% | 100.00% | ||
Other assets, percentage | 100.00% | 100.00% | 100.00% | ||
Total assets, percentage | 100.00% | 100.00% | 100.00% | ||
Internal credit grades | 0 to 0.60% | |||||
On-balance sheet: | |||||
Cash and balances at central banks | £ 238,574 | £ 90,633 | |||
Cash collateral and settlement balances | 83,257 | 191,127 | |||
Reverse repurchase agreements and other similar secured lending | 3,141 | 9,019 | |||
Trading portfolio assets | 46,824 | 52,099 | |||
Financial assets at fair value through the income statement | 129,561 | 113,299 | |||
Derivative financial instruments | 246,628 | 282,617 | |||
Financial assets measured at fair value through other comprehensive income | 60,845 | 77,919 | |||
Other assets | 1,155 | 778 | |||
Total assets | £ 1,101,786 | £ 1,090,077 | |||
On-balance sheet, percentage | |||||
Cash and balances at central banks, percentage | 100.00% | 100.00% | 100.00% | ||
Cash collateral and settlement balance, percentage | 90.00% | 90.00% | 89.00% | ||
Reverse repurchase agreements, percentage | 97.00% | 97.00% | 100.00% | ||
Trading portfolio assets, percentage | 74.00% | 74.00% | 81.00% | ||
Financial assets at fair value through the income statement, percentage | 70.00% | 70.00% | 67.00% | ||
Derivative financial instruments, percentage | 94.00% | 94.00% | 94.00% | ||
Financial assets at fair value through other comprehensive income, percentage | 100.00% | 100.00% | 100.00% | ||
Other assets, percentage | 95.00% | 95.00% | 92.00% | ||
Total assets, percentage | 87.00% | 87.00% | 87.00% | ||
Internal credit grades | 0.60 to 11.35% | |||||
On-balance sheet: | |||||
Cash and balances at central banks | £ 0 | £ 10,725 | |||
Cash collateral and settlement balances | 9,275 | 0 | |||
Reverse repurchase agreements and other similar secured lending | 86 | 12 | |||
Trading portfolio assets | 15,879 | 9,978 | |||
Financial assets at fair value through the income statement | 55,908 | 56,469 | |||
Derivative financial instruments | 15,678 | 19,352 | |||
Financial assets measured at fair value through other comprehensive income | 6 | 8 | |||
Other assets | 55 | 68 | |||
Total assets | £ 157,164 | £ 156,887 | |||
On-balance sheet, percentage | |||||
Cash and balances at central banks, percentage | 0.00% | 0.00% | 0.00% | ||
Cash collateral and settlement balance, percentage | 10.00% | 10.00% | 11.00% | ||
Reverse repurchase agreements, percentage | 3.00% | 3.00% | 0.00% | ||
Trading portfolio assets, percentage | 25.00% | 25.00% | 15.00% | ||
Financial assets at fair value through the income statement, percentage | 30.00% | 30.00% | 33.00% | ||
Derivative financial instruments, percentage | 6.00% | 6.00% | 6.00% | ||
Financial assets at fair value through other comprehensive income, percentage | 0.00% | 0.00% | 0.00% | ||
Other assets, percentage | 5.00% | 5.00% | 8.00% | ||
Total assets, percentage | 12.00% | 12.00% | 12.00% | ||
Internal credit grades | 11.35 to 100% | |||||
On-balance sheet: | |||||
Cash and balances at central banks | £ 0 | £ 9 | |||
Cash collateral and settlement balances | 10 | 0 | |||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | |||
Trading portfolio assets | 686 | 2,753 | |||
Financial assets at fair value through the income statement | 628 | 763 | |||
Derivative financial instruments | 266 | 477 | |||
Financial assets measured at fair value through other comprehensive income | 0 | 0 | |||
Other assets | 2 | 4 | |||
Total assets | £ 10,965 | £ 13,777 | |||
On-balance sheet, percentage | |||||
Cash and balances at central banks, percentage | 0.00% | 0.00% | 0.00% | ||
Cash collateral and settlement balance, percentage | 0.00% | 0.00% | 0.00% | ||
Reverse repurchase agreements, percentage | 0.00% | 0.00% | 0.00% | ||
Trading portfolio assets, percentage | 1.00% | 1.00% | 4.00% | ||
Financial assets at fair value through the income statement, percentage | 0.00% | 0.00% | 0.00% | ||
Derivative financial instruments, percentage | 0.00% | 0.00% | 0.00% | ||
Financial assets at fair value through other comprehensive income, percentage | 0.00% | 0.00% | 0.00% | ||
Other assets, percentage | 0.00% | 0.00% | 0.00% | ||
Total assets, percentage | 1.00% | 1.00% | 1.00% | ||
Internal credit grades | Loans and advances at amortised cost | |||||
On-balance sheet: | |||||
Loans and advances at amortised cost | £ 361,451 | £ 342,632 | |||
On-balance sheet, percentage | |||||
Loans and advances at amortised cost, percentage | 100.00% | 100.00% | 100.00% | ||
Internal credit grades | Loans and advances at amortised cost | 0 to 0.60% | |||||
On-balance sheet: | |||||
Loans and advances at amortised cost | £ 291,801 | £ 272,586 | |||
On-balance sheet, percentage | |||||
Loans and advances at amortised cost, percentage | 80.00% | 80.00% | 79.00% | ||
Internal credit grades | Loans and advances at amortised cost | 0.60 to 11.35% | |||||
On-balance sheet: | |||||
Loans and advances at amortised cost | £ 60,277 | £ 60,275 | |||
On-balance sheet, percentage | |||||
Loans and advances at amortised cost, percentage | 17.00% | 17.00% | 18.00% | ||
Internal credit grades | Loans and advances at amortised cost | 11.35 to 100% | |||||
On-balance sheet: | |||||
Loans and advances at amortised cost | £ 9,373 | £ 9,771 | |||
On-balance sheet, percentage | |||||
Loans and advances at amortised cost, percentage | 3.00% | 3.00% | 3.00% | ||
Internal credit grades | Home loans | |||||
On-balance sheet: | |||||
Loans and advances at amortised cost | £ 169,205 | £ 159,647 | |||
On-balance sheet, percentage | |||||
Loans and advances at amortised cost, percentage | 100.00% | 100.00% | 100.00% | ||
Internal credit grades | Home loans | 0 to 0.60% | |||||
On-balance sheet: | |||||
Loans and advances at amortised cost | £ 161,314 | £ 150,748 | |||
On-balance sheet, percentage | |||||
Loans and advances at amortised cost, percentage | 96.00% | 96.00% | 94.00% | ||
Internal credit grades | Home loans | 0.60 to 11.35% | |||||
On-balance sheet: | |||||
Loans and advances at amortised cost | £ 5,547 | £ 6,310 | |||
On-balance sheet, percentage | |||||
Loans and advances at amortised cost, percentage | 3.00% | 3.00% | 4.00% | ||
Internal credit grades | Home loans | 11.35 to 100% | |||||
On-balance sheet: | |||||
Loans and advances at amortised cost | £ 2,344 | £ 2,589 | |||
On-balance sheet, percentage | |||||
Loans and advances at amortised cost, percentage | 1.00% | 1.00% | 2.00% | ||
Internal credit grades | Credit cards, unsecured and other retail lending | |||||
On-balance sheet: | |||||
Loans and advances at amortised cost | £ 41,793 | £ 40,813 | |||
On-balance sheet, percentage | |||||
Loans and advances at amortised cost, percentage | 100.00% | 100.00% | 100.00% | ||
Internal credit grades | Credit cards, unsecured and other retail lending | 0 to 0.60% | |||||
On-balance sheet: | |||||
Loans and advances at amortised cost | £ 25,664 | £ 15,870 | |||
On-balance sheet, percentage | |||||
Loans and advances at amortised cost, percentage | 62.00% | 62.00% | 39.00% | ||
Internal credit grades | Credit cards, unsecured and other retail lending | 0.60 to 11.35% | |||||
On-balance sheet: | |||||
Loans and advances at amortised cost | £ 14,293 | £ 22,427 | |||
On-balance sheet, percentage | |||||
Loans and advances at amortised cost, percentage | 34.00% | 34.00% | 55.00% | ||
Internal credit grades | Credit cards, unsecured and other retail lending | 11.35 to 100% | |||||
On-balance sheet: | |||||
Loans and advances at amortised cost | £ 1,836 | £ 2,516 | |||
On-balance sheet, percentage | |||||
Loans and advances at amortised cost, percentage | 4.00% | 4.00% | 6.00% | ||
Internal credit grades | Wholesale loans | |||||
On-balance sheet: | |||||
Loans and advances at amortised cost | £ 150,453 | £ 142,172 | |||
On-balance sheet, percentage | |||||
Loans and advances at amortised cost, percentage | 100.00% | 100.00% | 100.00% | ||
Internal credit grades | Wholesale loans | 0 to 0.60% | |||||
On-balance sheet: | |||||
Loans and advances at amortised cost | £ 104,823 | £ 105,968 | |||
On-balance sheet, percentage | |||||
Loans and advances at amortised cost, percentage | 70.00% | 70.00% | 75.00% | ||
Internal credit grades | Wholesale loans | 0.60 to 11.35% | |||||
On-balance sheet: | |||||
Loans and advances at amortised cost | £ 40,437 | £ 31,538 | |||
On-balance sheet, percentage | |||||
Loans and advances at amortised cost, percentage | 27.00% | 27.00% | 22.00% | ||
Internal credit grades | Wholesale loans | 11.35 to 100% | |||||
On-balance sheet: | |||||
Loans and advances at amortised cost | £ 5,193 | £ 4,666 | |||
On-balance sheet, percentage | |||||
Loans and advances at amortised cost, percentage | 3.00% | 3.00% | 3.00% | ||
Internal credit grades | Loans and advances | |||||
On-balance sheet: | |||||
Financial assets at fair value through the income statement | £ 38,667 | £ 30,879 | |||
On-balance sheet, percentage | |||||
Financial assets at fair value through the income statement, percentage | 100.00% | 100.00% | 100.00% | ||
Internal credit grades | Loans and advances | 0 to 0.60% | |||||
On-balance sheet: | |||||
Financial assets at fair value through the income statement | £ 19,642 | £ 16,467 | |||
On-balance sheet, percentage | |||||
Financial assets at fair value through the income statement, percentage | 51.00% | 51.00% | 53.00% | ||
Internal credit grades | Loans and advances | 0.60 to 11.35% | |||||
On-balance sheet: | |||||
Financial assets at fair value through the income statement | £ 18,979 | £ 14,369 | |||
On-balance sheet, percentage | |||||
Financial assets at fair value through the income statement, percentage | 49.00% | 49.00% | 47.00% | ||
Internal credit grades | Loans and advances | 11.35 to 100% | |||||
On-balance sheet: | |||||
Financial assets at fair value through the income statement | £ 46 | £ 43 | |||
On-balance sheet, percentage | |||||
Financial assets at fair value through the income statement, percentage | 0.00% | 0.00% | 0.00% | ||
Internal credit grades | Reverse repurchase agreements | |||||
On-balance sheet: | |||||
Financial assets at fair value through the income statement | £ 145,014 | £ 137,616 | |||
On-balance sheet, percentage | |||||
Financial assets at fair value through the income statement, percentage | 100.00% | 100.00% | 100.00% | ||
Internal credit grades | Reverse repurchase agreements | 0 to 0.60% | |||||
On-balance sheet: | |||||
Financial assets at fair value through the income statement | £ 108,437 | £ 95,376 | |||
On-balance sheet, percentage | |||||
Financial assets at fair value through the income statement, percentage | 75.00% | 75.00% | 70.00% | ||
Internal credit grades | Reverse repurchase agreements | 0.60 to 11.35% | |||||
On-balance sheet: | |||||
Financial assets at fair value through the income statement | £ 36,047 | £ 41,566 | |||
On-balance sheet, percentage | |||||
Financial assets at fair value through the income statement, percentage | 25.00% | 25.00% | 30.00% | ||
Internal credit grades | Reverse repurchase agreements | 11.35 to 100% | |||||
On-balance sheet: | |||||
Financial assets at fair value through the income statement | £ 530 | £ 674 | |||
On-balance sheet, percentage | |||||
Financial assets at fair value through the income statement, percentage | 0.00% | 0.00% | 0.00% | ||
Internal credit grades | Other financial assets measured at cost | |||||
On-balance sheet: | |||||
Financial assets at fair value through the income statement | £ 111 | £ 343 | |||
On-balance sheet, percentage | |||||
Financial assets at fair value through the income statement, percentage | 100.00% | 100.00% | 100.00% | ||
Internal credit grades | Other financial assets measured at cost | 0 to 0.60% | |||||
On-balance sheet: | |||||
Financial assets at fair value through the income statement | £ 93 | £ 330 | |||
On-balance sheet, percentage | |||||
Financial assets at fair value through the income statement, percentage | 84.00% | 84.00% | 96.00% | ||
Internal credit grades | Other financial assets measured at cost | 0.60 to 11.35% | |||||
On-balance sheet: | |||||
Financial assets at fair value through the income statement | £ 18 | £ 13 | |||
On-balance sheet, percentage | |||||
Financial assets at fair value through the income statement, percentage | 16.00% | 16.00% | 4.00% | ||
Internal credit grades | Other financial assets measured at cost | 11.35 to 100% | |||||
On-balance sheet: | |||||
Financial assets at fair value through the income statement | £ 0 | £ 0 | |||
On-balance sheet, percentage | |||||
Financial assets at fair value through the income statement, percentage | 0.00% | 0.00% | 0.00% | ||
Internal credit grades | Debt securities classified at amortised cost | |||||
On-balance sheet: | |||||
Trading portfolio assets | £ 50,864 | £ 56,482 | |||
Financial assets at fair value through the income statement | £ 2,305 | £ 1,693 | |||
On-balance sheet, percentage | |||||
Trading portfolio assets, percentage | 100.00% | 100.00% | 100.00% | ||
Financial assets at fair value through the income statement, percentage | 100.00% | 100.00% | 100.00% | ||
Internal credit grades | Debt securities classified at amortised cost | 0 to 0.60% | |||||
On-balance sheet: | |||||
Trading portfolio assets | £ 44,652 | £ 51,395 | |||
Financial assets at fair value through the income statement | £ 1,389 | £ 1,126 | |||
On-balance sheet, percentage | |||||
Trading portfolio assets, percentage | 88.00% | 88.00% | 91.00% | ||
Financial assets at fair value through the income statement, percentage | 61.00% | 61.00% | 66.00% | ||
Internal credit grades | Debt securities classified at amortised cost | 0.60 to 11.35% | |||||
On-balance sheet: | |||||
Trading portfolio assets | £ 5,735 | £ 4,871 | |||
Financial assets at fair value through the income statement | £ 864 | £ 521 | |||
On-balance sheet, percentage | |||||
Trading portfolio assets, percentage | 11.00% | 11.00% | 9.00% | ||
Financial assets at fair value through the income statement, percentage | 37.00% | 37.00% | 31.00% | ||
Internal credit grades | Debt securities classified at amortised cost | 11.35 to 100% | |||||
On-balance sheet: | |||||
Trading portfolio assets | £ 477 | £ 216 | |||
Financial assets at fair value through the income statement | £ 52 | £ 46 | |||
On-balance sheet, percentage | |||||
Trading portfolio assets, percentage | 1.00% | 1.00% | 0.00% | ||
Financial assets at fair value through the income statement, percentage | 2.00% | 2.00% | 3.00% | ||
Internal credit grades | Traded loans | |||||
On-balance sheet: | |||||
Trading portfolio assets | £ 12,525 | £ 8,348 | |||
On-balance sheet, percentage | |||||
Trading portfolio assets, percentage | 100.00% | 100.00% | 100.00% | ||
Internal credit grades | Traded loans | 0 to 0.60% | |||||
On-balance sheet: | |||||
Trading portfolio assets | £ 2,172 | £ 704 | |||
On-balance sheet, percentage | |||||
Trading portfolio assets, percentage | 17.00% | 17.00% | 9.00% | ||
Internal credit grades | Traded loans | 0.60 to 11.35% | |||||
On-balance sheet: | |||||
Trading portfolio assets | £ 10,144 | £ 5,107 | |||
On-balance sheet, percentage | |||||
Trading portfolio assets, percentage | 81.00% | 81.00% | 61.00% | ||
Internal credit grades | Traded loans | 11.35 to 100% | |||||
On-balance sheet: | |||||
Trading portfolio assets | £ 209 | £ 2,537 | |||
On-balance sheet, percentage | |||||
Trading portfolio assets, percentage | 2.00% | 2.00% | 30.00% | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Other disclosures - Risk Man_16
Other disclosures - Risk Management and Principal Risks - Credit exposures by internal PD grade (audited) (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Net gains on financial instruments designated at fair value | Carrying amount | ||
Disclosure of internal credit grades [line items] | ||
Exposure to credit risk on loan commitments and financial guarantee contracts | £ 18,800 | £ 9,500 |
Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 5,000 | |
Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 20,906 | £ 21,098 |
ECL coverage | 1.00% | 1.30% |
Contingent liabilities [member] | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 21,115 | £ 21,380 |
Contingent liabilities [member] | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 17,663 | 17,256 |
Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,272 | 3,470 |
Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 180 | 654 |
Contingent liabilities [member] | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 209 | 282 |
Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 64 | 44 |
Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 143 | 228 |
Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2 | 10 |
Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 326,807 | £ 322,998 |
ECL coverage | 0.10% | 0.20% |
Total commitments | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 327,140 | £ 323,780 |
Total commitments | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 294,479 | 272,683 |
Total commitments | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 31,543 | 49,421 |
Total commitments | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,118 | 1,676 |
Total commitments | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 333 | 782 |
Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 153 | 212 |
Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 159 | 530 |
Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 21 | 40 |
Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 361,451 | £ 342,632 |
ECL coverage | 1.60% | 2.40% |
Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 367,193 | £ 350,967 |
Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 318,865 | 290,964 |
Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 41,093 | 51,006 |
Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 7,235 | 8,997 |
Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 5,742 | 8,335 |
Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,206 | 1,033 |
Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,015 | 3,564 |
Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,521 | 3,738 |
100% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 178 | £ 644 |
ECL coverage | 1.10% | 1.50% |
100% | Contingent liabilities [member] | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 180 | £ 654 |
100% | Contingent liabilities [member] | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 180 | 654 |
100% | Contingent liabilities [member] | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2 | 10 |
100% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2 | 10 |
100% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 1,097 | £ 1,636 |
ECL coverage | 1.90% | 2.40% |
100% | Total commitments | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 1,118 | £ 1,676 |
100% | Total commitments | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,118 | 1,676 |
100% | Total commitments | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 21 | 40 |
100% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 21 | 40 |
100% | Total commitments | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,521 | 3,738 |
100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 4,714 | £ 5,259 |
ECL coverage | 34.80% | 41.50% |
100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 7,235 | £ 8,997 |
100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 7,235 | 8,997 |
100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,521 | 3,738 |
100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 6,552 | £ 6,366 |
ECL coverage | 0.10% | 0.00% |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 6,561 | £ 6,367 |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 6,389 | 6,178 |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 172 | 189 |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 9 | 1 |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 8 | 1 |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1 | 0 |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.0 to 0.05% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 107,228 | £ 66,044 |
ECL coverage | 0.00% | 0.00% |
Strong | 0.0 to 0.05% | Total commitments | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 107,238 | £ 66,050 |
Strong | 0.0 to 0.05% | Total commitments | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 104,204 | 60,525 |
Strong | 0.0 to 0.05% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,034 | 5,525 |
Strong | 0.0 to 0.05% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.0 to 0.05% | Total commitments | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 10 | 6 |
Strong | 0.0 to 0.05% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 6 | 4 |
Strong | 0.0 to 0.05% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 4 | 2 |
Strong | 0.0 to 0.05% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.0 to 0.05% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 97,058 | £ 85,366 |
ECL coverage | 0.30% | 0.00% |
Strong | 0.0 to 0.05% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 97,349 | £ 85,407 |
Strong | 0.0 to 0.05% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 95,795 | 82,312 |
Strong | 0.0 to 0.05% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,554 | 3,095 |
Strong | 0.0 to 0.05% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.0 to 0.05% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 291 | 41 |
Strong | 0.0 to 0.05% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 283 | 6 |
Strong | 0.0 to 0.05% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 8 | 35 |
Strong | 0.0 to 0.05% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 3,428 | £ 3,188 |
ECL coverage | 0.10% | 0.20% |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 3,432 | £ 3,193 |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,929 | 2,765 |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 503 | 428 |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 4 | 5 |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2 | 3 |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2 | 2 |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.05 to 0.15% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 74,495 | £ 81,154 |
ECL coverage | 0.00% | 0.00% |
Strong | 0.05 to 0.15% | Total commitments | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 74,510 | £ 81,182 |
Strong | 0.05 to 0.15% | Total commitments | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 68,986 | 74,860 |
Strong | 0.05 to 0.15% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 5,524 | 6,322 |
Strong | 0.05 to 0.15% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.05 to 0.15% | Total commitments | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 15 | 28 |
Strong | 0.05 to 0.15% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 10 | 12 |
Strong | 0.05 to 0.15% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 5 | 16 |
Strong | 0.05 to 0.15% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.05 to 0.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 87,380 | £ 110,965 |
ECL coverage | 0.00% | 0.10% |
Strong | 0.05 to 0.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 87,402 | £ 111,024 |
Strong | 0.05 to 0.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 83,818 | 101,309 |
Strong | 0.05 to 0.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,584 | 9,715 |
Strong | 0.05 to 0.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.05 to 0.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 22 | 59 |
Strong | 0.05 to 0.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 19 | 34 |
Strong | 0.05 to 0.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3 | 25 |
Strong | 0.05 to 0.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 2,191 | £ 1,627 |
ECL coverage | 0.20% | 0.40% |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 2,195 | £ 1,633 |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,996 | 1,468 |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 199 | 165 |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 4 | 6 |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2 | 3 |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2 | 3 |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.15 to 0.30% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 33,341 | £ 57,910 |
ECL coverage | 0.00% | 0.10% |
Strong | 0.15 to 0.30% | Total commitments | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 33,355 | £ 57,974 |
Strong | 0.15 to 0.30% | Total commitments | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 30,968 | 51,255 |
Strong | 0.15 to 0.30% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,387 | 6,719 |
Strong | 0.15 to 0.30% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.15 to 0.30% | Total commitments | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 14 | 64 |
Strong | 0.15 to 0.30% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 8 | 17 |
Strong | 0.15 to 0.30% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 6 | 47 |
Strong | 0.15 to 0.30% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.15 to 0.30% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 68,078 | £ 36,849 |
ECL coverage | 0.10% | 0.30% |
Strong | 0.15 to 0.30% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 68,131 | £ 36,960 |
Strong | 0.15 to 0.30% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 58,409 | 30,697 |
Strong | 0.15 to 0.30% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 9,722 | 6,263 |
Strong | 0.15 to 0.30% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.15 to 0.30% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 53 | 111 |
Strong | 0.15 to 0.30% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 41 | 47 |
Strong | 0.15 to 0.30% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 12 | 64 |
Strong | 0.15 to 0.30% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 3,005 | £ 4,038 |
ECL coverage | 0.20% | 0.90% |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 3,010 | £ 4,076 |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,794 | 3,524 |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 216 | 552 |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 5 | 38 |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 4 | 5 |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1 | 33 |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.30 to 0.60% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 43,049 | £ 50,511 |
ECL coverage | 0.00% | 0.20% |
Strong | 0.30 to 0.60% | Total commitments | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 43,063 | £ 50,600 |
Strong | 0.30 to 0.60% | Total commitments | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 40,539 | 43,650 |
Strong | 0.30 to 0.60% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,524 | 6,950 |
Strong | 0.30 to 0.60% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.30 to 0.60% | Total commitments | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 14 | 89 |
Strong | 0.30 to 0.60% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 8 | 17 |
Strong | 0.30 to 0.60% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 6 | 72 |
Strong | 0.30 to 0.60% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.30 to 0.60% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 39,285 | £ 39,406 |
ECL coverage | 0.40% | 0.70% |
Strong | 0.30 to 0.60% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 39,443 | £ 39,694 |
Strong | 0.30 to 0.60% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 35,794 | 34,601 |
Strong | 0.30 to 0.60% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,649 | 5,093 |
Strong | 0.30 to 0.60% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.30 to 0.60% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 158 | 288 |
Strong | 0.30 to 0.60% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 129 | 120 |
Strong | 0.30 to 0.60% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 29 | 168 |
Strong | 0.30 to 0.60% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 2,250 | £ 3,225 |
ECL coverage | 1.20% | 1.00% |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 2,277 | £ 3,258 |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,990 | 2,712 |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 287 | 546 |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 27 | 33 |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 19 | 8 |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 8 | 25 |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 0.60 to 2.15% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 34,667 | £ 40,652 |
ECL coverage | 0.30% | 0.60% |
Satisfactory | 0.60 to 2.15% | Total commitments | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 34,778 | £ 40,902 |
Satisfactory | 0.60 to 2.15% | Total commitments | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 30,065 | 30,994 |
Satisfactory | 0.60 to 2.15% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 4,713 | 9,908 |
Satisfactory | 0.60 to 2.15% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 0.60 to 2.15% | Total commitments | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 111 | 250 |
Satisfactory | 0.60 to 2.15% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 81 | 119 |
Satisfactory | 0.60 to 2.15% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 30 | 131 |
Satisfactory | 0.60 to 2.15% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 0.60 to 2.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 37,154 | £ 36,925 |
ECL coverage | 1.60% | 2.60% |
Satisfactory | 0.60 to 2.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 37,744 | £ 37,897 |
Satisfactory | 0.60 to 2.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 30,654 | 29,498 |
Satisfactory | 0.60 to 2.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 7,090 | 8,399 |
Satisfactory | 0.60 to 2.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 0.60 to 2.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 590 | 972 |
Satisfactory | 0.60 to 2.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 326 | 379 |
Satisfactory | 0.60 to 2.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 264 | 593 |
Satisfactory | 0.60 to 2.15% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 1,281 | £ 675 |
ECL coverage | 1.20% | 4.00% |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 1,296 | £ 703 |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 817 | 305 |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 479 | 398 |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 15 | 28 |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 5 | 7 |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 10 | 21 |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 2.15 to 10% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 10,549 | £ 10,533 |
ECL coverage | 0.50% | 1.30% |
Satisfactory | 2.15 to 10% | Total commitments | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 10,607 | £ 10,673 |
Satisfactory | 2.15 to 10% | Total commitments | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 7,091 | 5,702 |
Satisfactory | 2.15 to 10% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,516 | 4,971 |
Satisfactory | 2.15 to 10% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 2.15 to 10% | Total commitments | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 58 | 140 |
Satisfactory | 2.15 to 10% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 21 | 27 |
Satisfactory | 2.15 to 10% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 37 | 113 |
Satisfactory | 2.15 to 10% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 2.15 to 10% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 13,612 | £ 15,676 |
ECL coverage | 6.90% | 9.20% |
Satisfactory | 2.15 to 10% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 14,622 | £ 17,261 |
Satisfactory | 2.15 to 10% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 7,977 | 8,125 |
Satisfactory | 2.15 to 10% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 6,645 | 9,136 |
Satisfactory | 2.15 to 10% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 2.15 to 10% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,010 | 1,585 |
Satisfactory | 2.15 to 10% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 230 | 302 |
Satisfactory | 2.15 to 10% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 780 | 1,283 |
Satisfactory | 2.15 to 10% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 798 | £ 587 |
ECL coverage | 7.30% | 14.60% |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 861 | £ 687 |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 607 | 264 |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 254 | 423 |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 63 | 100 |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 21 | 17 |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 42 | 83 |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 10 to 11.35% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 13,477 | £ 9,979 |
ECL coverage | 0.20% | 0.40% |
Satisfactory | 10 to 11.35% | Total commitments | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 13,498 | £ 10,015 |
Satisfactory | 10 to 11.35% | Total commitments | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 10,407 | 4,886 |
Satisfactory | 10 to 11.35% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,091 | 5,129 |
Satisfactory | 10 to 11.35% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 10 to 11.35% | Total commitments | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 21 | 36 |
Satisfactory | 10 to 11.35% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 8 | 11 |
Satisfactory | 10 to 11.35% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 13 | 25 |
Satisfactory | 10 to 11.35% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 10 to 11.35% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 9,511 | £ 7,674 |
ECL coverage | 4.30% | 3.40% |
Satisfactory | 10 to 11.35% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 9,936 | £ 7,942 |
Satisfactory | 10 to 11.35% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 5,572 | 3,505 |
Satisfactory | 10 to 11.35% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 4,364 | 4,437 |
Satisfactory | 10 to 11.35% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 10 to 11.35% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 425 | 268 |
Satisfactory | 10 to 11.35% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 99 | 73 |
Satisfactory | 10 to 11.35% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 326 | 195 |
Satisfactory | 10 to 11.35% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Higher Risk | 11.35 to 100% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 1,223 | £ 748 |
ECL coverage | 6.10% | 7.50% |
Higher Risk | 11.35 to 100% | Contingent liabilities [member] | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 1,303 | £ 809 |
Higher Risk | 11.35 to 100% | Contingent liabilities [member] | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 141 | 40 |
Higher Risk | 11.35 to 100% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,162 | 769 |
Higher Risk | 11.35 to 100% | Contingent liabilities [member] | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Higher Risk | 11.35 to 100% | Contingent liabilities [member] | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 80 | 61 |
Higher Risk | 11.35 to 100% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3 | 0 |
Higher Risk | 11.35 to 100% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 77 | 61 |
Higher Risk | 11.35 to 100% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Higher Risk | 11.35 to 100% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 8,904 | £ 4,579 |
ECL coverage | 0.80% | 2.70% |
Higher Risk | 11.35 to 100% | Total commitments | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 8,973 | £ 4,708 |
Higher Risk | 11.35 to 100% | Total commitments | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,219 | 811 |
Higher Risk | 11.35 to 100% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 6,754 | 3,897 |
Higher Risk | 11.35 to 100% | Total commitments | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Higher Risk | 11.35 to 100% | Total commitments | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 69 | 129 |
Higher Risk | 11.35 to 100% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 11 | 5 |
Higher Risk | 11.35 to 100% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 58 | 124 |
Higher Risk | 11.35 to 100% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Higher Risk | 11.35 to 100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 4,659 | £ 4,512 |
ECL coverage | 12.60% | 22.00% |
Higher Risk | 11.35 to 100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 5,331 | £ 5,785 |
Higher Risk | 11.35 to 100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 846 | 917 |
Higher Risk | 11.35 to 100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 4,485 | 4,868 |
Higher Risk | 11.35 to 100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | Carrying amount | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Higher Risk | 11.35 to 100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 672 | 1,273 |
Higher Risk | 11.35 to 100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 79 | 72 |
Higher Risk | 11.35 to 100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 593 | 1,201 |
Higher Risk | 11.35 to 100% | Total commitments | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 0 | £ 0 |
Other disclosures - Risk Man_17
Other disclosures - Risk Management and Principal Risks - Derivative assets (audited) (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Credit derivatives | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Balance sheet assets | £ 1,636,972 | £ 1,615,399 |
Counterparty netting | 207,520 | 240,068 |
Cash collateral held | 38,590 | 46,508 |
Derivatives | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Balance sheet assets | 262,572 | 302,446 |
Counterparty netting | 202,520 | 233,080 |
Net exposure | 60,052 | 69,366 |
Cash collateral held | 34,598 | 43,291 |
Net exposure less collateral | 25,454 | 26,075 |
Derivatives | Foreign exchange derivatives | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Balance sheet assets | 76,975 | 85,115 |
Counterparty netting | 60,525 | 68,108 |
Net exposure | 16,450 | 17,007 |
Derivatives | Interest rate derivatives | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Balance sheet assets | 125,905 | 172,334 |
Counterparty netting | 92,669 | 128,072 |
Net exposure | 33,236 | 44,262 |
Derivatives | Credit derivatives | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Balance sheet assets | 5,682 | 4,605 |
Counterparty netting | 4,525 | 3,584 |
Net exposure | 1,157 | 1,021 |
Derivatives | Equity and stock index derivatives | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Balance sheet assets | 51,723 | 38,972 |
Counterparty netting | 43,084 | 32,183 |
Net exposure | 8,639 | 6,789 |
Derivatives | Commodity derivatives | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Balance sheet assets | 2,287 | 1,420 |
Counterparty netting | 1,717 | 1,133 |
Net exposure | £ 570 | £ 287 |
Other disclosures - Risk Man_18
Other disclosures - Risk Management and Principal Risks - Management VaR (95%, one day) (audited) (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
US | Over issuance of securities | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Increase (decrease) in other provisions | £ 220 | £ 0 |
Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 19 | 32 |
Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 36 | 57 |
Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 6 | 18 |
Credit risk | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 14 | 20 |
Credit risk | Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 30 | 38 |
Credit risk | Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 7 | 10 |
Interest rate risk | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 7 | 10 |
Interest rate risk | Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 15 | 17 |
Interest rate risk | Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 4 | 6 |
Equity and stock index derivatives | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 9 | 13 |
Equity and stock index derivatives | Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 29 | 35 |
Equity and stock index derivatives | Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 4 | 6 |
Basis risk | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 6 | 10 |
Basis risk | Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 10 | 16 |
Basis risk | Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 3 | 7 |
Spread risk | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 4 | 5 |
Spread risk | Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 6 | 9 |
Spread risk | Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 3 | 3 |
Foreign exchange risk | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 4 | 5 |
Foreign exchange risk | Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 16 | 7 |
Foreign exchange risk | Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 1 | 2 |
Commodity risk | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 0 | 1 |
Commodity risk | Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 1 | 1 |
Commodity risk | Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 0 | 0 |
Inflation risk | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 3 | 2 |
Inflation risk | Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 5 | 3 |
Inflation risk | Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 2 | 1 |
Diversification effect | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | £ (28) | £ (34) |
Other disclosures - Risk Man_19
Other disclosures - Risk Management and Principal Risks - Deposit funding (audited) (Details) - GBP (£) £ in Billions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of operating segments [line items] | ||
Loans and advances at amortised cost | £ 361 | |
Deposits at amortised cost | £ 519 | |
Loan: deposit ratio | 70.00% | 71.00% |
Head Office | ||
Disclosure of operating segments [line items] | ||
Loans and advances at amortised cost | £ 5 | |
Deposits at amortised cost | 0 | |
Barclays UK | Operating segments | ||
Disclosure of operating segments [line items] | ||
Loans and advances at amortised cost | 222 | |
Deposits at amortised cost | £ 260 | |
Loan: deposit ratio | 85.00% | 89.00% |
Barclays International | Operating segments | ||
Disclosure of operating segments [line items] | ||
Loans and advances at amortised cost | £ 134 | |
Deposits at amortised cost | £ 259 | |
Loan: deposit ratio | 52.00% | 51.00% |
Other disclosures - Risk Man_20
Other disclosures - Risk Management and Principal Risks - Contractural maturity of financial assets and liabilities (audited) (Details) £ in Millions, $ in Billions | 12 Months Ended | |||||||
Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | Dec. 31, 2018GBP (£) | ||||
Assets | ||||||||
Cash and balances at central banks | £ 238,574 | [1] | £ 191,127 | £ 150,258 | ||||
Cash collateral and settlement balances | 92,542 | [2] | 101,367 | |||||
Loans and advances at amortised cost | 361,451 | [2] | 342,632 | |||||
Reverse repurchase agreements and other similar secured lending | 3,227 | [2] | 9,031 | |||||
Trading portfolio assets | 147,035 | [2] | 127,950 | |||||
Financial assets at fair value through the income statement | 191,972 | [2] | 175,151 | |||||
Derivative financial instruments | 262,572 | [2] | 302,446 | |||||
Financial assets at fair value through other comprehensive income | 61,753 | [2] | 78,688 | |||||
Other financial assets | 1,213 | 850 | ||||||
Non-derivative financial assets | 1,360,339 | 1,329,242 | ||||||
Other assets | 23,946 | 20,272 | ||||||
Total assets | 1,384,285 | [2] | $ 1,384.3 | 1,349,514 | 1,140,200 | |||
Liabilities | ||||||||
Deposits at amortised cost | 519,433 | [2] | 481,036 | |||||
Cash collateral and settlement balances | 79,371 | [2] | 85,423 | |||||
Repurchase agreements and other similar secured borrowing | 28,352 | [2] | 14,174 | |||||
Debt securities in issue | 98,867 | [2] | 75,796 | |||||
Subordinated liabilities | 12,759 | [2] | 16,341 | 18,156 | ||||
Trading portfolio liabilities | 54,169 | [2] | 47,405 | |||||
Financial liabilities designated at fair value | 250,960 | [2] | 249,765 | |||||
Derivative financial instruments | 256,883 | [2] | 300,775 | |||||
Other financial liabilities | 6,301 | 4,969 | ||||||
Total financial liabilities | 1,307,095 | 1,275,684 | ||||||
Other liabilities | 7,149 | 6,948 | ||||||
Total liabilities | 1,314,244 | [2] | 1,282,632 | |||||
Cumulative liquidity gap | 70,041 | [2] | 66,882 | [3] | £ 65,660 | [3] | £ 63,779 | |
On demand | ||||||||
Assets | ||||||||
Cash and balances at central banks | 238,369 | 190,347 | ||||||
Cash collateral and settlement balances | 2,807 | 1,177 | ||||||
Loans and advances at amortised cost | 19,749 | 14,098 | ||||||
Reverse repurchase agreements and other similar secured lending | 58 | 150 | ||||||
Trading portfolio assets | 147,035 | 127,950 | ||||||
Financial assets at fair value through the income statement | 24,257 | 17,377 | ||||||
Derivative financial instruments | 261,678 | 301,880 | ||||||
Financial assets at fair value through other comprehensive income | 0 | 0 | ||||||
Other financial assets | 707 | 357 | ||||||
Non-derivative financial assets | 694,660 | 653,336 | ||||||
Liabilities | ||||||||
Deposits at amortised cost | 454,961 | 410,894 | ||||||
Cash collateral and settlement balances | 2,983 | 1,900 | ||||||
Repurchase agreements and other similar secured borrowing | 20 | 4 | ||||||
Debt securities in issue | 0 | 0 | ||||||
Subordinated liabilities | 0 | 0 | ||||||
Trading portfolio liabilities | 54,169 | 47,405 | ||||||
Financial liabilities designated at fair value | 21,339 | 15,555 | ||||||
Derivative financial instruments | 255,747 | 299,795 | ||||||
Other financial liabilities | 184 | 101 | ||||||
Total financial liabilities | 789,403 | 775,654 | ||||||
Cumulative liquidity gap | (94,743) | (122,318) | ||||||
On demand | Over issuance of securities | ||||||||
Liabilities | ||||||||
Securities issues in excess of limit | 6,997 | |||||||
Not more than three months | ||||||||
Assets | ||||||||
Cash and balances at central banks | 205 | 182 | ||||||
Cash collateral and settlement balances | 89,735 | 100,190 | ||||||
Loans and advances at amortised cost | 8,670 | 11,970 | ||||||
Reverse repurchase agreements and other similar secured lending | 2,984 | 8,698 | ||||||
Trading portfolio assets | 0 | 0 | ||||||
Financial assets at fair value through the income statement | 127,085 | 123,044 | ||||||
Derivative financial instruments | 58 | 23 | ||||||
Financial assets at fair value through other comprehensive income | 4,280 | 9,655 | ||||||
Other financial assets | 474 | 451 | ||||||
Non-derivative financial assets | 233,491 | 254,213 | ||||||
Liabilities | ||||||||
Deposits at amortised cost | 40,755 | 41,468 | ||||||
Cash collateral and settlement balances | 76,388 | 83,523 | ||||||
Repurchase agreements and other similar secured borrowing | 6,621 | 3,276 | ||||||
Debt securities in issue | 24,399 | 16,344 | ||||||
Subordinated liabilities | 1,007 | 1,589 | ||||||
Trading portfolio liabilities | 0 | 0 | ||||||
Financial liabilities designated at fair value | 157,900 | 172,153 | ||||||
Derivative financial instruments | 4 | 1 | ||||||
Other financial liabilities | 4,331 | 2,915 | ||||||
Total financial liabilities | 311,405 | 321,269 | ||||||
Cumulative liquidity gap | (172,657) | (189,374) | ||||||
Over three months but not more than six months | ||||||||
Assets | ||||||||
Cash and balances at central banks | 0 | 598 | ||||||
Cash collateral and settlement balances | 0 | 0 | ||||||
Loans and advances at amortised cost | 8,879 | 8,388 | ||||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||||||
Trading portfolio assets | 0 | 0 | ||||||
Financial assets at fair value through the income statement | 9,281 | 7,548 | ||||||
Derivative financial instruments | 48 | 0 | ||||||
Financial assets at fair value through other comprehensive income | 1,488 | 3,517 | ||||||
Other financial assets | 26 | 19 | ||||||
Non-derivative financial assets | 19,722 | 20,070 | ||||||
Liabilities | ||||||||
Deposits at amortised cost | 13,524 | 15,886 | ||||||
Cash collateral and settlement balances | 0 | 0 | ||||||
Repurchase agreements and other similar secured borrowing | 0 | 0 | ||||||
Debt securities in issue | 12,606 | 4,048 | ||||||
Subordinated liabilities | 0 | 3,209 | ||||||
Trading portfolio liabilities | 0 | 0 | ||||||
Financial liabilities designated at fair value | 16,857 | 8,677 | ||||||
Derivative financial instruments | 22 | 49 | ||||||
Other financial liabilities | 43 | 49 | ||||||
Total financial liabilities | 43,052 | 31,918 | ||||||
Cumulative liquidity gap | (195,987) | (201,222) | ||||||
Over six months but not more than nine months | ||||||||
Assets | ||||||||
Cash and balances at central banks | 0 | 0 | ||||||
Cash collateral and settlement balances | 0 | 0 | ||||||
Loans and advances at amortised cost | 5,291 | 4,956 | ||||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||||||
Trading portfolio assets | 0 | 0 | ||||||
Financial assets at fair value through the income statement | 7,042 | 6,960 | ||||||
Derivative financial instruments | 0 | 0 | ||||||
Financial assets at fair value through other comprehensive income | 1,245 | 1,393 | ||||||
Other financial assets | 2 | 22 | ||||||
Non-derivative financial assets | 13,580 | 13,331 | ||||||
Liabilities | ||||||||
Deposits at amortised cost | 2,994 | 5,073 | ||||||
Cash collateral and settlement balances | 0 | 0 | ||||||
Repurchase agreements and other similar secured borrowing | 0 | 0 | ||||||
Debt securities in issue | 5,845 | 5,100 | ||||||
Subordinated liabilities | 74 | 294 | ||||||
Trading portfolio liabilities | 0 | 0 | ||||||
Financial liabilities designated at fair value | 10,268 | 5,067 | ||||||
Derivative financial instruments | 18 | 0 | ||||||
Other financial liabilities | 42 | 46 | ||||||
Total financial liabilities | 19,241 | 15,580 | ||||||
Cumulative liquidity gap | (201,648) | (203,471) | ||||||
Over nine months but not more than one year | ||||||||
Assets | ||||||||
Cash and balances at central banks | 0 | 0 | ||||||
Cash collateral and settlement balances | 0 | 0 | ||||||
Loans and advances at amortised cost | 10,192 | 5,234 | ||||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||||||
Trading portfolio assets | 0 | 0 | ||||||
Financial assets at fair value through the income statement | 3,451 | 4,151 | ||||||
Derivative financial instruments | 0 | 0 | ||||||
Financial assets at fair value through other comprehensive income | 1,419 | 948 | ||||||
Other financial assets | 0 | 0 | ||||||
Non-derivative financial assets | 15,062 | 10,333 | ||||||
Liabilities | ||||||||
Deposits at amortised cost | 3,724 | 3,082 | ||||||
Cash collateral and settlement balances | 0 | 0 | ||||||
Repurchase agreements and other similar secured borrowing | 0 | 0 | ||||||
Debt securities in issue | 3,254 | 1,937 | ||||||
Subordinated liabilities | 1,218 | 0 | ||||||
Trading portfolio liabilities | 0 | 0 | ||||||
Financial liabilities designated at fair value | 3,588 | 2,938 | ||||||
Derivative financial instruments | 5 | 0 | ||||||
Other financial liabilities | 40 | 45 | ||||||
Total financial liabilities | 11,829 | 8,002 | ||||||
Cumulative liquidity gap | (198,415) | (201,140) | ||||||
One to two year | ||||||||
Assets | ||||||||
Cash and balances at central banks | 0 | 0 | ||||||
Cash collateral and settlement balances | 0 | 0 | ||||||
Loans and advances at amortised cost | 23,716 | 25,392 | ||||||
Reverse repurchase agreements and other similar secured lending | 184 | 0 | ||||||
Trading portfolio assets | 0 | 0 | ||||||
Financial assets at fair value through the income statement | 5,889 | 4,911 | ||||||
Derivative financial instruments | 82 | 70 | ||||||
Financial assets at fair value through other comprehensive income | 3,834 | 6,469 | ||||||
Other financial assets | 1 | 1 | ||||||
Non-derivative financial assets | 33,706 | 36,843 | ||||||
Liabilities | ||||||||
Deposits at amortised cost | 2,025 | 2,264 | ||||||
Cash collateral and settlement balances | 0 | 0 | ||||||
Repurchase agreements and other similar secured borrowing | 2,195 | 1,400 | ||||||
Debt securities in issue | 9,792 | 5,780 | ||||||
Subordinated liabilities | 27 | 2,192 | ||||||
Trading portfolio liabilities | 0 | 0 | ||||||
Financial liabilities designated at fair value | 6,540 | 8,594 | ||||||
Derivative financial instruments | 124 | 79 | ||||||
Other financial liabilities | 691 | 738 | ||||||
Total financial liabilities | 21,394 | 21,047 | ||||||
Cumulative liquidity gap | (186,103) | (185,344) | ||||||
Two to three year | ||||||||
Assets | ||||||||
Cash and balances at central banks | 0 | 0 | ||||||
Cash collateral and settlement balances | 0 | 0 | ||||||
Loans and advances at amortised cost | 26,037 | 22,133 | ||||||
Reverse repurchase agreements and other similar secured lending | 0 | 183 | ||||||
Trading portfolio assets | 0 | 0 | ||||||
Financial assets at fair value through the income statement | 5,394 | 1,346 | ||||||
Derivative financial instruments | 145 | 55 | ||||||
Financial assets at fair value through other comprehensive income | 8,205 | 5,566 | ||||||
Other financial assets | 0 | 0 | ||||||
Non-derivative financial assets | 39,781 | 29,283 | ||||||
Liabilities | ||||||||
Deposits at amortised cost | 433 | 625 | ||||||
Cash collateral and settlement balances | 0 | 0 | ||||||
Repurchase agreements and other similar secured borrowing | 8,925 | 2,329 | ||||||
Debt securities in issue | 8,957 | 10,402 | ||||||
Subordinated liabilities | 1,063 | 14 | ||||||
Trading portfolio liabilities | 0 | 0 | ||||||
Financial liabilities designated at fair value | 6,114 | 6,939 | ||||||
Derivative financial instruments | 177 | 67 | ||||||
Other financial liabilities | 145 | 156 | ||||||
Total financial liabilities | 25,814 | 20,532 | ||||||
Cumulative liquidity gap | (172,136) | (176,593) | ||||||
Over three years but not more than five years | ||||||||
Assets | ||||||||
Cash and balances at central banks | 0 | 0 | ||||||
Cash collateral and settlement balances | 0 | 0 | ||||||
Loans and advances at amortised cost | 47,614 | 36,286 | ||||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||||||
Trading portfolio assets | 0 | 0 | ||||||
Financial assets at fair value through the income statement | 2,590 | 2,431 | ||||||
Derivative financial instruments | 537 | 310 | ||||||
Financial assets at fair value through other comprehensive income | 13,188 | 17,552 | ||||||
Other financial assets | 0 | 0 | ||||||
Non-derivative financial assets | 63,929 | 56,579 | ||||||
Liabilities | ||||||||
Deposits at amortised cost | 241 | 601 | ||||||
Cash collateral and settlement balances | 0 | 0 | ||||||
Repurchase agreements and other similar secured borrowing | 10,504 | 7,073 | ||||||
Debt securities in issue | 12,948 | 13,608 | ||||||
Subordinated liabilities | 1,885 | 989 | ||||||
Trading portfolio liabilities | 0 | 0 | ||||||
Financial liabilities designated at fair value | 7,734 | 8,580 | ||||||
Derivative financial instruments | 302 | 185 | ||||||
Other financial liabilities | 266 | 273 | ||||||
Total financial liabilities | 33,880 | 31,309 | ||||||
Cumulative liquidity gap | (142,087) | (151,323) | ||||||
Over five years but not more than ten years | ||||||||
Assets | ||||||||
Cash and balances at central banks | 0 | 0 | ||||||
Cash collateral and settlement balances | 0 | 0 | ||||||
Loans and advances at amortised cost | 39,822 | 47,944 | ||||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||||||
Trading portfolio assets | 0 | 0 | ||||||
Financial assets at fair value through the income statement | 2,564 | 2,345 | ||||||
Derivative financial instruments | 15 | 87 | ||||||
Financial assets at fair value through other comprehensive income | 18,226 | 24,450 | ||||||
Other financial assets | 1 | 0 | ||||||
Non-derivative financial assets | 60,628 | 74,826 | ||||||
Liabilities | ||||||||
Deposits at amortised cost | 545 | 764 | ||||||
Cash collateral and settlement balances | 0 | 0 | ||||||
Repurchase agreements and other similar secured borrowing | 0 | 0 | ||||||
Debt securities in issue | 12,218 | 12,721 | ||||||
Subordinated liabilities | 5,603 | 6,915 | ||||||
Trading portfolio liabilities | 0 | 0 | ||||||
Financial liabilities designated at fair value | 7,366 | 8,344 | ||||||
Derivative financial instruments | 122 | 196 | ||||||
Other financial liabilities | 420 | 436 | ||||||
Total financial liabilities | 26,274 | 29,376 | ||||||
Cumulative liquidity gap | (107,733) | (105,873) | ||||||
Over ten years | ||||||||
Assets | ||||||||
Cash and balances at central banks | 0 | 0 | ||||||
Cash collateral and settlement balances | 0 | 0 | ||||||
Loans and advances at amortised cost | 171,481 | 166,231 | ||||||
Reverse repurchase agreements and other similar secured lending | 1 | 0 | ||||||
Trading portfolio assets | 0 | 0 | ||||||
Financial assets at fair value through the income statement | 4,419 | 5,038 | ||||||
Derivative financial instruments | 9 | 21 | ||||||
Financial assets at fair value through other comprehensive income | 9,868 | 9,138 | ||||||
Other financial assets | 2 | 0 | ||||||
Non-derivative financial assets | 185,780 | 180,428 | ||||||
Liabilities | ||||||||
Deposits at amortised cost | 231 | 379 | ||||||
Cash collateral and settlement balances | 0 | 0 | ||||||
Repurchase agreements and other similar secured borrowing | 87 | 92 | ||||||
Debt securities in issue | 8,848 | 5,856 | ||||||
Subordinated liabilities | 1,882 | 1,139 | ||||||
Trading portfolio liabilities | 0 | 0 | ||||||
Financial liabilities designated at fair value | 13,254 | 12,918 | ||||||
Derivative financial instruments | 362 | 403 | ||||||
Other financial liabilities | 139 | 210 | ||||||
Total financial liabilities | 24,803 | 20,997 | ||||||
Cumulative liquidity gap | £ 53,244 | £ 53,558 | ||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Other disclosures - Risk Man_21
Other disclosures - Risk Management and Principal Risks - Contractural maturity of financial liabilities - undiscounted (audited) (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | £ 519,478 | £ 481,049 |
Cash collateral and settlement balances, undiscounted | 79,371 | 85,423 |
Repurchase agreements and other similar secured lending, undiscounted | 29,028 | 14,252 |
Debt securities in issue, undiscounted | 107,272 | 83,620 |
Subordinated liabilities, undiscounted | 15,465 | 19,051 |
Trading portfolio liabilities, undiscounted | 54,169 | 47,405 |
Financial liabilities designated at fair value, undiscounted | 260,454 | 257,825 |
Derivative financial instruments, undiscounted | 257,002 | 300,826 |
Other financial liabilities, undiscounted | 6,619 | 5,332 |
Total financial liabilities, undiscounted cash flows | 1,328,858 | 1,294,783 |
On demand | ||
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | 454,961 | 410,894 |
Cash collateral and settlement balances, undiscounted | 2,983 | 1,900 |
Repurchase agreements and other similar secured lending, undiscounted | 20 | 4 |
Debt securities in issue, undiscounted | 0 | 0 |
Subordinated liabilities, undiscounted | 0 | 0 |
Trading portfolio liabilities, undiscounted | 54,169 | 47,405 |
Financial liabilities designated at fair value, undiscounted | 21,339 | 15,555 |
Derivative financial instruments, undiscounted | 255,747 | 299,795 |
Other financial liabilities, undiscounted | 184 | 101 |
Total financial liabilities, undiscounted cash flows | 789,403 | 775,654 |
On demand | Over issuance of securities | ||
Disclosure of financial liabilities [line items] | ||
Securities issues in excess of limit, undiscounted | 6,997 | |
Not more than three months | ||
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | 40,755 | 41,468 |
Cash collateral and settlement balances, undiscounted | 76,388 | 83,523 |
Repurchase agreements and other similar secured lending, undiscounted | 6,621 | 3,276 |
Debt securities in issue, undiscounted | 24,450 | 16,368 |
Subordinated liabilities, undiscounted | 1,063 | 1,597 |
Trading portfolio liabilities, undiscounted | 0 | 0 |
Financial liabilities designated at fair value, undiscounted | 158,070 | 172,186 |
Derivative financial instruments, undiscounted | 5 | 1 |
Other financial liabilities, undiscounted | 4,344 | 2,929 |
Total financial liabilities, undiscounted cash flows | 311,696 | 321,348 |
Over three months but not more than six months | ||
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | 13,524 | 15,886 |
Cash collateral and settlement balances, undiscounted | 0 | 0 |
Repurchase agreements and other similar secured lending, undiscounted | 0 | 0 |
Debt securities in issue, undiscounted | 12,625 | 4,058 |
Subordinated liabilities, undiscounted | 0 | 3,328 |
Trading portfolio liabilities, undiscounted | 0 | 0 |
Financial liabilities designated at fair value, undiscounted | 16,887 | 8,683 |
Derivative financial instruments, undiscounted | 22 | 49 |
Other financial liabilities, undiscounted | 57 | 62 |
Total financial liabilities, undiscounted cash flows | 43,115 | 32,066 |
Over six months but not more than one year | ||
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | 6,718 | 8,156 |
Cash collateral and settlement balances, undiscounted | 0 | 0 |
Repurchase agreements and other similar secured lending, undiscounted | 0 | 0 |
Debt securities in issue, undiscounted | 9,075 | 7,061 |
Subordinated liabilities, undiscounted | 1,379 | 311 |
Trading portfolio liabilities, undiscounted | 0 | 0 |
Financial liabilities designated at fair value, undiscounted | 13,946 | 8,007 |
Derivative financial instruments, undiscounted | 24 | 0 |
Other financial liabilities, undiscounted | 111 | 116 |
Total financial liabilities, undiscounted cash flows | 31,253 | 23,651 |
Over one year but not more than three years | ||
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | 2,461 | 2,893 |
Cash collateral and settlement balances, undiscounted | 0 | 0 |
Repurchase agreements and other similar secured lending, undiscounted | 11,356 | 3,729 |
Debt securities in issue, undiscounted | 19,225 | 16,684 |
Subordinated liabilities, undiscounted | 1,213 | 2,498 |
Trading portfolio liabilities, undiscounted | 0 | 0 |
Financial liabilities designated at fair value, undiscounted | 12,944 | 15,604 |
Derivative financial instruments, undiscounted | 305 | 147 |
Other financial liabilities, undiscounted | 932 | 981 |
Total financial liabilities, undiscounted cash flows | 48,436 | 42,536 |
Over three years but not more than five years | ||
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | 239 | 599 |
Cash collateral and settlement balances, undiscounted | 0 | 0 |
Repurchase agreements and other similar secured lending, undiscounted | 10,885 | 7,089 |
Debt securities in issue, undiscounted | 14,060 | 14,715 |
Subordinated liabilities, undiscounted | 2,316 | 1,152 |
Trading portfolio liabilities, undiscounted | 0 | 0 |
Financial liabilities designated at fair value, undiscounted | 8,086 | 8,586 |
Derivative financial instruments, undiscounted | 316 | 187 |
Other financial liabilities, undiscounted | 327 | 338 |
Total financial liabilities, undiscounted cash flows | 36,229 | 32,666 |
Over five years but not more than ten years | ||
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | 559 | 768 |
Cash collateral and settlement balances, undiscounted | 0 | 0 |
Repurchase agreements and other similar secured lending, undiscounted | 0 | 0 |
Debt securities in issue, undiscounted | 14,147 | 14,882 |
Subordinated liabilities, undiscounted | 6,627 | 8,578 |
Trading portfolio liabilities, undiscounted | 0 | 0 |
Financial liabilities designated at fair value, undiscounted | 7,544 | 8,369 |
Derivative financial instruments, undiscounted | 134 | 204 |
Other financial liabilities, undiscounted | 502 | 557 |
Total financial liabilities, undiscounted cash flows | 29,513 | 33,358 |
Over ten years | ||
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | 261 | 385 |
Cash collateral and settlement balances, undiscounted | 0 | 0 |
Repurchase agreements and other similar secured lending, undiscounted | 146 | 154 |
Debt securities in issue, undiscounted | 13,690 | 9,852 |
Subordinated liabilities, undiscounted | 2,867 | 1,587 |
Trading portfolio liabilities, undiscounted | 0 | 0 |
Financial liabilities designated at fair value, undiscounted | 21,638 | 20,835 |
Derivative financial instruments, undiscounted | 449 | 443 |
Other financial liabilities, undiscounted | 162 | 248 |
Total financial liabilities, undiscounted cash flows | £ 39,213 | £ 33,504 |
Other disclosures - Risk Man_22
Other disclosures - Risk Management and Principal Risks - Maturity analysis of off-balance sheet commitments received (audited) (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of contingent liabilities [line items] | ||
Contingent liabilities | £ 21,346 | £ 21,609 |
Documentary credits and other short-term trade related transactions | 1,584 | 1,086 |
Standby facilities, credit lines and other commitments | 344,127 | 331,963 |
Total off-balance sheet | 367,057 | 354,658 |
Off Balance sheet commitments received | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 25,870 | 26,711 |
Other commitments received | 455 | 92 |
Total off-balance sheet commitments received | 26,325 | 26,803 |
On demand | ||
Disclosure of contingent liabilities [line items] | ||
Contingent liabilities | 21,207 | 21,307 |
Documentary credits and other short-term trade related transactions | 1,582 | 1,084 |
Standby facilities, credit lines and other commitments | 344,055 | 330,499 |
Total off-balance sheet | 366,844 | 352,890 |
On demand | Off Balance sheet commitments received | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 25,613 | 26,368 |
Other commitments received | 455 | 92 |
Total off-balance sheet commitments received | 26,068 | 26,460 |
Not more than three months | ||
Disclosure of contingent liabilities [line items] | ||
Contingent liabilities | 135 | 213 |
Documentary credits and other short-term trade related transactions | 2 | 1 |
Standby facilities, credit lines and other commitments | 0 | 564 |
Total off-balance sheet | 137 | 778 |
Not more than three months | Off Balance sheet commitments received | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 31 | 86 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 31 | 86 |
Over three months but not more than six months | ||
Disclosure of contingent liabilities [line items] | ||
Contingent liabilities | 4 | 57 |
Documentary credits and other short-term trade related transactions | 0 | 1 |
Standby facilities, credit lines and other commitments | 0 | 93 |
Total off-balance sheet | 4 | 151 |
Over three months but not more than six months | Off Balance sheet commitments received | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 21 | 37 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 21 | 37 |
Over six months but not more than nine months | ||
Disclosure of contingent liabilities [line items] | ||
Contingent liabilities | 0 | 6 |
Documentary credits and other short-term trade related transactions | 0 | 0 |
Standby facilities, credit lines and other commitments | 0 | 123 |
Total off-balance sheet | 0 | 129 |
Over six months but not more than nine months | Off Balance sheet commitments received | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 10 | 68 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 10 | 68 |
Over nine months but not more than one year | ||
Disclosure of contingent liabilities [line items] | ||
Contingent liabilities | 0 | 1 |
Documentary credits and other short-term trade related transactions | 0 | 0 |
Standby facilities, credit lines and other commitments | 0 | 95 |
Total off-balance sheet | 0 | 96 |
Over nine months but not more than one year | Off Balance sheet commitments received | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 12 | 8 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 12 | 8 |
One to two year | ||
Disclosure of contingent liabilities [line items] | ||
Contingent liabilities | 0 | 25 |
Documentary credits and other short-term trade related transactions | 0 | 0 |
Standby facilities, credit lines and other commitments | 72 | 160 |
Total off-balance sheet | 72 | 185 |
One to two year | Off Balance sheet commitments received | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 4 | 18 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 4 | 18 |
Two to three year | ||
Disclosure of contingent liabilities [line items] | ||
Contingent liabilities | 0 | 0 |
Documentary credits and other short-term trade related transactions | 0 | 0 |
Standby facilities, credit lines and other commitments | 0 | 199 |
Total off-balance sheet | 0 | 199 |
Two to three year | Off Balance sheet commitments received | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 12 | 14 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 12 | 14 |
Over three years but not more than five years | ||
Disclosure of contingent liabilities [line items] | ||
Contingent liabilities | 0 | 0 |
Documentary credits and other short-term trade related transactions | 0 | 0 |
Standby facilities, credit lines and other commitments | 0 | 202 |
Total off-balance sheet | 0 | 202 |
Over three years but not more than five years | Off Balance sheet commitments received | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 83 | 47 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 83 | 47 |
Over five years but not more than ten years | ||
Disclosure of contingent liabilities [line items] | ||
Contingent liabilities | 0 | 0 |
Documentary credits and other short-term trade related transactions | 0 | 0 |
Standby facilities, credit lines and other commitments | 0 | 21 |
Total off-balance sheet | 0 | 21 |
Over five years but not more than ten years | Off Balance sheet commitments received | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 65 | 40 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 65 | 40 |
Over ten years | ||
Disclosure of contingent liabilities [line items] | ||
Contingent liabilities | 0 | 0 |
Documentary credits and other short-term trade related transactions | 0 | 0 |
Standby facilities, credit lines and other commitments | 0 | 7 |
Total off-balance sheet | 0 | 7 |
Over ten years | Off Balance sheet commitments received | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 19 | 25 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | £ 19 | £ 25 |
Other disclosures - Risk Man_23
Other disclosures - Risk Management and Principal Risks - Capital resources (audited) (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Capital resources [abstract] | ||||
Total equity (excluding non-controlling interests) per the balance sheet | £ 69,052 | [1] | £ 65,797 | |
Less: other equity instruments (recognised as AT1 capital) | (12,259) | [1] | (11,172) | |
Adjustment to retained earnings for foreseeable ordinary share dividends | (666) | (174) | ||
Adjustment to retained earnings for foreseeable repurchase of shares | 0 | 0 | ||
Adjustment to retained earnings for foreseeable other equity coupons | (32) | (30) | ||
Goodwill and intangible assets | (8,061) | [1] | (7,948) | |
Fair value reserves related to gains or losses on cash flow hedges | 853 | (1,575) | £ (1,002) | |
Defined benefit pension fund assets | (3,879) | [1] | (1,814) | |
Total RWAs | 314,136 | 306,203 | ||
T1 capital | ||||
Capital resources [abstract] | ||||
PRA transitional total regulatory capital | 60,143 | 58,034 | ||
CET1 capital | ||||
Capital resources [abstract] | ||||
Additional value adjustments (PVA) | (1,585) | (1,146) | ||
Goodwill and intangible assets | (6,804) | (6,914) | ||
Deferred tax assets that rely on future profitability excluding temporary differences | (1,028) | (595) | ||
Fair value reserves related to gains or losses on cash flow hedges | (852) | 1,575 | ||
Gains or losses on liabilities at fair value resulting from own credit | 892 | 870 | ||
Defined benefit pension fund assets | (2,619) | (1,326) | ||
Direct and indirect holdings by an institution of own CET1 instruments | (50) | (50) | ||
Adjustment under IFRS 9 transitional arrangements | 1,229 | 2,556 | ||
Other regulatory adjustments and deductions | 345 | 55 | ||
PRA transitional total regulatory capital | 47,327 | 46,296 | ||
AT1 capital | ||||
Capital resources [abstract] | ||||
Total equity (excluding non-controlling interests) per the balance sheet | 12,259 | 11,172 | ||
Qualifying capital (including minority interests) issued by subsidiaries | 637 | 646 | ||
Other regulatory adjustments and deductions | (80) | (80) | ||
PRA transitional total regulatory capital | 12,816 | 11,738 | ||
T2 capital | ||||
Capital resources [abstract] | ||||
Total equity (excluding non-controlling interests) per the balance sheet | 8,713 | 7,836 | ||
Adjustment under IFRS 9 transitional arrangements | 73 | 57 | ||
Qualifying capital (including minority interests) issued by subsidiaries | 1,113 | 1,893 | ||
Other regulatory adjustments and deductions | (160) | (160) | ||
PRA transitional total regulatory capital | £ 69,882 | £ 67,660 | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Other disclosures - Risk Man_24
Other disclosures - Risk Management and Principal Risks - Functional currency of the operations (audited) (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of risk management strategy related to hedge accounting [line items] | ||
Financial instrument which hedge net investments, Hedges | £ 13,600 | £ 9,500 |
Foreign exchange risk | ||
Disclosure of risk management strategy related to hedge accounting [line items] | ||
Foreign currency net investments | 37,473 | 32,081 |
Borrowings which hedge the net investments | (11,212) | (8,660) |
Derivatives which hedge the net investments | (2,423) | (791) |
Structural currency exposures pre-economic hedges | 23,838 | 22,630 |
Economic hedges | (7,657) | (6,479) |
Remaining structural currency exposures | 16,181 | 16,151 |
Increase (decrease) in foreign currency net investments, hedged item | 5,400 | |
Increase (decrease) in financial instruments which hedge net investments, Hedges | 4,100 | |
USD foreign operations | ||
Disclosure of risk management strategy related to hedge accounting [line items] | ||
Foreign currency net investments | 25,958 | 24,204 |
Borrowings which hedge the net investments | (7,707) | (7,666) |
Derivatives which hedge the net investments | (2,356) | (764) |
Structural currency exposures pre-economic hedges | 15,895 | 15,774 |
Economic hedges | (7,389) | (6,193) |
Remaining structural currency exposures | 8,506 | 9,581 |
Increase (decrease) in financial instruments which hedge net investments, Hedges | 500 | |
EUR foreign operations | ||
Disclosure of risk management strategy related to hedge accounting [line items] | ||
Foreign currency net investments | 8,453 | 5,275 |
Borrowings which hedge the net investments | (3,408) | (952) |
Derivatives which hedge the net investments | (3) | (3) |
Structural currency exposures pre-economic hedges | 5,042 | 4,320 |
Economic hedges | (268) | (286) |
Remaining structural currency exposures | 4,774 | 4,034 |
Increase (decrease) in financial instruments which hedge net investments, Hedges | (3,200) | |
JPY foreign operations | ||
Disclosure of risk management strategy related to hedge accounting [line items] | ||
Foreign currency net investments | 614 | 582 |
Borrowings which hedge the net investments | (97) | 0 |
Derivatives which hedge the net investments | 0 | 0 |
Structural currency exposures pre-economic hedges | 517 | 582 |
Economic hedges | 0 | 0 |
Remaining structural currency exposures | 517 | 582 |
Other foreign operations | ||
Disclosure of risk management strategy related to hedge accounting [line items] | ||
Foreign currency net investments | 2,448 | 2,020 |
Borrowings which hedge the net investments | 0 | (42) |
Derivatives which hedge the net investments | (64) | (24) |
Structural currency exposures pre-economic hedges | 2,384 | 1,954 |
Economic hedges | 0 | 0 |
Remaining structural currency exposures | 2,384 | £ 1,954 |
Increase (decrease) in financial instruments which hedge net investments, Hedges | £ (1,700) |
Other disclosures - Risk Man_25
Other disclosures - Risk Management and Principal Risks - Interest Income sensitivity (AEaR) by business unit (audited) (Details) - Interest rate risk - +/- 25bps - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | £ 71 | £ 100 |
Net interest income sensitivity (AEaR), decrease | (158) | (408) |
Pro Forma | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | 83 | |
Net interest income sensitivity (AEaR), increase, without hedging | 218 | |
Net interest income sensitivity (AEaR), decrease, without hedging | (305) | |
Head Office | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | 5 | 4 |
Net interest income sensitivity (AEaR), decrease | (5) | (4) |
Barclays UK | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | (2) | 10 |
Net interest income sensitivity (AEaR), decrease | (54) | (141) |
Barclays International | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | 68 | 86 |
Net interest income sensitivity (AEaR), decrease | £ (99) | (263) |
Barclays International | Pro Forma | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | £ 121 |
Other disclosures - Risk Man_26
Other disclosures - Risk Management and Principal Risks - Interest Income sensitivity (AEaR) by currency (audited) (Details) - +/- 25bps - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Interest rate risk | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | £ 71 | £ 100 |
Net interest income sensitivity (AEaR), decrease | (158) | (408) |
Interest rate risk | Pro Forma | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | 83 | |
GBP London Interbank Offered rate (LIBOR) | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | 14 | 48 |
Net interest income sensitivity (AEaR), decrease | (85) | (313) |
USD LIBOR | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | 58 | 48 |
Net interest income sensitivity (AEaR), decrease | (62) | (63) |
EUR LIBOR | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | 5 | 10 |
Net interest income sensitivity (AEaR), decrease | (15) | (34) |
Other currencies | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | (6) | (6) |
Net interest income sensitivity (AEaR), decrease | £ 4 | £ 2 |
Other disclosures - Risk Man_27
Other disclosures - Risk Management and Principal Risks - Analysis of equity sensitivity (audited) (Details) - Interest rate risk - +/- 25bps - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of sensitivity analysis to changes in risk exposures that arise from contracts within scope of IFRS 17 [line items] | ||
Effect on profit for the year, increase | £ 71 | £ 100 |
Effect on profit for the year, decrease | (158) | (408) |
Effect on equity, increase | (921) | (662) |
Effect on equity, decrease | 800 | 449 |
Pro Forma | ||
Disclosure of sensitivity analysis to changes in risk exposures that arise from contracts within scope of IFRS 17 [line items] | ||
Effect on profit for the year, increase | 83 | |
Effect on equity, increase | (636) | |
Retained earnings | ||
Disclosure of sensitivity analysis to changes in risk exposures that arise from contracts within scope of IFRS 17 [line items] | ||
Effect on profit for the year, increase | 56 | 73 |
Effect on profit for the year, decrease | £ (125) | £ (298) |
As percentage, increase | 0.80% | 3.00% |
As percentage, decrease | (1.80%) | (12.10%) |
Effect on equity, increase | £ 56 | £ 73 |
Effect on equity, decrease | (125) | (298) |
Taxation effects on the above | ||
Disclosure of sensitivity analysis to changes in risk exposures that arise from contracts within scope of IFRS 17 [line items] | ||
Effect on profit for the year, increase | (15) | (27) |
Effect on profit for the year, decrease | 33 | 110 |
Effect on equity, increase | 361 | 272 |
Effect on equity, decrease | (342) | (276) |
Fair value through other comprehensive income reserve | ||
Disclosure of sensitivity analysis to changes in risk exposures that arise from contracts within scope of IFRS 17 [line items] | ||
Effect on equity, increase | (479) | (437) |
Effect on equity, decrease | 408 | 453 |
Cash flow hedge reserve | ||
Disclosure of sensitivity analysis to changes in risk exposures that arise from contracts within scope of IFRS 17 [line items] | ||
Effect on equity, increase | (859) | (570) |
Effect on equity, decrease | £ 859 | £ 570 |
Equity attributable to owners of parent | ||
Disclosure of sensitivity analysis to changes in risk exposures that arise from contracts within scope of IFRS 17 [line items] | ||
As percentage, increase | (1.30%) | (1.00%) |
As percentage, decrease | 1.20% | 0.70% |
Significant accounting polici_3
Significant accounting policies - Narrative (Details) R / shares in Units, £ in Millions, shares in Millions, R in Billions, $ in Billions | Sep. 30, 2022 | Apr. 29, 2022GBP (£) | Apr. 21, 2022GBP (£) | Apr. 21, 2022ZAR (R)R / sharesshares | Aug. 01, 2019 | Jun. 30, 2022 | Dec. 31, 2021GBP (£) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | Mar. 10, 2022USD ($) | Mar. 31, 2022GBP (£) | Sep. 30, 2021GBP (£) | |
Disclosure of retrospective restatement [Line Items] | |||||||||||||
Litigation and conduct | £ 397 | [1] | £ 153 | £ 1,849 | |||||||||
Operating expense | 14,659 | [1] | 13,886 | 15,434 | |||||||||
Provisions | 1,908 | [2] | 2,304 | ||||||||||
Taxation | (1,138) | [1] | (604) | (1,003) | |||||||||
Current tax liabilities | 689 | [2] | 645 | ||||||||||
Profit after tax | 7,056 | [1],[3] | 2,461 | 3,354 | |||||||||
Proceeds from sale or redemption of debt securities at amortised cost | 3,757 | [4] | 8,480 | £ 3,590 | |||||||||
Surplus (deficit) in plan | 3,568 | 1,523 | |||||||||||
UK | Pension defined benefit plans | Of which relates to UKRF | |||||||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||||||
Surplus (deficit) in plan | 3,819 | 1,807 | £ 600 | ||||||||||
Financial assets at amortised cost | The senior notes | UK | |||||||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||||||
Notional contract amount | 1,250 | 1,250 | |||||||||||
Forecast | |||||||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||||||
Potential decrease in capital ratio | 0.30% | (0.10%) | |||||||||||
CET1 capital | |||||||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||||||
PRA transitional regulatory capital | (47,327) | £ (46,296) | |||||||||||
Adjustments | |||||||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||||||
Litigation and conduct | 220 | ||||||||||||
Operating expense | 220 | ||||||||||||
Provisions | 220 | ||||||||||||
Taxation | 50 | ||||||||||||
Current tax liabilities | (50) | ||||||||||||
Profit after tax | (170) | ||||||||||||
Previously stated | |||||||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||||||
Litigation and conduct | 177 | ||||||||||||
Operating expense | 14,439 | ||||||||||||
Provisions | 1,688 | ||||||||||||
Taxation | (1,188) | ||||||||||||
Current tax liabilities | 739 | ||||||||||||
Profit after tax | £ 7,226 | ||||||||||||
Disclosure of post year end balances | UK | Pension defined benefit plans | Of which relates to UKRF | |||||||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||||||
Surplus (deficit) in plan | £ 4,400 | ||||||||||||
Disclosure of post year end balances | Customer remediation provision | |||||||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||||||
Other provisions | £ 181 | ||||||||||||
Disclosure of post year end balances | Forecast | |||||||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||||||
Potential decrease in capital ratio | 0.30% | ||||||||||||
Other disposals of assets | Absa Group Limited | |||||||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||||||
Number of shares sold (in shares) | shares | 63 | ||||||||||||
Number of shares sold as % of total shares | 7.40% | ||||||||||||
Price per share (in ZAR per share) | R / shares | R 164 | ||||||||||||
Proceeds from sale or redemption of debt securities at amortised cost | £ 516 | R 10.3 | |||||||||||
Loss on disposals of investments | £ 42 | ||||||||||||
Capital contribution from parent entity | |||||||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||||||
Increase through other contributions by owners, equity | £ 750 | ||||||||||||
US | Over issuance of securities | |||||||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||||||
Validity term | 3 years | ||||||||||||
US | Disclosure of post year end balances | Over issuance of securities | |||||||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||||||
Securities issues in excess of limit | $ | $ 13 | ||||||||||||
US | Over issuance of securities | Disclosure of post year end balances | |||||||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||||||
Securities issue limit | $ | 20.8 | ||||||||||||
Securities issues in excess of limit | $ | $ 15 | ||||||||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||||||||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||||||||||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details | ||||||||||||
[4] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Significant accounting polici_4
Significant accounting policies (Details) - GBP (£) £ in Millions | 12 Months Ended | ||||||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | ||||
Disclosure of retrospective restatement [Line Items] | |||||||
Litigation and conduct | £ 397 | [1] | £ 153 | £ 1,849 | |||
Operating expenses | (14,659) | [1] | (13,886) | (15,434) | |||
Profit/(loss) before tax | 8,194 | [2] | 3,065 | 4,357 | |||
Taxation | 1,138 | [1] | 604 | 1,003 | |||
Profit after tax | 7,056 | [1],[3] | 2,461 | 3,354 | |||
Profit after tax and other comprehensive income | 4,838 | [3],[4] | 2,066 | [4] | 2,793 | ||
Current tax liabilities | (689) | [5] | (645) | ||||
Provisions | (1,908) | [5] | (2,304) | ||||
Total liabilities | (1,314,244) | [5] | (1,282,632) | ||||
Retained earnings | 50,487 | [5] | 45,527 | ||||
Total equity | 70,041 | [5] | 66,882 | [4] | 65,660 | [4] | £ 63,779 |
Adjustments for non-cash items: | |||||||
Other provisions, including pensions | 468 | [2] | £ 1,365 | £ 2,336 | |||
Previously stated | |||||||
Disclosure of retrospective restatement [Line Items] | |||||||
Litigation and conduct | 177 | ||||||
Operating expenses | (14,439) | ||||||
Profit/(loss) before tax | 8,414 | ||||||
Taxation | 1,188 | ||||||
Profit after tax | 7,226 | ||||||
Profit after tax and other comprehensive income | 5,008 | ||||||
Current tax liabilities | (739) | ||||||
Provisions | (1,688) | ||||||
Total liabilities | (1,314,074) | ||||||
Retained earnings | 50,657 | ||||||
Total equity | 70,211 | ||||||
Adjustments for non-cash items: | |||||||
Other provisions, including pensions | 248 | ||||||
Adjustments | |||||||
Disclosure of retrospective restatement [Line Items] | |||||||
Litigation and conduct | 220 | ||||||
Operating expenses | (220) | ||||||
Profit/(loss) before tax | (220) | ||||||
Taxation | (50) | ||||||
Profit after tax | (170) | ||||||
Profit after tax and other comprehensive income | (170) | ||||||
Current tax liabilities | 50 | ||||||
Provisions | (220) | ||||||
Total liabilities | (170) | ||||||
Retained earnings | (170) | ||||||
Total equity | (170) | ||||||
Adjustments for non-cash items: | |||||||
Other provisions, including pensions | £ 220 | ||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details | ||||||
[4] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||||
[5] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Segmental reporting - Narrative
Segmental reporting - Narrative (Details) | Dec. 31, 2021Segments |
Disclosure of operating segments [abstract] | |
Number of operating segments | 2 |
Segmental reporting - Analysis
Segmental reporting - Analysis of results by business (Details) $ in Billions | Apr. 01, 2020GBP (£) | Dec. 31, 2021GBP (£)Employees | Dec. 31, 2020GBP (£)Employees | Dec. 31, 2019GBP (£)Employees | Dec. 31, 2021USD ($)Employees | |
Disclosure of operating segments [line items] | ||||||
Total income | £ 21,940,000,000 | [1] | £ 21,766,000,000 | £ 21,632,000,000 | ||
Credit impairment releases | (653,000,000) | [1] | 4,838,000,000 | 1,912,000,000 | ||
Net operating income | 22,593,000,000 | [1] | 16,928,000,000 | 19,720,000,000 | ||
Operating costs | (14,092,000,000) | (13,434,000,000) | (13,359,000,000) | |||
UK bank levy | (170,000,000) | (299,000,000) | (226,000,000) | |||
Litigation and conduct | (397,000,000) | (153,000,000) | (1,849,000,000) | |||
Operating expenses | (14,659,000,000) | [1] | (13,886,000,000) | (15,434,000,000) | ||
Other net income | 260,000,000 | 23,000,000 | 71,000,000 | |||
Profit before tax | 8,194,000,000 | [2] | 3,065,000,000 | 4,357,000,000 | ||
Total assets (£bn) | £ 1,384,285,000,000 | [3] | £ 1,349,514,000,000 | £ 1,140,200,000,000 | $ 1,384.3 | |
Number of employees (full time equivalent) | 81,600 | 83,000 | 80,800 | 81,600 | ||
Average number of employees (full time equivalent) | Employees | 82,900 | 81,800 | 82,700 | |||
Barclays UK | ||||||
Disclosure of operating segments [line items] | ||||||
Increase (decrease) in employees | Employees | (10,700) | (10,700) | ||||
Operating segments | Barclays UK | ||||||
Disclosure of operating segments [line items] | ||||||
Total income | £ 6,536,000,000 | £ 6,347,000,000 | £ 7,353,000,000 | |||
Credit impairment releases | (365,000,000) | 1,467,000,000 | 712,000,000 | |||
Net operating income | 6,901,000,000 | 4,880,000,000 | 6,641,000,000 | |||
Operating costs | (4,357,000,000) | (4,270,000,000) | (3,996,000,000) | |||
UK bank levy | (36,000,000) | (50,000,000) | (41,000,000) | |||
Litigation and conduct | (37,000,000) | (32,000,000) | (1,582,000,000) | |||
Operating expenses | (4,430,000,000) | (4,352,000,000) | (5,619,000,000) | |||
Other net income | 0 | 18,000,000 | 0 | |||
Profit before tax | 2,471,000,000 | 546,000,000 | 1,022,000,000 | |||
Total assets (£bn) | £ 321,200,000,000 | £ 289,100,000,000 | £ 257,800,000,000 | |||
Number of employees (full time equivalent) | 7,100 | 21,300 | 21,400 | 7,100 | ||
Operating segments | Barclays International | ||||||
Disclosure of operating segments [line items] | ||||||
Total income | £ 15,665,000,000 | £ 15,921,000,000 | £ 14,675,000,000 | |||
Credit impairment releases | (288,000,000) | 3,280,000,000 | 1,173,000,000 | |||
Net operating income | 15,953,000,000 | 12,641,000,000 | 13,502,000,000 | |||
Operating costs | (9,076,000,000) | (8,765,000,000) | (9,163,000,000) | |||
UK bank levy | (134,000,000) | (240,000,000) | (174,000,000) | |||
Litigation and conduct | (345,000,000) | (48,000,000) | (116,000,000) | |||
Operating expenses | (9,555,000,000) | (9,053,000,000) | (9,453,000,000) | |||
Other net income | 40,000,000 | 28,000,000 | 69,000,000 | |||
Profit before tax | 6,438,000,000 | 3,616,000,000 | 4,118,000,000 | |||
Total assets (£bn) | £ 1,044,100,000,000 | £ 1,041,800,000,000 | £ 861,400,000,000 | |||
Number of employees (full time equivalent) | 10,400 | 10,800 | 11,200 | 10,400 | ||
Operating segments | Barclays Partner Finance | ||||||
Disclosure of operating segments [line items] | ||||||
Net operating income | £ 19,000,000 | |||||
Profit before tax | (5,000,000) | |||||
Total assets (£bn) | £ 2,200,000,000 | |||||
Head Office | ||||||
Disclosure of operating segments [line items] | ||||||
Total income | £ (261,000,000) | £ (502,000,000) | £ (396,000,000) | |||
Credit impairment releases | 0 | 91,000,000 | 27,000,000 | |||
Net operating income | (261,000,000) | (593,000,000) | (423,000,000) | |||
Operating costs | (659,000,000) | (399,000,000) | (200,000,000) | |||
UK bank levy | 0 | (9,000,000) | (11,000,000) | |||
Litigation and conduct | (15,000,000) | (73,000,000) | (151,000,000) | |||
Operating expenses | (674,000,000) | (481,000,000) | (362,000,000) | |||
Other net income | 220,000,000 | (23,000,000) | 2,000,000 | |||
Profit before tax | (715,000,000) | (1,097,000,000) | (783,000,000) | |||
Total assets (£bn) | £ 19,000,000,000 | £ 18,600,000,000 | £ 21,000,000,000 | |||
Number of employees (full time equivalent) | 64,100 | 50,900 | 48,200 | 64,100 | ||
Increase (decrease) in employees | Employees | 10,700 | 10,700 | ||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Segmental reporting - Income by
Segmental reporting - Income by geographic region (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of operating segments [line items] | ||||
Total income | £ 21,940 | [1] | £ 21,766 | £ 21,632 |
United Kingdom | ||||
Disclosure of operating segments [line items] | ||||
Total income | 11,256 | 11,211 | 11,809 | |
Europe | ||||
Disclosure of operating segments [line items] | ||||
Total income | 2,372 | 2,059 | 1,754 | |
Americas | ||||
Disclosure of operating segments [line items] | ||||
Total income | 7,199 | 7,425 | 7,064 | |
Africa and Middle East | ||||
Disclosure of operating segments [line items] | ||||
Total income | 45 | 36 | 59 | |
Asia | ||||
Disclosure of operating segments [line items] | ||||
Total income | 1,068 | 1,035 | 946 | |
United States | ||||
Disclosure of operating segments [line items] | ||||
Total income | £ 7,048 | £ 7,318 | £ 6,939 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Net interest income - Summary (
Net interest income - Summary (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of attribution of expenses by nature to their function [line items] | ||||
Cash and balances at central banks | £ 184 | £ 275 | £ 1,091 | |
Loans and advances at amortised cost | 9,540 | 10,180 | 12,450 | |
Fair value through other comprehensive income | 550 | 776 | 1,032 | |
Negative interest on liabilities | 248 | 68 | 13 | |
Other | 718 | 593 | 870 | |
Interest and similar income | 11,240 | [1] | 11,892 | 15,456 |
Deposits at amortised cost | (561) | (1,030) | (2,449) | |
Debt securities in issue | (1,340) | (1,360) | (1,906) | |
Subordinated liabilities | (507) | (670) | (1,068) | |
Negative interest on assets | (374) | (344) | (278) | |
Other | (385) | (366) | (348) | |
Interest and similar expense | (3,167) | [1] | (3,770) | (6,049) |
Net interest income | 8,073 | [1] | 8,122 | 9,407 |
Interest expense | £ 3,167 | [1] | £ 3,770 | 6,049 |
Total contingent liabilities and financial guarantees | ||||
Disclosure of attribution of expenses by nature to their function [line items] | ||||
Interest and similar expense | (25) | |||
Interest expense | £ 25 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Net interest income - Narrative
Net interest income - Narrative (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of detailed information about financial instruments [line items] | |||
Costs to originate credit card balances | £ 652 | £ 698 | £ 697 |
Interest income on impaired financial assets accrued | 37 | 40 | 48 |
Interest expense on lease liabilities | £ 64 | £ 70 | £ 76 |
Net fee and commission income -
Net fee and commission income - Summary (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | £ 9,759 | £ 8,522 | £ 9,006 | |
Other non-contract fee income | 121 | 119 | 116 | |
Total fee and commission income | 9,880 | [1] | 8,641 | 9,122 |
Fee and commission expense | (2,206) | [1] | (2,070) | (2,362) |
Net fee and commission income | 7,674 | [1] | 6,571 | 6,760 |
Transactional | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 3,443 | 3,163 | 3,883 | |
Advisory | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 1,269 | 854 | 1,080 | |
Brokerage and execution | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 1,363 | 1,385 | 1,339 | |
Underwriting and syndication | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 3,425 | 2,867 | 2,358 | |
Other | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 259 | 253 | 346 | |
Operating segments | Barclays UK | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 1,345 | 1,252 | 1,551 | |
Other non-contract fee income | 0 | 0 | 0 | |
Total fee and commission income | 1,345 | 1,252 | 1,551 | |
Fee and commission expense | (218) | (308) | (365) | |
Net fee and commission income | 1,127 | 944 | 1,186 | |
Operating segments | Barclays UK | Transactional | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 871 | 810 | 1,074 | |
Operating segments | Barclays UK | Advisory | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 172 | 159 | 177 | |
Operating segments | Barclays UK | Brokerage and execution | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 228 | 212 | 208 | |
Operating segments | Barclays UK | Underwriting and syndication | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 0 | 0 | 0 | |
Operating segments | Barclays UK | Other | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 74 | 71 | 92 | |
Operating segments | Barclays International | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 8,410 | 7,259 | 7,443 | |
Other non-contract fee income | 121 | 119 | 116 | |
Total fee and commission income | 8,531 | 7,378 | 7,559 | |
Fee and commission expense | (1,983) | (1,754) | (1,990) | |
Net fee and commission income | 6,548 | 5,624 | 5,569 | |
Operating segments | Barclays International | Transactional | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 2,572 | 2,353 | 2,809 | |
Operating segments | Barclays International | Advisory | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 1,096 | 693 | 903 | |
Operating segments | Barclays International | Brokerage and execution | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 1,135 | 1,173 | 1,131 | |
Operating segments | Barclays International | Underwriting and syndication | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 3,425 | 2,867 | 2,358 | |
Operating segments | Barclays International | Other | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 182 | 173 | 242 | |
Head Office | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 4 | 11 | 12 | |
Other non-contract fee income | 0 | 0 | 0 | |
Total fee and commission income | 4 | 11 | 12 | |
Fee and commission expense | (5) | (8) | (7) | |
Net fee and commission income | (1) | 3 | 5 | |
Head Office | Transactional | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 0 | 0 | 0 | |
Head Office | Advisory | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 1 | 2 | 0 | |
Head Office | Brokerage and execution | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 0 | 0 | 0 | |
Head Office | Underwriting and syndication | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 0 | 0 | 0 | |
Head Office | Other | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | £ 3 | £ 9 | £ 12 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Net fee and commission income_2
Net fee and commission income - Narrative (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Fee and commission income (expense) [abstract] | |||
Contract assets | £ 0 | £ 0 | £ 0 |
Contract liabilities | 0 | 0 | 0 |
Impairment loss on receivables or contract assets arising from contracts with customers | 0 | 0 | 0 |
Capitalised contract costs | 154 | 141 | 159 |
Amortisation, capitalised contract costs | 36 | 36 | 30 |
Impairment loss, capitalised contract costs | £ 0 | £ 0 | £ 0 |
Net trading income (Details)
Net trading income (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of detailed information about financial instruments [line items] | ||||
Net trading income | £ 5,794 | [1] | £ 7,029 | £ 4,235 |
Net gains on financial instruments held for trading | Trading portfolio liabilities | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Net trading income | 3,992 | 5,342 | 2,941 | |
Net gains on financial instruments designated at fair value | Financial liabilities designated at fair value | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Net trading income | 692 | 700 | 256 | |
Net gains on financial instruments mandatorily at fair value | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Net trading income | £ 1,110 | £ 987 | £ 1,038 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Net investment income (Details)
Net investment income (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of detailed information about financial instruments [line items] | ||||
Net gains/(losses) from financial instruments mandatorily at fair value | £ 73 | £ (50) | £ 510 | |
Net gains from disposal of debt instruments at fair value through other comprehensive income | 305 | 295 | 502 | |
Net (losses)/gains from disposal of financial assets and liabilities measured at amortised cost | 114 | (61) | 257 | |
Dividend income | 20 | 37 | 76 | |
Net (losses)/gains on other investments | (201) | (208) | (214) | |
Net investment income | 311 | [1] | 13 | 1,131 |
Total contingent liabilities and financial guarantees | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Net investment income | 25 | |||
Debt securities classified at amortised cost | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Net (losses)/gains from disposal of financial assets and liabilities measured at amortised cost | (115) | |||
Barclays PLC | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Dividend income | 1,356 | £ 763 | £ 1,560 | |
Barclays PLC | Fixed rate resetting perpetual subordinated contingent convertible Securities | AT1 Securities | Fixed interest rate | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Net (losses)/gains from disposal of financial assets and liabilities measured at amortised cost | £ 83 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Credit impairment charges_(re_3
Credit impairment charges/(release) - Narrative (Details) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021GBP (£)economic_scenarioeconomicVariable | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | |
Disclosure of impairment loss and reversal of impairment loss [line items] | |||
Number of economic scenarios, percentage | 100.00% | ||
Credit derivatives | |||
Disclosure of impairment loss and reversal of impairment loss [line items] | |||
Number of economic scenarios | 5 | ||
Number of economic variables | economicVariable | 8 | ||
Stress horizon period, ECL | 5 years | ||
Term at which scenario converges to steady state | 8 years | ||
Downside scenario | Credit derivatives | |||
Disclosure of impairment loss and reversal of impairment loss [line items] | |||
Number of economic scenarios | 2 | ||
Upside scenario | Credit derivatives | |||
Disclosure of impairment loss and reversal of impairment loss [line items] | |||
Number of economic scenarios | 2 | ||
Wholesale portfolios | |||
Disclosure of impairment loss and reversal of impairment loss [line items] | |||
Changes in inputs, assumptions and estimation techniques used for ECL, probability | 100.00% | ||
Impairment (release) loss recognised in profit or loss | £ | £ 346 | £ 1,569 | £ 208 |
Wholesale portfolios | Bottom of range | |||
Disclosure of impairment loss and reversal of impairment loss [line items] | |||
Inputs, assumptions and estimation techniques used for ECL, probability | 0.20% | ||
Retail portfolios | |||
Disclosure of impairment loss and reversal of impairment loss [line items] | |||
Impairment (release) loss recognised in profit or loss | £ | £ (289) | £ 3,116 | £ 1,696 |
Retail portfolios | Bottom of range | Minimum | |||
Disclosure of impairment loss and reversal of impairment loss [line items] | |||
Inputs, assumptions and estimation techniques used for ECL, probability | 50.00% | ||
Retail portfolios | Bottom of range | Maximum | |||
Disclosure of impairment loss and reversal of impairment loss [line items] | |||
Inputs, assumptions and estimation techniques used for ECL, probability | 100.00% | ||
Retail portfolios | Top of range | |||
Disclosure of impairment loss and reversal of impairment loss [line items] | |||
Inputs, assumptions and estimation techniques used for ECL, probability | 400.00% |
Credit impairment charges_(re_4
Credit impairment charges/(release) - Charges, recoveries and reimbursements (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Impairment charges | £ (893) | £ 5,237 | £ 2,036 | |
Recoveries and reimbursements | 240 | (399) | (124) | |
Credit impairment (releases)/charges | (653) | [1] | 4,838 | 1,912 |
Gain on recovery of loans and advances previously written off | 66 | 35 | ||
Provision for undrawn contractually committed facilities and guarantees provided | ||||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Provision for undrawn contractually committed facilities and guarantees provided, impairment charges | (514) | 776 | 71 | |
Provision for undrawn contractually committed facilities and guarantees provided, recoveries and reimbursements | 0 | 0 | 0 | |
Credit impairment (releases)/charges | (514) | 776 | 71 | |
Total contingent liabilities and financial guarantees | ||||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Recoveries and reimbursements | (306) | (364) | ||
Gain on recovery of loans and advances previously written off | 35 | |||
Total contingent liabilities and financial guarantees | Third parties | ||||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Credit impairment (releases)/charges | 306 | (364) | ||
Loans and advances at amortised cost | ||||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Loan impairment, impairment charges | (875) | 5,084 | 2,028 | |
Loans impairment, recoveries and reimbursements | 240 | (399) | (124) | |
Credit impairment (releases)/charges | (635) | 4,685 | 1,904 | |
Financial assets at fair value through other comprehensive income | ||||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Impairment charges | (8) | 2 | 1 | |
Recoveries and reimbursements | 0 | 0 | 0 | |
Credit impairment (releases)/charges | (8) | 2 | 1 | |
Financial assets at amortised cost | Loans and advances at amortised cost | ||||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Loans and advances, impairment charges | (361) | 4,308 | 1,957 | |
Loans and advances, recoveries and reimbursements | 240 | (399) | (124) | |
Credit impairment (releases)/charges | (121) | 3,909 | 1,833 | |
Cash collateral and settlement balances | ||||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Impairment charges | (4) | 2 | 1 | |
Recoveries and reimbursements | 0 | 0 | 0 | |
Credit impairment (releases)/charges | (4) | 2 | 1 | |
Other financial assets measured at cost | Financial assets at amortised cost | ||||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Impairment charges | (6) | 149 | 6 | |
Recoveries and reimbursements | 0 | 0 | 0 | |
Credit impairment (releases)/charges | £ (6) | £ 149 | £ 6 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Credit impairment charges_(re_5
Credit impairment charges/(release) - Modification of financial assets (Narrative) (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of impairment loss and reversal of impairment loss [abstract] | ||
Financial assets written and subject to enforcement activity, contractual amount outstanding | £ 1,190 | £ 1,246 |
Amortised cost before modification | 3,446 | 4,275 |
Net modification loss | 11 | 34 |
Carrying amount of financial assets for which loss allowance has changed to 12-month measurement | £ 419 | £ 1,194 |
Operating expenses (Details)
Operating expenses (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Infrastructure costs | ||||
Property and equipment | £ 1,506 | £ 1,556 | £ 1,409 | |
Depreciation and amortisation | 1,673 | 1,539 | 1,487 | |
Lease payments | 32 | 34 | 41 | |
Impairment of property, equipment and intangible assets | 403 | 194 | 33 | |
Total infrastructure costs | 3,614 | [1] | 3,323 | 2,970 |
Administration and general expenses | ||||
Consultancy, legal and professional fees | 610 | 567 | 590 | |
Marketing and advertising | 399 | 330 | 425 | |
UK bank levy | 170 | 299 | 226 | |
Other administration and general expenses | 958 | 1,117 | 1,059 | |
Total administration and general expenses | 2,137 | [1] | 2,313 | 2,300 |
Staff costs | 8,511 | [1] | 8,097 | 8,315 |
Provisions for litigation and conduct | 397 | [1] | 153 | 1,849 |
Operating expense | 14,659 | [1] | £ 13,886 | £ 15,434 |
Operating expenses - structural costs | 648 | |||
Impairment loss - structural costs | £ 266 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Tax - Tax Charge (Details)
Tax - Tax Charge (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Current tax charge/(credit) | ||||
Current year | £ 1,417 | £ 1,255 | £ 1,037 | |
Adjustments in respect of prior years | 317 | 31 | (45) | |
Total | 1,734 | 1,286 | 992 | |
Deferred tax (credit)/charge | ||||
Current year | (352) | (830) | 86 | |
Adjustments in respect of prior years | (244) | 148 | (75) | |
Total | (596) | (682) | 11 | |
Tax charge | £ 1,138 | [1] | £ 604 | £ 1,003 |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Tax - Reconciliation between th
Tax - Reconciliation between the actual tax charge and the corporate tax rate (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Profit before tax | £ 8,194 | [1] | £ 3,065 | £ 4,357 |
Tax charge based on the standard UK corporation tax rate of 19% (2020: 19%; 2019: 19% ) | 1,557 | 582 | 828 | |
Impact of profits/losses earned in territories with different statutory rates to the UK (weighted average tax rate is 22.4% (2020: 25.1%; 2019: 24.2% )) | £ 277 | £ 188 | £ 227 | |
Tax, percentage [abstract] | ||||
Applicable tax rate | 19.00% | 19.00% | 19.00% | |
Tax rate impact of profits/losses earned in territories with different statutory rates to the UK | 3.40% | 6.10% | 5.20% | |
Recurring items: | ||||
Non-creditable taxes including withholding taxes | £ 134 | £ 109 | £ 150 | |
Banking surcharge and other items | 83 | 6 | 57 | |
Non-deductible expenses | 80 | 48 | 45 | |
Adjustments in respect of prior years | 73 | 179 | (120) | |
Impact of UK bank levy being non-deductible | 32 | 57 | 43 | |
Impact of Barclays Bank PLC's overseas branches being taxed both locally and in the UK | 25 | 25 | 15 | |
Tax adjustments in respect of share-based payments | (5) | 26 | (6) | |
Changes in recognition of deferred tax and effect of unrecognised tax losses | (140) | (123) | (82) | |
Tax relief on payments made under AT1 instruments | (149) | (165) | (157) | |
Non-taxable gains and income | £ (367) | £ (208) | £ (260) | |
Recurring items, percentages [abstract] | ||||
Non-creditable taxes including withholding taxes, percentage | 1.60% | 3.50% | 3.40% | |
Banking surcharge and other items, percentage | 1.00% | 0.20% | 1.30% | |
Non-deductible expenses, percentage | 1.00% | 1.60% | 1.00% | |
Adjustments in respect of prior years, percentage | 0.90% | 5.80% | (2.70%) | |
Impact of UK bank levy being non-deductible, percentage | 0.40% | 1.90% | 1.00% | |
Impact of Barclays Bank PLC's overseas branches being taxed both locally and in the UK, percentage | 0.30% | 0.80% | 0.30% | |
Tax adjustments in respect of share-based payments, percentage | (0.10%) | 0.80% | (0.10%) | |
Changes in recognition of deferred tax and effect of unrecognised tax losses, percentage | (1.70%) | (4.00%) | (1.90%) | |
Tax relief on payments made under AT1 instruments, percentage | (1.80%) | (5.40%) | (3.60%) | |
Non-taxable gains and income, percentage | (4.50%) | (6.80%) | (6.00%) | |
Non-recurring items: | ||||
Remeasurement of UK deferred tax assets due to tax rate changes | £ (462) | £ (118) | £ 0 | |
Non-deductible provisions for UK customer redress | 0 | (7) | 263 | |
Non-deductible provisions for investigations and litigation | £ 0 | £ 5 | £ 0 | |
Non-recurring items, percentages [abstract] | ||||
Remeasurement of UK deferred tax assets due to tax rate changes, percentage | (5.60%) | (3.80%) | 0.00% | |
Non-deductible provisions for UK customer redress, percentage | 0.00% | (0.20%) | 6.10% | |
Non-deductible provisions for investigations and litigation, percentage | 0.00% | 0.20% | 0.00% | |
Tax charge | £ 1,138 | [2] | £ 604 | £ 1,003 |
Total tax charge, percentage | 13.90% | 19.70% | 23.00% | |
Weighted average | ||||
Tax, percentage [abstract] | ||||
Tax rate impact of profits/losses earned in territories with different statutory rates to the UK | 22.40% | 25.10% | 24.20% | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Tax - Narrative (Details)
Tax - Narrative (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Average effective tax rate | 13.90% | 19.70% | 23.00% | |
Applicable tax rate | 19.00% | 19.00% | 19.00% | |
Income tax credit relating to other comprehensive income | £ 0 | £ 5 | ||
Current tax relating to items credited directly to equity | 58 | 18 | ||
Deferred tax assets | 4,619 | [1] | 3,444 | |
Deferred tax liabilities | 37 | [1] | 15 | |
Unused tax credits for which no deferred tax asset recognised | 283 | 236 | ||
Temporary differences associated with investments in related entities for which deferred tax liabilities have not been recognised | 900 | 800 | ||
After more than 12 months | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 5,886 | 4,544 | ||
Deferred tax liabilities | 1,778 | 1,510 | ||
Within five years | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Unused tax credits for which no deferred tax asset recognised | 63 | 139 | ||
Within six to ten years | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Unused tax credits for which no deferred tax asset recognised | 370 | 236 | ||
Within eleven to twenty years | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Unused tax credits for which no deferred tax asset recognised | 10,529 | 7,271 | ||
Indefinitely | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Unused tax credits for which no deferred tax asset recognised | 11,873 | 13,267 | ||
Temporary differences | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deductible temporary differences for which no deferred tax asset is recognised | 110 | 125 | ||
Unused tax losses | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deductible temporary differences for which no deferred tax asset is recognised | 22,835 | 20,913 | ||
Capital losses | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deductible temporary differences for which no deferred tax asset is recognised | 3,981 | 3,947 | ||
US Intermediate Holding Company Tax Group ('IHC Tax Group') | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 1,004 | 1,001 | ||
US Intermediate Holding Company Tax Group ('IHC Tax Group') | Unused tax losses | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 1 | 0 | ||
US Intermediate Holding Company Tax Group ('IHC Tax Group') | Loss in current or prior year | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 301 | 330 | ||
Barclays Bank PLC | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 1,002 | 1,048 | ||
UK Tax Group | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 2,183 | 886 | ||
UK Tax Group | Unused tax losses | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 1,098 | 565 | ||
Other (outside the UK and US tax groups) | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 430 | 509 | ||
Other (outside the UK and US tax groups) | Unused tax losses | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 121 | 170 | ||
Other (outside the UK and US tax groups) | Loss in current or prior year | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 9 | 8 | ||
UK | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax expense (income) relating to tax rate changes or imposition of new taxes, other comprehensive income | £ 111 | 52 | ||
UK | Pro Forma | Changes in tax rates or tax laws enacted or announced | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax expense (income) relating to tax rate changes or imposition of new taxes | 346 | |||
Deferred tax expense (income) relating to tax rate changes or imposition of new taxes, other comprehensive income | £ (87) | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Tax - Deferred tax assets and l
Tax - Deferred tax assets and liabilities (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax asset | £ 4,619 | [1] | £ 3,444 |
Deferred tax liability | (37) | [1] | (15) |
Net deferred tax asset | 4,582 | 3,429 | |
UK Tax Group | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax asset | 2,183 | 886 | |
US Intermediate Holding Company Tax Group ('IHC Tax Group') | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax asset | 1,004 | 1,001 | |
US Branch Tax Group | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax asset | 1,002 | 1,048 | |
Other (outside the UK and US tax groups) | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax asset | £ 430 | £ 509 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Tax - Movements on deferred tax
Tax - Movements on deferred tax assets and liabilities during the year before offsetting (Details) £ in Millions, $ in Millions | 12 Months Ended | |||
Dec. 31, 2021GBP (£) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | Dec. 31, 2020USD ($) | |
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Assets | £ 6,364 | £ 4,979 | £ 4,449 | |
Liabilities | (1,782) | (1,550) | (1,182) | |
Net deferred tax asset | 4,582 | 3,429 | 3,267 | |
At 1 January | (3,429) | (3,267) | ||
Income statement | 596 | 682 | (11) | |
Other comprehensive income and reserves | 564 | (462) | ||
Other movements | (7) | (58) | ||
At 31 December | (4,582) | (3,429) | (3,267) | |
Share-based payments and deferred compensation | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Assets | 414 | 363 | 344 | |
Liabilities | 0 | 0 | 0 | |
Net deferred tax asset | 414 | 363 | 344 | |
At 1 January | (363) | (344) | ||
Income statement | 12 | 20 | ||
Other comprehensive income and reserves | 36 | 5 | ||
Other movements | 3 | (6) | ||
At 31 December | (414) | (363) | (344) | |
Other provisions | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Assets | 150 | 143 | 128 | |
Liabilities | 0 | 0 | 0 | |
Net deferred tax asset | 150 | 143 | 128 | |
At 1 January | (143) | (128) | ||
Income statement | 7 | 22 | ||
Other comprehensive income and reserves | 0 | 0 | ||
Other movements | 0 | (7) | ||
At 31 December | (150) | (143) | (128) | |
Retirement benefit obligations | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Assets | 40 | 43 | 38 | |
Liabilities | (1,674) | (826) | (640) | |
Net deferred tax asset | (1,634) | (783) | (602) | |
At 1 January | 783 | 602 | ||
Income statement | 5 | 6 | ||
Other comprehensive income and reserves | (855) | (191) | ||
Other movements | (1) | 4 | ||
At 31 December | 1,634 | 783 | 602 | |
Cash flow hedges | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Assets | 521 | 0 | 0 | |
Liabilities | 0 | (566) | (181) | |
Net deferred tax asset | 521 | (566) | (181) | |
At 1 January | 566 | 181 | ||
Income statement | 0 | 0 | ||
Other comprehensive income and reserves | 1,088 | (377) | ||
Other movements | (1) | (8) | ||
At 31 December | (521) | 566 | 181 | |
Fair value through other comprehensive income | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Assets | 155 | 0 | 119 | |
Liabilities | 0 | (38) | (18) | |
Net deferred tax asset | 155 | (38) | 101 | |
At 1 January | 38 | (101) | ||
Income statement | (6) | 0 | ||
Other comprehensive income and reserves | 198 | (137) | ||
Other movements | 1 | (2) | ||
At 31 December | (155) | 38 | (101) | |
Fixed asset timing differences | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Assets | 1,647 | 1,465 | 1,338 | |
Liabilities | (42) | (41) | (31) | $ (41) |
Net deferred tax asset | 1,605 | 1,424 | 1,307 | |
At 1 January | (1,424) | (1,307) | ||
Income statement | 184 | 129 | ||
Other comprehensive income and reserves | 0 | 0 | ||
Other movements | (3) | (12) | ||
At 31 December | (1,605) | (1,424) | (1,307) | |
Loan impairment allowance | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Assets | 693 | 666 | 501 | |
Liabilities | 0 | 0 | 0 | |
Net deferred tax asset | 693 | 666 | 501 | |
At 1 January | (666) | (501) | ||
Income statement | 39 | 156 | ||
Other comprehensive income and reserves | 0 | 0 | ||
Other movements | (12) | 9 | ||
At 31 December | (693) | (666) | (501) | |
Other temporary differences | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Assets | 1,524 | 1,564 | 1,458 | |
Liabilities | (66) | (79) | (312) | |
Net deferred tax asset | 1,458 | 1,485 | 1,146 | |
At 1 January | (1,485) | (1,146) | ||
Income statement | (130) | 134 | ||
Other comprehensive income and reserves | 97 | 238 | ||
Other movements | 6 | (33) | ||
At 31 December | (1,458) | (1,485) | (1,146) | |
Tax losses carried forward | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Assets | 1,220 | 735 | 523 | |
Liabilities | 0 | 0 | 0 | |
Net deferred tax asset | 1,220 | 735 | 523 | |
At 1 January | (735) | (523) | ||
Income statement | 485 | 215 | ||
Other comprehensive income and reserves | 0 | 0 | ||
Other movements | 0 | (3) | ||
At 31 December | £ (1,220) | £ (735) | £ (523) |
Earnings per share - Summary (D
Earnings per share - Summary (Details) - GBP (£) £ / shares in Units, £ in Millions, shares in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Earnings per share [abstract] | ||||
Profit attributable to ordinary equity holders of the parent | £ 6,205 | [1] | £ 1,526 | £ 2,461 |
Basic weighted average number of shares in issue (in shares) | 16,985 | 17,300 | 17,200 | |
Number of potential ordinary shares (in shares) | 435 | 368 | 282 | |
Diluted weighted average number of shares (in shares) | 17,420 | 17,668 | 17,482 | |
Basic earnings per ordinary share (in GBP per share) | £ 0.365 | [1] | £ 0.088 | £ 0.143 |
Diluted earnings per ordinary share (in GBP per share) | £ 0.356 | [1] | £ 0.086 | £ 0.141 |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Earnings per share - Narrative
Earnings per share - Narrative (Details) - £ / shares shares in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Number of potential ordinary shares (in shares) | 435 | 368 | 282 |
Weighted average number of ordinary shares outstanding (in shares) | 16,985 | 17,300 | 17,200 |
Bottom of range | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Strike price (in GBP per share) | £ 0.84 | ||
Top of range | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Strike price (in GBP per share) | £ 1.66 | ||
Employee share schemes | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Number of potential ordinary shares (in shares) | 688 | 719 | |
Employee share schemes | Weighted average | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
(Decrease) increase in number of shares outstanding (in shares) | (315) | 100 | |
Anti-dilutive | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Weighted average number of ordinary shares outstanding (in shares) | 5 | 69 |
Dividends on ordinary shares (D
Dividends on ordinary shares (Details) £ / shares in Units, £ in Millions, shares in Millions | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||
Jun. 30, 2021GBP (£) | Jun. 30, 2020GBP (£) | Dec. 31, 2021GBP (£)shareBuyback£ / sharesshares | Jun. 30, 2021GBP (£) | Dec. 31, 2020GBP (£) | Jun. 30, 2020GBP (£) | Dec. 31, 2021GBP (£)shareBuyback£ / sharesshares | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | May 05, 2021£ / shares | ||
Dividends recognised as distributions to owners of parent, relating to current year | £ 339 | £ 0 | |||||||||
Dividends paid, relating to prior years | £ 173 | £ 0 | |||||||||
Number of share buybacks | shareBuyback | 2 | 2 | |||||||||
Repurchase of shares | £ 1,275 | [1] | £ 1,056 | £ 2,668 | |||||||
Intention to initiate share buyback | Forecast | |||||||||||
Repurchase of shares | £ 1,000 | ||||||||||
Ordinary shares | |||||||||||
Dividends approved, per share (in GBP per share) | £ / shares | £ 0.04 | £ 0.06 | |||||||||
Par value per share (in GBP per share) | £ / shares | £ 0.25 | £ 0.25 | £ 0.25 | ||||||||
Ordinary shares in issue (in shares) | shares | 16,752 | 16,752 | |||||||||
Repurchase of shares | £ 500 | £ 700 | £ 0 | £ 0 | |||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Trading portfolio (Details)
Trading portfolio (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | £ 147,035 | [1] | £ 127,950 |
Trading portfolio liabilities | (54,169) | [1] | (47,405) |
Debt securities and other eligible bills | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | 50,864 | 56,482 | |
Trading portfolio liabilities | (34,957) | (30,102) | |
Equity securities | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | 83,113 | 62,192 | |
Trading portfolio liabilities | (19,212) | (17,303) | |
Traded loans | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | 12,525 | 8,348 | |
Trading portfolio liabilities | 0 | 0 | |
Commodities | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | 533 | 928 | |
Trading portfolio liabilities | £ 0 | £ 0 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Financial assets at fair valu_5
Financial assets at fair value through the income statement (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of financial assets [line items] | |||
Loans and advances | £ 361,451 | [1] | £ 342,632 |
Reverse repurchase agreements and other similar secured lending | 3,227 | [1] | 9,031 |
Other financial assets | 1,213 | 850 | |
Financial assets at fair value through the income statement | 191,972 | [1] | 175,151 |
Financial assets at fair value through the income statement | |||
Disclosure of financial assets [line items] | |||
Loans and advances | 38,667 | 30,879 | |
Debt securities | 2,305 | 1,693 | |
Equity securities | 5,875 | 4,620 | |
Reverse repurchase agreements and other similar secured lending | 145,014 | 137,616 | |
Other financial assets | 111 | 343 | |
Designated at fair value | |||
Disclosure of financial assets [line items] | |||
Loans and advances | 5,579 | 5,600 | |
Debt securities | 319 | 292 | |
Equity securities | 0 | 0 | |
Reverse repurchase agreements and other similar secured lending | 0 | 19 | |
Other financial assets | 0 | 0 | |
Financial assets at fair value through the income statement | 5,898 | 5,911 | |
Mandatorily at fair value | |||
Disclosure of financial assets [line items] | |||
Loans and advances | 33,088 | 25,279 | |
Debt securities | 1,986 | 1,401 | |
Equity securities | 5,875 | 4,620 | |
Reverse repurchase agreements and other similar secured lending | 145,014 | 137,597 | |
Other financial assets | 111 | 343 | |
Financial assets at fair value through the income statement | £ 186,074 | £ 169,240 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Financial assets at fair valu_6
Financial assets at fair value through the income statement - Credit risk of loans and advances designated at fair value and related credit derivatives (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Credit derivatives | Derivatives | ||
Disclosure of financial assets [line items] | ||
Value mitigated by related credit derivatives | £ 1,617 | £ 795 |
Changes in fair value during the year ended | (3) | 3 |
Cumulative changes in fair value from inception | (3) | 3 |
Loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Loans and advances designated at fair value, attributable to credit risk | 5,579 | 5,600 |
Changes in fair value during the year ended | 5 | (47) |
Cumulative changes in fair value from inception | £ (19) | £ (73) |
Derivative financial instrume_3
Derivative financial instruments - Narrative (Details) £ in Millions | 12 Months Ended | |
Dec. 31, 2021GBP (£)Hedges | Dec. 31, 2020GBP (£)Hedges | |
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Amounts reclassified in relation to cash flows affecting profit or loss | £ | £ 630 | £ 268 |
Bottom of range | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Hedging effectiveness | 80.00% | |
Top of range | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Hedging effectiveness | 125.00% | |
Central Counterparty Clearing House (CCP) | Derivatives | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Increase nominal amount | £ | £ 1,828,000 | |
Cash flow hedges | Foreign exchange risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Number of hedges | 36 | 29 |
Average rate of hedging instrument | 137.85% | 135.29% |
Fair value hedges | Interest rate risk | Fixed interest rate | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Number of hedges | 1,782 | 1,906 |
Average rate of hedging instrument | 1.88% | 1.87% |
Fair value hedges | Inflation risk | Fixed interest rate | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Number of hedges | 96 | 104 |
Average rate of hedging instrument | 0.51% | 0.63% |
Derivative financial instrume_4
Derivative financial instruments - Total Derivatives (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of risk management strategy related to hedge accounting [line items] | |||
Derivative financial assets | £ 262,572 | [1] | £ 302,446 |
Derivative liabilities | (256,883) | [1] | (300,775) |
Derivatives | |||
Disclosure of risk management strategy related to hedge accounting [line items] | |||
Notional contract amount | 48,032,325 | 43,359,755 | |
Fair value | |||
Disclosure of risk management strategy related to hedge accounting [line items] | |||
Derivative financial assets | 262,572 | 302,446 | |
Derivative liabilities | (256,883) | (300,775) | |
Derivatives held for risk management | Derivatives | |||
Disclosure of risk management strategy related to hedge accounting [line items] | |||
Notional contract amount | 219,551 | 189,784 | |
Derivatives held for risk management | Fair value | |||
Disclosure of risk management strategy related to hedge accounting [line items] | |||
Derivative assets held for held for risk management | 894 | 566 | |
Derivative liabilities held for risk management | (1,136) | (980) | |
Derivatives held for trading | Derivatives | |||
Disclosure of risk management strategy related to hedge accounting [line items] | |||
Notional contract amount | 47,812,774 | 43,169,971 | |
Derivatives held for trading | Fair value | |||
Disclosure of risk management strategy related to hedge accounting [line items] | |||
Derivative assets held for trading | 261,678 | 301,880 | |
Derivative liabilities held for trading | £ (255,747) | £ (299,795) | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Derivative financial instrume_5
Derivative financial instruments - Derivatives held for trading and risk management (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | £ 48,032,325 | £ 43,359,755 |
Derivatives held for trading | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 261,678 | 301,880 |
Derivative liabilities held for trading | (255,747) | (299,795) |
Derivatives held for trading | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 222,663 | 277,779 |
Derivative liabilities held for trading | (216,604) | (275,313) |
Derivatives held for trading | Fair value | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 2,968 | 2,231 |
Derivative liabilities held for trading | (2,862) | (2,315) |
Derivatives held for trading | Fair value | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 36,047 | 21,870 |
Derivative liabilities held for trading | (36,281) | (22,167) |
Derivatives held for trading | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 47,812,774 | 43,169,971 |
Derivatives held for trading | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 20,811,811 | 19,864,342 |
Derivatives held for trading | Derivatives | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 20,164,012 | 19,279,306 |
Derivatives held for trading | Derivatives | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 6,836,951 | 4,026,323 |
Derivatives held for trading | Foreign exchange derivatives | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 76,140 | 84,739 |
Derivative liabilities held for trading | (74,437) | (84,381) |
Derivatives held for trading | Foreign exchange derivatives | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 75,959 | 84,401 |
Derivative liabilities held for trading | (74,226) | (84,043) |
Derivatives held for trading | Foreign exchange derivatives | Fair value | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 171 | 335 |
Derivative liabilities held for trading | (208) | (335) |
Derivatives held for trading | Foreign exchange derivatives | Fair value | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 10 | 3 |
Derivative liabilities held for trading | (3) | (3) |
Derivatives held for trading | Foreign exchange derivatives | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 5,824,856 | 5,554,037 |
Derivatives held for trading | Foreign exchange derivatives | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 5,705,108 | 5,461,057 |
Derivatives held for trading | Foreign exchange derivatives | Derivatives | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 99,664 | 78,946 |
Derivatives held for trading | Foreign exchange derivatives | Derivatives | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 20,084 | 14,034 |
Derivatives held for trading | Interest rate derivatives | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 125,846 | 172,144 |
Derivative liabilities held for trading | (114,803) | (162,402) |
Derivatives held for trading | Interest rate derivatives | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 123,819 | 170,808 |
Derivative liabilities held for trading | (113,051) | (161,157) |
Derivatives held for trading | Interest rate derivatives | Fair value | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 1,122 | 965 |
Derivative liabilities held for trading | (845) | (885) |
Derivatives held for trading | Interest rate derivatives | Fair value | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 905 | 371 |
Derivative liabilities held for trading | (907) | (360) |
Derivatives held for trading | Interest rate derivatives | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 38,816,432 | 35,257,371 |
Derivatives held for trading | Interest rate derivatives | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 14,216,846 | 13,547,990 |
Derivatives held for trading | Interest rate derivatives | Derivatives | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 19,398,748 | 18,737,415 |
Derivatives held for trading | Interest rate derivatives | Derivatives | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 5,200,838 | 2,971,966 |
Derivatives held for trading | Credit derivatives | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 5,682 | 4,605 |
Derivative liabilities held for trading | (6,561) | (5,004) |
Derivatives held for trading | Credit derivatives | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 4,007 | 3,674 |
Derivative liabilities held for trading | (4,752) | (3,909) |
Derivatives held for trading | Credit derivatives | Fair value | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 1,675 | 931 |
Derivative liabilities held for trading | (1,809) | (1,095) |
Derivatives held for trading | Credit derivatives | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 1,272,104 | 847,845 |
Derivatives held for trading | Credit derivatives | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 606,504 | 384,900 |
Derivatives held for trading | Credit derivatives | Derivatives | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 665,600 | 462,945 |
Derivatives held for trading | Equity and stock index derivatives | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 51,723 | 38,972 |
Derivative liabilities held for trading | (57,642) | (46,615) |
Derivatives held for trading | Equity and stock index derivatives | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 18,822 | 18,807 |
Derivative liabilities held for trading | (24,468) | (26,094) |
Derivatives held for trading | Equity and stock index derivatives | Fair value | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 32,901 | 20,165 |
Derivative liabilities held for trading | (33,174) | (20,521) |
Derivatives held for trading | Equity and stock index derivatives | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 1,747,761 | 1,393,265 |
Derivatives held for trading | Equity and stock index derivatives | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 278,683 | 466,151 |
Derivatives held for trading | Equity and stock index derivatives | Derivatives | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 1,469,078 | 927,114 |
Derivatives held for trading | Commodity derivatives | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 2,287 | 1,420 |
Derivative liabilities held for trading | (2,304) | (1,393) |
Derivatives held for trading | Commodity derivatives | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 56 | 89 |
Derivative liabilities held for trading | (107) | (110) |
Derivatives held for trading | Commodity derivatives | Fair value | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 2,231 | 1,331 |
Derivative liabilities held for trading | (2,197) | (1,283) |
Derivatives held for trading | Commodity derivatives | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 151,621 | 117,453 |
Derivatives held for trading | Commodity derivatives | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 4,670 | 4,244 |
Derivatives held for trading | Commodity derivatives | Derivatives | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 146,951 | 113,209 |
Derivatives held for risk management | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for held for risk management | 894 | 566 |
Derivative liabilities held for risk management | (1,136) | (980) |
Derivatives held for risk management | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for held for risk management | 894 | 566 |
Derivative liabilities held for risk management | (1,125) | (980) |
Derivatives held for risk management | Fair value | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for held for risk management | 0 | 0 |
Derivative liabilities held for risk management | (11) | 0 |
Derivatives held for risk management | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 219,551 | 189,784 |
Derivatives held for risk management | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 19,283 | 20,936 |
Derivatives held for risk management | Derivatives | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 200,268 | 168,848 |
Derivatives held for risk management | Derivatives designated as cash flow hedges | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for held for risk management | 798 | 386 |
Derivative liabilities held for risk management | (3) | 0 |
Derivatives held for risk management | Derivatives designated as cash flow hedges | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 114,313 | 74,437 |
Derivatives held for risk management | Fair value hedges | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for held for risk management | 59 | 155 |
Derivative liabilities held for risk management | (1,129) | (980) |
Derivatives held for risk management | Fair value hedges | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 102,815 | 114,556 |
Derivatives held for risk management | Derivatives designated as hedges of net investments | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for held for risk management | 37 | 25 |
Derivative liabilities held for risk management | (4) | 0 |
Derivatives held for risk management | Derivatives designated as hedges of net investments | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 2,423 | 791 |
Derivatives held for risk management | Foreign exchange derivatives | Derivatives designated as cash flow hedges | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for held for risk management | 798 | 351 |
Derivative liabilities held for risk management | 0 | 0 |
Derivatives held for risk management | Foreign exchange derivatives | Derivatives designated as cash flow hedges | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 7,592 | 6,596 |
Derivatives held for risk management | Foreign exchange derivatives | Derivatives designated as hedges of net investments | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for held for risk management | 37 | 25 |
Derivative liabilities held for risk management | (4) | 0 |
Derivatives held for risk management | Foreign exchange derivatives | Derivatives designated as hedges of net investments | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 2,423 | 791 |
Derivatives held for risk management | Interest rate derivatives | Derivatives designated as cash flow hedges | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for held for risk management | 0 | 35 |
Derivative liabilities held for risk management | (3) | 0 |
Derivatives held for risk management | Interest rate derivatives | Derivatives designated as cash flow hedges | Fair value | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for held for risk management | 0 | 0 |
Derivative liabilities held for risk management | 0 | 0 |
Derivatives held for risk management | Interest rate derivatives | Derivatives designated as cash flow hedges | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 788 | 2,433 |
Derivatives held for risk management | Interest rate derivatives | Derivatives designated as cash flow hedges | Derivatives | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 105,933 | 65,408 |
Derivatives held for risk management | Interest rate derivatives | Fair value hedges | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for held for risk management | 59 | 155 |
Derivative liabilities held for risk management | (1,118) | (980) |
Derivatives held for risk management | Interest rate derivatives | Fair value hedges | Fair value | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for held for risk management | 0 | 0 |
Derivative liabilities held for risk management | (11) | 0 |
Derivatives held for risk management | Interest rate derivatives | Fair value hedges | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 8,480 | 11,116 |
Derivatives held for risk management | Interest rate derivatives | Fair value hedges | Derivatives | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | £ 94,335 | £ 103,440 |
Derivative financial instrume_6
Derivative financial instruments - The significant hedge accounting exposures impacted by the IBOR reform (Details) - IBOR reform £ / shares in Millions, £ in Millions | Dec. 31, 2021GBP (£)£ / shares |
Disclosure of risk management strategy related to hedge accounting [line items] | |
Nominal amount of hedged items directly impacted by IBOR reform | £ 35,886 |
Nominal amount of hedging instruments directly impacted by IBOR reform | 25,598 |
GBP London Interbank Offered rate (LIBOR) | |
Disclosure of risk management strategy related to hedge accounting [line items] | |
Nominal amount of hedged items directly impacted by IBOR reform | £ 10,032 |
Nominal amount of hedging instruments directly impacted by IBOR reform | 200 |
USD LIBOR | |
Disclosure of risk management strategy related to hedge accounting [line items] | |
Nominal amount of hedged items directly impacted by IBOR reform | £ 25,744 |
Nominal amount of hedging instruments directly impacted by IBOR reform | 25,288 |
Singapore Swap Offered Rate (SOR) | |
Disclosure of risk management strategy related to hedge accounting [line items] | |
Nominal amount of hedged items directly impacted by IBOR reform | £ 110 |
Nominal amount of hedging instruments directly impacted by IBOR reform | £ / shares | 110 |
Derivative financial instrume_7
Derivative financial instruments - Hedged items in fair value hedges (Details) - Fair value hedges - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Liabilities | ||
Hedged Items, net | £ 6,833 | £ 17,841 |
Accumulated fair value adjustment included in carrying amount | 514 | 1,406 |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship | (556) | (320) |
Change in fair value used as a basis to determine ineffectiveness | (1,394) | 1,745 |
Hedge ineffectiveness recognised in the income statements | (18) | (42) |
Hedged assets | ||
Assets | ||
Carrying amount, hedged assets | 55,084 | 68,279 |
Accumulated fair value adjustment included in carrying amount, assets | 1,598 | 4,265 |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship, assets | (642) | (296) |
Liabilities | ||
Change in fair value used as a basis to determine ineffectiveness | (3,000) | 3,211 |
Hedge ineffectiveness recognised in the income statements | (66) | (98) |
Hedged assets | Debt securities classified at amortised cost | Interest rate risk | ||
Assets | ||
Carrying amount, hedged assets | 1,378 | 1,440 |
Accumulated fair value adjustment included in carrying amount, assets | (39) | 23 |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship, assets | 0 | 0 |
Liabilities | ||
Change in fair value used as a basis to determine ineffectiveness | (75) | 18 |
Hedge ineffectiveness recognised in the income statements | 18 | 7 |
Hedged assets | Debt securities classified at amortised cost | Inflation risk | ||
Assets | ||
Carrying amount, hedged assets | 4,087 | 4,071 |
Accumulated fair value adjustment included in carrying amount, assets | 400 | (43) |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship, assets | 0 | 0 |
Liabilities | ||
Change in fair value used as a basis to determine ineffectiveness | (16) | 453 |
Hedge ineffectiveness recognised in the income statements | 1 | (3) |
Hedged assets | Fair value through other comprehensive income | Interest rate risk | ||
Assets | ||
Carrying amount, hedged assets | 31,485 | 41,544 |
Accumulated fair value adjustment included in carrying amount, assets | (258) | 1,284 |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship, assets | 32 | 351 |
Liabilities | ||
Change in fair value used as a basis to determine ineffectiveness | (1,436) | 825 |
Hedge ineffectiveness recognised in the income statements | (39) | 13 |
Hedged assets | Fair value through other comprehensive income | Inflation risk | ||
Assets | ||
Carrying amount, hedged assets | 9,066 | 10,821 |
Accumulated fair value adjustment included in carrying amount, assets | 470 | 367 |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship, assets | (32) | (9) |
Liabilities | ||
Change in fair value used as a basis to determine ineffectiveness | 161 | 307 |
Hedge ineffectiveness recognised in the income statements | (13) | (1) |
Loans and advances at amortised cost | Financial assets at amortised cost | Interest rate risk | ||
Assets | ||
Carrying amount, hedged assets | 8,512 | 9,858 |
Accumulated fair value adjustment included in carrying amount, assets | 671 | 2,289 |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship, assets | (642) | (638) |
Liabilities | ||
Change in fair value used as a basis to determine ineffectiveness | (1,643) | 1,583 |
Hedge ineffectiveness recognised in the income statements | (33) | (111) |
Loans and advances at amortised cost | Financial assets at amortised cost | Inflation risk | ||
Assets | ||
Carrying amount, hedged assets | 556 | 545 |
Accumulated fair value adjustment included in carrying amount, assets | 354 | 345 |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship, assets | 0 | 0 |
Liabilities | ||
Change in fair value used as a basis to determine ineffectiveness | 9 | 25 |
Hedge ineffectiveness recognised in the income statements | 0 | (3) |
Hedged liabilities | ||
Liabilities | ||
Carrying amount, hedged liabilities | (48,251) | (50,438) |
Accumulated fair value adjustment included in carrying amount, liabilities | (1,084) | (2,859) |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship, liabilities | 86 | (24) |
Change in fair value used as a basis to determine ineffectiveness | 1,606 | (1,466) |
Hedge ineffectiveness recognised in the income statements | 48 | 56 |
Debt securities classified at amortised cost | Interest rate risk | ||
Liabilities | ||
Carrying amount, hedged liabilities | (48,251) | (50,438) |
Accumulated fair value adjustment included in carrying amount, liabilities | (1,084) | (2,859) |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship, liabilities | 86 | (24) |
Change in fair value used as a basis to determine ineffectiveness | 1,606 | (1,466) |
Hedge ineffectiveness recognised in the income statements | £ 48 | £ 56 |
Derivative financial instrume_8
Derivative financial instruments - Hedging instruments which are carried on the Group balance sheet (Fair value hedges) (Details) £ / shares in Millions, £ in Millions | 12 Months Ended | |
Dec. 31, 2021GBP (£)£ / shares | Dec. 31, 2020GBP (£)£ / shares | |
Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | 25,598 | |
Fair value hedges | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 102,815 | 114,556 |
Change in fair value used as a basis to determine ineffectiveness | £ 1,412 | £ (1,703) |
Fair value hedges | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 17,201 | 31,559 |
Fair value hedges | Interest rate risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 92,447 | 103,623 |
Change in fair value used as a basis to determine ineffectiveness | £ 1,554 | £ (925) |
Fair value hedges | Interest rate risk | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 15,577 | 30,072 |
Fair value hedges | Inflation risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 10,368 | 10,933 |
Change in fair value used as a basis to determine ineffectiveness | £ (142) | £ (778) |
Fair value hedges | Inflation risk | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 1,624 | 1,487 |
Derivatives | Fair value hedges | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | £ 59 | £ 155 |
Hedging instrument, liabilities | (1,129) | (980) |
Derivatives | Fair value hedges | Interest rate risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | 54 | 120 |
Hedging instrument, liabilities | (11) | (166) |
Derivatives | Fair value hedges | Inflation risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | 5 | 35 |
Hedging instrument, liabilities | (1,118) | (815) |
Loan liabilities | Fair value hedges | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Fair value hedges | Interest rate risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Fair value hedges | Inflation risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | £ 0 | £ 0 |
Derivative financial instrume_9
Derivative financial instruments - The expected notional values of current hedging instruments in future years (Details) - Fair value hedges - £ / shares £ / shares in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 102,815 | 114,556 |
Interest rate risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 92,447 | 103,623 |
Inflation risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 10,368 | 10,933 |
2021 | Interest rate risk | Fixed interest rate | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 92,447 | |
2021 | Inflation risk | Fixed interest rate | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 10,368 | |
2022 | Interest rate risk | Fixed interest rate | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 87,025 | |
2022 | Inflation risk | Fixed interest rate | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 9,874 | |
2023 | Interest rate risk | Fixed interest rate | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 79,475 | |
2023 | Inflation risk | Fixed interest rate | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 8,999 | |
2024 | Interest rate risk | Fixed interest rate | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 67,206 | |
2024 | Inflation risk | Fixed interest rate | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 6,503 | |
2025 | Interest rate risk | Fixed interest rate | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 55,080 | |
2025 | Inflation risk | Fixed interest rate | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 5,445 | |
2026 | Interest rate risk | Fixed interest rate | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 44,801 | |
2026 | Inflation risk | Fixed interest rate | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 3,472 | |
2027 and later | Interest rate risk | Fixed interest rate | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 37,652 | |
2027 and later | Inflation risk | Fixed interest rate | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 1,159 |
Derivative financial instrum_10
Derivative financial instruments - Hedged items in cash flow hedges of net investments in foreign operations (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of detailed information about hedged items [line items] | |||
Balance in currency translation reserve for continuing hedges | £ 2,740 | £ 2,871 | £ 3,344 |
Cash flow hedges | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in value of hedged item used as the basis for recognising ineffectiveness | 2,273 | (1,513) | |
Balance in cash flow hedging reserve for continuing hedges | 1,847 | (743) | |
Balance in currency translation reserve for continuing hedges | 0 | 0 | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | (504) | (1,370) | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 0 | 0 | |
Hedging gains or losses recognised in other comprehensive income | 2,273 | (1,513) | |
Hedge ineffectiveness recognised in the income statementa | (367) | 28 | |
Cash flow hedges | Loans and advances at amortised cost | Financial assets at amortised cost | Interest rate risk | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in value of hedged item used as the basis for recognising ineffectiveness | 2,465 | (1,124) | |
Balance in cash flow hedging reserve for continuing hedges | 1,536 | (598) | |
Balance in currency translation reserve for continuing hedges | 0 | 0 | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | (492) | (1,370) | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 0 | 0 | |
Hedging gains or losses recognised in other comprehensive income | 2,465 | (1,124) | |
Hedge ineffectiveness recognised in the income statementa | (347) | 27 | |
Cash flow hedges | Loans and advances at amortised cost | Financial assets at amortised cost | Foreign exchange risk | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in value of hedged item used as the basis for recognising ineffectiveness | (88) | (70) | |
Balance in cash flow hedging reserve for continuing hedges | (16) | (15) | |
Balance in currency translation reserve for continuing hedges | 0 | 0 | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | 0 | 0 | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 0 | 0 | |
Hedging gains or losses recognised in other comprehensive income | (88) | (70) | |
Hedge ineffectiveness recognised in the income statementa | 1 | 0 | |
Cash flow hedges | Debt securities classified at amortised cost | Financial assets at amortised cost | Foreign exchange risk | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in value of hedged item used as the basis for recognising ineffectiveness | (356) | (278) | |
Balance in cash flow hedging reserve for continuing hedges | 123 | (65) | |
Balance in currency translation reserve for continuing hedges | 0 | 0 | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | 0 | 0 | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 0 | 0 | |
Hedging gains or losses recognised in other comprehensive income | (356) | (278) | |
Hedge ineffectiveness recognised in the income statementa | 1 | 0 | |
Cash flow hedges | Debt securities classified at amortised cost | Financial assets at amortised cost | Inflation risk | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in value of hedged item used as the basis for recognising ineffectiveness | 252 | (41) | |
Balance in cash flow hedging reserve for continuing hedges | 204 | (65) | |
Balance in currency translation reserve for continuing hedges | 0 | 0 | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | (12) | 0 | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 0 | 0 | |
Hedging gains or losses recognised in other comprehensive income | 252 | (41) | |
Hedge ineffectiveness recognised in the income statementa | (22) | 1 | |
Hedge of net investment in foreign operations | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in value of hedged item used as the basis for recognising ineffectiveness | 18 | (266) | |
Balance in cash flow hedging reserve for continuing hedges | 0 | 0 | |
Balance in currency translation reserve for continuing hedges | 1,087 | 902 | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | 0 | 0 | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 186 | 186 | |
Hedging gains or losses recognised in other comprehensive income | 18 | (266) | |
Hedge ineffectiveness recognised in the income statementa | 0 | 0 | |
Hedge of net investment in foreign operations | USD foreign operations | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in value of hedged item used as the basis for recognising ineffectiveness | 138 | (240) | |
Balance in cash flow hedging reserve for continuing hedges | 0 | 0 | |
Balance in currency translation reserve for continuing hedges | 943 | 857 | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | 0 | 0 | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 0 | 0 | |
Hedging gains or losses recognised in other comprehensive income | 138 | (240) | |
Hedge ineffectiveness recognised in the income statementa | 0 | 0 | |
Hedge of net investment in foreign operations | EUR foreign operations | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in value of hedged item used as the basis for recognising ineffectiveness | (117) | (17) | |
Balance in cash flow hedging reserve for continuing hedges | 0 | 0 | |
Balance in currency translation reserve for continuing hedges | 100 | (2) | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | 0 | 0 | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 0 | 0 | |
Hedging gains or losses recognised in other comprehensive income | (117) | (17) | |
Hedge ineffectiveness recognised in the income statementa | 0 | 0 | |
Hedge of net investment in foreign operations | Other foreign operations | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in value of hedged item used as the basis for recognising ineffectiveness | (3) | (9) | |
Balance in cash flow hedging reserve for continuing hedges | 0 | 0 | |
Balance in currency translation reserve for continuing hedges | 44 | 47 | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | 0 | 0 | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 186 | 186 | |
Hedging gains or losses recognised in other comprehensive income | (3) | (9) | |
Hedge ineffectiveness recognised in the income statementa | £ 0 | £ 0 |
Derivative financial instrum_11
Derivative financial instruments - Hedging instruments which are carried on the Group balance sheet (Cash flow hedges and hedges of net investments in foreign operations) (Details) £ / shares in Millions, £ in Millions | 12 Months Ended | |
Dec. 31, 2021GBP (£)£ / shares | Dec. 31, 2020GBP (£)£ / shares | |
Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | 25,598 | |
Cash flow hedges | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 114,313 | 74,437 |
Change in fair value used as a basis to determine ineffectiveness | £ (2,640) | £ 1,541 |
Cash flow hedges | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 8,397 | 18,195 |
Cash flow hedges | Interest rate risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 102,629 | 65,042 |
Change in fair value used as a basis to determine ineffectiveness | £ (2,812) | £ 1,151 |
Cash flow hedges | Interest rate risk | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 8,397 | 18,195 |
Cash flow hedges | Foreign exchange risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 7,592 | 6,596 |
Change in fair value used as a basis to determine ineffectiveness | £ 446 | £ 348 |
Cash flow hedges | Foreign exchange risk | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 0 | 0 |
Cash flow hedges | Inflation risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 4,092 | 2,799 |
Change in fair value used as a basis to determine ineffectiveness | £ (274) | £ 42 |
Cash flow hedges | Inflation risk | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 0 | 0 |
Derivatives designated as hedges of net investments | Foreign exchange risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 13,635 | 9,451 |
Change in fair value used as a basis to determine ineffectiveness | £ (239) | £ 265 |
Derivatives designated as hedges of net investments | Foreign exchange risk | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 0 | 0 |
Derivatives | Cash flow hedges | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | £ 798 | £ 386 |
Hedging instrument, liabilities | (3) | 0 |
Derivatives | Cash flow hedges | Interest rate risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | 0 | 33 |
Hedging instrument, liabilities | 0 | 0 |
Derivatives | Cash flow hedges | Foreign exchange risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | 798 | 351 |
Hedging instrument, liabilities | 0 | 0 |
Derivatives | Cash flow hedges | Inflation risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | 0 | 2 |
Hedging instrument, liabilities | (3) | 0 |
Derivatives | Derivatives designated as hedges of net investments | Foreign exchange risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | 37 | 25 |
Hedging instrument, liabilities | (4) | 0 |
Loan liabilities | Cash flow hedges | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Cash flow hedges | Interest rate risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Cash flow hedges | Foreign exchange risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Cash flow hedges | Inflation risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Derivatives designated as hedges of net investments | Foreign exchange risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | £ (11,212) | £ (8,660) |
Derivative financial instrum_12
Derivative financial instruments - Effect on the income statement and OCI of recycling amounts in respect of Cash flow hedges and Net investment hedges of foreign operations (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of information about amounts that affected statement of comprehensive income as result of hedge accounting [line items] | ||
Amounts reclassified in relation to cash flows affecting profit or loss | £ 630 | £ 268 |
Recycled to other income | ||
Disclosure of information about amounts that affected statement of comprehensive income as result of hedge accounting [line items] | ||
Amounts reclassified in relation to cash flows affecting profit or loss | 0 | 0 |
Amount recycled from OCI due to sale of investment or cash flows no longer expected to occur, hedges of net investments in foreign operations | (26) | (4) |
Interest rate risk | Recycled to net interest income | ||
Disclosure of information about amounts that affected statement of comprehensive income as result of hedge accounting [line items] | ||
Amount recycled from OCI due to hedged item affecting income statement, cash flow hedges | 541 | 489 |
Amount recycled from OCI due to sale of investment or cash flows no longer expected to occur, cash flow hedges | 2 | 17 |
Foreign exchange risk | Recycled to net interest income | ||
Disclosure of information about amounts that affected statement of comprehensive income as result of hedge accounting [line items] | ||
Amounts reclassified in relation to cash flows affecting profit or loss | 630 | 268 |
Amount recycled from OCI due to sale of investment or cash flows no longer expected to occur, hedges of net investments in foreign operations | £ 0 | £ 0 |
Derivative financial instrum_13
Derivative financial instruments - Reconciliation of movement of reserves (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Reconciliation of hedging reserve | ||||
Reserve of cash flow hedges, beginning of period | £ 1,575 | £ 1,002 | ||
Currency translation movements | (7) | 50 | ||
Hedging gains/(losses) for the year | (2,273) | 1,249 | ||
Amounts reclassified in relation to cash flows affecting profit or loss | (1,173) | [1] | (510) | £ (277) |
Tax | 1,025 | [1] | (216) | (105) |
Reserve of cash flow hedges, end of period | (853) | 1,575 | 1,002 | |
Reconciliation of currency translation reserve [Roll Forward] | ||||
Currency translation reserve, beginning of period | 2,871 | 3,344 | ||
Currency translation movements | (139) | (743) | ||
Hedging gains/(losses) for the year | (18) | 266 | ||
Amounts reclassified in relation to cash flows affecting profit or loss | 26 | 4 | ||
Tax | 0 | 0 | ||
Currency translation reserve, end of period | £ 2,740 | £ 2,871 | £ 3,344 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details |
Financial assets at fair valu_7
Financial assets at fair value through other comprehensive income (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of financial assets [line items] | |||
Financial assets at fair value through other comprehensive income | £ 61,753 | [1] | £ 78,688 |
Loans and advances | |||
Disclosure of financial assets [line items] | |||
Financial assets at fair value through other comprehensive income | 53 | 191 | |
Debt securities and other eligible bills | |||
Disclosure of financial assets [line items] | |||
Financial assets at fair value through other comprehensive income | 60,798 | 77,736 | |
Equity securities | |||
Disclosure of financial assets [line items] | |||
Financial assets at fair value through other comprehensive income | £ 902 | £ 761 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Financial assets at fair valu_8
Financial assets at fair value through other comprehensive income - Narrative (Details) R / shares in Units, £ in Millions, shares in Millions | Sep. 30, 2022 | Apr. 21, 2022GBP (£) | Apr. 21, 2022ZAR (R)R / sharesshares | Jun. 30, 2022 | Dec. 31, 2021GBP (£) | [1] | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) |
Disclosure of financial assets [line items] | ||||||||
Proceeds from sales of investments | £ 3,757 | £ 8,480 | £ 3,590 | |||||
South African Rand | ||||||||
Disclosure of financial assets [line items] | ||||||||
Exchange rate | R | 20.04 | |||||||
Forecast | ||||||||
Disclosure of financial assets [line items] | ||||||||
Potential increase in capital ratio | (0.30%) | 0.10% | ||||||
Absa Group Limited | Other disposals of assets | ||||||||
Disclosure of financial assets [line items] | ||||||||
Number of shares sold (in shares) | shares | 63 | |||||||
Number of shares sold as % of total shares | 7.40% | |||||||
Price per share (in ZAR per share) | R / shares | R 164 | |||||||
Proceeds from sales of investments | £ 516 | R 10,300,000,000 | ||||||
Loss on disposals of investments | £ 42 | |||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Financial liabilities designa_3
Financial liabilities designated at fair value (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of financial liabilities [line items] | |||
Debt securities | £ 98,867 | [1] | £ 75,796 |
Repurchase agreements and other similar secured borrowing | 28,352 | [1] | 14,174 |
Other financial liabilities | 6,301 | 4,969 | |
Financial liabilities designated at fair value | 250,960 | [1] | 249,765 |
Cumulative own credit net loss recognised | 960 | 954 | |
Contractual amount due on maturity | |||
Disclosure of financial liabilities [line items] | |||
Debt securities | 61,946 | 57,650 | |
Deposits | 29,673 | 22,107 | |
Repurchase agreements and other similar secured borrowing | 168,129 | 177,389 | |
Other financial liabilities | 7 | 251 | |
Financial liabilities designated at fair value | 259,755 | 257,397 | |
Fair value | |||
Disclosure of financial liabilities [line items] | |||
Debt securities | 53,647 | 50,437 | |
Deposits | 29,246 | 21,706 | |
Repurchase agreements and other similar secured borrowing | 168,060 | 177,371 | |
Other financial liabilities | 7 | 251 | |
Financial liabilities designated at fair value | £ 250,960 | £ 249,765 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Fair value of financial instr_3
Fair value of financial instruments - Assets and liabilities held at fair value disaggregated by valuation technique (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Assets | |||
Trading portfolio assets | £ 147,035 | [1] | £ 127,950 |
Financial assets at fair value through the income statement | 191,972 | [1] | 175,151 |
Derivative financial assets | 262,572 | [1] | 302,446 |
Financial assets at fair value through other comprehensive income | 61,753 | [1] | 78,688 |
Liabilities | |||
Trading portfolio liabilities | (54,169) | [1] | (47,405) |
Financial liabilities designated at fair value | (250,960) | [1] | (249,765) |
Derivative financial liabilities | (256,883) | [1] | (300,775) |
Fair value | |||
Assets | |||
Trading portfolio assets | 147,035 | 127,950 | |
Financial assets at fair value through the income statement | 191,972 | 175,151 | |
Derivative financial assets | 262,572 | 302,446 | |
Financial assets at fair value through other comprehensive income | 61,753 | 78,688 | |
Investment property | 7 | 10 | |
Total assets | 663,339 | 684,245 | |
Liabilities | |||
Trading portfolio liabilities | (54,169) | (47,405) | |
Financial liabilities designated at fair value | (250,960) | (249,765) | |
Derivative financial liabilities | (256,883) | (300,775) | |
Total liabilities | (562,012) | (597,945) | |
Level 1 | Fair value | |||
Assets | |||
Trading portfolio assets | 80,926 | 60,671 | |
Financial assets at fair value through the income statement | 5,093 | 4,503 | |
Derivative financial assets | 6,150 | 9,155 | |
Financial assets at fair value through other comprehensive income | 22,009 | 19,792 | |
Investment property | 0 | 0 | |
Total assets | 114,178 | 94,121 | |
Liabilities | |||
Trading portfolio liabilities | (27,529) | (24,391) | |
Financial liabilities designated at fair value | (174) | (159) | |
Derivative financial liabilities | (6,571) | (8,762) | |
Total liabilities | (34,274) | (33,312) | |
Level 2 | Fair value | |||
Assets | |||
Trading portfolio assets | 63,828 | 65,416 | |
Financial assets at fair value through the income statement | 177,167 | 162,142 | |
Derivative financial assets | 252,412 | 288,822 | |
Financial assets at fair value through other comprehensive income | 39,706 | 58,743 | |
Investment property | 0 | 0 | |
Total assets | 533,113 | 575,123 | |
Liabilities | |||
Trading portfolio liabilities | (26,613) | (22,986) | |
Financial liabilities designated at fair value | (250,376) | (249,251) | |
Derivative financial liabilities | (244,253) | (285,774) | |
Total liabilities | (521,242) | (558,011) | |
Level 3 | |||
Assets | |||
Total assets | 16,048 | 15,001 | |
Liabilities | |||
Total liabilities | (6,496) | (6,622) | |
Level 3 | Fair value | |||
Assets | |||
Trading portfolio assets | 2,281 | 1,863 | |
Financial assets at fair value through the income statement | 9,712 | 8,506 | |
Derivative financial assets | 4,010 | 4,469 | |
Financial assets at fair value through other comprehensive income | 38 | 153 | |
Investment property | 7 | 10 | |
Total assets | 16,048 | 15,001 | |
Liabilities | |||
Trading portfolio liabilities | (27) | (28) | |
Financial liabilities designated at fair value | (410) | (355) | |
Derivative financial liabilities | (6,059) | (6,239) | |
Total liabilities | £ (6,496) | £ (6,622) | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Fair value of financial instr_4
Fair value of financial instruments - Assets and liabilities held at fair value disaggregated by product type (Details) - Level 3 - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of detailed information about financial instruments [line items] | ||
Assets | £ (16,048) | £ (15,001) |
Liabilities | (6,496) | (6,622) |
Asset backed securities | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | (558) | (767) |
Liabilities | 0 | (24) |
Corporate debt | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | (1,205) | (698) |
Liabilities | (21) | (3) |
Reverse repurchase and repurchase agreements | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | (13) | 0 |
Liabilities | (172) | (174) |
Non-asset backed loans | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | (6,405) | (6,394) |
Liabilities | 0 | 0 |
Equity cash products | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | (393) | (542) |
Liabilities | 0 | 0 |
Private equity investments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | (1,095) | (873) |
Liabilities | (6) | (14) |
Other | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | (2,369) | (1,276) |
Liabilities | (238) | (186) |
Interest rate derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | (1,091) | (1,613) |
Liabilities | (1,351) | (1,615) |
Foreign exchange derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | (376) | (144) |
Liabilities | (374) | (143) |
Credit derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | (323) | (196) |
Liabilities | (709) | (351) |
Equity derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | (2,220) | (2,498) |
Liabilities | £ (3,625) | £ (4,112) |
Fair value of financial instr_5
Fair value of financial instruments - Analysis of movements in Level 3 assets and liabilities (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | ||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Derivative financial assets | £ 262,572 | [1] | £ 302,446 |
Derivative financial instruments | 256,883 | [1] | 300,775 |
Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 15,001 | ||
Ending balance, financial assets | 16,048 | 15,001 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (6,622) | ||
Ending balance, financial liabilities | (6,496) | (6,622) | |
Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Beginning balance, Assets (liabilities) net | 8,379 | 10,010 | |
Purchases, fair value measurement, assets (liabilities) net | (14,925) | (6,580) | |
Sales, fair value measurement, assets (liabilities) net | (12,488) | (7,177) | |
Issues, fair value measurement, assets (liabilities) net | 101 | 21 | |
Settlements, fair value measurement, assets (liabilities) net | (952) | (1,189) | |
Gains (losses) recognised in other comprehensive income, fair value measurement, assets (liabilities) net | (2) | (4) | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | (752) | (455) | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | (572) | (411) | |
Ending balance, Assets (liabilities) net | 9,552 | 8,379 | |
Derivative financial assets | 4,010 | 4,469 | |
Derivative financial instruments | 6,059 | 6,239 | |
Recurring fair value measurement | Level 3 | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (403) | 268 | |
Recurring fair value measurement | Level 3 | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 14 | (132) | |
Recurring fair value measurement | Investment property | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 10 | 13 | |
Purchases, fair value measurement, assets | 0 | 0 | |
Sales, fair value measurement, assets | (2) | (2) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | 0 | 0 | |
Total gains or (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | |
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | |
Ending balance, financial assets | 7 | 10 | |
Recurring fair value measurement | Investment property | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Recurring fair value measurement | Investment property | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | (1) | (1) | |
Recurring fair value measurement | Net derivative financial instruments | Level 3 | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Beginning balance, Assets (liabilities) net | (1,770) | (834) | |
Purchases, fair value measurement, assets (liabilities) net | 129 | 807 | |
Sales, fair value measurement, assets (liabilities) net | 8 | (31) | |
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | |
Settlements, fair value measurement, assets (liabilities) net | 85 | (160) | |
Gains (losses) recognised in other comprehensive income, fair value measurement, assets (liabilities) net | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | (107) | 71 | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | (123) | 117 | |
Ending balance, Assets (liabilities) net | (2,049) | (1,770) | |
Recurring fair value measurement | Net derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (227) | 16 | |
Recurring fair value measurement | Net derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | |
Trading portfolio liabilities | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (28) | 0 | |
Purchases, fair value measurement, liabilities | (5) | (27) | |
Sales, fair value measurement, liabilities | (23) | 0 | |
Issues, fair value measurement, liabilities | 0 | 0 | |
Settlements, fair value measurement, liabilities | 0 | 0 | |
Total gains or (losses) recognised in OCI, liabilities | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, liabilities | (12) | 0 | |
Transfers out of Level 3 of fair value hierarchy, liabilities | (1) | 0 | |
Ending balance, financial liabilities | (27) | (28) | |
Trading portfolio liabilities | Recurring fair value measurement | Level 3 | Financial liabilities at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, liabilities | (6) | (1) | |
Trading portfolio liabilities | Recurring fair value measurement | Level 3 | Financial liabilities at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, liabilities | 0 | 0 | |
Financial liabilities designated at fair value | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (355) | (362) | |
Purchases, fair value measurement, liabilities | (4) | 0 | |
Sales, fair value measurement, liabilities | 0 | (3) | |
Issues, fair value measurement, liabilities | (101) | (21) | |
Settlements, fair value measurement, liabilities | 66 | 1 | |
Total gains or (losses) recognised in OCI, liabilities | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, liabilities | (68) | (38) | |
Transfers out of Level 3 of fair value hierarchy, liabilities | (32) | (38) | |
Ending balance, financial liabilities | (410) | (355) | |
Financial liabilities designated at fair value | Recurring fair value measurement | Level 3 | Financial liabilities at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, liabilities | 21 | 20 | |
Financial liabilities designated at fair value | Recurring fair value measurement | Level 3 | Financial liabilities at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, liabilities | (1) | 4 | |
Asset backed securities | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Derivative financial assets | 0 | 0 | |
Derivative financial instruments | 0 | 0 | |
Asset backed securities | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 767 | ||
Ending balance, financial assets | 558 | 767 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (24) | ||
Ending balance, financial liabilities | 0 | (24) | |
Interest rate derivatives | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 1,613 | ||
Ending balance, financial assets | 1,091 | 1,613 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (1,615) | ||
Ending balance, financial liabilities | (1,351) | (1,615) | |
Interest rate derivatives | Recurring fair value measurement | Net derivative financial instruments | Level 3 | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Beginning balance, Assets (liabilities) net | (2) | (206) | |
Purchases, fair value measurement, assets (liabilities) net | (20) | (17) | |
Sales, fair value measurement, assets (liabilities) net | 0 | (12) | |
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | |
Settlements, fair value measurement, assets (liabilities) net | 105 | 85 | |
Gains (losses) recognised in other comprehensive income, fair value measurement, assets (liabilities) net | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | (90) | 18 | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | (218) | 23 | |
Ending balance, Assets (liabilities) net | (260) | (2) | |
Interest rate derivatives | Recurring fair value measurement | Net derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (255) | 109 | |
Interest rate derivatives | Recurring fair value measurement | Net derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | |
Foreign exchange derivatives | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 144 | ||
Ending balance, financial assets | 376 | 144 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (143) | ||
Ending balance, financial liabilities | (374) | (143) | |
Foreign exchange derivatives | Recurring fair value measurement | Net derivative financial instruments | Level 3 | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Beginning balance, Assets (liabilities) net | 1 | (7) | |
Purchases, fair value measurement, assets (liabilities) net | 0 | 0 | |
Sales, fair value measurement, assets (liabilities) net | 0 | 0 | |
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | |
Settlements, fair value measurement, assets (liabilities) net | 40 | 21 | |
Gains (losses) recognised in other comprehensive income, fair value measurement, assets (liabilities) net | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | (10) | 19 | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | (47) | 22 | |
Ending balance, Assets (liabilities) net | 2 | 1 | |
Foreign exchange derivatives | Recurring fair value measurement | Net derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (2) | (16) | |
Foreign exchange derivatives | Recurring fair value measurement | Net derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | |
Credit derivatives | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Derivative financial assets | 262,572 | 302,446 | |
Credit derivatives | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 196 | ||
Ending balance, financial assets | 323 | 196 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (351) | ||
Ending balance, financial liabilities | (709) | (351) | |
Credit derivatives | Recurring fair value measurement | Net derivative financial instruments | Level 3 | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Beginning balance, Assets (liabilities) net | (155) | 198 | |
Purchases, fair value measurement, assets (liabilities) net | 239 | 125 | |
Sales, fair value measurement, assets (liabilities) net | 9 | 24 | |
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | |
Settlements, fair value measurement, assets (liabilities) net | (45) | (371) | |
Gains (losses) recognised in other comprehensive income, fair value measurement, assets (liabilities) net | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | (10) | 21 | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | 0 | 116 | |
Ending balance, Assets (liabilities) net | (386) | (155) | |
Credit derivatives | Recurring fair value measurement | Net derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 34 | 24 | |
Credit derivatives | Recurring fair value measurement | Net derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | |
Equity and stock index derivatives | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 2,498 | ||
Ending balance, financial assets | 2,220 | 2,498 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (4,112) | ||
Ending balance, financial liabilities | (3,625) | (4,112) | |
Equity and stock index derivatives | Recurring fair value measurement | Net derivative financial instruments | Level 3 | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Beginning balance, Assets (liabilities) net | (1,614) | (819) | |
Purchases, fair value measurement, assets (liabilities) net | (90) | 699 | |
Sales, fair value measurement, assets (liabilities) net | (1) | (43) | |
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | |
Settlements, fair value measurement, assets (liabilities) net | (15) | 105 | |
Gains (losses) recognised in other comprehensive income, fair value measurement, assets (liabilities) net | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | 3 | 13 | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | 142 | (44) | |
Ending balance, Assets (liabilities) net | (1,405) | (1,614) | |
Equity and stock index derivatives | Recurring fair value measurement | Net derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (4) | (101) | |
Equity and stock index derivatives | Recurring fair value measurement | Net derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | |
Wholesale loans | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 698 | ||
Ending balance, financial assets | 1,205 | 698 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (3) | ||
Ending balance, financial liabilities | (21) | (3) | |
Non-asset backed loans | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 6,394 | ||
Ending balance, financial assets | 6,405 | 6,394 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | 0 | ||
Ending balance, financial liabilities | 0 | 0 | |
Equity cash products | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 542 | ||
Ending balance, financial assets | 393 | 542 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | 0 | ||
Ending balance, financial liabilities | 0 | 0 | |
Private equity investments | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 873 | ||
Ending balance, financial assets | 1,095 | 873 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (14) | ||
Ending balance, financial liabilities | (6) | (14) | |
Other | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 1,276 | ||
Ending balance, financial assets | 2,369 | 1,276 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (186) | ||
Ending balance, financial liabilities | (238) | (186) | |
Trading portfolio assets | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 1,863 | 2,264 | |
Purchases, fair value measurement, assets | 2,261 | 2,495 | |
Sales, fair value measurement, assets | (1,957) | (2,765) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (154) | (52) | |
Total gains or (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 528 | 154 | |
Transfers out of Level 3 of fair value hierarchy, assets | (248) | (101) | |
Ending balance, financial assets | 2,281 | 1,863 | |
Trading portfolio assets | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | (12) | (132) | |
Trading portfolio assets | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Trading portfolio assets | Asset backed securities | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 686 | 656 | |
Purchases, fair value measurement, assets | 209 | 458 | |
Sales, fair value measurement, assets | (370) | (428) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | 0 | (40) | |
Total gains or (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 114 | 90 | |
Transfers out of Level 3 of fair value hierarchy, assets | (116) | (25) | |
Ending balance, financial assets | 454 | 686 | |
Trading portfolio assets | Asset backed securities | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | (69) | (25) | |
Trading portfolio assets | Asset backed securities | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Trading portfolio assets | Wholesale loans | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 151 | 120 | |
Purchases, fair value measurement, assets | 310 | 77 | |
Sales, fair value measurement, assets | (123) | (6) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (12) | 0 | |
Total gains or (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 41 | 12 | |
Transfers out of Level 3 of fair value hierarchy, assets | (16) | (17) | |
Ending balance, financial assets | 389 | 151 | |
Trading portfolio assets | Wholesale loans | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 38 | (35) | |
Trading portfolio assets | Wholesale loans | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Trading portfolio assets | Non-asset backed loans | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 709 | 974 | |
Purchases, fair value measurement, assets | 1,580 | 1,955 | |
Sales, fair value measurement, assets | (1,409) | (2,182) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (85) | (12) | |
Total gains or (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 45 | 39 | |
Transfers out of Level 3 of fair value hierarchy, assets | (81) | (55) | |
Ending balance, financial assets | 758 | 709 | |
Trading portfolio assets | Non-asset backed loans | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | (1) | (10) | |
Trading portfolio assets | Non-asset backed loans | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Trading portfolio assets | Equity cash products | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 214 | 392 | |
Purchases, fair value measurement, assets | 45 | 5 | |
Sales, fair value measurement, assets | (53) | (149) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | 4 | 0 | |
Total gains or (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 80 | 11 | |
Transfers out of Level 3 of fair value hierarchy, assets | (10) | (4) | |
Ending balance, financial assets | 303 | 214 | |
Trading portfolio assets | Equity cash products | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 23 | (41) | |
Trading portfolio assets | Equity cash products | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Trading portfolio assets | Other | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 103 | 122 | |
Purchases, fair value measurement, assets | 117 | 0 | |
Sales, fair value measurement, assets | (2) | 0 | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (61) | 0 | |
Total gains or (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 248 | 2 | |
Transfers out of Level 3 of fair value hierarchy, assets | (25) | 0 | |
Ending balance, financial assets | 377 | 103 | |
Trading portfolio assets | Other | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | (3) | (21) | |
Trading portfolio assets | Other | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Financial assets at fair value through the income statement | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 8,506 | 8,500 | |
Purchases, fair value measurement, assets | 12,802 | 4,919 | |
Sales, fair value measurement, assets | (10,560) | (4,347) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (942) | (741) | |
Total gains or (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 197 | 410 | |
Transfers out of Level 3 of fair value hierarchy, assets | (128) | (465) | |
Ending balance, financial assets | 9,712 | 8,506 | |
Financial assets at fair value through the income statement | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | (179) | 365 | |
Financial assets at fair value through the income statement | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 16 | (135) | |
Financial assets at fair value through the income statement | Non-asset backed loans | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 5,580 | 5,494 | |
Purchases, fair value measurement, assets | 1,380 | 1,102 | |
Sales, fair value measurement, assets | (306) | (283) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (748) | (706) | |
Total gains or (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 113 | 0 | |
Transfers out of Level 3 of fair value hierarchy, assets | (17) | (453) | |
Ending balance, financial assets | 5,647 | 5,580 | |
Financial assets at fair value through the income statement | Non-asset backed loans | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | (181) | 426 | |
Financial assets at fair value through the income statement | Non-asset backed loans | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | (174) | 0 | |
Financial assets at fair value through the income statement | Equity cash products | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 326 | 835 | |
Purchases, fair value measurement, assets | 3 | 15 | |
Sales, fair value measurement, assets | (247) | (404) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | 0 | 0 | |
Total gains or (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 1 | 9 | |
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | |
Ending balance, financial assets | 90 | 326 | |
Financial assets at fair value through the income statement | Equity cash products | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | (93) | |
Financial assets at fair value through the income statement | Equity cash products | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 7 | (36) | |
Financial assets at fair value through the income statement | Private equity investments | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 874 | 900 | |
Purchases, fair value measurement, assets | 166 | 84 | |
Sales, fair value measurement, assets | (24) | (54) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (9) | (3) | |
Total gains or (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 35 | 15 | |
Transfers out of Level 3 of fair value hierarchy, assets | (110) | (12) | |
Ending balance, financial assets | 1,095 | 874 | |
Financial assets at fair value through the income statement | Private equity investments | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Financial assets at fair value through the income statement | Private equity investments | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 163 | (56) | |
Financial assets at fair value through the income statement | Other | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 1,726 | 1,271 | |
Purchases, fair value measurement, assets | 11,253 | 3,718 | |
Sales, fair value measurement, assets | (9,983) | (3,606) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (185) | (32) | |
Total gains or (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 48 | 386 | |
Transfers out of Level 3 of fair value hierarchy, assets | (1) | 0 | |
Ending balance, financial assets | 2,880 | 1,726 | |
Financial assets at fair value through the income statement | Other | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 2 | 32 | |
Financial assets at fair value through the income statement | Other | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 20 | (43) | |
Fair value through other comprehensive income | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 153 | 429 | |
Purchases, fair value measurement, assets | 0 | 0 | |
Sales, fair value measurement, assets | 0 | (35) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (7) | (237) | |
Total gains or (losses) recognised in OCI, assets | (2) | (4) | |
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | |
Transfers out of Level 3 of fair value hierarchy, assets | (106) | 0 | |
Ending balance, financial assets | 38 | 153 | |
Fair value through other comprehensive income | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Fair value through other comprehensive income | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Fair value through other comprehensive income | Asset backed securities | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 47 | 86 | |
Purchases, fair value measurement, assets | 0 | 0 | |
Sales, fair value measurement, assets | 0 | (35) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (7) | 0 | |
Total gains or (losses) recognised in OCI, assets | (2) | (4) | |
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | |
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | |
Ending balance, financial assets | 38 | 47 | |
Fair value through other comprehensive income | Asset backed securities | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Fair value through other comprehensive income | Asset backed securities | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Fair value through other comprehensive income | Non-asset backed loans | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 106 | 343 | |
Purchases, fair value measurement, assets | 0 | 0 | |
Sales, fair value measurement, assets | 0 | 0 | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | 0 | (237) | |
Total gains or (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | |
Transfers out of Level 3 of fair value hierarchy, assets | (106) | 0 | |
Ending balance, financial assets | 0 | 106 | |
Fair value through other comprehensive income | Non-asset backed loans | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Fair value through other comprehensive income | Non-asset backed loans | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and (losses) in the period recognised in the income statement, assets | £ 0 | £ 0 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Fair value of financial instr_6
Fair value of financial instruments - Unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at year end (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | £ 5,794 | [1] | £ 7,029 | £ 4,235 |
Other income | 88 | [1] | 31 | 99 |
Other comprehensive income | (2,218) | [2] | (395) | (561) |
Level 3 | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | (428) | 214 | ||
Other income | 153 | (91) | ||
Other comprehensive income | 0 | (1) | ||
Total | (275) | 122 | ||
Level 3 | Investment property | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | 0 | 0 | ||
Other income | 0 | (1) | ||
Other comprehensive income | 0 | 0 | ||
Total | 0 | (1) | ||
Level 3 | Net derivative financial instruments | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | (196) | (91) | ||
Other income | 0 | 0 | ||
Other comprehensive income | 0 | 0 | ||
Total | (196) | (91) | ||
Trading portfolio liabilities | Level 3 | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | (5) | 0 | ||
Other income | 0 | 0 | ||
Other comprehensive income | 0 | 0 | ||
Total | (5) | 0 | ||
Financial liabilities designated at fair value | Level 3 | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | 16 | 20 | ||
Other income | (1) | (1) | ||
Other comprehensive income | 0 | 0 | ||
Total | 15 | 19 | ||
Trading portfolio assets | Level 3 | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | (67) | (114) | ||
Other income | 0 | 0 | ||
Other comprehensive income | 0 | 0 | ||
Total | (67) | (114) | ||
Trading portfolio assets | Trading portfolio liabilities | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | 3,992 | 5,342 | £ 2,941 | |
Financial assets at fair value through the income statement | Level 3 | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | (176) | 399 | ||
Other income | 154 | (89) | ||
Other comprehensive income | 0 | 0 | ||
Total | (22) | 310 | ||
Fair value through other comprehensive income | Level 3 | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | 0 | 0 | ||
Other income | 0 | 0 | ||
Other comprehensive income | 0 | (1) | ||
Total | £ 0 | £ (1) | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details |
Fair value of financial instr_7
Fair value of financial instruments - Significant unobservable inputs (Details) - Level 3 | Dec. 31, 2021 | Dec. 31, 2020 |
Bottom of range | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0032 | 0.0017 |
Top of range | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.1848 | 0.1831 |
Asset backed securities | Bottom of range | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0 |
Asset backed securities | Top of range | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 120 | 112 |
Non-asset backed loans | Bottom of range | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0200 | 0.0200 |
Non-asset backed loans | Bottom of range | Discounted cash flows | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0 |
Non-asset backed loans | Bottom of range | Discounted cash flows | Volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 3 | 0.05 |
Non-asset backed loans | Bottom of range | Discounted cash flows | Loan spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0031 | 0.0031 |
Non-asset backed loans | Bottom of range | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0 |
Non-asset backed loans | Top of range | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0300 | 0.0300 |
Non-asset backed loans | Top of range | Discounted cash flows | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 112 | 104 |
Non-asset backed loans | Top of range | Discounted cash flows | Volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 10 | 0.08 |
Non-asset backed loans | Top of range | Discounted cash flows | Loan spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.1552 | 0.1518 |
Non-asset backed loans | Top of range | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 145 | 137 |
Private equity investments | Bottom of range | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.08 | 0.01 |
Private equity investments | Bottom of range | Discounted cash flows | Discounted margin | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0725 | 0.1387 |
Private equity investments | Bottom of range | EBITDA multiple | EBITDA multiple | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 16 | 14 |
Private equity investments | Bottom of range | Earnings multiple | Earnings multiple | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 5 | 3 |
Private equity investments | Top of range | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.10 | 0.10 |
Private equity investments | Top of range | Discounted cash flows | Discounted margin | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.1916 | 0.1916 |
Private equity investments | Top of range | EBITDA multiple | EBITDA multiple | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 20 | 16 |
Private equity investments | Top of range | Earnings multiple | Earnings multiple | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 28 | 28 |
Wholesale loans | Bottom of range | Discounted cash flows | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0 |
Wholesale loans | Bottom of range | Discounted cash flows | Loan spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0229 | 0 |
Wholesale loans | Bottom of range | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0 |
Wholesale loans | Top of range | Discounted cash flows | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 100 | 104 |
Wholesale loans | Top of range | Discounted cash flows | Loan spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0854 | 0 |
Wholesale loans | Top of range | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 284 | 127 |
Commercial Real Estate loans | Bottom of range | Discounted cash flows | Discounted margin | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0068 | 0.0146 |
Commercial Real Estate loans | Top of range | Discounted cash flows | Discounted margin | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0543 | 0.0483 |
Equity cash products | Bottom of range | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0026 | 0.0049 |
Equity cash products | Top of range | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0034 | 0.0049 |
Interest rate derivatives | Bottom of range | Discounted cash flows | Inflation forwards | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0.01 |
Interest rate derivatives | Bottom of range | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0009 | 0.0017 |
Interest rate derivatives | Bottom of range | Correlation Model | Inflation forwards | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | (0.20) | (0.20) |
Interest rate derivatives | Bottom of range | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0 |
Interest rate derivatives | Bottom of range | Option model | Volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0031 | 0.0031 |
Interest rate derivatives | Bottom of range | Option model | Interest rate volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0005 | 0.0006 |
Interest rate derivatives | Bottom of range | Option model | FX - IR correlation | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | (20) | (0.30) |
Interest rate derivatives | Bottom of range | Option model | IR - IR correlation | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | (100) | (0.20) |
Interest rate derivatives | Top of range | Discounted cash flows | Inflation forwards | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.03 | 0.03 |
Interest rate derivatives | Top of range | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.1848 | 0.1831 |
Interest rate derivatives | Top of range | Correlation Model | Inflation forwards | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | (0.13) | (0.13) |
Interest rate derivatives | Top of range | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 38 | 84 |
Interest rate derivatives | Top of range | Option model | Volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0130 | 0.0227 |
Interest rate derivatives | Top of range | Option model | Interest rate volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0600 | 0.0489 |
Interest rate derivatives | Top of range | Option model | FX - IR correlation | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 78 | 0.78 |
Interest rate derivatives | Top of range | Option model | IR - IR correlation | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 99 | 0.99 |
Credit derivatives | Bottom of range | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0002 | 0.0005 |
Credit derivatives | Bottom of range | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0 |
Credit derivatives | Top of range | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.2925 | 0.0480 |
Credit derivatives | Top of range | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 100 |
Equity and stock index derivatives | Bottom of range | Discounted cash flows | Discounted margin | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | (0.0129) | (0.0225) |
Equity and stock index derivatives | Bottom of range | Option model | Volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 2 | 0.01 |
Equity and stock index derivatives | Bottom of range | Option model | Equity - equity correlation | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 10 | (0.45) |
Equity and stock index derivatives | Top of range | Discounted cash flows | Discounted margin | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0093 | 0.3000 |
Equity and stock index derivatives | Top of range | Option model | Volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 108 | 1.10 |
Equity and stock index derivatives | Top of range | Option model | Equity - equity correlation | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 100 | 1 |
Foreign exchange derivatives | Bottom of range | Option model | Volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0 |
Foreign exchange derivatives | Top of range | Option model | Volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 100 | 30 |
Fair value of financial instr_8
Fair value of financial instruments - Narrative (Details) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021GBP (£) | Dec. 31, 2020GBP (£) | ||
Disclosure of detailed information about financial instruments [line items] | |||
Deposits at amortised cost | £ 519,433 | [1] | £ 481,036 |
Brokered certificates of deposit | |||
Disclosure of detailed information about financial instruments [line items] | |||
Deposits at amortised cost | 790 | 1,494 | |
Derivative credit valuation adjustments | |||
Disclosure of detailed information about financial instruments [line items] | |||
Increase (decrease) in fair value adjustments | 56 | ||
Fair value adjustments | (212) | ||
Level 3 | Exit price adjustments derived from market bid-offer spreads | |||
Disclosure of detailed information about financial instruments [line items] | |||
Increase (decrease) in fair value adjustments | 13 | ||
Fair value adjustments | 506 | 493 | |
Level 3 | Uncollateralised derivative funding | |||
Disclosure of detailed information about financial instruments [line items] | |||
Increase (decrease) in fair value adjustments | 12 | ||
Fair value adjustments | 127 | 115 | |
Level 3 | Derivative credit valuation adjustments | |||
Disclosure of detailed information about financial instruments [line items] | |||
Fair value adjustments | 212 | 268 | |
Level 3 | Derivative debit valuation adjustments | |||
Disclosure of detailed information about financial instruments [line items] | |||
Increase (decrease) in fair value adjustments | (22) | ||
Fair value adjustments | (91) | (113) | |
Top of range | Level 3 | |||
Disclosure of detailed information about financial instruments [line items] | |||
Favorable changes | 880 | 906 | |
Unfavorable changes | £ 1,005 | £ 1,174 | |
Education, social housing, and local authority porfolio | Level 3 | |||
Disclosure of detailed information about financial instruments [line items] | |||
Fixed rate loan notional amount concentrated towards bottom of range, percentage | 97.00% | ||
Education, social housing, and local authority porfolio | Level 3 | Loan spread | Maximum | |||
Disclosure of detailed information about financial instruments [line items] | |||
Significant unobservable input, assets | 200 | ||
Education, social housing, and local authority porfolio | Bottom of range | Level 3 | Loan spread | |||
Disclosure of detailed information about financial instruments [line items] | |||
Significant unobservable input, assets | 0.0031 | 0.0031 | |
Education, social housing, and local authority porfolio | Top of range | Level 3 | Loan spread | |||
Disclosure of detailed information about financial instruments [line items] | |||
Significant unobservable input, assets | 0.1552 | 0.1518 | |
Financial instruments at fair value | Level 3 | |||
Disclosure of detailed information about financial instruments [line items] | |||
Difference between inital FV and transaction price to be recognised in profit or loss | £ 133 | £ 116 | |
Difference between inital FV and transaction price to be recognised in profit or loss, Additions | 59 | 27 | |
Difference between inital FV and transaction price to be recognised in profit or loss, Amortisation and releases | 42 | 24 | |
Financial instruments at amortised cost | Level 3 | |||
Disclosure of detailed information about financial instruments [line items] | |||
Difference between inital FV and transaction price to be recognised in profit or loss | 230 | 247 | |
Difference between inital FV and transaction price to be recognised in profit or loss, Additions | 0 | 6 | |
Difference between inital FV and transaction price to be recognised in profit or loss, Amortisation and releases | £ 17 | £ 14 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Fair value of financial instr_9
Fair value of financial instruments - Sensitivity analysis of valuations using unobservable inputs (Details) - Level 3 - Derivatives - Recurring fair value measurement - GBP (£) £ in Millions | 1 Months Ended | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | |
Favourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Favorable changes, Income statement | £ 880 | £ 903 | |
Favourable changes, Equity | £ 0 | 3 | |
Unfavourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Unfavourable changes, Income Statement | (1,005) | (1,171) | |
Unfavourable changes, Equity | 0 | (3) | |
Corporate debt | Favourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Favorable changes, Income statement | 38 | 16 | |
Favourable changes, Equity | 0 | 0 | |
Corporate debt | Unfavourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Unfavourable changes, Income Statement | (28) | (14) | |
Unfavourable changes, Equity | 0 | 0 | |
Non-asset backed loans | Favourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Favorable changes, Income statement | 165 | 190 | |
Favourable changes, Equity | 0 | 3 | |
Non-asset backed loans | Unfavourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Unfavourable changes, Income Statement | (256) | (409) | |
Unfavourable changes, Equity | 0 | (3) | |
Equity cash products | Favourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Favorable changes, Income statement | 42 | 158 | |
Favourable changes, Equity | 0 | 0 | |
Equity cash products | Unfavourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Unfavourable changes, Income Statement | (61) | (141) | |
Unfavourable changes, Equity | 0 | 0 | |
Private equity investments | Favourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Favorable changes, Income statement | 246 | 199 | |
Favourable changes, Equity | 0 | 0 | |
Private equity investments | Unfavourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Unfavourable changes, Income Statement | (236) | (227) | |
Unfavourable changes, Equity | 0 | 0 | |
Other | Favourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Favorable changes, Income statement | 20 | 23 | |
Favourable changes, Equity | 0 | 0 | |
Other | Unfavourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Unfavourable changes, Income Statement | (19) | (23) | |
Unfavourable changes, Equity | 0 | 0 | |
Interest rate derivatives | Favourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Favorable changes, Income statement | 51 | 82 | |
Favourable changes, Equity | 0 | 0 | |
Interest rate derivatives | Unfavourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Unfavourable changes, Income Statement | (79) | (123) | |
Unfavourable changes, Equity | 0 | 0 | |
Foreign exchange derivatives | Favourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Favorable changes, Income statement | 20 | 6 | |
Favourable changes, Equity | 0 | 0 | |
Foreign exchange derivatives | Unfavourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Unfavourable changes, Income Statement | (28) | (11) | |
Unfavourable changes, Equity | 0 | 0 | |
Credit derivatives | Favourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Favorable changes, Income statement | 111 | 55 | |
Favourable changes, Equity | 0 | 0 | |
Credit derivatives | Unfavourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Unfavourable changes, Income Statement | (103) | (44) | |
Unfavourable changes, Equity | 0 | 0 | |
Equity derivatives | Favourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Favorable changes, Income statement | 187 | 174 | |
Favourable changes, Equity | 0 | 0 | |
Equity derivatives | Unfavourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Unfavourable changes, Income Statement | (195) | (179) | |
Unfavourable changes, Equity | £ 0 | £ 0 |
Fair value of financial inst_10
Fair value of financial instruments - Fair value adjustments (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Exit price adjustments derived from market bid-offer spreads | Level 3 | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | £ (506) | £ (493) |
Uncollateralised derivative funding | Level 3 | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | (127) | (115) |
Derivative credit valuation adjustments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | 212 | |
Derivative credit valuation adjustments | Level 3 | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | (212) | (268) |
Derivative debit valuation adjustments | Level 3 | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | £ 91 | £ 113 |
Fair value of financial inst_11
Fair value of financial instruments - Comparison of carrying amounts and fair values for assets and liabilities not held at fair value (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Financial assets | ||||
Loans and advances at amortised cost | £ 361,451 | [1] | £ 342,632 | |
Reverse repurchase agreements and other similar secured lending | 3,227 | [1] | 9,031 | |
Financial liabilities | ||||
Repurchase agreements and other similar secured borrowing | (28,352) | [1] | (14,174) | |
Debt securities in issue | (98,867) | [1] | (75,796) | |
Subordinated liabilities | (12,759) | [1] | (16,341) | £ (18,156) |
Not held at fair value | ||||
Financial assets | ||||
Loans and advances at amortised cost | 362,424 | 340,516 | ||
Reverse repurchase agreements and other similar secured lending | 3,227 | 9,031 | ||
Financial liabilities | ||||
Deposits at amortised cost | (519,436) | (481,106) | ||
Repurchase agreements and other similar secured borrowing | (28,358) | (14,174) | ||
Debt securities in issue | (100,657) | (77,813) | ||
Subordinated liabilities | (13,334) | (16,918) | ||
Not held at fair value | Level 1 | ||||
Financial assets | ||||
Loans and advances at amortised cost | 17,381 | 8,824 | ||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||
Financial liabilities | ||||
Deposits at amortised cost | (434,431) | (396,124) | ||
Repurchase agreements and other similar secured borrowing | 0 | 0 | ||
Debt securities in issue | 0 | 0 | ||
Subordinated liabilities | 0 | 0 | ||
Not held at fair value | Level 2 | ||||
Financial assets | ||||
Loans and advances at amortised cost | 83,191 | 81,322 | ||
Reverse repurchase agreements and other similar secured lending | 3,227 | 9,031 | ||
Financial liabilities | ||||
Deposits at amortised cost | (83,501) | (82,874) | ||
Repurchase agreements and other similar secured borrowing | (28,358) | (14,174) | ||
Debt securities in issue | (98,364) | (75,957) | ||
Subordinated liabilities | (13,267) | (16,918) | ||
Not held at fair value | Level 3 | ||||
Financial assets | ||||
Loans and advances at amortised cost | 261,852 | 250,370 | ||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||
Financial liabilities | ||||
Deposits at amortised cost | (1,504) | (2,108) | ||
Repurchase agreements and other similar secured borrowing | 0 | 0 | ||
Debt securities in issue | (2,293) | (1,856) | ||
Subordinated liabilities | (67) | 0 | ||
Carrying amount | ||||
Financial assets | ||||
Loans and advances at amortised cost | 361,451 | 342,632 | ||
Reverse repurchase agreements and other similar secured lending | 3,227 | 9,031 | ||
Financial liabilities | ||||
Deposits at amortised cost | (519,433) | (481,036) | ||
Repurchase agreements and other similar secured borrowing | (28,352) | (14,174) | ||
Debt securities in issue | (98,867) | (75,796) | ||
Subordinated liabilities | £ (12,759) | £ (16,341) | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Offsetting financial assets a_3
Offsetting financial assets and financial liabilities (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial assets [abstract] | |||
Derivative financial assets | £ 262,572 | [1] | £ 302,446 |
Reverse repurchase agreements and other similar secured lending | 3,227 | [1] | 9,031 |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities [abstract] | |||
Derivative liabilities | (256,883) | [1] | (300,775) |
Repurchase agreements and other similar secured borrowing | (28,352) | [1] | (14,174) |
Settlements assets liabilities offset amounts | 22,837 | 18,143 | |
Financial liabilities subject to offsetting | |||
Net financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements in statement of financial position [abstract] | |||
Gross amounts | (810,009) | (810,855) | |
Amounts offset | 393,609 | 348,380 | |
Net amounts reported on the balance sheet | (416,400) | (462,475) | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities [abstract] | |||
Financial instruments | 202,519 | 233,080 | |
Financial collateral pledged subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities | 199,971 | 217,318 | |
Derivative liability expsoure | (13,910) | (12,077) | |
Amounts not subject to enforceable netting arrangements | (36,895) | (29,845) | |
Total liabilities | (453,295) | (492,320) | |
Repurchase agreements and other similar secured borrowing | |||
Net financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements in statement of financial position [abstract] | |||
Gross amounts | (535,653) | (476,912) | |
Amounts offset | 370,003 | 306,398 | |
Net amounts reported on the balance sheet | (165,650) | (170,514) | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities [abstract] | |||
Financial instruments | 0 | 0 | |
Financial collateral pledged subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities | 165,650 | 170,514 | |
Derivative liability expsoure | 0 | 0 | |
Amounts not subject to enforceable netting arrangements | (30,762) | (21,031) | |
Repurchase agreements and other similar secured borrowing | (196,412) | (191,545) | |
Repurchase agreements and other similar secured borrowing | Financial liabilities at fair value | |||
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities [abstract] | |||
Derivative liability expsoure | (168,060) | (177,371) | |
Repurchase agreements and other similar secured borrowing | Financial liabilities at amortised cost | |||
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities [abstract] | |||
Derivative liability expsoure | (28,352) | (14,174) | |
Derivatives | |||
Net financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements in statement of financial position [abstract] | |||
Gross amounts | (274,356) | (333,943) | |
Amounts offset | 23,606 | 41,982 | |
Net amounts reported on the balance sheet | (250,750) | (291,961) | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities [abstract] | |||
Financial instruments | 202,519 | 233,080 | |
Financial collateral pledged subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities | 34,321 | 46,804 | |
Derivative liability expsoure | (13,910) | (12,077) | |
Amounts not subject to enforceable netting arrangements | (6,133) | (8,814) | |
Derivative liabilities | (256,883) | (300,775) | |
Cash collateral pledged | 32,031 | 42,730 | |
Non-cash assets pledged as collateral | 2,290 | 4,074 | |
Cash collateral netted | Derivatives | |||
Net financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements in statement of financial position [abstract] | |||
Amounts offset | 4,346 | 7,313 | |
Financial assets subject to offsetting | |||
Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements [abstract] | |||
Gross amounts | 793,928 | 790,783 | |
Amounts offset | (394,140) | (350,703) | |
Net amounts reported on the balance sheet | 399,788 | 440,080 | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial assets [abstract] | |||
Netting and set-off | (202,519) | (233,080) | |
Financial collateral received subject to enforceable master netting arrangement or similar agreement not set off against financial assets | (184,339) | (189,416) | |
Maximum exposure | 12,930 | 17,584 | |
Amounts not subject to enforceable netting arrangements | 11,025 | 9,013 | |
Total assets | 410,813 | 449,093 | |
Derivatives | |||
Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements [abstract] | |||
Gross amounts | 279,568 | 342,649 | |
Amounts offset | (24,137) | (44,305) | |
Net amounts reported on the balance sheet | 255,431 | 298,344 | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial assets [abstract] | |||
Netting and set-off | (202,519) | (233,080) | |
Financial collateral received subject to enforceable master netting arrangement or similar agreement not set off against financial assets | (40,485) | (48,064) | |
Maximum exposure | 12,427 | 17,200 | |
Amounts not subject to enforceable netting arrangements | 7,141 | 4,102 | |
Derivative financial assets | 262,572 | 302,446 | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities [abstract] | |||
Cash collateral | 34,598 | 43,291 | |
Non-cash collateral received subject to enforceable master netting arrangements or similar agreement not set off against financial assets | 5,887 | 4,773 | |
Derivatives | Cash collateral netted | |||
Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements [abstract] | |||
Amounts offset | (3,815) | (4,990) | |
Reverse repurchase agreements and other similar secured lending | |||
Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements [abstract] | |||
Gross amounts | 514,360 | 448,134 | |
Amounts offset | (370,003) | (306,398) | |
Net amounts reported on the balance sheet | 144,357 | 141,736 | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial assets [abstract] | |||
Netting and set-off | 0 | 0 | |
Financial collateral received subject to enforceable master netting arrangement or similar agreement not set off against financial assets | (143,854) | (141,352) | |
Maximum exposure | 503 | 384 | |
Amounts not subject to enforceable netting arrangements | 3,884 | 4,911 | |
Reverse repurchase agreements and other similar secured lending | 148,241 | 146,647 | |
Reverse repurchase agreements and other similar secured lending | Net gains on financial instruments designated at fair value | |||
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial assets [abstract] | |||
Maximum exposure | 145,014 | 137,616 | |
Reverse repurchase agreements and other similar secured lending | Financial assets at amortised cost | |||
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial assets [abstract] | |||
Maximum exposure | £ 3,227 | £ 9,031 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Loans and advances and deposi_3
Loans and advances and deposits at amortised cost (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Deposits | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total deposits at amortised cost | £ 519,433 | £ 481,036 |
Deposits | Banks | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total deposits at amortised cost | 17,819 | 17,343 |
Deposits | Customers | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total deposits at amortised cost | 501,614 | 463,693 |
Loans and advances | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total loans and advances at amortised cost | 361,451 | 342,632 |
Loans and advances | Banks | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total loans and advances at amortised cost | 9,698 | 8,900 |
Loans and advances | Customers | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total loans and advances at amortised cost | 319,922 | 309,927 |
Debt securities classified at amortised cost | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total loans and advances at amortised cost | £ 31,831 | £ 23,805 |
Property, plant and equipment -
Property, plant and equipment - Depreciation rates (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Freehold buildings and long-leasehold property (more than 50 years to run) | Bottom of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 2.00% |
Freehold buildings and long-leasehold property (more than 50 years to run) | Top of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 3.30% |
Costs of adaptation of freehold and leasehold property | Bottom of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 6.00% |
Costs of adaptation of freehold and leasehold property | Top of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 10.00% |
Equipment installed in freehold and leasehold property | Bottom of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 6.00% |
Equipment installed in freehold and leasehold property | Top of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 10.00% |
Computers and similar equipment | Bottom of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 17.00% |
Computers and similar equipment | Top of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 33.00% |
Fixtures and fittings and other equipment | Bottom of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 9.00% |
Fixtures and fittings and other equipment | Top of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 20.00% |
Property, plant and equipment_2
Property, plant and equipment (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | £ 4,036 | |||
Ending balance, Property, plant and equipment | 3,555 | [1] | £ 4,036 | |
Impairment loss - structural costs | 266 | |||
Other income | 88 | [2] | 31 | £ 99 |
Cost | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 9,037 | 8,763 | ||
Additions | 495 | 524 | ||
Disposals | (350) | (211) | ||
Exchange and other movements | 86 | (39) | ||
Ending balance, Property, plant and equipment | 9,268 | 9,037 | 8,763 | |
Accumulated depreciation and impairment | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | (5,001) | (4,548) | ||
Depreciation charge | (675) | (641) | ||
Impairment | 276 | 42 | ||
Disposals | 262 | 176 | ||
Exchange and other movements | (23) | 54 | ||
Ending balance, Property, plant and equipment | (5,713) | (5,001) | (4,548) | |
Property | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 1,989 | |||
Ending balance, Property, plant and equipment | 1,876 | 1,989 | ||
Property | Cost | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 4,002 | 3,938 | ||
Additions | 274 | 193 | ||
Disposals | (160) | (96) | ||
Exchange and other movements | 15 | (33) | ||
Ending balance, Property, plant and equipment | 4,131 | 4,002 | 3,938 | |
Property | Accumulated depreciation and impairment | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | (2,013) | (1,901) | ||
Depreciation charge | (249) | (187) | ||
Impairment | 106 | 25 | ||
Disposals | 136 | 82 | ||
Exchange and other movements | (23) | 18 | ||
Ending balance, Property, plant and equipment | (2,255) | (2,013) | (1,901) | |
Equipment | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 670 | |||
Ending balance, Property, plant and equipment | 624 | 670 | ||
Equipment | Cost | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 3,091 | 2,986 | ||
Additions | 189 | 246 | ||
Disposals | (74) | (100) | ||
Exchange and other movements | 4 | (41) | ||
Ending balance, Property, plant and equipment | 3,210 | 3,091 | 2,986 | |
Equipment | Accumulated depreciation and impairment | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | (2,421) | (2,315) | ||
Depreciation charge | (222) | (223) | ||
Impairment | 0 | 2 | ||
Disposals | 66 | 92 | ||
Exchange and other movements | (9) | 27 | ||
Ending balance, Property, plant and equipment | (2,586) | (2,421) | (2,315) | |
Investment property | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 10 | |||
Ending balance, Property, plant and equipment | 7 | 10 | ||
Other income | 16 | 11 | ||
Investment property | Cost | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 10 | 13 | ||
Additions | 0 | 0 | ||
Disposals | (2) | (1) | ||
Exchange and other movements | (1) | (2) | ||
Ending balance, Property, plant and equipment | 7 | 10 | 13 | |
Investment property | Accumulated depreciation and impairment | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 0 | 0 | ||
Depreciation charge | 0 | 0 | ||
Impairment | 0 | 0 | ||
Disposals | 0 | 0 | ||
Exchange and other movements | 0 | 0 | ||
Ending balance, Property, plant and equipment | 0 | 0 | 0 | |
Right-of-use assets | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 1,367 | |||
Ending balance, Property, plant and equipment | 1,048 | 1,367 | ||
Right-of-use assets | Cost | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 1,934 | 1,826 | ||
Additions | 32 | 85 | ||
Disposals | (114) | (14) | ||
Exchange and other movements | 68 | 37 | ||
Ending balance, Property, plant and equipment | 1,920 | 1,934 | 1,826 | |
Right-of-use assets | Accumulated depreciation and impairment | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | (567) | (332) | ||
Depreciation charge | (204) | (231) | ||
Impairment | 170 | 15 | ||
Disposals | 60 | 2 | ||
Exchange and other movements | 9 | 9 | ||
Ending balance, Property, plant and equipment | £ (872) | £ (567) | £ (332) | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Leases - Maturity analysis of l
Leases - Maturity analysis of lease receivables (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of maturity analysis of finance lease payments receivable [line items] | ||
Gross investment in finance lease receivables | £ 58 | £ 1,245 |
Future finance income | (5) | (63) |
Present value of minimum lease payments receivable | 53 | 1,182 |
Unguaranteed residual values | 0 | 225 |
Not more than one year | ||
Disclosure of maturity analysis of finance lease payments receivable [line items] | ||
Gross investment in finance lease receivables | 29 | 535 |
Future finance income | (3) | (26) |
Present value of minimum lease payments receivable | 26 | 509 |
Unguaranteed residual values | 0 | 70 |
One to two year | ||
Disclosure of maturity analysis of finance lease payments receivable [line items] | ||
Gross investment in finance lease receivables | 19 | 312 |
Future finance income | (2) | (15) |
Present value of minimum lease payments receivable | 17 | 297 |
Unguaranteed residual values | 0 | 45 |
Two to three year | ||
Disclosure of maturity analysis of finance lease payments receivable [line items] | ||
Gross investment in finance lease receivables | 6 | 215 |
Future finance income | 0 | (12) |
Present value of minimum lease payments receivable | 6 | 203 |
Unguaranteed residual values | 0 | 52 |
Three to four year | ||
Disclosure of maturity analysis of finance lease payments receivable [line items] | ||
Gross investment in finance lease receivables | 2 | 107 |
Future finance income | 0 | (6) |
Present value of minimum lease payments receivable | 2 | 101 |
Unguaranteed residual values | 0 | 27 |
Four to five year | ||
Disclosure of maturity analysis of finance lease payments receivable [line items] | ||
Gross investment in finance lease receivables | 1 | 52 |
Future finance income | 0 | (3) |
Present value of minimum lease payments receivable | 1 | 49 |
Unguaranteed residual values | 0 | 18 |
Over five years | ||
Disclosure of maturity analysis of finance lease payments receivable [line items] | ||
Gross investment in finance lease receivables | 1 | 24 |
Future finance income | 0 | (1) |
Present value of minimum lease payments receivable | 1 | 23 |
Unguaranteed residual values | £ 0 | £ 13 |
Leases - Narrative (Details)
Leases - Narrative (Details) £ in Millions | 12 Months Ended | |
Dec. 31, 2021GBP (£)leases | Dec. 31, 2020GBP (£)leases | |
As a Lessor | ||
Finance lease receivables | £ 58 | £ 1,245 |
As a Lessee | ||
Expense relating to short-term leases for which recognition exemption has been used | £ 3 | £ 4 |
Number of leases with variable lease payment terms | leases | 609 | 809 |
Number of leases | leases | 1,111 | 1,329 |
Expense relating to variable lease payments not included in measurement of lease liabilities | £ 1,196 | £ 1,096 |
Extension and termination options reasonably certain to be exercised | 434 | 446 |
Gains arising from sale and leaseback transactions | 33 | |
ECL | ||
As a Lessor | ||
Finance lease receivables | £ 0 | £ 29 |
Leases - Finance lease income (
Leases - Finance lease income (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Finance leases | ||
Finance income from net investment in lease | £ 21 | £ 55 |
Profit/(loss) on sales | £ 1 | £ (25) |
Leases - Lease liabilities (Det
Leases - Lease liabilities (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Reconciliation of lease liabilities [Roll Forward] | |||
As at 1 January | £ 1,444 | £ 1,563 | |
Interest expense | 64 | 70 | £ 76 |
New leases | 43 | 85 | |
Disposals | (54) | (15) | |
Cash payments | (258) | (306) | |
Exchange and other movements | 78 | 47 | |
As at 31 December (see Note 23) | £ 1,317 | £ 1,444 | £ 1,563 |
Leases - Lease liability maturi
Leases - Lease liability maturity analysis (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Total undiscounted lease liabilities | £ 1,639 | £ 1,817 |
Not more than one year | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Total undiscounted lease liabilities | 230 | 255 |
One to two year | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Total undiscounted lease liabilities | 215 | 221 |
Two to three year | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Total undiscounted lease liabilities | 197 | 198 |
Three to four year | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Total undiscounted lease liabilities | 182 | 176 |
Four to five year | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Total undiscounted lease liabilities | 149 | 162 |
Five to ten years | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Total undiscounted lease liabilities | 503 | 557 |
Greater than ten years | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Total undiscounted lease liabilities | £ 163 | £ 248 |
Goodwill and intangible asset_2
Goodwill and intangible assets - Amortisation periods (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Software | Internally generated | Bottom of range | |
Disclosure of detailed information about intangible assets [line items] | |
Amortisation period | 12 months |
Software | Internally generated | Top of range | |
Disclosure of detailed information about intangible assets [line items] | |
Amortisation period | 6 years |
Software | Other | Bottom of range | |
Disclosure of detailed information about intangible assets [line items] | |
Amortisation period | 12 months |
Software | Other | Top of range | |
Disclosure of detailed information about intangible assets [line items] | |
Amortisation period | 6 years |
Customer lists | Bottom of range | |
Disclosure of detailed information about intangible assets [line items] | |
Amortisation period | 12 months |
Customer lists | Top of range | |
Disclosure of detailed information about intangible assets [line items] | |
Amortisation period | 25 years |
Licences and other | Bottom of range | |
Disclosure of detailed information about intangible assets [line items] | |
Amortisation period | 12 months |
Licences and other | Top of range | |
Disclosure of detailed information about intangible assets [line items] | |
Amortisation period | 25 years |
Certain core banking platforms | Internally generated | Bottom of range | |
Disclosure of detailed information about intangible assets [line items] | |
Amortisation period | 10 years |
Certain core banking platforms | Internally generated | Top of range | |
Disclosure of detailed information about intangible assets [line items] | |
Amortisation period | 15 years |
Goodwill and intangible asset_3
Goodwill and intangible assets - Goodwill and Intangible assets (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | ||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | £ 7,948 | ||
Intangible assets and goodwill at end of period | 8,061 | [1] | £ 7,948 |
Cost | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | 14,511 | 13,862 | |
Additions and disposals | 338 | 762 | |
Exchange and other movements | 14 | (113) | |
Intangible assets and goodwill at end of period | 14,863 | 14,511 | |
Accumulated amortisation and impairment | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | (6,563) | (5,743) | |
Disposals | 917 | 147 | |
Amortisation charge | (998) | (898) | |
Impairment charge | (127) | (153) | |
Exchange and other movements | (31) | 84 | |
Intangible assets and goodwill at end of period | (6,802) | (6,563) | |
Goodwill | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | 3,891 | ||
Intangible assets and goodwill at end of period | 3,893 | 3,891 | |
Goodwill | Cost | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | 4,716 | 4,760 | |
Additions and disposals | 0 | (37) | |
Exchange and other movements | 2 | (7) | |
Intangible assets and goodwill at end of period | 4,718 | 4,716 | |
Goodwill | Accumulated amortisation and impairment | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | (825) | (861) | |
Disposals | 0 | 37 | |
Amortisation charge | 0 | 0 | |
Impairment charge | 0 | 0 | |
Exchange and other movements | 0 | (1) | |
Intangible assets and goodwill at end of period | (825) | (825) | |
Software | Internally generated | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | 3,468 | ||
Intangible assets and goodwill at end of period | 3,296 | 3,468 | |
Software | Other | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | 311 | ||
Intangible assets and goodwill at end of period | 262 | 311 | |
Software | Cost | Internally generated | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | 7,247 | 6,643 | |
Additions and disposals | (52) | 646 | |
Exchange and other movements | (15) | (42) | |
Intangible assets and goodwill at end of period | 7,180 | 7,247 | |
Software | Cost | Other | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | 639 | 505 | |
Additions and disposals | (9) | 131 | |
Exchange and other movements | (4) | 3 | |
Intangible assets and goodwill at end of period | 626 | 639 | |
Software | Accumulated amortisation and impairment | Internally generated | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | (3,779) | (2,989) | |
Disposals | 894 | 97 | |
Amortisation charge | (867) | (771) | |
Impairment charge | (127) | (147) | |
Exchange and other movements | (5) | 31 | |
Intangible assets and goodwill at end of period | (3,884) | (3,779) | |
Software | Accumulated amortisation and impairment | Other | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | (328) | (279) | |
Disposals | 15 | 10 | |
Amortisation charge | (51) | (51) | |
Impairment charge | 0 | (6) | |
Exchange and other movements | 0 | (2) | |
Intangible assets and goodwill at end of period | (364) | (328) | |
Customer lists | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | 167 | ||
Intangible assets and goodwill at end of period | 131 | 167 | |
Customer lists | Cost | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | 1,419 | 1,465 | |
Additions and disposals | (5) | 0 | |
Exchange and other movements | 17 | (46) | |
Intangible assets and goodwill at end of period | 1,431 | 1,419 | |
Customer lists | Accumulated amortisation and impairment | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | (1,252) | (1,250) | |
Disposals | 5 | 0 | |
Amortisation charge | (36) | (43) | |
Impairment charge | 0 | 0 | |
Exchange and other movements | (17) | 41 | |
Intangible assets and goodwill at end of period | (1,300) | (1,252) | |
Licences and other | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | 111 | ||
Intangible assets and goodwill at end of period | 479 | 111 | |
Licences and other | Cost | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | 490 | 489 | |
Additions and disposals | 404 | 22 | |
Exchange and other movements | 14 | (21) | |
Intangible assets and goodwill at end of period | 908 | 490 | |
Licences and other | Accumulated amortisation and impairment | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill at beginning of period | (379) | (364) | |
Disposals | 3 | 3 | |
Amortisation charge | (44) | (33) | |
Impairment charge | 0 | 0 | |
Exchange and other movements | (9) | 15 | |
Intangible assets and goodwill at end of period | £ (429) | £ (379) | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Goodwill and intangible asset_4
Goodwill and intangible assets - Narrative (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | ||
VIU forecast period | 5 years | |
Yield used to discount cash flows that do not vary based on returns on underlying items | 0.15% | |
Goodwill | £ 3,893 | £ 3,891 |
Intangibles | £ 4,168 | 4,057 |
Cards and Payments | ||
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | ||
Discount rate | 14.70% | |
Terminal growth rate | 2.00% | |
Goodwill | £ 195 | |
Intangibles | 1,351 | 1,096 |
Personal Banking | Barclays UK | ||
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | ||
Goodwill | 2,752 | 2,752 |
Woolwich | Barclays UK | ||
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | ||
Goodwill | 2,501 | 2,501 |
Business Banking | Barclays UK | ||
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | ||
Goodwill | £ 629 | £ 629 |
Bottom of range | ||
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | ||
Discount rate | 12.50% | 12.00% |
Terminal growth rate | 2.00% | 2.00% |
Top of range | ||
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | ||
Discount rate | 15.10% | 16.30% |
Goodwill and intangible asset_5
Goodwill and intangible assets - Goodwill allocated to business operations according to business segments (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | |||
Goodwill | £ 3,893 | £ 3,891 | |
Intangibles | 4,168 | 4,057 | |
Total | 8,061 | [1] | 7,948 |
Head Office | |||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | |||
Goodwill | 42 | 42 | |
Intangibles | 5 | 4 | |
Total | 47 | 46 | |
Barclays UK | Operating segments | |||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | |||
Goodwill | 3,560 | 3,560 | |
Intangibles | 1,233 | 1,618 | |
Total | 4,793 | 5,178 | |
Barclays International | Operating segments | |||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | |||
Goodwill | 291 | 289 | |
Intangibles | 2,930 | 2,435 | |
Total | £ 3,221 | £ 2,724 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Goodwill and intangible asset_6
Goodwill and intangible assets - The outcome the impairment review for Personal Banking and Business Banking (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Outcome of goodwill and intangibles review and Other intangible assets | |||
Goodwill | £ 3,893 | £ 3,891 | |
Intangibles | 4,168 | 4,057 | |
Total | 8,061 | [1] | 7,948 |
Individual assets or cash-generating units | |||
Outcome of goodwill and intangibles review and Other intangible assets | |||
Tangible equity | 9,599 | ||
Goodwill | 3,576 | ||
Intangibles | 2,517 | ||
Total | 15,692 | ||
Value in use | 21,829 | ||
Value in use exceeding carrying value | 6,137 | 2,223 | |
Personal Banking | |||
Outcome of goodwill and intangibles review and Other intangible assets | |||
Tangible equity | 5,194 | ||
Goodwill | 2,752 | ||
Intangibles | 997 | ||
Total | 8,943 | ||
Value in use | 10,432 | ||
Value in use exceeding carrying value | 1,489 | 123 | |
Business Banking | |||
Outcome of goodwill and intangibles review and Other intangible assets | |||
Tangible equity | 1,459 | ||
Goodwill | 629 | ||
Intangibles | 169 | ||
Total | 2,257 | ||
Value in use | 5,880 | ||
Value in use exceeding carrying value | 3,623 | 740 | |
Cards and Payments | |||
Outcome of goodwill and intangibles review and Other intangible assets | |||
Tangible equity | 2,946 | ||
Goodwill | 195 | ||
Intangibles | 1,351 | 1,096 | |
Total | 4,492 | ||
Value in use | 5,517 | ||
Value in use exceeding carrying value | £ 1,025 | £ 1,360 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Goodwill and intangible asset_7
Goodwill and intangible assets - The sensitivity of the value in use to key judgements in the calculations (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Personal Banking UK And Card And Payments | ||
Disclosure of information for cash-generating units [line items] | ||
Carrying value | £ 13,435 | |
Value in use | 15,949 | |
Value in use exceeding carrying value | 2,514 | |
Personal Banking | ||
Disclosure of information for cash-generating units [line items] | ||
Carrying value | 8,943 | |
Value in use | 10,432 | |
Value in use exceeding carrying value | £ 1,489 | £ 123 |
Discount rate | 14.20% | |
Terminal growth rate | 2.00% | |
Sensitivity of key judgements | ||
100 bps increase in the discount rate | £ (946) | |
100 bps decrease in terminal growth rate | (655) | |
50 bps increase to allocated capital rate | (291) | |
10% reduction in forecasted cash flows | (1,219) | |
Cards and Payments | ||
Disclosure of information for cash-generating units [line items] | ||
Carrying value | 4,492 | |
Value in use | 5,517 | |
Value in use exceeding carrying value | £ 1,025 | £ 1,360 |
Discount rate | 14.70% | |
Terminal growth rate | 2.00% | |
Sensitivity of key judgements | ||
100 bps increase in the discount rate | £ (597) | |
100 bps decrease in terminal growth rate | (433) | |
50 bps increase to allocated capital rate | (227) | |
10% reduction in forecasted cash flows | £ (774) | |
Discount rate | Personal Banking | ||
Sensitivity of key judgements | ||
Change required to reduce headroom to zero | 0.017 | |
Discount rate | Cards and Payments | ||
Sensitivity of key judgements | ||
Change required to reduce headroom to zero | 0.018 | |
Terminal growth rate | Personal Banking | ||
Sensitivity of key judgements | ||
Change required to reduce headroom to zero | (0.026) | |
Terminal growth rate | Cards and Payments | ||
Sensitivity of key judgements | ||
Change required to reduce headroom to zero | (0.027) | |
Allocated capital rate | Personal Banking | ||
Sensitivity of key judgements | ||
Change required to reduce headroom to zero | 0.026 | |
Allocated capital rate | Cards and Payments | ||
Sensitivity of key judgements | ||
Change required to reduce headroom to zero | 0.023 | |
Cashflows | Personal Banking | ||
Sensitivity of key judgements | ||
Change required to reduce headroom to zero | (0.122) | |
Cashflows | Cards and Payments | ||
Sensitivity of key judgements | ||
Change required to reduce headroom to zero | (0.133) |
Other liabilities (Details)
Other liabilities (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Accruals and deferred income including contract liabilities [abstract] | |||
Accruals and deferred income | £ 4,173 | £ 3,683 | |
Other creditors | 4,793 | 3,447 | |
Items in the course of collection due to other banks | 202 | 88 | |
Lease liabilities (refer to Note 21) | 1,317 | 1,444 | |
Liabilities included in disposal groups classified as held for sale | 20 | 0 | |
Other liabilities | £ 10,505 | [1] | £ 8,662 |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Provisions - Movement in reserv
Provisions - Movement in reserves (Details) £ in Millions | 12 Months Ended | |
Dec. 31, 2021GBP (£) | ||
Reconciliation of changes in other provisions [abstract] | ||
Provisions, Beginning balance | £ 2,304 | |
Additions | 1,124 | |
Amounts utilised | (613) | |
Unused amounts reversed | (880) | |
Exchange and other movements | (27) | |
Provisions, Ending balance | 1,908 | [1] |
Onerous contracts | ||
Reconciliation of changes in other provisions [abstract] | ||
Provisions, Beginning balance | 28 | |
Additions | 6 | |
Amounts utilised | (11) | |
Unused amounts reversed | (18) | |
Exchange and other movements | 0 | |
Provisions, Ending balance | 5 | |
Redundancy and restructuring | ||
Reconciliation of changes in other provisions [abstract] | ||
Provisions, Beginning balance | 158 | |
Additions | 316 | |
Amounts utilised | (82) | |
Unused amounts reversed | (25) | |
Exchange and other movements | (41) | |
Provisions, Ending balance | 326 | |
Undrawn contractually committed facilities and guarantees | ||
Reconciliation of changes in other provisions [abstract] | ||
Provisions, Beginning balance | 1,064 | |
Additions | 124 | |
Amounts utilised | 0 | |
Unused amounts reversed | (638) | |
Exchange and other movements | (8) | |
Provisions, Ending balance | 542 | |
Customer redress | ||
Reconciliation of changes in other provisions [abstract] | ||
Provisions, Beginning balance | 497 | |
Additions | 408 | |
Amounts utilised | (318) | |
Unused amounts reversed | (54) | |
Exchange and other movements | (3) | |
Provisions, Ending balance | 530 | |
Legal, competition and regulatory matters | ||
Reconciliation of changes in other provisions [abstract] | ||
Provisions, Beginning balance | 268 | |
Additions | 72 | |
Amounts utilised | (62) | |
Unused amounts reversed | (44) | |
Exchange and other movements | (8) | |
Provisions, Ending balance | 226 | |
Sundry provisions | ||
Reconciliation of changes in other provisions [abstract] | ||
Provisions, Beginning balance | 289 | |
Additions | 198 | |
Amounts utilised | (140) | |
Unused amounts reversed | (101) | |
Exchange and other movements | 33 | |
Provisions, Ending balance | £ 279 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Provisions - Narrative (Details
Provisions - Narrative (Details) £ in Millions, $ in Billions | Dec. 31, 2021GBP (£) | Dec. 31, 2020GBP (£) | Mar. 10, 2022USD ($) |
US | Over issuance of securities | |||
Disclosure of other provisions [line items] | |||
Increase (decrease) in other provisions | £ 220 | £ 0 | |
US | Over issuance of securities | Disclosure of post year end balances | |||
Disclosure of other provisions [line items] | |||
Securities issues in excess of limit | $ | $ 13 | ||
Not more than one year | |||
Disclosure of other provisions [line items] | |||
Expected reimbursement | £ 1,754 | £ 1,751 |
Contingent liabilities and co_3
Contingent liabilities and commitments - Summary (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Total contingent liabilities and financial guarantees | ||
Disclosure of contingent liabilities [line items] | ||
Notional contract amount | £ 21,346 | £ 21,609 |
Total commitments | ||
Disclosure of contingent liabilities [line items] | ||
Notional contract amount | 345,711 | 333,049 |
of which: carried at fair value | Total contingent liabilities and financial guarantees | ||
Disclosure of contingent liabilities [line items] | ||
Notional contract amount | 231 | 229 |
of which: carried at fair value | Total commitments | ||
Disclosure of contingent liabilities [line items] | ||
Notional contract amount | 18,571 | 9,269 |
Guarantees and letters of credit pledged as collateral security | Total contingent liabilities and financial guarantees | ||
Disclosure of contingent liabilities [line items] | ||
Notional contract amount | 15,549 | 15,665 |
Performance guarantees, acceptances and endorsements | Total contingent liabilities and financial guarantees | ||
Disclosure of contingent liabilities [line items] | ||
Notional contract amount | 5,797 | 5,944 |
Documentary credits and other short-term trade related transactions | Total commitments | ||
Disclosure of contingent liabilities [line items] | ||
Notional contract amount | 1,584 | 1,086 |
Standby facilities, credit lines and other commitments | Total commitments | ||
Disclosure of contingent liabilities [line items] | ||
Notional contract amount | £ 344,127 | £ 331,963 |
Contingent liabilities and co_4
Contingent liabilities and commitments - Narrative (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of contingent liabilities [line items] | |||
Provisions | £ 1,908 | [1] | £ 2,304 |
Expected credit losses held against contingent liabilities and commitments | |||
Disclosure of contingent liabilities [line items] | |||
Provisions | £ 542 | £ 1,064 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Legal, competition and regula_2
Legal, competition and regulatory matters (Narrative) (Details) € in Millions, £ in Millions, SFr in Millions, $ in Millions | Dec. 31, 2021GBP (£) | Dec. 31, 2021EUR (€) | Jun. 30, 2021USD ($) | Apr. 30, 2021USD ($) | Dec. 31, 2020USD ($)defendantpensionFund | Jun. 30, 2019CHF (SFr)settlement | May 31, 2019EUR (€)settlement | May 31, 2021USD ($) | Jul. 01, 2007lawsuits | Dec. 31, 2021GBP (£)plaintifflawsuitssettlement | Dec. 31, 2021EUR (€)plaintifflawsuitssettlement | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | Dec. 31, 2018GBP (£) | Dec. 31, 2018USD ($) | Dec. 31, 2016lawsuits | Dec. 31, 2015USD ($) | Dec. 31, 2013GBP (£) | Dec. 31, 2012USD ($)lawsuits | Dec. 31, 2008USD ($)agreement | Mar. 10, 2022USD ($) | Mar. 31, 2022GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Aug. 31, 2020GBP (£) | |
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Litigation and conduct | £ | £ 397 | [1] | £ 153 | £ 1,849 | ||||||||||||||||||||||
Contingent liabilities | £ | £ 21,346 | £ 21,346 | 21,609 | |||||||||||||||||||||||
Customer remediation provision | Disclosure of post year end balances | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Other provisions | £ | £ 181 | |||||||||||||||||||||||||
Over issuance of securities | US | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Increase (decrease) in other provisions | £ | £ 220 | £ 0 | ||||||||||||||||||||||||
Over issuance of securities | US | Disclosure of post year end balances | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Securities issues in excess of limit | $ 13,000 | |||||||||||||||||||||||||
USD LIBOR cases in MDL court | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Number of court approved settlements | settlement | 2 | 2 | ||||||||||||||||||||||||
Sterling LIBOR case in SDNY | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Number of lawsuits with damages sought | lawsuits | 2 | |||||||||||||||||||||||||
Foreign exchange investigations | SEC | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Litigation and conduct | SFr | SFr 27 | |||||||||||||||||||||||||
Foreign exchange investigations | Fines settlement | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Number of court approved settlements | settlement | 2 | 2 | ||||||||||||||||||||||||
Litigation and conduct | € | € 54 | € 210 | ||||||||||||||||||||||||
Non-US forex civil actions | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Number of lawsuits with damages sought | lawsuits | 2 | 2 | ||||||||||||||||||||||||
Metals related civil actions | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Litigation and conduct | € | € 50 | |||||||||||||||||||||||||
US residential and commercial mortgage-related activity and litigation | RMBS repurchase requests | Originated and sold to third parties by acquired subsidiary | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Number of lawsuits with damages sought | 4 | 2 | 2 | |||||||||||||||||||||||
Number of court approved settlements | settlement | 1 | 1 | ||||||||||||||||||||||||
Number of lawsuits dismissed | settlement | 1 | 1 | ||||||||||||||||||||||||
US residential and commercial mortgage-related activity and litigation | Legacy RMBS purchases | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Litigation and conduct | $ 32.5 | |||||||||||||||||||||||||
Number of defendants | defendant | 6 | |||||||||||||||||||||||||
Asset-backed debt instruments held | $ 22 | |||||||||||||||||||||||||
US residential and commercial mortgage-related activity and litigation | Legacy RMBS purchases | NEW MEXICO | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Number of retirement benefit funds | pensionFund | 2 | |||||||||||||||||||||||||
Supranational, Sovereign and Agency Bonds civil actions | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Number of lawsuits dismissed | lawsuits | 1 | 1 | ||||||||||||||||||||||||
Civil Actions In Respect Of VRDO - Private Plaintiffs | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Number of lawsuits with damages sought | lawsuits | 2 | 2 | ||||||||||||||||||||||||
Civil actions in respect of VRDO - SNDY | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Number of lawsuits with damages sought | lawsuits | 3 | 3 | ||||||||||||||||||||||||
Government and agency securities civil actions and related matters | Barclays Capital Inc. | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Litigation and conduct | $ 87 | |||||||||||||||||||||||||
Civil actions in respect of the US Anti-Terrorism Act - EDNY | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Number of lawsuits with damages sought | lawsuits | 6 | 6 | ||||||||||||||||||||||||
Number of lawsuits dismissed | lawsuits | 3 | 3 | ||||||||||||||||||||||||
Number of plaintiffs | plaintiff | 4,000 | 4,000 | ||||||||||||||||||||||||
Number of lawsuits subject to appeal | lawsuits | 1 | 1 | ||||||||||||||||||||||||
Civil actions in respect of the US Anti-Terrorism Act - SDNY | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Number of lawsuits with damages sought | lawsuits | 2 | 2 | ||||||||||||||||||||||||
Derivative transactions civil action | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Value of damages sought | £ | £ 329 | |||||||||||||||||||||||||
CFS remediation of ASL loans | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Expected reimbursement | £ | £ 37.4 | |||||||||||||||||||||||||
HMRC assessments concerning UK VAT | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Value of damages sought | £ | £ 181 | |||||||||||||||||||||||||
HMRC assessments concerning UK VAT | Barclays UK | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Value of damages sought | £ | 128 | |||||||||||||||||||||||||
Over issuance of securities | US | Disclosure of post year end balances | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Securities issue limit | 20,800 | |||||||||||||||||||||||||
Securities issues in excess of limit | 15,000 | |||||||||||||||||||||||||
Contingent liabilities | $ 2,000 | |||||||||||||||||||||||||
Barclays Bank PLC | FCA Proceedings and other investigations | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Number of advisory service agreements | agreement | 2 | |||||||||||||||||||||||||
Financial penalty warning | £ | £ 50 | |||||||||||||||||||||||||
Barclays Bank PLC | USD LIBOR cases in MDL court | Lawsuits with damages sought | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Number of lawsuits with damages sought | lawsuits | 3 | |||||||||||||||||||||||||
Value of damages sought | $ 100 | |||||||||||||||||||||||||
Barclays Bank PLC | USD LIBOR cases in MDL court | Exchange-based class claims | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Litigation and conduct | $ 7.5 | $ 7.1 | ||||||||||||||||||||||||
Barclays Bank PLC | USD LIBOR cases in MDL court | Debt securities class claims | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Litigation and conduct | $ 20 | |||||||||||||||||||||||||
Barclays Bank PLC | Foreign exchange investigations | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Litigation and conduct | $ 2,380 | |||||||||||||||||||||||||
Barclays Bank PLC | Consolidated FX action | Barclays Capital Inc. | SEC | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Litigation and conduct | $ 384 | |||||||||||||||||||||||||
Barclays Bank PLC | US residential and commercial mortgage-related activity and litigation | RMBS repurchase requests | Originated and sold to third parties by acquired subsidiary | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Unpaid principal balance at time of sale | $ 2,100 | |||||||||||||||||||||||||
Barclays Bank PLC | Government and agency securities civil actions and related matters | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Litigation and conduct | $ 5.7 | |||||||||||||||||||||||||
Barclays Bank PLC | BDC Finance LLC | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Value of litigation settlements approved | $ 3.3 | $ 298 | ||||||||||||||||||||||||
Barclays Bank PLC | HMRC assessments concerning UK VAT | ||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||
Value of damages sought | £ | £ 53 | |||||||||||||||||||||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Subordinated liabilities - Acco
Subordinated liabilities - Accounting for subordinated liabilities (Details) £ in Millions, $ in Millions | 12 Months Ended | ||||
Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | ||
Subordinated liabilities [abstract] | |||||
As at 1 January | £ 16,341 | £ 18,156 | |||
Issuance of subordinated liabilities | 1,890 | [1] | $ 1,890 | 1,438 | £ 1,352 |
Redemptions | (4,807) | (3,464) | |||
Other | (665) | 211 | |||
As at 31 December | £ 12,759 | [2] | £ 16,341 | £ 18,156 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Subordinated liabilities - Narr
Subordinated liabilities - Narrative (Details) £ in Millions, $ in Millions | 1 Months Ended | 12 Months Ended | ||||
Dec. 31, 2020USD ($) | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | ||
Disclosure of detailed information about borrowings [line items] | ||||||
Issuance of subordinated liabilities | £ 1,890 | [1] | $ 1,890 | £ 1,438 | £ 1,352 | |
Redemption of subordinated debt | 4,807 | [1] | 3,258 | 3,248 | ||
Barclays PLC | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Issuance of subordinated liabilities | 1,579 | £ 158 | £ 1,194 | |||
1.125% Fixed Rate Resetting Subordinated Callable Notes (EUR 1,000m) | Fixed interest rate | Barclays PLC | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Issuance of subordinated liabilities | £ 855 | |||||
Interest rate | 1.125% | 1.125% | ||||
3.811% Fixed Rate Resetting Subordinated Callable Notes due 2042 | Fixed interest rate | Barclays PLC | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Issuance of subordinated liabilities | £ 724 | |||||
Interest rate | 3.811% | 3.811% | ||||
USD Notes | Floating interest rate | Other (outside the UK and US tax groups) | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Issuance of subordinated liabilities | £ 229 | |||||
Redemption of subordinated debt | 146 | |||||
South African Rand notes | Floating interest rate | Other (outside the UK and US tax groups) | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Issuance of subordinated liabilities | £ 82 | |||||
10% Fixed Rate Subordinated Notes, Due 2021 | Fixed interest rate | Barclays Bank PLC | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Interest rate | 10.00% | 10.00% | 10.00% | 10.00% | ||
Redemption of subordinated debt | £ 1,961 | |||||
6% Fixed Rate Subordinated Notes (EUR 1,500m), Due 2021 | Fixed interest rate | Barclays Bank PLC | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Interest rate | 6.00% | 6.00% | 6.00% | 6.00% | ||
Redemption of subordinated debt | £ 1,339 | |||||
10.179% Fixed Rate Subordinated Notes (USD 1,521m), Due 2021 | Fixed interest rate | Barclays Bank PLC | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Interest rate | 10.179% | 10.179% | 10.179% | 10.179% | ||
Redemption of subordinated debt | £ 1,075 | |||||
9.5% Subordinated Bonds (ex-Woolwich Plc), Due 2021 | Barclays Bank PLC | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Interest rate | 9.50% | 9.50% | 9.50% | 9.50% | ||
Redemption of subordinated debt | £ 200 | |||||
Subordinated Floating Rate Notes (EUR 68m), Due 2040 | Floating interest rate | Barclays Bank PLC | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Redemption of subordinated debt | £ 86 | |||||
Junior Undated Floating Rate Notes (GBP 67m) | Floating interest rate | Other (outside the UK and US tax groups) | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Reclassification from debt instruments | $ | $ 67 | |||||
4.836% Fixed Rate Subordinated Callable Notes due 2028 | Fixed interest rate | Barclays PLC | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Interest rate | 4.836% | 4.836% | ||||
3.75% Resetting Subordinated Callable Note (SGD 200m), Due 2030 | Fixed interest rate | Barclays PLC | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Interest rate | 3.75% | 3.75% | ||||
3.75% Resetting Subordinated Callable Notes (GBP 500m), Due 2030 | Fixed interest rate | Barclays PLC | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Interest rate | 3.75% | 3.75% | ||||
3.564% Fixed Rate Resetting Subordinated Callable Notes due 2035 | Fixed interest rate | Barclays PLC | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Interest rate | 3.564% | 3.564% | ||||
5.088% Fixed-to-Floating Rate Subordinated Notes due 2030 | Fixed-to-Floating Interest Rate | Barclays PLC | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Interest rate | 5.088% | 5.088% | ||||
7.625% Contingent Capital Notes (USD 3,000m), Due 2022 | Barclays Bank PLC | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Interest rate | 7.625% | 7.625% | ||||
Consideration if CET1 ratio falls below threshold | £ 0 | |||||
7.625% Contingent Capital Notes (USD 3,000m), Due 2022 | Barclays Bank PLC | Minimum | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Transitional CET1 ratio | 7.00% | 7.00% | ||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Subordinated liabilities - Unda
Subordinated liabilities - Undated and dated (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Subordinated liabilities [abstract] | ||||
Undated subordinated liabilities | £ 355 | £ 308 | ||
Dated subordinated liabilities | 12,404 | 16,033 | ||
Total subordinated liabilities | £ 12,759 | [1] | £ 16,341 | £ 18,156 |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Subordinated liabilities - Un_2
Subordinated liabilities - Undated (Details) £ in Millions, $ in Millions | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) |
Disclosure of detailed information about borrowings [line items] | |||
Undated subordinated liabilities | £ 355 | £ 308 | |
Barclays Bank PLC | |||
Disclosure of detailed information about borrowings [line items] | |||
Undated subordinated liabilities | 355 | 308 | |
6% Callable Perpetual Core Tier One Notes | Barclays Bank PLC | |||
Disclosure of detailed information about borrowings [line items] | |||
Undated subordinated liabilities | £ 15 | 17 | |
Interest rate | 6.00% | 6.00% | |
6.86% Callable Perpetual Core Tier One Notes (USD 179m) | Barclays Bank PLC | |||
Disclosure of detailed information about borrowings [line items] | |||
Undated subordinated liabilities | £ 194 | 205 | |
Interest rate | 6.86% | 6.86% | |
Notional contract amount | $ | $ 179 | ||
5.3304% Step-up Callable Perpetual Reserve Capital Instruments | Barclays Bank PLC | |||
Disclosure of detailed information about borrowings [line items] | |||
Undated subordinated liabilities | £ 51 | 56 | |
Interest rate | 5.3304% | 5.3304% | |
Junior Undated Floating Rate Notes (USD 38m) | Floating interest rate | Barclays Bank PLC | |||
Disclosure of detailed information about borrowings [line items] | |||
Undated subordinated liabilities | £ 28 | 28 | |
Notional contract amount | $ | $ 38 | ||
Junior Undated Floating Rate Notes (GBP 67m) | Floating interest rate | Other (outside the UK and US tax groups) | |||
Disclosure of detailed information about borrowings [line items] | |||
Undated subordinated liabilities | £ 67 | £ 0 | |
Notional contract amount | $ | $ 67 |
Subordinated liabilities - Date
Subordinated liabilities - Dated (Details) | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2021EUR (€) | Dec. 31, 2021SGD ($) | Dec. 31, 2021JPY (¥) | Dec. 31, 2020GBP (£) | Dec. 31, 2020USD ($) | Dec. 31, 2020EUR (€) |
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 12,404,000,000 | £ 16,033,000,000 | ||||||
External issuances by other subsidiaries | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | 311,000,000 | 146,000,000 | ||||||
2% Fixed Rate Subordinated Callable Notes (EUR 1,500m), Due 2028 | Fixed interest rate | Barclays PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 1,283,000,000 | 1,384,000,000 | ||||||
Interest rate | 2.00% | 2.00% | 2.00% | 2.00% | 2.00% | |||
Notional contract amount | € | € 1,500,000,000 | |||||||
4.375% Fixed Rate Subordinated Notes due 2024 | Fixed interest rate | Barclays PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 974,000,000 | 990,000,000 | ||||||
Interest rate | 4.375% | 4.375% | 4.375% | 4.375% | 4.375% | |||
Notional contract amount | $ | $ 1,250,000,000 | |||||||
3.75% Resetting Subordinated Callable Notes (GBP 500m), Due 2030 | Fixed interest rate | Barclays PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 483,000,000 | 504,000,000 | ||||||
Interest rate | 3.75% | 3.75% | 3.75% | 3.75% | 3.75% | |||
Notional contract amount | £ 500,000,000 | |||||||
3.75% Resetting Subordinated Callable Note (SGD 200m), Due 2030 | Fixed interest rate | Barclays PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 113,000,000 | 119,000,000 | ||||||
Interest rate | 3.75% | 3.75% | 3.75% | 3.75% | 3.75% | |||
Notional contract amount | $ | $ 200,000,000 | |||||||
5.20% Fixed Rate Subordinated Notes due 2026 | Fixed interest rate | Barclays PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 1,564,000,000 | 1,610,000,000 | ||||||
Interest rate | 5.20% | 5.20% | 5.20% | 5.20% | 5.20% | |||
Notional contract amount | $ | $ 2,050,000,000 | |||||||
1.125% Fixed Rate Resetting Subordinated Callable Notes (EUR 1,000m) | Fixed interest rate | Barclays PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 833,000,000 | 0 | ||||||
Interest rate | 1.125% | 1.125% | 1.125% | 1.125% | 1.125% | |||
Notional contract amount | € | € 1,000,000,000 | |||||||
4.836% Fixed Rate Subordinated Callable Notes due 2028 | Fixed interest rate | Barclays PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 1,564,000,000 | 1,627,000,000 | ||||||
Interest rate | 4.836% | 4.836% | 4.836% | 4.836% | 4.836% | |||
Notional contract amount | $ | $ 2,000,000,000 | |||||||
5.088% Fixed-to-Floating Rate Subordinated Notes due 2030 | Fixed-to-Floating Interest Rate | Barclays PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 1,162,000,000 | 1,213,000,000 | ||||||
Interest rate | 5.088% | 5.088% | 5.088% | 5.088% | 5.088% | |||
Notional contract amount | $ | $ 1,500,000,000 | |||||||
3.564% Fixed Rate Resetting Subordinated Callable Notes due 2035 | Fixed interest rate | Barclays PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 696,000,000 | 703,000,000 | ||||||
Interest rate | 3.564% | 3.564% | 3.564% | 3.564% | 3.564% | |||
Notional contract amount | $ | $ 1,000,000,000 | |||||||
3.811% Fixed Rate Resetting Subordinated Callable Notes due 2042 | Fixed interest rate | Barclays PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 782,000,000 | 0 | ||||||
Interest rate | 3.811% | 3.811% | 3.811% | 3.811% | 3.811% | |||
Notional contract amount | $ | $ 1,000,000,000 | |||||||
6% Fixed Rate Subordinated Notes (EUR 1,500m), Due 2021 | Fixed interest rate | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 0 | £ 1,427,000,000 | ||||||
Interest rate | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% |
Notional contract amount | € | € 1,500,000,000 | |||||||
9.5% Subordinated Bonds (ex-Woolwich Plc), Due 2021 | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 0 | £ 221,000,000 | ||||||
Interest rate | 9.50% | 9.50% | 9.50% | 9.50% | 9.50% | 9.50% | 9.50% | 9.50% |
Subordinated Floating Rate Notes (EUR 100m), Due 2021 | Floating interest rate | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 0 | £ 90,000,000 | ||||||
Notional contract amount | € | € 100,000,000 | |||||||
10% Fixed Rate Subordinated Notes, Due 2021 | Fixed interest rate | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 0 | £ 2,108,000,000 | ||||||
Interest rate | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% |
10.179% Fixed Rate Subordinated Notes (USD 1,521m), Due 2021 | Fixed interest rate | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 0 | £ 1,101,000,000 | ||||||
Interest rate | 10.179% | 10.179% | 10.179% | 10.179% | 10.179% | 10.179% | 10.179% | 10.179% |
Notional contract amount | $ | $ 1,521,000,000 | |||||||
Subordinated Floating Rate Notes (EUR 50m), Due 2022 | Floating interest rate | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 42,000,000 | £ 45,000,000 | ||||||
Notional contract amount | € | € 50,000,000 | |||||||
6.625% Fixed Rate Subordinated Notes (EUR 1,000m), Due 2022 | Fixed interest rate | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 889,000,000 | 982,000,000 | ||||||
Interest rate | 6.625% | 6.625% | 6.625% | 6.625% | 6.625% | |||
Notional contract amount | € | € 1,000,000,000 | |||||||
7.625% Contingent Capital Notes (USD 3,000m), Due 2022 | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 1,133,000,000 | 1,132,000,000 | ||||||
Interest rate | 7.625% | 7.625% | 7.625% | 7.625% | 7.625% | |||
Notional contract amount | $ | $ 3,000,000,000 | |||||||
Subordinated Floating Rate Notes (EUR 50m), Due 2023 BCS23C | Floating interest rate | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 42,000,000 | 45,000,000 | ||||||
Notional contract amount | € | € 50,000,000 | |||||||
5.75% Fixed Rate Subordinated Notes, Due 2026 | Fixed interest rate | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 322,000,000 | 351,000,000 | ||||||
Interest rate | 5.75% | 5.75% | 5.75% | 5.75% | 5.75% | |||
5.4% Reverse Dual Currency Subordinated Loan (JPY 15,000m), Due 2027 | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 97,000,000 | 108,000,000 | ||||||
Interest rate | 5.40% | 5.40% | 5.40% | 5.40% | 5.40% | |||
Notional contract amount | ¥ | ¥ 15,000,000,000 | |||||||
6.33% Subordinated Notes, Due 2032 | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 59,000,000 | 64,000,000 | ||||||
Interest rate | 6.33% | 6.33% | 6.33% | 6.33% | 6.33% | |||
Subordinated Floating Rate Notes (EUR 68m), Due 2040 | Floating interest rate | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 57,000,000 | £ 61,000,000 | ||||||
Notional contract amount | € | € 68,000,000 |
Ordinary shares, share premiu_3
Ordinary shares, share premium, and other equity - Called up share capital, allotted and fully paid (Details) - GBP (£) £ in Millions, shares in Millions | 12 Months Ended | ||||||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |||||
Reconciliation of equity instruments [Roll Forward] | |||||||
Beginning balance, equity | £ 66,882 | [1] | £ 65,660 | [1] | £ 63,779 | ||
Issue of shares under employee share schemes | 295 | [1] | 346 | [1] | 579 | ||
Repurchase of shares | [1] | (1,200) | |||||
Other movements | (14) | [1] | 5 | [1] | 3 | ||
Ending balance, equity | 70,041 | [2] | 66,882 | [1] | 65,660 | [1] | |
Total share capital and share premium | |||||||
Reconciliation of equity instruments [Roll Forward] | |||||||
Beginning balance, equity | [3] | 4,637 | 4,594 | 4,311 | |||
Issue of shares under employee share schemes | [3] | 60 | 43 | 101 | |||
AT1 securities issuance | 0 | 0 | |||||
Repurchase of shares | [3] | (161) | |||||
AT1 securities redemption | 0 | ||||||
Other movements | 0 | 0 | |||||
Ending balance, equity | [3] | 4,536 | 4,637 | 4,594 | |||
Other equity instruments | |||||||
Reconciliation of equity instruments [Roll Forward] | |||||||
Beginning balance, equity | [3] | 11,172 | 10,871 | 9,632 | |||
Issue of shares under employee share schemes | 0 | 0 | |||||
AT1 securities issuance | 1,078 | 1,142 | |||||
Repurchase of shares | 0 | ||||||
AT1 securities redemption | (831) | ||||||
Other movements | [3] | 9 | (10) | 1 | |||
Ending balance, equity | [3] | £ 12,259 | £ 11,172 | £ 10,871 | |||
Ordinary shares | |||||||
Reconciliation of number of shares outstanding [abstract] | |||||||
Beginning balance, shares | 17,359 | 17,322 | |||||
Issued to staff under share incentive plans | 37 | 37 | |||||
Repurchase of shares | (644) | ||||||
Ending balance, shares | 16,752 | 17,359 | 17,322 | ||||
Ordinary shares | Ordinary share capital | |||||||
Reconciliation of equity instruments [Roll Forward] | |||||||
Beginning balance, equity | £ 4,340 | £ 4,331 | |||||
Issue of shares under employee share schemes | 9 | 9 | |||||
AT1 securities issuance | 0 | 0 | |||||
Repurchase of shares | (161) | 0 | |||||
AT1 securities redemption | 0 | ||||||
Other movements | 0 | 0 | |||||
Ending balance, equity | 4,188 | 4,340 | £ 4,331 | ||||
Ordinary shares | Ordinary share premium | |||||||
Reconciliation of equity instruments [Roll Forward] | |||||||
Beginning balance, equity | 297 | 263 | |||||
Issue of shares under employee share schemes | 51 | 34 | |||||
AT1 securities issuance | 0 | 0 | |||||
Repurchase of shares | 0 | ||||||
AT1 securities redemption | 0 | ||||||
Other movements | 0 | 0 | |||||
Ending balance, equity | £ 348 | £ 297 | £ 263 | ||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||||
[3] | For further details refer to Note 28. |
Ordinary shares, share premiu_4
Ordinary shares, share premium, and other equity - Narrative (Details) £ / shares in Units, £ in Millions, shares in Millions | 12 Months Ended | ||||||||
Dec. 31, 2021GBP (£)dummyRedemptions£ / sharesshares | Dec. 31, 2020GBP (£)dummyRedemptionsshares | May 05, 2021£ / sharesshares | Dec. 31, 2019GBP (£)shares | Dec. 31, 2018GBP (£) | |||||
Repurchase of shares | [1] | £ 1,200 | |||||||
Total equity | £ 70,041 | [2] | £ 66,882 | [1] | £ 65,660 | [1] | £ 63,779 | ||
Ordinary shares | |||||||||
Number of shares outstanding (in shares) | shares | 16,752 | 17,359 | 17,322 | ||||||
Par value per share (in GBP per share) | £ / shares | £ 0.25 | £ 0.25 | |||||||
Shares authorized for repurchase (in shares) | shares | 1,737 | ||||||||
Repurchase of shares | shares | 644 | ||||||||
Ordinary share capital | Ordinary shares | |||||||||
Repurchase of shares | £ 161 | £ 0 | |||||||
Total equity | 4,188 | 4,340 | £ 4,331 | ||||||
AT1 securities issuance | 0 | 0 | |||||||
Reduction of issued capital | 0 | ||||||||
Other equity instruments | |||||||||
Repurchase of shares | 0 | ||||||||
Total equity | [3] | 12,259 | 11,172 | £ 10,871 | £ 9,632 | ||||
AT1 securities issuance | £ 1,078 | 1,142 | |||||||
Reduction of issued capital | £ 831 | ||||||||
AT1 Securities | Fixed rate resetting perpetual subordinated contingent convertible Securities | |||||||||
Number of convertible instruments issued | dummy | 1 | 1 | |||||||
AT1 securities issuance | £ 1,078 | £ 1,142 | |||||||
Issuance costs | £ 4 | £ 4 | |||||||
Number of convertible instruments redeemed | Redemptions | 0 | 1 | |||||||
Reduction of issued capital | £ 831 | ||||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||||||
[3] | For further details refer to Note 28. |
Ordinary shares, share premiu_5
Ordinary shares, share premium, and other equity - AT1 Equity instruments (Details) £ in Millions, $ in Millions | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | |
Other equity instruments | £ 12,259 | [1] | £ 11,172 | |
Barclays PLC | ||||
Other equity instruments | 12,241 | 11,169 | ||
AT1 equity instruments | Barclays PLC | Fixed interest rate | ||||
Other equity instruments | 12,259 | 11,172 | ||
AT1 equity instruments | 7.875% Perpetual Subordinated Contingent Convertible Securities | Barclays PLC | Fixed interest rate | ||||
Other equity instruments | £ 995 | 986 | ||
Interest rate | 7.875% | 7.875% | ||
AT1 equity instruments | 7.875% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) | Barclays PLC | Fixed interest rate | ||||
Other equity instruments | £ 1,131 | 1,131 | ||
Interest rate | 7.875% | 7.875% | ||
Notional contract amount | $ | $ 1,500 | |||
AT1 equity instruments | 7.25% Perpetual Subordinated Contingent Convertible Securities | Barclays PLC | Fixed interest rate | ||||
Other equity instruments | £ 1,245 | 1,245 | ||
Interest rate | 7.25% | 7.25% | ||
AT1 equity instruments | 7.75% Perpetual Subordinated Contingent Convertible Securities (USD 2,500m) | Barclays PLC | Fixed interest rate | ||||
Other equity instruments | £ 1,924 | 1,925 | ||
Interest rate | 7.75% | 7.75% | ||
Notional contract amount | $ | $ 2,500 | |||
AT1 equity instruments | 5.875% Perpetual Subordinated Contingent Convertible Securities | Barclays PLC | Fixed interest rate | ||||
Other equity instruments | £ 1,244 | 1,244 | ||
Interest rate | 5.875% | 5.875% | ||
AT1 equity instruments | 8% Perpetual Subordinated Contingent Convertible Securities (USD 2,000m) | Barclays PLC | Fixed interest rate | ||||
Other equity instruments | £ 1,509 | 1,509 | ||
Interest rate | 8.00% | 8.00% | ||
Notional contract amount | $ | $ 2,000 | |||
AT1 equity instruments | 7.125% Perpetual Subordinated Contingent Convertible Securities | Barclays PLC | Fixed interest rate | ||||
Other equity instruments | £ 996 | 994 | ||
Interest rate | 7.125% | 7.125% | ||
AT1 equity instruments | 6.375% Perpetual Subordinated Contingent Convertible Securities | Barclays PLC | Fixed interest rate | ||||
Other equity instruments | £ 996 | 996 | ||
Interest rate | 6.375% | 6.375% | ||
AT1 equity instruments | 6.125% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) | Barclays PLC | Fixed interest rate | ||||
Other equity instruments | £ 1,141 | 1,142 | ||
Interest rate | 6.125% | 6.125% | ||
Notional contract amount | $ | $ 1,500 | |||
AT1 equity instruments | 4.375% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) | Barclays PLC | Fixed interest rate | ||||
Other equity instruments | £ 1,078 | £ 0 | ||
Interest rate | 4.375% | 4.375% | ||
Notional contract amount | $ | $ 1,500 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Reserves (Details)
Reserves (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of reserves within equity [line items] | |||
Total Reserves | £ 1,770 | [1] | £ 4,461 |
Currency translation reserve | |||
Disclosure of reserves within equity [line items] | |||
Total Reserves | 2,740 | 2,871 | |
Fair value through other comprehensive income reserve | |||
Disclosure of reserves within equity [line items] | |||
Total Reserves | (283) | 5 | |
Cash flow hedging reserve | |||
Disclosure of reserves within equity [line items] | |||
Total Reserves | (853) | 1,575 | |
Own credit reserve | |||
Disclosure of reserves within equity [line items] | |||
Total Reserves | (960) | (954) | |
Other reserves and treasury shares | |||
Disclosure of reserves within equity [line items] | |||
Total Reserves | £ 1,126 | £ 964 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Non-controlling interests - by
Non-controlling interests - by group (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of classes of share capital [line items] | ||||
Profit attributable to non-controlling interest | £ 47 | [1] | £ 78 | £ 80 |
Equity attributable to non-controlling interest | 989 | [2] | 1,085 | |
Dividends paid to non-controlling interest | 44 | 79 | ||
Other non-controlling interests | ||||
Disclosure of classes of share capital [line items] | ||||
Profit attributable to non-controlling interest | 3 | (1) | ||
Equity attributable to non-controlling interest | 2 | 23 | ||
Dividends paid to non-controlling interest | 0 | 0 | ||
– Preference shares | Barclays Bank PLC | ||||
Disclosure of classes of share capital [line items] | ||||
Profit attributable to non-controlling interest | 27 | 42 | ||
Equity attributable to non-controlling interest | 529 | 529 | ||
Dividends paid to non-controlling interest | 27 | 42 | ||
– Upper Tier 2 instruments | Barclays Bank PLC | ||||
Disclosure of classes of share capital [line items] | ||||
Profit attributable to non-controlling interest | 17 | 37 | ||
Equity attributable to non-controlling interest | 458 | 533 | ||
Dividends paid to non-controlling interest | £ 17 | £ 37 | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Non-controlling interests - Nar
Non-controlling interests - Narrative (Details) £ in Millions | 12 Months Ended | |
Dec. 31, 2021GBP (£)dummyRedemptions | Dec. 31, 2020GBP (£)dummy | |
Non-controlling interests | – Upper Tier 2 instruments | ||
Disclosure of classes of share capital [line items] | ||
Number of instruments or interests issued or issuable | dummy | 0 | 0 |
Number of convertible instruments redeemed | Redemptions | 1 | |
Instruments redeemed | £ | £ 75 | £ 158 |
Barclays Bank PLC | 9.25% Perpetual Subordinated Bonds (ex Woolwich) (£150m) | – Upper Tier 2 instruments | ||
Disclosure of classes of share capital [line items] | ||
Interest rate | 9.25% | |
Barclays Bank PLC | 9% Permanent Interest Bearing Capital Bonds (£100m) | – Upper Tier 2 instruments | ||
Disclosure of classes of share capital [line items] | ||
Interest rate | 9.00% | |
Barclays Bank PLC | 6.125% Undated Subordinated Notes (£550m) | – Upper Tier 2 instruments | ||
Disclosure of classes of share capital [line items] | ||
Interest rate | 6.125% | |
Barclays Bank PLC | Barclays Bank PLC | ||
Disclosure of classes of share capital [line items] | ||
Non-controlling interests - proportion of voting interests | 100.00% |
Non-controlling interests - b_2
Non-controlling interests - by instruments (Details) £ in Millions, ¥ in Billions | Dec. 31, 2021GBP (£) | Dec. 31, 2021JPY (¥) | Dec. 31, 2020GBP (£) | |
Disclosure of classes of share capital [line items] | ||||
Non-controlling interests | £ 989 | [1] | £ 1,085 | |
– Preference shares | Barclays Bank PLC | ||||
Disclosure of classes of share capital [line items] | ||||
Non-controlling interests | 529 | 529 | ||
– Preference shares | US Dollar Preference Shares | Barclays Bank PLC | ||||
Disclosure of classes of share capital [line items] | ||||
Non-controlling interests | 318 | 318 | ||
– Preference shares | Euro Preference Shares | Barclays Bank PLC | ||||
Disclosure of classes of share capital [line items] | ||||
Non-controlling interests | 211 | 211 | ||
– Upper Tier 2 instruments | Barclays Bank PLC | ||||
Disclosure of classes of share capital [line items] | ||||
Non-controlling interests | 458 | 533 | ||
– Upper Tier 2 instruments | Undated Floating Rate Primary Capital Notes Series 1 | Barclays Bank PLC | Floating interest rate | ||||
Disclosure of classes of share capital [line items] | ||||
Non-controlling interests | 93 | 93 | ||
– Upper Tier 2 instruments | Undated Floating Rate Primary Capital Notes Series 2 | Barclays Bank PLC | Floating interest rate | ||||
Disclosure of classes of share capital [line items] | ||||
Non-controlling interests | 179 | 179 | ||
– Upper Tier 2 instruments | 5.03% Undated Reverse Dual Currency Subordinated Loan (JPY8bn) | Barclays Bank PLC | ||||
Disclosure of classes of share capital [line items] | ||||
Non-controlling interests | £ 39 | 39 | ||
Interest rate | 5.03% | 5.03% | ||
Notional contract amount | ¥ | ¥ 8 | |||
– Upper Tier 2 instruments | 5.0% Reverse Dual Currency Undated Subordinated Loan (JPY12bn) | Barclays Bank PLC | ||||
Disclosure of classes of share capital [line items] | ||||
Non-controlling interests | £ 53 | 53 | ||
Interest rate | 5.00% | 5.00% | ||
Notional contract amount | ¥ | ¥ 12 | |||
– Upper Tier 2 instruments | Undated Floating Rate Primary Capital Notes Series 3 (£145m) | Barclays Bank PLC | Floating interest rate | ||||
Disclosure of classes of share capital [line items] | ||||
Non-controlling interests | £ 20 | 20 | ||
Notional contract amount | 145 | |||
– Upper Tier 2 instruments | 9% Permanent Interest Bearing Capital Bonds (£100m) | Barclays Bank PLC | ||||
Disclosure of classes of share capital [line items] | ||||
Non-controlling interests | £ 40 | 40 | ||
Interest rate | 9.00% | 9.00% | ||
Notional contract amount | £ 100 | |||
– Upper Tier 2 instruments | 6.125% Undated Subordinated Notes (£550m) | Barclays Bank PLC | ||||
Disclosure of classes of share capital [line items] | ||||
Non-controlling interests | £ 34 | 34 | ||
Interest rate | 6.125% | 6.125% | ||
Notional contract amount | £ 550 | |||
– Upper Tier 2 instruments | 9.25% Perpetual Subordinated Bonds (ex Woolwich) (£150m) | Barclays Bank PLC | ||||
Disclosure of classes of share capital [line items] | ||||
Non-controlling interests | £ 0 | 75 | ||
Interest rate | 9.25% | 9.25% | ||
Notional contract amount | £ 150 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Staff costs (Details)
Staff costs (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Incentive awards granted: | ||||
Current year bonus | £ 1,278 | £ 1,090 | £ 1,058 | |
Deferred bonus | 667 | 490 | 432 | |
Total incentive awards granted | 1,945 | 1,580 | 1,490 | |
Reconciliation of incentive awards granted to income statement charge: | ||||
Less: deferred bonuses granted but not charged in current year | (457) | (335) | (293) | |
Add: current year charges for deferred bonuses from previous years | 280 | 293 | 308 | |
Other differences between incentive awards granted and income statement charge | (23) | (34) | (48) | |
Income statement charge for performance costs | 1,745 | 1,504 | 1,457 | |
Other income statement charges: | ||||
Salaries | 4,290 | 4,322 | 4,332 | |
Social security costs | 619 | 613 | 573 | |
Post-retirement benefits | 539 | 519 | 501 | |
Other compensation costs | 431 | 479 | 480 | |
Total compensation costs | 7,624 | 7,437 | 7,343 | |
Other resourcing costs: | ||||
Outsourcing | 357 | 342 | 433 | |
Redundancy and restructuring | 296 | 102 | 132 | |
Temporary staff costs | 109 | 102 | 256 | |
Other | 125 | 114 | 151 | |
Total other resourcing costs | 887 | 660 | 972 | |
Total staff costs | 8,511 | [1] | 8,097 | 8,315 |
Accruing benefits under defined benefit scheme | 539 | 519 | 501 | |
Compensation Costs | 7,624 | 7,437 | 7,343 | |
Internally generated | ||||
Other income statement charges: | ||||
Total compensation costs | 484 | 451 | 439 | |
Other resourcing costs: | ||||
Compensation Costs | 484 | 451 | 439 | |
Defined contribution schemes | ||||
Other income statement charges: | ||||
Post-retirement benefits | 289 | 279 | 270 | |
Other resourcing costs: | ||||
Accruing benefits under defined benefit scheme | 289 | 279 | 270 | |
Pension defined benefit plans | ||||
Other income statement charges: | ||||
Post-retirement benefits | 250 | 240 | 231 | |
Other resourcing costs: | ||||
Accruing benefits under defined benefit scheme | £ 250 | £ 240 | £ 231 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Share-based payments - Share ba
Share-based payments - Share based payments (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Total equity settled | £ 472 | £ 429 | £ 478 |
Cash settled | 5 | 2 | 3 |
Total share-based payments | 477 | 431 | 481 |
Deferred Share Value Plan and Share Value Plan | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Total equity settled | 256 | 245 | 272 |
Others | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Total equity settled | £ 216 | £ 184 | £ 206 |
Share-based payments - Share op
Share-based payments - Share options and awards (Details) £ / shares in Units, shares in Thousands | 12 Months Ended | ||
Dec. 31, 2021GBP (£)shares£ / shares | Dec. 31, 2020GBP (£)shares£ / shares | Dec. 31, 2019shares | |
Share value plan | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Weighted average fair value per award granted in year | £ | £ 1.62 | £ 1.06 | |
Weighted average share price at exercise/release during year | £ / shares | £ 1.76 | £ 1.24 | |
Weighted average remaining contractual life | 1 year | 1 year | |
Number of options/ awards outstanding | shares | 413,859 | 416,941 | 331,491 |
Others | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Number of options/ awards outstanding | shares | 335,976 | 356,033 | 232,259 |
Others | Bottom of range | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Weighted average fair value per award granted in year | £ | £ 0.64 | £ 0.23 | |
Weighted average share price at exercise/release during year | £ / shares | £ 1.75 | £ 1.04 | |
Weighted average remaining contractual life | 0 years | 0 years | |
Others | Top of range | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Weighted average fair value per award granted in year | £ | £ 1.80 | £ 1.24 | |
Weighted average share price at exercise/release during year | £ / shares | £ 1.92 | £ 1.68 | |
Weighted average remaining contractual life | 3 years | 3 years |
Share-based payments - Narrativ
Share-based payments - Narrative (Details) £ / shares in Units, £ in Millions | 12 Months Ended | ||||
Dec. 31, 2021GBP (£)shares£ / shares | Dec. 31, 2020GBP (£)shares£ / shares | Dec. 31, 2019GBP (£) | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Total liability arising from cash-settled share-based payments transactions | £ 5 | £ 2 | |||
Employee share schemes and hedging thereof | 295 | [1] | 346 | [1] | £ 579 |
Retained earnings | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Employee share schemes and hedging thereof | £ 235 | [1] | £ 303 | [1] | £ 478 |
Sharesave | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Number of options exercisable | shares | 8,821,715 | ||||
Number of options excercisable, Weighted average exercise price | £ / shares | £ 1.23 | £ 1.66 | |||
Share value plan | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Weighted average remaining contractual life | 1 year | 1 year | |||
Number of options exercisable | shares | 0 | 0 | |||
Employee benefit and other trusts | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Total number of Barclays shares held | shares | 12,900,000 | 17,100,000 | |||
Number of options excercisable, Weighted average exercise price | £ / shares | £ 1.87 | £ 1.27 | |||
Total market value of the shares held in trust | £ 24 | £ 22 | |||
Certain share-based payment schemes | Retained earnings | Forward contract | At cost | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Employee share schemes and hedging thereof | £ 416 | ||||
Bottom of range | Sharesave | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Weighted average remaining contractual life | 3 years | ||||
Expected volatility, share options granted | 30.97% | ||||
Risk free interest rate, share options granted | 1.20% | ||||
Top of range | Sharesave | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Weighted average remaining contractual life | 5 years | ||||
Expected volatility, share options granted | 29.76% | ||||
Risk free interest rate, share options granted | 1.18% | ||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Share-based payments - Movement
Share-based payments - Movements in option and award plans (Details) | 12 Months Ended | |
Dec. 31, 2021shares£ / shares | Dec. 31, 2020shares£ / shares | |
Share value plan | ||
Reconciliation of options and award plans [Roll Forward] | ||
Outstanding at beginning of year/acquisition date, Number of options | 416,941,000 | 331,491,000 |
Granted in the year, number of options | 187,667,000 | 232,379,000 |
Exercised/released in the year, number of options | (160,460,000) | (132,376,000) |
Less: forfeited in the year, number of options | (30,289,000) | (14,553,000) |
Less: expired in the year, number of options | 0 | 0 |
Outstanding at end of year, Number of options | 413,859,000 | 416,941,000 |
Number of options exercisable | 0 | 0 |
Reconciliation of share price of options and award plans [Roll Forward] | ||
Outstanding at beginning of year, Weighted average exercise price | £ / shares | £ 1.24 | |
Outstanding at end of year, Weighted average exercise price | £ / shares | £ 1.76 | £ 1.24 |
Others | ||
Reconciliation of options and award plans [Roll Forward] | ||
Outstanding at beginning of year/acquisition date, Number of options | 356,033,000 | 232,259,000 |
Granted in the year, number of options | 120,385,000 | 365,166,000 |
Exercised/released in the year, number of options | (107,688,000) | (123,042,000) |
Less: forfeited in the year, number of options | (24,489,000) | (105,068,000) |
Less: expired in the year, number of options | (8,265,000) | (13,282,000) |
Outstanding at end of year, Number of options | 335,976,000 | 356,033,000 |
Number of options exercisable | 28,609,000 | 30,833,000 |
Sharesave | ||
Reconciliation of options and award plans [Roll Forward] | ||
Number of options exercisable | 8,821,715 | |
Reconciliation of share price of options and award plans [Roll Forward] | ||
Outstanding at beginning of year, Weighted average exercise price | £ / shares | £ 0.96 | £ 1.29 |
Granted in the year, weighted average exercise price | £ / shares | 1.43 | 0.84 |
Exercised/released in the year, weighted average exercise price | £ / shares | 1.38 | 1.22 |
Less: forfeited in the year, weighted average exercise price | £ / shares | 0.95 | 1.24 |
Less: expired in the year, weighted average exercise price | £ / shares | 1.67 | 1.35 |
Outstanding at end of year, Weighted average exercise price | £ / shares | 0.95 | 0.96 |
Number of options excercisable, Weighted average exercise price | £ / shares | £ 1.23 | £ 1.66 |
Pensions and post-retirement be
Pensions and post-retirement benefits - Narrative (Details) £ in Millions, $ in Millions | Sep. 30, 2022 | Jun. 12, 2020GBP (£) | Jun. 30, 2022 | Dec. 31, 2021GBP (£)directortranche | Sep. 30, 2021GBP (£) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | Mar. 31, 2022GBP (£) | Dec. 31, 2020USD ($) | Sep. 30, 2020GBP (£) | ||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Net defined benefit liability (asset) | £ (3,568) | £ (1,523) | ||||||||||
Surplus (deficit) in plan | 3,568 | 1,523 | ||||||||||
Assets of benefit plan | 3,879 | [1] | 1,814 | |||||||||
Proceeds from maturity of financial instruments | 89,342 | [2] | 80,895 | £ 81,202 | ||||||||
Forecast | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Potential decrease in capital ratio | 0.30% | (0.10%) | ||||||||||
Forecast | Disclosure of post year end balances | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Potential decrease in capital ratio | 0.30% | |||||||||||
Barclays PLC | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Net increase in debt securities in issue | [3] | 4,939 | 3,720 | 2,588 | ||||||||
Retirement benefit obligations | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Net defined benefit liability (asset) | 31,899 | 33,190 | 30,333 | $ 33,190 | ||||||||
Benefits paid | 1,309 | 1,406 | ||||||||||
Fair value of plan assets | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Net defined benefit liability (asset) | (35,467) | (34,713) | (32,093) | |||||||||
Benefits paid | (1,309) | (1,406) | ||||||||||
Fair value of plan assets | Barclays PLC | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Equities | 0 | 0 | ||||||||||
Bonds | £ 0 | 0 | ||||||||||
Director | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Number of directors on trustee board | director | 6 | |||||||||||
Independent director | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Number of directors on trustee board | director | 3 | |||||||||||
Member nominated director | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Number of directors on trustee board | director | 3 | |||||||||||
UK | The senior notes | Financial assets at amortised cost | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Number of tranches | tranche | 3 | |||||||||||
Notional contract amount | £ 1,250 | 1,250 | ||||||||||
Maturity period | 5 years | |||||||||||
UK | The senior notes | Financial assets at amortised cost | Heron Issuer Limited | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Notional contract amount | £ 500 | |||||||||||
UK | The senior notes | Financial assets at amortised cost | Heron Issuer Number 2 Limited | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Notional contract amount | 750 | |||||||||||
UK | One to two year | The senior notes | Financial assets at amortised cost | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Proceeds from maturity of financial instruments | 250 | |||||||||||
UK | Two to three year | The senior notes | Financial assets at amortised cost | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Proceeds from maturity of financial instruments | 750 | |||||||||||
UK | Three to four year | The senior notes | Financial assets at amortised cost | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Proceeds from maturity of financial instruments | £ 250 | |||||||||||
Of which relates to UKRF | UK | Fair value of plan assets | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Percentage of fair value of scheme assets invested in liability driven investment strategies | 45.00% | |||||||||||
Section 75 contributions | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Defined benefit contributions paid | £ 0 | 0 | 0 | |||||||||
Pension defined benefit plans | Foreign countries | Retirement benefit obligations | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Net defined benefit liability (asset) | £ 821 | 867 | ||||||||||
Pension defined benefit plans | Of which relates to UKRF | UK | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Scheme as a percentage of total retirement benefit obligations | 97.00% | |||||||||||
Net defined benefit liability (asset) | £ (3,819) | (1,807) | ||||||||||
Surplus (deficit) in plan | 3,819 | £ 600 | 1,807 | |||||||||
Benefits paid | 1,268 | 1,370 | ||||||||||
Transfers out of the fund and contribution refunds | 419 | 520 | ||||||||||
Assets of benefit plan | 3,819 | 1,807 | ||||||||||
Deficit reduction contributions | 700 | |||||||||||
Defined benefit contributions paid | 955 | 748 | 1,231 | |||||||||
Estimate of contributions expected to be paid to plan for next annual reporting period | 546 | 959 | ||||||||||
Pension defined benefit plans | Of which relates to UKRF | UK | Disclosure of post year end balances | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Surplus (deficit) in plan | £ 4,400 | |||||||||||
Pension defined benefit plans | Of which relates to UKRF | UK | Deficit reduction contributions 30 September 2020 valuation [member] | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Surplus (deficit) in plan | £ 600 | |||||||||||
Pension defined benefit plans | Of which relates to UKRF | UK | Deficit reduction contributions under the 30 September 2019 valuation | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Surplus (deficit) in plan | £ (900) | |||||||||||
Deficit reduction contributions | 700 | |||||||||||
Pension defined benefit plans | Of which relates to UKRF | UK | Barclays Bank PLC | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Maximum funding deficit secured by collateral pool | £ 9,000 | |||||||||||
Pension defined benefit plans | Of which relates to UKRF | UK | Swaps | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Assets of benefit plan | 5,000 | |||||||||||
Pension defined benefit plans | Of which relates to UKRF | UK | Key UKRF financial assumptions | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Assumption for future inflation decreases | (0.20%) | |||||||||||
Assumption for future mortality improvements, percentage | 1.50% | |||||||||||
Pension defined benefit plans | Of which relates to UKRF | UK | 2021 | Deficit reduction contributions under the 30 September 2019 valuation | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Deficit reduction contributions | £ 700 | |||||||||||
Pension defined benefit plans | Of which relates to UKRF | UK | One to two year | Deficit reduction contributions under the 30 September 2019 valuation | Forecast | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Deficit reduction contributions | £ 294 | |||||||||||
Pension defined benefit plans | Of which relates to UKRF | UK | Two to three year | Deficit reduction contributions under the 30 September 2019 valuation | Forecast | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Deficit reduction contributions | £ 286 | |||||||||||
Pension defined benefit plans | Of which relates to UKRF | UK | Bottom of range | Barclays Bank PLC | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Percentage of funding deficit secured by collateral pool | 100.00% | |||||||||||
Pension defined benefit plans | Of which relates to UKRF | UK | Retirement benefit obligations | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Net defined benefit liability (asset) | £ 30,859 | 32,108 | 29,304 | |||||||||
Weighted average duration of the benefit payments reflected in defined benefit obligation, UKRF | 16 years | |||||||||||
Benefits paid | £ 1,268 | 1,370 | ||||||||||
Pension defined benefit plans | Of which relates to UKRF | UK | Retirement benefit obligations | Within 10 years | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Percentage of benefits are expected to be paid | 25.00% | |||||||||||
Pension defined benefit plans | Of which relates to UKRF | UK | Retirement benefit obligations | In years 11 to 20 | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Percentage of benefits are expected to be paid | 30.00% | |||||||||||
Pension defined benefit plans | Of which relates to UKRF | UK | Retirement benefit obligations | In years 20 to 30 | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Percentage of benefits are expected to be paid | 25.00% | |||||||||||
Pension defined benefit plans | Of which relates to UKRF | UK | Fair value of plan assets | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Net defined benefit liability (asset) | £ (34,678) | (33,915) | £ (31,362) | |||||||||
Benefits paid | (1,268) | (1,370) | ||||||||||
Post-employment medical defined benefit plans | Other | Retirement benefit obligations | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Net defined benefit liability (asset) | 219 | 215 | ||||||||||
Defined contribution schemes | Of which relates to UKRF | UK | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Estimate of contributions expected to be paid to plan for next annual reporting period | 33 | 35 | ||||||||||
Defined contribution schemes | BPSP | UK | ||||||||||||
Disclosure of net defined benefit liability (asset) [line items] | ||||||||||||
Estimate of contributions expected to be paid to plan for next annual reporting period | £ 221 | £ 209 | ||||||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||||||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||||||||
[3] | Includes financial liabilities designated at fair value. |
Pensions and post-retirement _2
Pensions and post-retirement benefits - Income statement charge (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of defined benefit plans [abstract] | |||
Current service cost | £ 247 | £ 243 | £ 231 |
Net finance cost | (26) | (40) | (48) |
Past service cost | 0 | (4) | 0 |
Other movements | 3 | 1 | 0 |
Total | £ 224 | £ 200 | £ 183 |
Pensions and post-retirement _3
Pensions and post-retirement benefits - Balance sheet reconciliation (Details) £ in Millions, $ in Millions | 12 Months Ended | |||||
Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | Sep. 30, 2021GBP (£) | ||
Reconciliation of changes in net assets available for benefits [abstract] | ||||||
Net defined benefit liability (asset), beginning of period | £ 1,523 | |||||
Current service cost | (247) | £ (243) | £ (231) | |||
Interest costs or income on scheme liabilities or assets | 26 | 40 | 48 | |||
Past service cost | 0 | 4 | 0 | |||
Net defined benefit liability (asset), end of period | 3,568 | 1,523 | ||||
Net surplus | 3,568 | 1,523 | ||||
Retirement benefit assets | 3,879 | [1] | 1,814 | |||
Retirement benefit liabilities | (311) | [1] | (291) | |||
Of which relates to UKRF | UK | Pension defined benefit plans | ||||||
Reconciliation of changes in net assets available for benefits [abstract] | ||||||
Net defined benefit liability (asset), beginning of period | 1,807 | |||||
Benefits paid | 1,268 | 1,370 | ||||
Net defined benefit liability (asset), end of period | 3,819 | 1,807 | ||||
Net surplus | 3,819 | 1,807 | £ 600 | |||
Retirement benefit assets | 3,819 | 1,807 | ||||
Retirement benefit liabilities | 0 | 0 | ||||
Retirement benefit obligations | ||||||
Reconciliation of changes in net assets available for benefits [abstract] | ||||||
Net defined benefit liability (asset), beginning of period | (33,190) | $ (33,190) | (30,333) | |||
Current service cost | (247) | (243) | ||||
Interest costs or income on scheme liabilities or assets | (422) | (573) | ||||
Past service cost | 0 | 4 | ||||
Remeasurement (loss)/gain – financial | 848 | (3,439) | ||||
Remeasurement (loss)/gain – demographic | 53 | (281) | ||||
Remeasurement (loss)/gain – experience | (249) | 244 | ||||
Employee contributions | (4) | (5) | ||||
Benefits paid | 1,309 | 1,406 | ||||
Exchange and other movements | 3 | 30 | ||||
Net defined benefit liability (asset), end of period | (31,899) | (33,190) | (30,333) | |||
Retirement benefit obligations | Of which relates to UKRF | UK | Pension defined benefit plans | ||||||
Reconciliation of changes in net assets available for benefits [abstract] | ||||||
Net defined benefit liability (asset), beginning of period | (32,108) | (29,304) | ||||
Current service cost | (225) | (217) | ||||
Interest costs or income on scheme liabilities or assets | (405) | (549) | ||||
Past service cost | 0 | 0 | ||||
Remeasurement (loss)/gain – financial | 820 | (3,358) | ||||
Remeasurement (loss)/gain – demographic | 50 | (286) | ||||
Remeasurement (loss)/gain – experience | (259) | 237 | ||||
Employee contributions | 0 | (1) | ||||
Benefits paid | 1,268 | 1,370 | ||||
Exchange and other movements | 0 | 0 | ||||
Net defined benefit liability (asset), end of period | (30,859) | (32,108) | (29,304) | |||
Fair value of plan assets | ||||||
Reconciliation of changes in net assets available for benefits [abstract] | ||||||
Net defined benefit liability (asset), beginning of period | 34,713 | 32,093 | ||||
Interest costs or income on scheme liabilities or assets | 448 | 613 | ||||
Employer contribution | 971 | 265 | ||||
Employee contributions | 4 | 5 | ||||
Benefits paid | (1,309) | (1,406) | ||||
Remeasurement – return on scheme assets greater than discount rate | 653 | 3,411 | ||||
Exchange and other movements | (13) | (268) | ||||
Net defined benefit liability (asset), end of period | 35,467 | 34,713 | 32,093 | |||
Fair value of plan assets | Of which relates to UKRF | UK | Pension defined benefit plans | ||||||
Reconciliation of changes in net assets available for benefits [abstract] | ||||||
Net defined benefit liability (asset), beginning of period | 33,915 | 31,362 | ||||
Interest costs or income on scheme liabilities or assets | 434 | 595 | ||||
Employer contribution | 955 | 248 | ||||
Employee contributions | 0 | 1 | ||||
Benefits paid | (1,268) | (1,370) | ||||
Remeasurement – return on scheme assets greater than discount rate | 642 | 3,328 | ||||
Exchange and other movements | 0 | (249) | ||||
Net defined benefit liability (asset), end of period | £ 34,678 | £ 33,915 | £ 31,362 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Pensions and post-retirement _4
Pensions and post-retirement benefits - Actuarial valuation of schemes (Details) - Of which relates to UKRF - UK - Pension defined benefit plans - GBP (£) £ in Billions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Key UKRF financial assumptions | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
Discount rate | 1.84% | 1.29% | |
Inflation rate (RPI) | 3.56% | 2.99% | |
Life expectancy at 60 for current pensioners, males | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
Assumed life expectancy at 60 | 27 years 3 months 18 days | 27 years 2 months 12 days | 27 years 1 month 6 days |
Life expectancy at 60 for current pensioners, females | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
Assumed life expectancy at 60 | 29 years 7 months 6 days | 29 years 4 months 24 days | 29 years 3 months 18 days |
Life expectancy at 60 for future pensioners at 40 years, males | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
Assumed life expectancy at 60 | 29 years 1 month 6 days | 29 years | 28 years 10 months 24 days |
Life expectancy at 60 for future pensioners at 40 years, females | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
Assumed life expectancy at 60 | 31 years 4 months 24 days | 31 years 2 months 12 days | 31 years 1 month 6 days |
0.5% change in discount rate per annum | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
(Decrease)/Increase in UKRF defined benefit obligations, due to increase in actuarial assumption | £ (2.3) | £ (2.5) | |
(Decrease)/Increase in UKRF defined benefit obligations, due to decrease in actuarial assumption | 2.6 | 2.9 | |
0.25% change in discount rate per annum | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
(Decrease)/Increase in UKRF defined benefit obligations, due to increase in actuarial assumption | (1.2) | (1.3) | |
(Decrease)/Increase in UKRF defined benefit obligations, due to decrease in actuarial assumption | 1.3 | 1.4 | |
0.5% change in RPI per annum | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
(Decrease)/Increase in UKRF defined benefit obligations, due to increase in actuarial assumption | 1.6 | 1.8 | |
(Decrease)/Increase in UKRF defined benefit obligations, due to decrease in actuarial assumption | (1.6) | (1.8) | |
0.25% change in RPI per annum | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
(Decrease)/Increase in UKRF defined benefit obligations, due to increase in actuarial assumption | 0.8 | 0.9 | |
(Decrease)/Increase in UKRF defined benefit obligations, due to decrease in actuarial assumption | (0.8) | (0.9) | |
Change in life expectancy by 1 year | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
(Decrease)/Increase in UKRF defined benefit obligations, due to increase in actuarial assumption | 1.2 | 1.2 | |
(Decrease)/Increase in UKRF defined benefit obligations, due to decrease in actuarial assumption | £ (1.2) | £ (1.2) |
Pensions and post-retirement _5
Pensions and post-retirement benefits - Analysis of scheme assets (Details) - Fair value of plan assets - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Disclosure of fair value of plan assets [line items] | |||
Net retirement benefit assets/(liabilities) | £ 35,467 | £ 34,713 | |
% of total fair value of scheme assets % | 100.00% | 100.00% | |
Equities | |||
Disclosure of fair value of plan assets [line items] | |||
Equities | £ 1,591 | £ 2,065 | |
% of total fair value of scheme assets % | 4.50% | 5.90% | |
Private equities | |||
Disclosure of fair value of plan assets [line items] | |||
Equities | £ 2,991 | £ 2,233 | |
% of total fair value of scheme assets % | 8.40% | 6.40% | |
Bonds - fixed government | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | £ 2,482 | £ 4,315 | |
% of total fair value of scheme assets % | 7.00% | 12.40% | |
Bonds - index-linked government | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | £ 14,157 | £ 11,720 | |
% of total fair value of scheme assets % | 39.90% | 33.80% | |
Bonds - corporate and other | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | £ 9,077 | £ 9,117 | |
% of total fair value of scheme assets % | 25.60% | 26.30% | |
Property | |||
Disclosure of fair value of plan assets [line items] | |||
Property | £ 1,504 | £ 1,426 | |
% of total fair value of scheme assets % | 4.30% | 4.10% | |
Infrastructure | |||
Disclosure of fair value of plan assets [line items] | |||
Infrastructure | £ 1,815 | £ 1,812 | |
% of total fair value of scheme assets % | 5.10% | 5.20% | |
Cash and liquid assets | |||
Disclosure of fair value of plan assets [line items] | |||
Cash and liquid assets | £ 1,766 | £ 1,894 | |
% of total fair value of scheme assets % | 5.00% | 5.50% | |
Mixed investment funds | |||
Disclosure of fair value of plan assets [line items] | |||
Mixed investment funds | £ 9 | £ 9 | |
% of total fair value of scheme assets % | 0.00% | 0.00% | |
Other | |||
Disclosure of fair value of plan assets [line items] | |||
Other | £ 75 | £ 122 | |
% of total fair value of scheme assets % | 0.20% | 0.40% | |
Equities - Quoted | |||
Disclosure of fair value of plan assets [line items] | |||
Net retirement benefit assets/(liabilities) | £ 22,533 | £ 23,014 | |
Equities - Quoted | Equities | |||
Disclosure of fair value of plan assets [line items] | |||
Equities | 214 | 567 | |
Equities - Quoted | Private equities | |||
Disclosure of fair value of plan assets [line items] | |||
Equities | 0 | 0 | |
Equities - Quoted | Bonds - fixed government | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | 2,387 | 4,205 | |
Equities - Quoted | Bonds - index-linked government | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | 13,478 | 10,706 | |
Equities - Quoted | Bonds - corporate and other | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | 6,223 | 7,439 | |
Equities - Quoted | Property | |||
Disclosure of fair value of plan assets [line items] | |||
Property | 14 | 10 | |
Equities - Quoted | Infrastructure | |||
Disclosure of fair value of plan assets [line items] | |||
Infrastructure | 0 | 0 | |
Equities - Quoted | Cash and liquid assets | |||
Disclosure of fair value of plan assets [line items] | |||
Cash and liquid assets | 189 | 64 | |
Equities - Quoted | Mixed investment funds | |||
Disclosure of fair value of plan assets [line items] | |||
Mixed investment funds | 9 | 9 | |
Equities - Quoted | Other | |||
Disclosure of fair value of plan assets [line items] | |||
Other | 19 | 14 | |
Equities non-quoted | |||
Disclosure of fair value of plan assets [line items] | |||
Net retirement benefit assets/(liabilities) | 12,934 | 11,699 | |
Equities non-quoted | Equities | |||
Disclosure of fair value of plan assets [line items] | |||
Equities | 1,377 | 1,498 | |
Equities non-quoted | Private equities | |||
Disclosure of fair value of plan assets [line items] | |||
Equities | 2,991 | 2,233 | |
Equities non-quoted | Bonds - fixed government | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | 95 | 110 | |
Equities non-quoted | Bonds - index-linked government | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | 679 | 1,014 | |
Equities non-quoted | Bonds - corporate and other | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | 2,854 | 1,678 | |
Equities non-quoted | Property | |||
Disclosure of fair value of plan assets [line items] | |||
Property | 1,490 | 1,416 | |
Equities non-quoted | Infrastructure | |||
Disclosure of fair value of plan assets [line items] | |||
Infrastructure | 1,815 | 1,812 | |
Equities non-quoted | Cash and liquid assets | |||
Disclosure of fair value of plan assets [line items] | |||
Cash and liquid assets | 1,577 | 1,830 | |
Equities non-quoted | Mixed investment funds | |||
Disclosure of fair value of plan assets [line items] | |||
Mixed investment funds | 0 | 0 | |
Equities non-quoted | Other | |||
Disclosure of fair value of plan assets [line items] | |||
Other | 56 | 108 | |
Of which relates to UKRF | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Net retirement benefit assets/(liabilities) | £ 34,678 | £ 33,915 | |
% of total fair value of scheme assets % | 100.00% | 100.00% | |
Of which relates to UKRF | Equities | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Equities | £ 1,463 | £ 1,876 | |
% of total fair value of scheme assets % | 4.20% | 5.50% | |
Of which relates to UKRF | Private equities | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Equities | £ 2,991 | £ 2,233 | |
% of total fair value of scheme assets % | 8.60% | 6.60% | |
Of which relates to UKRF | Bonds - fixed government | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | £ 2,178 | £ 4,042 | |
% of total fair value of scheme assets % | 6.30% | 11.90% | |
Of which relates to UKRF | Bonds - index-linked government | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | £ 14,134 | £ 11,711 | |
% of total fair value of scheme assets % | 40.80% | 34.60% | |
Of which relates to UKRF | Bonds - corporate and other | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | £ 8,840 | £ 8,892 | |
% of total fair value of scheme assets % | 25.50% | 26.20% | |
Of which relates to UKRF | Property | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Property | £ 1,490 | £ 1,416 | |
% of total fair value of scheme assets % | 4.30% | 4.20% | |
Of which relates to UKRF | Infrastructure | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Infrastructure | £ 1,815 | £ 1,812 | |
% of total fair value of scheme assets % | 5.20% | 5.30% | |
Of which relates to UKRF | Cash and liquid assets | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Cash and liquid assets | £ 1,753 | £ 1,876 | |
% of total fair value of scheme assets % | 5.10% | 5.50% | |
Of which relates to UKRF | Mixed investment funds | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Mixed investment funds | £ 0 | £ 0 | |
% of total fair value of scheme assets % | 0.00% | 0.00% | |
Of which relates to UKRF | Other | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Other | £ 14 | £ 57 | |
% of total fair value of scheme assets % | 0.00% | 0.20% | |
Of which relates to UKRF | Equities - Quoted | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Net retirement benefit assets/(liabilities) | £ 21,786 | £ 22,267 | |
Of which relates to UKRF | Equities - Quoted | Equities | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Equities | 86 | 378 | |
Of which relates to UKRF | Equities - Quoted | Private equities | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Equities | 0 | 0 | |
Of which relates to UKRF | Equities - Quoted | Bonds - fixed government | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | 2,083 | 3,932 | |
Of which relates to UKRF | Equities - Quoted | Bonds - index-linked government | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | 13,455 | 10,697 | |
Of which relates to UKRF | Equities - Quoted | Bonds - corporate and other | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | 5,986 | 7,214 | |
Of which relates to UKRF | Equities - Quoted | Property | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Property | 0 | 0 | |
Of which relates to UKRF | Equities - Quoted | Infrastructure | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Infrastructure | 0 | 0 | |
Of which relates to UKRF | Equities - Quoted | Cash and liquid assets | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Cash and liquid assets | 176 | 46 | |
Of which relates to UKRF | Equities - Quoted | Mixed investment funds | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Mixed investment funds | 0 | 0 | |
Of which relates to UKRF | Equities - Quoted | Other | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Other | 0 | 0 | |
Of which relates to UKRF | Equities non-quoted | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Net retirement benefit assets/(liabilities) | 12,892 | 11,648 | |
Of which relates to UKRF | Equities non-quoted | Equities | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Equities | 1,377 | 1,498 | |
Of which relates to UKRF | Equities non-quoted | Private equities | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Equities | 2,991 | 2,233 | |
Of which relates to UKRF | Equities non-quoted | Bonds - fixed government | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | 95 | 110 | |
Of which relates to UKRF | Equities non-quoted | Bonds - index-linked government | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | 679 | 1,014 | |
Of which relates to UKRF | Equities non-quoted | Bonds - corporate and other | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Bonds | 2,854 | 1,678 | |
Of which relates to UKRF | Equities non-quoted | Property | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Property | 1,490 | 1,416 | |
Of which relates to UKRF | Equities non-quoted | Infrastructure | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Infrastructure | 1,815 | 1,812 | |
Of which relates to UKRF | Equities non-quoted | Cash and liquid assets | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Cash and liquid assets | 1,577 | 1,830 | |
Of which relates to UKRF | Equities non-quoted | Mixed investment funds | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Mixed investment funds | 0 | 0 | |
Of which relates to UKRF | Equities non-quoted | Other | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Other | £ 14 | £ 57 |
Pensions and post-retirement _6
Pensions and post-retirement benefits - Deficit reduction contributions (Details) - Of which relates to UKRF - Pension defined benefit plans - UK - GBP (£) £ in Millions | Jun. 12, 2020 | Dec. 31, 2021 | Sep. 30, 2021 |
Disclosure of fair value of plan assets [line items] | |||
Deficit reduction contributions | £ 700 | ||
Deficit reduction contributions under the 30 September 2019 valuation | |||
Disclosure of fair value of plan assets [line items] | |||
Deficit reduction contributions | £ 700 | ||
2021 | Deficit reduction contributions under the 30 September 2019 valuation | |||
Disclosure of fair value of plan assets [line items] | |||
Deficit reduction contributions | £ 700 | ||
2022 | Deficit reduction contributions under the 30 September 2019 valuation | Forecast | |||
Disclosure of fair value of plan assets [line items] | |||
Deficit reduction contributions | 294 | ||
2023 | Deficit reduction contributions under the 30 September 2019 valuation | Forecast | |||
Disclosure of fair value of plan assets [line items] | |||
Deficit reduction contributions | 286 | ||
2024 and beyond | Deficit reduction contributions under the 30 September 2019 valuation | Forecast | |||
Disclosure of fair value of plan assets [line items] | |||
Deficit reduction contributions | £ 0 |
Pensions and post-retirement _7
Pensions and post-retirement benefits - Contributions paid (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Of which relates to UKRF | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Defined benefit contributions paid | £ 955 | £ 748 | £ 1,231 |
Principal subsidiaries - Signif
Principal subsidiaries - Significant subsidiaries (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Barclays Bank PLC | |
Disclosure of subsidiaries [line items] | |
Percentage of voting rights held | 100.00% |
Non-controlling interests - proportion of ownership interests | 2.00% |
Non-controlling interests - proportion of voting interests | 0.00% |
Barclays Bank UK PLC | |
Disclosure of subsidiaries [line items] | |
Percentage of voting rights held | 100.00% |
Non-controlling interests - proportion of ownership interests | 0.00% |
Non-controlling interests - proportion of voting interests | 0.00% |
Barclays Bank Ireland PLC | |
Disclosure of subsidiaries [line items] | |
Percentage of voting rights held | 100.00% |
Non-controlling interests - proportion of ownership interests | 0.00% |
Non-controlling interests - proportion of voting interests | 0.00% |
Barclays Execution Services Limited | |
Disclosure of subsidiaries [line items] | |
Percentage of voting rights held | 100.00% |
Non-controlling interests - proportion of ownership interests | 0.00% |
Non-controlling interests - proportion of voting interests | 0.00% |
Barclays Capital Inc. | |
Disclosure of subsidiaries [line items] | |
Percentage of voting rights held | 100.00% |
Non-controlling interests - proportion of ownership interests | 0.00% |
Non-controlling interests - proportion of voting interests | 0.00% |
Barclays Capital Securities Limited | |
Disclosure of subsidiaries [line items] | |
Percentage of voting rights held | 100.00% |
Non-controlling interests - proportion of ownership interests | 0.00% |
Non-controlling interests - proportion of voting interests | 0.00% |
Barclays Securities Japan Limited | |
Disclosure of subsidiaries [line items] | |
Percentage of voting rights held | 100.00% |
Non-controlling interests - proportion of ownership interests | 0.00% |
Non-controlling interests - proportion of voting interests | 0.00% |
Barclays US LLC | |
Disclosure of subsidiaries [line items] | |
Percentage of voting rights held | 100.00% |
Non-controlling interests - proportion of ownership interests | 0.00% |
Non-controlling interests - proportion of voting interests | 0.00% |
Barclays Bank Delaware | |
Disclosure of subsidiaries [line items] | |
Percentage of voting rights held | 100.00% |
Non-controlling interests - proportion of ownership interests | 0.00% |
Non-controlling interests - proportion of voting interests | 0.00% |
Principal subsidiaries - Exclud
Principal subsidiaries - Excluded from consolidation because the Group does not have exposure to its variable returns (Details) - Unconsolidated structured entities £ in Millions | 12 Months Ended |
Dec. 31, 2021GBP (£) | |
Disclosure of unconsolidated structured entities [line items] | |
Percentage of voting rights held | 100.00% |
Equity shareholders' funds | £ 0 |
Retained profit for the year | £ 0 |
Principal subsidiaries (Narrati
Principal subsidiaries (Narrative) (Details) £ in Millions, $ in Billions | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | |
Disclosure of subsidiaries [line items] | |||||
Total assets | £ 1,384,285 | [1] | $ 1,384.3 | £ 1,349,514 | £ 1,140,200 |
Total liabilities | 1,314,244 | [1] | 1,282,632 | ||
Balances with banks and other regulatory authorities | 4,750 | 3,392 | £ 4,893 | ||
Principal subsidiary companies | |||||
Disclosure of subsidiaries [line items] | |||||
Total assets | 1,833,000 | 1,795,000 | |||
Total liabilities | £ 1,737,000 | £ 1,703,000 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Structured entities - Narrative
Structured entities - Narrative (Details) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021GBP (£)entity | Dec. 31, 2020GBP (£)entity | Dec. 31, 2019GBP (£) | |
Disclosure of unconsolidated structured entities [line items] | |||
Number of structured entities | entity | 5,891,000,000 | ||
Impairment cost of loan facilities | £ (893) | £ 5,237 | £ 2,036 |
Assets transferred to sponsored unconsolidated structured entities | 1,662 | 730 | |
Structured entities | Derivatives | |||
Disclosure of unconsolidated structured entities [line items] | |||
Notional value of guarantee | 217,055 | 153,894 | |
Commercial paper (CP) and medium-term note conduits | Contractual Backstop Liquidity Facilities | |||
Disclosure of unconsolidated structured entities [line items] | |||
Standby facilities, credit lines and other commitments | 17,200 | 16,900 | |
Employee benefit and other trusts | |||
Disclosure of unconsolidated structured entities [line items] | |||
Standby facilities, credit lines and other commitments | £ 3,300 | £ 2,900 | |
Securitisation vehicles | |||
Disclosure of unconsolidated structured entities [line items] | |||
Number of structured entities | entity | 3,394,000,000 | ||
Securitisation vehicles | Debt securities classified at amortised cost | Not more than three months | |||
Disclosure of unconsolidated structured entities [line items] | |||
Maturity period | 90 days | ||
Lending | Debt securities classified at amortised cost | |||
Disclosure of unconsolidated structured entities [line items] | |||
Impairment cost of loan facilities | £ 28 | £ 23 |
Structured entities - Summary o
Structured entities - Summary of interests in unconsolidated structured entities (Details) £ in Millions, $ in Billions | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | |
Disclosure of unconsolidated structured entities [line items] | |||||
Trading portfolio assets | £ 147,035 | [1] | £ 127,950 | ||
Financial assets at fair value through the income statement | 191,972 | [1] | 175,151 | ||
Derivative financial instruments | 262,572 | [1] | 302,446 | ||
Financial assets at fair value through other comprehensive income | 61,753 | [1] | 78,688 | ||
Loans and advances at amortised cost | 361,451 | [1] | 342,632 | ||
Reverse repurchase agreements and other similar secured lending | 3,227 | [1] | 9,031 | ||
Other assets | 3,785 | [1] | 2,622 | ||
Total assets | 1,384,285 | [1] | $ 1,384.3 | 1,349,514 | £ 1,140,200 |
Derivative financial instruments | 256,883 | [1] | 300,775 | ||
Structured entities | |||||
Disclosure of unconsolidated structured entities [line items] | |||||
Trading portfolio assets | 7,170 | 11,361 | |||
Financial assets at fair value through the income statement | 65,306 | 59,129 | |||
Derivative financial instruments | 5,160 | 2,968 | |||
Financial assets at fair value through other comprehensive income | 91 | 153 | |||
Loans and advances at amortised cost | 28,227 | 20,946 | |||
Reverse repurchase agreements and other similar secured lending | 104 | 10 | |||
Other assets | 17 | 16 | |||
Total assets | 106,075 | 94,583 | |||
Derivative financial instruments | 9,543 | 7,075 | |||
Secured financing | |||||
Disclosure of unconsolidated structured entities [line items] | |||||
Trading portfolio assets | 0 | 0 | |||
Financial assets at fair value through the income statement | 61,816 | 56,265 | |||
Derivative financial instruments | 0 | 0 | |||
Financial assets at fair value through other comprehensive income | 0 | 0 | |||
Loans and advances at amortised cost | 0 | 0 | |||
Reverse repurchase agreements and other similar secured lending | 104 | 10 | |||
Other assets | 0 | 0 | |||
Total assets | 61,920 | 56,275 | |||
Derivative financial instruments | 0 | 0 | |||
Short-term traded interests | |||||
Disclosure of unconsolidated structured entities [line items] | |||||
Trading portfolio assets | 7,170 | 11,361 | |||
Financial assets at fair value through the income statement | 0 | 0 | |||
Derivative financial instruments | 0 | 0 | |||
Financial assets at fair value through other comprehensive income | 0 | 0 | |||
Loans and advances at amortised cost | 0 | 0 | |||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | |||
Other assets | 0 | 0 | |||
Total assets | 7,170 | 11,361 | |||
Derivative financial instruments | 0 | 0 | |||
Traded derivatives | |||||
Disclosure of unconsolidated structured entities [line items] | |||||
Trading portfolio assets | 0 | 0 | |||
Financial assets at fair value through the income statement | 0 | 0 | |||
Derivative financial instruments | 5,160 | 2,968 | |||
Financial assets at fair value through other comprehensive income | 0 | 0 | |||
Loans and advances at amortised cost | 0 | 0 | |||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | |||
Other assets | 0 | 0 | |||
Total assets | 5,160 | 2,968 | |||
Derivative financial instruments | 9,543 | 7,075 | |||
Other interests | |||||
Disclosure of unconsolidated structured entities [line items] | |||||
Trading portfolio assets | 0 | 0 | |||
Financial assets at fair value through the income statement | 3,490 | 2,864 | |||
Derivative financial instruments | 0 | 0 | |||
Financial assets at fair value through other comprehensive income | 91 | 153 | |||
Loans and advances at amortised cost | 28,227 | 20,946 | |||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | |||
Other assets | 17 | 16 | |||
Total assets | 31,825 | 23,979 | |||
Derivative financial instruments | £ 0 | £ 0 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Structured entities - Nature of
Structured entities - Nature of interests (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of unconsolidated structured entities [line items] | |||
Financial assets at fair value through the income statement | £ 191,972 | [1] | £ 175,151 |
Financial assets at fair value through other comprehensive income | 61,753 | [1] | 78,688 |
Loans and advances at amortised cost | 361,451 | [1] | 342,632 |
Other assets | 3,785 | [1] | 2,622 |
Other interests | |||
Disclosure of unconsolidated structured entities [line items] | |||
Financial assets at fair value through the income statement | 3,490 | 2,864 | |
Financial assets at fair value through other comprehensive income | 91 | 153 | |
Loans and advances at amortised cost | 28,227 | 20,946 | |
Other assets | 17 | 16 | |
Total on-balance sheet exposures | 31,825 | 23,979 | |
Total off-balance sheet notional amounts | 20,441 | 19,305 | |
Maximum exposure to loss | 52,266 | 43,284 | |
Total assets of the entity | 284,552 | 291,170 | |
Other interests | Of which: Barclays owned, not consolidated entities | |||
Disclosure of unconsolidated structured entities [line items] | |||
Financial assets at fair value through the income statement | 3,335 | 2,698 | |
Financial assets at fair value through other comprehensive income | 0 | 0 | |
Other assets | 0 | 0 | |
Total on-balance sheet exposures | 3,335 | 2,698 | |
Total off-balance sheet notional amounts | 0 | 0 | |
Maximum exposure to loss | 3,335 | 2,698 | |
Total assets of the entity | 11,513 | 11,008 | |
Other interests | Financial assets at amortised cost | |||
Disclosure of unconsolidated structured entities [line items] | |||
Loans and advances at amortised cost | 28,227 | 20,946 | |
Other interests | Financial assets at amortised cost | Of which: Barclays owned, not consolidated entities | |||
Disclosure of unconsolidated structured entities [line items] | |||
Loans and advances at amortised cost | 0 | 0 | |
Multi-seller conduit programme | |||
Disclosure of unconsolidated structured entities [line items] | |||
Financial assets at fair value through the income statement | 0 | 0 | |
Financial assets at fair value through other comprehensive income | 0 | 0 | |
Other assets | 8 | 8 | |
Total on-balance sheet exposures | 5,192 | 5,154 | |
Total off-balance sheet notional amounts | 11,015 | 11,750 | |
Maximum exposure to loss | 16,207 | 16,904 | |
Total assets of the entity | 65,441 | 87,004 | |
Multi-seller conduit programme | Financial assets at amortised cost | |||
Disclosure of unconsolidated structured entities [line items] | |||
Loans and advances at amortised cost | 5,184 | 5,146 | |
Lending | |||
Disclosure of unconsolidated structured entities [line items] | |||
Financial assets at fair value through the income statement | 70 | 98 | |
Financial assets at fair value through other comprehensive income | 53 | 106 | |
Other assets | 4 | 3 | |
Total on-balance sheet exposures | 14,665 | 12,928 | |
Total off-balance sheet notional amounts | 9,426 | 7,555 | |
Maximum exposure to loss | 24,091 | 20,483 | |
Total assets of the entity | 166,238 | 159,804 | |
Lending | Financial assets at amortised cost | |||
Disclosure of unconsolidated structured entities [line items] | |||
Loans and advances at amortised cost | 14,538 | 12,721 | |
Other | |||
Disclosure of unconsolidated structured entities [line items] | |||
Financial assets at fair value through the income statement | 3,420 | 2,766 | |
Financial assets at fair value through other comprehensive income | 38 | 47 | |
Other assets | 5 | 5 | |
Total on-balance sheet exposures | 11,968 | 5,897 | |
Total off-balance sheet notional amounts | 0 | 0 | |
Maximum exposure to loss | 11,968 | 5,897 | |
Total assets of the entity | 52,873 | 44,362 | |
Other | Financial assets at amortised cost | |||
Disclosure of unconsolidated structured entities [line items] | |||
Loans and advances at amortised cost | £ 8,505 | £ 3,079 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Investments in associates and_3
Investments in associates and joint ventures - Narrative (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of associates [line items] | ||
Investments in associates accounted for using equity method | £ 722 | £ 464 |
Associates | Joint ventures | ||
Disclosure of associates [line items] | ||
Unrecognised share of losses of associates and joint ventures | 0 | 0 |
Unutilised credit facilities | 1,760 | 1,897 |
Commitments in relation to joint ventures and associates | 482 | 443 |
Business Growth Fund | ||
Disclosure of associates [line items] | ||
Share of fair value gains (losses) on investments of associates | 220 | (23) |
Investments in associates accounted for using equity method | £ 699 | £ 441 |
Bottom of range | ||
Disclosure of associates [line items] | ||
Voting rights, Associates | 20.00% | |
Top of range | ||
Disclosure of associates [line items] | ||
Voting rights, Associates | 50.00% |
Investments in associates and_4
Investments in associates and joint ventures (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | ||
Disclosure of associates [line items] | |||
Investments in associates accounted for using equity method | £ 722 | £ 464 | |
Held at fair value through profit or loss, Associates | 0 | 0 | |
Associates | 722 | 464 | |
Investments in joint ventures accounted for using equity method | 277 | 317 | |
Held at fair value through profit or loss, Joint ventures | 444 | 437 | |
Joint ventures | 721 | 754 | |
Equity accounted | 999 | [1] | 781 |
Held at fair value through profit or loss | 444 | 437 | |
Total | 1,443 | 1,218 | |
Joint ventures | |||
Disclosure of associates [line items] | |||
Profit/(loss) from continuing operations | 35 | 24 | |
Other comprehensive income/(loss) | 5 | (6) | |
Total comprehensive income/(loss) from continuing operations | 40 | 18 | |
Associates | |||
Disclosure of associates [line items] | |||
Profit/(loss) from continuing operations | 219 | (24) | |
Other comprehensive income/(loss) | 1 | (3) | |
Total comprehensive income/(loss) from continuing operations | 220 | (27) | |
Business Growth Fund | |||
Disclosure of associates [line items] | |||
Investments in associates accounted for using equity method | £ 699 | £ 441 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Securitisations - Transfers of
Securitisations - Transfers of financial assets that do not result in derecognition (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Assets carrying amount | £ 222,215 | £ 214,266 |
Associated liabilities | (128,408) | (129,058) |
Credit cards, unsecured and other retail lending | Loans and advances at amortised cost | ||
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Assets carrying amount | 1,303 | 1,033 |
Assets Fair value | 1,423 | 1,121 |
Associated liabilities | (1,225) | (1,019) |
Liabilities fair value | (1,219) | (1,033) |
Assets that entity continues to recognise to extent of continuing involvement | £ 249 | £ 0 |
Securitisations - Continuing in
Securitisations - Continuing involvement in financial assets that have been derecognised (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of continuing involvement in derecognised financial assets [line items] | ||
Carrying amount | £ 910 | £ 348 |
Fair value | 906 | 342 |
Maximum exposure to loss | 910 | 348 |
Gain (loss) from continuing involvement for the year | 9 | 4 |
Gain (loss) from continuing involvement, cumulative | 17 | 8 |
Asset backed securities | ||
Disclosure of continuing involvement in derecognised financial assets [line items] | ||
Carrying amount | 25 | 56 |
Fair value | 25 | 56 |
Maximum exposure to loss | 25 | 56 |
Gain (loss) from continuing involvement for the year | 1 | 1 |
Gain (loss) from continuing involvement, cumulative | 2 | 1 |
Residential mortgage backed securities | ||
Disclosure of continuing involvement in derecognised financial assets [line items] | ||
Carrying amount | 574 | 49 |
Fair value | 574 | 49 |
Maximum exposure to loss | 574 | 49 |
Gain (loss) from continuing involvement for the year | 3 | 1 |
Gain (loss) from continuing involvement, cumulative | 4 | 1 |
Commercial mortgage backed securities | ||
Disclosure of continuing involvement in derecognised financial assets [line items] | ||
Carrying amount | 311 | 243 |
Fair value | 307 | 237 |
Maximum exposure to loss | 311 | 243 |
Gain (loss) from continuing involvement for the year | 5 | 2 |
Gain (loss) from continuing involvement, cumulative | £ 11 | £ 6 |
Assets pledged, collateral re_3
Assets pledged, collateral received and assets transferred - Carrying amount of the assets pledged as security against liabilities (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of offsetting of financial liabilities [line items] | ||
Assets pledged | £ 222,215 | £ 214,266 |
Cash collateral and settlement balances | ||
Disclosure of offsetting of financial liabilities [line items] | ||
Assets pledged | 66,138 | 72,042 |
Loans and advances at amortised cost | ||
Disclosure of offsetting of financial liabilities [line items] | ||
Assets pledged | 65,216 | 37,257 |
Trading portfolio assets | ||
Disclosure of offsetting of financial liabilities [line items] | ||
Assets pledged | 71,518 | 77,198 |
Financial assets at fair value through the income statement | ||
Disclosure of offsetting of financial liabilities [line items] | ||
Assets pledged | 5,595 | 5,584 |
Fair value through other comprehensive income | ||
Disclosure of offsetting of financial liabilities [line items] | ||
Assets pledged | £ 13,748 | £ 22,185 |
Assets pledged, collateral re_4
Assets pledged, collateral received and assets transferred - Transferred financial assets and the associated liabilities (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Transferred assets | £ 222,215 | £ 214,266 |
Associated liabilities | (128,408) | (129,058) |
Derivatives | ||
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Transferred assets | 66,744 | 77,574 |
Associated liabilities | (66,744) | (77,574) |
Repurchase agreements | ||
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Transferred assets | 71,820 | 65,673 |
Associated liabilities | (49,543) | (44,076) |
Securities lending arrangements | ||
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Transferred assets | 69,316 | 61,183 |
Associated liabilities | 0 | 0 |
Other | ||
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Transferred assets | 14,335 | 9,836 |
Associated liabilities | £ (12,121) | £ (7,408) |
Assets pledged, collateral re_5
Assets pledged, collateral received and assets transferred - Recourse to transferred assets (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Transferred assets | £ 222,215 | £ 214,266 |
Associated liabilities | (128,408) | (129,058) |
Other | ||
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Transferred assets | 14,335 | 9,836 |
Associated liabilities | (12,121) | (7,408) |
Other | Securitisation vehicles | ||
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Transferred assets | 1,303 | 1,033 |
Associated liabilities | (1,225) | (1,019) |
Transferred assets, fair value | 1,423 | 1,121 |
Associated liabilities, fair value | (1,219) | (1,033) |
Net position | £ 204 | £ 88 |
Assets pledged, collateral re_6
Assets pledged, collateral received and assets transferred - Narrative (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of unconsolidated structured entities [line items] | |||
Loans and advances | £ 361,451 | [1] | £ 342,632 |
Asset backed funding programmes | |||
Disclosure of unconsolidated structured entities [line items] | |||
Loans and advances | £ 5,800 | £ 6,300 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Assets pledged, collateral re_7
Assets pledged, collateral received and assets transferred - Fair value at the balance sheet date of collateral accepted and re-pledged to others (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Assets pledged, collateral received and assets transferred [Abstract] | ||
Fair value of securities accepted as collateral | £ 928,999 | £ 793,573 |
Of which fair value of securities re-pledged/transferred to others | £ 814,448 | £ 685,300 |
Related party transactions an_3
Related party transactions and Directors' remuneration - Group's financial statements (Details) £ in Millions, $ in Billions | 12 Months Ended | ||||
Dec. 31, 2021GBP (£) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | Dec. 31, 2021USD ($) | ||
Disclosure of transactions between related parties [line items] | |||||
Total income | £ 21,940 | [1] | £ 21,766 | £ 21,632 | |
Credit impairment releases/(charges) | 653 | [1] | (4,838) | (1,912) | |
Operating expenses | (14,659) | [1] | (13,886) | (15,434) | |
Total assets | 1,384,285 | [2] | 1,349,514 | £ 1,140,200 | $ 1,384.3 |
Total liabilities | 1,314,244 | [2] | 1,282,632 | ||
Associates | |||||
Disclosure of transactions between related parties [line items] | |||||
Total income | 0 | 0 | |||
Credit impairment releases/(charges) | 0 | 0 | |||
Operating expenses | (20) | (26) | |||
Total assets | 0 | 0 | |||
Total liabilities | 177 | 66 | |||
Joint ventures | |||||
Disclosure of transactions between related parties [line items] | |||||
Total income | 50 | 10 | |||
Credit impairment releases/(charges) | 0 | 0 | |||
Operating expenses | 0 | 0 | |||
Total assets | 1,278 | 1,388 | |||
Total liabilities | 0 | 0 | |||
Pension funds | |||||
Disclosure of transactions between related parties [line items] | |||||
Total income | 5 | 5 | |||
Credit impairment releases/(charges) | 0 | 0 | |||
Operating expenses | (1) | (1) | |||
Total assets | 3 | 4 | |||
Total liabilities | £ 81 | £ 69 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Related party transactions an_4
Related party transactions and Directors' remuneration - Narrative (Details) £ / shares in Units, $ in Millions | 12 Months Ended | |||||
Dec. 31, 2021GBP (£)sharesdirectorEmployees£ / shares | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£)sharesEmployees | Dec. 31, 2020USD ($) | Dec. 31, 2019GBP (£) | May 05, 2021£ / shares | |
Disclosure of transactions between related parties [line items] | ||||||
Accruing benefits under defined benefit scheme | £ 539,000,000 | £ 519,000,000 | £ 501,000,000 | |||
Number of directors | 81,600 | 83,000 | 80,800 | |||
Defined contribution schemes | ||||||
Disclosure of transactions between related parties [line items] | ||||||
Accruing benefits under defined benefit scheme | £ 289,000,000 | £ 279,000,000 | £ 270,000,000 | |||
Sharesave | ||||||
Disclosure of transactions between related parties [line items] | ||||||
Number of options exercisable | shares | 8,821,715 | |||||
Ordinary shares | ||||||
Disclosure of transactions between related parties [line items] | ||||||
Par value per share (in GBP per share) | £ / shares | £ 0.25 | £ 0.25 | ||||
Pension funds | ||||||
Disclosure of transactions between related parties [line items] | ||||||
Derivatives transacted | £ 18,000,000 | 13,000,000 | ||||
Key management personnel and connected persons | ||||||
Disclosure of transactions between related parties [line items] | ||||||
Total commitments outstanding | 600,000 | 900,000 | ||||
Loans issued during the year | 400,000 | 2,300,000 | ||||
Directors | ||||||
Disclosure of transactions between related parties [line items] | ||||||
Total value of guarantees entered into on behalf of Directors | 0 | $ 0 | $ 0 | |||
Accruing benefits under defined benefit scheme | 0 | |||||
Loans issued during the year | 200,000 | 100,000 | ||||
Directors | Defined contribution schemes | ||||||
Disclosure of transactions between related parties [line items] | ||||||
Notional contract amount | £ 0 | £ 0 | ||||
Directors and officers | Ordinary shares | ||||||
Disclosure of transactions between related parties [line items] | ||||||
Number of shares issued and fully paid (in shares) | shares | 17,876,352 | 27,470,067 | ||||
Par value per share (in GBP per share) | £ / shares | £ 0.25 | |||||
Percentage of ordinary share capital outstanding | 0.11% | |||||
Number of directors | director | 22 | |||||
Directors and officers | Ordinary shares | Sharesave | ||||||
Disclosure of transactions between related parties [line items] | ||||||
Par value per share (in GBP per share) | £ / shares | £ 0.25 | |||||
Number of directors | director | 12 | |||||
Number of options exercisable | shares | 62,268 | 78,495 | ||||
Strike price (in GBP per share) | £ / shares | £ 0.93 |
Related party transactions an_5
Related party transactions and Directors' remuneration - Loans and deposits outstanding (Details) - Key management personnel and connected persons - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Reconciliation of receivables from related parties [Roll Forward] | ||
Loans outstanding beginning balance | £ 9.2 | £ 7.2 |
Loans issued during the year | 0.4 | 2.3 |
Loan repayments during the year | (1.8) | (0.3) |
Loan outstanding ending balance | 7.8 | 9.2 |
Deposits outstanding beginning balance | 10.4 | 12.1 |
Deposits received during the year | 37.6 | 41.6 |
Deposits repaid during the year | (38.9) | (43.3) |
Deposits oustanding ending balance | £ 9.1 | £ 10.4 |
Related party transactions an_6
Related party transactions and Directors' remuneration - Remuneration of Directors and other Key Management Personnel (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of transactions between related parties [abstract] | ||
Salaries and other short-term benefits | £ 37.8 | £ 41.6 |
Pension costs | 0 | 0 |
Other long-term benefits | 8.5 | 8.2 |
Share-based payments | 12.2 | 13.2 |
Employer social security charges on emoluments | 7.2 | 7.2 |
Costs recognised for accounting purposes | 65.7 | 70.2 |
Employer social security charges on emoluments | (7.2) | (7.2) |
Other long-term benefits – difference between awards granted and costs recognised | 3.1 | 0 |
Share-based payments – difference between awards granted and costs recognised | 6.9 | 1.1 |
Total remuneration awarded | £ 68.5 | £ 64.1 |
Related party transactions an_7
Related party transactions and Directors' remuneration - Disclosure required by the Companies Act 2006 (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of transactions between related parties [line items] | ||
Aggregate emoluments | £ 8.2 | £ 8.4 |
Amounts paid under LTIPs | 1.2 | 0 |
Total directors expense in accordance with companies act 2006 | 9.4 | 8.4 |
Directors | Share value plan | ||
Disclosure of transactions between related parties [line items] | ||
Aggregate emoluments | £ 1.4 | £ 0.6 |
Auditor's remuneration (Details
Auditor's remuneration (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of products and services [line items] | |||
Audit of the Barclays Group's annual accounts | £ 9 | £ 9 | £ 10 |
Total Auditor's remuneration | 62 | 59 | 56 |
KPMG | |||
Disclosure of products and services [line items] | |||
Audit of the Barclays Group's annual accounts | 55 | 52 | 50 |
Other services | 1 | 1 | 1 |
Tax fees | 0 | 0 | 0 |
Subsidiaries | |||
Disclosure of products and services [line items] | |||
Audit of the Barclays Group's annual accounts | 41 | 38 | 35 |
Other audit related fees | |||
Disclosure of products and services [line items] | |||
Audit of the Barclays Group's annual accounts | 10 | 10 | 9 |
Other audit related fees | KPMG | |||
Disclosure of products and services [line items] | |||
Audit of the Barclays Group's annual accounts | 6 | 6 | 5 |
Other services | |||
Disclosure of products and services [line items] | |||
Other services | 2 | 2 | £ 2 |
Audit fee relating to previous year | |||
Disclosure of products and services [line items] | |||
Other services | £ 3 | £ 2 |
Interest rate benchmark refor_2
Interest rate benchmark reform - Significant exposures impacted by the IBOR reform (Details) - GBP (£) £ in Millions | 12 Months Ended | |||||||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | £ 361,451 | [1] | £ 342,632 | |||||
Reverse repurchase agreements and other similar secured lending | 3,227 | [1] | 9,031 | |||||
Financial assets at fair value through the income statement | 191,972 | [1] | 175,151 | |||||
Financial assets at fair value through other comprehensive income | 61,753 | [1] | 78,688 | |||||
Non-derivative financial assets | 1,360,339 | 1,329,242 | ||||||
Debt securities in issue | (98,867) | [1] | (75,796) | |||||
Subordinated liabilities | (12,759) | [1] | (16,341) | £ (18,156) | ||||
Financial liabilities designated at fair value | (250,960) | [1] | (249,765) | |||||
Non-derivative financial liabilities | (1,307,095) | (1,275,684) | ||||||
Equity | (70,041) | [1] | (66,882) | [2] | (65,660) | [2] | £ (63,779) | |
Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | [3] | (12,259) | (11,172) | £ (10,871) | £ (9,632) | |||
IBOR reform | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 30,663 | 50,204 | ||||||
Reverse repurchase agreements and other similar secured lending | 186 | 334 | ||||||
Financial assets at fair value through the income statement | 9,249 | 10,361 | ||||||
Financial assets at fair value through other comprehensive income | 0 | 308 | ||||||
Non-derivative financial assets | 40,098 | 61,207 | ||||||
Debt securities in issue | (7,220) | (12,942) | ||||||
Subordinated liabilities | (1,201) | (1,663) | ||||||
Financial liabilities designated at fair value | (920) | (2,320) | ||||||
Non-derivative financial liabilities | (9,341) | (16,925) | ||||||
Standby facilities, credit lines and other commitments | 117,636 | 108,980 | ||||||
IBOR reform | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | (3,466) | (6,631) | ||||||
IBOR reform | GBP LIBOR | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 14,166 | 30,179 | ||||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||||||
Financial assets at fair value through the income statement | 185 | 3,496 | ||||||
Financial assets at fair value through other comprehensive income | 0 | 186 | ||||||
Non-derivative financial assets | 14,351 | 33,861 | ||||||
Debt securities in issue | 0 | (1,023) | ||||||
Subordinated liabilities | 0 | (71) | ||||||
Financial liabilities designated at fair value | (708) | (149) | ||||||
Non-derivative financial liabilities | (708) | (1,243) | ||||||
Standby facilities, credit lines and other commitments | 60,490 | 18,944 | ||||||
Increase (Decrease) In Undrawn Borrowing Facilities | (34,000) | |||||||
IBOR reform | GBP LIBOR | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | 0 | (3,500) | ||||||
IBOR reform | USD LIBOR | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 15,812 | 18,109 | ||||||
Reverse repurchase agreements and other similar secured lending | 186 | 334 | ||||||
Financial assets at fair value through the income statement | 8,538 | 6,373 | ||||||
Financial assets at fair value through other comprehensive income | 0 | 114 | ||||||
Non-derivative financial assets | 24,536 | 24,930 | ||||||
Debt securities in issue | (6,137) | (10,718) | ||||||
Subordinated liabilities | (1,088) | (1,592) | ||||||
Financial liabilities designated at fair value | (212) | (1,273) | ||||||
Non-derivative financial liabilities | (7,437) | (13,583) | ||||||
Standby facilities, credit lines and other commitments | 42,767 | 74,011 | ||||||
Increase (Decrease) In Undrawn Borrowing Facilities | 34,000 | |||||||
IBOR reform | USD LIBOR | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | (3,374) | (3,131) | ||||||
IBOR reform | JPY LIBOR | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 25 | 173 | ||||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||||||
Financial assets at fair value through the income statement | 5 | 0 | ||||||
Financial assets at fair value through other comprehensive income | 0 | 0 | ||||||
Non-derivative financial assets | 30 | 173 | ||||||
Debt securities in issue | (1,083) | (1,201) | ||||||
Subordinated liabilities | 0 | 0 | ||||||
Financial liabilities designated at fair value | (759) | |||||||
Non-derivative financial liabilities | (1,083) | (1,960) | ||||||
Standby facilities, credit lines and other commitments | 1,284 | 0 | ||||||
IBOR reform | JPY LIBOR | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | (92) | 0 | ||||||
IBOR reform | CHF LIBOR | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 229 | 18 | ||||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||||||
Financial assets at fair value through the income statement | 327 | 283 | ||||||
Financial assets at fair value through other comprehensive income | 0 | 0 | ||||||
Non-derivative financial assets | 556 | 301 | ||||||
Debt securities in issue | 0 | 0 | ||||||
Subordinated liabilities | 0 | 0 | ||||||
Financial liabilities designated at fair value | 0 | |||||||
Non-derivative financial liabilities | 0 | 0 | ||||||
Standby facilities, credit lines and other commitments | 371 | 74 | ||||||
IBOR reform | CHF LIBOR | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | 0 | 0 | ||||||
IBOR reform | Others | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 431 | 1,725 | ||||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||||||
Financial assets at fair value through the income statement | 194 | 209 | ||||||
Financial assets at fair value through other comprehensive income | 0 | 8 | ||||||
Non-derivative financial assets | 625 | 1,942 | ||||||
Debt securities in issue | 0 | 0 | ||||||
Subordinated liabilities | (113) | 0 | ||||||
Financial liabilities designated at fair value | (139) | |||||||
Non-derivative financial liabilities | (113) | (139) | ||||||
Standby facilities, credit lines and other commitments | 12,724 | 15,951 | ||||||
IBOR reform | Others | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | £ 0 | £ 0 | ||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||||
[3] | For further details refer to Note 28. |
Interest rate benchmark refor_3
Interest rate benchmark reform - Significant exposures impacted by the interest rate benchmark reform - Derivative notional contract amount (Details) - IBOR reform - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | £ 6,413,555 | £ 12,850,082 |
GBP LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 423,660 | 2,734,692 |
USD LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 5,449,603 | 6,654,816 |
EUR LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 7,811 | 1,096,590 |
JPY LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 263,180 | 1,940,722 |
CHF LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 37,296 | 179,305 |
Others | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 232,005 | 243,957 |
OTC derivatives | Interest rate derivatives | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 2,737,920 | 4,705,142 |
OTC derivatives | Interest rate derivatives | GBP LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 240,183 | 592,827 |
OTC derivatives | Interest rate derivatives | USD LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 2,283,236 | 2,832,802 |
OTC derivatives | Interest rate derivatives | EUR LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 7,811 | 457,844 |
OTC derivatives | Interest rate derivatives | JPY LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 140,357 | 754,206 |
OTC derivatives | Interest rate derivatives | CHF LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 4,396 | 25,681 |
OTC derivatives | Interest rate derivatives | Others | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 61,937 | 41,782 |
OTC derivatives | Foreign exchange derivatives | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 802,299 | 870,905 |
OTC derivatives | Foreign exchange derivatives | GBP LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 183,477 | 155,285 |
OTC derivatives | Foreign exchange derivatives | USD LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 461,680 | 589,334 |
OTC derivatives | Foreign exchange derivatives | EUR LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 0 |
OTC derivatives | Foreign exchange derivatives | JPY LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 122,823 | 93,108 |
OTC derivatives | Foreign exchange derivatives | CHF LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 32,900 | 31,257 |
OTC derivatives | Foreign exchange derivatives | Others | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 1,419 | 1,921 |
OTC derivatives | Equity derivatives | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 9,949 | 14,896 |
OTC derivatives | Equity derivatives | GBP LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 1,845 |
OTC derivatives | Equity derivatives | USD LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 9,949 | 7,946 |
OTC derivatives | Equity derivatives | EUR LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 544 |
OTC derivatives | Equity derivatives | JPY LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 1,929 |
OTC derivatives | Equity derivatives | CHF LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 491 |
OTC derivatives | Equity derivatives | Others | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 2,141 |
Cleared by central counterparty | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 2,397,048 | 6,622,758 |
Cleared by central counterparty | GBP LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 1,684,553 |
Cleared by central counterparty | USD LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 2,228,399 | 2,891,029 |
Cleared by central counterparty | EUR LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 638,202 |
Cleared by central counterparty | JPY LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 1,091,479 |
Cleared by central counterparty | CHF LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 119,382 |
Cleared by central counterparty | Others | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 168,649 | 198,113 |
Exchange traded derivatives | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 466,339 | 636,381 |
Exchange traded derivatives | GBP LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 300,182 |
Exchange traded derivatives | USD LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 466,339 | 333,705 |
Exchange traded derivatives | EUR LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 0 |
Exchange traded derivatives | JPY LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 0 |
Exchange traded derivatives | CHF LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 2,494 |
Exchange traded derivatives | Others | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | £ 0 | £ 0 |
Interest rate benchmark refor_4
Interest rate benchmark reform - Narrative (Details) - IBOR reform - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | £ 6,413,555 | £ 12,850,082 |
Expected credit losses held against contingent liabilities and commitments | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Retained debt issuance | 9,000 | 28,000 |
Currency swaps | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | £ 256,000 | £ 264,000 |
Interest rate benchmark refor_5
Interest rate benchmark reform - Exposures with or without fallback clauses (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | ||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | £ 361,451 | [1] | £ 342,632 | |||||
Financial assets at fair value through the income statement | 191,972 | [1] | 175,151 | |||||
Non-derivative financial assets | 1,360,339 | 1,329,242 | ||||||
Debt instruments issued | (98,867) | [1] | (75,796) | |||||
Subordinated liabilities | (12,759) | [1] | (16,341) | £ (18,156) | ||||
Financial liabilities designated at fair value | (250,960) | [1] | (249,765) | |||||
Non-derivative financial liabilities | (1,307,095) | (1,275,684) | ||||||
Equity | (70,041) | [1] | (66,882) | [2] | (65,660) | [2] | £ (63,779) | |
Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | [3] | (12,259) | (11,172) | £ (10,871) | £ (9,632) | |||
IBOR reform | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 30,663 | 50,204 | ||||||
Financial assets at fair value through the income statement | 9,249 | 10,361 | ||||||
Non-derivative financial assets | 40,098 | 61,207 | ||||||
Debt instruments issued | (7,220) | (12,942) | ||||||
Subordinated liabilities | (1,201) | (1,663) | ||||||
Financial liabilities designated at fair value | (920) | (2,320) | ||||||
Non-derivative financial liabilities | (9,341) | (16,925) | ||||||
Standby facilities, credit lines and other commitments | 117,636 | 108,980 | ||||||
Notional contract amount | 6,413,555 | 12,850,082 | ||||||
IBOR reform | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 2,737,920 | 4,705,142 | ||||||
IBOR reform | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 802,299 | 870,905 | ||||||
IBOR reform | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | (3,466) | (6,631) | ||||||
IBOR reform | With appropriate fallback clause | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 10,066 | |||||||
Financial assets at fair value through the income statement | 465 | |||||||
Non-derivative financial assets | 10,531 | |||||||
Debt instruments issued | (1,083) | |||||||
Subordinated liabilities | 0 | |||||||
Financial liabilities designated at fair value | (708) | |||||||
Non-derivative financial liabilities | (1,791) | |||||||
Standby facilities, credit lines and other commitments | 46,959 | |||||||
Notional contract amount | 721,166 | |||||||
IBOR reform | With appropriate fallback clause | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 382,241 | |||||||
IBOR reform | With appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 338,925 | |||||||
IBOR reform | With appropriate fallback clause | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | (92) | |||||||
IBOR reform | Without appropriate fallback clause | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 4,785 | |||||||
Financial assets at fair value through the income statement | 246 | |||||||
Non-derivative financial assets | 5,031 | |||||||
Debt instruments issued | 0 | |||||||
Subordinated liabilities | 0 | |||||||
Financial liabilities designated at fair value | 0 | |||||||
Non-derivative financial liabilities | 0 | |||||||
Standby facilities, credit lines and other commitments | 27,910 | |||||||
Notional contract amount | 14,810 | |||||||
IBOR reform | Without appropriate fallback clause | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 14,535 | |||||||
IBOR reform | Without appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 275 | |||||||
IBOR reform | Without appropriate fallback clause | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | 0 | |||||||
GBP LIBOR | IBOR reform | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 14,166 | 30,179 | ||||||
Financial assets at fair value through the income statement | 185 | 3,496 | ||||||
Non-derivative financial assets | 14,351 | 33,861 | ||||||
Debt instruments issued | 0 | (1,023) | ||||||
Subordinated liabilities | 0 | (71) | ||||||
Financial liabilities designated at fair value | (708) | (149) | ||||||
Non-derivative financial liabilities | (708) | (1,243) | ||||||
Standby facilities, credit lines and other commitments | 60,490 | 18,944 | ||||||
Notional contract amount | 423,660 | 2,734,692 | ||||||
GBP LIBOR | IBOR reform | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 240,183 | 592,827 | ||||||
GBP LIBOR | IBOR reform | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 183,477 | 155,285 | ||||||
GBP LIBOR | IBOR reform | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | 0 | (3,500) | ||||||
GBP LIBOR | IBOR reform | With appropriate fallback clause | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 9,434 | |||||||
Financial assets at fair value through the income statement | 125 | |||||||
Non-derivative financial assets | 9,559 | |||||||
Debt instruments issued | 0 | |||||||
Subordinated liabilities | 0 | |||||||
Financial liabilities designated at fair value | (708) | |||||||
Non-derivative financial liabilities | (708) | |||||||
Standby facilities, credit lines and other commitments | 36,573 | |||||||
Notional contract amount | 414,170 | |||||||
GBP LIBOR | IBOR reform | With appropriate fallback clause | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 230,967 | |||||||
GBP LIBOR | IBOR reform | With appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 183,203 | |||||||
GBP LIBOR | IBOR reform | With appropriate fallback clause | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | 0 | |||||||
GBP LIBOR | IBOR reform | Without appropriate fallback clause | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 4,732 | |||||||
Financial assets at fair value through the income statement | 60 | |||||||
Non-derivative financial assets | 4,792 | |||||||
Debt instruments issued | 0 | |||||||
Subordinated liabilities | 0 | |||||||
Financial liabilities designated at fair value | 0 | |||||||
Non-derivative financial liabilities | 0 | |||||||
Standby facilities, credit lines and other commitments | 23,917 | |||||||
Notional contract amount | 9,490 | |||||||
GBP LIBOR | IBOR reform | Without appropriate fallback clause | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 9,216 | |||||||
GBP LIBOR | IBOR reform | Without appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 274 | |||||||
GBP LIBOR | IBOR reform | Without appropriate fallback clause | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | 0 | |||||||
EONIA | IBOR reform | With appropriate fallback clause | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 7,568 | |||||||
EONIA | IBOR reform | With appropriate fallback clause | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 7,568 | |||||||
EONIA | IBOR reform | With appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 0 | |||||||
EONIA | IBOR reform | Without appropriate fallback clause | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 243 | |||||||
EONIA | IBOR reform | Without appropriate fallback clause | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 243 | |||||||
EONIA | IBOR reform | Without appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 0 | |||||||
JPY LIBOR | IBOR reform | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 25 | 173 | ||||||
Financial assets at fair value through the income statement | 5 | 0 | ||||||
Non-derivative financial assets | 30 | 173 | ||||||
Debt instruments issued | (1,083) | (1,201) | ||||||
Subordinated liabilities | 0 | 0 | ||||||
Financial liabilities designated at fair value | (759) | |||||||
Non-derivative financial liabilities | (1,083) | (1,960) | ||||||
Standby facilities, credit lines and other commitments | 1,284 | 0 | ||||||
Notional contract amount | 263,180 | 1,940,722 | ||||||
JPY LIBOR | IBOR reform | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 140,357 | 754,206 | ||||||
JPY LIBOR | IBOR reform | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 122,823 | 93,108 | ||||||
JPY LIBOR | IBOR reform | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | (92) | 0 | ||||||
JPY LIBOR | IBOR reform | With appropriate fallback clause | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 5 | |||||||
Financial assets at fair value through the income statement | 5 | |||||||
Non-derivative financial assets | 10 | |||||||
Debt instruments issued | (1,083) | |||||||
Subordinated liabilities | 0 | |||||||
Financial liabilities designated at fair value | 0 | |||||||
Non-derivative financial liabilities | (1,083) | |||||||
Standby facilities, credit lines and other commitments | 653 | |||||||
Notional contract amount | 258,541 | |||||||
JPY LIBOR | IBOR reform | With appropriate fallback clause | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 135,719 | |||||||
JPY LIBOR | IBOR reform | With appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 122,822 | |||||||
JPY LIBOR | IBOR reform | With appropriate fallback clause | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | (92) | |||||||
JPY LIBOR | IBOR reform | Without appropriate fallback clause | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 20 | |||||||
Financial assets at fair value through the income statement | 0 | |||||||
Non-derivative financial assets | 20 | |||||||
Debt instruments issued | 0 | |||||||
Subordinated liabilities | 0 | |||||||
Financial liabilities designated at fair value | 0 | |||||||
Non-derivative financial liabilities | 0 | |||||||
Standby facilities, credit lines and other commitments | 631 | |||||||
Notional contract amount | 4,639 | |||||||
JPY LIBOR | IBOR reform | Without appropriate fallback clause | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 4,638 | |||||||
JPY LIBOR | IBOR reform | Without appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 1 | |||||||
JPY LIBOR | IBOR reform | Without appropriate fallback clause | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | 0 | |||||||
CHF LIBOR | IBOR reform | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 229 | 18 | ||||||
Financial assets at fair value through the income statement | 327 | 283 | ||||||
Non-derivative financial assets | 556 | 301 | ||||||
Debt instruments issued | 0 | 0 | ||||||
Subordinated liabilities | 0 | 0 | ||||||
Financial liabilities designated at fair value | 0 | |||||||
Non-derivative financial liabilities | 0 | 0 | ||||||
Standby facilities, credit lines and other commitments | 371 | 74 | ||||||
Notional contract amount | 37,296 | 179,305 | ||||||
CHF LIBOR | IBOR reform | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 4,396 | 25,681 | ||||||
CHF LIBOR | IBOR reform | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 32,900 | 31,257 | ||||||
CHF LIBOR | IBOR reform | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | 0 | 0 | ||||||
CHF LIBOR | IBOR reform | With appropriate fallback clause | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 215 | |||||||
Financial assets at fair value through the income statement | 327 | |||||||
Non-derivative financial assets | 542 | |||||||
Debt instruments issued | 0 | |||||||
Subordinated liabilities | 0 | |||||||
Financial liabilities designated at fair value | 0 | |||||||
Non-derivative financial liabilities | 0 | |||||||
Standby facilities, credit lines and other commitments | 371 | |||||||
Notional contract amount | 37,261 | |||||||
CHF LIBOR | IBOR reform | With appropriate fallback clause | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 4,361 | |||||||
CHF LIBOR | IBOR reform | With appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 32,900 | |||||||
CHF LIBOR | IBOR reform | With appropriate fallback clause | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | 0 | |||||||
CHF LIBOR | IBOR reform | Without appropriate fallback clause | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 14 | |||||||
Financial assets at fair value through the income statement | 0 | |||||||
Non-derivative financial assets | 14 | |||||||
Debt instruments issued | 0 | |||||||
Subordinated liabilities | 0 | |||||||
Financial liabilities designated at fair value | 0 | |||||||
Non-derivative financial liabilities | 0 | |||||||
Standby facilities, credit lines and other commitments | 0 | |||||||
Notional contract amount | 35 | |||||||
CHF LIBOR | IBOR reform | Without appropriate fallback clause | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 35 | |||||||
CHF LIBOR | IBOR reform | Without appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 0 | |||||||
CHF LIBOR | IBOR reform | Without appropriate fallback clause | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | 0 | |||||||
EUR LIBOR | IBOR reform | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 7,811 | 1,096,590 | ||||||
EUR LIBOR | IBOR reform | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 7,811 | 457,844 | ||||||
EUR LIBOR | IBOR reform | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 0 | £ 0 | ||||||
EUR LIBOR | IBOR reform | With appropriate fallback clause | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 412 | |||||||
Financial assets at fair value through the income statement | 8 | |||||||
Non-derivative financial assets | 420 | |||||||
Debt instruments issued | 0 | |||||||
Subordinated liabilities | 0 | |||||||
Financial liabilities designated at fair value | 0 | |||||||
Non-derivative financial liabilities | 0 | |||||||
Standby facilities, credit lines and other commitments | 9,362 | |||||||
Notional contract amount | 3,626 | |||||||
EUR LIBOR | IBOR reform | With appropriate fallback clause | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 3,626 | |||||||
EUR LIBOR | IBOR reform | With appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 0 | |||||||
EUR LIBOR | IBOR reform | With appropriate fallback clause | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | 0 | |||||||
EUR LIBOR | IBOR reform | Without appropriate fallback clause | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Loans and advances at amortised cost | 19 | |||||||
Financial assets at fair value through the income statement | 186 | |||||||
Non-derivative financial assets | 205 | |||||||
Debt instruments issued | 0 | |||||||
Subordinated liabilities | 0 | |||||||
Financial liabilities designated at fair value | 0 | |||||||
Non-derivative financial liabilities | 0 | |||||||
Standby facilities, credit lines and other commitments | 3,362 | |||||||
Notional contract amount | 403 | |||||||
EUR LIBOR | IBOR reform | Without appropriate fallback clause | OTC derivatives | Interest rate risk | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 403 | |||||||
EUR LIBOR | IBOR reform | Without appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Notional contract amount | 0 | |||||||
EUR LIBOR | IBOR reform | Without appropriate fallback clause | Other equity instruments | ||||||||
Disclosure of financial instruments by type of interest rate [line items] | ||||||||
Equity | £ 0 | |||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||||
[3] | For further details refer to Note 28. |
Barclays PLC (the Parent comp_2
Barclays PLC (the Parent company) - Total income (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of transactions between related parties [line items] | ||||
Dividends received from subsidiary | £ 20 | £ 37 | £ 76 | |
Other income | 88 | [1] | 31 | 99 |
Fair value and foreign exchange losses on other positions with subsidiaries | 139 | 743 | ||
Barclays PLC | ||||
Disclosure of transactions between related parties [line items] | ||||
Dividends received from subsidiary | 1,356 | 763 | 1,560 | |
Other income | 659 | 1,192 | 1,760 | |
Barclays PLC | AT1 Securities | ||||
Disclosure of transactions between related parties [line items] | ||||
Other income | 804 | 857 | £ 813 | |
Barclays PLC | Subsidiaries | ||||
Disclosure of transactions between related parties [line items] | ||||
Fair value and foreign exchange losses on other positions with subsidiaries | 250 | £ 248 | ||
Barclays PLC | Barclays Bank PLC | ||||
Disclosure of transactions between related parties [line items] | ||||
Dividends received from subsidiary | 794 | |||
Barclays PLC | Barclays Execution Services Limited | ||||
Disclosure of transactions between related parties [line items] | ||||
Dividends received from subsidiary | 510 | |||
Barclays PLC | Barclays UK | ||||
Disclosure of transactions between related parties [line items] | ||||
Dividends received from subsidiary | £ 82 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. |
Barclays PLC (the Parent comp_3
Barclays PLC (the Parent company) - Total assets and liabilities (Details) € in Millions, £ in Millions, $ in Millions | Apr. 29, 2022GBP (£) | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2021EUR (€) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | ||
Loans and advances in subsidiaries | ||||||||
Loans and advances at amortised cost | £ 361,451 | [1] | £ 342,632 | |||||
Financial assets and liabilities designated at fair value | ||||||||
Financial liabilities designated at fair value | 250,960 | [1] | 249,765 | |||||
Financial assets at fair value through the income statement | 191,972 | [1] | 175,151 | |||||
Subordinated liabilities and debt securities in issue | ||||||||
Issuance of subordinated liabilities | 1,890 | [2] | $ 1,890 | 1,438 | £ 1,352 | |||
Subordinated liabilities | 12,759 | [1] | 16,341 | 18,156 | ||||
Debt securities in issue | 98,867 | [1] | 75,796 | |||||
Callable | ||||||||
Loans and advances in subsidiaries | ||||||||
Loans and advances at amortised cost | 19,749 | 14,098 | ||||||
Financial assets and liabilities designated at fair value | ||||||||
Financial liabilities designated at fair value | 21,339 | 15,555 | ||||||
Financial assets at fair value through the income statement | 24,257 | 17,377 | ||||||
Subordinated liabilities and debt securities in issue | ||||||||
Subordinated liabilities | 0 | 0 | ||||||
Debt securities in issue | 0 | 0 | ||||||
Barclays PLC | ||||||||
Investment in subsidiaries | ||||||||
Investment in subsidiaries | 62,528 | 58,886 | ||||||
Increase through change in equity of subsidiaries | 3,642 | |||||||
Loans and advances in subsidiaries | ||||||||
Decrease in loans and advances to subsidiaries of the Parent | [3],[4] | 6,118 | 4,732 | 4,464 | ||||
Loans and advances at amortised cost | 22,072 | 24,710 | ||||||
Financial assets and liabilities designated at fair value | ||||||||
Financial liabilities designated at fair value | 16,319 | 9,507 | ||||||
Net increase in debt securities in issue | [5] | 4,939 | 3,720 | 2,588 | ||||
Financial assets at fair value through the income statement | 25,091 | 17,521 | ||||||
Difference between the financial liabilities' carrying amount and the contractual amount on maturity | 271 | 324 | ||||||
Subordinated liabilities and debt securities in issue | ||||||||
Issuance of subordinated liabilities | 1,579 | 158 | £ 1,194 | |||||
Subordinated liabilities | 9,301 | 7,724 | ||||||
Debt securities in issue | 25,658 | 28,428 | ||||||
Barclays PLC | Callable | Fixed interest rate | ||||||||
Subordinated liabilities and debt securities in issue | ||||||||
Issuance of subordinated liabilities | € | € 1,000 | |||||||
Barclays PLC | Senior Notes | Callable | Fixed interest rate | ||||||||
Financial assets and liabilities designated at fair value | ||||||||
Net increase in debt securities in issue | 5,000 | 1,500 | ||||||
Barclays PLC | Senior Notes | Callable | Fixed and Floating Rate | ||||||||
Financial assets and liabilities designated at fair value | ||||||||
Net increase in debt securities in issue | € | € 750 | |||||||
Barclays PLC | Zero coupon | Callable | ||||||||
Financial assets and liabilities designated at fair value | ||||||||
Net increase in debt securities in issue | $ | 500 | |||||||
Barclays PLC | Barclays Bank PLC | ||||||||
Investment in subsidiaries | ||||||||
Investment in subsidiaries | 35,590 | 35,590 | ||||||
Loans and advances in subsidiaries | ||||||||
Decrease through conversion of convertible instruments | 2,400 | |||||||
Barclays PLC | Barclays Bank PLC | Capital contribution from parent entity | ||||||||
Investment in subsidiaries | ||||||||
Increase through change in equity of subsidiaries | £ 750 | |||||||
Barclays PLC | Barclays Bank PLC | AT1 Securities | ||||||||
Investment in subsidiaries | ||||||||
Investment in subsidiaries | 9,493 | 8,425 | ||||||
Barclays PLC | Barclays UK | ||||||||
Investment in subsidiaries | ||||||||
Investment in subsidiaries | £ 14,245 | 11,675 | ||||||
Reversal of impairment loss recognised in profit or loss | 2,573 | |||||||
Impairment in subsidiaries | ||||||||
Reversal of impairment loss recognised in profit or loss | £ 2,573 | |||||||
Discount rate applied to cash flow projections | 14.50% | 13.80% | ||||||
Terminal growth rate | 2.00% | 2.00% | ||||||
Barclays PLC | Barclays UK | Subordinated Notes | ||||||||
Loans and advances in subsidiaries | ||||||||
Cash advances and loans made to related parties | £ (1,600) | |||||||
Barclays PLC | Barclays UK | AT1 Securities | ||||||||
Investment in subsidiaries | ||||||||
Investment in subsidiaries | 2,570 | £ 2,570 | ||||||
Increase through change in equity of subsidiaries | $ | 1,500 | |||||||
Barclays PLC | Subsidiaries | ||||||||
Loans and advances in subsidiaries | ||||||||
Decrease in loans and advances to subsidiaries of the Parent | 2,638 | |||||||
Barclays PLC | Subsidiaries | Callable | Fixed interest rate | ||||||||
Subordinated liabilities and debt securities in issue | ||||||||
Issuance of subordinated liabilities | $ | $ 1,000 | |||||||
Barclays PLC | Subsidiaries | Subordinated Notes | ||||||||
Loans and advances in subsidiaries | ||||||||
Decrease in loans and advances to subsidiaries of the Parent | £ (1,100) | |||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | |||||||
[3] | Following a review of the Barclays parent company cash flow statement, in order to make the cash flow statement more relevant, cash movements resulting from loans and advances to subsidiaries are now presented within investing activities, whereas previously they were presented in financing activities. Comparatives have been restated. The effect of this change was to increase the net cash outflow due to investing activities increased by £4,732m in 2020 and £4,464m in 2019, with the net cash inflow relating to financing activities increasing by the same amount . | |||||||
[4] | Includes financial assets at fair value through the income statement. | |||||||
[5] | Includes financial liabilities designated at fair value. |
Barclays PLC (the Parent comp_4
Barclays PLC (the Parent company) - Total equity (Narrative) (Details) £ in Millions, $ in Millions | 12 Months Ended | ||||||||
Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | Dec. 31, 2018GBP (£) | |||||
Disclosure of transactions between related parties [line items] | |||||||||
Total equity | £ 70,041 | [1] | £ 66,882 | [2] | £ 65,660 | [2] | £ 63,779 | ||
Called up share capital and share premium | |||||||||
Disclosure of transactions between related parties [line items] | |||||||||
Total equity | [3] | 4,536 | 4,637 | 4,594 | 4,311 | ||||
AT1 securities issuance | 0 | 0 | |||||||
Other equity instruments | |||||||||
Disclosure of transactions between related parties [line items] | |||||||||
Total equity | [3] | 12,259 | 11,172 | 10,871 | 9,632 | ||||
AT1 securities issuance | 1,078 | 1,142 | |||||||
Barclays PLC | |||||||||
Disclosure of transactions between related parties [line items] | |||||||||
Total equity | 57,837 | 54,872 | 56,467 | 54,180 | |||||
Barclays PLC | Called up share capital and share premium | |||||||||
Disclosure of transactions between related parties [line items] | |||||||||
Total equity | 4,536 | 4,637 | 4,594 | 4,311 | |||||
Barclays PLC | Other equity instruments | |||||||||
Disclosure of transactions between related parties [line items] | |||||||||
Total equity | 12,241 | £ 11,169 | £ 10,865 | £ 9,633 | |||||
Barclays PLC | AT1 Securities | |||||||||
Disclosure of transactions between related parties [line items] | |||||||||
AT1 securities issuance | £ 1,078 | $ 1,500 | |||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under BBPLC's 2019 F-3. See Restatement of financial statements (Note 1a) on page 228 for further details. | ||||||||
[3] | For further details refer to Note 28. |